1	nature	NN	O	nature	nn	4	SENT_1	[p1l21t124r112b145],
2	publishing	NN	O	publishing	nn	4	SENT_1	[p1l121t121r269b152],
3	group	NN	O	group	nn	4	SENT_1	[p1l278t128r362b152],
4	S	NN	O	s	_	0	SENT_1	[p1l1761t108r1783b145],
5	悕	CD	NUMBER	悕	number	6	SENT_1	[p1l1790t108r1873b145],
6	*	CD	NUMBER	*	num	7	SENT_1	[p1l1790t108r1873b145],
7	E	NN	O	e	dep	4	SENT_1	[p1l1882t108r1902b145],
8	A	DT	O	a	det	10	SENT_1	[p1l2045t108r2073b145],
9	bn	NN	O	bn	nn	10	SENT_1	[p1l2082t108r2139b145],
10	*	NN	O	*	dep	7	SENT_1	[p1l2082t108r2139b145],

1	Current	JJ	DATE	current	amod	4	SENT_2	[p1l23t264r344b337],
2	Status	NNP	O	Status	nn	4	SENT_2	[p1l368t264r628b337],
3	ofTargeted	NNP	O	ofTargeted	nn	4	SENT_2	[p1l653t260r1126b357],
4	Therapy	NN	O	therapy	_	0	SENT_2	[p1l1146t261r1498b358],
5	for	IN	O	for	_	0	SENT_2	[p1l1517t260r1635b337],
6	Anaplastic	JJ	O	anaplastic	amod	8	SENT_2	[p1l1656t261r2102b356],
7	Lymphoma	NN	O	lymphoma	nn	8	SENT_2	[p1l27t373r506b471],
8	Kinase	NN	O	kinase	prep_for	4	SENT_2	[p1l537t373r1363b470],
9	.	.	O	.	_	0	SENT_2	[p1l537t373r1363b470],

1	—	NN	O	—	_	0	SENT_3	[p1l537t373r1363b470],
2	.	.	O	.	_	0	SENT_3	[p1l537t373r1363b470],

1	Rearranged	VBN	O	rearrange	_	0	SENT_4	[p1l537t373r1363b470],
2	Non	NNP	O	Non	dobj	1	SENT_4	[p1l1395t373r1853b449],
3	.	.	O	.	_	0	SENT_4	[p1l1395t373r1853b449],

1	—	NN	O	—	_	0	SENT_5	[p1l1395t373r1853b449],
2	.	.	O	.	_	0	SENT_5	[p1l1395t373r1853b449],

1	Sma	NN	O	sma	_	0	SENT_6	[p1l1395t373r1853b449],
2	|	CD	NUMBER	|	number	3	SENT_6	[p1l1395t373r1853b449],
3	|	CD	NUMBER	|	num	7	SENT_6	[p1l1395t373r1853b449],
4	Cell	NN	O	cell	nn	7	SENT_6	[p1l1881t373r2030b449],
5	Lung	NN	O	lung	nn	7	SENT_6	[p1l27t489r233b582],
6	Cancer	NN	O	cancer	nn	7	SENT_6	[p1l261t488r556b561],
7	B	NN	O	b	dep	1	SENT_6	[p1l21t637r48b670],
8	Solomon	NNP	O	Solomon	nn	9	SENT_6	[p1l61t629r300b676],
9	”	NNP	O	”	dep	1	SENT_6	[p1l61t629r300b676],
10	,	,	O	,	_	0	SENT_6	[p1l61t629r300b676],
11	KD	NN	O	kd	nn	12	SENT_6	[p1l312t637r381b670],
12	Wilner3	NN	O	wilner3	appos	9	SENT_6	[p1l392t629r552b670],
13	and	CC	O	and	_	0	SENT_6	[p1l564t634r640b670],
14	AT	IN	O	at	conj_and	12	SENT_6	[p1l649t635r711b670],
15	Shaw4	NN	O	shaw4	pobj	14	SENT_6	[p1l722t629r846b670],

1	The	DT	O	the	det	2	SENT_7	[p1l19t751r84b782],
2	identification	NN	O	identification	nsubj	50	SENT_7	[p1l94t751r328b782],
3	of	IN	O	of	_	0	SENT_7	[p1l339t751r375b782],
4	chromosomal	JJ	O	chromosomal	amod	5	SENT_7	[p1l382t751r623b782],
5	rearrangements	NNS	O	rearrangement	prep_of	2	SENT_7	[p1l635t756r917b790],
6	involving	VBG	O	involve	partmod	5	SENT_7	[p1l928t751r1089b790],
7	the	DT	O	the	det	14	SENT_7	[p1l1099t751r1157b782],
8	anaplastic	JJ	O	anaplastic	amod	14	SENT_7	[p1l1165t751r1345b789],
9	lymphoma	NN	O	lymphoma	nn	14	SENT_7	[p1l1355t751r1544b790],
10	kinase	NN	O	kinase	nn	14	SENT_7	[p1l1555t751r1667b782],
11	(	NN	O	(	nn	14	SENT_7	[p1l1677t752r1764b786],
12	ALK	NN	O	alk	nn	14	SENT_7	[p1l1677t752r1764b786],
13	)	NN	O	)	nn	14	SENT_7	[p1l1677t752r1764b786],
14	gene	NN	O	gene	dobj	6	SENT_7	[p1l1774t760r1862b790],
15	in	IN	O	in	_	0	SENT_7	[p1l1872t752r1901b781],
16	~	NN	O	~	nn	18	SENT_7	[p1l1912t753r2034b782],
17	3	CD	PERCENT	3	num	18	SENT_7	[p1l1912t753r2034b782],
18	—	NN	PERCENT	—	prep_in	14	SENT_7	[p1l1912t753r2034b782],
19	5	CD	PERCENT	5	num	20	SENT_7	[p1l1912t753r2034b782],
20	%	NN	PERCENT	%	dep	31	SENT_7	[p1l1912t753r2034b782],
21	of	IN	O	of	_	0	SENT_7	[p1l2042t751r2079b782],
22	non	JJ	O	non	amod	27	SENT_7	[p1l21t804r202b835],
23	—	JJ	O	—	amod	27	SENT_7	[p1l21t804r202b835],
24	small	JJ	O	small	amod	27	SENT_7	[p1l21t804r202b835],
25	cell	NN	O	cell	nn	27	SENT_7	[p1l212t804r269b835],
26	lung	NN	O	lung	nn	27	SENT_7	[p1l281t804r358b844],
27	cancer	NN	O	cancer	prep_of	20	SENT_7	[p1l368t813r483b835],
28	(	CD	NUMBER	(	num	29	SENT_7	[p1l493t805r630b840],
29	NSCLC	NN	O	nsclc	dep	31	SENT_7	[p1l493t805r630b840],
30	)	CD	NUMBER	)	num	31	SENT_7	[p1l493t805r630b840],
31	tissues	NNS	O	tissue	dep	18	SENT_7	[p1l639t805r759b835],
32	and	CC	O	and	_	0	SENT_7	[p1l768t804r833b835],
33	the	DT	O	the	det	34	SENT_7	[p1l842t804r900b835],
34	demonstration	NN	O	demonstration	dep	18	SENT_7	[p1l909t804r1171b835],
35	that	IN	O	that	dep	47	SENT_7	[p1l1181t804r1253b835],
36	the	DT	O	the	det	41	SENT_7	[p1l1261t804r1319b835],
37	first-in-class	JJ	O	first-in-class	amod	41	SENT_7	[p1l1327t804r1540b835],
38	ALK	NN	O	alk	nn	41	SENT_7	[p1l1548t806r1619b835],
39	tyrosine	NN	O	tyrosine	nn	41	SENT_7	[p1l1625t805r1769b844],
40	kinase	NN	O	kinase	nn	41	SENT_7	[p1l1780t804r1891b835],
41	inhibitor	NN	O	inhibitor	nsubj	47	SENT_7	[p1l1901t804r2060b840],
42	,	,	O	,	_	0	SENT_7	[p1l1901t804r2060b840],
43	crizotinib	NN	O	crizotinib	appos	41	SENT_7	[p1l20t859r195b894],
44	,	,	O	,	_	0	SENT_7	[p1l20t859r195b894],
45	can	MD	O	can	aux	47	SENT_7	[p1l204t868r263b889],
46	effectively	RB	O	effectively	advmod	47	SENT_7	[p1l273t858r457b898],
47	target	VB	O	target	dep	18	SENT_7	[p1l465t863r572b898],
48	these	DT	O	these	det	49	SENT_7	[p1l580t859r677b889],
49	tumors	NNS	O	tumor	dobj	47	SENT_7	[p1l685t863r811b889],
50	represent	VBP	O	represent	_	0	SENT_7	[p1l821t863r990b897],
51	a	DT	O	a	det	53	SENT_7	[p1l999t868r1016b889],
52	significant	JJ	O	significant	amod	53	SENT_7	[p1l1026t858r1210b898],
53	advance	NN	O	advance	dobj	50	SENT_7	[p1l1219t859r1367b889],
54	in	IN	O	in	_	0	SENT_7	[p1l1376t859r1406b889],
55	the	DT	O	the	det	56	SENT_7	[p1l1415t859r1473b889],
56	evolution	NN	O	evolution	prep_in	53	SENT_7	[p1l1482t859r1649b889],
57	of	IN	O	of	_	0	SENT_7	[p1l1660t858r1696b889],
58	personalized	JJ	O	personalized	amod	59	SENT_7	[p1l1704t859r1929b897],
59	medicine	NN	O	medicine	prep_of	56	SENT_7	[p1l1940t859r2102b889],
60	for	IN	O	for	_	0	SENT_7	[p1l19t912r69b943],
61	NSCLC	NNP	O	NSCLC	prep_for	59	SENT_7	[p1l79t913r202b943],
62	.	.	O	.	_	0	SENT_7	[p1l79t913r202b943],

1	Single-arm	JJ	O	single-arm	amod	2	SENT_8	[p1l211t912r403b951],
2	studies	NNS	O	study	nsubjpass	20	SENT_8	[p1l413t912r539b943],
3	demonstrating	VBG	O	demonstrate	partmod	2	SENT_8	[p1l548t912r810b951],
4	rapid	JJ	O	rapid	amod	7	SENT_8	[p1l822t912r911b950],
5	and	CC	O	and	_	0	SENT_8	[p1l921t912r986b943],
6	durable	JJ	O	durable	amod	7	SENT_8	[p1l996t912r1133b943],
7	responses	NNS	O	response	dobj	3	SENT_8	[p1l1143t921r1319b951],
8	in	IN	O	in	_	0	SENT_8	[p1l1329t913r1358b942],
9	the	DT	O	the	det	10	SENT_8	[p1l1368t912r1426b943],
10	majority	NN	O	majority	prep_in	3	SENT_8	[p1l1436t913r1584b951],
11	of	IN	O	of	_	0	SENT_8	[p1l1592t912r1629b943],
12	ALK-positive	JJ	O	alk-positive	amod	14	SENT_8	[p1l1635t913r1858b950],
13	NSCLC	NN	O	nsclc	nn	14	SENT_8	[p1l1868t913r1981b943],
14	patients	NNS	O	patient	prep_of	10	SENT_8	[p1l1991t913r2133b950],
15	treated	VBN	O	treat	partmod	14	SENT_8	[p1l20t965r147b996],
16	with	IN	O	with	_	0	SENT_8	[p1l156t965r233b996],
17	crizotinib	NN	O	crizotinib	prep_with	15	SENT_8	[p1l243t965r409b996],
18	have	VBP	O	have	aux	20	SENT_8	[p1l420t965r502b996],
19	been	VBN	O	be	auxpass	20	SENT_8	[p1l512t965r598b996],
20	followed	VBN	O	follow	_	0	SENT_8	[p1l607t965r760b996],
21	by	IN	O	by	_	0	SENT_8	[p1l771t965r814b1005],
22	a	DT	O	a	det	27	SENT_8	[p1l821t974r839b996],
23	randomized	JJ	O	randomized	amod	27	SENT_8	[p1l850t965r1061b996],
24	phase	NN	O	phase	nn	27	SENT_8	[p1l1072t965r1176b1004],
25	III	CD	NUMBER	iii	num	27	SENT_8	[p1l1187t967r1214b996],
26	clinical	JJ	O	clinical	amod	27	SENT_8	[p1l1224t965r1344b996],
27	trial	NN	O	trial	agent	20	SENT_8	[p1l1354t965r1422b996],
28	in	IN	O	in	_	0	SENT_8	[p1l1433t966r1463b996],
29	which	WDT	O	which	rel	36	SENT_8	[p1l1472t965r1577b996],
30	superiority	NN	O	superiority	nsubjpass	36	SENT_8	[p1l1587t966r1780b1005],
31	of	IN	O	of	_	0	SENT_8	[p1l1788t965r1825b996],
32	crizotinib	NN	O	crizotinib	prep_of	30	SENT_8	[p1l1831t965r1997b996],
33	over	IN	O	over	_	0	SENT_8	[p1l2006t974r2084b996],
34	chemotherapy	NN	O	chemotherapy	prep_over	32	SENT_8	[p1l20t1019r280b1058],
35	was	VBD	O	be	auxpass	36	SENT_8	[p1l287t1028r354b1050],
36	seen	VBN	O	see	rcmod	27	SENT_8	[p1l364t1028r443b1050],
37	in	IN	O	in	_	0	SENT_8	[p1l455t1020r484b1049],
38	previously	RB	DATE	previously	advmod	39	SENT_8	[p1l495t1019r679b1058],
39	treated	VBN	O	treat	amod	42	SENT_8	[p1l686t1019r814b1050],
40	ALK-positive	JJ	O	alk-positive	amod	42	SENT_8	[p1l823t1020r1046b1057],
41	NSCLC	NN	O	nsclc	nn	42	SENT_8	[p1l1056t1020r1169b1050],
42	patients	NNS	O	patient	prep_in	36	SENT_8	[p1l1180t1020r1331b1057],
43	.	.	O	.	_	0	SENT_8	[p1l1180t1020r1331b1057],

1	However	RB	O	however	advmod	10	SENT_9	[p1l1342t1021r1504b1054],
2	,	,	O	,	_	0	SENT_9	[p1l1342t1021r1504b1054],
3	despite	IN	O	despite	_	0	SENT_9	[p1l1513t1019r1643b1057],
4	the	DT	O	the	det	6	SENT_9	[p1l1651t1019r1709b1050],
5	initial	JJ	O	initial	amod	6	SENT_9	[p1l1719t1019r1815b1050],
6	responses	NNS	O	response	prep_despite	10	SENT_9	[p1l1827t1028r2012b1057],
7	,	,	O	,	_	0	SENT_9	[p1l1827t1028r2012b1057],
8	most	JJS	O	most	amod	9	SENT_9	[p1l2022t1023r2109b1050],
9	patients	NNS	O	patient	nsubj	10	SENT_9	[p1l21t1074r164b1112],
10	develop	VBP	O	develop	_	0	SENT_9	[p1l173t1073r316b1111],
11	acquired	VBN	O	acquire	amod	12	SENT_9	[p1l325t1073r478b1111],
12	resistance	NN	O	resistance	dobj	10	SENT_9	[p1l489t1074r665b1104],
13	to	TO	O	to	_	0	SENT_9	[p1l673t1077r709b1104],
14	crizotinib	NN	O	crizotinib	prep_to	10	SENT_9	[p1l718t1073r892b1104],
15	.	.	O	.	_	0	SENT_9	[p1l718t1073r892b1104],

1	Several	JJ	O	several	amod	4	SENT_10	[p1l901t1073r1028b1104],
2	novel	JJ	O	novel	amod	4	SENT_10	[p1l1039t1073r1133b1104],
3	therapeutic	JJ	O	therapeutic	amod	4	SENT_10	[p1l1143t1073r1348b1111],
4	approaches	NNS	O	approach	nsubj	8	SENT_10	[p1l1357t1073r1563b1111],
5	targeting	VBG	O	target	partmod	4	SENT_10	[p1l1571t1074r1735b1112],
6	ALK-positive	JJ	O	alk-positive	amod	7	SENT_10	[p1l1745t1074r1968b1111],
7	NSCLC	NN	O	nsclc	dobj	5	SENT_10	[p1l1978t1074r2091b1104],
8	are	VBP	O	be	_	0	SENT_10	[p1l20t1135r75b1156],
9	currently	RB	DATE	currently	advmod	8	SENT_10	[p1l84t1126r243b1165],
10	under	IN	O	under	_	0	SENT_10	[p1l253t1126r357b1156],
11	evaluation	NN	O	evaluation	prep_under	8	SENT_10	[p1l365t1126r551b1156],
12	in	IN	O	in	_	0	SENT_10	[p1l562t1127r592b1156],
13	clinical	JJ	O	clinical	amod	14	SENT_10	[p1l602t1126r722b1156],
14	trials	NNS	O	trial	prep_in	11	SENT_10	[p1l731t1126r827b1161],
15	,	,	O	,	_	0	SENT_10	[p1l731t1126r827b1161],
16	including	VBG	O	include	_	0	SENT_10	[p1l837t1126r1001b1165],
17	second-generation	JJ	O	second-generation	amod	19	SENT_10	[p1l1011t1126r1345b1165],
18	ALK	NN	O	alk	nn	19	SENT_10	[p1l1355t1127r1425b1156],
19	inhibitors	NNS	O	inhibitor	prep_including	8	SENT_10	[p1l1434t1126r1612b1161],
20	,	,	O	,	_	0	SENT_10	[p1l1434t1126r1612b1161],
21	such	JJ	O	such	_	0	SENT_10	[p1l1621t1126r1700b1156],
22	as	IN	O	as	_	0	SENT_10	[p1l1710t1135r1746b1156],
23	LDK378	NN	O	ldk378	prep_such_as	19	SENT_10	[p1l1756t1127r1901b1161],
24	,	,	O	,	_	0	SENT_10	[p1l1756t1127r1901b1161],
25	CH5424802	NN	O	ch5424802	nn	28	SENT_10	[p1l1910t1127r2114b1156],
26	(	CD	NUMBER	(	num	28	SENT_10	[p1l21t1180r326b1215],
27	RO5424802802	NN	O	ro5424802802	nn	28	SENT_10	[p1l21t1180r326b1215],
28	)	NN	O	)	conj_and	23	SENT_10	[p1l21t1180r326b1215],
29	,	,	O	,	_	0	SENT_10	[p1l21t1180r326b1215],
30	and	CC	O	and	_	0	SENT_10	[p1l335t1179r400b1210],
31	AP261	NN	O	ap261	conj_and	23	SENT_10	[p1l410t1180r518b1210],
32	13	CD	NUMBER	13	num	31	SENT_10	[p1l529t1181r578b1215],
33	,	,	O	,	_	0	SENT_10	[p1l529t1181r578b1215],
34	and	CC	O	and	_	0	SENT_10	[p1l587t1179r652b1210],
35	heat	NN	O	heat	nn	37	SENT_10	[p1l663t1179r740b1210],
36	shock	NN	O	shock	nn	37	SENT_10	[p1l749t1179r852b1210],
37	protein	NN	O	protein	conj_and	19	SENT_10	[p1l860t1180r987b1218],
38	90	CD	NUMBER	90	num	39	SENT_10	[p1l997t1181r1039b1210],
39	inhibitors	NNS	O	inhibitor	dep	37	SENT_10	[p1l1049t1179r1227b1210],
40	.	.	O	.	_	0	SENT_10	[p1l1049t1179r1227b1210],

1	Anaplastic	JJ	O	anaplastic	dep	108	SENT_11	[p1l8t1374r368b1457],
2	lymphoma	NN	O	lymphoma	dep	108	SENT_11	[p1l387t1374r755b1458],
3	kinase	NN	O	kinase	dep	108	SENT_11	[p1l773t1374r989b1437],
4	(	NN	O	(	dep	108	SENT_11	[p1l1013t1374r1220b1451],
5	ALK	NN	O	alk	dep	108	SENT_11	[p1l1013t1374r1220b1451],
6	)	NN	O	)	dep	108	SENT_11	[p1l1013t1374r1220b1451],
7	was	VBD	O	be	dep	108	SENT_11	[p1l1242t1397r1368b1437],
8	originally	RB	O	originally	dep	108	SENT_11	[p1l1390t1374r1718b1458],
9	identiﬁed	VBN	O	identiﬁed	dep	108	SENT_11	[p1l1735t1374r2060b1437],
10	in	IN	O	in	dep	108	SENT_11	[p1l2079t1380r2145b1436],
11	1994	CD	DATE	1994	dep	108	SENT_11	[p1l15t1484r173b1540],
12	as	IN	O	as	dep	108	SENT_11	[p1l198t1500r263b1540],
13	the	DT	O	the	dep	108	SENT_11	[p1l286t1477r394b1540],
14	tyrosine	NN	O	tyrosine	dep	108	SENT_11	[p1l417t1483r700b1561],
15	kinase	NN	O	kinase	dep	108	SENT_11	[p1l722t1477r944b1540],
16	component	NN	O	component	dep	108	SENT_11	[p1l968t1489r1365b1560],
17	of	IN	O	of	dep	108	SENT_11	[p1l1388t1477r1464b1540],
18	a	DT	O	a	dep	108	SENT_11	[p1l1478t1500r1513b1540],
19	novel	JJ	O	novel	dep	108	SENT_11	[p1l1534t1477r1722b1540],
20	fusion	NN	O	fusion	dep	108	SENT_11	[p1l1745t1477r1962b1540],
21	gene	NN	O	gene	dep	108	SENT_11	[p1l1986t1500r2145b1561],
22	that	WDT	O	that	dep	108	SENT_11	[p1l8t1579r141b1642],
23	results	VBZ	O	result	dep	108	SENT_11	[p1l161t1579r380b1642],
24	from	IN	O	from	dep	108	SENT_11	[p1l401t1579r569b1642],
25	a	DT	O	a	dep	108	SENT_11	[p1l590t1602r625b1642],
26	chromosomal	JJ	O	chromosomal	dep	108	SENT_11	[p1l645t1579r1118b1642],
27	translocation	NN	O	translocation	dep	108	SENT_11	[p1l1137t1579r1588b1642],
28	in	IN	O	in	dep	108	SENT_11	[p1l1609t1585r1676b1641],
29	a	DT	O	a	dep	108	SENT_11	[p1l1697t1602r1731b1642],
30	rare	JJ	O	rare	dep	108	SENT_11	[p1l1751t1602r1883b1642],
31	human	JJ	O	human	dep	108	SENT_11	[p1l1904t1579r2146b1642],
32	lymphoma	NN	O	lymphoma	dep	108	SENT_11	[p1l7t1681r391b1765],
33	,	,	O	,	_	0	SENT_11	[p1l7t1681r391b1765],
34	anaplastic	JJ	O	anaplastic	dep	108	SENT_11	[p1l414t1681r748b1764],
35	large	JJ	O	large	dep	108	SENT_11	[p1l767t1681r1077b1765],
36	—	NN	O	—	dep	108	SENT_11	[p1l767t1681r1077b1765],
37	cell	NN	O	cell	dep	108	SENT_11	[p1l767t1681r1077b1765],
38	lymphoma	NN	O	lymphoma	dep	108	SENT_11	[p1l1095t1673r1508b1765],
39	.1	CD	NUMBER	.1	dep	108	SENT_11	[p1l1095t1673r1508b1765],
40	Activation	NN	O	activation	dep	108	SENT_11	[p1l1532t1685r1885b1744],
41	of	IN	O	of	dep	108	SENT_11	[p1l1906t1681r1979b1744],
42	ALK	NN	O	alk	dep	108	SENT_11	[p1l1986t1685r2152b1743],
43	by	IN	O	by	dep	108	SENT_11	[p1l7t1785r92b1869],
44	gene	NN	O	gene	dep	108	SENT_11	[p1l113t1808r274b1869],
45	rearrangements	NNS	O	rearrangement	dep	108	SENT_11	[p1l298t1797r851b1869],
46	or	CC	O	or	dep	108	SENT_11	[p1l877t1808r951b1848],
47	mutations	NNS	O	mutation	dep	108	SENT_11	[p1l973t1791r1328b1848],
48	has	VBZ	O	have	dep	108	SENT_11	[p1l1352t1785r1467b1848],
49	subsequently	RB	O	subsequently	dep	108	SENT_11	[p1l1493t1785r1956b1869],
50	been	VBN	O	be	dep	108	SENT_11	[p1l1974t1785r2143b1848],
51	described	VBN	O	describe	dep	108	SENT_11	[p1l9t1888r340b1951],
52	in	IN	O	in	dep	108	SENT_11	[p1l360t1894r426b1950],
53	other	JJ	O	other	dep	108	SENT_11	[p1l447t1888r628b1951],
54	tumors	NNS	O	tumor	dep	108	SENT_11	[p1l646t1900r910b1960],
55	,	,	O	,	_	0	SENT_11	[p1l646t1900r910b1960],
56	including	VBG	O	include	dep	108	SENT_11	[p1l932t1888r1258b1972],
57	a	DT	O	a	dep	108	SENT_11	[p1l1278t1911r1312b1951],
58	subset	NN	O	subset	dep	108	SENT_11	[p1l1333t1888r1546b1951],
59	of	IN	O	of	dep	108	SENT_11	[p1l1565t1888r1639b1951],
60	non	JJ	O	non	dep	108	SENT_11	[p1l1650t1888r2014b1951],
61	—	JJ	O	—	dep	108	SENT_11	[p1l1650t1888r2014b1951],
62	small	JJ	O	small	dep	108	SENT_11	[p1l1650t1888r2014b1951],
63	cell	NN	O	cell	dep	108	SENT_11	[p1l2034t1888r2147b1951],
64	lung	NN	O	lung	dep	108	SENT_11	[p1l7t1990r163b2074],
65	cancer	NN	O	cancer	dep	108	SENT_11	[p1l185t2013r413b2053],
66	(	CD	NUMBER	(	dep	108	SENT_11	[p1l439t1982r862b2067],
67	NSCLC	NN	O	nsclc	dep	108	SENT_11	[p1l439t1982r862b2067],
68	)	CD	NUMBER	)	dep	108	SENT_11	[p1l439t1982r862b2067],
69	.2	NN	NUMBER	.2	dep	108	SENT_11	[p1l439t1982r862b2067],
70	=	JJ	O	=	dep	108	SENT_11	[p1l439t1982r862b2067],
71	3	CD	NUMBER	3	dep	108	SENT_11	[p1l439t1982r862b2067],
72	NSCLC	NN	ORGANIZATION	nsclc	dep	108	SENT_11	[p1l886t1994r1154b2053],
73	tissues	NNS	O	tissue	dep	108	SENT_11	[p1l1177t1996r1406b2053],
74	harboring	VBG	O	harbor	dep	108	SENT_11	[p1l1429t1990r1781b2074],
75	ALK	NN	O	alk	dep	108	SENT_11	[p1l1798t1994r1968b2052],
76	gene	NN	O	gene	dep	108	SENT_11	[p1l1985t2013r2144b2074],
77	rearrangements	NNS	O	rearrangement	dep	108	SENT_11	[p1l9t2105r545b2177],
78	have	VBP	O	have	dep	108	SENT_11	[p1l565t2093r720b2156],
79	the	DT	O	the	dep	108	SENT_11	[p1l740t2093r846b2156],
80	characteristics	NNS	O	characteristic	dep	108	SENT_11	[p1l868t2093r1357b2156],
81	of	IN	O	of	dep	108	SENT_11	[p1l1378t2093r1452b2156],
82	“	NN	O	“	dep	108	SENT_11	[p1l1464t2093r2147b2177],
83	oncogene	NN	O	oncogene	dep	108	SENT_11	[p1l1464t2093r2147b2177],
84	—	NN	O	—	dep	108	SENT_11	[p1l1464t2093r2147b2177],
85	addicted	VBN	O	addict	dep	108	SENT_11	[p1l1464t2093r2147b2177],
86	tumors	NNS	O	tumor	dep	108	SENT_11	[p1l8t2196r301b2268],
87	,	,	O	,	_	0	SENT_11	[p1l8t2196r301b2268],
88	”	RB	O	”	dep	108	SENT_11	[p1l8t2196r301b2268],
89	as	IN	O	as	dep	108	SENT_11	[p1l327t2219r392b2259],
90	evidenced	VBN	O	evidence	dep	108	SENT_11	[p1l418t2196r772b2259],
91	by	IN	O	by	dep	108	SENT_11	[p1l793t2196r878b2280],
92	the	DT	O	the	dep	108	SENT_11	[p1l898t2196r1006b2259],
93	dramatic	JJ	O	dramatic	dep	108	SENT_11	[p1l1031t2196r1342b2259],
94	and	CC	O	and	dep	108	SENT_11	[p1l1367t2196r1496b2259],
95	durable	JJ	O	durable	dep	108	SENT_11	[p1l1519t2196r1782b2259],
96	responses	NNS	O	response	dep	108	SENT_11	[p1l1806t2218r2146b2279],
97	observed	VBN	O	observe	dep	108	SENT_11	[p1l9t2299r332b2362],
98	to	TO	O	to	dep	108	SENT_11	[p1l356t2311r424b2362],
99	the	DT	O	the	dep	108	SENT_11	[p1l450t2299r561b2362],
100	ﬁrst	NN	O	ﬁrst	dep	108	SENT_11	[p1l587t2299r1028b2362],
101	—	CD	NUMBER	—	dep	108	SENT_11	[p1l587t2299r1028b2362],
102	in-class	JJ	O	in-class	dep	108	SENT_11	[p1l587t2299r1028b2362],
103	ALK	NN	O	alk	dep	108	SENT_11	[p1l1054t2303r1222b2361],
104	tyrosine	NN	O	tyrosine	dep	108	SENT_11	[p1l1246t2305r1534b2383],
105	kinase	NN	O	kinase	dep	108	SENT_11	[p1l1560t2299r1786b2362],
106	inhibitor	NN	O	inhibitor	dep	108	SENT_11	[p1l1813t2299r2142b2371],
107	,	,	O	,	_	0	SENT_11	[p1l1813t2299r2142b2371],
108	crizotinib	NN	O	crizotinib	_	0	SENT_11	[p1l9t2401r355b2464],
109	.	.	O	.	_	0	SENT_11	[p1l9t2401r355b2464],

1	Crizotinib	NNP	O	Crizotinib	nsubjpass	4	SENT_12	[p1l380t2401r731b2464],
2	is	VBZ	O	be	auxpass	4	SENT_12	[p1l753t2407r803b2464],
3	now	RB	DATE	now	advmod	4	SENT_12	[p1l825t2424r973b2464],
4	established	VBN	O	establish	_	0	SENT_12	[p1l991t2401r1368b2464],
5	as	IN	O	as	_	0	SENT_12	[p1l1390t2424r1453b2464],
6	the	DT	O	the	det	7	SENT_12	[p1l1474t2401r1580b2464],
7	standard	NN	O	standard	prep_as	4	SENT_12	[p1l1603t2401r1901b2464],
8	of	IN	O	of	_	0	SENT_12	[p1l1922t2401r1995b2464],
9	care	NN	O	care	prep_of	7	SENT_12	[p1l2008t2424r2145b2464],
10	for	IN	O	for	_	0	SENT_12	[p1l8t2504r109b2567],
11	the	DT	O	the	det	12	SENT_12	[p1l130t2504r240b2567],
12	management	NN	O	management	prep_for	4	SENT_12	[p1l264t2516r723b2588],
13	of	IN	O	of	_	0	SENT_12	[p1l746t2504r822b2567],
14	ALK-positive	JJ	O	alk-positive	amod	15	SENT_12	[p1l835t2508r1311b2587],
15	NSCLC	NN	O	nsclc	prep_of	12	SENT_12	[p1l1334t2508r1622b2567],
16	.	.	O	.	_	0	SENT_12	[p1l1334t2508r1622b2567],

1	In	IN	O	in	_	0	SENT_13	[p1l1650t2509r1722b2566],
2	this	DT	O	this	det	3	SENT_13	[p1l1746t2504r1874b2567],
3	review	NN	O	review	prep_in	6	SENT_13	[p1l1899t2510r2142b2576],
4	,	,	O	,	_	0	SENT_13	[p1l1899t2510r2142b2576],
5	we	PRP	O	we	nsubj	6	SENT_13	[p1l7t2630r102b2670],
6	describe	VBP	O	describe	_	0	SENT_13	[p1l126t2607r417b2670],
7	the	DT	O	the	det	8	SENT_13	[p1l440t2607r549b2670],
8	biology	NN	O	biology	dobj	6	SENT_13	[p1l571t2607r838b2691],
9	and	CC	O	and	_	0	SENT_13	[p1l858t2607r987b2670],
10	clinical	JJ	O	clinical	amod	11	SENT_13	[p1l1011t2607r1262b2670],
11	features	NNS	O	feature	dobj	6	SENT_13	[p1l1285t2607r1557b2670],
12	of	IN	O	of	_	0	SENT_13	[p1l1582t2607r1658b2670],
13	ALK-positive	JJ	O	alk-positive	amod	14	SENT_13	[p1l1671t2611r2145b2690],
14	NSCLC	NN	O	nsclc	prep_of	11	SENT_13	[p1l8t2714r298b2782],
15	,	,	O	,	_	0	SENT_13	[p1l8t2714r298b2782],
16	outline	VBP	O	outline	conj_and	6	SENT_13	[p1l327t2710r575b2773],
17	the	DT	O	the	det	19	SENT_13	[p1l600t2710r710b2773],
18	therapeutic	JJ	O	therapeutic	amod	19	SENT_13	[p1l735t2710r1140b2793],
19	efforts	NNS	O	effort	dobj	16	SENT_13	[p1l1166t2710r1388b2773],
20	undertaken	VBN	O	undertake	partmod	19	SENT_13	[p1l1414t2710r1825b2773],
21	to	TO	O	to	aux	22	SENT_13	[p1l1849t2722r1917b2773],
22	target	VB	O	target	xcomp	20	SENT_13	[p1l1943t2722r2148b2794],
23	ALK	NN	O	alk	dobj	22	SENT_13	[p1l8t2817r171b2875],
24	with	IN	O	with	_	0	SENT_13	[p1l190t2813r343b2876],
25	crizotinib	NN	O	crizotinib	prep_with	16	SENT_13	[p1l366t2813r714b2885],
26	,	,	O	,	_	0	SENT_13	[p1l366t2813r714b2885],
27	detail	NN	O	detail	dep	16	SENT_13	[p1l739t2813r927b2876],
28	the	DT	O	the	det	29	SENT_13	[p1l948t2813r1055b2876],
29	mechanisms	NNS	O	mechanism	dobj	27	SENT_13	[p1l1077t2813r1505b2876],
30	of	IN	O	of	_	0	SENT_13	[p1l1529t2813r1603b2876],
31	acquired	VBN	O	acquire	amod	32	SENT_13	[p1l1617t2813r1914b2896],
32	resistance	NN	O	resistance	prep_of	29	SENT_13	[p1l1936t2819r2140b2876, p1l9t2939r163b2979],
33	to	TO	O	to	_	0	SENT_13	[p1l185t2928r251b2979],
34	crizotinib	NN	O	crizotinib	prep_to	32	SENT_13	[p1l277t2916r627b2988],
35	,	,	O	,	_	0	SENT_13	[p1l277t2916r627b2988],
36	and	CC	O	and	_	0	SENT_13	[p1l652t2916r780b2979],
37	ﬁnally	RB	O	ﬁnally	advmod	6	SENT_13	[p1l801t2916r1018b3000],
38	discuss	VBP	O	discuss	conj_and	6	SENT_13	[p1l1038t2916r1282b2979],
39	novel	JJ	O	novel	amod	40	SENT_13	[p1l1305t2916r1491b2979],
40	strategies	NNS	O	strategy	dobj	38	SENT_13	[p1l1514t2922r1833b3000],
41	to	TO	O	to	aux	42	SENT_13	[p1l1856t2928r1922b2979],
42	target	VB	O	target	xcomp	38	SENT_13	[p1l1945t2928r2144b3000],
43	ALK	NNP	O	ALK	nsubj	44	SENT_13	[p1l8t3023r173b3081],
44	using	VBG	O	use	dep	42	SENT_13	[p1l195t3025r383b3103],
45	second-generation	JJ	O	second-generation	amod	47	SENT_13	[p1l406t3019r1054b3103],
46	ALK	NN	O	alk	nn	47	SENT_13	[p1l1076t3023r1242b3081],
47	inhibitors	NNS	O	inhibitor	nsubj	56	SENT_13	[p1l1264t3019r1602b3082],
48	and	CC	O	and	_	0	SENT_13	[p1l1627t3019r1755b3082],
49	heat	NN	O	heat	nn	51	SENT_13	[p1l1776t3019r1923b3082],
50	shock	NN	O	shock	nn	51	SENT_13	[p1l1946t3019r2149b3082],
51	protein	NN	O	protein	nsubj	56	SENT_13	[p1l7t3128r256b3205],
52	90	CD	NUMBER	90	number	53	SENT_13	[p1l279t3129r356b3185],
53	(	CD	NUMBER	(	num	56	SENT_13	[p1l382t3123r668b3198],
54	HSP90	NN	O	hsp90	nn	56	SENT_13	[p1l382t3123r668b3198],
55	)	NN	O	)	nn	56	SENT_13	[p1l382t3123r668b3198],
56	inhibitors	NNS	O	inhibitor	xcomp	44	SENT_13	[p1l694t3122r1044b3185],
57	.	.	O	.	_	0	SENT_13	[p1l694t3122r1044b3185],

1	BIOLOGY	NN	O	biology	_	0	SENT_14	[p1l12t3336r337b3392],
2	OF	IN	O	of	_	0	SENT_14	[p1l355t3336r448b3392],
3	ALK	NNP	O	ALK	nn	6	SENT_14	[p1l467t3337r609b3391],
4	AND	CC	O	and	_	0	SENT_14	[p1l625t3337r785b3391],
5	ALK	NNP	O	ALK	nn	6	SENT_14	[p1l803t3337r946b3391],
6	FUSIONS	NNS	O	fusion	prep_of	1	SENT_14	[p1l964t3336r1280b3392],

1	The	DT	O	the	det	3	SENT_15	[p2l8t27r137b90],
2	ALK	NN	O	alk	nn	3	SENT_15	[p2l161t31r334b89],
3	gene	NN	O	gene	nsubj	10	SENT_15	[p2l354t50r517b111],
4	is	VBZ	O	be	cop	5	SENT_15	[p2l545t33r597b90],
5	located	JJ	O	located	_	0	SENT_15	[p2l624t27r883b90],
6	on	IN	O	on	_	0	SENT_15	[p2l910t50r999b90],
7	chromosome	NN	O	chromosome	nn	8	SENT_15	[p2l1027t27r1496b90],
8	2p	NN	O	2p	prep_on	5	SENT_15	[p2l1524t34r1608b110],
9	and	CC	O	and	_	0	SENT_15	[p2l1638t27r1769b90],
10	encodes	VBZ	O	encode	conj_and	5	SENT_15	[p2l1796t27r2083b90],
11	a	DT	O	a	det	15	SENT_15	[p2l2111t50r2147b90],
12	1,620	CD	NUMBER	1,620	num	15	SENT_15	[p2l15t136r185b202],
13	amino	NN	O	amino	nn	15	SENT_15	[p2l206t136r418b193],
14	acid	NN	O	acid	nn	15	SENT_15	[p2l440t130r576b193],
15	receptor	NN	O	receptor	nsubj	17	SENT_15	[p2l595t142r872b213],
16	tyrosine	NN	O	tyrosine	nn	17	SENT_15	[p2l889t136r1160b214],
17	kinase	NN	O	kinase	xcomp	10	SENT_15	[p2l1178t130r1391b193],
18	in	IN	O	in	_	0	SENT_15	[p2l1411t136r1475b192],
19	the	DT	O	the	det	22	SENT_15	[p2l1494t130r1598b193],
20	insulin	NN	O	insulin	nn	22	SENT_15	[p2l1618t130r1848b193],
21	receptor	NN	O	receptor	nn	22	SENT_15	[p2l1868t142r2145b213],
22	superfamily	NN	O	superfamily	prep_in	17	SENT_15	[p2l9t233r430b317],
23	.	.	O	.	_	0	SENT_15	[p2l9t233r430b317],

1	ALK	NNP	O	ALK	nsubj	5	SENT_16	[p2l455t237r620b295],
2	is	VBZ	O	be	cop	5	SENT_16	[p2l642t239r692b296],
3	most	RBS	O	most	advmod	5	SENT_16	[p2l716t245r888b296],
4	closely	RB	O	closely	advmod	5	SENT_16	[p2l910t233r1144b317],
5	related	JJ	O	related	_	0	SENT_16	[p2l1164t233r1398b296],
6	to	TO	O	to	_	0	SENT_16	[p2l1419t245r1486b296],
7	leukocyte	NN	O	leukocyte	nn	9	SENT_16	[p2l1509t233r1842b317],
8	tyrosine	NN	O	tyrosine	nn	9	SENT_16	[p2l1865t239r2145b317],
9	kinase	NN	O	kinase	prep_to	5	SENT_16	[p2l7t336r246b408],
10	,	,	O	,	_	0	SENT_16	[p2l7t336r246b408],
11	c-ros	NN	O	c-ro	nn	12	SENT_16	[p2l271t359r442b399],
12	oncogene	NN	O	oncogene	prep_to	5	SENT_16	[p2l467t359r797b420],
13	1	CD	NUMBER	1	number	14	SENT_16	[p2l827t343r852b398],
14	(	CD	NUMBER	(	num	16	SENT_16	[p2l885t336r1159b413],
15	ROS1	NN	O	ros1	nn	16	SENT_16	[p2l885t336r1159b413],
16	)	NN	O	)	dep	12	SENT_16	[p2l885t336r1159b413],
17	,	,	O	,	_	0	SENT_16	[p2l885t336r1159b413],
18	insulin	NN	O	insulin	nn	19	SENT_16	[p2l1184t336r1581b399],
19	—	NN	O	—	conj_and	9	SENT_16	[p2l1184t336r1581b399],
20	like	IN	O	like	_	0	SENT_16	[p2l1184t336r1581b399],
21	growth	NN	O	growth	nn	23	SENT_16	[p2l1604t336r1850b420],
22	factor	NN	O	factor	nn	23	SENT_16	[p2l1873t336r2139b399],
23	—	NN	O	—	prep_like	19	SENT_16	[p2l1873t336r2139b399],
24	1	CD	NUMBER	1	num	25	SENT_16	[p2l1873t336r2139b399],
25	receptor	NN	O	receptor	dep	19	SENT_16	[p2l8t451r313b522],
26	,	,	O	,	_	0	SENT_16	[p2l8t451r313b522],
27	and	CC	O	and	_	0	SENT_16	[p2l340t439r470b502],
28	the	DT	O	the	det	30	SENT_16	[p2l492t439r602b502],
29	insulin	NN	O	insulin	nn	30	SENT_16	[p2l627t439r870b502],
30	receptor	NN	O	receptor	conj_and	9	SENT_16	[p2l895t451r1199b522],
31	.	.	O	.	_	0	SENT_16	[p2l895t451r1199b522],

1	Like	IN	O	like	_	0	SENT_17	[p2l1227t439r1376b502],
2	other	JJ	O	other	amod	6	SENT_17	[p2l1401t439r1589b502],
3	classic	JJ	O	classic	amod	6	SENT_17	[p2l1612t439r1835b502],
4	receptor	NN	O	receptor	nn	6	SENT_17	[p2l1859t451r2152b522],
5	tyrosine	NN	O	tyrosine	nn	6	SENT_17	[p2l6t548r282b626],
6	kinases	NNS	O	kinase	prep_like	12	SENT_17	[p2l301t542r568b614],
7	,	,	O	,	_	0	SENT_17	[p2l301t542r568b614],
8	the	DT	O	the	det	11	SENT_17	[p2l588t542r695b605],
9	native	JJ	O	native	amod	11	SENT_17	[p2l715t548r919b605],
10	ALK	NN	O	alk	nn	11	SENT_17	[p2l938t546r1101b604],
11	protein	NN	O	protein	nsubj	12	SENT_17	[p2l1119t548r1366b625],
12	consists	VBZ	O	consist	_	0	SENT_17	[p2l1387t548r1651b605],
13	of	IN	O	of	_	0	SENT_17	[p2l1673t542r1746b605],
14	an	DT	O	a	det	17	SENT_17	[p2l1758t565r1837b605],
15	extracellular	JJ	O	extracellular	amod	17	SENT_17	[p2l1858t542r2149b605, p2l6t645r168b708],
16	ligand-binding	JJ	O	ligand-binding	amod	17	SENT_17	[p2l189t645r720b729],
17	domain	NN	O	domain	prep_of	12	SENT_17	[p2l742t645r1031b717],
18	,	,	O	,	_	0	SENT_17	[p2l742t645r1031b717],
19	a	DT	O	a	det	22	SENT_17	[p2l1058t668r1093b708],
20	short	JJ	O	short	amod	22	SENT_17	[p2l1117t645r1298b708],
21	transmembrane	NN	O	transmembrane	nn	22	SENT_17	[p2l1320t645r1880b708],
22	region	NN	O	region	prep_of	12	SENT_17	[p2l1905t651r2148b729],
23	,	,	O	,	_	0	SENT_17	[p2l1905t651r2148b729],
24	and	CC	O	and	_	0	SENT_17	[p2l8t748r134b811],
25	an	DT	O	a	det	29	SENT_17	[p2l156t771r236b811],
26	intracellular	JJ	O	intracellular	amod	29	SENT_17	[p2l258t748r676b811],
27	tyrosine	NN	O	tyrosine	nn	29	SENT_17	[p2l696t754r974b832],
28	kinase	NN	O	kinase	nn	29	SENT_17	[p2l994t748r1213b811],
29	domain	NN	O	domain	conj_and	17	SENT_17	[p2l1235t748r1515b811],
30	.	.	O	.	_	0	SENT_17	[p2l1235t748r1515b811],

1	The	DT	O	the	det	4	SENT_18	[p2l81t850r206b914],
2	normal	JJ	O	normal	amod	4	SENT_18	[p2l227t850r478b914],
3	physiological	JJ	O	physiological	amod	4	SENT_18	[p2l497t850r951b935],
4	role	NN	O	role	nsubjpass	9	SENT_18	[p2l971t850r1100b914],
5	of	IN	O	of	_	0	SENT_18	[p2l1122t850r1196b914],
6	ALK	NNP	O	ALK	prep_of	4	SENT_18	[p2l1206t854r1369b913],
7	is	VBZ	O	be	auxpass	9	SENT_18	[p2l1388t857r1439b914],
8	poorly	RB	O	poorly	advmod	9	SENT_18	[p2l1459t850r1687b935],
9	understood	VBN	O	understand	_	0	SENT_18	[p2l1704t842r2151b914],
10	.4	CD	NUMBER	.4	num	11	SENT_18	[p2l1704t842r2151b914],
11	Activation	NN	O	activation	nsubjpass	13	SENT_18	[p2l6t958r363b1017],
12	is	VBZ	O	be	auxpass	13	SENT_18	[p2l384t960r433b1017],
13	believed	VBN	O	believe	ccomp	9	SENT_18	[p2l453t954r737b1017],
14	to	TO	O	to	aux	15	SENT_18	[p2l755t966r821b1017],
15	occur	VB	O	occur	xcomp	13	SENT_18	[p2l843t977r1036b1017],
16	through	IN	O	through	_	0	SENT_18	[p2l1054t954r1331b1038],
17	ligand-induced	JJ	O	ligand-induced	amod	20	SENT_18	[p2l1350t954r1873b1038],
18	dimeri	JJ	O	dimeri	amod	20	SENT_18	[p2l1893t954r2148b1017],
19	—	NN	O	—	nn	20	SENT_18	[p2l1893t954r2148b1017],
20	zation	NN	O	zation	prep_through	15	SENT_18	[p2l8t1063r240b1120],
21	.	.	O	.	_	0	SENT_18	[p2l8t1063r240b1120],

1	ALK	NN	O	alk	nn	2	SENT_19	[p2l266t1061r433b1119],
2	ligands	NNS	O	ligand	nsubjpass	5	SENT_19	[p2l454t1057r705b1141],
3	have	VBP	O	have	aux	5	SENT_19	[p2l728t1057r888b1120],
4	been	VBN	O	be	auxpass	5	SENT_19	[p2l910t1057r1078b1120],
5	identiﬁed	VBN	O	identiﬁed	_	0	SENT_19	[p2l1102t1057r1439b1120],
6	in	IN	O	in	_	0	SENT_19	[p2l1462t1063r1530b1119],
7	Drosophila	FW	O	drosophila	nn	11	SENT_19	[p2l1552t1057r1932b1141],
8	melanogaster	FW	O	melanogaster	nn	11	SENT_19	[p2l1959t1057r2149b1120, p2l10t1171r304b1244],
9	(	FW	O	(	nn	11	SENT_19	[p2l329t1159r715b1244],
10	Ielly	FW	O	ielly	nn	11	SENT_19	[p2l329t1159r715b1244],
11	—	FW	O	—	prep_in	5	SENT_19	[p2l329t1159r715b1244],
12	belly	NN	O	belly	dep	11	SENT_19	[p2l329t1159r715b1244],
13	or	CC	O	or	_	0	SENT_19	[p2l737t1182r811b1223],
14	Ieb	NN	O	ieb	prep_in	5	SENT_19	[p2l835t1151r1054b1237],
15	)	CD	NUMBER	)	num	14	SENT_19	[p2l835t1151r1054b1237],
16	5	CD	NUMBER	5	num	22	SENT_19	[p2l835t1151r1054b1237],
17	’	NN	O	’	nn	22	SENT_19	[p2l835t1151r1054b1237],
18	6	CD	NUMBER	6	num	17	SENT_19	[p2l835t1151r1054b1237],
19	and	CC	O	and	_	0	SENT_19	[p2l1080t1159r1210b1223],
20	in	IN	O	in	nn	22	SENT_19	[p2l1235t1166r1304b1222],
21	Caenorhabditis	NN	LOCATION	caenorhabditis	pobj	20	SENT_19	[p2l1330t1159r1878b1223],
22	elegans	NNS	O	elegan	nsubj	23	SENT_19	[p2l1905t1159r2151b1244],
23	(	VBP	O	(	rcmod	14	SENT_19	[p2l11t1256r376b1341],
24	HEN-1	NN	O	hen-1	dobj	23	SENT_19	[p2l11t1256r376b1341],
25	)	CD	NUMBER	)	number	26	SENT_19	[p2l11t1256r376b1341],
26	,7	CD	NUMBER	,7	dep	14	SENT_19	[p2l11t1256r376b1341],
27	but	CC	O	but	prep	26	SENT_19	[p2l397t1263r513b1327],
28	no	DT	O	no	det	29	SENT_19	[p2l535t1286r623b1327],
29	Ieb/HEN	NN	O	ieb/hen	dep	27	SENT_19	[p2l648t1263r1200b1340],
30	-1	CD	NUMBER	-1	num	31	SENT_19	[p2l648t1263r1200b1340],
31	—	CD	NUMBER	—	nsubjpass	37	SENT_19	[p2l648t1263r1200b1340],
32	like	IN	O	like	_	0	SENT_19	[p2l648t1263r1200b1340],
33	ligand	NN	O	ligand	prep_like	31	SENT_19	[p2l1223t1263r1442b1348],
34	has	VBZ	O	have	aux	37	SENT_19	[p2l1463t1263r1577b1327],
35	yet	RB	O	yet	advmod	37	SENT_19	[p2l1600t1275r1704b1348],
36	been	VBN	O	be	auxpass	37	SENT_19	[p2l1724t1263r1892b1327],
37	identiﬁed	VBN	O	identiﬁed	rcmod	29	SENT_19	[p2l1915t1263r2146b1327, p2l7t1367r131b1430],
38	in	IN	O	in	_	0	SENT_19	[p2l150t1373r215b1429],
39	vertebrates	NNS	O	vertebrate	prep_in	37	SENT_19	[p2l232t1367r617b1430],
40	.	.	O	.	_	0	SENT_19	[p2l232t1367r617b1430],

1	The	DT	O	the	det	4	SENT_20	[p2l639t1367r763b1430],
2	growth	NN	O	growth	nn	4	SENT_20	[p2l783t1367r1022b1451],
3	factors	NNS	O	factor	nn	4	SENT_20	[p2l1041t1367r1265b1430],
4	pleiotrophin	NN	O	pleiotrophin	nsubjpass	9	SENT_20	[p2l1284t1367r1705b1450],
5	and	CC	O	and	_	0	SENT_20	[p2l1726t1367r1849b1430],
6	midkine	NN	O	midkine	nsubjpass	9	SENT_20	[p2l1868t1367r2149b1430],
7	have	VBP	O	have	aux	9	SENT_20	[p2l6t1470r163b1533],
8	been	VBN	O	be	auxpass	9	SENT_20	[p2l184t1470r349b1533],
9	proposed	VBN	O	propose	_	0	SENT_20	[p2l371t1470r696b1553],
10	as	IN	O	as	_	0	SENT_20	[p2l719t1493r783b1533],
11	ligands	NNS	O	ligand	prep_as	9	SENT_20	[p2l806t1470r1051b1554],
12	for	IN	O	for	_	0	SENT_20	[p2l1075t1470r1173b1533],
13	mammalian	JJ	O	mammalian	amod	14	SENT_20	[p2l1194t1470r1612b1533],
14	ALK	NN	O	alk	prep_for	11	SENT_20	[p2l1634t1474r1798b1532],
15	and	CC	O	and	_	0	SENT_20	[p2l1820t1470r1947b1533],
16	other	JJ	O	other	amod	19	SENT_20	[p2l1970t1470r2153b1533],
17	receptor	NN	O	receptor	nn	19	SENT_20	[p2l7t1585r285b1656],
18	tyrosine	NN	O	tyrosine	nn	19	SENT_20	[p2l302t1579r573b1657],
19	kinases	NNS	O	kinase	conj_and	14	SENT_20	[p2l591t1573r853b1645],
20	,	,	O	,	_	0	SENT_20	[p2l591t1573r853b1645],
21	but	CC	O	but	_	0	SENT_20	[p2l872t1573r983b1636],
22	their	PRP$	O	they	poss	23	SENT_20	[p2l1001t1573r1160b1636],
23	role	NN	O	role	nsubj	35	SENT_20	[p2l1179t1573r1304b1636],
24	in	IN	O	in	_	0	SENT_20	[p2l1324t1579r1390b1635],
25	activating	VBG	O	activate	prepc_in	23	SENT_20	[p2l1410t1579r1737b1657],
26	ALK	NNP	O	ALK	nsubj	32	SENT_20	[p2l1754t1577r1914b1635],
27	is	VBZ	O	be	cop	32	SENT_20	[p2l1932t1579r1981b1636],
28	controversial	JJ	O	controversial	amod	32	SENT_20	[p2l2002t1596r2149b1636, p2l6t1668r368b1740],
29	.4	CD	NUMBER	.4	tmod	28	SENT_20	[p2l2002t1596r2149b1636, p2l6t1668r368b1740],
30	The	DT	O	the	det	32	SENT_20	[p2l387t1676r509b1740],
31	expression	NN	O	expression	nn	32	SENT_20	[p2l530t1683r882b1760],
32	pattern	NN	O	pattern	ccomp	25	SENT_20	[p2l901t1688r1142b1760],
33	of	IN	O	of	_	0	SENT_20	[p2l1162t1676r1234b1740],
34	ALK	NN	ORGANIZATION	alk	prep_of	32	SENT_20	[p2l1243t1680r1403b1739],
35	suggests	VBZ	O	suggest	conj_but	9	SENT_20	[p2l1422t1688r1694b1761],
36	an	DT	O	a	det	38	SENT_20	[p2l1715t1699r1793b1740],
37	important	JJ	O	important	amod	38	SENT_20	[p2l1813t1683r2152b1760],
38	role	NN	O	role	dobj	35	SENT_20	[p2l8t1780r136b1843],
39	in	IN	O	in	_	0	SENT_20	[p2l158t1786r225b1842],
40	the	DT	O	the	det	41	SENT_20	[p2l244t1780r351b1843],
41	development	NN	O	development	prep_in	38	SENT_20	[p2l373t1780r819b1863],
42	of	IN	O	of	_	0	SENT_20	[p2l839t1780r913b1843],
43	the	DT	O	the	det	45	SENT_20	[p2l924t1780r1030b1843],
44	nervous	JJ	O	nervous	amod	45	SENT_20	[p2l1052t1803r1326b1843],
45	system	NN	O	system	prep_of	41	SENT_20	[p2l1349t1792r1598b1864],
46	.	.	O	.	_	0	SENT_20	[p2l1349t1792r1598b1864],

1	However	RB	O	however	advmod	6	SENT_21	[p2l1623t1785r1943b1852],
2	,	,	O	,	_	0	SENT_21	[p2l1623t1785r1943b1852],
3	ALKknockout	NN	O	alkknockout	nn	4	SENT_21	[p2l1961t1784r2149b1842, p2l6t1883r324b1946],
4	mice	NNS	O	mouse	nsubj	6	SENT_21	[p2l342t1889r501b1946],
5	are	VBP	O	be	cop	6	SENT_21	[p2l522t1906r620b1946],
6	viable	JJ	O	viable	_	0	SENT_21	[p2l636t1883r833b1946],
7	and	CC	O	and	_	0	SENT_21	[p2l853t1883r976b1946],
8	exhibit	VBP	O	exhibit	conj_and	6	SENT_21	[p2l995t1883r1224b1946],
9	no	DT	O	no	dep	10	SENT_21	[p2l1242t1906r1326b1946],
10	apparent	JJ	O	apparent	dep	11	SENT_21	[p2l1348t1895r1640b1966],
11	developmental	JJ	O	developmental	dobj	8	SENT_21	[p2l1658t1883r2150b1966],
12	or	CC	O	or	_	0	SENT_21	[p2l8t2009r81b2049],
13	tissue	NN	O	tissue	nn	14	SENT_21	[p2l102t1992r297b2049],
14	abnormalities	NNS	O	abnormality	dobj	8	SENT_21	[p2l321t1986r814b2049],
15	.	.	O	.	_	0	SENT_21	[p2l321t1986r814b2049],

1	More	RBR	O	more	advmod	2	SENT_22	[p2l840t1991r1025b2049],
2	extensive	JJ	O	extensive	amod	3	SENT_22	[p2l1049t1992r1366b2049],
3	analyses	NNS	O	analysis	nsubj	8	SENT_22	[p2l1390t1986r1674b2070],
4	of	IN	O	of	_	0	SENT_22	[p2l1698t1986r1773b2049],
5	these	DT	O	these	det	6	SENT_22	[p2l1785t1986r1963b2049],
6	mice	NNS	O	mouse	prep_of	3	SENT_22	[p2l1986t1992r2152b2049],
7	have	VBP	O	have	aux	8	SENT_22	[p2l6t2090r165b2153],
8	revealed	VBN	O	reveal	_	0	SENT_22	[p2l189t2090r481b2153],
9	only	RB	O	only	advmod	11	SENT_22	[p2l504t2090r658b2174],
10	age-related	JJ	O	age-related	amod	11	SENT_22	[p2l679t2090r1064b2174],
11	increases	NNS	O	increase	dobj	8	SENT_22	[p2l1086t2096r1402b2153],
12	in	IN	O	in	_	0	SENT_22	[p2l1427t2096r1494b2152],
13	hippocampal	JJ	O	hippocampal	amod	15	SENT_22	[p2l1517t2090r1978b2173],
14	progenitor	NN	O	progenitor	nn	15	SENT_22	[p2l2000t2112r2147b2173, p2l7t2199r252b2277],
15	cells	NNS	O	cell	prep_in	8	SENT_22	[p2l274t2192r418b2256],
16	and	CC	O	and	_	0	SENT_22	[p2l440t2192r567b2256],
17	changes	NNS	O	change	prep_in	8	SENT_22	[p2l588t2192r858b2277],
18	in	IN	O	in	_	0	SENT_22	[p2l881t2199r948b2255],
19	behavioral	JJ	O	behavioral	amod	20	SENT_22	[p2l967t2192r1329b2256],
20	testing	NN	O	testing	prep_in	15	SENT_22	[p2l1350t2184r1629b2277],
21	.8	CD	NUMBER	.8	tmod	15	SENT_22	[p2l1350t2184r1629b2277],

1	Oncogenic	JJ	MISC	oncogenic	amod	2	SENT_23	[p2l82t2300r465b2380],
2	activation	NN	O	activation	nsubj	5	SENT_23	[p2l489t2302r837b2359],
3	of	IN	O	of	_	0	SENT_23	[p2l861t2296r937b2359],
4	ALK	NN	O	alk	prep_of	2	SENT_23	[p2l951t2300r1118b2358],
5	occurs	VBZ	O	occur	_	0	SENT_23	[p2l1141t2319r1371b2359],
6	in	IN	O	in	_	0	SENT_23	[p2l1395t2302r1464b2358],
7	a	DT	O	a	det	8	SENT_23	[p2l1488t2319r1524b2359],
8	variety	NN	O	variety	prep_in	5	SENT_23	[p2l1543t2302r1790b2380],
9	of	IN	O	of	_	0	SENT_23	[p2l1810t2296r1886b2359],
10	human	JJ	O	human	amod	11	SENT_23	[p2l1900t2296r2149b2359],
11	malignancies	NNS	O	malignancy	prep_of	8	SENT_23	[p2l7t2399r490b2483],
12	.	.	O	.	_	0	SENT_23	[p2l7t2399r490b2483],

1	In	IN	O	in	_	0	SENT_24	[p2l517t2404r590b2461],
2	most	JJS	O	most	amod	3	SENT_24	[p2l614t2411r788b2462],
3	cases	NNS	O	case	prep_in	8	SENT_24	[p2l812t2422r1007b2471],
4	,	,	O	,	_	0	SENT_24	[p2l812t2422r1007b2471],
5	ALK	NNP	O	ALK	nsubjpass	8	SENT_24	[p2l1032t2403r1199b2461],
6	is	VBZ	O	be	auxpass	8	SENT_24	[p2l1222t2405r1273b2462],
7	aberrantly	RB	O	aberrantly	advmod	8	SENT_24	[p2l1298t2399r1663b2483],
8	activated	VBN	O	activate	_	0	SENT_24	[p2l1684t2399r2000b2462],
9	due	JJ	O	due	_	0	SENT_24	[p2l2023t2399r2149b2462],
10	to	TO	O	to	_	0	SENT_24	[p2l6t2514r73b2565],
11	chromosomal	JJ	O	chromosomal	amod	12	SENT_24	[p2l99t2502r583b2565],
12	rearrangement	NN	O	rearrangement	prep_due_to	8	SENT_24	[p2l606t2514r1142b2586],
13	,	,	O	,	_	0	SENT_24	[p2l606t2514r1142b2586],
14	either	CC	O	either	dep	8	SENT_24	[p2l1167t2502r1369b2565],
15	an	DT	O	a	det	17	SENT_24	[p2l1392t2525r1474b2565],
16	intrachromosomal	JJ	O	intrachromosomal	amod	17	SENT_24	[p2l1497t2502r2151b2565],
17	inversion	NN	O	inversion	conj	8	SENT_24	[p2l7t2611r330b2669],
18	or	CC	O	or	_	0	SENT_24	[p2l353t2628r426b2669],
19	an	DT	O	a	det	21	SENT_24	[p2l449t2628r529b2669],
20	interchromosomal	JJ	O	interchromosomal	amod	21	SENT_24	[p2l553t2605r1199b2669],
21	translocation	NN	O	translocation	conj	8	SENT_24	[p2l1220t2605r1696b2669],
22	.	.	O	.	_	0	SENT_24	[p2l1220t2605r1696b2669],

1	First	JJ	ORDINAL	first	advmod	2	SENT_25	[p2l1723t2610r1879b2669],
2	discovered	VBN	O	discover	_	0	SENT_25	[p2l1902t2605r2150b2669, p2l8t2708r157b2772],
3	in	IN	O	in	_	0	SENT_25	[p2l179t2715r247b2771],
4	anaplasticlarge-celllymphoma	NN	O	anaplasticlarge-celllymphoma	prep_in	2	SENT_25	[p2l271t2700r1591b2793],
5	,1	CD	NUMBER	,1	num	8	SENT_25	[p2l271t2700r1591b2793],
6	ALK	NN	O	alk	nn	8	SENT_25	[p2l271t2700r1591b2793],
7	gene	NN	O	gene	nn	8	SENT_25	[p2l1607t2731r1765b2793],
8	rearrangements	NNS	O	rearrangement	nsubjpass	12	SENT_25	[p2l1788t2731r2148b2793, p2l7t2824r216b2875],
9	have	VBP	O	have	aux	12	SENT_25	[p2l238t2812r395b2875],
10	since	IN	O	since	advmod	12	SENT_25	[p2l419t2818r590b2875],
11	been	VBN	O	be	auxpass	12	SENT_25	[p2l611t2812r777b2875],
12	found	VBN	O	find	rcmod	4	SENT_25	[p2l800t2812r1005b2875],
13	in	IN	O	in	_	0	SENT_25	[p2l1027t2818r1094b2874],
14	inﬂammatory	JJ	O	inﬂammatory	amod	15	SENT_25	[p2l1117t2812r1596b2896],
15	myoﬁbroblastic	JJ	O	myoﬁbroblastic	prep_in	12	SENT_25	[p2l1615t2812r2152b2896],

1	‘	NNP	O	‘	nn	2	SENT_26	[p2l21t2943r191b2976],
2	Department	NNP	ORGANIZATION	Department	_	0	SENT_26	[p2l21t2943r191b2976],
3	of	IN	ORGANIZATION	of	_	0	SENT_26	[p2l198t2946r224b2970],
4	Medical	NNP	ORGANIZATION	Medical	nn	5	SENT_26	[p2l230t2946r328b2970],
5	Oncology	NNP	ORGANIZATION	Oncology	prep_of	2	SENT_26	[p2l337t2947r466b2976],
6	,	,	O	,	_	0	SENT_26	[p2l337t2947r466b2976],
7	Peter	NNP	PERSON	Peter	nn	8	SENT_26	[p2l475t2948r540b2970],
8	MacCa	NNP	PERSON	MacCa	nsubj	9	SENT_26	[p2l547t2946r689b2970],
9	|	VBD	O	|	dep	2	SENT_26	[p2l547t2946r689b2970],
10	|	CD	NUMBER	|	num	13	SENT_26	[p2l547t2946r689b2970],
11	um	NN	O	um	nn	13	SENT_26	[p2l547t2946r689b2970],
12	Cancer	NN	O	cancer	nn	13	SENT_26	[p2l697t2947r786b2970],
13	Centre	NNP	O	Centre	dobj	9	SENT_26	[p2l793t2947r883b2973],
14	,	,	O	,	_	0	SENT_26	[p2l793t2947r883b2973],
15	East	NNP	LOCATION	East	nn	16	SENT_26	[p2l892t2948r942b2970],
16	Melbourne	NNP	LOCATION	Melbourne	appos	13	SENT_26	[p2l950t2946r1097b2973],
17	,	,	O	,	_	0	SENT_26	[p2l950t2946r1097b2973],
18	Australia	NNP	LOCATION	Australia	appos	16	SENT_26	[p2l1104t2946r1223b2973],
19	;	:	O	;	_	0	SENT_26	[p2l1104t2946r1223b2973],
20	2Sir	NNP	O	2Sir	nn	22	SENT_26	[p2l1229t2943r1273b2970],
21	Peter	NNP	PERSON	Peter	nn	22	SENT_26	[p2l1281t2948r1346b2970],
22	MacCa	NNP	PERSON	MacCa	nsubj	23	SENT_26	[p2l1353t2946r1495b2970],
23	|	VBD	O	|	parataxis	9	SENT_26	[p2l1353t2946r1495b2970],
24	|	CD	NUMBER	|	dobj	23	SENT_26	[p2l1353t2946r1495b2970],
25	um	NNP	O	um	nn	27	SENT_26	[p2l1353t2946r1495b2970],
26	Department	NNP	O	Department	nn	27	SENT_26	[p2l1505t2948r1662b2976],
27	ofOnco	NNP	O	ofOnco	nsubj	28	SENT_26	[p2l1669t2946r1830b2976],
28	|	VBD	O	|	rcmod	24	SENT_26	[p2l1669t2946r1830b2976],
29	ogy	NN	O	ogy	dobj	28	SENT_26	[p2l1669t2946r1830b2976],
30	,	,	O	,	_	0	SENT_26	[p2l1669t2946r1830b2976],
31	University	NNP	ORGANIZATION	University	appos	2	SENT_26	[p2l1839t2948r1967b2976],
32	of	IN	ORGANIZATION	of	_	0	SENT_26	[p2l1973t2946r2000b2970],
33	Melbourne	NNP	ORGANIZATION	Melbourne	prep_of	31	SENT_26	[p2l21t2984r168b3011],
34	,	,	O	,	_	0	SENT_26	[p2l21t2984r168b3011],
35	Melbourne	NNP	LOCATION	Melbourne	appos	2	SENT_26	[p2l176t2984r323b3011],
36	,	,	O	,	_	0	SENT_26	[p2l176t2984r323b3011],
37	Australia	NNP	LOCATION	Australia	appos	2	SENT_26	[p2l330t2984r449b3011],
38	;	:	O	;	_	0	SENT_26	[p2l330t2984r449b3011],
39	3Pﬁzer	NNP	O	3Pﬁzer	dep	2	SENT_26	[p2l456t2981r543b3011],
40	,	,	O	,	_	0	SENT_26	[p2l456t2981r543b3011],
41	La	NNP	LOCATION	La	nn	42	SENT_26	[p2l551t2986r577b3007],
42	Jolla	NNP	LOCATION	Jolla	appos	39	SENT_26	[p2l584t2984r648b3011],
43	,	,	O	,	_	0	SENT_26	[p2l584t2984r648b3011],
44	California	NNP	LOCATION	California	appos	2	SENT_26	[p2l656t2984r784b3011],
45	,	,	O	,	_	0	SENT_26	[p2l656t2984r784b3011],
46	USA	NNP	LOCATION	USA	appos	2	SENT_26	[p2l792t2985r850b3011],
47	;	:	O	;	_	0	SENT_26	[p2l792t2985r850b3011],
48	‘	NNP	O	‘	nn	49	SENT_26	[p2l856t2981r1028b3013],
49	Department	NNP	ORGANIZATION	Department	dep	2	SENT_26	[p2l856t2981r1028b3013],
50	of	IN	ORGANIZATION	of	_	0	SENT_26	[p2l1035t2984r1061b3007],
51	Medicine	NNP	ORGANIZATION	Medicine	prep_of	49	SENT_26	[p2l1067t2984r1191b3011],
52	,	,	O	,	_	0	SENT_26	[p2l1067t2984r1191b3011],
53	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	57	SENT_26	[p2l1199t2984r1386b3007],
54	General	NNP	ORGANIZATION	General	nn	57	SENT_26	[p2l1393t2984r1492b3007],
55	Hospital	NNP	ORGANIZATION	Hospital	nn	57	SENT_26	[p2l1501t2984r1605b3013],
56	Cancer	NNP	ORGANIZATION	Cancer	nn	57	SENT_26	[p2l1613t2985r1702b3007],
57	Center	NNP	ORGANIZATION	Center	appos	2	SENT_26	[p2l1708t2985r1798b3011],
58	,	,	O	,	_	0	SENT_26	[p2l1708t2985r1798b3011],
59	Boston	NNP	LOCATION	Boston	appos	2	SENT_26	[p2l1806t2985r1901b3011],
60	,	,	O	,	_	0	SENT_26	[p2l1806t2985r1901b3011],
61	Massachusetts	NNP	LOCATION	Massachusetts	appos	2	SENT_26	[p2l1909t2984r2102b3011],
62	,	,	O	,	_	0	SENT_26	[p2l1909t2984r2102b3011],
63	USA	NNP	LOCATION	USA	appos	2	SENT_26	[p2l21t3022r79b3044],
64	.	.	O	.	_	0	SENT_26	[p2l21t3022r79b3044],

1	Correspondence	NN	O	correspondence	nsubj	15	SENT_27	[p2l87t3021r307b3050],
2	:	:	O	:	_	0	SENT_27	[p2l87t3021r307b3050],
3	AT	IN	ORGANIZATION	at	_	0	SENT_27	[p2l314t3022r345b3044],
4	Shaw	NNP	ORGANIZATION	Shaw	nn	6	SENT_27	[p2l352t3021r421b3044],
5	(	CD	NUMBER	(	num	6	SENT_27	[p2l428t3021r528b3047],
6	ashawl	NN	O	ashawl	prep_at	1	SENT_27	[p2l428t3021r528b3047],
7	@partners.org	NN	O	@partners.org	dep	6	SENT_27	[p2l535t3021r725b3050],
8	)	CD	NUMBER	)	num	7	SENT_27	[p2l535t3021r725b3050],
9	Received	VBN	O	receive	partmod	6	SENT_27	[p2l21t3062r130b3085],
10	6	CD	DATE	6	num	11	SENT_27	[p2l138t3064r152b3085],
11	September	NNP	DATE	September	dobj	9	SENT_27	[p2l159t3062r297b3091],
12	201	CD	NUMBER	201	num	11	SENT_27	[p2l304t3064r342b3085],
13	3	CD	NUMBER	3	dep	11	SENT_27	[p2l350t3064r368b3089],
14	;	:	O	;	_	0	SENT_27	[p2l350t3064r368b3089],
15	accepted	VBN	O	accept	_	0	SENT_27	[p2l375t3062r488b3091],
16	25	CD	DATE	25	num	17	SENT_27	[p2l497t3064r524b3085],
17	September	NNP	DATE	September	dobj	15	SENT_27	[p2l533t3062r671b3091],
18	201	CD	NUMBER	201	num	17	SENT_27	[p2l678t3064r716b3085],
19	3	CD	NUMBER	3	dep	17	SENT_27	[p2l723t3064r742b3089],
20	;	:	O	;	_	0	SENT_27	[p2l723t3064r742b3089],
21	advance	NN	O	advance	dep	17	SENT_27	[p2l749t3062r852b3085],
22	online	NN	O	online	prep	21	SENT_27	[p2l860t3062r936b3085],
23	publication	NN	O	publication	dep	22	SENT_27	[p2l945t3062r1083b3091],
24	13	CD	DATE	13	num	23	SENT_27	[p2l1094t3064r1119b3085],
25	November	NNP	DATE	November	tmod	21	SENT_27	[p2l1129t3062r1259b3085],
26	201	CD	NUMBER	201	num	25	SENT_27	[p2l1266t3064r1304b3085],
27	3	CD	NUMBER	3	dep	17	SENT_27	[p2l1312t3064r1330b3085],
28	.	.	O	.	_	0	SENT_27	[p2l1312t3064r1330b3085],

1	doizl	NN	O	doizl	nn	3	SENT_28	[p2l1337t3062r1391b3085],
2	O.l	NN	O	o.l	nn	3	SENT_28	[p2l1398t3064r1427b3085],
3	O38/c	NN	O	o38/c	dep	10	SENT_28	[p2l1434t3062r1582b3091],
4	|	CD	NUMBER	|	num	5	SENT_28	[p2l1434t3062r1582b3091],
5	pt	NN	O	pt	dep	3	SENT_28	[p2l1434t3062r1582b3091],
6	.20	CD	NUMBER	.20	num	7	SENT_28	[p2l1434t3062r1582b3091],
7	l	NN	O	l	tmod	5	SENT_28	[p2l1434t3062r1582b3091],
8	3200	CD	NUMBER	3200	dep	10	SENT_28	[p2l1590t3064r1654b3085],
9	CLINICAL	NNP	O	CLINICAL	nn	10	SENT_28	[p2l20t3106r140b3127],
10	PHARMACOLOGY	NNP	O	PHARMACOLOGY	dep	18	SENT_28	[p2l149t3106r373b3127],
11	&	CC	O	&	_	0	SENT_28	[p2l380t3106r600b3127],
12	THERAPEUT	NNP	O	THERAPEUT	conj_and	10	SENT_28	[p2l380t3106r600b3127],
13	|	CD	NUMBER	|	num	16	SENT_28	[p2l380t3106r600b3127],
14	CS	NNP	O	CS	nn	16	SENT_28	[p2l380t3106r600b3127],
15	[	CD	NUMBER	[	num	16	SENT_28	[p2l610t3104r728b3134],
16	VOLUME	NNP	O	VOLUME	dep	10	SENT_28	[p2l610t3104r728b3134],
17	95	CD	NUMBER	95	num	18	SENT_28	[p2l736t3106r763b3127],
18	NUMBER	NN	O	number	dep	23	SENT_28	[p2l774t3106r881b3127],
19	1	CD	NUMBER	1	number	20	SENT_28	[p2l891t3107r898b3127],
20	|	CD	NUMBER	|	dep	18	SENT_28	[p2l912t3104r914b3134],
21	JANUARY	NNP	DATE	JANUARY	dep	20	SENT_28	[p2l923t3106r1041b3127],
22	2014	CD	DATE	2014	num	23	SENT_28	[p2l1049t3106r1107b3127],
23	15	CD	DATE	15	_	0	SENT_28	[p2l2110t3107r2139b3127],

1	STATE	NN	O	state	nn	2	SENT_29	[p2l21t3249r163b3286],
2	ART	NN	O	art	_	0	SENT_29	[p2l306t3249r399b3286],

1	tumors	NNS	O	tumor	dep	9	SENT_30	[p2l8t3482r315b3562],
2	,9	CD	NUMBER	,9	num	3	SENT_30	[p2l8t3482r315b3562],
3	NSCLC	NN	O	nsclc	dep	1	SENT_30	[p2l340t3482r712b3562],
4	,2	CD	NUMBER	,2	num	5	SENT_30	[p2l340t3482r712b3562],
5	’	NN	O	’	dep	9	SENT_30	[p2l340t3482r712b3562],
6	3	CD	NUMBER	3	num	9	SENT_30	[p2l340t3482r712b3562],
7	renal	JJ	O	renal	amod	9	SENT_30	[p2l740t3490r919b3554],
8	cell	NN	O	cell	nn	9	SENT_30	[p2l944t3490r1063b3554],
9	carcinomas	NNS	O	carcinoma	dep	35	SENT_30	[p2l1089t3482r1580b3562],
10	,	,	O	,	_	0	SENT_30	[p2l1089t3482r1580b3562],
11	”	NN	O	”	appos	9	SENT_30	[p2l1089t3482r1580b3562],
12	and	CC	O	and	_	0	SENT_30	[p2l1607t3490r1737b3554],
13	other	JJ	O	other	amod	16	SENT_30	[p2l1762t3490r1951b3554],
14	solid	JJ	O	solid	amod	16	SENT_30	[p2l1977t3490r2146b3554],
15	tumors	NNS	O	tumor	nn	16	SENT_30	[p3l8t19r428b90],
16	.11	NN	NUMBER	.11	conj_and	9	SENT_30	[p3l8t19r428b90],
17	=	JJ	O	=	amod	16	SENT_30	[p3l8t19r428b90],
18	12	CD	NUMBER	12	tmod	17	SENT_30	[p3l8t19r428b90],
19	In	IN	O	in	_	0	SENT_30	[p3l455t32r528b89],
20	addition	NN	O	addition	nsubj	24	SENT_30	[p3l556t27r854b90],
21	to	TO	O	to	_	0	SENT_30	[p3l880t39r948b90],
22	rearrangements	NNS	O	rearrangement	prep_to	20	SENT_30	[p3l975t39r1554b111],
23	,	,	O	,	_	0	SENT_30	[p3l975t39r1554b111],
24	activating	VBG	O	activate	prepc_in	35	SENT_30	[p3l1583t33r1933b111],
25	point	NN	O	point	nn	26	SENT_30	[p3l1956t33r2146b110],
26	mutations	NNS	O	mutation	dobj	24	SENT_30	[p3l8t136r380b193],
27	in	IN	O	in	_	0	SENT_30	[p3l413t136r484b192],
28	the	DT	O	the	det	30	SENT_30	[p3l516t130r629b193],
29	ALK	NNP	O	ALK	nn	30	SENT_30	[p3l659t134r834b192],
30	tyrosine	NN	O	tyrosine	prep_in	24	SENT_30	[p3l859t136r1159b214],
31	kinase	NN	O	kinase	nn	32	SENT_30	[p3l1191t130r1425b193],
32	domain	NN	O	domain	nsubjpass	35	SENT_30	[p3l1460t130r1740b193],
33	have	VBP	O	have	aux	35	SENT_30	[p3l1772t130r1938b193],
34	been	VBN	O	be	auxpass	35	SENT_30	[p3l1969t130r2144b193],
35	reported	VBN	O	report	_	0	SENT_30	[p3l9t232r312b315],
36	in	IN	O	in	_	0	SENT_30	[p3l335t238r404b294],
37	pediatric	JJ	O	pediatric	amod	38	SENT_30	[p3l426t232r740b315],
38	neuroblastoma13	NN	O	neuroblastoma13	prep_in	35	SENT_30	[p3l764t224r1453b295],
39	‘	CD	NUMBER	‘	number	40	SENT_30	[p3l764t224r1453b295],
40	16	CD	NUMBER	16	dep	38	SENT_30	[p3l764t224r1453b295],
41	and	CC	O	and	_	0	SENT_30	[p3l1478t232r1608b295],
42	anaplastic	JJ	O	anaplastic	amod	44	SENT_30	[p3l1631t232r1980b315],
43	thyroid	NN	O	thyroid	nn	44	SENT_30	[p3l2002t232r2141b316, p3l9t334r148b398],
44	cancer	NN	O	cancer	prep_in	35	SENT_30	[p3l170t326r468b398],
45	.	.	O	.	_	0	SENT_30	[p3l170t326r468b398],

1	”	NN	O	”	_	0	SENT_31	[p3l170t326r468b398],

1	In	IN	O	in	_	0	SENT_32	[p3l83t443r156b500],
2	general	JJ	O	general	prep_in	8	SENT_32	[p3l185t438r466b522],
3	,	,	O	,	_	0	SENT_32	[p3l185t438r466b522],
4	chromosomal	JJ	O	chromosomal	amod	5	SENT_32	[p3l497t438r994b501],
5	rearrangements	NNS	O	rearrangement	nsubj	8	SENT_32	[p3l1022t450r1588b522],
6	of	IN	O	of	_	0	SENT_32	[p3l1617t438r1694b501],
7	ALK	NNP	O	ALK	prep_of	5	SENT_32	[p3l1708t442r1882b500],
8	lead	VBP	O	lead	_	0	SENT_32	[p3l1902t438r2050b501],
9	to	TO	O	to	_	0	SENT_32	[p3l2076t450r2144b501],
10	fusion	NN	O	fusion	prep_to	8	SENT_32	[p3l8t541r219b604],
11	of	IN	O	of	_	0	SENT_32	[p3l240t541r313b604],
12	the	DT	O	the	det	15	SENT_32	[p3l322t541r428b604],
13	tyrosine	NN	O	tyrosine	nn	15	SENT_32	[p3l447t547r720b625],
14	kinase	NN	O	kinase	nn	15	SENT_32	[p3l740t541r954b604],
15	domain	NN	O	domain	prep_of	10	SENT_32	[p3l976t541r1235b604],
16	of	IN	O	of	_	0	SENT_32	[p3l1256t541r1329b604],
17	ALK	NN	O	alk	prep_of	15	SENT_32	[p3l1338t545r1499b603],
18	with	IN	O	with	_	0	SENT_32	[p3l1516t541r1667b604],
19	a	DT	O	a	det	20	SENT_32	[p3l1688t564r1722b604],
20	5	CD	NUMBER	5	prep_with	8	SENT_32	[p3l1743t539r1959b604],
21	’	SYM	O	’	dep	20	SENT_32	[p3l1743t539r1959b604],
22	-	:	O	-	_	0	SENT_32	[p3l1743t539r1959b604],
23	end	VB	O	end	ccomp	8	SENT_32	[p3l1743t539r1959b604],
24	partner	NN	O	partner	dobj	23	SENT_32	[p3l1977t553r2142b624, p3l8t667r136b716],
25	,	,	O	,	_	0	SENT_32	[p3l1977t553r2142b624, p3l8t667r136b716],
26	such	JJ	O	such	_	0	SENT_32	[p3l163t644r321b707],
27	as	IN	O	as	_	0	SENT_32	[p3l345t667r411b707],
28	echinoderm	NN	O	echinoderm	nn	31	SENT_32	[p3l436t644r862b707],
29	microtubule-associated	JJ	O	microtubule-associated	amod	31	SENT_32	[p3l885t644r1710b707],
30	protein	NN	O	protein	nn	31	SENT_32	[p3l1731t644r2146b727],
31	—	NN	O	—	prep_such_as	24	SENT_32	[p3l1731t644r2146b727],
32	like	IN	O	like	_	0	SENT_32	[p3l1731t644r2146b727],
33	4	CD	NUMBER	4	number	34	SENT_32	[p3l8t753r47b808],
34	(	CD	NUMBER	(	num	36	SENT_32	[p3l74t747r343b823],
35	EML4	NN	O	eml4	nn	36	SENT_32	[p3l74t747r343b823],
36	)	NN	O	)	prep_like	23	SENT_32	[p3l74t747r343b823],
37	in	IN	O	in	_	0	SENT_32	[p3l371t752r439b808],
38	NSCLC2	NN	O	nsclc2	nn	43	SENT_32	[p3l462t738r762b810],
39	or	CC	O	or	_	0	SENT_32	[p3l788t769r861b809],
40	nucleophosmin	JJ	O	nucleophosmin	nn	43	SENT_32	[p3l883t746r1431b829],
41	(	CD	NUMBER	(	num	43	SENT_32	[p3l1458t738r1734b823],
42	NPM	NN	ORGANIZATION	npm	nn	43	SENT_32	[p3l1458t738r1734b823],
43	)	NN	O	)	prep_in	36	SENT_32	[p3l1458t738r1734b823],
44	1	CD	NUMBER	1	dep	23	SENT_32	[p3l1458t738r1734b823],
45	in	IN	O	in	_	0	SENT_32	[p3l1762t752r1830b808],
46	anaplastic	JJ	O	anaplastic	amod	48	SENT_32	[p3l1855t746r2142b829, p3l8t855r92b912],
47	large-cell	JJ	O	large-cell	amod	48	SENT_32	[p3l113t849r429b933],
48	lymphoma	NN	O	lymphoma	prep_in	44	SENT_32	[p3l450t849r839b933],
49	.	.	O	.	_	0	SENT_32	[p3l450t849r839b933],

1	The	DT	O	the	det	3	SENT_33	[p3l865t849r990b912],
2	break	NN	O	break	nn	3	SENT_33	[p3l1012t849r1206b912],
3	point	NN	O	point	nsubjpass	8	SENT_33	[p3l1225t855r1409b932],
4	within	IN	O	within	_	0	SENT_33	[p3l1429t849r1653b912],
5	ALK	NNP	O	ALK	prep_within	3	SENT_33	[p3l1672t853r1840b911],
6	is	VBZ	O	be	auxpass	8	SENT_33	[p3l1856t855r1906b912],
7	highly	RB	O	highly	advmod	8	SENT_33	[p3l1929t849r2149b933],
8	conserved	VBN	O	conserve	_	0	SENT_33	[p3l9t952r367b1015],
9	across	IN	O	across	_	0	SENT_33	[p3l391t975r604b1015],
10	all	DT	O	all	det	13	SENT_33	[p3l629t952r710b1015],
11	ALK	NN	O	alk	nn	13	SENT_33	[p3l729t956r900b1014],
12	fusion	NN	O	fusion	nn	13	SENT_33	[p3l916t952r1135b1015],
13	genes	NNS	O	gene	prep_across	8	SENT_33	[p3l1159t975r1370b1036],
14	,	,	O	,	_	0	SENT_33	[p3l1159t975r1370b1036],
15	residing	VBG	O	reside	xcomp	8	SENT_33	[p3l1396t952r1680b1036],
16	in	IN	O	in	_	0	SENT_33	[p3l1702t958r1770b1014],
17	the	DT	O	the	det	18	SENT_33	[p3l1793t952r1902b1015],
18	intron	NN	O	intron	prep_in	15	SENT_33	[p3l1926t958r2145b1015],
19	immediately	RB	O	immediately	advmod	20	SENT_33	[p3l9t1055r427b1139],
20	upstream	RB	O	upstream	advmod	15	SENT_33	[p3l443t1067r756b1138],
21	of	IN	O	of	_	0	SENT_33	[p3l776t1055r848b1118],
22	the	DT	O	the	det	23	SENT_33	[p3l857t1055r960b1118],
23	exons	NNS	O	exon	prep_of	20	SENT_33	[p3l981t1078r1169b1118],
24	encoding	VBG	O	encode	partmod	23	SENT_33	[p3l1190t1055r1500b1139],
25	the	DT	O	the	det	27	SENT_33	[p3l1517t1055r1620b1118],
26	kinase	NN	O	kinase	nn	27	SENT_33	[p3l1639t1055r1851b1118],
27	domain	NN	O	domain	dobj	24	SENT_33	[p3l1871t1055r2143b1118],
28	.	.	O	.	_	0	SENT_33	[p3l1871t1055r2143b1118],

1	Because	IN	O	because	mark	12	SENT_34	[p3l9t1163r278b1221],
2	the	DT	O	the	det	3	SENT_34	[p3l298t1158r403b1221],
3	portion	NN	O	portion	nsubj	12	SENT_34	[p3l422t1164r678b1241],
4	of	IN	O	of	_	0	SENT_34	[p3l699t1158r772b1221],
5	ALK	NN	O	alk	prep_of	3	SENT_34	[p3l779t1162r944b1220],
6	involved	VBN	O	involve	partmod	5	SENT_34	[p3l957t1158r1245b1221],
7	in	IN	O	in	_	0	SENT_34	[p3l1264t1164r1330b1220],
8	the	DT	O	the	det	9	SENT_34	[p3l1349t1158r1454b1221],
9	rearrangement	NN	O	rearrangement	prep_in	6	SENT_34	[p3l1474t1170r1974b1242],
10	does	VBZ	O	do	aux	12	SENT_34	[p3l1994t1158r2146b1221],
11	not	RB	O	not	neg	12	SENT_34	[p3l8t1273r125b1324],
12	include	VB	O	include	advcl	22	SENT_34	[p3l148t1261r406b1324],
13	the	DT	O	the	det	15	SENT_34	[p3l429t1261r539b1324],
14	transmembrane	JJ	O	transmembrane	amod	15	SENT_34	[p3l561t1261r1121b1324],
15	domain	NN	O	domain	dobj	12	SENT_34	[p3l1146t1261r1434b1333],
16	,	,	O	,	_	0	SENT_34	[p3l1146t1261r1434b1333],
17	the	DT	O	the	det	20	SENT_34	[p3l1458t1261r1568b1324],
18	resulting	VBG	O	result	amod	20	SENT_34	[p3l1592t1261r1902b1345],
19	fusion	NN	O	fusion	nn	20	SENT_34	[p3l1924t1261r2143b1324],
20	protein	NN	O	protein	nsubjpass	22	SENT_34	[p3l7t1370r259b1447],
21	is	VBZ	O	be	auxpass	22	SENT_34	[p3l282t1370r333b1427],
22	relocated	VBN	O	relocate	_	0	SENT_34	[p3l357t1364r674b1427],
23	from	IN	O	from	_	0	SENT_34	[p3l695t1364r865b1427],
24	the	DT	O	the	det	26	SENT_34	[p3l887t1364r995b1427],
25	cell	NN	O	cell	nn	26	SENT_34	[p3l1018t1364r1133b1427],
26	membrane	NN	O	membrane	prep_from	22	SENT_34	[p3l1155t1364r1529b1427],
27	to	TO	O	to	_	0	SENT_34	[p3l1551t1376r1617b1427],
28	the	DT	O	the	det	29	SENT_34	[p3l1641t1364r1748b1427],
29	cytoplasm	NN	O	cytoplasm	prep_to	22	SENT_34	[p3l1772t1364r2143b1448],
30	.	.	O	.	_	0	SENT_34	[p3l1772t1364r2143b1448],

1	The	DT	O	the	det	2	SENT_35	[p3l8t1467r133b1530],
2	5	CD	NUMBER	5	_	0	SENT_35	[p3l155t1465r373b1530],
3	’	SYM	O	’	dep	2	SENT_35	[p3l155t1465r373b1530],
4	-	:	O	-	_	0	SENT_35	[p3l155t1465r373b1530],
5	end	VB	O	end	dep	2	SENT_35	[p3l155t1465r373b1530],
6	partners	NNS	O	partner	nsubj	8	SENT_35	[p3l391t1479r676b1550],
7	typically	RB	O	typically	advmod	8	SENT_35	[p3l696t1467r988b1551],
8	contain	VBP	O	contain	ccomp	5	SENT_35	[p3l1005t1473r1259b1530],
9	coiled-coil	JJ	O	coiled-coil	amod	13	SENT_35	[p3l1280t1467r1639b1530],
10	or	CC	O	or	_	0	SENT_35	[p3l1659t1490r1731b1530],
11	leucine	NN	O	leucine	amod	13	SENT_35	[p3l1748t1467r1992b1530],
12	zipper	NN	O	zipper	nn	13	SENT_35	[p3l2014t1473r2140b1550, p3l7t1592r121b1653],
13	domains	NNS	O	domain	dobj	8	SENT_35	[p3l143t1570r436b1633],
14	that	WDT	O	that	nsubj	15	SENT_35	[p3l459t1570r593b1633],
15	enable	VBP	O	enable	rcmod	13	SENT_35	[p3l615t1570r834b1633],
16	oligomerization	NN	O	oligomerization	dobj	15	SENT_35	[p3l857t1570r1401b1654],
17	of	IN	O	of	_	0	SENT_35	[p3l1424t1570r1498b1633],
18	the	DT	O	the	det	20	SENT_35	[p3l1510t1570r1616b1633],
19	fusion	NN	O	fusion	nn	20	SENT_35	[p3l1639t1570r1853b1633],
20	protein	NN	O	protein	prep_of	16	SENT_35	[p3l1875t1576r2142b1653],
21	,	,	O	,	_	0	SENT_35	[p3l1875t1576r2142b1653],
22	leading	VBG	O	lead	partmod	15	SENT_35	[p3l7t1673r264b1757],
23	to	TO	O	to	_	0	SENT_35	[p3l285t1685r352b1736],
24	ligand-independent	JJ	O	ligand-independent	amod	25	SENT_35	[p3l375t1673r1069b1757],
25	activation	NN	O	activation	prep_to	22	SENT_35	[p3l1092t1679r1435b1736],
26	of	IN	O	of	_	0	SENT_35	[p3l1459t1673r1534b1736],
27	the	DT	O	the	det	30	SENT_35	[p3l1546t1673r1655b1736],
28	ALK	NNP	O	ALK	nn	30	SENT_35	[p3l1677t1677r1843b1735],
29	tyrosine	NN	O	tyrosine	nn	30	SENT_35	[p3l1863t1679r2146b1757],
30	kinase	NN	O	kinase	prep_of	25	SENT_35	[p3l7t1775r249b1838],
31	.	.	O	.	_	0	SENT_35	[p3l7t1775r249b1838],

1	This	DT	O	this	nsubj	4	SENT_36	[p3l277t1775r424b1838],
2	in	IN	O	in	_	0	SENT_36	[p3l450t1781r518b1837],
3	turn	NN	O	turn	prep_in	1	SENT_36	[p3l542t1787r695b1838],
4	leads	VBZ	O	lead	_	0	SENT_36	[p3l718t1775r895b1838],
5	to	TO	O	to	_	0	SENT_36	[p3l920t1787r987b1838],
6	constitutive	JJ	O	constitutive	amod	7	SENT_36	[p3l1014t1781r1426b1838],
7	activation	NN	O	activation	prep_to	4	SENT_36	[p3l1452t1781r1801b1838],
8	of	IN	O	of	_	0	SENT_36	[p3l1827t1775r1902b1838],
9	downstream	JJ	O	downstream	prep_of	7	SENT_36	[p3l1918t1775r2143b1838, p3l9t1890r238b1941],

1	signaling	NN	O	signaling	nn	2	SENT_37	[p3l259t1878r568b1962],
2	pathways	NNS	O	pathway	_	0	SENT_37	[p3l586t1878r920b1962],
3	,	,	O	,	_	0	SENT_37	[p3l586t1878r920b1962],
4	such	JJ	O	such	_	0	SENT_37	[p3l943t1878r1097b1941],
5	as	IN	O	as	_	0	SENT_37	[p3l1118t1901r1182b1941],
6	the	DT	O	the	det	7	SENT_37	[p3l1202t1878r1308b1941],
7	Ras/MAPK	NN	O	ras/mapk	prep_such_as	2	SENT_37	[p3l1329t1882r1738b1950],
8	,	,	O	,	_	0	SENT_37	[p3l1329t1882r1738b1950],
9	PI3K/AKT	NN	O	pi3k/akt	prep_such_as	2	SENT_37	[p3l1761t1881r2141b1950],
10	,	,	O	,	_	0	SENT_37	[p3l1761t1881r2141b1950],
11	and	CC	O	and	_	0	SENT_37	[p3l9t1981r136b2044],
12	]	CD	NUMBER	]	num	13	SENT_37	[p3l156t1985r323b2057],
13	AK	NN	O	ak	prep_such_as	2	SENT_37	[p3l156t1985r323b2057],
14	/	:	O	/	punct	18	SENT_37	[p3l156t1985r323b2057],
15	STAT	NN	O	stat	nn	16	SENT_37	[p3l329t1984r519b2044],
16	pathways	NNS	O	pathway	dep	18	SENT_37	[p3l539t1981r856b2065],
17	(	CD	NUMBER	(	num	18	SENT_37	[p3l882t1981r1141b2064],
18	Figure	NN	O	figure	dep	13	SENT_37	[p3l882t1981r1141b2064],
19	1	CD	NUMBER	1	num	20	SENT_37	[p3l1167t1981r1247b2058],
20	)	NN	O	)	dep	18	SENT_37	[p3l1167t1981r1247b2058],
21	.	.	O	.	_	0	SENT_37	[p3l1167t1981r1247b2058],

1	In	IN	O	in	_	0	SENT_38	[p3l83t2089r156b2146],
2	cell	NN	O	cell	nn	4	SENT_38	[p3l181t2084r299b2147],
3	line	NN	O	line	nn	4	SENT_38	[p3l321t2084r452b2147],
4	experiments	NNS	O	experiment	prep_in	14	SENT_38	[p3l477t2090r914b2167],
5	and	CC	O	and	_	0	SENT_38	[p3l940t2084r1070b2147],
6	genetically	RB	O	genetically	advmod	7	SENT_38	[p3l1094t2084r1476b2168],
7	engineered	VBN	O	engineer	amod	9	SENT_38	[p3l1498t2084r1890b2168],
8	mouse	NN	O	mouse	nn	9	SENT_38	[p3l1913t2107r2145b2147],
9	models	NNS	O	model	conj_and	4	SENT_38	[p3l8t2187r287b2259],
10	,	,	O	,	_	0	SENT_38	[p3l8t2187r287b2259],
11	ALK	NN	O	alk	nn	13	SENT_38	[p3l315t2191r485b2249],
12	fusion	NN	O	fusion	nn	13	SENT_38	[p3l511t2187r735b2250],
13	proteins	NNS	O	protein	nsubj	14	SENT_38	[p3l762t2193r1056b2270],
14	function	VBP	O	function	_	0	SENT_38	[p3l1085t2187r1392b2250],
15	as	IN	O	as	_	0	SENT_38	[p3l1421t2210r1488b2250],
16	potent	JJ	O	potent	amod	18	SENT_38	[p3l1515t2199r1749b2270],
17	oncogenic	JJ	O	oncogenic	amod	18	SENT_38	[p3l1777t2193r2144b2271],
18	drivers	NNS	O	driver	prep_as	14	SENT_38	[p3l9t2290r267b2353],
19	.	.	O	.	_	0	SENT_38	[p3l9t2290r267b2353],

1	For	IN	O	for	_	0	SENT_39	[p3l294t2295r411b2353],
2	example	NN	O	example	prep_for	6	SENT_39	[p3l434t2290r740b2373],
3	,	,	O	,	_	0	SENT_39	[p3l434t2290r740b2373],
4	transgenic	JJ	O	transgenic	amod	5	SENT_39	[p3l764t2296r1126b2374],
5	mice	NNS	O	mouse	nsubj	6	SENT_39	[p3l1149t2296r1315b2353],
6	expressing	VBG	O	express	_	0	SENT_39	[p3l1340t2296r1707b2374],
7	EML4	NN	O	eml4	dobj	6	SENT_39	[p3l1726t2294r2153b2352],
8	.	.	O	.	_	0	SENT_39	[p3l1726t2294r2153b2352],

1	—	NN	O	—	_	0	SENT_40	[p3l1726t2294r2153b2352],
2	.	.	O	.	_	0	SENT_40	[p3l1726t2294r2153b2352],

1	ALK	NNP	O	ALK	nsubj	7	SENT_41	[p3l1726t2294r2153b2352],
2	in	IN	O	in	_	0	SENT_41	[p3l9t2399r74b2455],
3	alveolar	JJ	O	alveolar	amod	6	SENT_41	[p3l95t2393r360b2456],
4	type	NN	O	type	amod	6	SENT_41	[p3l377t2405r522b2477],
5	2	CD	NUMBER	2	number	4	SENT_41	[p3l543t2400r578b2455],
6	pneumocytes	NNS	O	pneumocyte	prep_in	1	SENT_41	[p3l599t2405r1051b2477],
7	develop	VBP	O	develop	_	0	SENT_41	[p3l1072t2393r1333b2476],
8	multiple	JJ	O	multiple	amod	9	SENT_41	[p3l1354t2393r1635b2476],
9	adenocarcinomas	NNS	O	adenocarcinoma	dobj	7	SENT_41	[p3l1656t2393r2142b2456, p3l8t2519r145b2559],
10	throughout	IN	O	throughout	_	0	SENT_41	[p3l167t2496r563b2580],
11	the	DT	O	the	det	12	SENT_41	[p3l584t2496r691b2559],
12	lungs	NNS	O	lung	prep_throughout	7	SENT_41	[p3l713t2496r914b2580],
13	.	.	O	.	_	0	SENT_41	[p3l713t2496r914b2580],

1	These	DT	O	these	det	3	SENT_42	[p3l940t2496r1135b2559],
2	ALK	NNP	O	ALK	nn	3	SENT_42	[p3l1157t2496r1577b2559],
3	—	NN	O	—	nsubj	13	SENT_42	[p3l1157t2496r1577b2559],
4	driven	VBN	O	drive	partmod	3	SENT_42	[p3l1157t2496r1577b2559],
5	lung	NN	O	lung	nn	6	SENT_42	[p3l1598t2496r1753b2580],
6	tumors	NNS	O	tumor	dobj	4	SENT_42	[p3l1773t2508r2019b2559],
7	are	VBP	O	be	cop	8	SENT_42	[p3l2044t2519r2144b2559],
8	responsive	JJ	O	responsive	_	0	SENT_42	[p3l9t2605r376b2682],
9	to	TO	O	to	_	0	SENT_42	[p3l398t2611r465b2662],
10	ALK	NN	O	alk	nn	11	SENT_42	[p3l489t2603r654b2661],
11	inhibition	NN	O	inhibition	prep_to	8	SENT_42	[p3l676t2599r1023b2662],
12	and	CC	O	and	_	0	SENT_42	[p3l1047t2599r1175b2662],
13	regress	VBP	O	regress	conj_and	8	SENT_42	[p3l1198t2622r1436b2683],
14	on	IN	O	on	_	0	SENT_42	[p3l1461t2622r1548b2662],
15	treatment	NN	O	treatment	prep_on	13	SENT_42	[p3l1570t2611r1911b2662],
16	with	IN	O	with	_	0	SENT_42	[p3l1932t2599r2087b2662],
17	a	DT	O	a	det	21	SENT_42	[p3l2110t2622r2146b2662],
18	small-molecule	JJ	O	small-molecule	amod	21	SENT_42	[p3l9t2701r529b2764],
19	tyrosine	NN	O	tyrosine	nn	21	SENT_42	[p3l549t2707r822b2785],
20	kinase	NN	O	kinase	nn	21	SENT_42	[p3l841t2701r1056b2764],
21	inhibitor	NN	O	inhibitor	prep_with	13	SENT_42	[p3l1077t2701r1376b2764],
22	of	IN	O	of	_	0	SENT_42	[p3l1396t2701r1469b2764],
23	ALK	NNP	O	ALK	prep_of	21	SENT_42	[p3l1478t2693r1719b2764],
24	.18	CD	NUMBER	.18	num	23	SENT_42	[p3l1478t2693r1719b2764],
25	This	DT	O	this	det	26	SENT_42	[p3l1740t2701r1881b2764],
26	ﬁnding	NN	O	ﬁnding	nsubj	27	SENT_42	[p3l1902t2701r2147b2785],
27	illustrates	VBZ	O	illustrate	rcmod	21	SENT_42	[p3l9t2804r342b2867],
28	the	DT	O	the	det	29	SENT_42	[p3l365t2804r473b2867],
29	phenomenon	NN	O	phenomenon	dobj	27	SENT_42	[p3l495t2804r960b2887],
30	of	IN	O	of	_	0	SENT_42	[p3l985t2804r1059b2867],
31	“	NN	O	“	nn	33	SENT_42	[p3l1073t2804r1432b2888],
32	oncogene	NN	O	oncogene	nn	33	SENT_42	[p3l1073t2804r1432b2888],
33	addiction	NN	O	addiction	prep_of	29	SENT_42	[p3l1456t2804r1827b2876],
34	,	,	O	,	_	0	SENT_42	[p3l1456t2804r1827b2876],
35	”	CD	NUMBER	”	appos	33	SENT_42	[p3l1456t2804r1827b2876],
36	whereby	WRB	O	whereby	advmod	40	SENT_42	[p3l1850t2804r2148b2888],
37	cancer	NN	O	cancer	nn	38	SENT_42	[p3l9t2930r230b2970],
38	cells	NNS	O	cell	nsubjpass	40	SENT_42	[p3l250t2907r392b2970],
39	become	VBP	O	become	auxpass	40	SENT_42	[p3l412t2907r677b2970],
40	dependent	JJ	O	dependent	rcmod	35	SENT_42	[p3l698t2907r1058b2990],
41	on	IN	O	on	prep	40	SENT_42	[p3l1078t2930r1164b2970],
42	or	CC	O	or	_	0	SENT_42	[p3l1184t2930r1256b2970],
43	addicted	VBN	O	addict	conj_or	40	SENT_42	[p3l1276t2907r1568b2970],
44	to	TO	O	to	_	0	SENT_42	[p3l1587t2919r1652b2970],
45	the	DT	O	the	det	47	SENT_42	[p3l1672t2907r1778b2970],
46	oncogenic	JJ	O	oncogenic	amod	47	SENT_42	[p3l1799t2913r2147b2991],
47	driver	NN	O	driver	prep_to	43	SENT_42	[p3l9t3010r215b3073],
48	and	CC	O	and	_	0	SENT_42	[p3l237t3010r363b3073],
49	hence	RB	O	hence	advmod	52	SENT_42	[p3l384t3010r583b3073],
50	are	VBP	O	be	cop	52	SENT_42	[p3l607t3033r707b3073],
51	highly	RB	O	highly	advmod	52	SENT_42	[p3l728t3010r947b3094],
52	sensitive	JJ	O	sensitive	rcmod	21	SENT_42	[p3l967t3016r1257b3073],
53	to	TO	O	to	_	0	SENT_42	[p3l1279t3022r1345b3073],
54	inhibition	NN	O	inhibition	prep_to	52	SENT_42	[p3l1368t3010r1710b3073],
55	of	IN	O	of	_	0	SENT_42	[p3l1733t3010r1807b3073],
56	the	DT	O	the	det	57	SENT_42	[p3l1819t3010r1925b3073],
57	oncogene	NN	O	oncogene	prep_of	54	SENT_42	[p3l1948t3033r2142b3073, p3l8t3104r250b3196],
58	.	.	O	.	_	0	SENT_42	[p3l1948t3033r2142b3073, p3l8t3104r250b3196],

1	”	NN	O	”	_	0	SENT_43	[p3l1948t3033r2142b3073, p3l8t3104r250b3196],
2	At	IN	O	at	dep	1	SENT_43	[p3l274t3116r356b3175],
3	the	DT	O	the	det	5	SENT_43	[p3l377t3112r485b3175],
4	cellular	JJ	O	cellular	amod	5	SENT_43	[p3l509t3112r765b3175],
5	level	NN	O	level	pobj	2	SENT_43	[p3l786t3112r961b3184],
6	,	,	O	,	_	0	SENT_43	[p3l786t3112r961b3184],
7	ALK	NN	O	alk	nn	8	SENT_43	[p3l986t3116r1151b3174],
8	fusions	NNS	O	fusion	appos	5	SENT_43	[p3l1173t3112r1421b3175],
9	such	JJ	O	such	_	0	SENT_43	[p3l1447t3112r1604b3175],
10	as	IN	O	as	_	0	SENT_43	[p3l1628t3135r1693b3175],
11	EML4	NN	O	eml4	prep_such_as	8	SENT_43	[p3l1717t3116r2146b3174],
12	.	.	O	.	_	0	SENT_43	[p3l1717t3116r2146b3174],

1	—	NN	O	—	_	0	SENT_44	[p3l1717t3116r2146b3174],
2	.	.	O	.	_	0	SENT_44	[p3l1717t3116r2146b3174],

1	ALK	NNP	O	ALK	nsubj	5	SENT_45	[p3l1717t3116r2146b3174],
2	become	VB	O	become	cop	5	SENT_45	[p3l7t3215r267b3278],
3	the	DT	O	the	det	5	SENT_45	[p3l286t3215r390b3278],
4	sole	JJ	O	sole	amod	5	SENT_45	[p3l411t3215r537b3278],
5	regulator	NN	O	regulator	_	0	SENT_45	[p3l557t3215r861b3299],
6	of	IN	O	of	_	0	SENT_45	[p3l880t3215r952b3278],
7	critical	JJ	O	critical	amod	10	SENT_45	[p3l962t3215r1191b3278],
8	downstream	JJ	O	downstream	amod	10	SENT_45	[p3l1211t3215r1625b3278],
9	signaling	NN	O	signaling	nn	10	SENT_45	[p3l1645t3215r1948b3299],
10	pathways	NNS	O	pathway	prep_of	5	SENT_45	[p3l1965t3215r2141b3298, p3l7t3341r189b3402],
11	.	.	O	.	_	0	SENT_45	[p3l1965t3215r2141b3298, p3l7t3341r189b3402],

1	Inhibition	NN	O	inhibition	nsubj	4	SENT_46	[p3l216t3318r564b3381],
2	of	IN	O	of	_	0	SENT_46	[p3l587t3318r662b3381],
3	ALK	NNP	O	ALK	prep_of	1	SENT_46	[p3l674t3322r838b3380],
4	suppresses	VBZ	O	suppress	_	0	SENT_46	[p3l860t3340r1222b3401],
5	these	DT	O	these	det	6	SENT_46	[p3l1244t3318r1421b3381],
6	pathways	NNS	O	pathway	dobj	4	SENT_46	[p3l1443t3318r1780b3402],
7	,	,	O	,	_	0	SENT_46	[p3l1443t3318r1780b3402],
8	leading	VBG	O	lead	partmod	4	SENT_46	[p3l1804t3318r2058b3402],
9	to	TO	O	to	_	0	SENT_46	[p3l2077t3330r2144b3381],
10	growth	NN	O	growth	nn	11	SENT_46	[p3l8t3420r252b3504],
11	arrest	NN	O	arrest	prep_to	8	SENT_46	[p3l274t3432r466b3483],
12	and	CC	O	and	_	0	SENT_46	[p3l487t3420r613b3483],
13	cell	NN	O	cell	nn	14	SENT_46	[p3l634t3420r747b3483],
14	death	NN	O	death	prep_to	8	SENT_46	[p3l769t3412r1038b3483],
15	.20	CD	NUMBER	.20	dep	11	SENT_46	[p3l769t3412r1038b3483],

1	To	TO	O	to	_	0	SENT_47	[p3l82t3526r168b3586],
2	date	NN	O	date	prep_to	40	SENT_47	[p3l194t3523r356b3595],
3	,	,	O	,	_	0	SENT_47	[p3l194t3523r356b3595],
4	nearly	RB	O	nearly	quantmod	5	SENT_47	[p3l381t3523r601b3607],
5	20	CD	NUMBER	20	num	9	SENT_47	[p3l621t3530r701b3586],
6	different	JJ	O	different	amod	9	SENT_47	[p3l726t3523r1025b3586],
7	ALK	NN	O	alk	nn	9	SENT_47	[p3l1046t3527r1213b3585],
8	fusion	NN	O	fusion	nn	9	SENT_47	[p3l1235t3523r1454b3586],
9	partners	NNS	O	partner	nsubjpass	12	SENT_47	[p3l1477t3535r1771b3606],
10	have	VBP	O	have	aux	12	SENT_47	[p3l1795t3523r1954b3586],
11	been	VBN	O	be	auxpass	12	SENT_47	[p3l1976t3523r2144b3586],
12	identiﬁed	VBN	O	identiﬁed	dep	40	SENT_47	[p3l9t3626r339b3689],
13	across	IN	O	across	_	0	SENT_47	[p3l362t3649r572b3689],
14	the	DT	O	the	det	28	SENT_47	[p3l594t3626r702b3689],
15	diverse	JJ	O	diverse	amod	28	SENT_47	[p3l726t3626r969b3689],
16	tumor	NN	O	tumor	nn	17	SENT_47	[p3l991t3638r1208b3689],
17	types	NNS	O	type	dep	15	SENT_47	[p3l1229t3638r1409b3710],
18	harboring	VBG	O	harbor	dep	17	SENT_47	[p3l1431t3626r1779b3710],
19	ALK	NN	O	alk	nn	20	SENT_47	[p3l1797t3630r1965b3688],
20	rearrangements	NNS	O	rearrangement	dobj	18	SENT_47	[p3l1982t3649r2142b3689, p3l9t3741r446b3813],
21	,	,	O	,	_	0	SENT_47	[p3l1982t3649r2142b3689, p3l9t3741r446b3813],
22	including	VBG	O	include	_	0	SENT_47	[p3l475t3729r818b3813],
23	5	CD	NUMBER	5	prep_including	20	SENT_47	[p3l845t3737r879b3792],
24	in	IN	O	in	_	0	SENT_47	[p3l908t3735r977b3791],
25	NSCLC	NNP	O	NSCLC	prep_in	23	SENT_47	[p3l1004t3733r1276b3792],
26	(	CD	NUMBER	(	num	25	SENT_47	[p3l1307t3730r1605b3806],
27	EML4	NN	O	eml4	nn	28	SENT_47	[p3l1307t3730r1605b3806],
28	)	NN	O	)	prep_across	12	SENT_47	[p3l1307t3730r1605b3806],
29	,	,	O	,	_	0	SENT_47	[p3l1307t3730r1605b3806],
30	kinesin	NN	O	kinesin	nn	33	SENT_47	[p3l1632t3729r1894b3792],
31	family	NN	O	family	nn	33	SENT_47	[p3l1921t3729r2149b3813],
32	member	NN	O	member	nn	33	SENT_47	[p4l10t16r308b79],
33	5B	NN	O	5b	nsubj	40	SENT_47	[p4l334t21r441b88],
34	,	,	O	,	_	0	SENT_47	[p4l334t21r441b88],
35	kinesin	NN	O	kinesin	nn	37	SENT_47	[p4l466t16r726b79],
36	light	NN	O	light	nn	37	SENT_47	[p4l750t16r912b100],
37	chain	NN	O	chain	appos	33	SENT_47	[p4l937t16r1129b79],
38	1	CD	NUMBER	1	dep	37	SENT_47	[p4l1161t23r1212b88],
39	,	,	O	,	_	0	SENT_47	[p4l1161t23r1212b88],
40	transforming	VBG	O	transform	_	0	SENT_47	[p4l1238t16r1710b100],
41	growth	NN	O	growth	nn	42	SENT_47	[p4l1734t16r1986b100],
42	factor	NN	O	factor	dobj	40	SENT_47	[p4l2011t16r2140b79, p4l10t130r124b190],
43	,	,	O	,	_	0	SENT_47	[p4l2011t16r2140b79, p4l10t130r124b190],
44	and	CC	O	and	_	0	SENT_47	[p4l153t118r283b182],
45	striatin	NN	O	striatin	npadvmod	47	SENT_47	[p4l309t110r727b182],
46	.21	CD	NUMBER	.21	num	45	SENT_47	[p4l309t110r727b182],
47	>	JJR	O	>	ccomp	56	SENT_47	[p4l309t110r727b182],
48	22	CD	NUMBER	22	dep	47	SENT_47	[p4l309t110r727b182],
49	In	IN	O	in	dep	48	SENT_47	[p4l754t123r827b181],
50	NSCLC	NN	LOCATION	nsclc	pobj	49	SENT_47	[p4l852t122r1143b190],
51	,	,	O	,	_	0	SENT_47	[p4l852t122r1143b190],
52	EML4	NN	O	eml4	nsubj	56	SENT_47	[p4l1170t123r1387b181],
53	is	VBZ	O	be	cop	56	SENT_47	[p4l1413t125r1465b182],
54	the	DT	O	the	det	56	SENT_47	[p4l1490t118r1600b182],
55	most	RBS	O	most	advmod	56	SENT_47	[p4l1625t130r1801b182],
56	common	JJ	O	common	conj_and	40	SENT_47	[p4l1826t141r2143b182],

1	ALK	NN	O	alk	_	0	SENT_48	[p4l10t226r177b284],
2	fusion	NN	O	fusion	nn	3	SENT_48	[p4l201t222r422b285],
3	partner	NN	O	partner	dep	1	SENT_48	[p4l446t234r725b305],
4	,	,	O	,	_	0	SENT_48	[p4l446t234r725b305],
5	and	CC	O	and	_	0	SENT_48	[p4l753t222r883b285],
6	multiple	JJ	O	multiple	amod	7	SENT_48	[p4l908t222r1204b305],
7	EML4	NN	O	eml4	conj_and	3	SENT_48	[p4l1227t226r1660b284],
8	.	.	O	.	_	0	SENT_48	[p4l1227t226r1660b284],

1	—	NN	O	—	_	0	SENT_49	[p4l1227t226r1660b284],
2	.	.	O	.	_	0	SENT_49	[p4l1227t226r1660b284],

1	ALK	NN	O	alk	nn	2	SENT_50	[p4l1227t226r1660b284],
2	variants	NNS	O	variant	nsubjpass	5	SENT_50	[p4l1676t228r1959b285],
3	have	VBP	O	have	aux	5	SENT_50	[p4l1984t222r2145b285],
4	been	VBN	O	be	auxpass	5	SENT_50	[p4l8t324r176b387],
5	identiﬁed	VBN	O	identiﬁed	_	0	SENT_50	[p4l200t316r615b387],
6	.	.	O	.	_	0	SENT_50	[p4l200t316r615b387],

1	”	NN	O	”	nsubj	15	SENT_51	[p4l200t316r615b387],
2	All	DT	O	all	nsubj	6	SENT_51	[p4l642t324r746b386],
3	of	IN	O	of	_	0	SENT_51	[p4l770t324r846b387],
4	these	DT	O	these	det	5	SENT_51	[p4l858t324r1039b387],
5	variants	NNS	O	variant	prep_of	2	SENT_51	[p4l1060t330r1339b387],
6	contain	VBP	O	contain	rcmod	1	SENT_51	[p4l1365t330r1627b387],
7	essentially	RB	O	essentially	advmod	10	SENT_51	[p4l1651t324r2015b408],
8	the	DT	O	the	det	10	SENT_51	[p4l2034t324r2143b387],
9	same	JJ	O	same	amod	10	SENT_51	[p4l11t450r183b490],
10	portion	NN	O	portion	dobj	6	SENT_51	[p4l204t433r463b510],
11	of	IN	O	of	_	0	SENT_51	[p4l487t427r560b490],
12	the	DT	O	the	det	14	SENT_51	[p4l572t427r679b490],
13	ALK	NN	O	alk	nn	14	SENT_51	[p4l697t431r864b489],
14	gene	NN	O	gene	prep_of	10	SENT_51	[p4l880t450r1036b511],
15	fused	VBN	O	fuse	_	0	SENT_51	[p4l1058t427r1242b490],
16	to	TO	O	to	_	0	SENT_51	[p4l1263t439r1328b490],
17	different	JJ	O	different	amod	18	SENT_51	[p4l1353t427r1642b490],
18	truncations	NNS	O	truncation	prep_to	15	SENT_51	[p4l1662t433r2056b490],
19	of	IN	O	of	_	0	SENT_51	[p4l2079t427r2153b490],
20	the	DT	O	the	det	22	SENT_51	[p4l9t530r116b593],
21	EML4	NN	O	eml4	nn	22	SENT_51	[p4l137t535r347b592],
22	gene	NN	O	gene	prep_of	18	SENT_51	[p4l370t553r543b614],
23	.	.	O	.	_	0	SENT_51	[p4l370t553r543b614],

1	Whether	IN	O	whether	complm	7	SENT_52	[p4l568t530r875b593],
2	the	DT	O	the	det	4	SENT_52	[p4l895t530r1002b593],
3	different	JJ	O	different	amod	4	SENT_52	[p4l1026t530r1317b593],
4	fusions	NNS	O	fusion	nsubj	7	SENT_52	[p4l1338t530r1583b593],
5	or	CC	O	or	_	0	SENT_52	[p4l1607t553r1679b593],
6	variants	NNS	O	variant	nsubj	7	SENT_52	[p4l1698t536r1972b593],
7	possess	VBP	O	possess	csubj	12	SENT_52	[p4l1994t552r2141b613, p4l11t656r138b696],
8	different	JJ	O	different	amod	10	SENT_52	[p4l161t633r451b696],
9	biological	JJ	O	biological	amod	10	SENT_52	[p4l470t633r805b717],
10	properties	NNS	O	property	dobj	7	SENT_52	[p4l825t639r1174b716],
11	is	VBZ	O	be	cop	12	SENT_52	[p4l1197t639r1247b696],
12	uncertain	JJ	O	uncertain	_	0	SENT_52	[p4l1270t639r1616b696],
13	.	.	O	.	_	0	SENT_52	[p4l1270t639r1616b696],

1	In	FW	O	in	nn	3	SENT_53	[p4l1639t638r1707b696],
2	vitro	FW	O	vitro	nn	3	SENT_53	[p4l1732t639r1885b696],
3	studies	NNS	O	study	_	0	SENT_53	[p4l1909t633r2143b696],
4	comparing	VBG	O	compare	partmod	3	SENT_53	[p4l11t742r378b820],
5	three	CD	NUMBER	three	num	6	SENT_53	[p4l395t736r568b799],
6	EML4	NN	O	eml4	dobj	4	SENT_53	[p4l586t740r1000b798],
7	.	.	O	.	_	0	SENT_53	[p4l586t740r1000b798],

1	—	NN	O	—	_	0	SENT_54	[p4l586t740r1000b798],
2	.	.	O	.	_	0	SENT_54	[p4l586t740r1000b798],

1	ALK	NN	O	alk	nn	2	SENT_55	[p4l586t740r1000b798],
2	variants	NNS	O	variant	nsubj	3	SENT_55	[p4l1011t742r1279b799],
3	suggest	VBP	O	suggest	_	0	SENT_55	[p4l1301t748r1546b820],
4	that	IN	O	that	complm	8	SENT_55	[p4l1564t736r1696b799],
5	there	EX	O	there	expl	8	SENT_55	[p4l1714t736r1886b799],
6	may	MD	O	may	aux	8	SENT_55	[p4l1906t759r2051b820],
7	be	VB	O	be	cop	8	SENT_55	[p4l2065t736r2143b799],
8	differences	NNS	O	difference	ccomp	3	SENT_55	[p4l11t839r370b902],
9	in	IN	O	in	_	0	SENT_55	[p4l390t845r455b901],
10	sensitivity	NN	O	sensitivity	prep_in	8	SENT_55	[p4l476t845r814b923],
11	to	TO	O	to	_	0	SENT_55	[p4l829t851r893b902],
12	small	JJ	O	small	amod	16	SENT_55	[p4l915t839r1428b902],
13	—	NN	O	—	nn	16	SENT_55	[p4l915t839r1428b902],
14	molecule	NN	O	molecule	nn	16	SENT_55	[p4l915t839r1428b902],
15	ALK	NN	O	alk	nn	16	SENT_55	[p4l1447t843r1607b901],
16	inhibition	NN	O	inhibition	prep_to	10	SENT_55	[p4l1625t839r1976b911],
17	,	,	O	,	_	0	SENT_55	[p4l1625t839r1976b911],
18	possibly	RB	O	possibly	advmod	19	SENT_55	[p4l1996t861r2141b922, p4l11t941r166b1025],
19	related	JJ	O	related	dep	8	SENT_55	[p4l182t941r409b1004],
20	to	TO	O	to	_	0	SENT_55	[p4l427t953r491b1004],
21	differences	NNS	O	difference	prep_to	19	SENT_55	[p4l513t941r874b1004],
22	in	IN	O	in	_	0	SENT_55	[p4l894t947r960b1003],
23	fusion	NN	O	fusion	nn	25	SENT_55	[p4l979t941r1188b1004],
24	protein	NN	O	protein	nn	25	SENT_55	[p4l1207t947r1451b1024],
25	stability	NN	O	stability	prep_in	21	SENT_55	[p4l1472t933r1807b1025],
26	.23	CD	NUMBER	.23	dep	25	SENT_55	[p4l1472t933r1807b1025],
27	However	RB	O	however	advmod	21	SENT_55	[p4l1829t946r2142b1013],
28	,	,	O	,	_	0	SENT_55	[p4l1829t946r2142b1013],
29	in	IN	O	in	_	0	SENT_55	[p4l11t1049r78b1106],
30	the	DT	O	the	det	31	SENT_55	[p4l101t1043r210b1107],
31	clinic	NN	O	clinic	prep_in	8	SENT_55	[p4l234t1043r442b1115],
32	,	,	O	,	_	0	SENT_55	[p4l234t1043r442b1115],
33	no	DT	O	no	det	34	SENT_55	[p4l467t1066r555b1107],
34	correlation	NN	O	correlation	appos	8	SENT_55	[p4l580t1043r964b1107],
35	between	IN	O	between	_	0	SENT_55	[p4l986t1043r1278b1107],
36	EML4	NN	O	eml4	prep_between	34	SENT_55	[p4l1300t1047r1730b1106],
37	.	.	O	.	_	0	SENT_55	[p4l1300t1047r1730b1106],

1	—	NN	O	—	_	0	SENT_56	[p4l1300t1047r1730b1106],
2	.	.	O	.	_	0	SENT_56	[p4l1300t1047r1730b1106],

1	ALK	NN	O	alk	nn	2	SENT_57	[p4l1300t1047r1730b1106],
2	variant	NN	O	variant	nsubjpass	10	SENT_57	[p4l1743t1049r1992b1107],
3	and	CC	O	and	_	0	SENT_57	[p4l2016t1043r2145b1107],
4	objective	JJ	O	objective	amod	5	SENT_57	[p4l11t1146r315b1230],
5	response	NN	O	response	conj_and	2	SENT_57	[p4l337t1168r636b1229],
6	to	TO	O	to	_	0	SENT_57	[p4l657t1158r723b1209],
7	crizotinib	NN	O	crizotinib	prep_to	2	SENT_57	[p4l746t1146r1076b1209],
8	has	VBZ	O	have	aux	10	SENT_57	[p4l1098t1146r1209b1209],
9	been	VBN	O	be	auxpass	10	SENT_57	[p4l1229t1146r1393b1209],
10	observed	VBN	O	observe	_	0	SENT_57	[p4l1416t1138r1806b1209],
11	.	.	O	.	_	0	SENT_57	[p4l1416t1138r1806b1209],

1	“	NN	O	“	_	0	SENT_58	[p4l1416t1138r1806b1209],

1	ALK	NNP	O	ALK	_	0	SENT_59	[p4l10t1361r152b1415],
2	IN	IN	O	in	dep	1	SENT_59	[p4l171t1361r240b1415],
3	NSCLC	NNP	MISC	NSCLC	pobj	2	SENT_59	[p4l264t1361r491b1416],

1	ALK	NN	O	alk	dep	134	SENT_60	[p4l6t1460r170b1518],
2	gene	NN	O	gene	dep	134	SENT_60	[p4l183t1479r336b1540],
3	rearrangements	NNS	O	rearrangement	dep	134	SENT_60	[p4l356t1468r880b1540],
4	were	VBD	O	be	dep	134	SENT_60	[p4l899t1479r1056b1519],
5	ﬁrst	JJ	O	ﬁrst	dep	134	SENT_60	[p4l1076t1456r1206b1519],
6	identiﬁed	VBN	O	identiﬁed	dep	134	SENT_60	[p4l1225t1456r1545b1519],
7	in	IN	O	in	dep	134	SENT_60	[p4l1564t1462r1629b1518],
8	NSCLC	NN	ORGANIZATION	nsclc	dep	134	SENT_60	[p4l1648t1460r1905b1519],
9	by	IN	O	by	dep	134	SENT_60	[p4l1923t1456r2006b1540],
10	two	CD	NUMBER	two	dep	134	SENT_60	[p4l2021t1468r2143b1519],
11	independent	JJ	O	independent	dep	134	SENT_60	[p4l11t1558r455b1641],
12	groups	NNS	O	group	dep	134	SENT_60	[p4l477t1580r715b1642],
13	in	IN	O	in	dep	134	SENT_60	[p4l740t1564r807b1620],
14	2007	CD	DATE	2007	dep	134	SENT_60	[p4l831t1565r996b1621],
15	.2	NN	NUMBER	.2	dep	134	SENT_60	[p4l1004t1550r1094b1621],
16	=	JJ	O	=	dep	134	SENT_60	[p4l1004t1550r1094b1621],
17	3	CD	NUMBER	3	dep	134	SENT_60	[p4l1004t1550r1094b1621],
18	They	PRP	O	they	dep	134	SENT_60	[p4l1119t1558r1292b1642],
19	are	VBP	O	be	dep	134	SENT_60	[p4l1313t1581r1415b1621],
20	present	JJ	DATE	present	dep	134	SENT_60	[p4l1438t1570r1695b1641],
21	in	IN	O	in	dep	134	SENT_60	[p4l1718t1564r1786b1620],
22	~	NN	O	~	dep	134	SENT_60	[p4l1812t1564r2052b1623],
23	3	CD	NUMBER	3	dep	134	SENT_60	[p4l1812t1564r2052b1623],
24	—	NN	O	—	dep	134	SENT_60	[p4l1812t1564r2052b1623],
25	5	CD	PERCENT	5	dep	134	SENT_60	[p4l1812t1564r2052b1623],
26	%	NN	PERCENT	%	dep	134	SENT_60	[p4l1812t1564r2052b1623],
27	of	IN	O	of	dep	134	SENT_60	[p4l2078t1558r2153b1621],
28	NSCLC	NNP	O	NSCLC	dep	134	SENT_60	[p4l9t1665r284b1733],
29	,	,	O	,	_	0	SENT_60	[p4l9t1665r284b1733],
30	with	IN	O	with	dep	134	SENT_60	[p4l303t1661r453b1724],
31	wide	JJ	O	wide	dep	134	SENT_60	[p4l470t1661r629b1724],
32	variations	NNS	O	variation	dep	134	SENT_60	[p4l646t1667r977b1724],
33	in	IN	O	in	dep	134	SENT_60	[p4l997t1667r1062b1723],
34	the	DT	O	the	dep	134	SENT_60	[p4l1081t1661r1185b1724],
35	reported	VBN	O	report	dep	134	SENT_60	[p4l1205t1661r1493b1744],
36	frequency	NN	O	frequency	dep	134	SENT_60	[p4l1511t1661r1848b1745],
37	depending	VBG	O	depend	dep	134	SENT_60	[p4l1865t1661r2139b1744, p4l11t1770r121b1848],
38	on	IN	O	on	dep	134	SENT_60	[p4l144t1787r232b1827],
39	the	DT	O	the	dep	134	SENT_60	[p4l255t1764r364b1827],
40	criteria	NNS	O	criterion	dep	134	SENT_60	[p4l389t1770r641b1827],
41	used	VBN	O	use	dep	134	SENT_60	[p4l664t1764r826b1827],
42	for	IN	O	for	dep	134	SENT_60	[p4l849t1764r949b1827],
43	identifying	VBG	O	identify	dep	134	SENT_60	[p4l972t1764r1360b1848],
44	tumors	NNS	O	tumor	dep	134	SENT_60	[p4l1381t1776r1632b1827],
45	as	IN	O	as	dep	134	SENT_60	[p4l1658t1787r1724b1827],
46	positive	JJ	O	positive	dep	134	SENT_60	[p4l1747t1770r2022b1847],
47	for	IN	O	for	dep	134	SENT_60	[p4l2045t1764r2146b1827],
48	ALK	NNP	O	ALK	dep	134	SENT_60	[p4l6t1870r179b1928],
49	rearrangement	NN	O	rearrangement	dep	134	SENT_60	[p4l201t1878r736b1950],
50	and	CC	O	and	dep	134	SENT_60	[p4l764t1866r896b1929],
51	the	DT	O	the	dep	134	SENT_60	[p4l922t1866r1034b1929],
52	population	NN	O	population	dep	134	SENT_60	[p4l1061t1866r1458b1949],
53	evaluated	VBD	O	evaluate	dep	134	SENT_60	[p4l1487t1858r1915b1929],
54	.25	CD	NUMBER	.25	dep	134	SENT_60	[p4l1487t1858r1915b1929],
55	ALKpositive	JJ	O	alkpositive	dep	134	SENT_60	[p4l1943t1870r2141b1928, p4l9t1975r274b2052],
56	NSCLCS	NNS	O	nsclc	dep	134	SENT_60	[p4l294t1973r587b2032],
57	are	VBP	O	be	dep	134	SENT_60	[p4l608t1992r708b2032],
58	typically	RB	O	typically	dep	134	SENT_60	[p4l727t1969r1019b2053],
59	adenocarcinomas	NNS	O	adenocarcinoma	dep	134	SENT_60	[p4l1036t1969r1653b2041],
60	,	,	O	,	_	0	SENT_60	[p4l1036t1969r1653b2041],
61	are	VBP	O	be	dep	134	SENT_60	[p4l1676t1992r1775b2032],
62	associated	VBN	O	associate	dep	134	SENT_60	[p4l1797t1969r2143b2032],
63	with	IN	O	with	dep	134	SENT_60	[p4l9t2072r158b2135],
64	characteristic	JJ	O	characteristic	dep	134	SENT_60	[p4l178t2072r627b2135],
65	morphological	JJ	O	morphological	dep	134	SENT_60	[p4l646t2072r1140b2156],
66	features	NNS	O	feature	dep	134	SENT_60	[p4l1159t2072r1437b2144],
67	,	,	O	,	_	0	SENT_60	[p4l1159t2072r1437b2144],
68	such	JJ	O	such	dep	134	SENT_60	[p4l1459t2072r1611b2135],
69	as	IN	O	as	dep	134	SENT_60	[p4l1631t2095r1694b2135],
70	a	DT	O	a	dep	134	SENT_60	[p4l1715t2095r1749b2135],
71	solid	JJ	O	solid	dep	134	SENT_60	[p4l1769t2072r1928b2135],
72	Signet	NNP	O	Signet	dep	134	SENT_60	[p4l1948t2078r2146b2156],
73	ring	NN	O	ring	dep	134	SENT_60	[p4l11t2180r149b2258],
74	cell	NN	O	cell	dep	134	SENT_60	[p4l168t2174r280b2237],
75	pattern	NN	O	pattern	dep	134	SENT_60	[p4l298t2186r543b2257],
76	or	CC	O	or	dep	134	SENT_60	[p4l564t2197r635b2237],
77	mucinous	JJ	O	mucinous	dep	134	SENT_60	[p4l654t2180r988b2237],
78	cribriform	NN	O	cribriform	dep	134	SENT_60	[p4l1009t2174r1362b2237],
79	pattern	NN	O	pattern	dep	134	SENT_60	[p4l1381t2166r1802b2257],
80	,26	CD	NUMBER	,26	dep	134	SENT_60	[p4l1381t2166r1802b2257],
81	"	``	O	"	dep	134	SENT_60	[p4l1381t2166r1802b2257],
82	28	CD	NUMBER	28	dep	134	SENT_60	[p4l1381t2166r1802b2257],
83	and	CC	O	and	dep	134	SENT_60	[p4l1824t2174r1949b2237],
84	commonly	RB	O	commonly	dep	134	SENT_60	[p4l1969t2197r2141b2237, p4l10t2276r237b2360],
85	express	VBP	O	express	dep	134	SENT_60	[p4l258t2298r511b2359],
86	both	CC	O	both	dep	134	SENT_60	[p4l533t2276r697b2339],
87	thyroid	NN	O	thyroid	dep	134	SENT_60	[p4l719t2276r977b2360],
88	transcription	NN	O	transcription	dep	134	SENT_60	[p4l999t2282r1458b2359],
89	factor	NN	O	factor	dep	134	SENT_60	[p4l1482t2276r1750b2339],
90	—	NN	O	—	dep	134	SENT_60	[p4l1482t2276r1750b2339],
91	1	CD	NUMBER	1	dep	134	SENT_60	[p4l1482t2276r1750b2339],
92	and	CC	O	and	dep	134	SENT_60	[p4l1781t2276r1910b2339],
93	p63	NN	O	p63	dep	134	SENT_60	[p4l1931t2268r2144b2359],
94	.27	CD	NUMBER	.27	dep	134	SENT_60	[p4l1931t2268r2144b2359],
95	ALK-positive	JJ	O	alk-positive	dep	134	SENT_60	[p4l9t2383r468b2462],
96	NSCLC	NN	ORGANIZATION	nsclc	dep	134	SENT_60	[p4l488t2383r749b2442],
97	is	VBZ	O	be	dep	134	SENT_60	[p4l770t2385r819b2442],
98	associated	VBN	O	associate	dep	134	SENT_60	[p4l841t2379r1186b2442],
99	with	IN	O	with	dep	134	SENT_60	[p4l1204t2379r1356b2442],
100	a	DT	O	a	dep	134	SENT_60	[p4l1377t2402r1411b2442],
101	younger	JJR	O	younger	dep	134	SENT_60	[p4l1428t2402r1709b2463],
102	age	NN	O	age	dep	134	SENT_60	[p4l1729t2402r1838b2463],
103	of	IN	O	of	dep	134	SENT_60	[p4l1859t2379r1932b2442],
104	onset	NN	O	onset	dep	134	SENT_60	[p4l1943t2391r2141b2451],
105	,	,	O	,	_	0	SENT_60	[p4l1943t2391r2141b2451],
106	with	IN	O	with	dep	134	SENT_60	[p4l9t2481r164b2544],
107	a	DT	O	a	dep	134	SENT_60	[p4l188t2504r223b2544],
108	median	JJ	O	median	dep	134	SENT_60	[p4l245t2481r507b2544],
109	age	NN	O	age	dep	134	SENT_60	[p4l532t2504r643b2565],
110	of	IN	O	of	dep	134	SENT_60	[p4l667t2481r742b2544],
111	~	NN	O	~	dep	134	SENT_60	[p4l758t2488r886b2544],
112	50	CD	DURATION	50	dep	134	SENT_60	[p4l758t2488r886b2544],
113	years	NNS	NUMBER	year	dep	134	SENT_60	[p4l908t2504r1086b2565],
114	in	IN	O	in	dep	134	SENT_60	[p4l1110t2487r1178b2543],
115	ALK-positive	JJ	O	alk-positive	dep	134	SENT_60	[p4l1200t2485r1671b2564],
116	NSCLC	NN	O	nsclc	dep	134	SENT_60	[p4l1694t2473r2139b2553],
117	,29	CD	NUMBER	,29	dep	134	SENT_60	[p4l1694t2473r2139b2553],
118	‘	CD	NUMBER	‘	dep	134	SENT_60	[p4l1694t2473r2139b2553],
119	31	CD	NUMBER	31	dep	134	SENT_60	[p4l1694t2473r2139b2553],
120	in	IN	O	in	dep	134	SENT_60	[p4l11t2590r78b2646],
121	contrast	NN	O	contrast	dep	134	SENT_60	[p4l102t2596r384b2647],
122	to	TO	O	to	dep	134	SENT_60	[p4l406t2596r473b2647],
123	the	DT	O	the	dep	134	SENT_60	[p4l497t2584r605b2647],
124	median	JJ	O	median	dep	134	SENT_60	[p4l628t2584r891b2647],
125	age	NN	O	age	dep	134	SENT_60	[p4l915t2607r1026b2668],
126	of	IN	O	of	dep	134	SENT_60	[p4l1051t2584r1126b2647],
127	~	NN	O	~	dep	134	SENT_60	[p4l1142t2591r1270b2647],
128	70	CD	DURATION	70	dep	134	SENT_60	[p4l1142t2591r1270b2647],
129	years	NNS	NUMBER	year	dep	134	SENT_60	[p4l1292t2607r1471b2668],
130	in	IN	O	in	dep	134	SENT_60	[p4l1495t2590r1563b2646],
131	all	DT	O	all	dep	134	SENT_60	[p4l1587t2584r1668b2647],
132	patients	NNS	O	patient	dep	134	SENT_60	[p4l1689t2590r1964b2667],
133	with	IN	O	with	dep	134	SENT_60	[p4l1986t2584r2142b2647],
134	NSCLC	NN	ORGANIZATION	nsclc	_	0	SENT_60	[p4l10t2691r292b2750],
135	.	.	O	.	_	0	SENT_60	[p4l10t2691r292b2750],

1	Patients	NNS	O	patient	nsubjpass	27	SENT_61	[p4l320t2692r592b2750],
2	with	IN	O	with	_	0	SENT_61	[p4l614t2687r768b2750],
3	ALK	NN	O	alk	nn	4	SENT_61	[p4l788t2691r956b2749],
4	rearrangements	NNS	O	rearrangement	nsubj	7	SENT_61	[p4l973t2699r1517b2771],
5	are	VBP	O	be	cop	7	SENT_61	[p4l1541t2710r1642b2750],
6	more	RBR	O	more	advmod	7	SENT_61	[p4l1666t2710r1845b2750],
7	likely	JJ	O	likely	prep_with	1	SENT_61	[p4l1867t2687r2056b2771],
8	to	TO	O	to	aux	10	SENT_61	[p4l2074t2699r2141b2750],
9	be	VB	O	be	cop	10	SENT_61	[p4l8t2789r86b2852],
10	light	JJ	O	light	xcomp	7	SENT_61	[p4l105t2789r258b2873],
11	or	CC	O	or	_	0	SENT_61	[p4l277t2812r348b2852],
12	never-smokers	JJ	O	never-smokers	amod	13	SENT_61	[p4l366t2781r1113b2852],
13	.24	CD	NUMBER	.24	conj_or	7	SENT_61	[p4l366t2781r1113b2852],
14	’	CD	NUMBER	’	number	15	SENT_61	[p4l366t2781r1113b2852],
15	32	CD	NUMBER	32	num	16	SENT_61	[p4l366t2781r1113b2852],
16	‘	NN	O	‘	dep	13	SENT_61	[p4l366t2781r1113b2852],
17	34	CD	NUMBER	34	num	16	SENT_61	[p4l366t2781r1113b2852],
18	Of	IN	O	of	_	0	SENT_61	[p4l1135t2789r1227b2852],
19	signiﬁcance	NN	O	signiﬁcance	prep_of	16	SENT_61	[p4l1239t2789r1650b2873],
20	,	,	O	,	_	0	SENT_61	[p4l1239t2789r1650b2873],
21	however	RB	O	however	advmod	27	SENT_61	[p4l1671t2789r1968b2861],
22	,	,	O	,	_	0	SENT_61	[p4l1671t2789r1968b2861],
23	ALK	NN	O	alk	nn	24	SENT_61	[p4l1986t2793r2150b2851],
24	rearrangements	NNS	O	rearrangement	nsubjpass	27	SENT_61	[p4l11t2904r546b2976],
25	have	VBP	O	have	aux	27	SENT_61	[p4l567t2892r721b2955],
26	been	VBN	O	be	auxpass	27	SENT_61	[p4l740t2892r904b2955],
27	detected	VBN	O	detect	_	0	SENT_61	[p4l925t2892r1213b2955],
28	in	IN	O	in	_	0	SENT_61	[p4l1232t2898r1298b2954],
29	smokers	NNS	O	smoker	prep_in	27	SENT_61	[p4l1320t2892r1602b2955],
30	in	IN	O	in	_	0	SENT_61	[p4l1623t2898r1689b2954],
31	some	DT	O	some	det	32	SENT_61	[p4l1711t2915r1888b2955],
32	studies	NNS	O	study	prep_in	29	SENT_61	[p4l1910t2892r2144b2955],
33	and	CC	O	and	_	0	SENT_61	[p4l11t2995r137b3058],
34	rarely	RB	O	rarely	advmod	27	SENT_61	[p4l156t2995r352b3079],
35	in	IN	O	in	_	0	SENT_61	[p4l369t3001r434b3057],
36	patients	NNS	O	patient	prep_in	27	SENT_61	[p4l454t3001r721b3078],
37	with	IN	O	with	_	0	SENT_61	[p4l740t2995r892b3058],
38	squamous	JJ	O	squamous	amod	40	SENT_61	[p4l913t3018r1256b3078],
39	cell	NN	O	cell	nn	40	SENT_61	[p4l1277t2995r1390b3058],
40	carcinoma	NN	O	carcinoma	prep_with	36	SENT_61	[p4l1410t3001r1783b3058],
41	.	.	O	.	_	0	SENT_61	[p4l1410t3001r1783b3058],

1	ALK	NN	O	alk	nn	2	SENT_62	[p4l1802t2999r1969b3057],
2	rearrangements	NNS	O	rearrangement	nsubj	7	SENT_62	[p4l1982t3018r2141b3058, p4l11t3110r409b3182],
3	are	VBP	O	be	cop	7	SENT_62	[p4l433t3121r534b3161],
4	almost	RB	O	almost	advmod	7	SENT_62	[p4l557t3098r786b3161],
5	always	RB	O	always	advmod	7	SENT_62	[p4l808t3098r1030b3182],
6	mutually	RB	O	mutually	advmod	7	SENT_62	[p4l1053t3098r1360b3182],
7	exclusive	JJ	O	exclusive	_	0	SENT_62	[p4l1380t3098r1686b3161],
8	of	IN	O	of	_	0	SENT_62	[p4l1709t3098r1783b3161],
9	epidermal	JJ	O	epidermal	amod	12	SENT_62	[p4l1796t3098r2143b3181],
10	growth	NN	O	growth	nn	12	SENT_62	[p4l10t3200r253b3284],
11	factor	NN	O	factor	nn	12	SENT_62	[p4l274t3200r473b3263],
12	receptor	NN	O	receptor	prep_of	7	SENT_62	[p4l493t3212r776b3283],
13	(	CD	NUMBER	(	num	14	SENT_62	[p4l800t3201r1052b3277],
14	EGFR	NN	ORGANIZATION	egfr	dep	12	SENT_62	[p4l800t3201r1052b3277],
15	)	CD	NUMBER	)	dep	12	SENT_62	[p4l800t3201r1052b3277],
16	or	CC	O	or	_	0	SENT_62	[p4l1078t3223r1150b3263],
17	KRAS	NNP	ORGANIZATION	KRAS	nn	18	SENT_62	[p4l1168t3204r1372b3263],
18	mutations	NNS	O	mutation	conj_or	12	SENT_62	[p4l1392t3192r1817b3272],
19	,35	CD	NUMBER	,35	dep	18	SENT_62	[p4l1392t3192r1817b3272],
20	although	IN	O	although	mark	29	SENT_62	[p4l1841t3200r2144b3284],
21	uncommon	JJ	O	uncommon	amod	22	SENT_62	[p4l10t3325r417b3365],
22	exceptions	NNS	O	exception	nsubjpass	58	SENT_62	[p4l441t3308r809b3385],
23	to	TO	O	to	_	0	SENT_62	[p4l832t3314r899b3365],
24	this	DT	O	this	det	25	SENT_62	[p4l922t3302r1049b3365],
25	rule	NN	O	rule	prep_to	22	SENT_62	[p4l1073t3302r1209b3365],
26	have	VBP	O	have	aux	29	SENT_62	[p4l1232t3302r1390b3365],
27	also	RB	O	also	advmod	29	SENT_62	[p4l1414t3302r1547b3365],
28	been	VBN	O	be	auxpass	29	SENT_62	[p4l1570t3302r1736b3365],
29	reported	VBN	O	report	advcl	7	SENT_62	[p4l1760t3294r2144b3385],
30	.36	CD	NUMBER	.36	dobj	29	SENT_62	[p4l1760t3294r2144b3385],
31	Because	IN	O	because	mark	42	SENT_62	[p4l11t3410r289b3468],
32	many	JJ	O	many	nsubj	42	SENT_62	[p4l313t3428r509b3489],
33	of	IN	O	of	_	0	SENT_62	[p4l529t3405r604b3468],
34	the	DT	O	the	det	38	SENT_62	[p4l617t3405r725b3468],
35	clinical	JJ	O	clinical	amod	38	SENT_62	[p4l749t3405r999b3468],
36	and	CC	O	and	_	0	SENT_62	[p4l1023t3405r1151b3468],
37	pathologic	JJ	O	pathologic	amod	38	SENT_62	[p4l1172t3405r1542b3489],
38	features	NNS	O	feature	prep_of	32	SENT_62	[p4l1565t3405r1835b3468],
39	of	IN	O	of	_	0	SENT_62	[p4l1860t3405r1935b3468],
40	ALKpositive	JJ	O	alkpositive	amod	41	SENT_62	[p4l1948t3409r2140b3467, p4l9t3514r276b3591],
41	NSCLC	NN	O	nsclc	prep_of	38	SENT_62	[p4l298t3512r561b3571],
42	overlap	VBP	O	overlap	advcl	29	SENT_62	[p4l584t3508r833b3591],
43	with	IN	O	with	_	0	SENT_62	[p4l855t3508r1008b3571],
44	changes	NNS	O	change	prep_with	42	SENT_62	[p4l1031t3508r1300b3592],
45	in	IN	O	in	_	0	SENT_62	[p4l1323t3514r1390b3570],
46	other	JJ	O	other	amod	48	SENT_62	[p4l1413t3508r1594b3571],
47	molecular	JJ	O	molecular	amod	48	SENT_62	[p4l1616t3508r1961b3571],
48	entities	NNS	O	entity	prep_in	44	SENT_62	[p4l1984t3514r2139b3571, p4l9t3617r147b3683],
49	,	,	O	,	_	0	SENT_62	[p4l1984t3514r2139b3571, p4l9t3617r147b3683],
50	e.g.	FW	O	e.g.	prep_in	44	SENT_62	[p4l175t3634r309b3695],
51	,	,	O	,	_	0	SENT_62	[p4l175t3634r309b3695],
52	EGFR	NN	ORGANIZATION	egfr	nn	53	SENT_62	[p4l333t3615r542b3674],
53	mutations	NNS	O	mutation	prep_in	44	SENT_62	[p4l566t3617r921b3674],
54	and	CC	O	and	_	0	SENT_62	[p4l947t3611r1076b3674],
55	ROS	NN	O	ro	nn	56	SENT_62	[p4l1098t3615r1288b3674],
56	]	NN	O	]	prep_in	44	SENT_62	[p4l1098t3615r1288b3674],
57	and	CC	O	and	_	0	SENT_62	[p4l1320t3611r1450b3674],
58	Rearranged	VBN	O	rearrange	advcl	7	SENT_62	[p4l1474t3611r1882b3695],
59	during	IN	O	during	_	0	SENT_62	[p4l1906t3611r2144b3695],
60	transfection	NN	O	transfection	nn	63	SENT_62	[p4l9t3714r418b3777],
61	(	CD	NUMBER	(	num	63	SENT_62	[p4l441t3714r565b3791],
62	RE	NN	O	re	nn	63	SENT_62	[p4l441t3714r565b3791],
63	T	NN	O	t	prep_during	58	SENT_62	[p4l571t3715r639b3790],
64	)	NN	O	)	nn	66	SENT_62	[p4l571t3715r639b3790],
65	gene	NN	O	gene	nn	66	SENT_62	[p4l664t3737r819b3798],
66	rearrangements	NNS	O	rearrangement	dobj	29	SENT_62	[p4l839t3726r1391b3798],
67	,	,	O	,	_	0	SENT_62	[p4l839t3726r1391b3798],
68	molecular	JJ	O	molecular	amod	69	SENT_62	[p4l1413t3714r1755b3777],
69	characterization	NN	O	characterization	appos	66	SENT_62	[p4l1775t3714r2141b3777, p5l11t22r219b79],

1	is	VBZ	O	be	auxpass	2	SENT_63	[p5l241t22r290b79],
2	required	VBN	O	require	_	0	SENT_63	[p5l313t16r604b99],
3	to	TO	O	to	aux	5	SENT_63	[p5l624t28r689b79],
4	accurately	RB	O	accurately	advmod	5	SENT_63	[p5l713t16r1061b100],
5	identify	VB	O	identify	xcomp	2	SENT_63	[p5l1079t16r1346b100],
6	this	DT	O	this	det	7	SENT_63	[p5l1363t16r1487b79],
7	population	NN	O	population	dobj	5	SENT_63	[p5l1508t16r1900b99],
8	.	.	O	.	_	0	SENT_63	[p5l1508t16r1900b99],

1	C	NN	O	c	nn	2	SENT_64	[p5l1714t154r1732b176],
2	survi	NN	O	survus	_	0	SENT_64	[p5l1690t188r1748b209],
3	al	NNP	O	al	dep	2	SENT_64	[p5l1763t188r1783b209],
4	"	``	O	"	punct	3	SENT_64	[p5l1494t194r1501b195],
5	"	``	O	"	punct	7	SENT_64	[p5l1530t198r1539b199],
6	v	LS	O	v	dep	7	SENT_64	[p5l1749t194r1763b209],
7	EML4	NN	O	eml4	dep	3	SENT_64	[p5l781t225r914b246],
8	.	.	O	.	_	0	SENT_64	[p5l781t225r914b246],

1	—	NN	O	—	_	0	SENT_65	[p5l781t225r914b246],
2	.	.	O	.	_	0	SENT_65	[p5l781t225r914b246],

1	ALK	NNP	O	ALK	_	0	SENT_66	[p5l781t225r914b246],
2	.	.	O	.	_	0	SENT_66	[p5l1727t243r1728b247],

1	fusion	NN	O	fusion	nn	2	SENT_67	[p5l762t259r835b280],
2	protein	NN	O	protein	_	0	SENT_67	[p5l846t259r929b285],

1	*	NN	O	*	_	0	SENT_68	[p5l650t297r687b311],
2	‘	CD	NUMBER	‘	num	4	SENT_68	[p5l650t297r687b311],
3	STAT3/5	NN	O	stat3/5	nn	4	SENT_68	[p5l1127t302r1229b324],
4	s	NNS	O	s	dep	1	SENT_68	[p5l1247t306r1250b307],
5	T	NN	O	t	dep	1	SENT_68	[p5l1271t306r1346b307],

1	9	CD	NUMBER	9	num	2	SENT_69	[p5l340t375r388b397],
2	*	NN	O	*	dep	9	SENT_69	[p5l340t375r388b397],
3	W	NN	O	w	nn	4	SENT_69	[p5l401t372r554b435],
4	A.	NN	O	a.	dep	2	SENT_69	[p5l581t376r589b382],
5	P	NN	O	p	dep	9	SENT_69	[p5l608t376r631b411],
6	9	CD	NUMBER	9	num	5	SENT_69	[p5l608t376r631b411],
7	*	NN	O	*	nn	9	SENT_69	[p5l608t376r631b411],
8	F	NN	O	f	nn	9	SENT_69	[p5l650t307r689b425],
9	j.	NN	O	j.	dep	13	SENT_69	[p5l705t390r807b403],
10	5	CD	NUMBER	5	dep	9	SENT_69	[p5l823t331r883b465],
11	/	:	O	/	punct	13	SENT_69	[p5l1163t360r1177b391],
12	’	CD	NUMBER	’	num	13	SENT_69	[p5l1163t360r1177b391],
13	ovlhclzqell	NN	O	ovlhclzqell	_	0	SENT_69	[p5l1720t358r1799b413],

1	Tum	NN	O	tum	nn	4	SENT_70	[p5l1673t358r1724b380],
2	gr	NN	O	gr	nn	4	SENT_70	[p5l1696t397r1720b419],
3	mTOF	NN	O	mtof	nn	4	SENT_70	[p5l1308t425r1459b447],
4	(	NN	O	(	_	0	SENT_70	[p5l1308t425r1459b447],
5	.	.	O	.	_	0	SENT_70	[p5l1308t425r1459b447],

1	—	NN	O	—	_	0	SENT_71	[p5l1308t425r1459b447],
2	.	.	O	.	_	0	SENT_71	[p5l1308t425r1459b447],

1	-	:	O	-	_	0	SENT_72	[p5l1308t425r1459b447],
2	>	JJR	O	>	amod	3	SENT_72	[p5l1308t425r1459b447],
3	S6K	NN	O	s6k	_	0	SENT_72	[p5l1491t425r1543b447],
4	lm/T	NN	O	lm/t	dep	3	SENT_72	[p5l1561t420r1739b445],

1	1	CD	NUMBER	1	_	0	SENT_73	[p5l1505t181r1523b195],
2	;	:	O	;	_	0	SENT_73	[p5l1505t181r1523b195],
3	.	.	O	.	_	0	SENT_73	[p5l1505t181r1523b195],

1	in	IN	O	in	_	0	SENT_74	[p5l1531t180r1546b195],
2	m	NN	O	m	pobj	1	SENT_74	[p5l1565t175r1685b189],

1	Inversion	NN	O	inversion	nn	2	SENT_75	[p5l429t461r538b482],
2	n	NN	O	n	_	0	SENT_75	[p5l1132t535r1457b591],
3	-	:	O	-	_	0	SENT_75	[p5l1132t535r1457b591],
4	«	CD	NUMBER	«	dep	2	SENT_75	[p5l1132t535r1457b591],
5	I	PRP	O	I	dep	4	SENT_75	[p5l1132t535r1457b591],
6	-	:	O	-	_	0	SENT_75	[p5l1132t535r1457b591],
7	~	SYM	O	~	dep	9	SENT_75	[p5l1132t535r1457b591],
8	-	:	O	-	_	0	SENT_75	[p5l1471t535r1741b591],
9	r	NN	O	r	dep	5	SENT_75	[p5l1471t535r1741b591],
10	—	CD	NUMBER	—	num	11	SENT_75	[p5l1471t535r1741b591],
11	x.	NN	O	x.	dep	5	SENT_75	[p5l1471t535r1741b591],
12	.	.	O	.	_	0	SENT_75	[p5l1471t535r1741b591],

1	7	CD	NUMBER	7	num	2	SENT_76	[p5l1315t592r1320b593],
2	7	CD	NUMBER	7	_	0	SENT_76	[p5l1491t592r1496b593],
3	'	''	O	'	_	0	SENT_76	[p5l1529t592r1532b593],
4	Tumor	NN	O	tumor	nn	5	SENT_76	[p5l1661t603r1739b624],
5	cell	NN	O	cell	dep	2	SENT_76	[p5l1747t603r1787b624],
6	chromosome	NN	O	chromosome	nn	9	SENT_76	[p5l383t642r550b664],
7	2	CD	NUMBER	2	num	9	SENT_76	[p5l559t643r573b663],
8	V	NN	O	v	nn	9	SENT_76	[p5l1183t673r1186b674],
9	proliferation	NN	O	proliferation	dep	2	SENT_76	[p5l1653t636r1796b663],

1	Illustrated	NNP	O	Illustrated	_	0	SENT_77	[p5l1854t648r1875b766],
2	by	IN	O	by	dep	1	SENT_77	[p5l1854t610r1880b637],
3	Zina	NNP	PERSON	Zina	nn	4	SENT_77	[p5l1854t547r1875b601],
4	Deretsky	NNP	PERSON	Deretsky	pobj	2	SENT_77	[p5l1854t428r1880b537],

1	Figure	NNP	O	Figure	_	0	SENT_78	[p5l22t841r112b872],
2	1	CD	NUMBER	1	num	1	SENT_78	[p5l121t843r131b865],
3	ALK	NN	ORGANIZATION	alk	nn	4	SENT_78	[p5l158t842r210b865],
4	activation	NN	O	activation	dep	1	SENT_78	[p5l217t842r347b865],
5	and	CC	O	and	_	0	SENT_78	[p5l356t841r404b865],
6	downstream	JJ	O	downstream	amod	7	SENT_78	[p5l413t841r580b865],
7	signaling	NN	O	signaling	conj_and	4	SENT_78	[p5l589t841r708b872],
8	in	IN	O	in	_	0	SENT_78	[p5l718t842r739b865],
9	ALK-rearranged	JJ	O	alk-rearranged	amod	10	SENT_78	[p5l748t841r955b872],
10	NSCLC	NN	O	nsclc	prep_in	4	SENT_78	[p5l966t842r1057b865],
11	.	.	O	.	_	0	SENT_78	[p5l966t842r1057b865],

1	EML4	NN	O	eml4	_	0	SENT_79	[p5l1067t841r1307b865],
2	.	.	O	.	_	0	SENT_79	[p5l1067t841r1307b865],

1	—	NN	O	—	_	0	SENT_80	[p5l1067t841r1307b865],
2	.	.	O	.	_	0	SENT_80	[p5l1067t841r1307b865],

1	ALKfusions	NNS	O	alkfusion	nsubj	3	SENT_81	[p5l1067t841r1307b865],
2	are	VBP	O	be	cop	3	SENT_81	[p5l1315t848r1355b865],
3	due	JJ	O	due	_	0	SENT_81	[p5l1363t841r1413b865],
4	to	TO	O	to	_	0	SENT_81	[p5l1420t845r1447b865],
5	small	JJ	O	small	amod	6	SENT_81	[p5l1455t841r1522b865],
6	inversions	NNS	O	inversion	prep_to	3	SENT_81	[p5l1532t842r1664b865],
7	within	IN	O	within	_	0	SENT_81	[p5l1672t841r1754b865],
8	chromosome	NN	O	chromosome	nn	9	SENT_81	[p5l1763t841r1940b865],
9	2p	NN	O	2p	prep_within	6	SENT_81	[p5l1948t843r1981b872],
10	(	CD	NUMBER	(	num	13	SENT_81	[p5l1989t841r2139b869],
11	|	NN	O	|	nn	13	SENT_81	[p5l1989t841r2139b869],
12	eft	NN	O	eft	nn	13	SENT_81	[p5l1989t841r2139b869],
13	)	NN	O	)	dep	9	SENT_81	[p5l1989t841r2139b869],
14	.	.	O	.	_	0	SENT_81	[p5l1989t841r2139b869],

1	These	DT	O	these	det	2	SENT_82	[p5l1989t841r2139b869],
2	fusions	NNS	O	fusion	nsubj	3	SENT_82	[p5l20t882r114b906],
3	lead	VBP	O	lead	_	0	SENT_82	[p5l123t882r177b906],
4	to	TO	O	to	_	0	SENT_82	[p5l185t886r212b906],
5	aberrant	JJ	O	aberrant	amod	6	SENT_82	[p5l220t882r333b906],
6	expression	NN	O	expression	prep_to	3	SENT_82	[p5l341t883r481b912],
7	of	IN	O	of	_	0	SENT_82	[p5l490t882r518b906],
8	ALK	NNP	O	ALK	prep_of	6	SENT_82	[p5l523t883r575b906],
9	and	CC	O	and	_	0	SENT_82	[p5l582t882r631b906],
10	constitutive	JJ	O	constitutive	amod	11	SENT_82	[p5l640t883r796b906],
11	activation	NN	O	activation	prep_to	3	SENT_82	[p5l804t883r934b906],
12	of	IN	O	of	_	0	SENT_82	[p5l943t882r970b906],
13	the	DT	O	the	det	16	SENT_82	[p5l975t882r1018b906],
14	ALK	NNP	O	ALK	nn	16	SENT_82	[p5l1026t883r1078b906],
15	tyrosine	NN	O	tyrosine	nn	16	SENT_82	[p5l1084t884r1191b913],
16	kinase	NN	O	kinase	prep_of	11	SENT_82	[p5l1200t882r1282b906],
17	and	CC	O	and	_	0	SENT_82	[p5l1290t882r1339b906],
18	downstream	JJ	O	downstream	amod	20	SENT_82	[p5l1348t882r1514b906],
19	signaling	NN	O	signaling	nn	20	SENT_82	[p5l1523t882r1642b913],
20	pathways	NNS	O	pathway	conj_and	6	SENT_82	[p5l1652t882r1778b913],
21	(	RB	O	(	advmod	22	SENT_82	[p5l1786t882r1927b913],
22	right	JJ	O	right	amod	23	SENT_82	[p5l1786t882r1927b913],
23	)	NN	O	)	dep	20	SENT_82	[p5l1786t882r1927b913],
24	.	.	O	.	_	0	SENT_82	[p5l1786t882r1927b913],

1	The	DT	O	the	det	3	SENT_83	[p5l1786t882r1927b913],
2	end	NN	O	end	nn	3	SENT_83	[p5l1935t882r1984b906],
3	result	NN	O	result	nsubj	6	SENT_83	[p5l1994t882r2067b906],
4	is	VBZ	O	be	cop	6	SENT_83	[p5l21t924r39b947],
5	uncontrolled	JJ	O	uncontrolled	amod	6	SENT_83	[p5l48t923r217b947],
6	proliferation	NN	O	proliferation	_	0	SENT_83	[p5l227t923r388b953],
7	and	CC	O	and	_	0	SENT_83	[p5l397t923r446b947],
8	survival	NN	O	survival	nn	10	SENT_83	[p5l455t923r555b947],
9	ofcancer	NN	O	ofcancer	nn	10	SENT_83	[p5l564t923r685b947],
10	cells	NNS	O	cell	conj_and	6	SENT_83	[p5l692t923r754b947],
11	.	.	O	.	_	0	SENT_83	[p5l692t923r754b947],

1	ALK	NNP	O	ALK	_	0	SENT_84	[p5l762t924r820b951],
2	,	,	O	,	_	0	SENT_84	[p5l762t924r820b951],
3	anaplastic	JJ	O	anaplastic	amod	5	SENT_84	[p5l828t923r961b953],
4	lymphoma	NN	O	lymphoma	nn	5	SENT_84	[p5l970t923r1112b954],
5	kinase	NN	O	kinase	appos	1	SENT_84	[p5l1122t923r1211b951],
6	;	:	O	;	_	0	SENT_84	[p5l1122t923r1211b951],
7	EML4	NN	O	eml4	dep	1	SENT_84	[p5l1220t924r1297b951],
8	,	,	O	,	_	0	SENT_84	[p5l1220t924r1297b951],
9	echinoderm	NN	O	echinoderm	appos	7	SENT_84	[p5l1305t923r1465b947],
10	microtubule-associated	JJ	O	microtubule-associated	amod	9	SENT_84	[p5l1475t923r1787b947],
11	protein-like	JJ	O	protein-like	amod	9	SENT_84	[p5l1797t923r1948b953],
12	4	CD	NUMBER	4	tmod	11	SENT_84	[p5l1956t925r1978b951],
13	;	:	O	;	_	0	SENT_84	[p5l1956t925r1978b951],
14	NSCLC	NNP	LOCATION	NSCLC	dep	1	SENT_84	[p5l1987t924r2078b951],
15	,	,	O	,	_	0	SENT_84	[p5l1987t924r2078b951],
16	non	JJ	O	non	amod	17	SENT_84	[p5l22t964r157b988],
17	—	NN	O	—	appos	14	SENT_84	[p5l22t964r157b988],
18	small	JJ	O	small	amod	21	SENT_84	[p5l22t964r157b988],
19	cell	NN	O	cell	nn	21	SENT_84	[p5l166t964r209b988],
20	lung	NN	O	lung	nn	21	SENT_84	[p5l219t964r276b995],
21	cancer	NN	O	cancer	dep	17	SENT_84	[p5l285t971r376b988],
22	.	.	O	.	_	0	SENT_84	[p5l285t971r376b988],

1	16	CD	NUMBER	16	num	2	SENT_85	[p5l22t1063r51b1084],
2	VOLUME	NN	O	volume	_	0	SENT_85	[p5l1368t1063r1476b1084],
3	95	CD	NUMBER	95	num	4	SENT_85	[p5l1484t1063r1511b1084],
4	NUMBER	NN	O	number	dep	2	SENT_85	[p5l1521t1063r1629b1084],
5	1	CD	NUMBER	1	number	6	SENT_85	[p5l1639t1064r1646b1084],
6	|	CD	NUMBER	|	dep	4	SENT_85	[p5l1660t1061r1662b1091],
7	JANUARY	NNP	DATE	JANUARY	dep	6	SENT_85	[p5l1671t1063r1789b1084],
8	2014	CD	DATE	2014	num	7	SENT_85	[p5l1796t1063r1855b1084],
9	|	CD	NUMBER	|	num	10	SENT_85	[p5l1864t1061r1866b1091],
10	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	2	SENT_85	[p5l1875t1063r2140b1089],

1	STATE	NN	O	state	nn	2	SENT_86	[p5l1761t1206r1902b1243],
2	ART	NN	O	art	_	0	SENT_86	[p5l2045t1206r2139b1243],

1	The	DT	O	the	det	5	SENT_87	[p5l83t1439r208b1502],
2	prognosis	NN	O	prognosis	nn	5	SENT_87	[p5l228t1445r562b1523],
3	and	CC	O	and	_	0	SENT_87	[p5l584t1439r710b1502],
4	natural	JJ	O	natural	nn	5	SENT_87	[p5l731t1439r974b1502],
5	history	NN	O	history	nsubjpass	13	SENT_87	[p5l994t1439r1238b1523],
6	of	IN	O	of	_	0	SENT_87	[p5l1256t1439r1330b1502],
7	ALK	NN	O	alk	nn	8	SENT_87	[p5l1338t1443r1504b1501],
8	rearrangements	NNS	O	rearrangement	prep_of	5	SENT_87	[p5l1519t1451r2055b1523],
9	in	IN	O	in	_	0	SENT_87	[p5l2077t1445r2143b1501],
10	NSCLC	NNP	ORGANIZATION	NSCLC	prep_in	8	SENT_87	[p5l9t1546r273b1605],
11	have	VBP	O	have	aux	13	SENT_87	[p5l295t1542r452b1605],
12	been	VBN	O	be	auxpass	13	SENT_87	[p5l473t1542r638b1605],
13	explored	VBN	O	explore	_	0	SENT_87	[p5l661t1542r961b1625],
14	retrospectively	RB	O	retrospectively	advmod	13	SENT_87	[p5l983t1542r1500b1626],
15	.	.	O	.	_	0	SENT_87	[p5l983t1542r1500b1626],

1	In	IN	O	in	dep	103	SENT_88	[p5l1527t1547r1598b1604],
2	early	JJ	O	early	dep	103	SENT_88	[p5l1622t1542r1990b1626],
3	—	JJ	O	—	dep	103	SENT_88	[p5l1622t1542r1990b1626],
4	stage	NN	O	stage	dep	103	SENT_88	[p5l1622t1542r1990b1626],
5	disease	NN	O	disease	dep	103	SENT_88	[p5l2014t1542r2138b1605, p5l10t1668r172b1717],
6	,	,	O	,	_	0	SENT_88	[p5l2014t1542r2138b1605, p5l10t1668r172b1717],
7	the	DT	O	the	dep	103	SENT_88	[p5l197t1645r306b1708],
8	prognostic	JJ	O	prognostic	dep	103	SENT_88	[p5l329t1651r707b1729],
9	effect	NN	O	effect	dep	103	SENT_88	[p5l731t1645r918b1708],
10	of	IN	O	of	dep	103	SENT_88	[p5l941t1645r1017b1708],
11	ALK	NN	O	alk	dep	103	SENT_88	[p5l1027t1649r1198b1707],
12	rearrangements	NNS	O	rearrangement	dep	103	SENT_88	[p5l1215t1657r1767b1729],
13	is	VBZ	O	be	dep	103	SENT_88	[p5l1792t1651r1843b1708],
14	unclear	JJ	O	unclear	dep	103	SENT_88	[p5l1868t1645r2142b1717],
15	,	,	O	,	_	0	SENT_88	[p5l1868t1645r2142b1717],
16	with	IN	O	with	dep	103	SENT_88	[p5l8t1748r157b1811],
17	reports	NNS	O	report	dep	103	SENT_88	[p5l177t1760r413b1831],
18	of	IN	O	of	dep	103	SENT_88	[p5l434t1748r506b1811],
19	both	DT	O	both	dep	103	SENT_88	[p5l515t1748r670b1811],
20	improved	VBN	O	improve	dep	103	SENT_88	[p5l689t1748r1011b1831],
21	and	CC	O	and	dep	103	SENT_88	[p5l1030t1748r1154b1811],
22	worsened	VBN	O	worsen	dep	103	SENT_88	[p5l1170t1748r1493b1811],
23	survival	NN	O	survival	dep	103	SENT_88	[p5l1513t1748r1777b1811],
24	in	IN	O	in	dep	103	SENT_88	[p5l1796t1754r1861b1810],
25	patients	NNS	O	patient	dep	103	SENT_88	[p5l1879t1754r2141b1831],
26	with	IN	O	with	dep	103	SENT_88	[p5l8t1850r163b1913],
27	resected	JJ	O	resected	dep	103	SENT_88	[p5l186t1850r472b1913],
28	ALK-positive	JJ	O	alk-positive	dep	103	SENT_88	[p5l493t1854r962b1933],
29	NSCLC	NN	O	nsclc	dep	103	SENT_88	[p5l985t1842r1412b1914],
30	.37	CD	NUMBER	.37	dep	103	SENT_88	[p5l985t1842r1412b1914],
31	’38	CD	NUMBER	’38	dep	103	SENT_88	[p5l985t1842r1412b1914],
32	In	IN	O	in	dep	103	SENT_88	[p5l1437t1855r1509b1912],
33	the	DT	O	the	dep	103	SENT_88	[p5l1531t1850r1639b1913],
34	advanced	JJ	O	advanced	dep	103	SENT_88	[p5l1663t1850r1992b1913],
35	disease	NN	O	disease	dep	103	SENT_88	[p5l2015t1850r2140b1913, p5l10t1976r147b2016],
36	setting	NN	O	setting	dep	103	SENT_88	[p5l169t1959r410b2037],
37	,	,	O	,	_	0	SENT_88	[p5l169t1959r410b2037],
38	ALK-positive	JJ	O	alk-positive	dep	103	SENT_88	[p5l431t1957r885b2036],
39	patients	NNS	O	patient	dep	103	SENT_88	[p5l905t1959r1170b2036],
40	have	VBP	O	have	dep	103	SENT_88	[p5l1190t1953r1343b2016],
41	been	VBN	O	be	dep	103	SENT_88	[p5l1361t1953r1523b2016],
42	reported	VBN	O	report	dep	103	SENT_88	[p5l1543t1953r1834b2036],
43	to	TO	O	to	dep	103	SENT_88	[p5l1852t1965r1917b2016],
44	have	VB	O	have	dep	103	SENT_88	[p5l1937t1953r2090b2016],
45	a	DT	O	a	dep	103	SENT_88	[p5l2111t1976r2146b2016],
46	higher	JJR	O	higher	dep	103	SENT_88	[p5l9t2056r227b2140],
47	propensity	NN	O	propensity	dep	103	SENT_88	[p5l244t2062r605b2140],
48	for	IN	O	for	dep	103	SENT_88	[p5l622t2056r717b2119],
49	pericardial	JJ	O	pericardial	dep	103	SENT_88	[p5l734t2056r1097b2139],
50	and	CC	O	and	dep	103	SENT_88	[p5l1117t2056r1241b2119],
51	pleural	JJ	O	pleural	dep	103	SENT_88	[p5l1258t2056r1492b2139],
52	disease	NN	O	disease	dep	103	SENT_88	[p5l1512t2056r1747b2119],
53	than	IN	O	than	dep	103	SENT_88	[p5l1766t2056r1918b2119],
54	triplenegative	JJ	O	triplenegative	dep	103	SENT_88	[p5l1936t2056r2141b2139, p5l9t2164r300b2242],
55	patients	NNS	O	patient	dep	103	SENT_88	[p5l323t2164r600b2241],
56	(	IN	O	(	dep	103	SENT_88	[p5l629t2159r881b2234],
57	EGFR	NN	ORGANIZATION	egfr	dep	103	SENT_88	[p5l629t2159r881b2234],
58	,	,	O	,	_	0	SENT_88	[p5l629t2159r881b2234],
59	KRAS	NNP	ORGANIZATION	KRAS	dep	103	SENT_88	[p5l906t2162r1133b2230],
60	,	,	O	,	_	0	SENT_88	[p5l906t2162r1133b2230],
61	ALK	NNP	O	ALK	dep	103	SENT_88	[p5l1155t2162r1326b2220],
62	wild	JJ	O	wild	dep	103	SENT_88	[p5l1341t2158r1495b2221],
63	type	NN	O	type	dep	103	SENT_88	[p5l1517t2150r1783b2242],
64	)	CD	NUMBER	)	dep	103	SENT_88	[p5l1517t2150r1783b2242],
65	.39	CD	NUMBER	.39	dep	103	SENT_88	[p5l1517t2150r1783b2242],
66	Although	IN	O	although	dep	103	SENT_88	[p5l1807t2158r2143b2242],
67	brain	NN	O	brain	dep	103	SENT_88	[p5l8t2261r189b2324],
68	metastases	NNS	O	metastase	dep	103	SENT_88	[p5l212t2273r578b2324],
69	have	VBP	O	have	dep	103	SENT_88	[p5l601t2261r757b2324],
70	been	VBN	O	be	dep	103	SENT_88	[p5l777t2261r942b2324],
71	reported	VBN	O	report	dep	103	SENT_88	[p5l965t2261r1262b2344],
72	in	IN	O	in	dep	103	SENT_88	[p5l1284t2267r1351b2323],
73	~	NN	O	~	dep	103	SENT_88	[p5l1376t2267r1567b2326],
74	30	CD	PERCENT	30	dep	103	SENT_88	[p5l1376t2267r1567b2326],
75	%	NN	PERCENT	%	dep	103	SENT_88	[p5l1376t2267r1567b2326],
76	of	IN	O	of	dep	103	SENT_88	[p5l1593t2261r1667b2324],
77	ALK-positive	JJ	O	alk-positive	dep	103	SENT_88	[p5l1679t2265r2143b2344],
78	patients	NNS	O	patient	dep	103	SENT_88	[p5l8t2370r275b2447],
79	enrolled	VBN	O	enrol	dep	103	SENT_88	[p5l297t2364r576b2427],
80	in	IN	O	in	dep	103	SENT_88	[p5l596t2370r662b2426],
81	clinical	JJ	O	clinical	dep	103	SENT_88	[p5l683t2364r926b2427],
82	trials	NNS	O	trial	dep	103	SENT_88	[p5l944t2364r1113b2427],
83	of	IN	O	of	dep	103	SENT_88	[p5l1135t2364r1209b2427],
84	crizotinib	NN	O	crizotinib	dep	103	SENT_88	[p5l1220t2364r1563b2436],
85	,	,	O	,	_	0	SENT_88	[p5l1220t2364r1563b2436],
86	the	DT	O	the	dep	103	SENT_88	[p5l1585t2364r1690b2427],
87	lifetime	NN	O	lifetime	dep	103	SENT_88	[p5l1709t2364r1968b2427],
88	incidence	NN	O	incidence	dep	103	SENT_88	[p5l1989t2370r2141b2427, p5l10t2467r209b2530],
89	may	MD	O	may	dep	103	SENT_88	[p5l232t2490r379b2551],
90	be	VB	O	be	dep	103	SENT_88	[p5l396t2467r476b2530],
91	as	RB	O	as	dep	103	SENT_88	[p5l499t2490r564b2530],
92	high	JJ	O	high	dep	103	SENT_88	[p5l586t2467r741b2551],
93	as	IN	O	as	dep	103	SENT_88	[p5l764t2490r828b2530],
94	50	CD	PERCENT	50	dep	103	SENT_88	[p5l854t2473r995b2531],
95	%	NN	PERCENT	%	dep	103	SENT_88	[p5l854t2473r995b2531],
96	based	VBN	O	base	dep	103	SENT_88	[p5l1018t2467r1215b2530],
97	on	IN	O	on	dep	103	SENT_88	[p5l1237t2490r1323b2530],
98	a	DT	O	a	dep	103	SENT_88	[p5l1347t2490r1382b2530],
99	retrospective	JJ	O	retrospective	dep	103	SENT_88	[p5l1403t2473r1848b2550],
100	study	NN	O	study	dep	103	SENT_88	[p5l1872t2467r2059b2551],
101	of	IN	O	of	dep	103	SENT_88	[p5l2079t2467r2153b2530],
102	ALK-positive	JJ	O	alk-positive	dep	103	SENT_88	[p5l9t2574r466b2653],
103	patients	NNS	O	patient	_	0	SENT_88	[p5l485t2562r832b2653],
104	.	.	O	.	_	0	SENT_88	[p5l485t2562r832b2653],

1	”	NN	O	”	nsubjpass	19	SENT_89	[p5l485t2562r832b2653],
2	Whether	IN	O	whether	complm	5	SENT_89	[p5l852t2570r1155b2633],
3	ALK-positive	JJ	O	alk-positive	amod	4	SENT_89	[p5l1173t2574r1630b2653],
4	patients	NNS	O	patient	nsubj	5	SENT_89	[p5l1649t2576r1915b2653],
5	have	VBP	O	have	dep	19	SENT_89	[p5l1935t2570r2089b2633],
6	a	DT	O	a	det	8	SENT_89	[p5l2110t2593r2144b2633],
7	greater	JJR	O	greater	amod	8	SENT_89	[p5l9t2714r246b2786],
8	propensity	NN	O	propensity	dobj	5	SENT_89	[p5l264t2708r630b2786],
9	for	IN	O	for	_	0	SENT_89	[p5l647t2702r744b2765],
10	brain	NN	O	brain	nn	11	SENT_89	[p5l761t2702r941b2765],
11	metastases	NNS	O	metastase	prep_for	8	SENT_89	[p5l961t2714r1324b2765],
12	as	IN	O	as	advmod	5	SENT_89	[p5l1345t2725r1409b2765],
13	compared	VBN	O	compare	_	0	SENT_89	[p5l1431t2702r1771b2785],
14	with	IN	O	with	prepc_compared_with	5	SENT_89	[p5l1789t2702r1941b2765],
15	other	JJ	O	other	amod	16	SENT_89	[p5l1961t2702r2142b2765],
16	genotypes	NNS	O	genotype	pobj	5	SENT_89	[p5l9t2817r352b2889],
17	is	VBZ	O	be	auxpass	19	SENT_89	[p5l375t2811r424b2868],
18	not	RB	O	not	neg	19	SENT_89	[p5l446t2817r560b2868],
19	known	VBN	O	know	_	0	SENT_89	[p5l579t2805r833b2868],
20	.	.	O	.	_	0	SENT_89	[p5l579t2805r833b2868],

1	In	IN	O	in	_	0	SENT_90	[p5l84t2913r153b2970],
2	general	JJ	O	general	prep_in	14	SENT_90	[p5l173t2908r432b2992],
3	,	,	O	,	_	0	SENT_90	[p5l173t2908r432b2992],
4	the	DT	O	the	det	5	SENT_90	[p5l453t2908r556b2971],
5	response	NN	O	response	nsubj	14	SENT_90	[p5l576t2930r869b2991],
6	of	IN	O	of	_	0	SENT_90	[p5l889t2908r961b2971],
7	ALK-positive	JJ	O	alk-positive	amod	8	SENT_90	[p5l970t2912r1421b2991],
8	patients	NNS	O	patient	prep_of	5	SENT_90	[p5l1440t2914r1702b2991],
9	to	TO	O	to	_	0	SENT_90	[p5l1721t2920r1786b2971],
10	platinumdoublet	JJ	O	platinumdoublet	amod	11	SENT_90	[p5l1805t2908r2138b2991, p5l10t3011r271b3074],
11	chemotherapy	NN	O	chemotherapy	prep_to	8	SENT_90	[p5l293t3011r788b3095],
12	does	VBZ	O	do	aux	14	SENT_90	[p5l808t3011r962b3074],
13	not	RB	O	not	neg	14	SENT_90	[p5l985t3023r1100b3074],
14	appear	VB	O	appear	_	0	SENT_90	[p5l1122t3033r1353b3094],
15	to	TO	O	to	aux	17	SENT_90	[p5l1373t3023r1439b3074],
16	be	VB	O	be	cop	17	SENT_90	[p5l1461t3011r1541b3074],
17	different	JJ	O	different	xcomp	14	SENT_90	[p5l1565t3011r1856b3074],
18	as	IN	O	as	prep	17	SENT_90	[p5l1878t3034r1942b3074],
19	compared	VBN	O	compare	_	0	SENT_90	[p5l1966t3034r2141b3074, p5l8t3113r200b3196],
20	with	IN	O	with	prepc_compared_with	17	SENT_90	[p5l217t3113r367b3176],
21	patients	NNS	O	patient	pobj	17	SENT_90	[p5l386t3119r650b3196],
22	of	IN	O	of	_	0	SENT_90	[p5l671t3113r743b3176],
23	other	JJ	O	other	amod	24	SENT_90	[p5l754t3113r932b3176],
24	genotypes	NNS	O	genotype	prep_of	21	SENT_90	[p5l951t3105r1366b3197],
25	.	.	O	.	_	0	SENT_90	[p5l951t3105r1366b3197],

1	”	NN	O	”	dep	134	SENT_91	[p5l951t3105r1366b3197],
2	Interestingly	RB	O	interestingly	dep	134	SENT_91	[p5l1391t3113r1823b3197],
3	,	,	O	,	_	0	SENT_91	[p5l1391t3113r1823b3197],
4	however	RB	O	however	dep	134	SENT_91	[p5l1844t3113r2141b3185],
5	,	,	O	,	_	0	SENT_91	[p5l1844t3113r2141b3185],
6	ALK-rearranged	JJ	O	alk-rearranged	dep	134	SENT_91	[p5l6t3216r580b3300],
7	tumors	NNS	O	tumor	dep	134	SENT_91	[p5l601t3228r849b3279],
8	demonstrate	VBP	O	demonstrate	dep	134	SENT_91	[p5l873t3216r1305b3279],
9	relatively	RB	O	relatively	dep	134	SENT_91	[p5l1328t3216r1643b3300],
10	high	JJ	O	high	dep	134	SENT_91	[p5l1662t3216r1817b3300],
11	response	NN	O	response	dep	134	SENT_91	[p5l1840t3238r2143b3299],
12	rates	NNS	O	rate	dep	134	SENT_91	[p5l10t3331r170b3382],
13	to	TO	O	to	dep	134	SENT_91	[p5l193t3331r260b3382],
14	single-agent	JJ	O	single-agent	dep	134	SENT_91	[p5l286t3319r707b3403],
15	pemetreXed	JJ	O	pemetrexed	dep	134	SENT_91	[p5l727t3319r1377b3402],
16	—	NN	O	—	dep	134	SENT_91	[p5l727t3319r1377b3402],
17	with	IN	O	with	dep	134	SENT_91	[p5l727t3319r1377b3402],
18	an	DT	O	a	dep	134	SENT_91	[p5l1401t3342r1481b3382],
19	objective	JJ	O	objective	dep	134	SENT_91	[p5l1506t3319r1815b3403],
20	response	NN	O	response	dep	134	SENT_91	[p5l1839t3341r2143b3402],
21	rate	NN	O	rate	dep	134	SENT_91	[p5l10t3434r133b3485],
22	(	CD	NUMBER	(	dep	134	SENT_91	[p5l156t3422r371b3499],
23	ORR	NN	O	orr	dep	134	SENT_91	[p5l156t3422r371b3499],
24	)	NN	O	)	dep	134	SENT_91	[p5l156t3422r371b3499],
25	of	IN	O	of	dep	134	SENT_91	[p5l395t3422r467b3485],
26	29	CD	PERCENT	29	dep	134	SENT_91	[p5l478t3428r617b3487],
27	%	NN	PERCENT	%	dep	134	SENT_91	[p5l478t3428r617b3487],
28	observed	VBN	O	observe	dep	134	SENT_91	[p5l639t3422r942b3485],
29	in	IN	O	in	dep	134	SENT_91	[p5l960t3428r1025b3484],
30	a	DT	O	a	dep	134	SENT_91	[p5l1046t3445r1079b3485],
31	phase	NN	O	phase	dep	134	SENT_91	[p5l1097t3422r1287b3505],
32	III	CD	NUMBER	iii	dep	134	SENT_91	[p5l1307t3427r1388b3484],
33	study	NN	O	study	dep	134	SENT_91	[p5l1409t3422r1591b3506],
34	in	IN	O	in	dep	134	SENT_91	[p5l1607t3428r1672b3484],
35	ALK-positive	JJ	O	alk-positive	dep	134	SENT_91	[p5l1691t3426r2141b3505],
36	patients	NNS	O	patient	dep	134	SENT_91	[p5l8t3516r348b3607],
37	,31	CD	NUMBER	,31	dep	134	SENT_91	[p5l8t3516r348b3607],
38	as	IN	O	as	dep	134	SENT_91	[p5l373t3547r436b3587],
39	compared	VBN	O	compare	dep	134	SENT_91	[p5l457t3524r793b3607],
40	with	IN	O	with	dep	134	SENT_91	[p5l810t3524r960b3587],
41	RRs	NN	O	rr	dep	134	SENT_91	[p5l980t3529r1111b3587],
42	of	IN	O	of	dep	134	SENT_91	[p5l1132t3524r1205b3587],
43	~	NN	O	~	dep	134	SENT_91	[p5l1218t3559r1258b3571],
44	10	CD	PERCENT	10	dep	134	SENT_91	[p5l1271t3529r1404b3589],
45	%	NN	PERCENT	%	dep	134	SENT_91	[p5l1271t3529r1404b3589],
46	in	IN	O	in	dep	134	SENT_91	[p5l1426t3530r1492b3586],
47	unselected	JJ	O	unselected	dep	134	SENT_91	[p5l1511t3524r1867b3587],
48	NSCLC	NN	O	nsclc	dep	134	SENT_91	[p5l1885t3528r2143b3588],
49	patients	NNS	O	patient	dep	134	SENT_91	[p5l8t3618r358b3709],
50	.40	CD	NUMBER	.40	dep	134	SENT_91	[p5l8t3618r358b3709],
51	Although	IN	O	although	dep	134	SENT_91	[p5l378t3626r704b3710],
52	some	DT	O	some	dep	134	SENT_91	[p5l724t3649r902b3689],
53	retrospective	JJ	O	retrospective	dep	134	SENT_91	[p5l922t3632r1362b3709],
54	studies	NNS	O	study	dep	134	SENT_91	[p5l1384t3626r1617b3689],
55	have	VBP	O	have	dep	134	SENT_91	[p5l1637t3626r1791b3689],
56	suggested	VBN	O	suggest	dep	134	SENT_91	[p5l1813t3626r2142b3710],
57	improved	JJ	O	improved	dep	134	SENT_91	[p5l10t3729r357b3812],
58	progression-free	JJ	O	progression-free	dep	134	SENT_91	[p5l383t3729r982b3813],
59	survival	NN	O	survival	dep	134	SENT_91	[p5l1012t3729r1299b3792],
60	(	CD	NUMBER	(	dep	134	SENT_91	[p5l1331t3730r1524b3806],
61	PFS	NN	O	pf	dep	134	SENT_91	[p5l1331t3730r1524b3806],
62	)	NN	O	)	dep	134	SENT_91	[p5l1331t3730r1524b3806],
63	in	IN	O	in	dep	134	SENT_91	[p5l1558t3735r1627b3791],
64	ALK-positive	JJ	O	alk-positive	dep	134	SENT_91	[p5l1655t3733r2143b3812],
65	patients	NNS	O	patient	dep	134	SENT_91	[p6l8t26r281b103],
66	treated	VBN	O	treat	dep	134	SENT_91	[p6l304t20r545b83],
67	with	IN	O	with	dep	134	SENT_91	[p6l566t20r720b83],
68	pemetrexed	JJ	O	pemetrexed	dep	134	SENT_91	[p6l742t12r1231b103],
69	,41	CD	NUMBER	,41	dep	134	SENT_91	[p6l742t12r1231b103],
70	more	JJR	O	more	dep	134	SENT_91	[p6l1259t43r1438b83],
71	modest	JJ	O	modest	dep	134	SENT_91	[p6l1461t20r1718b83],
72	results	NNS	O	result	dep	134	SENT_91	[p6l1739t20r1962b83],
73	have	VBP	O	have	dep	134	SENT_91	[p6l1985t20r2142b83],
74	been	VBN	O	be	dep	134	SENT_91	[p6l8t122r174b185],
75	seen	VBN	O	see	dep	134	SENT_91	[p6l199t145r350b185],
76	in	IN	O	in	dep	134	SENT_91	[p6l373t128r441b184],
77	other	JJ	O	other	dep	134	SENT_91	[p6l465t122r649b185],
78	series42	NN	O	series42	dep	134	SENT_91	[p6l672t114r927b185],
79	and	CC	O	and	dep	134	SENT_91	[p6l952t122r1080b185],
80	in	IN	O	in	dep	134	SENT_91	[p6l1102t128r1170b184],
81	the	DT	O	the	dep	134	SENT_91	[p6l1192t122r1300b185],
82	recently	RB	DATE	recently	dep	134	SENT_91	[p6l1324t122r1604b206],
83	reported	VBN	O	report	dep	134	SENT_91	[p6l1623t122r1924b205],
84	phase	NN	O	phase	dep	134	SENT_91	[p6l1945t122r2143b205],
85	III	CD	NUMBER	iii	dep	134	SENT_91	[p6l10t229r91b286],
86	study	NN	O	study	dep	134	SENT_91	[p6l113t216r363b308],
87	.31	CD	NUMBER	.31	dep	134	SENT_91	[p6l113t216r363b308],
88	As	IN	O	as	dep	134	SENT_91	[p6l386t228r471b287],
89	expected	VBN	O	expect	dep	134	SENT_91	[p6l492t224r805b307],
90	,	,	O	,	_	0	SENT_91	[p6l492t224r805b307],
91	EGFR	NN	ORGANIZATION	egfr	dep	134	SENT_91	[p6l827t228r1033b287],
92	tyrosine	NN	O	tyrosine	dep	134	SENT_91	[p6l1049t230r1321b308],
93	kinase	NN	O	kinase	dep	134	SENT_91	[p6l1339t224r1553b287],
94	inhibitor	NN	O	inhibitor	dep	134	SENT_91	[p6l1573t224r1870b287],
95	therapy	NN	O	therapy	dep	134	SENT_91	[p6l1888t224r2145b308],
96	is	VBZ	O	be	dep	134	SENT_91	[p6l10t332r59b389],
97	ineffective	JJ	O	ineffective	dep	134	SENT_91	[p6l80t326r426b389],
98	in	IN	O	in	dep	134	SENT_91	[p6l446t332r512b388],
99	ALK-positive	JJ	O	alk-positive	dep	134	SENT_91	[p6l531t330r987b409],
100	patients	NNS	O	patient	dep	134	SENT_91	[p6l1006t318r1507b409],
101	.32	CD	NUMBER	.32	dep	134	SENT_91	[p6l1006t318r1507b409],
102	>	JJR	O	>	dep	134	SENT_91	[p6l1006t318r1507b409],
103	43	CD	NUMBER	43	dep	134	SENT_91	[p6l1006t318r1507b409],
104	>	JJR	O	>	dep	134	SENT_91	[p6l1006t318r1507b409],
105	44	CD	NUMBER	44	dep	134	SENT_91	[p6l1006t318r1507b409],
106	Most	JJS	O	most	dep	134	SENT_91	[p6l1527t331r1699b389],
107	signiﬁcantly	RB	O	signiﬁcantly	dep	134	SENT_91	[p6l1719t326r2141b410],
108	,	,	O	,	_	0	SENT_91	[p6l1719t326r2141b410],
109	ALK	NN	O	alk	dep	134	SENT_91	[p6l9t433r172b491],
110	positivity	NN	O	positivity	dep	134	SENT_91	[p6l192t435r517b513],
111	seems	VBZ	O	seem	dep	134	SENT_91	[p6l537t452r741b492],
112	to	TO	O	to	dep	134	SENT_91	[p6l763t441r829b492],
113	be	VB	O	be	dep	134	SENT_91	[p6l851t429r931b492],
114	associated	VBN	O	associate	dep	134	SENT_91	[p6l954t429r1304b492],
115	with	IN	O	with	dep	134	SENT_91	[p6l1324t429r1477b492],
116	an	DT	O	a	dep	134	SENT_91	[p6l1501t452r1581b492],
117	improved	VBN	O	improve	dep	134	SENT_91	[p6l1603t429r1934b512],
118	prognosis	NN	O	prognosis	dep	134	SENT_91	[p6l1955t451r2140b513, p6l9t538r205b604],
119	,	,	O	,	_	0	SENT_91	[p6l1955t451r2140b513, p6l9t538r205b604],
120	including	VBG	O	include	dep	134	SENT_91	[p6l230t532r564b616],
121	probable	JJ	O	probable	dep	134	SENT_91	[p6l584t532r889b615],
122	beneﬁcial	JJ	O	beneﬁcial	dep	134	SENT_91	[p6l911t532r1248b595],
123	effects	NNS	O	effect	dep	134	SENT_91	[p6l1272t532r1488b595],
124	on	IN	O	on	dep	134	SENT_91	[p6l1512t555r1600b595],
125	survival	NN	O	survival	dep	134	SENT_91	[p6l1624t532r1918b604],
126	,	,	O	,	_	0	SENT_91	[p6l1624t532r1918b604],
127	in	IN	O	in	dep	134	SENT_91	[p6l1943t538r2011b594],
128	the	DT	O	the	dep	134	SENT_91	[p6l2033t532r2142b595],
129	context	NN	O	context	dep	134	SENT_91	[p6l10t646r261b698],
130	of	IN	O	of	dep	134	SENT_91	[p6l283t634r356b698],
131	treatment	NN	O	treatment	dep	134	SENT_91	[p6l368t646r703b698],
132	with	IN	O	with	dep	134	SENT_91	[p6l721t634r874b698],
133	ALK	NN	O	alk	dep	134	SENT_91	[p6l894t639r1057b697],
134	inhibitors	NNS	O	inhibitor	_	0	SENT_91	[p6l1077t626r1492b698],
135	.	.	O	.	_	0	SENT_91	[p6l1077t626r1492b698],

1	”	NN	O	”	_	0	SENT_92	[p6l1077t626r1492b698],

1	DETECTION	NN	O	detection	_	0	SENT_93	[p6l13t849r422b905],
2	OF	IN	O	of	_	0	SENT_93	[p6l443t849r537b905],
3	ALK	NNP	O	ALK	prep_of	1	SENT_93	[p6l556t850r698b904],
4	IN	IN	O	in	_	0	SENT_93	[p6l717t850r786b904],
5	NSCLC	NNP	MISC	NSCLC	prep_in	1	SENT_93	[p6l809t850r1037b905],

1	ALK	NN	O	alk	nn	2	SENT_94	[p6l6t949r178b1007],
2	rearrangements	NNS	O	rearrangement	nsubjpass	7	SENT_94	[p6l200t957r765b1029],
3	in	IN	O	in	_	0	SENT_94	[p6l795t951r864b1007],
4	NSCLC	NNP	O	NSCLC	prep_in	2	SENT_94	[p6l891t949r1165b1008],
5	can	MD	O	can	aux	7	SENT_94	[p6l1194t968r1316b1008],
6	be	VB	O	be	auxpass	7	SENT_94	[p6l1342t945r1425b1008],
7	detected	VBN	O	detect	_	0	SENT_94	[p6l1454t945r1757b1008],
8	in	IN	O	in	_	0	SENT_94	[p6l1785t951r1854b1007],
9	clinical	JJ	O	clinical	amod	10	SENT_94	[p6l1883t945r2143b1008],
10	samples	NNS	O	sample	prep_in	7	SENT_94	[p6l10t1048r277b1131],
11	using	VBG	O	use	xcomp	7	SENT_94	[p6l297t1054r482b1132],
12	several	JJ	O	several	amod	13	SENT_94	[p6l501t1048r734b1111],
13	techniques	NNS	O	technique	dobj	11	SENT_94	[p6l752t1048r1138b1131],
14	,	,	O	,	_	0	SENT_94	[p6l752t1048r1138b1131],
15	primarily	RB	O	primarily	advmod	13	SENT_94	[p6l1159t1048r1483b1132],
16	ﬂuorescence	NN	O	ﬂuorescence	dep	13	SENT_94	[p6l1499t1048r1920b1111],
17	in	FW	O	in	nn	18	SENT_94	[p6l1943t1054r2003b1111],
18	situ	FW	O	situ	advmod	22	SENT_94	[p6l2023t1054r2142b1111],
19	hybridization	NN	O	hybridization	nn	22	SENT_94	[p6l9t1151r467b1235],
20	(	CD	NUMBER	(	num	22	SENT_94	[p6l491t1152r740b1228],
21	FISH	NN	O	fish	nn	22	SENT_94	[p6l491t1152r740b1228],
22	)	NN	O	)	rcmod	16	SENT_94	[p6l491t1152r740b1228],
23	,	,	O	,	_	0	SENT_94	[p6l491t1152r740b1228],
24	reverse	JJ	O	reverse	amod	26	SENT_94	[p6l763t1174r1001b1214],
25	transcriptase	NN	O	transcriptase	nn	26	SENT_94	[p6l1021t1157r1459b1234],
26	PCR	NN	MISC	pcr	rcmod	16	SENT_94	[p6l1480t1155r1653b1223],
27	,	,	O	,	_	0	SENT_94	[p6l1480t1155r1653b1223],
28	and	CC	O	and	_	0	SENT_94	[p6l1676t1151r1801b1214],
29	immunohistochemistry	NN	O	immunohistochemistry	rcmod	16	SENT_94	[p6l1820t1157r2141b1214, p6l9t1253r525b1337],
30	(	CD	NUMBER	(	num	31	SENT_94	[p6l546t1254r768b1329],
31	IHC	NNP	ORGANIZATION	IHC	tmod	11	SENT_94	[p6l546t1254r768b1329],
32	)	CD	NUMBER	)	num	31	SENT_94	[p6l546t1254r768b1329],
33	,	,	O	,	_	0	SENT_94	[p6l546t1254r768b1329],
34	each	DT	O	each	dobj	45	SENT_94	[p6l793t1253r945b1316],
35	with	IN	O	with	_	0	SENT_94	[p6l965t1253r1117b1316],
36	advantages	NNS	O	advantage	prep_with	34	SENT_94	[p6l1140t1253r1512b1337],
37	and	CC	O	and	_	0	SENT_94	[p6l1535t1253r1662b1316],
38	limitations	NNS	O	limitation	prep_with	34	SENT_94	[p6l1681t1245r2131b1316],
39	.45	CD	NUMBER	.45	num	40	SENT_94	[p6l1681t1245r2131b1316],
40	FISH	NN	O	fish	nsubj	45	SENT_94	[p6l84t1360r256b1419],
41	using	VBG	O	use	partmod	40	SENT_94	[p6l277t1362r459b1440],
42	break-apart	JJ	O	break-apart	amod	43	SENT_94	[p6l475t1356r869b1439],
43	probes	NNS	O	probe	dobj	41	SENT_94	[p6l886t1356r1110b1439],
44	has	VBZ	O	have	aux	45	SENT_94	[p6l1130t1356r1240b1419],
45	come	VBN	O	come	rcmod	31	SENT_94	[p6l1260t1379r1440b1419],
46	to	TO	O	to	aux	47	SENT_94	[p6l1458t1368r1523b1419],
47	represent	VB	O	represent	xcomp	45	SENT_94	[p6l1544t1368r1856b1439],
48	the	DT	O	the	det	50	SENT_94	[p6l1874t1356r1978b1419],
49	gold	JJ	O	gold	amod	50	SENT_94	[p6l1998t1356r2143b1440],
50	standard	NN	O	standard	dobj	47	SENT_94	[p6l10t1459r309b1522],
51	because	IN	O	because	mark	55	SENT_94	[p6l327t1459r595b1522],
52	it	PRP	O	it	nsubjpass	55	SENT_94	[p6l617t1465r663b1522],
53	was	VBD	O	be	auxpass	55	SENT_94	[p6l682t1482r808b1522],
54	clinically	RB	O	clinically	advmod	55	SENT_94	[p6l831t1459r1140b1543],
55	validated	VBN	O	validate	advcl	47	SENT_94	[p6l1155t1459r1469b1522],
56	in	IN	O	in	_	0	SENT_94	[p6l1490t1465r1557b1521],
57	trials	NNS	O	trial	prep_in	55	SENT_94	[p6l1578t1459r1749b1522],
58	with	IN	O	with	_	0	SENT_94	[p6l1769t1459r1922b1522],
59	crizo	NN	O	crizo	nn	61	SENT_94	[p6l1944t1465r2140b1522],
60	—	NN	O	—	nn	61	SENT_94	[p6l1944t1465r2140b1522],
61	tinib	NN	O	tinib	prep_with	57	SENT_94	[p6l9t1562r167b1625],
62	and	CC	O	and	_	0	SENT_94	[p6l189t1562r314b1625],
63	is	VBZ	O	be	auxpass	64	SENT_94	[p6l334t1568r383b1625],
64	approved	VBN	O	approve	rcmod	31	SENT_94	[p6l405t1562r719b1645],
65	by	IN	O	by	_	0	SENT_94	[p6l737t1562r820b1646],
66	the	DT	O	the	det	68	SENT_94	[p6l835t1562r941b1625],
67	US	NNP	ORGANIZATION	US	nn	68	SENT_94	[p6l962t1566r1060b1625],
68	Food	NNP	ORGANIZATION	Food	agent	64	SENT_94	[p6l1082t1562r1256b1625],
69	and	CC	ORGANIZATION	and	_	0	SENT_94	[p6l1277t1562r1402b1625],
70	Drug	NNP	ORGANIZATION	Drug	nn	74	SENT_94	[p6l1421t1567r1600b1646],
71	Administration	NNP	ORGANIZATION	Administration	nn	74	SENT_94	[p6l1618t1562r2144b1625],
72	(	CD	NUMBER	(	num	74	SENT_94	[p6l13t1666r231b1741],
73	FDA	NNP	ORGANIZATION	FDA	nn	74	SENT_94	[p6l13t1666r231b1741],
74	)	NN	O	)	conj_and	68	SENT_94	[p6l13t1666r231b1741],
75	for	IN	O	for	_	0	SENT_94	[p6l259t1665r358b1728],
76	this	DT	O	this	det	77	SENT_94	[p6l379t1665r505b1728],
77	indication	NN	O	indication	prep_for	68	SENT_94	[p6l529t1665r901b1728],
78	.	.	O	.	_	0	SENT_94	[p6l529t1665r901b1728],

1	The	DT	O	the	det	3	SENT_95	[p6l928t1665r1054b1728],
2	FISH	NN	O	fish	nn	3	SENT_95	[p6l1079t1669r1257b1728],
3	assay	NN	O	assay	nsubj	4	SENT_95	[p6l1283t1688r1462b1749],
4	uses	VBZ	O	use	_	0	SENT_95	[p6l1482t1688r1626b1728],
5	the	DT	O	the	det	9	SENT_95	[p6l1649t1665r1757b1728],
6	Vysis	NNP	ORGANIZATION	Vysis	nn	9	SENT_95	[p6l1780t1670r1960b1749],
7	ALK	NNP	ORGANIZATION	ALK	nn	9	SENT_95	[p6l1981t1669r2150b1727],
8	break-apart	JJ	O	break-apart	amod	9	SENT_95	[p6l8t1768r419b1851],
9	probes	NNS	O	probe	nsubj	10	SENT_95	[p6l440t1768r675b1851],
10	(	VBP	O	(	ccomp	4	SENT_95	[p6l702t1768r973b1844],
11	Abbott	NNP	ORGANIZATION	Abbott	nn	13	SENT_95	[p6l702t1768r973b1844],
12	Molecular	JJ	ORGANIZATION	molecular	amod	13	SENT_95	[p6l995t1768r1379b1845],
13	)	NN	O	)	dobj	10	SENT_95	[p6l995t1768r1379b1845],
14	and	CC	O	and	_	0	SENT_95	[p6l1408t1768r1537b1831],
15	involves	VBZ	O	involve	conj_and	10	SENT_95	[p6l1560t1768r1842b1831],
16	labeling	VBG	O	label	xcomp	15	SENT_95	[p6l1865t1768r2144b1852],
17	the	DT	O	the	dep	18	SENT_95	[p6l9t1871r114b1934],
18	5	CD	NUMBER	5	nsubj	32	SENT_95	[p6l136t1869r193b1934],
19	'	''	O	'	_	0	SENT_95	[p6l136t1869r193b1934],
20	and	CC	O	and	_	0	SENT_95	[p6l214t1871r339b1934],
21	3	CD	NUMBER	3	conj_and	18	SENT_95	[p6l360t1869r417b1934],
22	'	''	O	'	_	0	SENT_95	[p6l360t1869r417b1934],
23	ends	NNS	O	end	conj_and	18	SENT_95	[p6l438t1871r592b1934],
24	of	IN	O	of	_	0	SENT_95	[p6l613t1871r686b1934],
25	the	DT	O	the	det	27	SENT_95	[p6l696t1871r802b1934],
26	ALK	NN	O	alk	nn	27	SENT_95	[p6l819t1875r984b1933],
27	gene	NN	O	gene	prep_of	23	SENT_95	[p6l997t1894r1153b1955],
28	with	IN	O	with	prep	27	SENT_95	[p6l1171t1871r1323b1934],
29	differently	RB	O	differently	pcomp	28	SENT_95	[p6l1343t1871r1694b1955],
30	colored	VBN	O	color	amod	32	SENT_95	[p6l1711t1871r1964b1934],
31	ﬂuorescent	JJ	O	ﬂuorescent	amod	32	SENT_95	[p6l1984t1871r2141b1934, p6l10t1986r249b2037],
32	probes	NNS	O	probe	ccomp	16	SENT_95	[p6l266t1974r492b2057],
33	(	VBP	O	(	rcmod	32	SENT_95	[p6l516t1974r837b2058],
34	typically	RB	O	typically	advmod	33	SENT_95	[p6l516t1974r837b2058],
35	,	,	O	,	_	0	SENT_95	[p6l516t1974r837b2058],
36	red	JJ	O	red	amod	39	SENT_95	[p6l859t1974r968b2037],
37	and	CC	O	and	_	0	SENT_95	[p6l988t1974r1112b2037],
38	green	JJ	O	green	conj_and	36	SENT_95	[p6l1131t1975r1363b2058],
39	)	NN	O	)	dobj	32	SENT_95	[p6l1131t1975r1363b2058],
40	.	.	O	.	_	0	SENT_95	[p6l1131t1975r1363b2058],

1	Rearrangements	NNS	O	rearrangement	nsubj	2	SENT_96	[p6l1387t1979r1938b2058],
2	result	VBP	O	result	_	0	SENT_96	[p6l1959t1974r2145b2037],
3	in	IN	O	in	_	0	SENT_96	[p6l10t2083r76b2139],
4	a	DT	O	a	det	6	SENT_96	[p6l98t2100r133b2140],
5	split	JJ	O	split	amod	6	SENT_96	[p6l154t2077r296b2160],
6	appearance	NN	O	appearance	prep_in	2	SENT_96	[p6l317t2099r703b2160],
7	of	IN	O	of	_	0	SENT_96	[p6l725t2077r798b2140],
8	the	DT	O	the	det	11	SENT_96	[p6l809t2077r915b2140],
9	signal	NN	O	signal	nn	11	SENT_96	[p6l938t2077r1137b2161],
10	(	NN	O	(	nn	11	SENT_96	[p6l1161t2078r1380b2153],
11	~	NN	O	~	prep_of	6	SENT_96	[p6l1161t2078r1380b2153],
12	70	CD	PERCENT	70	number	13	SENT_96	[p6l1161t2078r1380b2153],
13	%	NN	PERCENT	%	amod	11	SENT_96	[p6l1161t2078r1380b2153],
14	of	IN	O	of	_	0	SENT_96	[p6l1404t2077r1477b2140],
15	cases	NNS	O	case	prep_of	11	SENT_96	[p6l1490t2078r1687b2154],
16	)	CD	NUMBER	)	num	15	SENT_96	[p6l1490t2078r1687b2154],
17	or	CC	O	or	_	0	SENT_96	[p6l1712t2100r1784b2140],
18	loss	NN	O	loss	prep_of	11	SENT_96	[p6l1803t2077r1929b2140],
19	of	IN	O	of	_	0	SENT_96	[p6l1952t2077r2025b2140],
20	the	DT	O	the	det	23	SENT_96	[p6l2036t2077r2142b2140],
21	5	CD	NUMBER	5	num	23	SENT_96	[p6l11t2177r68b2242],
22	’	NN	O	’	nn	23	SENT_96	[p6l11t2177r68b2242],
23	signal	NN	O	signal	prep_of	18	SENT_96	[p6l91t2179r290b2263],
24	(	CD	NUMBER	(	num	25	SENT_96	[p6l315t2180r561b2256],
25	~	NN	O	~	dobj	2	SENT_96	[p6l315t2180r561b2256],
26	30	CD	PERCENT	30	number	27	SENT_96	[p6l315t2180r561b2256],
27	%	NN	PERCENT	%	amod	25	SENT_96	[p6l315t2180r561b2256],
28	)	CD	NUMBER	)	nsubj	50	SENT_96	[p6l315t2180r561b2256],
29	in	IN	O	in	_	0	SENT_96	[p6l587t2185r654b2241],
30	at	IN	O	at	quantmod	32	SENT_96	[p6l677t2191r736b2242],
31	least	JJS	O	least	mwe	30	SENT_96	[p6l755t2179r908b2242],
32	15	CD	PERCENT	15	num	33	SENT_96	[p6l936t2185r1071b2244],
33	%	NN	PERCENT	%	prep_in	28	SENT_96	[p6l936t2185r1071b2244],
34	of	IN	O	of	_	0	SENT_96	[p6l1095t2179r1169b2242],
35	cells	NNS	O	cell	prep_of	33	SENT_96	[p6l1182t2179r1326b2242],
36	counted	VBN	O	count	partmod	35	SENT_96	[p6l1348t2171r1704b2242],
37	.45	CD	NUMBER	.45	num	38	SENT_96	[p6l1348t2171r1704b2242],
38	FISH	NN	O	fish	nsubjpass	41	SENT_96	[p6l1728t2183r1903b2242],
39	can	MD	O	can	aux	41	SENT_96	[p6l1927t2202r2043b2242],
40	be	VB	O	be	auxpass	41	SENT_96	[p6l2064t2179r2143b2242],
41	performed	VBN	O	perform	ccomp	36	SENT_96	[p6l8t2282r380b2365],
42	on	IN	O	on	_	0	SENT_96	[p6l403t2305r489b2345],
43	formalin	NN	O	formalin	prep_on	41	SENT_96	[p6l512t2282r1016b2345],
44	—	CD	NUMBER	—	num	43	SENT_96	[p6l512t2282r1016b2345],
45	ﬁxed	VBD	O	ﬁxed	rcmod	25	SENT_96	[p6l512t2282r1016b2345],
46	paraffin-embedded	JJ	O	paraffin-embedded	amod	47	SENT_96	[p6l1037t2282r1704b2365],
47	tissue	NN	O	tissue	dobj	45	SENT_96	[p6l1725t2288r1919b2345],
48	and	CC	O	and	_	0	SENT_96	[p6l1943t2282r2070b2345],
49	is	VBZ	O	be	cop	50	SENT_96	[p6l2093t2288r2143b2345],
50	able	JJ	O	able	rcmod	25	SENT_96	[p6l10t2385r145b2448],
51	to	TO	O	to	aux	52	SENT_96	[p6l168t2397r234b2448],
52	detect	VB	O	detect	xcomp	50	SENT_96	[p6l259t2385r466b2448],
53	fusions	NNS	O	fusion	dobj	52	SENT_96	[p6l488t2385r733b2448],
54	independently	RB	O	independently	advmod	53	SENT_96	[p6l757t2385r1259b2469],
55	of	IN	O	of	_	0	SENT_96	[p6l1279t2385r1353b2448],
56	knowledge	NN	O	knowledge	prep_of	53	SENT_96	[p6l1365t2385r1739b2469],
57	of	IN	O	of	_	0	SENT_96	[p6l1762t2385r1837b2448],
58	the	DT	O	the	det	61	SENT_96	[p6l1849t2385r1956b2448],
59	ALK	NNP	O	ALK	nn	61	SENT_96	[p6l1978t2389r2142b2447],
60	fusion	NN	O	fusion	nn	61	SENT_96	[p6l9t2488r229b2551],
61	partner	NN	O	partner	prep_of	56	SENT_96	[p6l253t2500r528b2571],
62	.	.	O	.	_	0	SENT_96	[p6l253t2500r528b2571],

1	However	RB	O	however	advmod	5	SENT_97	[p6l556t2493r885b2560],
2	,	,	O	,	_	0	SENT_97	[p6l556t2493r885b2560],
3	FISH	NN	O	fish	nsubj	18	SENT_97	[p6l912t2492r1092b2551],
4	is	VBZ	O	be	cop	5	SENT_97	[p6l1118t2494r1169b2551],
5	expensive	JJ	O	expensive	_	0	SENT_97	[p6l1195t2494r1557b2571],
6	,	,	O	,	_	0	SENT_97	[p6l1195t2494r1557b2571],
7	requires	VBZ	O	require	conj_and	5	SENT_97	[p6l1583t2494r1867b2571],
8	laboratories	NNS	O	laboratory	dobj	7	SENT_97	[p6l1891t2488r2141b2551, p6l9t2597r199b2654],
9	with	IN	O	with	_	0	SENT_97	[p6l221t2591r374b2654],
10	expertise	NN	O	expertise	prep_with	7	SENT_97	[p6l398t2597r707b2674],
11	because	IN	O	because	mark	16	SENT_97	[p6l728t2591r997b2654],
12	it	PRP	O	it	nsubj	16	SENT_97	[p6l1021t2597r1067b2654],
13	can	MD	O	can	aux	16	SENT_97	[p6l1089t2614r1206b2654],
14	be	VB	O	be	cop	16	SENT_97	[p6l1227t2591r1307b2654],
15	technically	RB	O	technically	advmod	16	SENT_97	[p6l1329t2591r1706b2675],
16	challenging	JJ	O	challenging	dep	10	SENT_97	[p6l1726t2591r2141b2675],
17	,	,	O	,	_	0	SENT_97	[p6l1726t2591r2141b2675],
18	requires	VBZ	O	require	conj_and	5	SENT_97	[p6l10t2701r281b2778],
19	ﬂuorescence	NN	O	ﬂuorescence	nn	20	SENT_97	[p6l301t2695r719b2758],
20	microscopy	NN	O	microscopy	dobj	18	SENT_97	[p6l739t2701r1143b2779],
21	,	,	O	,	_	0	SENT_97	[p6l739t2701r1143b2779],
22	and	CC	O	and	_	0	SENT_97	[p6l1165t2695r1290b2758],
23	may	MD	O	may	aux	24	SENT_97	[p6l1308t2718r1453b2779],
24	miss	VB	O	miss	conj_and	5	SENT_97	[p6l1470t2701r1620b2758],
25	rare	JJ	O	rare	amod	26	SENT_97	[p6l1641t2718r1772b2758],
26	rearrangements	NNS	O	rearrangement	dobj	24	SENT_97	[p6l1792t2718r2141b2779, p6l9t2810r230b2861],
27	.	.	O	.	_	0	SENT_97	[p6l1792t2718r2141b2779, p6l9t2810r230b2861],

1	More	RBR	O	more	advmod	2	SENT_98	[p6l253t2803r432b2861],
2	recently	RB	DATE	recently	advmod	24	SENT_98	[p6l453t2798r732b2882],
3	,	,	O	,	_	0	SENT_98	[p6l453t2798r732b2882],
4	methods	NNS	O	method	nsubjpass	24	SENT_98	[p6l753t2798r1047b2861],
5	that	WDT	O	that	nsubj	6	SENT_98	[p6l1067t2798r1199b2861],
6	use	VBP	O	use	rcmod	4	SENT_98	[p6l1218t2821r1327b2861],
7	bright-ﬁeld	JJ	O	bright-ﬁeld	amod	8	SENT_98	[p6l1345t2798r1731b2882],
8	microscopy	NN	O	microscopy	dobj	6	SENT_98	[p6l1750t2804r2146b2882],
9	obviating	VBG	O	obviate	xcomp	6	SENT_98	[p6l10t2901r323b2985],
10	the	DT	O	the	det	11	SENT_98	[p6l340t2901r444b2964],
11	need	NN	O	need	dobj	9	SENT_98	[p6l463t2901r624b2964],
12	for	IN	O	for	_	0	SENT_98	[p6l642t2901r737b2964],
13	ﬂuorescence	NN	O	ﬂuorescence	prep_for	9	SENT_98	[p6l756t2901r1186b2973],
14	,	,	O	,	_	0	SENT_98	[p6l756t2901r1186b2973],
15	namely	RB	O	namely	advmod	9	SENT_98	[p6l1207t2901r1462b2985],
16	,	,	O	,	_	0	SENT_98	[p6l1207t2901r1462b2985],
17	chromogenic	JJ	O	chromogenic	appos	4	SENT_98	[p6l1483t2901r1923b2985],
18	in	FW	O	in	nn	19	SENT_98	[p6l1945t2907r2004b2964],
19	situ	FW	O	situ	advmod	20	SENT_98	[p6l2023t2907r2140b2964],
20	hybridization	NN	O	hybridization	rcmod	17	SENT_98	[p6l9t3003r488b3087],
21	,	,	O	,	_	0	SENT_98	[p6l9t3003r488b3087],
22	have	VBP	O	have	aux	24	SENT_98	[p6l511t3003r666b3066],
23	been	VBN	O	be	auxpass	24	SENT_98	[p6l686t3003r850b3066],
24	developed	VBN	O	develop	_	0	SENT_98	[p6l872t2995r1301b3086],
25	.46	CD	NUMBER	.46	dobj	24	SENT_98	[p6l872t2995r1301b3086],

1	Reverse	JJ	O	reverse	amod	3	SENT_99	[p6l84t3111r347b3169],
2	transcriptase	NN	O	transcriptase	nn	3	SENT_99	[p6l368t3112r809b3189],
3	PCR	NN	O	pcr	nsubj	8	SENT_99	[p6l832t3110r990b3169],
4	is	VBZ	O	be	cop	8	SENT_99	[p6l1009t3112r1059b3169],
5	a	DT	O	a	det	8	SENT_99	[p6l1083t3129r1118b3169],
6	highly	RB	O	highly	advmod	7	SENT_99	[p6l1137t3106r1356b3190],
7	sensitive	JJ	O	sensitive	amod	8	SENT_99	[p6l1375t3112r1665b3169],
8	technique	NN	O	technique	_	0	SENT_99	[p6l1686t3106r2025b3189],
9	for	IN	O	for	_	0	SENT_99	[p6l2047t3106r2144b3169],
10	detection	NN	O	detection	prep_for	8	SENT_99	[p6l10t3208r342b3271],
11	of	IN	O	of	_	0	SENT_99	[p6l368t3208r444b3271],
12	mRNA	NN	O	mrna	prep_of	10	SENT_99	[p6l460t3212r709b3271],
13	for	IN	O	for	_	0	SENT_99	[p6l735t3208r836b3271],
14	ALK	NNP	O	ALK	prep_for	12	SENT_99	[p6l856t3212r1028b3270],
15	that	WDT	O	that	nsubj	17	SENT_99	[p6l1046t3208r1185b3271],
16	can	MD	O	can	aux	17	SENT_99	[p6l1210t3231r1331b3271],
17	deﬁne	VB	O	deﬁne	rcmod	10	SENT_99	[p6l1358t3208r1572b3271],
18	both	CC	O	both	preconj	21	SENT_99	[p6l1596t3208r1761b3271],
19	the	DT	O	the	det	21	SENT_99	[p6l1786t3208r1896b3271],
20	fusion	NN	O	fusion	nn	21	SENT_99	[p6l1922t3208r2144b3271],
21	partner	NN	O	partner	dobj	17	SENT_99	[p7l8t39r272b110],
22	and	CC	O	and	_	0	SENT_99	[p7l295t27r424b90],
23	the	DT	O	the	det	24	SENT_99	[p7l445t27r554b90],
24	variant	NN	O	variant	conj_and	21	SENT_99	[p7l575t33r840b90],
25	.	.	O	.	_	0	SENT_99	[p7l575t33r840b90],

1	Although	IN	O	although	mark	5	SENT_100	[p7l866t27r1201b111],
2	it	PRP	O	it	nsubj	5	SENT_100	[p7l1225t33r1271b90],
3	has	VBZ	O	have	aux	5	SENT_100	[p7l1292t27r1407b90],
4	historically	RB	O	historically	advmod	5	SENT_100	[p7l1430t27r1825b111],
5	required	VBN	O	require	advcl	18	SENT_100	[p7l1845t27r2144b110],
6	extraction	NN	O	extraction	dobj	5	SENT_100	[p7l9t136r364b193],
7	of	IN	O	of	_	0	SENT_100	[p7l387t130r462b193],
8	RNA	NN	O	rna	prep_of	6	SENT_100	[p7l477t134r650b193],
9	from	IN	O	from	_	0	SENT_100	[p7l673t130r844b193],
10	frozen	JJ	O	frozen	amod	11	SENT_100	[p7l867t130r1089b193],
11	tissue	NN	O	tissue	prep_from	5	SENT_100	[p7l1111t136r1326b202],
12	,	,	O	,	_	0	SENT_100	[p7l1111t136r1326b202],
13	the	DT	O	the	det	14	SENT_100	[p7l1349t130r1458b193],
14	technique	NN	O	technique	nsubjpass	18	SENT_100	[p7l1481t130r1826b213],
15	can	MD	O	can	aux	18	SENT_100	[p7l1850t153r1969b193],
16	now	RB	DATE	now	advmod	18	SENT_100	[p7l1993t153r2143b193],
17	be	VB	O	be	auxpass	18	SENT_100	[p7l6t233r85b296],
18	applied	VBN	O	apply	_	0	SENT_100	[p7l109t233r358b316],
19	to	TO	O	to	_	0	SENT_100	[p7l378t245r444b296],
20	limited	JJ	O	limited	amod	22	SENT_100	[p7l466t233r711b296],
21	tissue	NN	O	tissue	nn	22	SENT_100	[p7l732t239r923b296],
22	samples	NNS	O	sample	prep_to	18	SENT_100	[p7l947t233r1215b316],
23	such	JJ	O	such	_	0	SENT_100	[p7l1238t233r1393b296],
24	as	IN	O	as	_	0	SENT_100	[p7l1416t256r1480b296],
25	those	DT	O	those	prep_such_as	22	SENT_100	[p7l1502t233r1685b296],
26	from	IN	O	from	_	0	SENT_100	[p7l1707t233r1875b296],
27	clinical	JJ	O	clinical	amod	28	SENT_100	[p7l1898t233r2142b296],
28	biopsies	NNS	O	biopsy	prep_from	25	SENT_100	[p7l6t336r299b419],
29	.	.	O	.	_	0	SENT_100	[p7l6t336r299b419],

1	Finally	RB	O	finally	advmod	13	SENT_101	[p7l83t439r326b523],
2	,	,	O	,	_	0	SENT_101	[p7l83t439r326b523],
3	IHC	NNP	ORGANIZATION	IHC	nsubj	13	SENT_101	[p7l348t443r495b502],
4	is	VBZ	O	be	cop	13	SENT_101	[p7l516t445r566b502],
5	a	DT	O	a	det	13	SENT_101	[p7l587t462r622b502],
6	readily	RB	O	readily	advmod	7	SENT_101	[p7l641t439r876b523],
7	available	JJ	O	available	amod	13	SENT_101	[p7l893t439r1203b511],
8	,	,	O	,	_	0	SENT_101	[p7l893t439r1203b511],
9	rapid	JJ	O	rapid	amod	13	SENT_101	[p7l1225t439r1419b522],
10	,	,	O	,	_	0	SENT_101	[p7l1225t439r1419b522],
11	and	CC	O	and	_	0	SENT_101	[p7l1442t439r1567b502],
12	cheap	JJ	O	cheap	amod	13	SENT_101	[p7l1588t439r1781b522],
13	technique	NN	O	technique	_	0	SENT_101	[p7l1802t439r2139b522],
14	that	WDT	O	that	nsubj	16	SENT_101	[p7l7t542r139b605],
15	may	MD	O	may	aux	16	SENT_101	[p7l157t565r301b626],
16	have	VB	O	have	rcmod	13	SENT_101	[p7l317t542r469b605],
17	advantages	NNS	O	advantage	dobj	16	SENT_101	[p7l490t542r856b626],
18	over	IN	O	over	_	0	SENT_101	[p7l878t565r1022b605],
19	other	JJ	O	other	amod	20	SENT_101	[p7l1042t542r1220b605],
20	techniques	NNS	O	technique	prep_over	17	SENT_101	[p7l1237t542r1600b625],
21	for	IN	O	for	_	0	SENT_101	[p7l1621t542r1716b605],
22	screening	NN	O	screening	prep_for	16	SENT_101	[p7l1736t548r2058b626],
23	of	IN	O	of	_	0	SENT_101	[p7l2077t542r2149b605],
24	clinical	JJ	O	clinical	amod	25	SENT_101	[p7l9t645r254b708],
25	samples	NNS	O	sample	prep_of	22	SENT_101	[p7l274t645r542b728],
26	for	IN	O	for	_	0	SENT_101	[p7l563t645r660b708],
27	ALK	NN	O	alk	nn	28	SENT_101	[p7l676t649r843b707],
28	rearrangements	NNS	O	rearrangement	prep_for	25	SENT_101	[p7l857t657r1410b729],
29	.	.	O	.	_	0	SENT_101	[p7l857t657r1410b729],

1	The	DT	O	the	det	2	SENT_102	[p7l1433t645r1558b708],
2	basis	NN	O	basis	nsubj	6	SENT_102	[p7l1577t645r1743b708],
3	for	IN	O	for	_	0	SENT_102	[p7l1764t645r1861b708],
4	this	DT	O	this	det	5	SENT_102	[p7l1880t645r2004b708],
5	test	NN	O	test	prep_for	2	SENT_102	[p7l2024t657r2143b708],
6	is	VBZ	O	be	_	0	SENT_102	[p7l9t754r59b811],
7	that	IN	O	that	complm	12	SENT_102	[p7l83t748r220b811],
8	ALK	NNP	O	ALK	nsubjpass	12	SENT_102	[p7l241t752r407b810],
9	is	VBZ	O	be	auxpass	12	SENT_102	[p7l430t754r481b811],
10	not	RB	O	not	neg	12	SENT_102	[p7l505t760r621b811],
11	normally	RB	O	normally	advmod	12	SENT_102	[p7l644t748r966b832],
12	expressed	VBN	O	express	ccomp	6	SENT_102	[p7l987t748r1327b831],
13	in	IN	O	in	_	0	SENT_102	[p7l1350t754r1418b810],
14	lung	NN	O	lung	nn	15	SENT_102	[p7l1440t748r1597b832],
15	tumors	NNS	O	tumor	prep_in	12	SENT_102	[p7l1618t760r1868b811],
16	or	CC	O	or	_	0	SENT_102	[p7l1893t771r1966b811],
17	lung	NN	O	lung	nn	18	SENT_102	[p7l1987t748r2144b832],
18	tissue	NN	O	tissue	conj_or	15	SENT_102	[p7l7t857r218b914],
19	.	.	O	.	_	0	SENT_102	[p7l7t857r218b914],

1	In	IN	O	in	_	0	SENT_103	[p7l245t856r316b913],
2	the	DT	O	the	det	3	SENT_103	[p7l338t851r446b914],
3	setting	NN	O	setting	prep_in	19	SENT_103	[p7l470t857r701b935],
4	of	IN	O	of	_	0	SENT_103	[p7l723t851r798b914],
5	an	DT	O	a	det	7	SENT_103	[p7l812t874r892b914],
6	ALK	NN	O	alk	nn	7	SENT_103	[p7l911t855r1080b913],
7	rearrangement	NN	O	rearrangement	prep_of	3	SENT_103	[p7l1096t863r1626b935],
8	,	,	O	,	_	0	SENT_103	[p7l1096t863r1626b935],
9	aberrant	JJ	O	aberrant	amod	11	SENT_103	[p7l1651t851r1944b914],
10	cytoplasmic	JJ	O	cytoplasmic	amod	11	SENT_103	[p7l1966t863r2139b935, p7l7t954r275b1037],
11	expression	NN	O	expression	nsubjpass	19	SENT_103	[p7l298t960r665b1037],
12	of	IN	O	of	_	0	SENT_103	[p7l689t954r763b1017],
13	the	DT	O	the	det	16	SENT_103	[p7l776t954r883b1017],
14	ALK	NNP	O	ALK	nn	16	SENT_103	[p7l906t958r1071b1016],
15	fusion	NN	O	fusion	nn	16	SENT_103	[p7l1092t954r1308b1017],
16	protein	NN	O	protein	prep_of	11	SENT_103	[p7l1331t960r1582b1037],
17	can	MD	O	can	aux	19	SENT_103	[p7l1606t977r1724b1017],
18	be	VB	O	be	auxpass	19	SENT_103	[p7l1745t954r1826b1017],
19	detected	VBN	O	detect	_	0	SENT_103	[p7l1850t954r2142b1017],
20	by	IN	O	by	_	0	SENT_103	[p7l6t1057r88b1141],
21	ALK	NN	O	alk	nn	24	SENT_103	[p7l103t1057r542b1140],
22	—	CD	NUMBER	—	num	24	SENT_103	[p7l103t1057r542b1140],
23	speciﬁc	NN	O	speciﬁc	nn	24	SENT_103	[p7l103t1057r542b1140],
24	antibodies	NNS	O	antibody	agent	19	SENT_103	[p7l562t1057r924b1120],
25	.	.	O	.	_	0	SENT_103	[p7l562t1057r924b1120],

1	Three	CD	NUMBER	three	num	3	SENT_104	[p7l946t1057r1135b1120],
2	major	JJ	O	major	amod	3	SENT_104	[p7l1155t1063r1352b1141],
3	antibodies	NNS	O	antibody	nsubj	10	SENT_104	[p7l1371t1057r1716b1120],
4	are	VBP	O	be	cop	10	SENT_104	[p7l1737t1080r1834b1120],
5	available	JJ	O	available	amod	10	SENT_104	[p7l1855t1057r2141b1120],
6	(	NN	O	(	nn	10	SENT_104	[p7l12t1160r233b1237],
7	ALK1	NN	O	alk1	nn	10	SENT_104	[p7l12t1160r233b1237],
8	(	CD	NUMBER	(	num	10	SENT_104	[p7l265t1160r525b1236],
9	Dako	NNP	PERSON	Dako	nn	10	SENT_104	[p7l265t1160r525b1236],
10	)	NN	O	)	_	0	SENT_104	[p7l265t1160r525b1236],
11	,	,	O	,	_	0	SENT_104	[p7l265t1160r525b1236],
12	D5F3	NN	O	d5f3	nn	15	SENT_104	[p7l549t1165r734b1223],
13	(	CD	NUMBER	(	num	15	SENT_104	[p7l762t1160r925b1236],
14	Cell	NN	O	cell	nn	15	SENT_104	[p7l762t1160r925b1236],
15	Signaling	NN	O	signaling	conj_and	10	SENT_104	[p7l947t1160r1312b1244],
16	)	NN	O	)	dep	15	SENT_104	[p7l947t1160r1312b1244],
17	,	,	O	,	_	0	SENT_104	[p7l947t1160r1312b1244],
18	and	CC	O	and	_	0	SENT_104	[p7l1337t1160r1463b1223],
19	5A4	NN	O	5a4	nn	21	SENT_104	[p7l1485t1164r1622b1223],
20	(	CD	NUMBER	(	num	21	SENT_104	[p7l1648t1160r2140b1237],
21	Novocastra	NNP	O	Novocastra	conj_and	10	SENT_104	[p7l1648t1160r2140b1237],
22	)	CD	NUMBER	)	num	23	SENT_104	[p7l1648t1160r2140b1237],
23	)	NN	O	)	dep	21	SENT_104	[p7l1648t1160r2140b1237],
24	;	:	O	;	_	0	SENT_104	[p7l1648t1160r2140b1237],
25	these	DT	O	these	nsubjpass	28	SENT_104	[p7l7t1263r187b1326],
26	are	VBP	O	be	auxpass	28	SENT_104	[p7l211t1286r314b1326],
27	typically	RB	O	typically	advmod	28	SENT_104	[p7l337t1263r637b1347],
28	used	VBN	O	use	parataxis	10	SENT_104	[p7l657t1263r818b1326],
29	with	IN	O	with	_	0	SENT_104	[p7l839t1263r995b1326],
30	various	JJ	O	various	amod	33	SENT_104	[p7l1016t1269r1274b1326],
31	enhanced	VBN	O	enhance	amod	33	SENT_104	[p7l1299t1263r1637b1326],
32	detection	NN	O	detection	nn	33	SENT_104	[p7l1660t1263r1986b1326],
33	systems	NNS	O	system	prep_with	28	SENT_104	[p7l2011t1286r2140b1347, p7l7t1378r192b1438],
34	,	,	O	,	_	0	SENT_104	[p7l2011t1286r2140b1347, p7l7t1378r192b1438],
35	given	VBN	O	give	partmod	33	SENT_104	[p7l217t1372r404b1450],
36	the	DT	O	the	det	40	SENT_104	[p7l427t1366r536b1429],
37	relatively	RB	O	relatively	advmod	38	SENT_104	[p7l560t1366r880b1450],
38	low	JJ	O	low	amod	40	SENT_104	[p7l899t1366r1026b1429],
39	cytoplasmic	JJ	O	cytoplasmic	amod	40	SENT_104	[p7l1048t1366r1468b1450],
40	expression	NN	O	expression	dobj	35	SENT_104	[p7l1492t1372r1863b1449],
41	of	IN	O	of	_	0	SENT_104	[p7l1887t1366r1963b1429],
42	ALK	NNP	O	ALK	prep_of	40	SENT_104	[p7l1976t1370r2142b1428],
43	in	IN	O	in	_	0	SENT_104	[p7l9t1474r78b1530],
44	NSCLC	NNP	O	NSCLC	prep_in	35	SENT_104	[p7l104t1472r396b1531],
45	.	.	O	.	_	0	SENT_104	[p7l104t1472r396b1531],

1	Numerous	JJ	O	numerous	amod	2	SENT_105	[p7l426t1473r804b1531],
2	studies	NNS	O	study	nsubj	4	SENT_105	[p7l833t1468r1080b1531],
3	have	VBP	O	have	aux	4	SENT_105	[p7l1108t1468r1270b1531],
4	demonstrated	VBN	O	demonstrate	_	0	SENT_105	[p7l1299t1468r1796b1531],
5	that	IN	O	that	_	0	SENT_105	[p7l1822t1468r1962b1531],
6	IHC	NNP	O	IHC	prep_that	4	SENT_105	[p7l1989t1472r2142b1531],

1	for	IN	O	for	mark	3	SENT_106	[p7l8t1571r107b1634],
2	ALK	NNP	O	ALK	nsubj	3	SENT_106	[p7l127t1575r292b1633],
3	performs	VBZ	O	perform	advcl	28	SENT_106	[p7l312t1571r630b1654],
4	with	IN	O	with	_	0	SENT_106	[p7l652t1571r806b1634],
5	excellent	JJ	O	excellent	amod	6	SENT_106	[p7l830t1571r1133b1634],
6	sensitivity	NN	O	sensitivity	prep_with	3	SENT_106	[p7l1156t1577r1506b1655],
7	and	CC	O	and	_	0	SENT_106	[p7l1527t1571r1654b1634],
8	speciﬁcity	NN	O	speciﬁcity	prep_with	3	SENT_106	[p7l1677t1571r2026b1655],
9	for	IN	O	for	_	0	SENT_106	[p7l2045t1571r2143b1634],
10	detecting	VBG	O	detect	prepc_for	3	SENT_106	[p7l9t1673r335b1757],
11	ALK	NNP	O	ALK	nsubj	16	SENT_106	[p7l355t1677r522b1735],
12	in	IN	O	in	_	0	SENT_106	[p7l545t1679r613b1735],
13	clinical	JJ	O	clinical	amod	14	SENT_106	[p7l637t1673r889b1736],
14	samples	NNS	O	sample	prep_in	11	SENT_106	[p7l913t1665r1453b1756],
15	.34	CD	NUMBER	.34	npadvmod	16	SENT_106	[p7l913t1665r1453b1756],
16	>	JJR	O	>	xcomp	10	SENT_106	[p7l913t1665r1453b1756],
17	46	CD	NUMBER	46	num	18	SENT_106	[p7l913t1665r1453b1756],
18	‘	NN	O	‘	dep	16	SENT_106	[p7l913t1665r1453b1756],
19	54	CD	NUMBER	54	npadvmod	20	SENT_106	[p7l913t1665r1453b1756],
20	As	IN	O	as	dep	16	SENT_106	[p7l1475t1677r1563b1736],
21	a	DT	O	a	det	22	SENT_106	[p7l1589t1696r1624b1736],
22	result	NN	O	result	pobj	20	SENT_106	[p7l1647t1673r1859b1745],
23	,	,	O	,	_	0	SENT_106	[p7l1647t1673r1859b1745],
24	various	JJ	O	various	amod	25	SENT_106	[p7l1882t1679r2140b1736],
25	algorithms	NNS	O	algorithm	nsubjpass	28	SENT_106	[p7l9t1776r376b1860],
26	have	VBP	O	have	aux	28	SENT_106	[p7l399t1776r554b1839],
27	been	VBN	O	be	auxpass	28	SENT_106	[p7l575t1776r739b1839],
28	proposed	VBN	O	propose	_	0	SENT_106	[p7l760t1776r1083b1859],
29	to	TO	O	to	aux	30	SENT_106	[p7l1103t1788r1169b1839],
30	use	VB	O	use	xcomp	28	SENT_106	[p7l1193t1799r1304b1839],
31	IHC	NNP	O	IHC	dobj	30	SENT_106	[p7l1327t1780r1475b1839],
32	either	CC	O	either	preconj	30	SENT_106	[p7l1498t1776r1695b1839],
33	as	IN	O	as	_	0	SENT_106	[p7l1717t1799r1781b1839],
34	a	DT	O	a	det	35	SENT_106	[p7l1806t1799r1840b1839],
35	complement	NN	O	complement	prep_as	30	SENT_106	[p7l1862t1776r2137b1859, p7l8t1891r190b1942],
36	to	TO	O	to	_	0	SENT_106	[p7l212t1891r280b1942],
37	FISH	NN	O	fish	prep_to	35	SENT_106	[p7l307t1883r487b1942],
38	(	CD	NUMBER	(	num	37	SENT_106	[p7l517t1880r661b1955],
39	i.e.	FW	O	i.e.	amod	35	SENT_106	[p7l517t1880r661b1955],
40	,	,	O	,	_	0	SENT_106	[p7l517t1880r661b1955],
41	FISH	NN	O	fish	nn	42	SENT_106	[p7l689t1883r870b1942],
42	conﬁrmation	NN	O	conﬁrmation	dep	39	SENT_106	[p7l896t1879r1359b1942],
43	of	IN	O	of	_	0	SENT_106	[p7l1385t1879r1460b1942],
44	ALK	NNP	O	ALK	nn	48	SENT_106	[p7l1474t1883r1641b1941],
45	IHC	NNP	O	IHC	nn	48	SENT_106	[p7l1666t1883r2143b1962],
46	—	CD	NUMBER	—	npadvmod	47	SENT_106	[p7l1666t1883r2143b1962],
47	positive	JJ	O	positive	amod	48	SENT_106	[p7l1666t1883r2143b1962],
48	cases	NNS	O	case	prep_of	42	SENT_106	[p7l9t1983r201b2059],
49	)	CD	NUMBER	)	tmod	30	SENT_106	[p7l9t1983r201b2059],
50	or	CC	O	or	_	0	SENT_106	[p7l226t2005r296b2045],
51	as	IN	O	as	_	0	SENT_106	[p7l316t2005r378b2045],
52	a	DT	O	a	det	54	SENT_106	[p7l400t2005r433b2045],
53	single	JJ	O	single	amod	54	SENT_106	[p7l453t1982r645b2066],
54	test	NN	O	test	conj_or	35	SENT_106	[p7l664t1994r794b2045],
55	.	.	O	.	_	0	SENT_106	[p7l664t1994r794b2045],

1	Validation	NN	O	validation	nsubj	20	SENT_107	[p7l816t1982r1164b2045],
2	of	IN	O	of	_	0	SENT_107	[p7l1184t1982r1257b2045],
3	these	DT	O	these	det	4	SENT_107	[p7l1266t1982r1438b2045],
4	algorithms	NNS	O	algorithm	prep_of	1	SENT_107	[p7l1458t1982r1818b2066],
5	in	IN	O	in	_	0	SENT_107	[p7l1839t1988r1904b2044],
6	largerscale	JJ	O	largerscale	amod	8	SENT_107	[p7l1922t1982r2140b2066, p7l9t2085r170b2148],
7	concordance	NN	O	concordance	nn	8	SENT_107	[p7l191t2085r626b2148],
8	studies	NNS	O	study	prep_in	4	SENT_107	[p7l648t2085r882b2148],
9	and	CC	O	and	_	0	SENT_107	[p7l905t2085r1030b2148],
10	implementation	NN	O	implementation	conj_and	4	SENT_107	[p7l1050t2085r1597b2168],
11	of	IN	O	of	_	0	SENT_107	[p7l1618t2085r1692b2148],
12	standardized	JJ	O	standardized	amod	13	SENT_107	[p7l1704t2085r2144b2148],
13	protocols	NNS	O	protocol	prep_of	10	SENT_107	[p7l7t2188r335b2271],
14	and	CC	O	and	_	0	SENT_107	[p7l360t2188r489b2251],
15	quality	NN	O	quality	nn	17	SENT_107	[p7l513t2188r757b2272],
16	control	NN	O	control	nn	17	SENT_107	[p7l777t2188r1029b2251],
17	measures	NNS	O	measure	conj_and	13	SENT_107	[p7l1051t2211r1378b2251],
18	will	MD	O	will	aux	20	SENT_107	[p7l1400t2188r1529b2251],
19	be	VB	O	be	cop	20	SENT_107	[p7l1550t2188r1632b2251],
20	critical	JJ	O	critical	_	0	SENT_107	[p7l1656t2188r1898b2251],
21	before	IN	O	before	_	0	SENT_107	[p7l1919t2188r2140b2251],
22	their	PRP$	O	they	poss	24	SENT_107	[p7l7t2290r170b2353],
23	routine	JJ	O	routine	amod	24	SENT_107	[p7l191t2296r439b2353],
24	use	NN	O	use	prep_before	20	SENT_107	[p7l460t2313r571b2353],
25	in	IN	O	in	_	0	SENT_107	[p7l593t2296r659b2352],
26	the	DT	O	the	det	27	SENT_107	[p7l680t2290r786b2353],
27	clinic	NN	O	clinic	prep_in	24	SENT_107	[p7l808t2290r1009b2353],
28	.	.	O	.	_	0	SENT_107	[p7l808t2290r1009b2353],

1	In	IN	O	in	_	0	SENT_108	[p7l82t2398r153b2455],
2	addition	NN	O	addition	_	0	SENT_108	[p7l175t2393r462b2456],
3	to	TO	O	to	_	0	SENT_108	[p7l483t2405r548b2456],
4	FISH	NN	O	fish	prep_in_addition_to	37	SENT_108	[p7l572t2397r766b2465],
5	,	,	O	,	_	0	SENT_108	[p7l572t2397r766b2465],
6	PCR	NN	O	pcr	conj_and	37	SENT_108	[p7l791t2397r964b2465],
7	,	,	O	,	_	0	SENT_108	[p7l791t2397r964b2465],
8	and	CC	O	and	_	0	SENT_108	[p7l989t2393r1114b2456],
9	IHC	NNP	ORGANIZATION	IHC	conj_and	37	SENT_108	[p7l1136t2397r1283b2456],
10	performed	VBN	O	perform	partmod	9	SENT_108	[p7l1303t2393r1670b2476],
11	on	IN	O	on	_	0	SENT_108	[p7l1691t2416r1777b2456],
12	tumor	NN	O	tumor	nn	13	SENT_108	[p7l1798t2405r2013b2456],
13	tissue	NN	O	tissue	prep_on	10	SENT_108	[p7l2032t2399r2138b2456, p7l9t2519r138b2568],
14	,	,	O	,	_	0	SENT_108	[p7l2032t2399r2138b2456, p7l9t2519r138b2568],
15	newer	JJR	O	newer	amod	16	SENT_108	[p7l163t2519r376b2559],
16	techniques	NNS	O	technique	nsubjpass	37	SENT_108	[p7l397t2496r794b2579],
17	,	,	O	,	_	0	SENT_108	[p7l397t2496r794b2579],
18	including	VBG	O	include	_	0	SENT_108	[p7l819t2496r1152b2580],
19	detection	NN	O	detection	prep_including	16	SENT_108	[p7l1174t2496r1499b2559],
20	of	IN	O	of	_	0	SENT_108	[p7l1523t2496r1598b2559],
21	ALK	NN	O	alk	nn	23	SENT_108	[p7l1607t2500r1777b2558],
22	gene	NN	O	gene	nn	23	SENT_108	[p7l1793t2519r1952b2580],
23	rearrangements	NNS	O	rearrangement	prep_of	19	SENT_108	[p7l1976t2519r2139b2559, p7l9t2611r419b2683],
24	in	IN	O	in	_	0	SENT_108	[p7l445t2605r513b2661],
25	circulating	VBG	O	circulate	prepc_in	16	SENT_108	[p7l538t2599r917b2683],
26	tumor	NN	O	tumor	nn	27	SENT_108	[p7l939t2611r1160b2662],
27	cells55	NNS	O	cells55	dobj	25	SENT_108	[p7l1184t2592r1397b2662],
28	and	CC	O	and	_	0	SENT_108	[p7l1424t2599r1553b2662],
29	next	JJ	O	next	amod	32	SENT_108	[p7l1576t2611r1756b2662],
30	—	NN	O	—	nn	32	SENT_108	[p7l1576t2611r1756b2662],
31	generation	NN	O	generation	nn	32	SENT_108	[p7l1764t2605r2141b2683],
32	sequencing	NN	O	sequencing	nsubjpass	37	SENT_108	[p7l9t2693r470b2785],
33	,56	CD	NUMBER	,56	dep	32	SENT_108	[p7l9t2693r470b2785],
34	have	VBP	O	have	aux	37	SENT_108	[p7l490t2701r643b2764],
35	also	RB	O	also	advmod	37	SENT_108	[p7l664t2701r793b2764],
36	been	VBN	O	be	auxpass	37	SENT_108	[p7l812t2701r975b2764],
37	described	VBN	O	describe	_	0	SENT_108	[p7l996t2701r1337b2764],
38	.	.	O	.	_	0	SENT_108	[p7l996t2701r1337b2764],

1	The	DT	O	the	det	3	SENT_109	[p7l1360t2701r1484b2764],
2	latter	JJ	O	latter	amod	3	SENT_109	[p7l1503t2701r1678b2764],
3	approach	NN	O	approach	nsubj	4	SENT_109	[p7l1698t2701r2010b2784],
4	has	VBZ	O	have	_	0	SENT_109	[p7l2029t2701r2140b2764],
5	the	DT	O	the	det	7	SENT_109	[p7l7t2804r113b2867],
6	potential	JJ	O	potential	amod	7	SENT_109	[p7l133t2804r438b2887],
7	advantage	NN	O	advantage	dobj	4	SENT_109	[p7l459t2804r800b2888],
8	of	IN	O	of	_	0	SENT_109	[p7l821t2804r895b2867],
9	permitting	VBG	O	permit	prepc_of	7	SENT_109	[p7l905t2810r1274b2888],
10	simultaneous	JJ	O	simultaneous	amod	11	SENT_109	[p7l1293t2804r1747b2867],
11	assessment	NN	O	assessment	dobj	9	SENT_109	[p7l1768t2816r2145b2867],
12	of	IN	O	of	_	0	SENT_109	[p7l9t2907r82b2970],
13	multiple	JJ	O	multiple	amod	16	SENT_109	[p7l92t2907r373b2990],
14	potentially	RB	O	potentially	advmod	15	SENT_109	[p7l393t2907r759b2991],
15	actionable	JJ	O	actionable	amod	16	SENT_109	[p7l776t2907r1121b2970],
16	markers	NNS	O	marker	prep_of	11	SENT_109	[p7l1141t2907r1432b2970],
17	.	.	O	.	_	0	SENT_109	[p7l1141t2907r1432b2970],

1	Ultimately	RB	O	ultimately	advmod	12	SENT_110	[p7l1456t2907r1823b2991],
2	,	,	O	,	_	0	SENT_110	[p7l1456t2907r1823b2991],
3	the	DT	O	the	det	4	SENT_110	[p7l1844t2907r1949b2970],
4	technique	NN	O	technique	nsubj	12	SENT_110	[p7l1968t2907r2138b2970, p7l8t3016r199b3093],
5	used	VBN	O	use	partmod	4	SENT_110	[p7l219t3010r376b3073],
6	in	IN	O	in	_	0	SENT_110	[p7l396t3016r461b3072],
7	each	DT	O	each	det	9	SENT_110	[p7l483t3010r634b3073],
8	clinical	JJ	O	clinical	amod	9	SENT_110	[p7l655t3010r898b3073],
9	situation	NN	O	situation	prep_in	5	SENT_110	[p7l918t3016r1213b3073],
10	will	MD	O	will	aux	12	SENT_110	[p7l1231t3010r1356b3073],
11	be	VB	O	be	cop	12	SENT_110	[p7l1373t3010r1452b3073],
12	dependent	JJ	O	dependent	_	0	SENT_110	[p7l1474t3010r1834b3093],
13	on	IN	O	on	_	0	SENT_110	[p7l1853t3033r1939b3073],
14	available	JJ	O	available	amod	15	SENT_110	[p7l1960t3010r2140b3073, p7l9t3113r143b3176],
15	resources	NNS	O	resource	prep_on	12	SENT_110	[p7l165t3136r485b3176],
16	and	CC	O	and	_	0	SENT_110	[p7l508t3113r634b3176],
17	expertise	NN	O	expertise	prep_on	12	SENT_110	[p7l656t3119r980b3196],
18	,	,	O	,	_	0	SENT_110	[p7l656t3119r980b3196],
19	as	RB	O	as	_	0	SENT_110	[p7l1004t3136r1068b3176],
20	well	RB	O	well	_	0	SENT_110	[p7l1089t3113r1226b3176],
21	as	IN	O	as	_	0	SENT_110	[p7l1248t3136r1312b3176],
22	the	DT	O	the	det	23	SENT_110	[p7l1333t3113r1439b3176],
23	suitability	NN	O	suitability	prep_on	12	SENT_110	[p7l1462t3113r1801b3197],
24	of	IN	O	of	_	0	SENT_110	[p7l1819t3113r1893b3176],
25	tissue	NN	O	tissue	prep_of	23	SENT_110	[p7l1904t3119r2112b3176],
26	.	.	O	.	_	0	SENT_110	[p7l1904t3119r2112b3176],

1	TARGETING	VBG	O	target	_	0	SENT_111	[p7l8t3328r420b3382],
2	ALK-POSITIVE	JJ	O	alk-positive	amod	3	SENT_111	[p7l440t3327r943b3383],
3	NSCLC	NN	O	nsclc	dobj	1	SENT_111	[p7l965t3328r1191b3383],
4	WITH	IN	O	with	_	0	SENT_111	[p7l1206t3328r1394b3382],
5	CRIZOTINIB	NN	O	crizotinib	prep_with	1	SENT_111	[p7l1416t3327r1828b3383],

1	Crizotinib	NNP	O	Crizotinib	nn	3	SENT_112	[p7l10t3423r362b3487],
2	(	CD	NUMBER	(	num	3	SENT_112	[p7l389t3423r689b3499],
3	Xalkori	NNP	PERSON	Xalkori	nsubj	12	SENT_112	[p7l389t3423r689b3499],
4	,	,	O	,	_	0	SENT_112	[p7l389t3423r689b3499],
5	PF-02341066	NN	O	pf-02341066	nsubj	12	SENT_112	[p7l715t3428r1186b3495],
6	;	:	O	;	_	0	SENT_112	[p7l715t3428r1186b3495],
7	Pﬁzer	NNP	O	Pﬁzer	dep	5	SENT_112	[p7l1211t3423r1433b3500],
8	)	CD	NUMBER	)	num	7	SENT_112	[p7l1211t3423r1433b3500],
9	is	VBZ	O	be	cop	12	SENT_112	[p7l1460t3429r1510b3486],
10	a	DT	O	a	det	12	SENT_112	[p7l1535t3446r1569b3486],
11	selective	JJ	O	selective	amod	12	SENT_112	[p7l1592t3423r1879b3486],
12	adenosine	NN	O	adenosine	_	0	SENT_112	[p7l1903t3423r2139b3486, p8l9t26r147b83],

1	triphosphate	NN	O	triphosphate	npadvmod	3	SENT_113	[p8l170t20r1081b103],
2	—	CD	NUMBER	—	num	1	SENT_113	[p8l170t20r1081b103],
3	competitive	JJ	O	competitive	amod	6	SENT_113	[p8l170t20r1081b103],
4	small-molecule	JJ	O	small-molecule	amod	6	SENT_113	[p8l1107t20r1648b83],
5	oral	JJ	O	oral	amod	6	SENT_113	[p8l1673t20r1808b83],
6	inhibitor	NN	O	inhibitor	nsubj	24	SENT_113	[p8l1832t20r2144b83],
7	of	IN	O	of	_	0	SENT_113	[p8l9t123r83b186],
8	ALK	NNP	O	ALK	prep_of	6	SENT_113	[p8l96t127r277b195],
9	,	,	O	,	_	0	SENT_113	[p8l96t127r277b195],
10	c-MET/hepatocyte	NN	O	c-met/hepatocyte	nn	13	SENT_113	[p8l302t123r956b207],
11	growth	NN	O	growth	nn	13	SENT_113	[p8l978t123r1224b207],
12	factor	NN	O	factor	nn	13	SENT_113	[p8l1247t123r1448b186],
13	receptor	NN	O	receptor	prep_of	6	SENT_113	[p8l1471t135r1769b206],
14	,	,	O	,	_	0	SENT_113	[p8l1471t135r1769b206],
15	and	CC	O	and	_	0	SENT_113	[p8l1795t123r1922b186],
16	ROS1	NN	O	ros1	nn	19	SENT_113	[p8l1945t127r2136b186],
17	receptor	NN	O	receptor	nn	19	SENT_113	[p8l9t239r304b310],
18	tyrosine	NN	O	tyrosine	nn	19	SENT_113	[p8l328t233r616b311],
19	kinases	NNS	O	kinase	prep_of	6	SENT_113	[p8l641t227r900b290],
20	and	CC	O	and	_	0	SENT_113	[p8l927t227r1057b290],
21	their	PRP$	O	they	poss	23	SENT_113	[p8l1081t227r1251b290],
22	oncogenic	JJ	O	oncogenic	amod	23	SENT_113	[p8l1276t233r1640b311],
23	variants	NNS	O	variant	conj_and	8	SENT_113	[p8l1662t233r1946b290],
24	(	VBP	O	(	_	0	SENT_113	[p8l1977t228r2141b311],
25	e.g.	FW	O	e.g.	dobj	24	SENT_113	[p8l1977t228r2141b311],
26	,	,	O	,	_	0	SENT_113	[p8l1977t228r2141b311],
27	c-MET/hepatocyte	NN	O	c-met/hepatocyte	nn	28	SENT_113	[p8l9t330r654b414],
28	growth	NN	O	growth	dep	31	SENT_113	[p8l677t330r920b414],
29	factor	NN	O	factor	nn	31	SENT_113	[p8l942t330r1140b393],
30	receptor	NN	O	receptor	nn	31	SENT_113	[p8l1162t342r1445b413],
31	mutations	NNS	O	mutation	conj_and	24	SENT_113	[p8l1466t336r1810b393],
32	and	CC	O	and	_	0	SENT_113	[p8l1834t330r1960b393],
33	ALK	NN	O	alk	nn	37	SENT_113	[p8l1980t334r2143b392],
34	or	CC	O	or	_	0	SENT_113	[p8l9t455r83b495],
35	ROS1	NN	O	ros1	conj_or	33	SENT_113	[p8l107t436r302b495],
36	fusion	NN	O	fusion	nn	37	SENT_113	[p8l334t432r555b495],
37	proteins	NNS	O	protein	nsubj	38	SENT_113	[p8l578t424r1144b515],
38	)	VBP	O	)	conj_and	24	SENT_113	[p8l578t424r1144b515],
39	.24	CD	NUMBER	.24	npadvmod	40	SENT_113	[p8l578t424r1144b515],
40	>	JJR	O	>	acomp	38	SENT_113	[p8l578t424r1144b515],
41	57	CD	NUMBER	57	number	42	SENT_113	[p8l578t424r1144b515],
42	’58	CD	NUMBER	’58	num	44	SENT_113	[p8l578t424r1144b515],
43	The	DT	O	the	det	44	SENT_113	[p8l1170t432r1298b495],
44	efficacy	NN	O	efficacy	dep	40	SENT_113	[p8l1324t432r1590b516],
45	of	IN	O	of	_	0	SENT_113	[p8l1612t432r1688b495],
46	crizotinib	NN	O	crizotinib	prep_of	44	SENT_113	[p8l1704t432r2046b495],
47	in	IN	O	in	_	0	SENT_113	[p8l2073t438r2142b494],
48	patients	NNS	O	patient	prep_in	46	SENT_113	[p8l7t541r284b618],
49	with	IN	O	with	_	0	SENT_113	[p8l306t535r462b598],
50	ALK	NN	O	alk	prep_with	48	SENT_113	[p8l485t539r959b618],
51	—	CD	NUMBER	—	num	50	SENT_113	[p8l485t539r959b618],
52	positive	JJ	O	positive	amod	53	SENT_113	[p8l485t539r959b618],
53	advanced	JJ	O	advanced	amod	46	SENT_113	[p8l984t535r1315b598],
54	NSCLC	NNP	ORGANIZATION	NSCLC	nsubj	57	SENT_113	[p8l1337t539r1605b598],
55	has	VBZ	O	have	aux	57	SENT_113	[p8l1628t535r1743b598],
56	been	VBN	O	be	aux	57	SENT_113	[p8l1765t535r1933b598],
57	demonstrated	VBN	O	demonstrate	dep	53	SENT_113	[p8l1957t535r2138b598, p8l9t638r330b701],
58	in	IN	O	in	_	0	SENT_113	[p8l349t644r416b700],
59	two	CD	NUMBER	two	num	60	SENT_113	[p8l435t650r560b701],
60	multicenter	NNS	O	multicenter	prep_in	57	SENT_113	[p8l582t638r990b710],
61	,	,	O	,	_	0	SENT_113	[p8l582t638r990b710],
62	multinational	JJ	O	multinational	amod	65	SENT_113	[p8l1012t638r1496b710],
63	,	,	O	,	_	0	SENT_113	[p8l1012t638r1496b710],
64	single-arm	JJ	O	single-arm	amod	65	SENT_113	[p8l1519t638r1886b722],
65	studies	NNS	O	study	prep_in	57	SENT_113	[p8l1907t638r2142b701],
66	of	IN	O	of	_	0	SENT_113	[p8l9t741r85b804],
67	crizotinib	NN	O	crizotinib	nn	68	SENT_113	[p8l102t741r446b804],
68	(	NN	O	(	prep_of	65	SENT_113	[p8l477t742r628b817],
69	250	CD	NUMBER	250	num	72	SENT_113	[p8l477t742r628b817],
70	mg	NN	O	mg	nn	72	SENT_113	[p8l646t764r758b825],
71	b.i.d.	NN	O	b.i.d.	nn	72	SENT_113	[p8l780t741r981b818],
72	)	NN	O	)	dep	65	SENT_113	[p8l780t741r981b818],
73	and	CC	O	and	_	0	SENT_113	[p8l1012t741r1142b804],
74	a	DT	O	a	det	77	SENT_113	[p8l1168t764r1203b804],
75	recently	RB	DATE	recently	advmod	76	SENT_113	[p8l1228t741r1514b825],
76	completed	VBN	O	complete	amod	77	SENT_113	[p8l1537t741r1908b824],
77	openlabel	NN	O	openlabel	prep_in	57	SENT_113	[p8l1934t763r2138b824, p8l7t844r187b916],
78	,	,	O	,	_	0	SENT_113	[p8l1934t763r2138b824, p8l7t844r187b916],
79	randomized	VBN	O	randomize	dep	57	SENT_113	[p8l212t844r649b916],
80	,	,	O	,	_	0	SENT_113	[p8l212t844r649b916],
81	multicenter	NN	O	multicenter	dobj	57	SENT_113	[p8l673t844r1087b916],
82	,	,	O	,	_	0	SENT_113	[p8l673t844r1087b916],
83	multinational	JJ	O	multinational	dep	53	SENT_113	[p8l1112t844r1603b916],
84	,	,	O	,	_	0	SENT_113	[p8l1112t844r1603b916],
85	phase	NN	O	phase	prep_of	44	SENT_113	[p8l1626t844r1823b927],
86	III	CD	NUMBER	iii	num	87	SENT_113	[p8l1847t849r1931b906],
87	study	NN	O	study	nsubj	94	SENT_113	[p8l1956t844r2145b928],
88	of	IN	O	of	_	0	SENT_113	[p8l9t947r84b1010],
89	crizotinib	NN	O	crizotinib	prep_of	87	SENT_113	[p8l98t947r435b1010],
90	vs.	CC	O	vs.	prep	89	SENT_113	[p8l457t970r545b1010],
91	standard-of-care	JJ	O	standard-of-care	amod	93	SENT_113	[p8l573t947r1153b1010],
92	chemotherapy	NN	O	chemotherapy	nn	93	SENT_113	[p8l1177t947r1679b1031],
93	(	NN	O	(	dep	90	SENT_113	[p8l1703t947r2142b1030],
94	pemetrexed	VBD	O	pemetrex	rcmod	85	SENT_113	[p8l1703t947r2142b1030],
95	or	CC	O	or	_	0	SENT_113	[p8l9t1073r81b1113],
96	docetaxel	NN	O	docetaxel	nn	97	SENT_113	[p8l102t1050r470b1127],
97	)	NN	O	)	prep_of	44	SENT_113	[p8l102t1050r470b1127],
98	.	.	O	.	_	0	SENT_113	[p8l102t1050r470b1127],

1	The	DT	O	the	det	2	SENT_114	[p8l82t1153r210b1216],
2	ﬁrst	NN	O	ﬁrst	nsubj	8	SENT_114	[p8l235t1153r374b1216],
3	of	IN	O	of	_	0	SENT_114	[p8l399t1153r475b1216],
4	the	DT	O	the	det	7	SENT_114	[p8l490t1153r600b1216],
5	two	CD	NUMBER	two	num	7	SENT_114	[p8l625t1165r754b1216],
6	single-arm	JJ	O	single-arm	amod	7	SENT_114	[p8l782t1153r1164b1237],
7	studies	NNS	O	study	prep_of	2	SENT_114	[p8l1191t1153r1435b1216],
8	enrolled	VBD	O	enrol	_	0	SENT_114	[p8l1462t1153r1755b1216],
9	119	CD	NUMBER	119	dobj	8	SENT_114	[p8l1787t1160r1903b1216],
10	previously	RB	DATE	previously	advmod	11	SENT_114	[p8l1929t1159r2139b1236, p8l9t1256r188b1340],
11	treated	VBN	O	treat	partmod	9	SENT_114	[p8l203t1256r439b1319],
12	and	CC	O	and	_	0	SENT_114	[p8l459t1256r584b1319],
13	untreated	JJ	O	untreated	amod	14	SENT_114	[p8l603t1256r928b1319],
14	patients	NNS	O	patient	conj_and	9	SENT_114	[p8l946t1262r1213b1339],
15	who	WP	O	who	nsubj	16	SENT_114	[p8l1232t1256r1377b1319],
16	received	VBD	O	receive	rcmod	14	SENT_114	[p8l1399t1256r1679b1319],
17	crizotinib	NN	O	crizotinib	dobj	16	SENT_114	[p8l1699t1256r2026b1319],
18	for	IN	O	for	_	0	SENT_114	[p8l2047t1256r2143b1319],
19	a	DT	O	a	det	21	SENT_114	[p8l9t1382r43b1422],
20	median	JJ	O	median	amod	21	SENT_114	[p8l61t1359r312b1422],
21	duration	NN	O	duration	prep_for	16	SENT_114	[p8l332t1359r620b1422],
22	of	IN	O	of	_	0	SENT_114	[p8l640t1359r712b1422],
23	32	CD	DURATION	32	num	24	SENT_114	[p8l723t1366r798b1422],
24	weeks	NNS	NUMBER	week	prep_of	21	SENT_114	[p8l817t1359r1033b1422],
25	.	.	O	.	_	0	SENT_114	[p8l817t1359r1033b1422],

1	There	EX	O	there	expl	2	SENT_115	[p8l1056t1359r1244b1422],
2	were	VBD	O	be	_	0	SENT_115	[p8l1262t1382r1419b1422],
3	2	CD	NUMBER	2	num	5	SENT_115	[p8l1439t1366r1474b1421],
4	complete	JJ	O	complete	amod	5	SENT_115	[p8l1496t1359r1798b1442],
5	responses	NNS	O	response	nsubj	2	SENT_115	[p8l1818t1381r2140b1442],
6	and	CC	O	and	_	0	SENT_115	[p8l9t1462r140b1525],
7	69	CD	NUMBER	69	num	9	SENT_115	[p8l165t1468r245b1525],
8	partial	JJ	O	partial	amod	9	SENT_115	[p8l272t1462r506b1545],
9	responses	NNS	O	response	nsubj	2	SENT_115	[p8l532t1484r877b1545],
10	for	IN	O	for	_	0	SENT_115	[p8l904t1462r1005b1525],
11	an	DT	O	a	det	12	SENT_115	[p8l1031t1485r1114b1525],
12	ORR	NN	O	orr	prep_for	9	SENT_115	[p8l1141t1466r1315b1525],
13	of	IN	O	of	_	0	SENT_115	[p8l1340t1462r1416b1525],
14	61	CD	PERCENT	61	num	15	SENT_115	[p8l1433t1468r1601b1534],
15	%	NN	PERCENT	%	prep_of	12	SENT_115	[p8l1433t1468r1601b1534],
16	,	,	O	,	_	0	SENT_115	[p8l1433t1468r1601b1534],
17	with	IN	O	with	_	0	SENT_115	[p8l1627t1462r1786b1525],
18	a	DT	O	a	det	20	SENT_115	[p8l1813t1485r1848b1525],
19	median	JJ	O	median	amod	20	SENT_115	[p8l1873t1462r2140b1525],
20	duration	NN	O	duration	prep_with	2	SENT_115	[p8l9t1564r303b1627],
21	of	IN	O	of	_	0	SENT_115	[p8l326t1564r400b1627],
22	response	NN	O	response	prep_of	20	SENT_115	[p8l413t1586r712b1647],
23	of	IN	O	of	_	0	SENT_115	[p8l736t1564r809b1627],
24	48	CD	DURATION	48	num	25	SENT_115	[p8l821t1571r899b1627],
25	weeks	NNS	NUMBER	week	prep_of	22	SENT_115	[p8l921t1556r1209b1627],
26	.	.	O	.	_	0	SENT_115	[p8l921t1556r1209b1627],

1	“	NN	O	“	nsubjpass	6	SENT_116	[p8l921t1556r1209b1627],
2	These	DT	O	these	det	3	SENT_116	[p8l1230t1564r1424b1627],
3	results	NNS	O	result	dep	1	SENT_116	[p8l1447t1564r1666b1627],
4	were	VBD	O	be	auxpass	6	SENT_116	[p8l1687t1587r1848b1627],
5	recently	RB	DATE	recently	advmod	6	SENT_116	[p8l1871t1564r2145b1648],
6	updated	VBN	O	update	dep	18	SENT_116	[p8l8t1666r291b1749],
7	to	TO	O	to	aux	8	SENT_116	[p8l313t1678r379b1729],
8	include	VB	O	include	xcomp	6	SENT_116	[p8l404t1666r659b1729],
9	143	CD	NUMBER	143	num	10	SENT_116	[p8l690t1673r802b1729],
10	patients	NNS	O	patient	dobj	8	SENT_116	[p8l827t1672r1101b1749],
11	with	IN	O	with	_	0	SENT_116	[p8l1123t1666r1278b1729],
12	ALK-positive	JJ	O	alk-positive	amod	13	SENT_116	[p8l1300t1670r1769b1749],
13	NSCLC	NN	O	nsclc	prep_with	8	SENT_116	[p8l1792t1658r2141b1730],
14	.30	CD	NUMBER	.30	num	13	SENT_116	[p8l1792t1658r2141b1730],
15	The	DT	O	the	det	16	SENT_116	[p8l8t1768r136b1832],
16	ORR	NN	O	orr	dep	13	SENT_116	[p8l162t1772r336b1832],
17	was	VBD	O	be	auxpass	18	SENT_116	[p8l355t1791r485b1832],
18	maintained	VBN	O	maintain	_	0	SENT_116	[p8l510t1768r914b1832],
19	at	IN	O	at	_	0	SENT_116	[p8l939t1780r999b1832],
20	61	CD	PERCENT	61	num	21	SENT_116	[p8l1024t1773r1191b1840],
21	%	NN	PERCENT	%	prep_at	18	SENT_116	[p8l1024t1773r1191b1840],
22	,	,	O	,	_	0	SENT_116	[p8l1024t1773r1191b1840],
23	with	IN	O	with	_	0	SENT_116	[p8l1215t1768r1373b1832],
24	a	DT	O	a	det	26	SENT_116	[p8l1398t1791r1433b1832],
25	median	JJ	O	median	amod	26	SENT_116	[p8l1456t1768r1722b1832],
26	duration	NN	O	duration	prep_with	18	SENT_116	[p8l1747t1768r2052b1832],
27	of	IN	O	of	_	0	SENT_116	[p8l2077t1768r2153b1832],
28	response	NN	O	response	prep_of	26	SENT_116	[p8l9t1894r308b1955],
29	of	IN	O	of	_	0	SENT_116	[p8l331t1872r404b1935],
30	49	CD	DURATION	49	num	31	SENT_116	[p8l417t1879r495b1935],
31	weeks	NNS	NUMBER	week	prep_of	28	SENT_116	[p8l517t1872r721b1935],
32	(	CD	NUMBER	(	num	35	SENT_116	[p8l747t1873r1006b1955],
33	Figure	NN	O	figure	nn	35	SENT_116	[p8l747t1873r1006b1955],
34	2	CD	NUMBER	2	num	35	SENT_116	[p8l1027t1872r1112b1949],
35	)	NN	O	)	nsubjpass	18	SENT_116	[p8l1027t1872r1112b1949],
36	.	.	O	.	_	0	SENT_116	[p8l1027t1872r1112b1949],

1	The	DT	O	the	det	2	SENT_117	[p8l1138t1872r1263b1935],
2	ORR	NN	O	orr	nsubj	4	SENT_117	[p8l1287t1876r1455b1935],
3	was	VBD	O	be	cop	4	SENT_117	[p8l1473t1895r1599b1935],
4	independent	JJ	O	independent	_	0	SENT_117	[p8l1622t1872r2056b1955],
5	of	IN	O	of	_	0	SENT_117	[p8l2077t1872r2151b1935],
6	age	NN	O	age	nn	8	SENT_117	[p8l9t1998r136b2059],
7	,	,	O	,	_	0	SENT_117	[p8l9t1998r136b2059],
8	sex	NN	O	sex	prep_of	4	SENT_117	[p8l159t1998r282b2047],
9	,	,	O	,	_	0	SENT_117	[p8l159t1998r282b2047],
10	and	CC	O	and	_	0	SENT_117	[p8l305t1975r432b2038],
11	performance	NN	O	performance	nn	12	SENT_117	[p8l450t1975r891b2058],
12	status	NN	O	status	prep_of	4	SENT_117	[p8l913t1987r1122b2038],
13	.	.	O	.	_	0	SENT_117	[p8l913t1987r1122b2038],

1	Median	JJ	O	median	amod	2	SENT_118	[p8l1145t1975r1407b2038],
2	PFS	NN	O	pf	nsubjpass	4	SENT_118	[p8l1429t1979r1558b2038],
3	was	VBD	O	be	auxpass	4	SENT_118	[p8l1578t1998r1703b2038],
4	estimated	VBN	O	estimate	_	0	SENT_118	[p8l1726t1975r2056b2038],
5	to	TO	O	to	aux	8	SENT_118	[p8l2074t1987r2140b2038],
6	be	VB	O	be	cop	8	SENT_118	[p8l6t2077r85b2140],
7	9.7	CD	DURATION	9.7	num	8	SENT_118	[p8l108t2084r205b2140],
8	months	NNS	NUMBER	month	xcomp	4	SENT_118	[p8l227t2077r503b2140],
9	.	.	O	.	_	0	SENT_118	[p8l227t2077r503b2140],

1	The	DT	DATE	the	det	2	SENT_119	[p8l82t2180r209b2243],
2	second	NN	DATE	second	nsubj	8	SENT_119	[p8l234t2180r478b2243],
3	of	IN	O	of	_	0	SENT_119	[p8l501t2180r576b2243],
4	the	DT	O	the	det	7	SENT_119	[p8l589t2180r698b2243],
5	two	CD	NUMBER	two	num	7	SENT_119	[p8l720t2192r848b2243],
6	single-arm	JJ	O	single-arm	amod	7	SENT_119	[p8l874t2180r1251b2264],
7	studies	NNS	O	study	prep_of	2	SENT_119	[p8l1276t2180r1516b2243],
8	enrolled	VBD	O	enrol	_	0	SENT_119	[p8l1541t2180r1830b2243],
9	136	CD	NUMBER	136	dobj	8	SENT_119	[p8l1859t2186r1975b2243],
10	previously	RB	DATE	previously	advmod	11	SENT_119	[p8l1998t2202r2139b2263, p8l6t2283r259b2367],
11	treated	VBN	O	treat	partmod	9	SENT_119	[p8l278t2283r523b2346],
12	patients	NNS	O	patient	dobj	11	SENT_119	[p8l544t2289r821b2366],
13	who	WP	O	who	nsubj	14	SENT_119	[p8l843t2283r993b2346],
14	received	VBD	O	receive	rcmod	12	SENT_119	[p8l1018t2283r1309b2346],
15	crizotinib	NN	O	crizotinib	dobj	14	SENT_119	[p8l1332t2283r1671b2346],
16	for	IN	O	for	_	0	SENT_119	[p8l1696t2283r1796b2346],
17	a	DT	O	a	det	18	SENT_119	[p8l1819t2306r1855b2346],
18	median	NN	O	median	prep_for	14	SENT_119	[p8l1877t2283r2141b2346],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_120	[p8l20t2432r139b2453],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	dep	12	SENT_120	[p8l148t2432r373b2453],
3	&	CC	O	&	_	0	SENT_120	[p8l380t2432r600b2453],
4	THERAPEUT	NNP	O	THERAPEUT	nn	6	SENT_120	[p8l380t2432r600b2453],
5	|	CD	NUMBER	|	num	6	SENT_120	[p8l380t2432r600b2453],
6	CS	NNP	O	CS	conj_and	2	SENT_120	[p8l380t2432r600b2453],
7	|	NNP	O	|	nn	8	SENT_120	[p8l610t2430r612b2460],
8	VOLUME	NNP	O	VOLUME	dep	2	SENT_120	[p8l620t2432r728b2453],
9	95	CD	NUMBER	95	num	10	SENT_120	[p8l736t2432r763b2453],
10	NUMBER	NN	O	number	dep	12	SENT_120	[p8l773t2432r881b2453],
11	1	CD	NUMBER	1	num	12	SENT_120	[p8l891t2433r898b2453],
12	|	CD	NUMBER	|	dep	15	SENT_120	[p8l912t2430r914b2460],
13	JANUARY	NNP	DATE	JANUARY	dep	12	SENT_120	[p8l923t2432r1041b2453],
14	2014	CD	DATE	2014	num	15	SENT_120	[p8l1049t2432r1107b2453],
15	17	CD	DATE	17	_	0	SENT_120	[p8l2110t2433r2139b2453],

1	STATE	NN	O	state	nn	2	SENT_121	[p8l21t2575r163b2612],
2	ART	NN	O	art	_	0	SENT_121	[p8l306t2575r399b2612],

1	Q1	NN	O	q1	nn	3	SENT_122	[p9l1454t130r1504b164],
2	Progressive	JJ	O	progressive	amod	3	SENT_122	[p9l1527t130r1793b179],
3	disease	NN	O	disease	_	0	SENT_122	[p9l1811t130r1986b169],
4	I	PRP	O	I	dep	3	SENT_122	[p9l1450t188r1504b222],
5	Stable	JJ	O	stable	amod	6	SENT_122	[p9l1525t187r1667b227],
6	disease	NN	O	disease	dep	4	SENT_122	[p9l1685t188r1860b226],
7	It	PRP	O	it	dep	3	SENT_122	[p9l1450t247r1504b280],
8	Partial	JJ	O	partial	amod	9	SENT_122	[p9l1527t246r1667b284],
9	response	NN	O	response	dep	7	SENT_122	[p9l1688t255r1896b294],
10	!	.	O	!	_	0	SENT_122	[p9l1450t305r1500b342],

1	I	PRP	O	I	_	0	SENT_123	[p9l1450t305r1500b342],
2	Complete	JJ	O	complete	amod	3	SENT_123	[p9l1525t303r1743b353],
3	response	NN	O	response	dep	1	SENT_123	[p9l1763t313r1971b353],

1	CD	NNP	O	CD	nn	2	SENT_124	[p9l134t197r160b235],
2	O	NNP	O	O	_	0	SENT_124	[p9l163t197r189b235],
3	O	NN	O	o	nn	5	SENT_124	[p9l134t309r160b347],
4	)	CD	NUMBER	)	num	5	SENT_124	[p9l134t309r160b347],
5	O	NN	O	o	dep	2	SENT_124	[p9l163t309r189b347],
6	-	:	O	-	_	0	SENT_124	[p9l133t421r160b458],
7	l	NN	O	l	dep	2	SENT_124	[p9l133t421r160b458],
8	>	JJR	O	>	amod	9	SENT_124	[p9l133t421r160b458],
9	O	NN	O	o	dep	7	SENT_124	[p9l163t421r189b459],

1	Change	NNP	O	Change	_	0	SENT_125	[p9l14t787r64b965],
2	from	IN	O	from	_	0	SENT_125	[p9l14t670r54b770],
3	baseline	NN	O	baseline	prep_from	1	SENT_125	[p9l15t461r54b650],
4	(	CD	PERCENT	(	num	5	SENT_125	[p9l14t368r64b442],
5	%	NN	PERCENT	%	dep	1	SENT_125	[p9l14t368r64b442],
6	)	CD	NUMBER	)	dep	5	SENT_125	[p9l14t368r64b442],

1	O	NN	O	o	_	0	SENT_126	[p9l163t646r189b683],

1	Figure	NNP	O	Figure	dep	2	SENT_127	[p9l10t1363r197b1425],
2	2	CD	NUMBER	2	amod	4	SENT_127	[p9l212t1366r244b1411],
3	Waterfall	NNP	O	Waterfall	nn	4	SENT_127	[p9l293t1362r536b1412],
4	plot	NN	O	plot	nsubj	21	SENT_127	[p9l557t1363r663b1424],
5	of	IN	O	of	_	0	SENT_127	[p9l680t1362r736b1412],
6	best	JJS	O	best	amod	8	SENT_127	[p9l750t1363r865b1412],
7	percentage	NN	O	percentage	nn	8	SENT_127	[p9l882t1370r1193b1425],
8	change	NN	O	change	prep_of	4	SENT_127	[p9l1210t1363r1413b1425],
9	in	IN	O	in	_	0	SENT_127	[p9l1431t1365r1475b1411],
10	target	NN	O	target	nn	11	SENT_127	[p9l1493t1370r1659b1425],
11	lesions	NNS	O	lesion	prep_in	8	SENT_127	[p9l1677t1363r1861b1412],
12	from	IN	O	from	_	0	SENT_127	[p9l1877t1362r2005b1412],
13	baseline	NN	O	baseline	prep_from	11	SENT_127	[p9l11t1448r236b1497],
14	for	IN	O	for	_	0	SENT_127	[p9l251t1448r327b1497],
15	patients	NNS	O	patient	prep_for	13	SENT_127	[p9l344t1451r563b1510],
16	with	IN	O	with	_	0	SENT_127	[p9l579t1448r698b1497],
17	ALK	NN	O	alk	npadvmod	19	SENT_127	[p9l716t1451r1059b1510],
18	—	CD	NUMBER	—	num	17	SENT_127	[p9l716t1451r1059b1510],
19	positive	JJ	O	positive	amod	20	SENT_127	[p9l716t1451r1059b1510],
20	NSCLC	NN	O	nsclc	prep_with	15	SENT_127	[p9l1078t1450r1254b1497],
21	treated	VBN	O	treat	_	0	SENT_127	[p9l1270t1448r1466b1497],
22	in	IN	O	in	_	0	SENT_127	[p9l1486t1451r1531b1497],
23	the	DT	O	the	det	24	SENT_127	[p9l1548t1448r1638b1497],
24	phase	NN	O	phase	prep_in	21	SENT_127	[p9l1656t1448r1817b1510],
25	I	PRP	O	I	dep	26	SENT_127	[p9l1837t1451r1843b1497],
26	study	NN	O	study	dobj	21	SENT_127	[p9l1863t1448r2014b1511],
27	of	IN	O	of	_	0	SENT_127	[p9l8t1533r65b1583],
28	crizotinib	NN	O	crizotinib	prep_of	26	SENT_127	[p9l77t1533r345b1583],
29	.	.	O	.	_	0	SENT_127	[p9l77t1533r345b1583],

1	ALK	NNP	O	ALK	_	0	SENT_128	[p9l361t1536r481b1590],
2	,	,	O	,	_	0	SENT_128	[p9l361t1536r481b1590],
3	anaplastic	JJ	O	anaplastic	amod	5	SENT_128	[p9l497t1533r774b1595],
4	lymphoma	NN	O	lymphoma	nn	5	SENT_128	[p9l793t1533r1087b1596],
5	kinase	NN	O	kinase	appos	1	SENT_128	[p9l1108t1533r1293b1590],
6	;	:	O	;	_	0	SENT_128	[p9l1108t1533r1293b1590],
7	NSCLC	NNP	LOCATION	NSCLC	dep	1	SENT_128	[p9l1311t1535r1501b1590],
8	,	,	O	,	_	0	SENT_128	[p9l1311t1535r1501b1590],
9	non	JJ	O	non	amod	10	SENT_128	[p9l1520t1533r1801b1583],
10	—	NN	O	—	appos	7	SENT_128	[p9l1520t1533r1801b1583],
11	small	JJ	O	small	amod	14	SENT_128	[p9l1520t1533r1801b1583],
12	cell	NN	O	cell	nn	14	SENT_128	[p9l1820t1533r1907b1583],
13	lung	NN	O	lung	nn	14	SENT_128	[p9l1929t1533r2047b1596],
14	cancer	NN	O	cancer	dep	10	SENT_128	[p9l8t1633r198b1668],
15	.	.	O	.	_	0	SENT_128	[p9l8t1633r198b1668],

1	From	IN	O	from	_	0	SENT_129	[p9l217t1621r353b1668],
2	ref	NN	O	ref	pobj	1	SENT_129	[p9l374t1618r453b1668],
3	.	.	O	.	_	0	SENT_129	[p9l374t1618r453b1668],

1	30	CD	NUMBER	30	_	0	SENT_130	[p9l469t1622r547b1668],
2	.	.	O	.	_	0	SENT_130	[p9l469t1622r547b1668],

1	duration	NN	O	duration	_	0	SENT_131	[p9l9t1824r309b1887],
2	of	IN	O	of	_	0	SENT_131	[p9l333t1824r408b1887],
3	22	CD	DURATION	22	num	4	SENT_131	[p9l422t1831r501b1886],
4	weeks	NNS	NUMBER	week	prep_of	1	SENT_131	[p9l523t1824r749b1887],
5	.	.	O	.	_	0	SENT_131	[p9l523t1824r749b1887],

1	There	EX	O	there	expl	2	SENT_132	[p9l775t1824r971b1887],
2	were	VBD	O	be	dep	33	SENT_132	[p9l993t1847r1156b1887],
3	1	CD	NUMBER	1	num	5	SENT_132	[p9l1187t1831r1212b1886],
4	complete	JJ	O	complete	amod	5	SENT_132	[p9l1242t1824r1558b1907],
5	response	NN	O	response	nsubj	2	SENT_132	[p9l1581t1846r1887b1907],
6	and	CC	O	and	_	0	SENT_132	[p9l1911t1824r2039b1887],
7	67	CD	NUMBER	67	num	9	SENT_132	[p9l2062t1830r2141b1887],
8	partial	JJ	O	partial	amod	9	SENT_132	[p9l7t1927r230b2010],
9	responses	NNS	O	response	conj_and	5	SENT_132	[p9l249t1949r577b2010],
10	for	IN	O	for	_	0	SENT_132	[p9l598t1927r694b1990],
11	an	DT	O	a	det	12	SENT_132	[p9l714t1950r793b1990],
12	ORR	NN	O	orr	prep_for	2	SENT_132	[p9l815t1931r982b1990],
13	of	IN	O	of	_	0	SENT_132	[p9l1000t1927r1074b1990],
14	50	CD	PERCENT	50	num	15	SENT_132	[p9l1086t1932r1245b1999],
15	%	NN	PERCENT	%	prep_of	12	SENT_132	[p9l1086t1932r1245b1999],
16	,	,	O	,	_	0	SENT_132	[p9l1086t1932r1245b1999],
17	with	IN	O	with	advcl	2	SENT_132	[p9l1265t1927r1417b1990],
18	a	DT	O	a	det	20	SENT_132	[p9l1438t1950r1472b1990],
19	median	JJ	O	median	amod	20	SENT_132	[p9l1490t1927r1746b1990],
20	duration	NN	O	duration	dep	28	SENT_132	[p9l1767t1927r2059b1990],
21	of	IN	O	of	_	0	SENT_132	[p9l2079t1927r2153b1990],
22	response	NN	O	response	prep_of	20	SENT_132	[p9l9t2051r299b2112],
23	of	IN	O	of	_	0	SENT_132	[p9l319t2029r391b2092],
24	47	CD	DURATION	47	num	25	SENT_132	[p9l400t2036r477b2092],
25	weeks	NNS	NUMBER	week	prep_of	22	SENT_132	[p9l495t2021r773b2092],
26	.59	CD	NUMBER	.59	dep	28	SENT_132	[p9l495t2021r773b2092],
27	The	DT	O	the	det	28	SENT_132	[p9l793t2029r915b2092],
28	results	NNS	O	result	dep	17	SENT_132	[p9l934t2029r1147b2092],
29	of	IN	O	of	_	0	SENT_132	[p9l1167t2029r1239b2092],
30	this	DT	O	this	det	31	SENT_132	[p9l1248t2029r1368b2092],
31	study	NN	O	study	prep_of	28	SENT_132	[p9l1389t2029r1570b2113],
32	were	VBD	O	be	auxpass	33	SENT_132	[p9l1584t2052r1740b2092],
33	updated	VBN	O	update	_	0	SENT_132	[p9l1759t2029r2030b2112],
34	for	IN	O	for	_	0	SENT_132	[p9l2048t2029r2142b2092],
35	the	DT	O	the	det	36	SENT_132	[p9l8t2132r115b2195],
36	ﬁrst	NN	O	ﬁrst	prep_for	33	SENT_132	[p9l138t2132r273b2195],
37	261	CD	NUMBER	261	num	38	SENT_132	[p9l295t2138r410b2195],
38	patients	NNS	O	patient	nsubjpass	33	SENT_132	[p9l438t2138r710b2215],
39	with	IN	O	with	_	0	SENT_132	[p9l732t2132r887b2195],
40	ALK	NN	O	alk	prep_with	38	SENT_132	[p9l909t2136r1376b2215],
41	—	CD	NUMBER	—	num	43	SENT_132	[p9l909t2136r1376b2215],
42	positive	JJ	O	positive	amod	43	SENT_132	[p9l909t2136r1376b2215],
43	NSCLC	NN	O	nsclc	dep	38	SENT_132	[p9l1398t2136r1664b2195],
44	who	WP	O	who	nsubj	45	SENT_132	[p9l1685t2132r1833b2195],
45	enrolled	VBD	O	enrol	rcmod	43	SENT_132	[p9l1858t2132r2143b2195],
46	into	IN	O	into	_	0	SENT_132	[p9l9t2240r147b2297],
47	the	DT	O	the	det	48	SENT_132	[p9l172t2234r282b2297],
48	study	NN	O	study	prep_into	45	SENT_132	[p9l308t2226r575b2318],
49	.	.	O	.	_	0	SENT_132	[p9l308t2226r575b2318],

1	“	NN	O	“	nsubj	12	SENT_133	[p9l308t2226r575b2318],
2	The	DT	O	the	det	4	SENT_133	[p9l600t2234r729b2297],
3	median	JJ	O	median	amod	4	SENT_133	[p9l753t2234r1020b2297],
4	duration	NN	O	duration	dep	1	SENT_133	[p9l1045t2234r1351b2297],
5	of	IN	O	of	_	0	SENT_133	[p9l1376t2234r1452b2297],
6	treatment	NN	O	treatment	prep_of	1	SENT_133	[p9l1466t2246r1814b2297],
7	for	IN	O	for	_	0	SENT_133	[p9l1838t2234r1938b2297],
8	these	DT	O	these	det	9	SENT_133	[p9l1961t2234r2143b2297],
9	patients	NNS	O	patient	prep_for	6	SENT_133	[p9l7t2343r276b2420],
10	was	VBD	O	be	cop	12	SENT_133	[p9l296t2360r422b2400],
11	48	CD	DURATION	48	num	12	SENT_133	[p9l442t2344r520b2400],
12	weeks	NNS	NUMBER	week	_	0	SENT_133	[p9l541t2337r762b2400],
13	.	.	O	.	_	0	SENT_133	[p9l541t2337r762b2400],

1	The	DT	O	the	det	2	SENT_134	[p9l786t2337r911b2400],
2	ORR	NN	O	orr	nsubj	5	SENT_134	[p9l933t2341r1102b2400],
3	was	VBD	O	be	cop	5	SENT_134	[p9l1118t2360r1244b2400],
4	60	CD	PERCENT	60	num	5	SENT_134	[p9l1266t2342r1428b2409],
5	%	NN	PERCENT	%	_	0	SENT_134	[p9l1266t2342r1428b2409],
6	,	,	O	,	_	0	SENT_134	[p9l1266t2342r1428b2409],
7	with	IN	O	with	_	0	SENT_134	[p9l1449t2337r1602b2400],
8	a	DT	O	a	det	10	SENT_134	[p9l1623t2360r1657b2400],
9	median	JJ	O	median	amod	10	SENT_134	[p9l1676t2337r1934b2400],
10	duration	NN	O	duration	prep_with	5	SENT_134	[p9l1956t2337r2139b2400, p9l8t2446r145b2503],
11	of	IN	O	of	_	0	SENT_134	[p9l167t2440r240b2503],
12	response	NN	O	response	prep_of	10	SENT_134	[p9l252t2462r551b2523],
13	of	IN	O	of	_	0	SENT_134	[p9l573t2440r647b2503],
14	46	CD	DURATION	46	num	15	SENT_134	[p9l658t2446r737b2503],
15	weeks	NNS	NUMBER	week	prep_of	12	SENT_134	[p9l757t2440r978b2503],
16	.	.	O	.	_	0	SENT_134	[p9l757t2440r978b2503],

1	The	DT	O	the	det	3	SENT_135	[p9l1002t2440r1127b2503],
2	median	JJ	O	median	amod	3	SENT_135	[p9l1148t2440r1406b2503],
3	PFS	NN	O	pf	nsubjpass	5	SENT_135	[p9l1428t2444r1557b2503],
4	was	VBD	O	be	auxpass	5	SENT_135	[p9l1577t2463r1703b2503],
5	estimated	VBN	O	estimate	_	0	SENT_135	[p9l1726t2440r2056b2503],
6	to	TO	O	to	aux	9	SENT_135	[p9l2075t2452r2140b2503],
7	be	VB	O	be	cop	9	SENT_135	[p9l7t2542r85b2605],
8	8.1	CD	DURATION	8.1	num	9	SENT_135	[p9l107t2549r197b2605],
9	months	NNS	NUMBER	month	xcomp	5	SENT_135	[p9l223t2542r498b2605],
10	.	.	O	.	_	0	SENT_135	[p9l223t2542r498b2605],

1	These	DT	O	these	det	3	SENT_136	[p9l521t2542r713b2605],
2	two	CD	NUMBER	two	num	3	SENT_136	[p9l733t2554r857b2605],
3	studies	NNS	O	study	nsubj	4	SENT_136	[p9l879t2542r1111b2605],
4	formed	VBD	O	form	_	0	SENT_136	[p9l1132t2542r1381b2605],
5	the	DT	O	the	det	6	SENT_136	[p9l1399t2542r1505b2605],
6	basis	NN	O	basis	dobj	4	SENT_136	[p9l1523t2542r1688b2605],
7	for	IN	O	for	_	0	SENT_136	[p9l1708t2542r1805b2605],
8	the	DT	O	the	det	10	SENT_136	[p9l1823t2542r1928b2605],
9	accelerated	VBN	O	accelerate	amod	10	SENT_136	[p9l1950t2542r2140b2605, p9l9t2645r218b2708],
10	approval	NN	O	approval	prep_for	6	SENT_136	[p9l238t2645r531b2728],
11	of	IN	O	of	_	0	SENT_136	[p9l552t2645r625b2708],
12	crizotinib	NN	O	crizotinib	prep_of	10	SENT_136	[p9l636t2645r964b2708],
13	by	IN	O	by	_	0	SENT_136	[p9l984t2645r1068b2729],
14	the	DT	O	the	det	15	SENT_136	[p9l1083t2645r1189b2708],
15	FDA	NNP	ORGANIZATION	FDA	prep_by	4	SENT_136	[p9l1210t2649r1371b2707],
16	in	IN	O	in	_	0	SENT_136	[p9l1391t2651r1457b2707],
17	August	NNP	DATE	August	prep_in	15	SENT_136	[p9l1477t2649r1719b2729],
18	2011	CD	DATE	2011	num	17	SENT_136	[p9l1738t2652r1893b2708],
19	for	IN	O	for	_	0	SENT_136	[p9l1920t2645r2016b2708],
20	the	DT	O	the	det	21	SENT_136	[p9l2035t2645r2141b2708],
21	treatment	NN	O	treatment	prep_for	4	SENT_136	[p9l8t2760r343b2811],
22	of	IN	O	of	_	0	SENT_136	[p9l364t2748r437b2811],
23	advanced	JJ	O	advanced	amod	27	SENT_136	[p9l450t2748r773b2811],
24	ALK	NNP	O	ALK	dep	26	SENT_136	[p9l793t2752r1253b2831],
25	—	CD	NUMBER	—	num	24	SENT_136	[p9l793t2752r1253b2831],
26	positive	JJ	O	positive	amod	27	SENT_136	[p9l793t2752r1253b2831],
27	NSCLC	NN	O	nsclc	prep_of	21	SENT_136	[p9l1275t2752r1554b2811],
28	.	.	O	.	_	0	SENT_136	[p9l1275t2752r1554b2811],

1	The	DT	O	the	det	4	SENT_137	[p9l82t2851r209b2914],
2	phase	NN	O	phase	nn	4	SENT_137	[p9l234t2851r434b2934],
3	III	CD	NUMBER	iii	num	4	SENT_137	[p9l461t2856r547b2913],
4	study	NN	O	study	nsubj	9	SENT_137	[p9l574t2851r767b2935],
5	of	IN	O	of	_	0	SENT_137	[p9l790t2851r865b2914],
6	crizotinib	NN	O	crizotinib	prep_of	4	SENT_137	[p9l882t2851r1226b2914],
7	vs.	CC	O	vs.	prep	6	SENT_137	[p9l1250t2874r1340b2914],
8	chemotherapy	NN	O	chemotherapy	dep	7	SENT_137	[p9l1370t2851r1880b2935],
9	met	VBD	O	meet	_	0	SENT_137	[p9l1902t2863r2037b2914],
10	its	PRP$	O	its	poss	12	SENT_137	[p9l2061t2857r2140b2914],
11	primary	JJ	O	primary	amod	12	SENT_137	[p9l7t2961r306b3039],
12	objective	NN	O	objective	dobj	9	SENT_137	[p9l330t2955r654b3039],
13	by	IN	O	by	_	0	SENT_137	[p9l679t2955r766b3039],
14	demonstrating	VBG	O	demonstrate	prepc_by	9	SENT_137	[p9l790t2955r1324b3039],
15	that	IN	O	that	complm	31	SENT_137	[p9l1348t2955r1490b3018],
16	in	IN	O	in	_	0	SENT_137	[p9l1515t2961r1585b3017],
17	patients	NNS	O	patient	prep_in	31	SENT_137	[p9l1610t2961r1897b3038],
18	previously	RB	DATE	previously	advmod	19	SENT_137	[p9l1923t2961r2137b3038, p9l9t3058r199b3142],
19	treated	VBN	O	treat	partmod	17	SENT_137	[p9l220t3058r472b3121],
20	with	IN	O	with	_	0	SENT_137	[p9l495t3058r655b3121],
21	ﬁrst	NN	O	ﬁrst	nn	25	SENT_137	[p9l681t3058r990b3121],
22	—	CD	NUMBER	—	num	25	SENT_137	[p9l681t3058r990b3121],
23	line	NN	O	line	nn	25	SENT_137	[p9l681t3058r990b3121],
24	platinum	NN	O	platinum	nn	25	SENT_137	[p9l1015t3058r1587b3141],
25	—	NN	O	—	prep_with	19	SENT_137	[p9l1015t3058r1587b3141],
26	based	VBN	O	base	prep	19	SENT_137	[p9l1015t3058r1587b3141],
27	chemotherapy	NN	O	chemotherapy	dep	26	SENT_137	[p9l1613t3058r2142b3142],
28	,	,	O	,	_	0	SENT_137	[p9l1613t3058r2142b3142],
29	crizotinib	NN	O	crizotinib	nsubj	31	SENT_137	[p9l9t3161r371b3224],
30	significantly	RB	O	significantly	advmod	31	SENT_137	[p9l405t3161r869b3245],
31	prolonged	VBD	O	prolong	ccomp	14	SENT_137	[p9l895t3161r1276b3245],
32	PFS	NN	O	pf	dobj	31	SENT_137	[p9l1308t3165r1445b3224],
33	as	IN	O	as	mark	62	SENT_137	[p9l1478t3184r1546b3224],
34	compared	VBN	O	compare	prep	62	SENT_137	[p9l1579t3161r1948b3244],
35	with	IN	O	with	pcomp	34	SENT_137	[p9l1976t3161r2140b3224],
36	standard	NN	O	standard	pobj	35	SENT_137	[p9l9t3264r347b3336],
37	,	,	O	,	_	0	SENT_137	[p9l9t3264r347b3336],
38	single-agent	JJ	O	single-agent	amod	39	SENT_137	[p9l377t3264r822b3348],
39	chemotherapy	NN	O	chemotherapy	appos	36	SENT_137	[p9l850t3264r1385b3348],
40	,	,	O	,	_	0	SENT_137	[p9l850t3264r1385b3348],
41	as	IN	O	as	mark	42	SENT_137	[p9l1416t3287r1483b3327],
42	assessed	VBN	O	assess	dep	36	SENT_137	[p9l1512t3264r1813b3327],
43	by	IN	O	by	_	0	SENT_137	[p9l1838t3264r1926b3348],
44	independent	JJ	O	independent	amod	45	SENT_137	[p9l1950t3264r2139b3327, p9l7t3366r311b3449],
45	radiology	NN	O	radiology	prep_by	42	SENT_137	[p9l341t3366r698b3450],
46	I	PRP	O	I	nsubj	62	SENT_137	[p9l725t3358r1047b3429],
47	'	''	O	'	_	0	SENT_137	[p9l725t3358r1047b3429],
48	€	CD	NUMBER	€	num	51	SENT_137	[p9l725t3358r1047b3429],
49	Vi	NNP	O	Vi	nn	51	SENT_137	[p9l725t3358r1047b3429],
50	€	NNP	O	€	nn	51	SENT_137	[p9l725t3358r1047b3429],
51	W.	NNP	O	W.	rcmod	46	SENT_137	[p9l725t3358r1047b3429],
52	31	CD	NUMBER	31	dep	51	SENT_137	[p9l725t3358r1047b3429],
53	In	IN	O	in	dep	51	SENT_137	[p9l1082t3371r1157b3428],
54	the	DT	O	the	det	57	SENT_137	[p9l1186t3366r1300b3429],
55	primary	JJ	O	primary	amod	57	SENT_137	[p9l1329t3372r1634b3450],
56	PFS	NN	O	pf	nn	57	SENT_137	[p9l1661t3370r1798b3430],
57	analysis	NN	O	analysis	pobj	53	SENT_137	[p9l1830t3366r2141b3450],
58	,	,	O	,	_	0	SENT_137	[p9l1830t3366r2141b3450],
59	crizotinib	NN	O	crizotinib	npadvmod	61	SENT_137	[p9l9t3469r358b3532],
60	more	JJR	O	more	dep	59	SENT_137	[p9l384t3492r569b3532],
61	than	IN	O	than	advmod	62	SENT_137	[p9l594t3469r755b3532],
62	doubled	VBD	O	double	advcl	31	SENT_137	[p9l782t3469r1074b3532],
63	the	DT	O	the	det	65	SENT_137	[p9l1097t3469r1208b3532],
64	median	JJ	O	median	amod	65	SENT_137	[p9l1234t3469r1503b3532],
65	PFS	NN	O	pf	dobj	62	SENT_137	[p9l1530t3473r1663b3532],
66	as	IN	O	as	prep	62	SENT_137	[p9l1691t3492r1758b3532],
67	compared	VBN	O	compare	_	0	SENT_137	[p9l1785t3469r2143b3552],
68	with	IN	O	with	prepc_compared_with	62	SENT_137	[p9l7t3572r170b3635],
69	chemotherapy	NN	O	chemotherapy	pobj	62	SENT_137	[p9l200t3572r740b3656],
70	,	,	O	,	_	0	SENT_137	[p9l200t3572r740b3656],
71	with	IN	O	with	_	0	SENT_137	[p9l770t3572r933b3635],
72	a	DT	O	a	det	75	SENT_137	[p9l963t3595r998b3635],
73	median	JJ	O	median	amod	75	SENT_137	[p9l1026t3572r1301b3635],
74	PF	NN	O	pf	nn	75	SENT_137	[p9l1332t3577r1424b3634],
75	S	NN	O	s	prep_with	9	SENT_137	[p9l1433t3576r1468b3635],
76	of	IN	O	of	_	0	SENT_137	[p9l1500t3572r1578b3635],
77	7.7	CD	DURATION	7.7	num	78	SENT_137	[p9l1599t3580r1702b3635],
78	months	NNS	NUMBER	month	prep_of	75	SENT_137	[p9l1732t3572r2009b3635],
79	for	IN	O	for	_	0	SENT_137	[p9l2039t3572r2143b3635],
80	173	CD	NUMBER	173	num	81	SENT_137	[p9l15t3682r133b3738],
81	patients	NNS	O	patient	prep_for	78	SENT_137	[p9l163t3681r453b3758],
82	randomized	VBN	O	randomize	partmod	81	SENT_137	[p9l483t3675r926b3738],
83	to	TO	O	to	_	0	SENT_137	[p9l952t3687r1021b3738],
84	crizotinib	NN	O	crizotinib	prep_to	82	SENT_137	[p9l1052t3675r1408b3738],
85	and	CC	O	and	_	0	SENT_137	[p9l1439t3675r1572b3738],
86	3.0	CD	DURATION	3.0	num	87	SENT_137	[p9l1601t3682r1703b3738],
87	months	NNS	NUMBER	month	prep_to	82	SENT_137	[p9l1733t3675r2008b3738],
88	for	IN	O	for	prep	82	SENT_137	[p9l2038t3675r2141b3738],

1	174	CD	NUMBER	174	num	2	SENT_138	[p10l15t24r135b80],
2	patients	NNS	O	patient	nsubj	3	SENT_138	[p10l161t23r448b100],
3	randomized	VBN	O	randomize	_	0	SENT_138	[p10l476t17r916b80],
4	to	TO	O	to	_	0	SENT_138	[p10l941t29r1010b80],
5	chemotherapy	NN	O	chemotherapy	nn	7	SENT_138	[p10l1039t17r1561b101],
6	(	CD	NUMBER	(	num	7	SENT_138	[p10l1589t18r1865b100],
7	Figure	NNP	O	Figure	prep_to	3	SENT_138	[p10l1589t18r1865b100],
8	3	CD	NUMBER	3	num	9	SENT_138	[p10l1892t18r1982b93],
9	)	NN	O	)	dep	7	SENT_138	[p10l1892t18r1982b93],
10	.	.	O	.	_	0	SENT_138	[p10l1892t18r1982b93],

1	The	DT	O	the	det	3	SENT_139	[p10l2012t17r2142b80],
2	hazard	NN	O	hazard	nn	3	SENT_139	[p10l8t120r253b183],
3	ratio	NN	O	ratio	nsubj	14	SENT_139	[p10l279t126r447b183],
4	comparing	VBG	O	compare	partmod	3	SENT_139	[p10l476t126r870b204],
5	crizotinib	NN	O	crizotinib	dobj	4	SENT_139	[p10l896t120r1249b183],
6	with	IN	O	with	_	0	SENT_139	[p10l1275t120r1436b183],
7	chemotherapy	NN	O	chemotherapy	prep_with	4	SENT_139	[p10l1464t120r1986b204],
8	was	VBD	O	be	cop	14	SENT_139	[p10l2008t143r2140b183],
9	0.487	CD	PERCENT	0.487	number	10	SENT_139	[p10l9t230r190b286],
10	(	CD	PERCENT	(	amod	14	SENT_139	[p10l216t224r385b300],
11	95	CD	PERCENT	95	num	12	SENT_139	[p10l216t224r385b300],
12	%	NN	PERCENT	%	dep	10	SENT_139	[p10l216t224r385b300],
13	conﬁdence	NN	O	conﬁdence	nn	14	SENT_139	[p10l409t223r781b286],
14	interval	NN	O	interval	_	0	SENT_139	[p10l803t223r1084b286],
15	:	:	O	:	_	0	SENT_139	[p10l803t223r1084b286],
16	0371-0638	CD	DURATION	0371-0638	num	17	SENT_139	[p10l1110t224r1550b300],
17	)	NN	O	)	nsubj	22	SENT_139	[p10l1110t224r1550b300],
18	with	IN	O	with	_	0	SENT_139	[p10l1574t223r1727b287],
19	a	DT	O	a	det	21	SENT_139	[p10l1750t246r1784b286],
20	one	CD	NUMBER	one	num	21	SENT_139	[p10l1805t223r2144b286],
21	—	NN	O	—	prep_with	17	SENT_139	[p10l1805t223r2144b286],
22	sided	VBD	O	side	parataxis	14	SENT_139	[p10l1805t223r2144b286],
23	P	NN	O	p	nn	24	SENT_139	[p10l7t330r57b387],
24	value	NN	O	value	dobj	22	SENT_139	[p10l78t325r269b388],
25	of	IN	O	of	_	0	SENT_139	[p10l298t325r375b388],
26	<	VBG	O	<	prepc_of	24	SENT_139	[p10l395t332r674b388],
27	0.0001	CD	NUMBER	0.0001	num	28	SENT_139	[p10l395t332r674b388],
28	(	NN	O	(	nsubj	29	SENT_139	[p10l711t325r1064b401],
29	stratiﬁed	VBD	O	stratiﬁed	ccomp	26	SENT_139	[p10l711t325r1064b401],
30	log	NN	O	log	nn	33	SENT_139	[p10l1089t325r1406b409],
31	—	CD	NUMBER	—	num	33	SENT_139	[p10l1089t325r1406b409],
32	rank	NN	O	rank	nn	33	SENT_139	[p10l1089t325r1406b409],
33	test	NN	O	test	dobj	29	SENT_139	[p10l1429t317r1670b402],
34	)	CD	NUMBER	)	number	35	SENT_139	[p10l1429t317r1670b402],
35	.31	CD	NUMBER	.31	num	37	SENT_139	[p10l1429t317r1670b402],
36	Median	JJ	MISC	median	amod	37	SENT_139	[p10l1701t325r1977b388],
37	PFS	NN	MISC	pf	nsubj	42	SENT_139	[p10l2006t329r2141b388],
38	with	IN	O	with	_	0	SENT_139	[p10l7t428r169b491],
39	crizotinib	NN	O	crizotinib	prep_with	37	SENT_139	[p10l198t428r554b491],
40	was	VBD	O	be	cop	42	SENT_139	[p10l582t451r715b491],
41	also	RB	O	also	advmod	42	SENT_139	[p10l745t428r884b491],
42	superior	JJ	O	superior	rcmod	33	SENT_139	[p10l915t434r1222b511],
43	to	TO	O	to	_	0	SENT_139	[p10l1249t440r1318b491],
44	either	CC	O	either	dep	45	SENT_139	[p10l1348t428r1560b491],
45	type	NN	O	type	prep_to	42	SENT_139	[p10l1587t440r1742b512],
46	of	IN	O	of	_	0	SENT_139	[p10l1771t428r1848b491],
47	chemotherapy	NN	O	chemotherapy	prep_of	45	SENT_139	[p10l1868t428r2140b491, p10l8t531r279b615],
48	,	,	O	,	_	0	SENT_139	[p10l1868t428r2140b491, p10l8t531r279b615],
49	with	IN	O	with	mark	61	SENT_139	[p10l301t531r454b594],
50	median	JJ	O	median	amod	52	SENT_139	[p10l475t531r733b594],
51	PFS	NN	O	pf	nn	52	SENT_139	[p10l755t535r883b594],
52	rates	NNS	O	rate	nsubj	61	SENT_139	[p10l907t543r1066b594],
53	of	IN	O	of	_	0	SENT_139	[p10l1089t531r1162b594],
54	4.2	CD	NUMBER	4.2	nn	57	SENT_139	[p10l1174t538r1272b594],
55	and	CC	O	and	_	0	SENT_139	[p10l1296t531r1422b594],
56	2.6	CD	DURATION	2.6	nn	57	SENT_139	[p10l1443t537r1540b594],
57	months	NNS	NUMBER	month	prep_of	52	SENT_139	[p10l1563t531r1822b594],
58	for	IN	O	for	_	0	SENT_139	[p10l1845t531r1942b594],
59	pem	NN	O	pem	nn	60	SENT_139	[p10l1961t553r2139b614],
60	—	NN	O	—	prep_for	57	SENT_139	[p10l1961t553r2139b614],
61	etrexed	VBD	O	etrex	advcl	42	SENT_139	[p10l9t634r269b697],
62	and	CC	O	and	_	0	SENT_139	[p10l294t634r424b697],
63	docetaxel	NN	O	docetaxel	dobj	22	SENT_139	[p10l449t634r802b706],
64	,	,	O	,	_	0	SENT_139	[p10l449t634r802b706],
65	respectively	RB	O	respectively	advmod	63	SENT_139	[p10l830t634r1260b718],
66	.	.	O	.	_	0	SENT_139	[p10l830t634r1260b718],

1	Consistent	JJ	O	consistent	nsubj	11	SENT_140	[p10l1289t638r1668b697],
2	with	IN	O	with	_	0	SENT_140	[p10l1691t634r1848b697],
3	the	DT	O	the	det	6	SENT_140	[p10l1873t634r1982b697],
4	PF	NN	O	pf	nn	6	SENT_140	[p10l2009t639r2098b696],
5	S	NN	O	s	nn	6	SENT_140	[p10l2106t638r2141b697],
6	results	NNS	O	result	prep_with	1	SENT_140	[p10l9t737r261b809],
7	,	,	O	,	_	0	SENT_140	[p10l9t737r261b809],
8	crizotinib	NN	O	crizotinib	appos	6	SENT_140	[p10l289t737r638b800],
9	more	JJR	O	more	dep	10	SENT_140	[p10l665t760r849b800],
10	than	IN	O	than	advmod	11	SENT_140	[p10l874t737r1035b800],
11	tripled	VBD	O	triple	_	0	SENT_140	[p10l1060t737r1302b820],
12	the	DT	O	the	det	14	SENT_140	[p10l1326t737r1436b800],
13	response	NN	O	response	nn	14	SENT_140	[p10l1463t759r1777b820],
14	rate	NN	O	rate	dobj	11	SENT_140	[p10l1804t749r1956b809],
15	,	,	O	,	_	0	SENT_140	[p10l1804t749r1956b809],
16	with	IN	O	with	_	0	SENT_140	[p10l1982t737r2142b800],
17	an	DT	O	a	det	18	SENT_140	[p10l9t863r90b903],
18	ORR	NN	O	orr	prep_with	11	SENT_140	[p10l114t844r284b903],
19	of	IN	O	of	_	0	SENT_140	[p10l305t840r379b903],
20	65	CD	PERCENT	65	num	21	SENT_140	[p10l394t846r537b905],
21	%	NN	PERCENT	%	prep_of	18	SENT_140	[p10l394t846r537b905],
22	in	IN	O	in	_	0	SENT_140	[p10l562t846r629b902],
23	the	DT	O	the	det	25	SENT_140	[p10l652t840r760b903],
24	crizotinib	JJ	O	crizotinib	amod	25	SENT_140	[p10l783t840r1123b903],
25	group	NN	O	group	prep_in	21	SENT_140	[p10l1147t862r1351b924],
26	vs.	CC	O	vs.	prep	25	SENT_140	[p10l1372t863r1461b903],
27	19	CD	PERCENT	19	num	28	SENT_140	[p10l1494t845r1631b905],
28	%	NN	PERCENT	%	dep	26	SENT_140	[p10l1494t845r1631b905],
29	in	IN	O	in	_	0	SENT_140	[p10l1656t846r1724b902],
30	the	DT	O	the	det	32	SENT_140	[p10l1745t840r1854b903],
31	chemotherapy	NN	O	chemotherapy	nn	32	SENT_140	[p10l1878t840r2139b903, p10l8t943r270b1027],
32	group	NN	O	group	prep_in	28	SENT_140	[p10l289t965r505b1027],
33	.	.	O	.	_	0	SENT_140	[p10l289t965r505b1027],

1	By	IN	O	by	_	0	SENT_141	[p10l530t948r619b1027],
2	type	NN	O	type	prep_by	10	SENT_141	[p10l636t955r783b1027],
3	of	IN	O	of	_	0	SENT_141	[p10l805t943r879b1006],
4	chemotherapy	NN	O	chemotherapy	prep_of	2	SENT_141	[p10l892t943r1395b1027],
5	,	,	O	,	_	0	SENT_141	[p10l892t943r1395b1027],
6	the	DT	O	the	det	7	SENT_141	[p10l1418t943r1524b1006],
7	ORR	NNP	ORGANIZATION	ORR	nsubj	10	SENT_141	[p10l1547t947r1715b1006],
8	was	VBD	O	be	cop	10	SENT_141	[p10l1733t966r1858b1006],
9	29	CD	PERCENT	29	num	10	SENT_141	[p10l1881t948r2022b1007],
10	%	NN	PERCENT	%	_	0	SENT_141	[p10l1881t948r2022b1007],
11	for	IN	O	for	_	0	SENT_141	[p10l2046t943r2144b1006],
12	pemetrexed	JJ	O	pemetrexed	prep_for	10	SENT_141	[p10l7t1046r424b1129],
13	and	CC	O	and	_	0	SENT_141	[p10l449t1046r577b1109],
14	7	CD	PERCENT	7	num	15	SENT_141	[p10l602t1051r703b1111],
15	%	NN	PERCENT	%	conj_and	10	SENT_141	[p10l602t1051r703b1111],
16	for	IN	O	for	_	0	SENT_141	[p10l729t1046r829b1109],
17	docetaxel	NN	O	docetaxel	nn	18	SENT_141	[p10l853t1046r1186b1109],
18	chemotherapy	NN	O	chemotherapy	prep_for	15	SENT_141	[p10l1210t1046r1735b1130],
19	;	:	O	;	_	0	SENT_141	[p10l1210t1046r1735b1130],
20	differences	NNS	O	difference	nsubj	32	SENT_141	[p10l1762t1046r2141b1109],
21	in	IN	O	in	_	0	SENT_141	[p10l9t1155r77b1211],
22	ORRs	NNS	O	orr	prep_in	20	SENT_141	[p10l104t1153r307b1212],
23	between	IN	O	between	_	0	SENT_141	[p10l331t1149r627b1212],
24	crizotinib	NN	O	crizotinib	prep_between	22	SENT_141	[p10l654t1149r999b1212],
25	and	CC	O	and	_	0	SENT_141	[p10l1027t1149r1157b1212],
26	each	DT	O	each	det	27	SENT_141	[p10l1182t1149r1340b1212],
27	type	NN	O	type	conj_and	22	SENT_141	[p10l1365t1161r1516b1233],
28	of	IN	O	of	_	0	SENT_141	[p10l1542t1149r1618b1212],
29	chemotherapy	NN	O	chemotherapy	prep_of	27	SENT_141	[p10l1635t1149r2147b1233],
30	were	VBD	O	be	cop	32	SENT_141	[p10l7t1275r167b1315],
31	statistically	RB	O	statistically	advmod	32	SENT_141	[p10l189t1252r574b1336],
32	signiﬁcant	JJ	O	signiﬁcant	parataxis	10	SENT_141	[p10l594t1252r965b1336],
33	.	.	O	.	_	0	SENT_141	[p10l594t1252r965b1336],

1	A	DT	O	a	nsubj	23	SENT_142	[p10l989t1256r1045b1314],
2	randomized	VBN	O	randomize	csubj	22	SENT_142	[p10l1066t1252r1480b1315],
3	controlled	JJ	O	controlled	ccomp	2	SENT_142	[p10l1502t1252r1852b1315],
4	study	NN	O	study	dobj	3	SENT_142	[p10l1874t1252r2059b1336],
5	of	IN	O	of	_	0	SENT_142	[p10l2078t1252r2151b1315],
6	crizotinib	NN	O	crizotinib	prep_of	4	SENT_142	[p10l9t1355r350b1418],
7	vs.	CC	O	vs.	prep	6	SENT_142	[p10l373t1378r463b1418],
8	chemotherapy	NN	O	chemotherapy	dep	7	SENT_142	[p10l491t1355r997b1439],
9	in	IN	O	in	_	0	SENT_142	[p10l1019t1361r1086b1417],
10	patients	NNS	O	patient	prep_in	3	SENT_142	[p10l1109t1361r1387b1438],
11	with	IN	O	with	_	0	SENT_142	[p10l1411t1355r1567b1418],
12	advanced	JJ	O	advanced	amod	14	SENT_142	[p10l1592t1355r1924b1418],
13	ALKpositive	JJ	O	alkpositive	amod	14	SENT_142	[p10l1946t1359r2139b1417, p10l7t1464r278b1541],
14	NSCLC	NN	ORGANIZATION	nsclc	prep_with	2	SENT_142	[p10l299t1462r562b1521],
15	in	IN	O	in	_	0	SENT_142	[p10l585t1464r652b1520],
16	the	DT	O	the	det	19	SENT_142	[p10l673t1458r780b1521],
17	ﬁrst-line	JJ	O	ﬁrst-line	amod	19	SENT_142	[p10l802t1458r1098b1521],
18	treatment	NN	O	treatment	nn	19	SENT_142	[p10l1119t1470r1459b1521],
19	setting	NN	O	setting	prep_in	14	SENT_142	[p10l1481t1464r1712b1542],
20	has	VBZ	O	have	aux	22	SENT_142	[p10l1732t1458r1844b1521],
21	recently	RB	DATE	recently	advmod	22	SENT_142	[p10l1868t1458r2145b1542],
22	completed	VBN	O	complete	dep	1	SENT_142	[p10l9t1561r376b1644],
23	accrual	NN	O	accrual	_	0	SENT_142	[p10l400t1561r654b1624],
24	(	CD	NUMBER	(	num	26	SENT_142	[p10l681t1562r1273b1638],
25	NCT01154140	NN	O	nct01154140	nn	26	SENT_142	[p10l681t1562r1273b1638],
26	)	NN	O	)	dobj	23	SENT_142	[p10l681t1562r1273b1638],
27	.	.	O	.	_	0	SENT_142	[p10l681t1562r1273b1638],

1	In	IN	O	in	_	0	SENT_143	[p10l83t1669r155b1726],
2	addition	NN	O	addition	_	0	SENT_143	[p10l181t1664r478b1727],
3	to	TO	O	to	_	0	SENT_143	[p10l501t1676r569b1727],
4	ALK-positive	JJ	O	alk-positive	amod	5	SENT_143	[p10l595t1668r1072b1747],
5	NSCLC	NN	O	nsclc	prep_in_addition_to	13	SENT_143	[p10l1096t1668r1385b1736],
6	,	,	O	,	_	0	SENT_143	[p10l1096t1668r1385b1736],
7	complete	JJ	O	complete	amod	10	SENT_143	[p10l1413t1664r1732b1747],
8	and	CC	O	and	_	0	SENT_143	[p10l1759t1664r1888b1727],
9	partial	JJ	O	partial	amod	10	SENT_143	[p10l1911t1664r2143b1747],
10	responses	NNS	O	response	nsubjpass	13	SENT_143	[p10l9t1789r350b1850],
11	have	VBP	O	have	aux	13	SENT_143	[p10l374t1767r534b1830],
12	been	VBN	O	be	auxpass	13	SENT_143	[p10l556t1767r725b1830],
13	observed	VBN	O	observe	_	0	SENT_143	[p10l750t1767r1070b1830],
14	in	IN	O	in	_	0	SENT_143	[p10l1093t1773r1161b1829],
15	a	DT	O	a	det	16	SENT_143	[p10l1187t1790r1221b1830],
16	variety	NN	O	variety	prep_in	13	SENT_143	[p10l1242t1773r1488b1851],
17	of	IN	O	of	_	0	SENT_143	[p10l1509t1767r1585b1830],
18	other	JJ	O	other	amod	21	SENT_143	[p10l1600t1767r1787b1830],
19	advanced	JJ	O	advanced	amod	21	SENT_143	[p10l1811t1767r2144b1830],
20	solid	JJ	O	solid	amod	21	SENT_143	[p10l9t1870r175b1933],
21	tumors	NNS	O	tumor	prep_of	16	SENT_143	[p10l196t1882r444b1933],
22	treated	VBN	O	treat	partmod	21	SENT_143	[p10l466t1870r708b1933],
23	with	IN	O	with	_	0	SENT_143	[p10l728t1870r883b1933],
24	crizotinib	NN	O	crizotinib	prep_with	22	SENT_143	[p10l907t1870r1259b1942],
25	,	,	O	,	_	0	SENT_143	[p10l907t1870r1259b1942],
26	including	VBG	O	include	_	0	SENT_143	[p10l1284t1870r1615b1954],
27	ROS1-positive	JJ	O	ros1-positive	amod	28	SENT_143	[p10l1637t1874r2140b1953],
28	NSCLC	NN	O	nsclc	prep_including	21	SENT_143	[p10l8t1964r376b2044],
29	,	,	O	,	_	0	SENT_143	[p10l8t1964r376b2044],
30	“	CD	NUMBER	“	num	32	SENT_143	[p10l8t1964r376b2044],
31	c-MET-amplified	JJ	O	c-met-amplified	amod	32	SENT_143	[p10l417t1972r1070b2055],
32	glioblastoma	NN	O	glioblastoma	appos	28	SENT_143	[p10l1106t1972r1588b2056],
33	multiforme	JJ	O	multiforme	amod	32	SENT_143	[p10l1623t1964r2141b2044],
34	,62	CD	NUMBER	,62	tmod	33	SENT_143	[p10l1623t1964r2141b2044],

1	*	NN	O	*	nn	4	SENT_144	[p10l179t2513r215b2583],
2	3	CD	NUMBER	3	num	4	SENT_144	[p10l179t2513r215b2583],
3	’	NN	O	’	nn	4	SENT_144	[p10l179t2513r215b2583],
4	Hazard	NN	O	hazard	_	0	SENT_144	[p10l966t2521r1127b2560],
5	ratio	NN	O	ratio	dep	4	SENT_144	[p10l1148t2521r1253b2567],
6	,	,	O	,	_	0	SENT_144	[p10l1148t2521r1253b2567],
7	0.49	CD	PERCENT	0.49	number	8	SENT_144	[p10l1273t2522r1371b2560],
8	(	CD	PERCENT	(	appos	5	SENT_144	[p10l1390t2521r1507b2570],
9	95	CD	PERCENT	95	number	10	SENT_144	[p10l1390t2521r1507b2570],
10	%	NN	PERCENT	%	amod	11	SENT_144	[p10l1390t2521r1507b2570],
11	CI	NN	O	ci	dep	4	SENT_144	[p10l1525t2520r1583b2560],
12	:	:	O	:	_	0	SENT_144	[p10l1525t2520r1583b2560],
13	0.37	CD	NUMBER	0.37	number	15	SENT_144	[p10l1600t2522r1699b2560],
14	to	TO	O	to	dep	15	SENT_144	[p10l1715t2524r1756b2560],
15	0.64	CD	NUMBER	0.64	dep	11	SENT_144	[p10l1774t2521r1888b2570],
16	)	CD	NUMBER	)	num	17	SENT_144	[p10l1774t2521r1888b2570],
17	_	NN	O	_	dep	4	SENT_144	[p10l176t2588r215b2637],
18	§	CD	NUMBER	§	number	19	SENT_144	[p10l176t2588r215b2637],
19	80	CD	NUMBER	80	num	20	SENT_144	[p10l351t2564r406b2602],
20	P	NN	O	p	npadvmod	21	SENT_144	[p10l966t2584r1039b2622],
21	<	JJR	O	<	amod	17	SENT_144	[p10l966t2584r1039b2622],
22	0.001	CD	NUMBER	0.001	num	23	SENT_144	[p10l1056t2584r1174b2623],
23	E	NN	O	e	dep	4	SENT_144	[p10l187t2640r214b2676],
24	Z	NN	O	z	dep	23	SENT_144	[p10l238t2667r288b2679],
25	'	''	O	'	_	0	SENT_144	[p10l238t2667r288b2679],
26	\	JJ	O	\	amod	27	SENT_144	[p10l238t2667r288b2679],
27	§	NN	O	§	dep	4	SENT_144	[p10l176t2695r215b2756],
28	2	CD	PERCENT	2	number	29	SENT_144	[p10l238t2683r288b2742],
29	%	NN	PERCENT	%	amod	27	SENT_144	[p10l238t2683r288b2742],
30	-	:	O	-	_	0	SENT_144	[p10l176t2760r214b2810],
31	E	NN	O	e	dep	27	SENT_144	[p10l176t2760r214b2810],
32	8	CD	NUMBER	8	number	33	SENT_144	[p10l248t2762r278b2816],
33	60	CD	NUMBER	60	dep	31	SENT_144	[p10l351t2739r406b2777],
34	.	.	O	.	_	0	SENT_144	[p10l445t2770r448b2772],

1	.9	NN	NUMBER	.9	nn	3	SENT_145	[p10l857t2777r890b2799],
2	5	CD	NUMBER	5	num	3	SENT_145	[p10l186t2816r215b2867],
3	‘	NN	O	‘	_	0	SENT_145	[p10l186t2816r215b2867],
4	;	:	O	;	_	0	SENT_145	[p10l186t2816r215b2867],
5	171	CD	NUMBER	171	num	6	SENT_145	[p10l239t2820r278b2853],
6	A	NN	O	a	dep	3	SENT_145	[p10l915t2824r918b2826],
7	.	.	O	.	_	0	SENT_145	[p10l958t2843r961b2844],

1	.	.	O	.	_	0	SENT_146	[p10l986t2844r989b2847],

1	Crizotinib	NNP	O	Crizotinib	nn	3	SENT_147	[p10l1014t2812r1227b2852],
2	__	CD	NUMBER	__	num	3	SENT_147	[p10l176t2883r214b2897],
3	(	NN	O	(	_	0	SENT_147	[p10l248t2856r278b2879],
4	D	NN	O	d	dep	3	SENT_147	[p10l248t2856r278b2879],
5	°	CD	PERCENT	°	num	6	SENT_147	[p10l186t2899r215b2924],
6	%	NN	PERCENT	%	dobj	4	SENT_147	[p10l248t2882r288b2954],
7	40	CD	NUMBER	40	number	8	SENT_147	[p10l350t2915r406b2953],
8	1	CD	NUMBER	1	num	6	SENT_147	[p10l1011t2899r1013b2901],
9	E	NN	O	e	nn	11	SENT_147	[p10l176t2941r226b2989],
10	2	CD	NUMBER	2	num	11	SENT_147	[p10l248t2957r278b2998],
11	E	NN	O	e	dep	6	SENT_147	[p10l176t2995r215b3042],
12	Q.	NNP	O	Q.	nn	13	SENT_147	[p10l248t3004r288b3028],
13	g	NN	O	g	dep	6	SENT_147	[p10l176t3045r215b3100],
14	_	CD	NUMBER	_	num	13	SENT_147	[p10l931t3083r952b3084],
15	z	SYM	O	z	dep	6	SENT_147	[p10l990t3085r997b3092],
16	P	NN	O	p	dep	3	SENT_147	[p10l990t3085r997b3092],
17	*	CD	NUMBER	*	num	16	SENT_147	[p10l990t3085r997b3092],
18	o	NN	O	o	rcmod	16	SENT_147	[p10l186t3104r215b3130],
19	20	CD	NUMBER	20	num	18	SENT_147	[p10l350t3091r406b3129],
20	-	:	O	-	_	0	SENT_147	[p10l433t3116r448b3124],
21	"	``	O	"	punct	18	SENT_147	[p10l982t3101r989b3108],
22	at	IN	O	at	amod	23	SENT_147	[p10l176t3131r214b3179],
23	Chemotherapy	NNP	O	Chemotherapy	dep	18	SENT_147	[p10l628t3131r964b3181],

1	Months	NNS	DURATION	month	_	0	SENT_148	[p10l1189t3418r1354b3456],

1	No.	NN	O	no.	dep	7	SENT_149	[p10l30t3486r101b3524],
2	at	IN	O	at	_	0	SENT_149	[p10l118t3489r159b3524],
3	risk	NN	O	risk	prep_at	1	SENT_149	[p10l178t3486r256b3524],
4	Crizotinib	NN	O	crizotinib	dep	7	SENT_149	[p10l29t3546r241b3587],
5	173	CD	NUMBER	173	num	4	SENT_149	[p10l423t3549r503b3588],
6	93	CD	NUMBER	93	num	7	SENT_149	[p10l751t3549r805b3588],
7	38	CD	NUMBER	38	dep	14	SENT_149	[p10l1075t3549r1129b3588],
8	1	CD	NUMBER	1	number	9	SENT_149	[p10l1412t3549r1426b3587],
9	1	CD	NUMBER	1	dep	7	SENT_149	[p10l1441t3549r1455b3587],
10	2	CD	NUMBER	2	num	12	SENT_149	[p10l1745t3549r1771b3587],
11	O	NN	ORGANIZATION	o	nn	12	SENT_149	[p10l2080t3549r2105b3588],
12	Chemotherapy	NN	ORGANIZATION	chemotherapy	dep	9	SENT_149	[p10l29t3608r365b3658],
13	174	CD	NUMBER	174	num	14	SENT_149	[p10l423t3616r503b3653],
14	49	CD	NUMBER	49	_	0	SENT_149	[p10l750t3616r805b3654],
15	15	CD	NUMBER	15	number	16	SENT_149	[p10l1078t3616r1129b3654],
16	4	CD	NUMBER	4	dep	14	SENT_149	[p10l1423t3616r1449b3653],
17	1	CD	NUMBER	1	num	18	SENT_149	[p10l1749t3616r1763b3653],
18	o	NN	O	o	dep	16	SENT_149	[p10l2080t3616r2105b3654],

1	Figure	NNP	O	Figure	_	0	SENT_150	[p11l10t65r197b127],
2	3	CD	NUMBER	3	num	1	SENT_150	[p11l213t68r244b114],
3	Kap	NN	O	kap	dep	1	SENT_150	[p11l298t65r678b126],
4	|	CD	NUMBER	|	num	3	SENT_150	[p11l298t65r678b126],
5	an	DT	O	a	dep	3	SENT_150	[p11l298t65r678b126],
6	.	.	O	.	_	0	SENT_150	[p11l298t65r678b126],

1	—	NN	O	—	_	0	SENT_151	[p11l298t65r678b126],
2	.	.	O	.	_	0	SENT_151	[p11l298t65r678b126],

1	Meier	JJR	PERSON	meier	amod	2	SENT_152	[p11l298t65r678b126],
2	estimates	NNS	O	estimate	nsubj	6	SENT_152	[p11l693t67r956b114],
3	of	IN	O	of	_	0	SENT_152	[p11l973t64r1030b114],
4	progression	NN	O	progression	prep_of	2	SENT_152	[p11l1044t64r1495b127],
5	—	CD	NUMBER	—	num	4	SENT_152	[p11l1044t64r1495b127],
6	free	JJ	O	free	_	0	SENT_152	[p11l1044t64r1495b127],
7	survival	NN	O	survival	dobj	6	SENT_152	[p11l1512t65r1720b114],
8	in	IN	O	in	_	0	SENT_152	[p11l1741t67r1785b113],
9	the	DT	O	the	det	10	SENT_152	[p11l1803t65r1893b114],
10	phase	NN	O	phase	prep_in	7	SENT_152	[p11l1911t65r2073b126],
11	III	CD	NUMBER	iii	num	12	SENT_152	[p11l2092t67r2130b113],
12	study	NN	O	study	nsubj	18	SENT_152	[p11l9t150r160b213],
13	of	IN	O	of	_	0	SENT_152	[p11l175t150r233b199],
14	crizotinib	NN	O	crizotinib	prep_of	12	SENT_152	[p11l244t150r501b199],
15	vs.	CC	O	vs.	prep	14	SENT_152	[p11l516t164r585b199],
16	chemotherapy	NN	O	chemotherapy	nn	17	SENT_152	[p11l601t150r1008b213],
17	(	NN	O	(	dep	15	SENT_152	[p11l1025t150r1374b212],
18	pemetrexed	VBD	O	pemetrex	rcmod	10	SENT_152	[p11l1025t150r1374b212],
19	or	CC	O	or	_	0	SENT_152	[p11l1393t164r1449b199],
20	docetaxe	JJ	O	docetaxe	amod	22	SENT_152	[p11l1464t150r1877b207],
21	|	NN	O	|	nn	22	SENT_152	[p11l1464t150r1877b207],
22	)	NN	O	)	prep_in	7	SENT_152	[p11l1464t150r1877b207],
23	.	.	O	.	_	0	SENT_152	[p11l1464t150r1877b207],

1	The	DT	O	the	det	6	SENT_153	[p11l1464t150r1877b207],
2	median	JJ	O	median	amod	6	SENT_153	[p11l1896t150r2100b199],
3	progression	NN	O	progression	nn	6	SENT_153	[p11l10t236r462b299],
4	—	CD	NUMBER	—	num	6	SENT_153	[p11l10t236r462b299],
5	free	JJ	O	free	amod	6	SENT_153	[p11l10t236r462b299],
6	survival	NN	O	survival	nsubj	9	SENT_153	[p11l479t237r687b286],
7	was	VBD	O	be	cop	9	SENT_153	[p11l705t251r809b286],
8	7.7	CD	DURATION	7.7	num	9	SENT_153	[p11l827t241r904b286],
9	months	NNS	NUMBER	month	_	0	SENT_153	[p11l923t237r1132b286],
10	with	IN	O	with	_	0	SENT_153	[p11l1148t237r1267b286],
11	crizotinib	NN	O	crizotinib	prep_with	9	SENT_153	[p11l1285t237r1542b286],
12	as	IN	O	as	_	0	SENT_153	[p11l1559t251r1613b286],
13	compared	VBN	O	compare	prepc_as	11	SENT_153	[p11l1631t237r1909b298],
14	with	IN	O	with	pcomp	13	SENT_153	[p11l1927t237r2046b286],
15	3.0	CD	DURATION	3.0	num	16	SENT_153	[p11l9t327r86b373],
16	months	NNS	NUMBER	month	pobj	14	SENT_153	[p11l105t324r314b373],
17	with	IN	O	with	_	0	SENT_153	[p11l330t324r449b373],
18	chemotherapy	NN	O	chemotherapy	nn	21	SENT_153	[p11l468t324r875b386],
19	(	NN	O	(	nn	21	SENT_153	[p11l891t324r1091b380],
20	hazard	NN	O	hazard	nn	21	SENT_153	[p11l891t324r1091b380],
21	ratio	NN	O	ratio	prep_with	16	SENT_153	[p11l1113t326r1247b373],
22	:	:	O	:	_	0	SENT_153	[p11l1113t326r1247b373],
23	0.49	CD	PERCENT	0.49	number	24	SENT_153	[p11l1264t327r1377b373],
24	(	CD	PERCENT	(	dep	9	SENT_153	[p11l1395t325r1530b380],
25	95	CD	PERCENT	95	num	28	SENT_153	[p11l1395t325r1530b380],
26	%	NN	PERCENT	%	nn	28	SENT_153	[p11l1395t325r1530b380],
27	confidence	NN	O	confidence	nn	28	SENT_153	[p11l1547t323r1853b373],
28	interval	NN	O	interval	dep	24	SENT_153	[p11l1871t324r2090b373],
29	:	:	O	:	_	0	SENT_153	[p11l1871t324r2090b373],
30	0.37-0	CD	NUMBER	0.37-0	dep	9	SENT_153	[p11l8t409r304b465],
31	.64	CD	NUMBER	.64	num	32	SENT_153	[p11l8t409r304b465],
32	)	NN	O	)	dep	30	SENT_153	[p11l8t409r304b465],
33	;	:	O	;	_	0	SENT_153	[p11l8t409r304b465],
34	P	NN	O	p	dep	35	SENT_153	[p11l320t410r353b457],
35	<	JJR	O	<	dep	9	SENT_153	[p11l369t420r400b456],
36	0.001	CD	NUMBER	0.001	num	37	SENT_153	[p11l419t409r599b465],
37	)	NN	O	)	dep	9	SENT_153	[p11l419t409r599b465],
38	.	.	O	.	_	0	SENT_153	[p11l419t409r599b465],

1	Reprinted	VBN	O	reprint	_	0	SENT_154	[p11l618t408r884b470],
2	with	IN	O	with	_	0	SENT_154	[p11l902t408r1021b457],
3	permission	NN	O	permission	prep_with	1	SENT_154	[p11l1042t411r1341b470],
4	from	IN	O	from	_	0	SENT_154	[p11l1358t408r1487b457],
5	ref	NN	O	ref	prep_from	1	SENT_154	[p11l1508t408r1587b457],
6	.	.	O	.	_	0	SENT_154	[p11l1508t408r1587b457],

1	31	CD	NUMBER	31	_	0	SENT_155	[p11l1605t411r1682b457],
2	.	.	O	.	_	0	SENT_155	[p11l1605t411r1682b457],

1	c-MET	NN	O	c-met	_	0	SENT_156	[p11l9t634r602b718],
2	—	CD	NUMBER	—	num	5	SENT_156	[p11l9t634r602b718],
3	ampliﬁed	JJ	O	ampliﬁed	amod	5	SENT_156	[p11l9t634r602b718],
4	gastroesophageal	NN	O	gastroesophageal	nn	5	SENT_156	[p11l621t634r1207b719],
5	carcinoma	NN	O	carcinoma	dep	1	SENT_156	[p11l1227t626r1666b707],
6	,	,	O	,	_	0	SENT_156	[p11l1227t626r1666b707],
7	“	CD	NUMBER	“	num	8	SENT_156	[p11l1227t626r1666b707],
8	ALK	NN	O	alk	appos	5	SENT_156	[p11l1688t638r2148b718],
9	—	CD	NUMBER	—	num	13	SENT_156	[p11l1688t638r2148b718],
10	positive	JJ	O	positive	amod	11	SENT_156	[p11l1688t638r2148b718],
11	inﬂammatory	JJ	O	inﬂammatory	amod	13	SENT_156	[p11l9t737r498b822],
12	myoﬁbroblastic	JJ	O	myoﬁbroblastic	amod	13	SENT_156	[p11l518t737r1067b822],
13	tumor	NN	O	tumor	dep	1	SENT_156	[p11l1090t729r1390b810],
14	,64	CD	NUMBER	,64	num	15	SENT_156	[p11l1090t729r1390b810],
15	ALK	NNP	O	ALK	dep	13	SENT_156	[p11l1412t742r1889b821],
16	—	CD	NUMBER	—	num	15	SENT_156	[p11l1412t742r1889b821],
17	positive	JJ	O	positive	amod	21	SENT_156	[p11l1412t742r1889b821],
18	diffuse	JJ	O	diffuse	amod	21	SENT_156	[p11l1914t737r2149b801],
19	large	JJ	O	large	amod	21	SENT_156	[p11l7t840r170b925],
20	B-cell	NN	MISC	b-cell	nn	21	SENT_156	[p11l190t841r384b904],
21	lymphoma	NN	O	lymphoma	dep	1	SENT_156	[p11l401t832r848b925],
22	,65	CD	NUMBER	,65	dep	21	SENT_156	[p11l401t832r848b925],
23	pediatric	JJ	O	pediatric	dep	1	SENT_156	[p11l868t840r1170b924],
24	and	CC	O	and	_	0	SENT_156	[p11l1191t840r1316b904],
25	adult	JJ	O	adult	amod	26	SENT_156	[p11l1335t840r1506b904],
26	ALK	NNP	O	ALK	dep	1	SENT_156	[p11l1524t844r1981b924],
27	—	CD	NUMBER	—	num	33	SENT_156	[p11l1524t844r1981b924],
28	positive	JJ	O	positive	amod	33	SENT_156	[p11l1524t844r1981b924],
29	anaplastic	JJ	O	anaplastic	amod	33	SENT_156	[p11l2002t863r2146b904, p11l7t943r233b1027],
30	large	JJ	O	large	amod	33	SENT_156	[p11l255t943r453b1028],
31	—	NN	O	—	nn	33	SENT_156	[p11l255t943r453b1028],
32	cell	NN	O	cell	nn	33	SENT_156	[p11l481t943r598b1007],
33	lymphoma	NN	O	lymphoma	dep	1	SENT_156	[p11l619t935r1162b1028],
34	,65	CD	NUMBER	,65	num	35	SENT_156	[p11l619t935r1162b1028],
35	>	JJR	O	>	dep	33	SENT_156	[p11l619t935r1162b1028],
36	66	CD	NUMBER	66	dep	1	SENT_156	[p11l619t935r1162b1028],
37	and	CC	O	and	_	0	SENT_156	[p11l1187t943r1316b1007],
38	pediatric	JJ	O	pediatric	amod	40	SENT_156	[p11l1337t943r1652b1027],
39	ALK-positive	JJ	MISC	alk-positive	amod	40	SENT_156	[p11l1674t948r2149b1027],
40	neuroblastoma	NN	O	neuroblastoma	conj_and	36	SENT_156	[p11l8t1038r604b1110],
41	.	.	O	.	_	0	SENT_156	[p11l8t1038r604b1110],

1	“	NN	O	“	_	0	SENT_157	[p11l8t1038r604b1110],

1	In	IN	O	in	_	0	SENT_158	[p11l83t1155r157b1212],
2	the	DT	O	the	det	3	SENT_158	[p11l187t1150r299b1213],
3	phase	NN	O	phase	prep_in	30	SENT_158	[p11l328t1150r535b1233],
4	I	PRP	O	I	dep	3	SENT_158	[p11l566t1155r612b1222],
5	,	,	O	,	_	0	SENT_158	[p11l566t1155r612b1222],
6	II	CD	NUMBER	ii	prep_in	30	SENT_158	[p11l645t1155r723b1222],
7	,	,	O	,	_	0	SENT_158	[p11l645t1155r723b1222],
8	and	CC	O	and	_	0	SENT_158	[p11l756t1150r888b1213],
9	III	NNP	O	III	nn	10	SENT_158	[p11l919t1155r1007b1212],
10	studies	NNS	O	study	prep_in	30	SENT_158	[p11l1040t1150r1291b1213],
11	of	IN	O	of	_	0	SENT_158	[p11l1322t1150r1400b1213],
12	crizotinib	NN	O	crizotinib	prep_of	10	SENT_158	[p11l1421t1150r1794b1222],
13	,	,	O	,	_	0	SENT_158	[p11l1421t1150r1794b1222],
14	the	DT	O	the	det	19	SENT_158	[p11l1825t1150r1938b1213],
15	most	RBS	O	most	advmod	17	SENT_158	[p11l1969t1162r2148b1213],
16	commonly	RB	O	commonly	advmod	17	SENT_158	[p11l9t1253r394b1337],
17	reported	VBN	O	report	amod	19	SENT_158	[p11l416t1253r723b1336],
18	treatment	NN	O	treatment	nn	19	SENT_158	[p11l746t1253r1371b1316],
19	—	NN	O	—	appos	10	SENT_158	[p11l746t1253r1371b1316],
20	related	JJ	O	related	amod	22	SENT_158	[p11l746t1253r1371b1316],
21	adverse	JJ	O	adverse	amod	22	SENT_158	[p11l1397t1253r1661b1316],
22	events	NNS	O	event	nsubj	30	SENT_158	[p11l1688t1265r1908b1316],
23	of	IN	O	of	_	0	SENT_158	[p11l1934t1253r2011b1316],
24	any	DT	O	any	det	25	SENT_158	[p11l2027t1276r2152b1337],
25	severity	NN	O	severity	prep_of	22	SENT_158	[p11l9t1362r274b1440],
26	and	CC	O	and	_	0	SENT_158	[p11l292t1356r418b1419],
27	grade	NN	O	grade	prep_of	22	SENT_158	[p11l437t1356r626b1440],
28	were	VBD	O	be	cop	30	SENT_158	[p11l644t1379r805b1419],
29	vision	NN	O	vision	nn	30	SENT_158	[p11l822t1362r1029b1419],
30	disorder	NN	O	disorder	_	0	SENT_158	[p11l1050t1356r1347b1428],
31	,	,	O	,	_	0	SENT_158	[p11l1050t1356r1347b1428],
32	nausea	NN	O	nausea	appos	30	SENT_158	[p11l1369t1379r1619b1428],
33	,	,	O	,	_	0	SENT_158	[p11l1369t1379r1619b1428],
34	diarrhea	NN	O	diarrhea	appos	30	SENT_158	[p11l1642t1356r1946b1428],
35	,	,	O	,	_	0	SENT_158	[p11l1642t1356r1946b1428],
36	vomiting	VBG	O	vomit	appos	30	SENT_158	[p11l1965t1379r2145b1419, p11l8t1465r182b1543],
37	,	,	O	,	_	0	SENT_158	[p11l1965t1379r2145b1419, p11l8t1465r182b1543],
38	edema	NN	O	edema	appos	36	SENT_158	[p11l207t1459r449b1531],
39	,	,	O	,	_	0	SENT_158	[p11l207t1459r449b1531],
40	constipation	NN	O	constipation	appos	30	SENT_158	[p11l475t1465r918b1542],
41	,	,	O	,	_	0	SENT_158	[p11l475t1465r918b1542],
42	and	CC	O	and	_	0	SENT_158	[p11l943t1459r1069b1522],
43	elevated	JJ	O	elevated	amod	44	SENT_158	[p11l1092t1459r1370b1522],
44	levels	NNS	O	level	nsubj	49	SENT_158	[p11l1390t1459r1576b1522],
45	of	IN	O	of	_	0	SENT_158	[p11l1599t1459r1674b1522],
46	the	DT	O	the	det	48	SENT_158	[p11l1686t1459r1792b1522],
47	transami	NN	O	transamus	nn	48	SENT_158	[p11l1814t1465r2146b1522],
48	—	NN	O	—	prep_of	44	SENT_158	[p11l1814t1465r2146b1522],
49	nases	VBZ	O	nase	conj_and	30	SENT_158	[p11l8t1553r491b1625],
50	.3	NN	NUMBER	.3	dep	58	SENT_158	[p11l8t1553r491b1625],
51	°	CD	NUMBER	°	number	52	SENT_158	[p11l8t1553r491b1625],
52	’	CD	NUMBER	’	dep	50	SENT_158	[p11l8t1553r491b1625],
53	31	CD	NUMBER	31	num	54	SENT_158	[p11l8t1553r491b1625],
54	’	NN	O	’	dep	52	SENT_158	[p11l8t1553r491b1625],
55	59	CD	NUMBER	59	num	56	SENT_158	[p11l8t1553r491b1625],
56	’	NN	O	’	dep	58	SENT_158	[p11l8t1553r491b1625],
57	6	CD	NUMBER	6	num	58	SENT_158	[p11l8t1553r491b1625],
58	°	CD	NUMBER	°	dep	72	SENT_158	[p11l8t1553r491b1625],
59	The	DT	O	the	det	62	SENT_158	[p11l511t1561r633b1625],
60	most	RBS	O	most	advmod	61	SENT_158	[p11l653t1573r820b1625],
61	common	JJ	O	common	amod	62	SENT_158	[p11l839t1584r1139b1625],
62	grade	NN	O	grade	dep	58	SENT_158	[p11l1159t1561r1344b1646],
63	3	CD	NUMBER	3	num	67	SENT_158	[p11l1365t1568r1398b1625],
64	or	CC	O	or	_	0	SENT_158	[p11l1421t1584r1491b1625],
65	4	CD	NUMBER	4	conj_or	63	SENT_158	[p11l1509t1568r1547b1624],
66	crizotinib	NN	O	crizotinib	nn	67	SENT_158	[p11l1567t1561r2150b1625],
67	—	NN	O	—	npadvmod	68	SENT_158	[p11l1567t1561r2150b1625],
68	related	JJ	O	related	amod	62	SENT_158	[p11l1567t1561r2150b1625],
69	adverse	JJ	O	adverse	amod	70	SENT_158	[p11l9t1665r260b1728],
70	events	NNS	O	event	nsubj	72	SENT_158	[p11l281t1677r490b1728],
71	were	VBD	O	be	cop	72	SENT_158	[p11l508t1688r667b1728],
72	neutropenia	NN	O	neutropenia	dep	49	SENT_158	[p11l687t1671r1099b1748],
73	and	CC	O	and	_	0	SENT_158	[p11l1118t1665r1243b1728],
74	elevated	JJ	O	elevated	amod	76	SENT_158	[p11l1262t1665r1535b1728],
75	transaminase	NN	O	transaminase	nn	76	SENT_158	[p11l1553t1671r2003b1728],
76	levels	NNS	O	level	dep	81	SENT_158	[p11l2022t1665r2144b1728, p11l9t1759r402b1831],
77	.3	NN	NUMBER	.3	dep	76	SENT_158	[p11l2022t1665r2144b1728, p11l9t1759r402b1831],
78	°	CD	NUMBER	°	num	77	SENT_158	[p11l2022t1665r2144b1728, p11l9t1759r402b1831],
79	’	CD	NUMBER	’	dep	81	SENT_158	[p11l2022t1665r2144b1728, p11l9t1759r402b1831],
80	31	CD	NUMBER	31	num	81	SENT_158	[p11l2022t1665r2144b1728, p11l9t1759r402b1831],
81	’	NN	O	’	dep	88	SENT_158	[p11l2022t1665r2144b1728, p11l9t1759r402b1831],
82	59	CD	NUMBER	59	num	83	SENT_158	[p11l2022t1665r2144b1728, p11l9t1759r402b1831],
83	’	NN	O	’	dep	81	SENT_158	[p11l2022t1665r2144b1728, p11l9t1759r402b1831],
84	6	CD	NUMBER	6	num	87	SENT_158	[p11l2022t1665r2144b1728, p11l9t1759r402b1831],
85	°	NN	O	°	nn	87	SENT_158	[p11l2022t1665r2144b1728, p11l9t1759r402b1831],
86	Drug	NN	O	drug	nn	87	SENT_158	[p11l423t1767r908b1852],
87	—	NN	O	—	nsubj	88	SENT_158	[p11l423t1767r908b1852],
88	induced	VBD	O	induce	conj_and	72	SENT_158	[p11l423t1767r908b1852],
89	pneumonitis	NN	O	pneumonitis	nsubjpass	92	SENT_158	[p11l926t1774r1356b1851],
90	has	VBZ	O	have	aux	92	SENT_158	[p11l1376t1767r1487b1831],
91	been	VBN	O	be	auxpass	92	SENT_158	[p11l1506t1767r1668b1831],
92	reported	VBN	O	report	ccomp	88	SENT_158	[p11l1689t1767r1981b1851],
93	with	IN	O	with	_	0	SENT_158	[p11l1998t1767r2149b1831],
94	crizotinib	NN	O	crizotinib	prep_with	92	SENT_158	[p11l9t1870r353b1934],
95	.	.	O	.	_	0	SENT_158	[p11l9t1870r353b1934],

1	To	TO	O	to	_	0	SENT_159	[p11l376t1873r460b1934],
2	date	NN	O	date	prep_to	25	SENT_159	[p11l482t1870r639b1942],
3	,	,	O	,	_	0	SENT_159	[p11l482t1870r639b1942],
4	across	IN	O	across	_	0	SENT_159	[p11l662t1893r868b1934],
5	all	DT	O	all	det	6	SENT_159	[p11l890t1870r968b1934],
6	studies	NNS	O	study	prep_across	25	SENT_159	[p11l989t1870r1222b1934],
7	of	IN	O	of	_	0	SENT_159	[p11l1244t1870r1317b1934],
8	crizotinib	NN	O	crizotinib	prep_of	6	SENT_159	[p11l1329t1870r1674b1942],
9	,	,	O	,	_	0	SENT_159	[p11l1329t1870r1674b1942],
10	the	DT	O	the	det	12	SENT_159	[p11l1695t1870r1801b1934],
11	estimated	VBN	O	estimate	amod	12	SENT_159	[p11l1822t1870r2151b1934],
12	incidence	NN	O	incidence	nsubj	25	SENT_159	[p11l9t1974r342b2037],
13	of	IN	O	of	_	0	SENT_159	[p11l366t1974r441b2037],
14	grade	NN	O	grade	prep_of	12	SENT_159	[p11l454t1974r647b2058],
15	3	CD	NUMBER	3	num	14	SENT_159	[p11l672t1981r705b2037],
16	or	CC	O	or	_	0	SENT_159	[p11l732t1997r805b2037],
17	higher	JJR	O	higher	amod	18	SENT_159	[p11l826t1974r1053b2058],
18	treatment	NN	O	treatment	conj_or	12	SENT_159	[p11l1074t1974r1685b2037],
19	—	RB	O	—	advmod	20	SENT_159	[p11l1074t1974r1685b2037],
20	related	JJ	O	related	amod	21	SENT_159	[p11l1074t1974r1685b2037],
21	pneumonitis	NN	O	pneumonitis	dep	18	SENT_159	[p11l1706t1980r2148b2057],
22	was	VBD	O	be	cop	25	SENT_159	[p11l7t2100r131b2140],
23	~	CD	NUMBER	~	number	24	SENT_159	[p11l155t2082r407b2149],
24	1	CD	NUMBER	1	num	25	SENT_159	[p11l155t2082r407b2149],
25	—	NN	O	—	_	0	SENT_159	[p11l155t2082r407b2149],
26	5	CD	PERCENT	5	number	27	SENT_159	[p11l155t2082r407b2149],
27	%	NN	PERCENT	%	amod	25	SENT_159	[p11l155t2082r407b2149],
28	,	,	O	,	_	0	SENT_159	[p11l155t2082r407b2149],
29	similar	JJ	O	similar	dep	25	SENT_159	[p11l430t2077r665b2140],
30	to	TO	O	to	_	0	SENT_159	[p11l683t2089r748b2140],
31	that	DT	O	that	prep_to	29	SENT_159	[p11l768t2077r901b2140],
32	observed	VBN	O	observe	partmod	31	SENT_159	[p11l920t2077r1227b2140],
33	with	IN	O	with	_	0	SENT_159	[p11l1245t2077r1396b2140],
34	EGFR	NN	ORGANIZATION	egfr	nn	37	SENT_159	[p11l1416t2081r1623b2140],
35	tyrosine	NN	O	tyrosine	nn	37	SENT_159	[p11l1640t2083r1914b2161],
36	kinase	NN	O	kinase	nn	37	SENT_159	[p11l1933t2077r2148b2140],
37	inhibitors	NNS	O	inhibitor	prep_with	32	SENT_159	[p11l9t2172r431b2244],
38	.	.	O	.	_	0	SENT_159	[p11l9t2172r431b2244],

1	“	NN	O	“	npadvmod	18	SENT_160	[p11l9t2172r431b2244],
2	In	IN	O	in	_	0	SENT_160	[p11l460t2186r532b2243],
3	addition	NN	O	addition	prep_in	18	SENT_160	[p11l557t2180r871b2253],
4	,	,	O	,	_	0	SENT_160	[p11l557t2180r871b2253],
5	in	IN	O	in	_	0	SENT_160	[p11l896t2187r964b2243],
6	small	JJ	O	small	amod	7	SENT_160	[p11l989t2180r1174b2244],
7	retrospective	JJ	O	retrospective	amod	8	SENT_160	[p11l1198t2187r1653b2264],
8	studies	NNS	O	study	prep_in	18	SENT_160	[p11l1678t2180r1938b2253],
9	,	,	O	,	_	0	SENT_160	[p11l1678t2180r1938b2253],
10	other	JJ	O	other	amod	12	SENT_160	[p11l1964t2180r2151b2244],
11	adverse	JJ	O	adverse	amod	12	SENT_160	[p11l9t2283r266b2347],
12	events	NNS	O	event	nsubjpass	24	SENT_160	[p11l290t2295r503b2347],
13	associated	VBN	O	associate	partmod	12	SENT_160	[p11l528t2283r878b2347],
14	with	IN	O	with	_	0	SENT_160	[p11l898t2283r1052b2347],
15	crizotinib	NN	O	crizotinib	prep_with	13	SENT_160	[p11l1075t2283r1408b2347],
16	have	VBP	O	have	aux	18	SENT_160	[p11l1431t2283r1588b2347],
17	been	VBN	O	be	auxpass	18	SENT_160	[p11l1609t2283r1774b2347],
18	described	VBN	O	describe	_	0	SENT_160	[p11l1798t2283r2148b2355],
19	,	,	O	,	_	0	SENT_160	[p11l1798t2283r2148b2355],
20	including	VBG	O	include	_	0	SENT_160	[p11l8t2386r336b2471],
21	asymptomatic	JJ	O	asymptomatic	amod	22	SENT_160	[p11l356t2393r838b2471],
22	bradycardia67	NN	O	bradycardia67	prep_including	18	SENT_160	[p11l857t2378r1327b2471],
23	and	CC	O	and	_	0	SENT_160	[p11l1349t2386r1475b2450],
24	decreased	VBD	O	decrease	conj_and	18	SENT_160	[p11l1496t2386r1834b2450],
25	total	JJ	O	total	amod	26	SENT_160	[p11l1853t2386r2007b2450],
26	testosterone	NN	O	testosterone	dobj	24	SENT_160	[p11l2026t2398r2146b2450, p11l7t2502r326b2554],
27	in	IN	O	in	_	0	SENT_160	[p11l348t2497r415b2553],
28	male	JJ	O	male	amod	29	SENT_160	[p11l436t2490r600b2554],
29	patients	NNS	O	patient	prep_in	24	SENT_160	[p11l621t2482r973b2574],
30	.	.	O	.	_	0	SENT_160	[p11l621t2482r973b2574],

1	“	NN	O	“	_	0	SENT_161	[p11l621t2482r973b2574],

1	The	DT	O	the	det	2	SENT_162	[p11l82t2594r211b2657],
2	pharmacokinetics	NNS	O	pharmacokinetic	nsubjpass	6	SENT_162	[p11l239t2594r887b2677],
3	of	IN	O	of	_	0	SENT_162	[p11l917t2594r994b2657],
4	crizotinib	NN	O	crizotinib	prep_of	2	SENT_162	[p11l1014t2594r1364b2657],
5	was	VBD	O	be	auxpass	6	SENT_162	[p11l1392t2617r1523b2657],
6	evaluated	VBN	O	evaluate	ccomp	63	SENT_162	[p11l1553t2594r1896b2657],
7	in	IN	O	in	_	0	SENT_162	[p11l1924t2600r1993b2656],
8	167	CD	NUMBER	167	num	10	SENT_162	[p11l2028t2600r2147b2657],
9	cancer	NN	O	cancer	nn	10	SENT_162	[p11l9t2719r233b2760],
10	patients	NNS	O	patient	prep_in	6	SENT_162	[p11l253t2688r606b2780],
11	.69	CD	NUMBER	.69	nsubjpass	25	SENT_162	[p11l253t2688r606b2780],
12	After	IN	O	after	_	0	SENT_162	[p11l629t2696r806b2760],
13	oral	JJ	O	oral	amod	14	SENT_162	[p11l829t2696r961b2760],
14	administration	NN	O	administration	prep_after	11	SENT_162	[p11l984t2696r1496b2760],
15	of	IN	O	of	_	0	SENT_162	[p11l1519t2696r1593b2760],
16	a	DT	O	a	det	19	SENT_162	[p11l1607t2719r1642b2760],
17	single	JJ	O	single	amod	19	SENT_162	[p11l1664t2696r1861b2781],
18	250-mg	JJ	O	250-mg	amod	19	SENT_162	[p11l1884t2703r2149b2781],
19	dose	NN	O	dose	prep_of	14	SENT_162	[p11l9t2800r184b2872],
20	,	,	O	,	_	0	SENT_162	[p11l9t2800r184b2872],
21	crizotinib	JJ	O	crizotinib	amod	23	SENT_162	[p11l210t2800r546b2863],
22	peak	NN	O	peak	nn	23	SENT_162	[p11l570t2800r737b2883],
23	concentration	NN	O	concentration	appos	19	SENT_162	[p11l758t2806r1244b2863],
24	was	VBD	O	be	auxpass	25	SENT_162	[p11l1265t2823r1393b2863],
25	achieved	VBN	O	achieve	rcmod	10	SENT_162	[p11l1418t2800r1723b2863],
26	at	IN	O	at	_	0	SENT_162	[p11l1746t2812r1806b2863],
27	a	DT	O	a	det	29	SENT_162	[p11l1829t2823r1864b2863],
28	median	JJ	O	median	amod	29	SENT_162	[p11l1885t2800r2148b2863],
29	time	NN	O	time	prep_at	25	SENT_162	[p11l7t2909r161b2966],
30	to	TO	O	to	aux	31	SENT_162	[p11l183t2915r248b2966],
31	peak	VB	O	peak	xcomp	25	SENT_162	[p11l270t2903r436b2986],
32	concentration	NN	O	concentration	dobj	31	SENT_162	[p11l454t2909r932b2966],
33	of	IN	O	of	_	0	SENT_162	[p11l954t2903r1028b2966],
34	4	CD	NUMBER	4	num	35	SENT_162	[p11l1039t2910r1078b2965],
35	h	NN	O	h	prep_of	32	SENT_162	[p11l1092t2903r1135b2965],
36	and	CC	O	and	_	0	SENT_162	[p11l1157t2903r1284b2966],
37	then	RB	O	then	advmod	38	SENT_162	[p11l1303t2903r1457b2966],
38	declined	VBD	O	decline	conj_and	25	SENT_162	[p11l1480t2903r1770b2966],
39	in	IN	O	in	_	0	SENT_162	[p11l1791t2909r1858b2965],
40	a	DT	O	a	det	42	SENT_162	[p11l1880t2926r1915b2966],
41	multiexponential	JJ	O	multiexponential	amod	42	SENT_162	[p11l1935t2903r2146b2966, p11l9t3006r416b3089],
42	manner	NN	O	manner	prep_in	38	SENT_162	[p11l438t3029r708b3069],
43	with	IN	O	with	_	0	SENT_162	[p11l728t3006r883b3069],
44	a	DT	O	a	det	46	SENT_162	[p11l906t3029r941b3069],
45	median	JJ	O	median	amod	46	SENT_162	[p11l962t3006r1222b3069],
46	half-life	NN	O	half-life	prep_with	38	SENT_162	[p11l1244t3006r1513b3069],
47	of	IN	O	of	_	0	SENT_162	[p11l1537t3006r1611b3069],
48	42	CD	NUMBER	42	num	49	SENT_162	[p11l1623t3013r1703b3068],
49	h.	NN	O	h.	prep_of	46	SENT_162	[p11l1719t3006r1779b3069],
50	Following	VBG	O	follow	_	0	SENT_162	[p11l1806t3006r2150b3090],
51	repeat	NN	O	repeat	nn	52	SENT_162	[p11l9t3121r220b3192],
52	dosing	NN	O	dosing	prep_following	49	SENT_162	[p11l240t3109r469b3193],
53	at	IN	O	at	_	0	SENT_162	[p11l489t3121r548b3172],
54	250	CD	NUMBER	250	num	56	SENT_162	[p11l568t3116r688b3172],
55	mg	NN	O	mg	nn	56	SENT_162	[p11l703t3132r812b3193],
56	b.i.d.	NN	O	b.i.d.	prep_at	52	SENT_162	[p11l829t3109r1014b3181],
57	,	,	O	,	_	0	SENT_162	[p11l829t3109r1014b3181],
58	steady	JJ	O	steady	amod	61	SENT_162	[p11l1038t3109r1438b3193],
59	—	NN	O	—	nn	61	SENT_162	[p11l1038t3109r1438b3193],
60	state	NN	O	state	nn	61	SENT_162	[p11l1038t3109r1438b3193],
61	concentrations	NNS	O	concentration	nsubjpass	63	SENT_162	[p11l1460t3115r1968b3172],
62	were	VBD	O	be	auxpass	63	SENT_162	[p11l1987t3132r2149b3172],
63	reached	VBN	O	reach	_	0	SENT_162	[p11l9t3212r270b3275],
64	within	IN	O	within	_	0	SENT_162	[p11l287t3212r505b3275],
65	15	CD	DURATION	15	num	66	SENT_162	[p11l531t3219r600b3275],
66	days	NNS	NUMBER	day	prep_within	63	SENT_162	[p11l623t3212r784b3296],
67	.	.	O	.	_	0	SENT_162	[p11l623t3212r784b3296],

1	Steady-state	JJ	O	steady-state	amod	2	SENT_163	[p11l808t3212r1207b3296],
2	concentrations	NNS	O	concentration	nsubj	5	SENT_163	[p11l1227t3218r1722b3275],
3	of	IN	O	of	_	0	SENT_163	[p11l1743t3212r1815b3275],
4	crizotinib	NN	O	crizotinib	prep_of	2	SENT_163	[p11l1826t3212r2148b3275],
5	exceeded	VBD	O	exceed	_	0	SENT_163	[p11l9t3315r323b3378],
6	the	DT	O	the	det	7	SENT_163	[p11l344t3315r451b3378],
7	target	NN	O	target	iobj	5	SENT_163	[p11l473t3327r671b3399],
8	efﬁcacious	JJ	O	efﬁcacious	amod	9	SENT_163	[p11l692t3315r1050b3378],
9	concentrations	NNS	O	concentration	dobj	5	SENT_163	[p11l1074t3321r1583b3378],
10	for	IN	O	for	_	0	SENT_163	[p11l1607t3315r1705b3378],
11	ALK	NNP	O	ALK	prep_for	9	SENT_163	[p11l1725t3319r1906b3387],
12	,	,	O	,	_	0	SENT_163	[p11l1725t3319r1906b3387],
13	ROS1	NN	O	ros1	prep_for	9	SENT_163	[p11l1931t3319r2146b3387],
14	,	,	O	,	_	0	SENT_163	[p11l1931t3319r2146b3387],
15	or	CC	O	or	_	0	SENT_163	[p11l9t3441r81b3481],
16	c-MET	NN	O	c-met	nn	17	SENT_163	[p11l103t3421r346b3481],
17	inhibition	NN	O	inhibition	prep_for	9	SENT_163	[p11l369t3418r728b3481],
18	.	.	O	.	_	0	SENT_163	[p11l369t3418r728b3481],

1	Crizotinib	NN	O	crizotinib	nsubj	2	SENT_164	[p11l755t3418r1107b3481],
2	appeared	VBD	O	appear	_	0	SENT_164	[p11l1132t3418r1445b3501],
3	to	TO	O	to	aux	4	SENT_164	[p11l1465t3430r1531b3481],
4	exhibit	VB	O	exhibit	xcomp	2	SENT_164	[p11l1556t3418r1792b3481],
5	nonlinear	JJ	O	nonlinear	amod	6	SENT_164	[p11l1813t3418r2148b3481],
6	pharmacokinetics	NNS	O	pharmacokinetic	dobj	4	SENT_164	[p11l7t3521r632b3604],
7	,	,	O	,	_	0	SENT_164	[p11l7t3521r632b3604],
8	reﬂected	VBN	O	reﬂected	partmod	6	SENT_164	[p11l655t3521r945b3584],
9	by	IN	O	by	_	0	SENT_164	[p11l962t3521r1045b3605],
10	a	DT	O	a	det	11	SENT_164	[p11l1063t3544r1097b3584],
11	decrease	NN	O	decrease	agent	8	SENT_164	[p11l1117t3521r1403b3584],
12	in	IN	O	in	_	0	SENT_164	[p11l1423t3527r1489b3583],
13	clearance	NN	O	clearance	prep_in	11	SENT_164	[p11l1510t3521r1823b3584],
14	observed	VBN	O	observe	partmod	13	SENT_164	[p11l1844t3521r2151b3584],
15	with	IN	O	with	_	0	SENT_164	[p11l7t3624r160b3687],
16	multiple	JJ	O	multiple	amod	17	SENT_164	[p11l181t3624r466b3707],
17	dosing	NN	O	dosing	prep_with	14	SENT_164	[p11l489t3624r733b3708],
18	.	.	O	.	_	0	SENT_164	[p11l489t3624r733b3708],

1	RESISTANCE	NN	O	resistance	nsubjpass	43	SENT_165	[p12l12t76r447b131],
2	TO	TO	O	to	aux	3	SENT_165	[p12l462t75r558b131],
3	CRIZOTINIB	NNP	O	CRIZOTINIB	infmod	1	SENT_165	[p12l577t75r991b131],
4	Despite	IN	O	despite	_	0	SENT_165	[p12l9t176r259b254],
5	often	RB	O	often	advmod	6	SENT_165	[p12l280t171r448b234],
6	marked	JJ	O	marked	amod	8	SENT_165	[p12l468t171r724b234],
7	initial	JJ	O	initial	amod	8	SENT_165	[p12l742t171r937b234],
8	responses	NNS	O	response	prep_despite	3	SENT_165	[p12l956t193r1279b254],
9	to	TO	O	to	_	0	SENT_165	[p12l1299t183r1363b234],
10	crizotinib	NN	O	crizotinib	prep_to	8	SENT_165	[p12l1385t171r1723b243],
11	,	,	O	,	_	0	SENT_165	[p12l1385t171r1723b243],
12	the	DT	O	the	det	13	SENT_165	[p12l1743t171r1847b234],
13	majority	NN	O	majority	appos	1	SENT_165	[p12l1867t177r2153b255],
14	of	IN	O	of	_	0	SENT_165	[p12l9t274r83b337],
15	patients	NNS	O	patient	nn	16	SENT_165	[p12l95t280r367b357],
16	relapse	NN	O	relapse	prep_of	13	SENT_165	[p12l391t274r629b357],
17	during	IN	O	during	_	0	SENT_165	[p12l653t274r885b358],
18	the	DT	O	the	det	20	SENT_165	[p12l906t274r1013b337],
19	ﬁrst	NN	O	ﬁrst	nn	20	SENT_165	[p12l1036t274r1170b337],
20	year	NN	DURATION	year	prep_during	16	SENT_165	[p12l1190t297r1336b358],
21	of	IN	O	of	_	0	SENT_165	[p12l1358t274r1433b337],
22	treatment	NN	O	treatment	prep_of	20	SENT_165	[p12l1445t286r1784b337],
23	due	JJ	O	due	_	0	SENT_165	[p12l1806t274r1930b337],
24	to	TO	O	to	_	0	SENT_165	[p12l1952t286r2018b337],
25	the	DT	O	the	det	26	SENT_165	[p12l2041t274r2149b337],
26	development	NN	O	development	prep_due_to	13	SENT_165	[p12l9t376r459b460],
27	of	IN	O	of	_	0	SENT_165	[p12l482t376r556b440],
28	resistance	NN	O	resistance	nn	29	SENT_165	[p12l570t368r1065b440],
29	.3	NN	NUMBER	.3	prep_of	26	SENT_165	[p12l570t368r1065b440],
30	°	CD	NUMBER	°	number	31	SENT_165	[p12l570t368r1065b440],
31	’31	CD	NUMBER	’31	num	33	SENT_165	[p12l570t368r1065b440],
32	This	DT	O	this	det	33	SENT_165	[p12l1092t376r1237b440],
33	type	NN	O	type	dep	29	SENT_165	[p12l1260t388r1408b461],
34	of	IN	O	of	_	0	SENT_165	[p12l1432t376r1506b440],
35	resistance	NN	O	resistance	prep_of	33	SENT_165	[p12l1520t383r1876b449],
36	,	,	O	,	_	0	SENT_165	[p12l1520t383r1876b449],
37	termed	VBN	O	term	partmod	13	SENT_165	[p12l1900t376r2150b440],
38	acquired	VBN	O	acquire	amod	39	SENT_165	[p12l9t480r300b563],
39	resistance	NN	O	resistance	dobj	37	SENT_165	[p12l319t486r662b552],
40	,	,	O	,	_	0	SENT_165	[p12l319t486r662b552],
41	has	VBZ	O	have	aux	43	SENT_165	[p12l682t480r792b543],
42	been	VBN	O	be	auxpass	43	SENT_165	[p12l810t480r971b543],
43	observed	VBN	O	observe	_	0	SENT_165	[p12l991t480r1295b543],
44	in	IN	O	in	_	0	SENT_165	[p12l1314t486r1379b542],
45	other	JJ	O	other	amod	48	SENT_165	[p12l1399t480r1577b543],
46	oncogene	NN	O	oncogene	nn	48	SENT_165	[p12l1596t503r1916b564],
47	addiction	NN	O	addiction	nn	48	SENT_165	[p12l1936t480r2144b543, p12l7t589r151b646],
48	paradigms	NNS	O	paradigm	prep_in	43	SENT_165	[p12l177t583r575b667],
49	,	,	O	,	_	0	SENT_165	[p12l177t583r575b667],
50	such	JJ	O	such	_	0	SENT_165	[p12l604t583r766b646],
51	as	IN	O	as	_	0	SENT_165	[p12l793t606r860b646],
52	EGFR-mutant	JJ	O	egfr-mutant	amod	53	SENT_165	[p12l885t587r1392b646],
53	NSCLC	NN	O	nsclc	prep_such_as	48	SENT_165	[p12l1416t587r1689b646],
54	treated	VBN	O	treat	partmod	53	SENT_165	[p12l1716t583r1965b646],
55	with	IN	O	with	prep	54	SENT_165	[p12l1989t583r2149b646],

1	VOLUME	NN	O	volume	nn	3	SENT_166	[p12l543t802r767b844],
2	95	CD	NUMBER	95	num	3	SENT_166	[p12l784t803r840b844],
3	NUMBER	NN	O	number	_	0	SENT_166	[p12l862t802r1086b844],
4	1	CD	NUMBER	1	number	5	SENT_166	[p12l1107t804r1120b844],
5	[	CD	NUMBER	[	dep	3	SENT_166	[p12l1150t798r1418b859],
6	JANUARY	NNP	DATE	JANUARY	dep	5	SENT_166	[p12l1150t798r1418b859],
7	2014	CD	DATE	2014	num	6	SENT_166	[p12l1434t803r1556b844],
8	|	CD	NUMBER	|	num	9	SENT_166	[p12l1574t798r1579b859],
9	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	3	SENT_166	[p12l1598t802r2149b855],

1	STATE	NN	O	state	nn	2	SENT_167	[p12l1761t974r1902b1011],
2	ART	NN	O	art	_	0	SENT_167	[p12l2045t974r2139b1011],

1	T	NN	O	t	_	0	SENT_168	[p12l1928t1027r2023b1051],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_169	[p12l8t1211r224b1270],
2	inhibitors	NNS	O	inhibitor	nsubj	7	SENT_169	[p12l246t1207r591b1270],
3	and	CC	O	and	_	0	SENT_169	[p12l617t1207r747b1270],
4	chronic	JJ	O	chronic	amod	6	SENT_169	[p12l771t1207r1039b1270],
5	myelogenous	JJ	O	myelogenous	amod	6	SENT_169	[p12l1064t1207r1529b1291],
6	leukemia	NN	O	leukemia	nsubj	7	SENT_169	[p12l1553t1207r1878b1270],
7	treated	VBN	O	treat	_	0	SENT_169	[p12l1901t1207r2148b1270],
8	with	IN	O	with	_	0	SENT_169	[p12l7t1309r160b1372],
9	ABL	NN	ORGANIZATION	abl	nn	10	SENT_169	[p12l180t1313r334b1371],
10	inhibitors	NNS	O	inhibitor	prep_with	7	SENT_169	[p12l356t1309r706b1372],
11	.	.	O	.	_	0	SENT_169	[p12l356t1309r706b1372],

1	Mechanisms	NNS	O	mechanism	nsubjpass	8	SENT_170	[p12l82t1412r506b1475],
2	of	IN	O	of	_	0	SENT_170	[p12l527t1412r599b1475],
3	acquired	VBN	O	acquire	amod	5	SENT_170	[p12l610t1412r902b1495],
4	crizotinib	JJ	O	crizotinib	amod	5	SENT_170	[p12l921t1412r1245b1475],
5	resistance	NN	O	resistance	prep_of	1	SENT_170	[p12l1266t1418r1594b1475],
6	can	MD	O	can	aux	8	SENT_170	[p12l1614t1435r1729b1475],
7	be	VB	O	be	auxpass	8	SENT_170	[p12l1746t1412r1825b1475],
8	classiﬁed	VBN	O	classiﬁed	_	0	SENT_170	[p12l1845t1412r2147b1475],
9	into	IN	O	into	_	0	SENT_170	[p12l9t1521r138b1578],
10	two	CD	NUMBER	two	num	12	SENT_170	[p12l158t1527r280b1578],
11	general	JJ	O	general	amod	12	SENT_170	[p12l300t1515r543b1599],
12	categories	NNS	O	category	prep_into	8	SENT_170	[p12l561t1521r889b1599],
13	(	CD	NUMBER	(	num	14	SENT_170	[p12l912t1515r1164b1598],
14	Figure	NN	O	figure	dep	12	SENT_170	[p12l912t1515r1164b1598],
15	4	CD	NUMBER	4	num	16	SENT_170	[p12l1180t1515r1265b1592],
16	)	NN	O	)	dep	14	SENT_170	[p12l1180t1515r1265b1592],
17	.	.	O	.	_	0	SENT_170	[p12l1180t1515r1265b1592],

1	The	DT	O	the	det	3	SENT_171	[p12l1287t1515r1410b1578],
2	ﬁrst	NN	O	ﬁrst	nn	3	SENT_171	[p12l1429t1515r1558b1578],
3	category	NN	O	category	nsubj	4	SENT_171	[p12l1577t1527r1861b1599],
4	involves	VBZ	O	involve	_	0	SENT_171	[p12l1877t1515r2144b1578],
5	genetic	JJ	O	genetic	amod	6	SENT_171	[p12l9t1624r256b1702],
6	alteration	NN	O	alteration	dobj	4	SENT_171	[p12l281t1618r613b1681],
7	of	IN	O	of	_	0	SENT_171	[p12l637t1618r712b1681],
8	the	DT	O	the	det	9	SENT_171	[p12l724t1618r833b1681],
9	target	NN	O	target	prep_of	6	SENT_171	[p12l855t1630r1073b1702],
10	,	,	O	,	_	0	SENT_171	[p12l855t1630r1073b1702],
11	i.e.	FW	O	i.e.	dep	6	SENT_171	[p12l1098t1624r1213b1690],
12	,	,	O	,	_	0	SENT_171	[p12l1098t1624r1213b1690],
13	ALK	NNP	O	ALK	appos	6	SENT_171	[p12l1234t1622r1417b1690],
14	,	,	O	,	_	0	SENT_171	[p12l1234t1622r1417b1690],
15	by	IN	O	by	_	0	SENT_171	[p12l1440t1618r1526b1702],
16	mutation	NN	O	mutation	nn	19	SENT_171	[p12l1545t1624r1866b1681],
17	or	CC	O	or	_	0	SENT_171	[p12l1889t1641r1963b1681],
18	gene	NN	O	gene	nn	19	SENT_171	[p12l1985t1641r2144b1702],
19	ampliﬁcation	NN	O	ampliﬁcation	prep_by	4	SENT_171	[p12l9t1721r473b1804],
20	.	.	O	.	_	0	SENT_171	[p12l9t1721r473b1804],

1	In	IN	O	in	_	0	SENT_172	[p12l499t1726r569b1783],
2	the	DT	O	the	det	4	SENT_172	[p12l590t1721r696b1784],
3	ﬁrst	NN	O	ﬁrst	nn	4	SENT_172	[p12l717t1721r849b1784],
4	report	NN	O	report	prep_in	25	SENT_172	[p12l870t1733r1082b1804],
5	of	IN	O	of	_	0	SENT_172	[p12l1103t1721r1176b1784],
6	acquired	VBN	O	acquire	amod	7	SENT_172	[p12l1189t1721r1484b1804],
7	resistance	NN	O	resistance	prep_of	4	SENT_172	[p12l1505t1727r1836b1784],
8	to	TO	O	to	_	0	SENT_172	[p12l1857t1733r1922b1784],
9	crizotinib	NN	O	crizotinib	prep_to	7	SENT_172	[p12l1946t1727r2140b1784, p12l8t1825r180b1897],
10	,	,	O	,	_	0	SENT_172	[p12l1946t1727r2140b1784, p12l8t1825r180b1897],
11	deep	JJ	O	deep	amod	12	SENT_172	[p12l202t1825r358b1908],
12	sequencing	NN	O	sequencing	nsubj	25	SENT_172	[p12l379t1831r758b1909],
13	of	IN	O	of	_	0	SENT_172	[p12l776t1825r849b1888],
14	a	DT	O	a	det	17	SENT_172	[p12l859t1848r893b1888],
15	pleural	JJ	O	pleural	amod	17	SENT_172	[p12l910t1825r1145b1908],
16	ﬂuid	NN	O	ﬂuid	nn	17	SENT_172	[p12l1163t1825r1317b1888],
17	specimen	NN	O	specimen	prep_of	12	SENT_172	[p12l1337t1831r1655b1908],
18	from	IN	O	from	_	0	SENT_172	[p12l1673t1825r1839b1888],
19	a	DT	O	a	det	20	SENT_172	[p12l1858t1848r1893b1888],
20	patient	NN	O	patient	prep_from	17	SENT_172	[p12l1910t1831r2144b1908],
21	relapsing	VBG	O	relapse	partmod	20	SENT_172	[p12l9t1928r316b2012],
22	during	IN	O	during	_	0	SENT_172	[p12l336t1928r565b2012],
23	crizotinib	NN	O	crizotinib	nn	24	SENT_172	[p12l584t1928r910b1991],
24	treatment	NN	O	treatment	prep_during	21	SENT_172	[p12l932t1940r1264b1991],
25	revealed	VBD	O	reveal	_	0	SENT_172	[p12l1284t1928r1566b1991],
26	two	CD	NUMBER	two	num	30	SENT_172	[p12l1585t1940r1709b1991],
27	nonoverlap	JJ	O	nonoverlap	amod	30	SENT_172	[p12l1731t1928r2142b2011],
28	—	NN	O	—	nn	30	SENT_172	[p12l1731t1928r2142b2011],
29	ping	NN	O	ping	nn	30	SENT_172	[p12l7t2037r165b2115],
30	mutations	NNS	O	mutation	dobj	25	SENT_172	[p12l188t2037r542b2094],
31	in	IN	O	in	_	0	SENT_172	[p12l568t2037r636b2093],
32	the	DT	O	the	det	36	SENT_172	[p12l660t2031r769b2094],
33	ALK	NNP	O	ALK	nn	36	SENT_172	[p12l790t2035r961b2093],
34	tyrosine	NN	O	tyrosine	nn	36	SENT_172	[p12l978t2037r1263b2115],
35	kinase	NN	O	kinase	nn	36	SENT_172	[p12l1287t2031r1510b2094],
36	domain	NN	O	domain	prep_in	30	SENT_172	[p12l1536t2031r1824b2103],
37	,	,	O	,	_	0	SENT_172	[p12l1536t2031r1824b2103],
38	L1196M	NN	O	l1196m	prep_in	30	SENT_172	[p12l1852t2036r2144b2094],
39	and	CC	O	and	_	0	SENT_172	[p12l9t2134r135b2197],
40	C1156Y	NN	O	c1156y	conj_and	36	SENT_172	[p12l157t2138r436b2206],
41	,	,	O	,	_	0	SENT_172	[p12l157t2138r436b2206],
42	each	DT	O	each	nsubj	46	SENT_172	[p12l460t2134r612b2197],
43	of	IN	O	of	_	0	SENT_172	[p12l634t2134r707b2197],
44	which	WDT	O	which	prep_of	42	SENT_172	[p12l718t2134r926b2197],
45	independently	RB	O	independently	advmod	46	SENT_172	[p12l947t2134r1441b2218],
46	confers	VBZ	O	confer	rcmod	30	SENT_172	[p12l1459t2134r1704b2197],
47	resistance	NN	O	resistance	dobj	46	SENT_172	[p12l1726t2140r2057b2197],
48	to	TO	O	to	_	0	SENT_172	[p12l2078t2146r2143b2197],
49	crizotinib	NN	O	crizotinib	prep_to	46	SENT_172	[p12l9t2236r330b2299],
50	in	IN	O	in	_	0	SENT_172	[p12l353t2242r412b2299],
51	vitr0	NN	O	vitr0	prep_in	49	SENT_172	[p12l434t2228r662b2299],
52	.70	CD	NUMBER	.70	num	51	SENT_172	[p12l434t2228r662b2299],
53	Of	IN	O	of	_	0	SENT_172	[p12l683t2236r776b2300],
54	note	NN	O	note	prep_of	59	SENT_172	[p12l786t2248r948b2308],
55	,	,	O	,	_	0	SENT_172	[p12l786t2248r948b2308],
56	the	DT	O	the	det	58	SENT_172	[p12l968t2236r1071b2299],
57	L1196M	NN	O	l1196m	nn	58	SENT_172	[p12l1092t2241r1370b2300],
58	substitution	NN	O	substitution	nsubj	59	SENT_172	[p12l1391t2236r1786b2299],
59	represents	VBZ	O	represent	rcmod	51	SENT_172	[p12l1805t2248r2144b2319],
60	the	DT	O	the	det	64	SENT_172	[p12l8t2339r113b2402],
61	“	JJ	O	“	amod	64	SENT_172	[p12l134t2339r553b2423],
62	gatekeeper	NN	O	gatekeeper	nn	64	SENT_172	[p12l134t2339r553b2423],
63	”	NN	O	”	nn	64	SENT_172	[p12l134t2339r553b2423],
64	mutation	NN	O	mutation	dobj	59	SENT_172	[p12l575t2345r903b2411],
65	,	,	O	,	_	0	SENT_172	[p12l575t2345r903b2411],
66	which	WDT	O	which	nsubjpass	68	SENT_172	[p12l922t2339r1130b2402],
67	is	VBZ	O	be	auxpass	68	SENT_172	[p12l1150t2345r1199b2402],
68	believed	VBN	O	believe	rcmod	64	SENT_172	[p12l1217t2339r1499b2402],
69	to	TO	O	to	aux	70	SENT_172	[p12l1517t2351r1582b2402],
70	cause	VB	O	cause	xcomp	68	SENT_172	[p12l1604t2362r1785b2402],
71	steric	JJ	O	steric	amod	72	SENT_172	[p12l1806t2345r1985b2402],
72	hindrance	NN	O	hindrance	dobj	70	SENT_172	[p12l2004t2339r2144b2401, p12l9t2442r235b2505],
73	of	IN	O	of	_	0	SENT_172	[p12l255t2442r327b2505],
74	drug	NN	O	drug	nn	75	SENT_172	[p12l337t2442r496b2526],
75	binding	NN	O	binding	prep_of	72	SENT_172	[p12l512t2442r775b2526],
76	and	CC	O	and	_	0	SENT_172	[p12l793t2442r917b2505],
77	is	VBZ	O	be	cop	78	SENT_172	[p12l935t2448r984b2505],
78	analogous	JJ	O	analogous	rcmod	30	SENT_172	[p12l1005t2442r1340b2526],
79	to	TO	O	to	_	0	SENT_172	[p12l1360t2454r1424b2505],
80	the	DT	O	the	det	82	SENT_172	[p12l1444t2442r1548b2505],
81	gatekeeper	NN	O	gatekeeper	nn	82	SENT_172	[p12l1567t2442r1926b2526],
82	mutations	NNS	O	mutation	prep_to	78	SENT_172	[p12l1944t2454r2143b2505, p12l8t2551r173b2608],
83	in	IN	O	in	_	0	SENT_172	[p12l196t2551r262b2607],
84	EGFR	NN	ORGANIZATION	egfr	nn	88	SENT_172	[p12l283t2549r491b2608],
85	and	CC	O	and	_	0	SENT_172	[p12l510t2545r636b2608],
86	ABL	NN	ORGANIZATION	abl	nn	88	SENT_172	[p12l655t2549r809b2607],
87	kinase	NN	O	kinase	nn	88	SENT_172	[p12l828t2545r1043b2608],
88	domains	NNS	O	domain	prep_in	82	SENT_172	[p12l1066t2545r1373b2608],
89	.	.	O	.	_	0	SENT_172	[p12l1066t2545r1373b2608],

1	In	IN	O	in	dep	107	SENT_173	[p12l1398t2550r1468b2607],
2	subsequent	JJ	O	subsequent	dep	107	SENT_173	[p12l1491t2545r1872b2628],
3	studies	NNS	O	study	dep	107	SENT_173	[p12l1893t2545r2143b2617],
4	,	,	O	,	_	0	SENT_173	[p12l1893t2545r2143b2617],
5	numerous	JJ	O	numerous	dep	107	SENT_173	[p12l8t2670r349b2710],
6	other	JJ	O	other	dep	107	SENT_173	[p12l370t2647r548b2710],
7	resistance	NN	O	resistance	dep	107	SENT_173	[p12l566t2653r894b2710],
8	mutations	NNS	O	mutation	dep	107	SENT_173	[p12l913t2653r1252b2710],
9	in	IN	O	in	dep	107	SENT_173	[p12l1272t2653r1338b2709],
10	the	DT	O	the	dep	107	SENT_173	[p12l1356t2647r1461b2710],
11	ALK	NN	O	alk	dep	107	SENT_173	[p12l1477t2651r1642b2709],
12	kinase	NN	O	kinase	dep	107	SENT_173	[p12l1653t2647r1867b2710],
13	domain	NN	O	domain	dep	107	SENT_173	[p12l1888t2647r2146b2710],
14	have	VBP	O	have	dep	107	SENT_173	[p12l8t2750r164b2813],
15	been	VBN	O	be	dep	107	SENT_173	[p12l185t2750r350b2813],
16	identiﬁed	VBN	O	identiﬁed	dep	107	SENT_173	[p12l373t2750r703b2813],
17	from	IN	O	from	dep	107	SENT_173	[p12l724t2750r893b2813],
18	patient	NN	O	patient	dep	107	SENT_173	[p12l914t2756r1155b2833],
19	samples	NNS	O	sample	dep	107	SENT_173	[p12l1177t2750r1466b2833],
20	,	,	O	,	_	0	SENT_173	[p12l1177t2750r1466b2833],
21	including	VBG	O	include	dep	107	SENT_173	[p12l1491t2750r1820b2834],
22	G1269A	NN	O	g1269a	dep	107	SENT_173	[p12l1841t2754r2145b2822],
23	,	,	O	,	_	0	SENT_173	[p12l1841t2754r2145b2822],
24	1151Tins	NNS	O	1151tin	dep	107	SENT_173	[p12l15t2855r345b2924],
25	,	,	O	,	_	0	SENT_173	[p12l15t2855r345b2924],
26	L1152R	NN	O	l1152r	dep	107	SENT_173	[p12l370t2857r653b2924],
27	,	,	O	,	_	0	SENT_173	[p12l370t2857r653b2924],
28	G1202R	NN	O	g1202r	dep	107	SENT_173	[p12l679t2856r977b2924],
29	,	,	O	,	_	0	SENT_173	[p12l679t2856r977b2924],
30	and	CC	O	and	dep	107	SENT_173	[p12l1002t2852r1129b2916],
31	s1206Y	NN	O	s1206y	dep	107	SENT_173	[p12l1152t2844r1658b2916],
32	.2	NN	NUMBER	.2	dep	107	SENT_173	[p12l1152t2844r1658b2916],
33	°	CD	NUMBER	°	dep	107	SENT_173	[p12l1152t2844r1658b2916],
34	»	CD	NUMBER	»	dep	107	SENT_173	[p12l1152t2844r1658b2916],
35	71-74	CD	NUMBER	71-74	dep	107	SENT_173	[p12l1152t2844r1658b2916],
36	In	FW	O	in	dep	107	SENT_173	[p12l1678t2858r1746b2916],
37	vitro	FW	O	vitro	dep	107	SENT_173	[p12l1772t2858r1945b2924],
38	,	,	O	,	_	0	SENT_173	[p12l1772t2858r1945b2924],
39	these	DT	O	these	dep	107	SENT_173	[p12l1968t2852r2145b2916],
40	secondary	JJ	O	secondary	dep	107	SENT_173	[p12l9t2956r354b3040],
41	mutations	NNS	O	mutation	dep	107	SENT_173	[p12l370t2962r707b3019],
42	appear	VBP	O	appear	dep	107	SENT_173	[p12l727t2978r953b3039],
43	to	TO	O	to	dep	107	SENT_173	[p12l970t2968r1035b3019],
44	confer	VB	O	confer	dep	107	SENT_173	[p12l1056t2956r1269b3019],
45	different	JJ	O	different	dep	107	SENT_173	[p12l1287t2956r1571b3019],
46	degrees	NNS	O	degree	dep	107	SENT_173	[p12l1589t2956r1839b3040],
47	of	IN	O	of	dep	107	SENT_173	[p12l1859t2956r1932b3019],
48	resistance	NN	O	resistance	dep	107	SENT_173	[p12l1942t2962r2141b3019, p12l9t3081r159b3121],
49	to	TO	O	to	dep	107	SENT_173	[p12l177t3070r242b3121],
50	crizotinib	NN	O	crizotinib	dep	107	SENT_173	[p12l263t3050r664b3121],
51	.2	NN	NUMBER	.2	dep	107	SENT_173	[p12l263t3050r664b3121],
52	°	CD	NUMBER	°	dep	107	SENT_173	[p12l263t3050r664b3121],
53	In	IN	O	in	dep	107	SENT_173	[p12l685t3063r755b3120],
54	addition	NN	O	addition	dep	107	SENT_173	[p12l775t3058r1073b3130],
55	,	,	O	,	_	0	SENT_173	[p12l775t3058r1073b3130],
56	ampliﬁcation	NN	O	ampliﬁcation	dep	107	SENT_173	[p12l1095t3058r1536b3141],
57	of	IN	O	of	dep	107	SENT_173	[p12l1557t3058r1629b3121],
58	the	DT	O	the	dep	107	SENT_173	[p12l1638t3058r1742b3121],
59	ALK	NNP	O	ALK	dep	107	SENT_173	[p12l1758t3062r1923b3120],
60	fusion	NN	O	fusion	dep	107	SENT_173	[p12l1935t3058r2144b3121],
61	gene	NN	O	gene	dep	107	SENT_173	[p12l8t3184r160b3245],
62	has	VBZ	O	have	dep	107	SENT_173	[p12l178t3161r286b3224],
63	also	RB	O	also	dep	107	SENT_173	[p12l307t3161r433b3224],
64	been	VBN	O	be	dep	107	SENT_173	[p12l450t3161r610b3224],
65	identiﬁed	VBN	O	identiﬁed	dep	107	SENT_173	[p12l629t3161r945b3224],
66	as	IN	O	as	dep	107	SENT_173	[p12l963t3184r1026b3224],
67	a	DT	O	a	dep	107	SENT_173	[p12l1046t3184r1080b3224],
68	bona	FW	O	bona	dep	107	SENT_173	[p12l1095t3161r1262b3224],
69	ﬁde	FW	O	ﬁde	dep	107	SENT_173	[p12l1280t3161r1401b3224],
70	resistance	NN	O	resistance	dep	107	SENT_173	[p12l1420t3167r1741b3224],
71	mechanism	NN	O	mechanism	dep	107	SENT_173	[p12l1760t3161r2144b3224],
72	both	CC	O	both	dep	107	SENT_173	[p12l7t3263r166b3326],
73	in	FW	O	in	dep	107	SENT_173	[p12l191t3269r252b3326],
74	vitro	FW	O	vitro	dep	107	SENT_173	[p12l278t3269r431b3326],
75	and	CC	O	and	dep	107	SENT_173	[p12l454t3263r581b3326],
76	in	IN	O	in	dep	107	SENT_173	[p12l605t3269r666b3326],
77	vz	NN	O	vz	dep	107	SENT_173	[p12l691t3255r982b3326],
78	'	''	O	'	_	0	SENT_173	[p12l691t3255r982b3326],
79	v0	NN	O	v0	dep	107	SENT_173	[p12l691t3255r982b3326],
80	.2	NN	NUMBER	.2	dep	107	SENT_173	[p12l691t3255r982b3326],
81	°	CD	NUMBER	°	dep	107	SENT_173	[p12l691t3255r982b3326],
82	’71	CD	NUMBER	’71	dep	107	SENT_173	[p12l691t3255r982b3326],
83	Overall	JJ	O	overall	dep	107	SENT_173	[p12l1011t3263r1280b3335],
84	,	,	O	,	_	0	SENT_173	[p12l1011t3263r1280b3335],
85	approximately	RB	O	approximately	dep	107	SENT_173	[p12l1305t3263r1798b3347],
86	one-third	NN	ORDINAL	one-third	dep	107	SENT_173	[p12l1818t3263r2146b3326],
87	of	IN	O	of	dep	107	SENT_173	[p12l9t3366r84b3429],
88	patients	NNS	O	patient	dep	107	SENT_173	[p12l96t3372r371b3449],
89	relapse	NN	O	relapse	dep	107	SENT_173	[p12l395t3366r636b3449],
90	during	IN	O	during	dep	107	SENT_173	[p12l660t3366r895b3450],
91	crizotinib	NN	O	crizotinib	dep	107	SENT_173	[p12l917t3366r1254b3429],
92	treatment	NN	O	treatment	dep	107	SENT_173	[p12l1277t3378r1620b3429],
93	due	JJ	O	due	dep	107	SENT_173	[p12l1642t3366r1767b3429],
94	to	TO	O	to	dep	107	SENT_173	[p12l1790t3378r1857b3429],
95	an	DT	O	a	dep	107	SENT_173	[p12l1882t3389r1963b3429],
96	ALK	NN	O	alk	dep	107	SENT_173	[p12l1982t3370r2153b3428],
97	resistance	NN	O	resistance	dep	107	SENT_173	[p12l9t3475r332b3532],
98	mutation	NN	O	mutation	dep	107	SENT_173	[p12l351t3475r656b3532],
99	and	CC	O	and	dep	107	SENT_173	[p12l675t3469r824b3535],
100	/	:	O	/	dep	107	SENT_173	[p12l675t3469r824b3535],
101	or	CC	O	or	dep	107	SENT_173	[p12l829t3492r899b3532],
102	ampliﬁcation	NN	O	ampliﬁcation	dep	107	SENT_173	[p12l917t3469r1355b3552],
103	of	IN	O	of	dep	107	SENT_173	[p12l1375t3469r1447b3532],
104	the	DT	O	the	dep	107	SENT_173	[p12l1455t3469r1559b3532],
105	ALK	NNP	O	ALK	dep	107	SENT_173	[p12l1574t3473r1738b3531],
106	fusion	NN	O	fusion	dep	107	SENT_173	[p12l1750t3469r1957b3532],
107	gene	NN	O	gene	_	0	SENT_173	[p12l1975t3492r2143b3553],
108	.	.	O	.	_	0	SENT_173	[p12l1975t3492r2143b3553],

1	The	DT	O	the	det	3	SENT_174	[p12l82t3572r210b3635],
2	secondary	JJ	O	secondary	amod	3	SENT_174	[p12l235t3572r597b3656],
3	category	NN	O	category	nsubj	7	SENT_174	[p12l618t3584r918b3656],
4	of	IN	O	of	_	0	SENT_174	[p12l939t3572r1014b3635],
5	resistance	NN	O	resistance	nn	6	SENT_174	[p12l1029t3578r1372b3635],
6	mechanisms	NNS	O	mechanism	prep_of	3	SENT_174	[p12l1396t3572r1834b3635],
7	involves	VBZ	O	involve	_	0	SENT_174	[p12l1859t3572r2143b3635],
8	activation	NN	O	activation	dobj	7	SENT_174	[p12l9t3681r338b3738],
9	of	IN	O	of	_	0	SENT_174	[p12l359t3675r431b3738],
10	alternative	JJ	O	alternative	amod	12	SENT_174	[p12l442t3675r793b3738],
11	signaling	NN	O	signaling	nn	12	SENT_174	[p12l814t3675r1117b3759],
12	pathways	NNS	O	pathway	prep_of	8	SENT_174	[p12l1134t3675r1444b3759],
13	that	WDT	O	that	nsubj	15	SENT_174	[p12l1464t3675r1595b3738],
14	can	MD	O	can	aux	15	SENT_174	[p12l1614t3698r1729b3738],
15	bypass	VB	O	bypass	rcmod	8	SENT_174	[p12l1746t3675r1968b3759],
16	ALK	NNP	O	ALK	dobj	15	SENT_174	[p12l1988t3679r2147b3737],

1	(	CD	NUMBER	(	num	2	SENT_175	[p13l12t17r277b99],
2	Figure	NN	O	figure	_	0	SENT_175	[p13l12t17r277b99],
3	2	CD	NUMBER	2	num	4	SENT_175	[p13l300t17r388b93],
4	)	NN	O	)	dep	2	SENT_175	[p13l300t17r388b93],
5	.	.	O	.	_	0	SENT_175	[p13l300t17r388b93],

1	For	IN	O	for	_	0	SENT_176	[p13l416t21r534b79],
2	example	NN	O	example	prep_for	10	SENT_176	[p13l557t16r865b99],
3	,	,	O	,	_	0	SENT_176	[p13l557t16r865b99],
4	upregulation	NN	O	upregulation	nsubjpass	10	SENT_176	[p13l890t16r1341b100],
5	of	IN	O	of	_	0	SENT_176	[p13l1365t16r1441b79],
6	EGFR	NN	ORGANIZATION	egfr	nn	7	SENT_176	[p13l1454t20r1668b79],
7	signaling	NN	O	signaling	prep_of	4	SENT_176	[p13l1690t16r2009b100],
8	has	VBZ	O	have	aux	10	SENT_176	[p13l2030t16r2144b79],
9	been	VBN	O	be	auxpass	10	SENT_176	[p13l7t119r171b182],
10	observed	VBN	O	observe	dep	17	SENT_176	[p13l194t119r505b182],
11	in	IN	O	in	_	0	SENT_176	[p13l527t125r593b181],
12	ALK	NNP	O	ALK	prep_in	10	SENT_176	[p13l615t123r1078b202],
13	—	CD	NUMBER	—	num	12	SENT_176	[p13l615t123r1078b202],
14	positive	JJ	O	positive	amod	16	SENT_176	[p13l615t123r1078b202],
15	cell	NN	O	cell	nn	16	SENT_176	[p13l1101t119r1215b182],
16	lines	NNS	O	line	nsubj	17	SENT_176	[p13l1235t119r1392b182],
17	made	VBD	O	make	_	0	SENT_176	[p13l1416t119r1603b182],
18	resistant	JJ	O	resistant	acomp	17	SENT_176	[p13l1626t125r1913b182],
19	to	TO	O	to	_	0	SENT_176	[p13l1934t131r2000b182],
20	crizotinib	NN	O	crizotinib	prep_to	18	SENT_176	[p13l2024t125r2140b182, p13l9t221r249b284],
21	in	FW	O	in	nn	23	SENT_176	[p13l275t227r336b284],
22	vitro	FW	O	vitro	dep	23	SENT_176	[p13l362t213r676b284],
23	.2072	CD	NUMBER	.2072	advmod	17	SENT_176	[p13l362t213r676b284],
24	Consistent	JJ	O	consistent	dobj	37	SENT_176	[p13l701t225r1068b285],
25	with	IN	O	with	_	0	SENT_176	[p13l1088t221r1242b284],
26	these	DT	O	these	det	28	SENT_176	[p13l1264t221r1441b284],
27	preclinical	JJ	O	preclinical	amod	28	SENT_176	[p13l1462t221r1824b304],
28	ﬁndings	NNS	O	ﬁndings	prep_with	24	SENT_176	[p13l1846t221r2144b305],
29	,	,	O	,	_	0	SENT_176	[p13l1846t221r2144b305],
30	nearly	RB	O	nearly	quantmod	31	SENT_176	[p13l8t324r221b408],
31	one-half	NN	O	one-half	appos	28	SENT_176	[p13l239t324r532b387],
32	of	IN	O	of	_	0	SENT_176	[p13l543t324r617b387],
33	ALK	NNP	O	ALK	prep_of	31	SENT_176	[p13l627t328r1087b407],
34	—	CD	NUMBER	—	num	33	SENT_176	[p13l627t328r1087b407],
35	positive	JJ	O	positive	amod	36	SENT_176	[p13l627t328r1087b407],
36	tumors	NNS	O	tumor	nsubj	37	SENT_176	[p13l1106t336r1350b387],
37	demonstrate	VBP	O	demonstrate	ccomp	17	SENT_176	[p13l1371t324r1797b387],
38	immunohistochemical	JJ	O	immunohistochemical	amod	39	SENT_176	[p13l1817t330r2140b387, p13l7t426r483b489],
39	evidence	NN	O	evidence	dobj	37	SENT_176	[p13l503t426r800b489],
40	of	IN	O	of	_	0	SENT_176	[p13l821t426r895b489],
41	EGF	NN	O	egf	nn	43	SENT_176	[p13l905t430r1056b489],
42	R	NN	O	r	nn	43	SENT_176	[p13l1062t431r1113b488],
43	activation	NN	O	activation	prep_of	39	SENT_176	[p13l1132t432r1466b489],
44	at	IN	O	at	_	0	SENT_176	[p13l1487t438r1546b489],
45	the	DT	O	the	det	46	SENT_176	[p13l1564t426r1669b489],
46	time	NN	O	time	prep_at	43	SENT_176	[p13l1690t432r1843b489],
47	of	IN	O	of	_	0	SENT_176	[p13l1863t426r1937b489],
48	crizotinib	JJ	O	crizotinib	amod	49	SENT_176	[p13l1948t432r2143b489, p13l8t528r169b591],
49	resistance	NN	O	resistance	prep_of	46	SENT_176	[p13l194t520r615b591],
50	.	.	O	.	_	0	SENT_176	[p13l194t520r615b591],

1	”	RB	O	”	dep	2	SENT_177	[p13l194t520r615b591],
2	CKIT	NNP	O	CKIT	_	0	SENT_177	[p13l639t531r845b600],
3	,	,	O	,	_	0	SENT_177	[p13l639t531r845b600],
4	also	RB	O	also	advmod	5	SENT_177	[p13l871t528r1003b591],
5	known	VBN	O	know	partmod	2	SENT_177	[p13l1025t528r1266b591],
6	as	IN	O	as	_	0	SENT_177	[p13l1289t551r1354b591],
7	mast/stem	NN	O	mast/stem	nn	9	SENT_177	[p13l1377t532r1738b594],
8	cell	NN	O	cell	nn	9	SENT_177	[p13l1761t528r1877b591],
9	growth	NN	O	growth	prep_as	5	SENT_177	[p13l1899t528r2145b612],

1	Crizotinib	NNP	O	Crizotinib	_	0	SENT_178	[p13l469t768r709b813],
2	mechanism	NN	O	mechanism	dep	1	SENT_178	[p13l323t839r616b882],
3	of	IN	O	of	_	0	SENT_178	[p13l638t838r684b882],
4	action	NN	O	action	prep_of	2	SENT_178	[p13l703t839r855b882],

1	Alteration	NN	O	alteration	_	0	SENT_179	[p13l1549t905r1774b946],
2	of	IN	O	of	_	0	SENT_179	[p13l1794t905r1837b946],
3	target	NN	O	target	prep_of	1	SENT_179	[p13l1853t908r1990b957],

1	(	NN	O	(	nn	2	SENT_180	[p13l1418t969r1644b1021],
2	crizotinib	NN	O	crizotinib	nsubj	6	SENT_180	[p13l1418t969r1644b1021],
3	can	MD	O	can	aux	6	SENT_180	[p13l1662t980r1745b1011],
4	no	RB	O	no	advmod	5	SENT_180	[p13l1766t980r1822b1011],
5	longer	RB	O	longer	advmod	6	SENT_180	[p13l1842t970r1990b1022],
6	bind	VBP	O	bind	_	0	SENT_180	[p13l2007t969r2121b1021],
7	)	NN	O	)	dobj	6	SENT_180	[p13l2007t969r2121b1021],

1	EML4-A	NN	O	eml4-a	_	0	SENT_181	[p13l6t1078r263b1141],
2	|	NN	O	|	dep	1	SENT_181	[p13l6t1078r263b1141],
3	.	.	O	.	_	0	SENT_181	[p13l6t1078r263b1141],

1	_	NN	O	_	nn	2	SENT_182	[p13l6t1078r263b1141],
2	K	NN	O	k	_	0	SENT_182	[p13l6t1078r263b1141],

1	Crizotinib	NNP	O	Crizotinib	nsubj	4	SENT_183	[p13l23t1454r244b1494],
2	I	PRP	O	I	dep	1	SENT_183	[p13l338t1425r359b1439],
3	I	PRP	O	I	dep	1	SENT_183	[p13l386t1422r531b1501],
4	o.	VBP	O	o.	_	0	SENT_183	[p13l546t1428r572b1483],
5	A	DT	O	a	det	6	SENT_183	[p13l546t1428r572b1483],
6	G	NN	O	g	nsubj	7	SENT_183	[p13l546t1428r572b1483],
7	+	CC	O	+	xcomp	4	SENT_183	[p13l546t1428r572b1483],

1	J	NN	O	j	_	0	SENT_184	[p13l267t1925r302b1972],
2	!	.	O	!	_	0	SENT_184	[p13l267t1925r302b1972],
3	"	''	O	"	punct	1	SENT_184	[p13l267t1925r302b1972],

1	*	NN	O	*	_	0	SENT_185	[p13l206t1986r260b2066],
2	5	CD	NUMBER	5	dep	1	SENT_185	[p13l206t1986r260b2066],
3	.	.	O	.	_	0	SENT_185	[p13l206t1986r260b2066],

1	factor	NN	O	factor	nn	2	SENT_186	[p13l7t2403r213b2466],
2	receptor	NN	O	receptor	dep	5	SENT_186	[p13l235t2415r528b2486],
3	(	CD	NUMBER	(	num	5	SENT_186	[p13l555t2403r808b2480],
4	SCFR	NN	O	scfr	nn	5	SENT_186	[p13l555t2403r808b2480],
5	)	NN	O	)	dep	38	SENT_186	[p13l555t2403r808b2480],
6	or	CC	O	or	_	0	SENT_186	[p13l837t2426r910b2466],
7	CD117	NN	O	cd117	dep	38	SENT_186	[p13l935t2407r1200b2475],
8	,	,	O	,	_	0	SENT_186	[p13l935t2407r1200b2475],
9	has	VBZ	O	have	aux	12	SENT_186	[p13l1225t2403r1340b2466],
10	also	RB	O	also	advmod	12	SENT_186	[p13l1366t2403r1500b2466],
11	been	VBN	O	be	auxpass	12	SENT_186	[p13l1523t2403r1692b2466],
12	identiﬁed	VBN	O	identiﬁed	parataxis	38	SENT_186	[p13l1716t2403r2054b2466],
13	as	IN	O	as	_	0	SENT_186	[p13l2077t2426r2143b2466],
14	a	DT	O	a	det	17	SENT_186	[p13l8t2528r43b2568],
15	potential	JJ	O	potential	amod	17	SENT_186	[p13l64t2505r376b2588],
16	bypass	NN	O	bypass	nn	17	SENT_186	[p13l396t2505r627b2589],
17	track	NN	O	track	prep_as	12	SENT_186	[p13l650t2505r830b2568],
18	in	IN	O	in	_	0	SENT_186	[p13l849t2511r917b2567],
19	crizotinib	JJ	O	crizotinib	amod	20	SENT_186	[p13l941t2505r1607b2568],
20	—	NN	O	—	prep_in	17	SENT_186	[p13l941t2505r1607b2568],
21	resistant	JJ	O	resistant	amod	22	SENT_186	[p13l941t2505r1607b2568],
22	patients	NNS	O	patient	nsubjpass	12	SENT_186	[p13l1628t2497r1986b2588],
23	.20	CD	NUMBER	.20	dep	12	SENT_186	[p13l1628t2497r1986b2588],
24	In	IN	O	in	_	0	SENT_186	[p13l2010t2510r2082b2567],
25	2	CD	TIME	2	number	27	SENT_186	[p13l2106t2512r2142b2567],
26	of	IN	TIME	of	quantmod	27	SENT_186	[p13l8t2608r82b2671],
27	13	CD	TIME	13	num	29	SENT_186	[p13l100t2615r170b2671],
28	crizotinib	NN	O	crizotinib	nn	29	SENT_186	[p13l195t2608r848b2671],
29	—	NN	O	—	npadvmod	30	SENT_186	[p13l195t2608r848b2671],
30	resistant	JJ	O	resistant	amod	31	SENT_186	[p13l195t2608r848b2671],
31	tumors	NNS	O	tumor	prep_in	12	SENT_186	[p13l868t2620r1131b2680],
32	,	,	O	,	_	0	SENT_186	[p13l868t2620r1131b2680],
33	CKI	NNP	ORGANIZATION	CKI	nn	36	SENT_186	[p13l1156t2612r1299b2671],
34	T	NN	O	t	nn	36	SENT_186	[p13l1303t2611r1352b2670],
35	gene	NN	O	gene	nn	36	SENT_186	[p13l1367t2631r1523b2692],
36	ampliﬁcation	NN	O	ampliﬁcation	nsubjpass	38	SENT_186	[p13l1546t2608r1998b2691],
37	was	VBD	O	be	auxpass	38	SENT_186	[p13l2017t2631r2143b2671],
38	identiﬁed	VBN	O	identiﬁed	_	0	SENT_186	[p13l7t2711r329b2774],
39	by	IN	O	by	_	0	SENT_186	[p13l345t2711r428b2795],
40	FISH	NN	O	fish	agent	38	SENT_186	[p13l445t2715r635b2774],
41	.	.	O	.	_	0	SENT_186	[p13l445t2715r635b2774],

1	In	IN	O	in	_	0	SENT_187	[p13l659t2716r729b2773],
2	cell	NN	O	cell	nn	4	SENT_187	[p13l749t2711r860b2774],
3	line	NN	O	line	nn	4	SENT_187	[p13l878t2711r1002b2774],
4	studies	NNS	O	study	prep_in	13	SENT_187	[p13l1022t2711r1271b2783],
5	,	,	O	,	_	0	SENT_187	[p13l1022t2711r1271b2783],
6	activation	NN	O	activation	nsubj	13	SENT_187	[p13l1293t2717r1624b2774],
7	of	IN	O	of	_	0	SENT_187	[p13l1644t2711r1717b2774],
8	either	CC	O	either	preconj	9	SENT_187	[p13l1728t2711r1921b2774],
9	EGFR	NN	ORGANIZATION	egfr	prep_of	6	SENT_187	[p13l1940t2715r2146b2774],
10	or	CC	O	or	_	0	SENT_187	[p13l8t2837r80b2877],
11	CKIT	NN	O	ckit	prep_of	6	SENT_187	[p13l100t2817r294b2877],
12	is	VBZ	O	be	cop	13	SENT_187	[p13l315t2820r365b2877],
13	capable	JJ	O	capable	_	0	SENT_187	[p13l387t2814r641b2897],
14	of	IN	O	of	_	0	SENT_187	[p13l662t2814r736b2877],
15	conferring	VBG	O	confer	prepc_of	13	SENT_187	[p13l748t2814r1110b2898],
16	resistance	NN	O	resistance	dobj	15	SENT_187	[p13l1129t2820r1463b2877],
17	to	TO	O	to	_	0	SENT_187	[p13l1483t2826r1549b2877],
18	crizotinib	NN	O	crizotinib	prep_to	15	SENT_187	[p13l1571t2814r1917b2877],
19	.	.	O	.	_	0	SENT_187	[p13l1571t2814r1917b2877],

1	Other	JJ	O	other	amod	4	SENT_188	[p13l1942t2814r2145b2877],
2	potential	JJ	O	potential	amod	4	SENT_188	[p13l6t2917r312b3000],
3	bypass	NN	O	bypass	nn	4	SENT_188	[p13l332t2917r559b3001],
4	mechanisms	NNS	O	mechanism	nsubj	9	SENT_188	[p13l582t2917r1008b2980],
5	that	WDT	O	that	nsubjpass	8	SENT_188	[p13l1031t2917r1165b2980],
6	have	VBP	O	have	aux	8	SENT_188	[p13l1185t2917r1341b2980],
7	been	VBN	O	be	auxpass	8	SENT_188	[p13l1362t2917r1526b2980],
8	proposed	VBN	O	propose	rcmod	4	SENT_188	[p13l1547t2917r1870b3000],
9	include	VBP	O	include	_	0	SENT_188	[p13l1891t2917r2143b2980],
10	the	DT	O	the	det	11	SENT_188	[p13l6t3019r112b3082],
11	acquisition	NN	O	acquisition	dobj	9	SENT_188	[p13l133t3025r508b3102],
12	of	IN	O	of	_	0	SENT_188	[p13l529t3019r602b3082],
13	activating	VBG	O	activate	amod	14	SENT_188	[p13l614t3025r948b3103],
14	mutations	NNS	O	mutation	prep_of	11	SENT_188	[p13l966t3025r1309b3082],
15	in	IN	O	in	_	0	SENT_188	[p13l1330t3025r1396b3081],
16	EGFR	NN	ORGANIZATION	egfr	prep_in	14	SENT_188	[p13l1414t3023r1617b3083],
17	and	CC	O	and	_	0	SENT_188	[p13l1638t3019r1763b3082],
18	KRAS	NNP	ORGANIZATION	KRAS	dep	20	SENT_188	[p13l1781t3011r2144b3083],
19	.71	CD	NUMBER	.71	num	18	SENT_188	[p13l1781t3011r2144b3083],
20	>	JJR	O	>	ccomp	32	SENT_188	[p13l1781t3011r2144b3083],
21	74	CD	NUMBER	74	npadvmod	22	SENT_188	[p13l1781t3011r2144b3083],
22	Of	IN	O	of	dep	20	SENT_188	[p13l9t3122r106b3185],
23	note	NN	O	note	pobj	22	SENT_188	[p13l120t3134r293b3194],
24	,	,	O	,	_	0	SENT_188	[p13l120t3134r293b3194],
25	multiple	JJ	O	multiple	amod	27	SENT_188	[p13l319t3122r614b3205],
26	different	JJ	O	different	amod	27	SENT_188	[p13l640t3122r940b3185],
27	mechanisms	NNS	O	mechanism	nsubj	32	SENT_188	[p13l963t3122r1404b3185],
28	of	IN	O	of	_	0	SENT_188	[p13l1430t3122r1506b3185],
29	resistance	NN	O	resistance	prep_of	27	SENT_188	[p13l1521t3128r1867b3185],
30	may	MD	O	may	aux	32	SENT_188	[p13l1892t3145r2043b3206],
31	be	VB	O	be	cop	32	SENT_188	[p13l2061t3122r2143b3185],
32	present	JJ	DATE	present	conj_and	9	SENT_188	[p13l6t3236r267b3307],
33	within	IN	O	within	_	0	SENT_188	[p13l289t3224r520b3287],
34	the	DT	O	the	det	36	SENT_188	[p13l544t3224r654b3287],
35	same	JJ	O	same	amod	36	SENT_188	[p13l681t3247r858b3287],
36	patient	NN	O	patient	prep_within	32	SENT_188	[p13l882t3216r1295b3307],
37	,20	CD	NUMBER	,20	npadvmod	38	SENT_188	[p13l882t3216r1295b3307],
38	>	JJR	O	>	amod	36	SENT_188	[p13l882t3216r1295b3307],
39	74	CD	NUMBER	74	tmod	32	SENT_188	[p13l882t3216r1295b3307],
40	suggesting	VBG	O	suggest	xcomp	32	SENT_188	[p13l1320t3230r1693b3308],
41	the	DT	O	the	det	42	SENT_188	[p13l1716t3224r1826b3287],
42	need	NN	O	need	dobj	40	SENT_188	[p13l1851t3224r2020b3287],
43	for	IN	O	for	_	0	SENT_188	[p13l2045t3224r2145b3287],
44	combination	NN	O	combination	nn	45	SENT_188	[p13l8t3327r451b3390],
45	therapies	NNS	O	therapy	prep_for	42	SENT_188	[p13l473t3327r789b3410],
46	to	TO	O	to	aux	47	SENT_188	[p13l812t3339r879b3390],
47	induce	VB	O	induce	xcomp	40	SENT_188	[p13l904t3327r1138b3390],
48	the	DT	O	the	det	51	SENT_188	[p13l1160t3327r1269b3390],
49	most	RBS	O	most	advmod	51	SENT_188	[p13l1292t3339r1465b3390],
50	durable	JJ	O	durable	amod	51	SENT_188	[p13l1487t3327r1749b3390],
51	remissions	NNS	O	remission	dobj	47	SENT_188	[p13l1773t3333r2144b3390],
52	in	IN	O	in	_	0	SENT_188	[p13l7t3436r74b3492],
53	patients	NNS	O	patient	prep_in	51	SENT_188	[p13l94t3436r363b3513],
54	with	IN	O	with	_	0	SENT_188	[p13l384t3430r537b3493],
55	crizotinib	NN	O	crizotinib	npadvmod	57	SENT_188	[p13l559t3430r1212b3493],
56	—	CD	NUMBER	—	num	55	SENT_188	[p13l559t3430r1212b3493],
57	resistant	JJ	O	resistant	amod	58	SENT_188	[p13l559t3430r1212b3493],
58	disease	NN	O	disease	prep_with	53	SENT_188	[p13l1233t3430r1490b3493],
59	.	.	O	.	_	0	SENT_188	[p13l1233t3430r1490b3493],

1	In	IN	O	in	_	0	SENT_189	[p13l82t3538r152b3595],
2	the	DT	O	the	det	3	SENT_189	[p13l173t3533r279b3596],
3	clinic	NN	O	clinic	prep_in	10	SENT_189	[p13l301t3533r503b3605],
4	,	,	O	,	_	0	SENT_189	[p13l301t3533r503b3605],
5	relapses	NNS	O	relapse	nsubj	10	SENT_189	[p13l526t3533r793b3616],
6	during	IN	O	during	_	0	SENT_189	[p13l816t3533r1047b3617],
7	crizotinib	NN	O	crizotinib	nn	8	SENT_189	[p13l1067t3533r1397b3596],
8	treatment	NN	O	treatment	prep_during	5	SENT_189	[p13l1419t3545r1755b3596],
9	commonly	RB	O	commonly	advmod	10	SENT_189	[p13l1775t3533r2147b3617],
10	involve	VBP	O	involve	_	0	SENT_189	[p13l7t3636r246b3699],
11	the	DT	O	the	det	17	SENT_189	[p13l265t3636r369b3699],
12	central	JJ	O	central	amod	17	SENT_189	[p13l389t3636r618b3699],
13	nervous	JJ	O	nervous	amod	17	SENT_189	[p13l636t3659r904b3699],
14	system	NN	O	system	nn	17	SENT_189	[p13l925t3648r1151b3720],
15	(	CD	NUMBER	(	num	17	SENT_189	[p13l1174t3637r1400b3713],
16	CNS	NN	O	cn	nn	17	SENT_189	[p13l1174t3637r1400b3713],
17	)	NN	O	)	dobj	10	SENT_189	[p13l1174t3637r1400b3713],
18	.	.	O	.	_	0	SENT_189	[p13l1174t3637r1400b3713],

1	In	IN	O	in	dep	107	SENT_190	[p13l1424t3641r1493b3698],
2	one	CD	NUMBER	one	dep	107	SENT_190	[p13l1513t3659r1633b3699],
3	study	NN	O	study	dep	107	SENT_190	[p13l1653t3636r1843b3720],
4	,	,	O	,	_	0	SENT_190	[p13l1653t3636r1843b3720],
5	the	DT	O	the	dep	107	SENT_190	[p13l1863t3636r1967b3699],
6	CNS	NN	ORGANIZATION	cn	dep	107	SENT_190	[p13l1988t3640r2142b3699],
7	was	VBD	O	be	dep	107	SENT_190	[p13l6t3762r130b3802],
8	the	DT	O	the	dep	107	SENT_190	[p13l150t3739r255b3802],
9	ﬁrst	NN	O	ﬁrst	dep	107	SENT_190	[p13l276t3739r407b3802],
10	site	NN	O	site	dep	107	SENT_190	[p13l427t3745r537b3802],
11	of	IN	O	of	dep	107	SENT_190	[p13l558t3739r631b3802],
12	disease	NN	O	disease	dep	107	SENT_190	[p13l643t3739r880b3802],
13	progression	NN	O	progression	dep	107	SENT_190	[p13l900t3745r1297b3823],
14	in	IN	O	in	dep	107	SENT_190	[p13l1318t3745r1384b3801],
15	13	CD	NUMBER	13	dep	107	SENT_190	[p13l1410t3746r1479b3802],
16	of	IN	O	of	dep	107	SENT_190	[p13l1503t3739r1576b3802],
17	28	CD	NUMBER	28	dep	107	SENT_190	[p13l1586t3746r1663b3802],
18	ALK	NN	O	alk	dep	107	SENT_190	[p13l1684t3743r2141b3822],
19	—	CD	NUMBER	—	dep	107	SENT_190	[p13l1684t3743r2141b3822],
20	positive	JJ	O	positive	dep	107	SENT_190	[p13l1684t3743r2141b3822],
21	patients	NNS	O	patient	dep	107	SENT_190	[p14l6t25r284b102],
22	(	IN	O	(	dep	107	SENT_190	[p14l312t19r514b96],
23	46	CD	PERCENT	46	dep	107	SENT_190	[p14l312t19r514b96],
24	%	NN	PERCENT	%	dep	107	SENT_190	[p14l312t19r514b96],
25	)	CD	NUMBER	)	dep	107	SENT_190	[p14l312t19r514b96],
26	treated	VBN	O	treat	dep	107	SENT_190	[p14l541t19r787b82],
27	with	IN	O	with	dep	107	SENT_190	[p14l808t19r965b82],
28	crizotinib	NN	O	crizotinib	dep	107	SENT_190	[p14l989t12r1412b82],
29	.75	CD	NUMBER	.75	dep	107	SENT_190	[p14l989t12r1412b82],
30	The	DT	O	the	dep	107	SENT_190	[p14l1436t19r1565b82],
31	exposure	NN	O	exposure	dep	107	SENT_190	[p14l1589t41r1907b102],
32	of	IN	O	of	dep	107	SENT_190	[p14l1931t19r2007b82],
33	crizotinib	NN	O	crizotinib	dep	107	SENT_190	[p14l2022t25r2141b82, p14l8t122r252b185],
34	in	IN	O	in	dep	107	SENT_190	[p14l278t128r346b184],
35	the	DT	O	the	dep	107	SENT_190	[p14l368t122r478b185],
36	CNS	NN	O	cn	dep	107	SENT_190	[p14l503t126r663b185],
37	is	VBZ	O	be	dep	107	SENT_190	[p14l689t128r740b185],
38	uncertain	JJ	O	uncertain	dep	107	SENT_190	[p14l764t128r1122b194],
39	;	:	O	;	_	0	SENT_190	[p14l764t128r1122b194],
40	however	RB	O	however	dep	107	SENT_190	[p14l1147t122r1458b194],
41	,	,	O	,	_	0	SENT_190	[p14l1147t122r1458b194],
42	in	IN	O	in	dep	107	SENT_190	[p14l1483t128r1551b184],
43	one	CD	NUMBER	one	dep	107	SENT_190	[p14l1576t145r1701b185],
44	patient	NN	O	patient	dep	107	SENT_190	[p14l1724t128r1970b205],
45	who	WP	O	who	dep	107	SENT_190	[p14l1991t122r2141b185],
46	developed	VBD	O	develop	dep	107	SENT_190	[p14l8t225r366b308],
47	CNS	NN	O	cn	dep	107	SENT_190	[p14l390t229r550b288],
48	disease	NN	O	disease	dep	107	SENT_190	[p14l575t225r822b288],
49	during	IN	O	during	dep	107	SENT_190	[p14l847t225r1083b309],
50	crizotinib	NN	O	crizotinib	dep	107	SENT_190	[p14l1105t225r1444b288],
51	treatment	NN	O	treatment	dep	107	SENT_190	[p14l1468t237r1830b297],
52	,	,	O	,	_	0	SENT_190	[p14l1468t237r1830b297],
53	the	DT	O	the	dep	107	SENT_190	[p14l1855t225r1963b288],
54	level	NN	O	level	dep	107	SENT_190	[p14l1986t225r2145b288],
55	of	IN	O	of	dep	107	SENT_190	[p14l8t328r82b391],
56	drug	NN	O	drug	dep	107	SENT_190	[p14l95t328r257b412],
57	in	IN	O	in	dep	107	SENT_190	[p14l279t334r345b390],
58	the	DT	O	the	dep	107	SENT_190	[p14l367t328r473b391],
59	cerebrospinal	JJ	O	cerebrospinal	dep	107	SENT_190	[p14l497t328r958b411],
60	ﬂuid	NN	O	ﬂuid	dep	107	SENT_190	[p14l980t328r1137b391],
61	was	VBD	O	be	dep	107	SENT_190	[p14l1156t351r1282b391],
62	extremely	RB	O	extremely	dep	107	SENT_190	[p14l1307t328r1646b412],
63	low	JJ	O	low	dep	107	SENT_190	[p14l1664t328r1788b391],
64	relative	JJ	O	relative	dep	107	SENT_190	[p14l1807t328r2055b391],
65	to	TO	O	to	dep	107	SENT_190	[p14l2077t340r2142b391],
66	plasma	NN	O	plasma	dep	107	SENT_190	[p14l6t430r246b513],
67	drug	NN	O	drug	dep	107	SENT_190	[p14l265t430r425b514],
68	levels	NNS	O	level	dep	107	SENT_190	[p14l442t430r642b502],
69	,	,	O	,	_	0	SENT_190	[p14l442t430r642b502],
70	suggesting	VBG	O	suggest	dep	107	SENT_190	[p14l664t436r1019b514],
71	poor	JJ	O	poor	dep	107	SENT_190	[p14l1036t452r1198b513],
72	penetration	NN	O	penetration	dep	107	SENT_190	[p14l1215t436r1608b513],
73	into	IN	O	into	dep	107	SENT_190	[p14l1629t436r1760b493],
74	the	DT	O	the	dep	107	SENT_190	[p14l1780t430r1885b493],
75	CNS	NN	O	cn	dep	107	SENT_190	[p14l1906t422r2144b494],
76	.76	CD	NUMBER	.76	dep	107	SENT_190	[p14l1906t422r2144b494],
77	This	DT	O	this	dep	107	SENT_190	[p14l7t533r150b596],
78	ﬁnding	NN	O	ﬁnding	dep	107	SENT_190	[p14l172t533r419b617],
79	raises	VBZ	O	raise	dep	107	SENT_190	[p14l440t539r628b596],
80	the	DT	O	the	dep	107	SENT_190	[p14l649t533r756b596],
81	possibility	NN	O	possibility	dep	107	SENT_190	[p14l776t533r1130b617],
82	that	IN	O	that	dep	107	SENT_190	[p14l1147t533r1281b596],
83	a	DT	O	a	dep	107	SENT_190	[p14l1302t556r1336b596],
84	pharmacokinetic	JJ	O	pharmacokinetic	dep	107	SENT_190	[p14l1355t533r1939b616],
85	issue	NN	O	issue	dep	107	SENT_190	[p14l1961t539r2142b605],
86	,	,	O	,	_	0	SENT_190	[p14l1961t539r2142b605],
87	namely	RB	O	namely	dep	107	SENT_190	[p14l7t637r277b721],
88	,	,	O	,	_	0	SENT_190	[p14l7t637r277b721],
89	inadequate	JJ	O	inadequate	dep	107	SENT_190	[p14l305t637r695b720],
90	drug	NN	O	drug	dep	107	SENT_190	[p14l721t637r889b721],
91	exposure	NN	O	exposure	dep	107	SENT_190	[p14l913t659r1233b720],
92	in	IN	O	in	dep	107	SENT_190	[p14l1259t643r1328b699],
93	a	DT	O	a	dep	107	SENT_190	[p14l1354t660r1389b700],
94	sanctuary	NN	O	sanctuary	dep	107	SENT_190	[p14l1415t649r1763b721],
95	site	NN	O	site	dep	107	SENT_190	[p14l1786t643r1921b709],
96	,	,	O	,	_	0	SENT_190	[p14l1786t643r1921b709],
97	could	MD	O	could	dep	107	SENT_190	[p14l1949t637r2146b700],
98	underlie	VB	O	underlie	dep	107	SENT_190	[p14l7t740r292b803],
99	the	DT	O	the	dep	107	SENT_190	[p14l312t740r418b803],
100	high	JJ	O	high	dep	107	SENT_190	[p14l439t740r593b824],
101	rate	NN	O	rate	dep	107	SENT_190	[p14l614t752r740b803],
102	of	IN	O	of	dep	107	SENT_190	[p14l763t740r836b803],
103	CNS	NN	O	cn	dep	107	SENT_190	[p14l849t744r1006b803],
104	relapse	NN	O	relapse	dep	107	SENT_190	[p14l1028t740r1264b823],
105	in	IN	O	in	dep	107	SENT_190	[p14l1285t746r1352b802],
106	ALK-positive	JJ	O	alk-positive	dep	107	SENT_190	[p14l1372t744r1834b823],
107	patients	NNS	O	patient	_	0	SENT_190	[p14l1854t746r2141b823],
108	.	.	O	.	_	0	SENT_190	[p14l1854t746r2141b823],

1	Many	JJ	O	many	nsubjpass	15	SENT_191	[p14l7t848r205b927],
2	of	IN	O	of	_	0	SENT_191	[p14l222t843r296b906],
3	the	DT	O	the	det	7	SENT_191	[p14l306t843r412b906],
4	next	JJ	O	next	amod	7	SENT_191	[p14l433t855r608b906],
5	-	:	O	-	_	0	SENT_191	[p14l433t855r608b906],
6	generation	NN	O	generation	nn	7	SENT_191	[p14l615t849r980b927],
7	ALK	NN	O	alk	prep_of	1	SENT_191	[p14l1000t847r1163b905],
8	inhibitors	NNS	O	inhibitor	nsubj	9	SENT_191	[p14l1182t843r1515b906],
9	(	VBP	O	(	rcmod	1	SENT_191	[p14l1539t843r1894b920],
10	discussed	VBN	O	discuss	dep	9	SENT_191	[p14l1539t843r1894b920],
11	below	IN	O	below	_	0	SENT_191	[p14l1911t843r2140b920],
12	)	NN	O	)	prep_below	10	SENT_191	[p14l1911t843r2140b920],
13	are	VBP	O	be	aux	15	SENT_191	[p14l8t969r108b1009],
14	being	VBG	O	be	auxpass	15	SENT_191	[p14l128t946r320b1030],
15	developed	VBN	O	develop	_	0	SENT_191	[p14l341t946r691b1029],
16	in	IN	O	in	_	0	SENT_191	[p14l712t952r779b1008],
17	part	NN	O	part	prep_in	15	SENT_191	[p14l800t958r941b1029],
18	to	TO	O	to	aux	19	SENT_191	[p14l961t958r1026b1009],
19	address	VB	O	address	xcomp	15	SENT_191	[p14l1050t946r1305b1009],
20	this	DT	O	this	det	22	SENT_191	[p14l1327t946r1451b1009],
21	potential	JJ	O	potential	amod	22	SENT_191	[p14l1473t946r1779b1029],
22	liability	NN	O	liability	dobj	19	SENT_191	[p14l1800t946r2060b1030],
23	of	IN	O	of	_	0	SENT_191	[p14l2079t946r2153b1009],
24	crizotinib	NN	O	crizotinib	prep_of	22	SENT_191	[p14l8t1049r361b1112],
25	.	.	O	.	_	0	SENT_191	[p14l8t1049r361b1112],

1	Whether	IN	O	whether	complm	10	SENT_192	[p14l387t1049r699b1112],
2	ALK	NN	O	alk	nn	4	SENT_192	[p14l717t1053r887b1111],
3	gene	NN	O	gene	nn	4	SENT_192	[p14l903t1072r1063b1133],
4	alterations	NNS	O	alteration	nsubj	10	SENT_192	[p14l1088t1049r1452b1112],
5	or	CC	O	or	_	0	SENT_192	[p14l1477t1072r1550b1112],
6	bypass	NN	O	bypass	nn	7	SENT_192	[p14l1570t1049r1801b1133],
7	signaling	NN	O	signaling	nsubj	10	SENT_192	[p14l1826t1049r2144b1133],
8	may	MD	O	may	aux	10	SENT_192	[p14l7t1175r154b1236],
9	also	RB	O	also	advmod	10	SENT_192	[p14l172t1152r303b1215],
10	contribute	VB	O	contribute	csubj	17	SENT_192	[p14l327t1152r680b1215],
11	to	TO	O	to	_	0	SENT_192	[p14l700t1164r766b1215],
12	resistance	NN	O	resistance	prep_to	10	SENT_192	[p14l790t1158r1123b1215],
13	in	IN	O	in	_	0	SENT_192	[p14l1145t1158r1212b1214],
14	the	DT	O	the	det	15	SENT_192	[p14l1232t1152r1339b1215],
15	CNS	NN	O	cn	prep_in	12	SENT_192	[p14l1362t1156r1518b1215],
16	is	VBZ	O	be	cop	17	SENT_192	[p14l1541t1158r1591b1215],
17	unknown	JJ	O	unknown	_	0	SENT_192	[p14l1613t1152r1959b1215],
18	.	.	O	.	_	0	SENT_192	[p14l1613t1152r1959b1215],

1	SECOND-GENERATION	JJ	O	second-generation	amod	2	SENT_193	[p14l9t1366r807b1422],
2	ALK	NNP	O	ALK	_	0	SENT_193	[p14l827t1367r970b1421],
3	INHIBITORS	NNS	O	inhibitor	dep	2	SENT_193	[p14l989t1366r1405b1422],

1	LDK378	NN	O	ldk378	nn	2	SENT_194	[p14l10t1470r277b1525],
2	LDK378	NN	O	ldk378	_	0	SENT_194	[p14l8t1570r305b1628],
3	(	CD	NUMBER	(	num	6	SENT_194	[p14l338t1565r672b1642],
4	Novartis	NNP	ORGANIZATION	Novartis	nn	6	SENT_194	[p14l338t1565r672b1642],
5	Pharmaceuticals	NNP	ORGANIZATION	Pharmaceuticals	nn	6	SENT_194	[p14l700t1565r1320b1642],
6	)	NN	O	)	nsubj	19	SENT_194	[p14l700t1565r1320b1642],
7	is	VBZ	O	be	cop	19	SENT_194	[p14l1352t1571r1404b1628],
8	a	DT	O	a	det	19	SENT_194	[p14l1432t1588r1468b1628],
9	novel	JJ	O	novel	dep	15	SENT_194	[p14l1494t1565r1705b1637],
10	,	,	O	,	_	0	SENT_194	[p14l1494t1565r1705b1637],
11	potent	JJ	O	potent	conj_and	15	SENT_194	[p14l1732t1577r1983b1648],
12	,	,	O	,	_	0	SENT_194	[p14l1732t1577r1983b1648],
13	and	CC	O	and	_	0	SENT_194	[p14l2013t1565r2144b1628],
14	selective	JJ	O	selective	conj_and	15	SENT_194	[p14l8t1668r308b1731],
15	small-molecule	JJ	O	small-molecule	amod	17	SENT_194	[p14l336t1668r886b1731],
16	tyrosine	NN	O	tyrosine	nn	17	SENT_194	[p14l912t1674r1202b1752],
17	kinase	NN	O	kinase	nn	19	SENT_194	[p14l1228t1668r1455b1731],
18	inhibitor	NN	O	inhibitor	nn	19	SENT_194	[p14l1482t1668r1800b1731],
19	targeting	NN	O	targeting	rcmod	2	SENT_194	[p14l1825t1674r2147b1752],

1	Crizotinib	JJ	O	crizotinib	amod	2	SENT_195	[p14l242t1995r483b2040],
2	resistance	NN	O	resistance	_	0	SENT_195	[p14l505t1996r767b2040],

1	Activation	NN	O	activation	_	0	SENT_196	[p14l102t2251r450b2312],
2	of	IN	O	of	_	0	SENT_196	[p14l480t2251r546b2312],
3	alternative	JJ	O	alternative	amod	4	SENT_196	[p14l572t2251r945b2312],
4	pathways	NNS	O	pathway	prep_of	1	SENT_196	[p14l975t2251r1311b2329],

1	(	NN	O	(	nn	2	SENT_197	[p14l380t2347r558b2425],
2	ALK	NN	O	alk	nsubjpass	4	SENT_197	[p14l380t2347r558b2425],
3	is	VBZ	O	be	auxpass	4	SENT_197	[p14l586t2348r638b2409],
4	bypassed	VBN	O	bypass	_	0	SENT_197	[p14l668t2347r1035b2425],
5	)	IN	O	)	prep	4	SENT_197	[p14l668t2347r1035b2425],

1	ts	NNS	O	t	nsubj	2	SENT_198	[p14l2079t3534r2137b3594],
2	ky	VBP	O	ky	_	0	SENT_198	[p14l2076t3450r2153b3526],

1	STAT	NN	O	stat	_	0	SENT_199	[p15l87t539r273b602],
2	'	''	O	'	_	0	SENT_199	[p15l383t513r395b664],

1	Figure	NNP	O	Figure	_	0	SENT_200	[p15l21t920r112b950],
2	4	CD	NUMBER	4	num	3	SENT_200	[p15l118t922r135b944],
3	Mechanisms	NNS	O	mechanism	dep	1	SENT_200	[p15l159t920r324b944],
4	of	IN	O	of	_	0	SENT_200	[p15l332t920r360b944],
5	crizotinib	JJ	O	crizotinib	amod	6	SENT_200	[p15l365t920r489b944],
6	resistance	NN	O	resistance	prep_of	3	SENT_200	[p15l498t921r635b944],
7	.	.	O	.	_	0	SENT_200	[p15l498t921r635b944],

1	The	DT	O	the	det	3	SENT_201	[p15l640t920r689b944],
2	left	JJ	O	left	amod	3	SENT_201	[p15l698t920r740b944],
3	panel	NN	O	panel	nsubj	4	SENT_201	[p15l748t920r819b950],
4	depicts	VBZ	O	depict	_	0	SENT_201	[p15l828t920r925b950],
5	crizotinib-sensitive	JJ	O	crizotinib-sensitive	amod	7	SENT_201	[p15l933t920r1183b944],
6	cancer	NN	O	cancer	nn	7	SENT_201	[p15l1191t927r1278b944],
7	cells	NNS	O	cell	dobj	4	SENT_201	[p15l1285t920r1341b944],
8	expressing	VBG	O	express	xcomp	4	SENT_201	[p15l1349t921r1491b950],
9	EML4	NN	O	eml4	dobj	8	SENT_201	[p15l1501t921r1647b944],
10	.	.	O	.	_	0	SENT_201	[p15l1501t921r1647b944],

1	—	NN	O	—	_	0	SENT_202	[p15l1501t921r1647b944],
2	.	.	O	.	_	0	SENT_202	[p15l1501t921r1647b944],

1	ALK	NNP	O	ALK	_	0	SENT_203	[p15l1501t921r1647b944],
2	.	.	O	.	_	0	SENT_203	[p15l1501t921r1647b944],

1	Crizotinib	NN	O	crizotinib	nsubj	9	SENT_204	[p15l1655t920r1782b944],
2	binds	VBZ	O	bind	_	0	SENT_204	[p15l1791t920r1863b944],
3	and	CC	O	and	_	0	SENT_204	[p15l1871t920r1920b944],
4	inactivates	VBZ	O	inactivate	conj_and	2	SENT_204	[p15l1929t921r2070b944],
5	the	DT	O	the	det	7	SENT_204	[p15l20t961r63b985],
6	ALK	NN	O	alk	nn	7	SENT_204	[p15l71t962r123b985],
7	fusion	NN	O	fusion	dobj	4	SENT_204	[p15l129t961r217b989],
8	,	,	O	,	_	0	SENT_204	[p15l129t961r217b989],
9	disrupting	VBG	O	disrupt	conj_and	2	SENT_204	[p15l225t961r361b992],
10	downstream	JJ	O	downstream	amod	11	SENT_204	[p15l370t961r536b985],
11	signaling	NN	O	signaling	dobj	9	SENT_204	[p15l545t961r672b992],
12	.	.	O	.	_	0	SENT_204	[p15l545t961r672b992],

1	The	DT	O	the	det	3	SENT_205	[p15l677t961r726b985],
2	right	JJ	O	right	amod	3	SENT_205	[p15l735t961r797b992],
3	panel	NN	O	panel	nsubj	4	SENT_205	[p15l806t961r877b992],
4	depicts	VBZ	O	depict	_	0	SENT_205	[p15l886t961r982b992],
5	two	CD	NUMBER	two	num	7	SENT_205	[p15l989t965r1040b985],
6	general	JJ	O	general	amod	7	SENT_205	[p15l1048t961r1147b992],
7	classes	NNS	O	class	dobj	4	SENT_205	[p15l1156t961r1246b985],
8	of	IN	O	of	_	0	SENT_205	[p15l1254t961r1281b985],
9	crizotinib	JJ	O	crizotinib	amod	10	SENT_205	[p15l1287t961r1410b985],
10	resistance	NN	O	resistance	prep_of	7	SENT_205	[p15l1419t962r1556b985],
11	:	:	O	:	_	0	SENT_205	[p15l1419t962r1556b985],
12	one	CD	NUMBER	one	conj_and	7	SENT_205	[p15l1564t968r1614b985],
13	mediated	VBN	O	mediate	partmod	12	SENT_205	[p15l1623t961r1748b985],
14	by	IN	O	by	_	0	SENT_205	[p15l1758t961r1789b992],
15	genetic	JJ	O	genetic	amod	16	SENT_205	[p15l1796t962r1895b992],
16	mutation	NN	O	mutation	agent	13	SENT_205	[p15l1903t962r2024b985],
17	of	IN	O	of	_	0	SENT_205	[p15l2033t961r2060b985],
18	the	DT	O	the	det	19	SENT_205	[p15l2065t961r2109b985],
19	target	NN	O	target	prep_of	16	SENT_205	[p15l20t1006r100b1033],
20	so	IN	O	so	mark	26	SENT_205	[p15l108t1009r136b1026],
21	that	IN	O	that	dep	26	SENT_205	[p15l143t1002r197b1026],
22	crizotinib	NN	O	crizotinib	nsubj	26	SENT_205	[p15l205t1002r328b1026],
23	can	MD	O	can	aux	26	SENT_205	[p15l336t1009r381b1026],
24	no	RB	O	no	advmod	25	SENT_205	[p15l391t1009r424b1026],
25	longer	RB	O	longer	advmod	26	SENT_205	[p15l433t1002r518b1033],
26	bind	VBP	O	bind	advcl	13	SENT_205	[p15l526t1002r584b1026],
27	to	TO	O	to	_	0	SENT_205	[p15l592t1006r619b1026],
28	the	DT	O	the	det	30	SENT_205	[p15l626t1002r670b1026],
29	active	JJ	O	active	amod	30	SENT_205	[p15l678t1003r756b1026],
30	site	NN	O	site	prep_to	26	SENT_205	[p15l764t1004r814b1030],
31	,	,	O	,	_	0	SENT_205	[p15l764t1004r814b1030],
32	and	CC	O	and	_	0	SENT_205	[p15l822t1002r871b1026],
33	the	DT	O	the	det	34	SENT_205	[p15l879t1002r923b1026],
34	other	JJ	O	other	dobj	4	SENT_205	[p15l931t1002r1002b1026],
35	mediated	VBN	O	mediate	partmod	34	SENT_205	[p15l1010t1002r1135b1026],
36	by	IN	O	by	_	0	SENT_205	[p15l1145t1002r1177b1033],
37	activation	NN	O	activation	agent	35	SENT_205	[p15l1184t1003r1313b1026],
38	of	IN	O	of	_	0	SENT_205	[p15l1322t1002r1350b1026],
39	alternative	JJ	O	alternative	amod	40	SENT_205	[p15l1355t1002r1496b1026],
40	pathways	NNS	O	pathway	prep_of	37	SENT_205	[p15l1505t1002r1631b1033],
41	(	CD	NUMBER	(	nsubj	45	SENT_205	[p15l1639t1003r1675b1030],
42	or	CC	O	or	_	0	SENT_205	[p15l1639t1003r1675b1030],
43	bypass	NN	O	bypass	nn	44	SENT_205	[p15l1683t1002r1772b1033],
44	tracks	NNS	O	track	conj_or	41	SENT_205	[p15l1780t1002r1865b1030],
45	)	VBP	O	)	rcmod	40	SENT_205	[p15l1780t1002r1865b1030],
46	that	IN	O	that	complm	48	SENT_205	[p15l1873t1002r1927b1026],
47	can	MD	O	can	aux	48	SENT_205	[p15l1935t1009r1980b1026],
48	engage	VB	O	engage	ccomp	45	SENT_205	[p15l1988t1009r2088b1033],
49	downstream	JJ	O	downstream	amod	51	SENT_205	[p15l21t1043r187b1067],
50	signaling	NN	O	signaling	nn	51	SENT_205	[p15l196t1043r315b1074],
51	pathways	NNS	O	pathway	dobj	48	SENT_205	[p15l325t1043r451b1074],
52	even	RB	O	even	advmod	48	SENT_205	[p15l459t1050r521b1067],
53	when	WRB	O	when	advmod	56	SENT_205	[p15l529t1043r603b1067],
54	ALK	NNP	O	ALK	nsubjpass	56	SENT_205	[p15l611t1044r663b1067],
55	is	VBZ	O	be	auxpass	56	SENT_205	[p15l671t1044r688b1067],
56	inhibited	VBN	O	inhibit	advcl	48	SENT_205	[p15l697t1043r822b1067],
57	.	.	O	.	_	0	SENT_205	[p15l697t1043r822b1067],

1	ALK	NNP	O	ALK	_	0	SENT_206	[p15l829t1044r887b1071],
2	,	,	O	,	_	0	SENT_206	[p15l829t1044r887b1071],
3	anaplastic	JJ	O	anaplastic	amod	5	SENT_206	[p15l895t1043r1029b1074],
4	lymphoma	NN	O	lymphoma	nn	5	SENT_206	[p15l1038t1043r1180b1074],
5	kinase	NN	O	kinase	appos	1	SENT_206	[p15l1190t1043r1279b1071],
6	;	:	O	;	_	0	SENT_206	[p15l1190t1043r1279b1071],
7	EML4	NN	O	eml4	dep	1	SENT_206	[p15l1288t1044r1365b1071],
8	,	,	O	,	_	0	SENT_206	[p15l1288t1044r1365b1071],
9	echinoderm	NN	O	echinoderm	appos	7	SENT_206	[p15l1373t1043r1533b1067],
10	microtubule-associated	JJ	O	microtubule-associated	amod	9	SENT_206	[p15l1543t1043r1855b1067],
11	protein-like	JJ	O	protein-like	amod	9	SENT_206	[p15l1865t1043r2016b1073],
12	4	CD	NUMBER	4	tmod	11	SENT_206	[p15l2023t1045r2045b1071],
13	;	:	O	;	_	0	SENT_206	[p15l2023t1045r2045b1071],
14	RTK	NNP	O	RTK	dep	1	SENT_206	[p15l2054t1044r2109b1071],
15	,	,	O	,	_	0	SENT_206	[p15l2054t1044r2109b1071],
16	receptor	NN	O	receptor	nn	18	SENT_206	[p15l22t1088r133b1115],
17	tyrosine	NN	O	tyrosine	nn	18	SENT_206	[p15l139t1085r246b1115],
18	kinase	NN	O	kinase	appos	14	SENT_206	[p15l255t1084r344b1108],
19	.	.	O	.	_	0	SENT_206	[p15l255t1084r344b1108],

1	Illustrated	NNP	O	Illustrated	_	0	SENT_207	[p15l2076t501r2137b845],
2	by	IN	O	by	dep	1	SENT_207	[p15l2076t390r2153b471],
3	Zina	NNP	PERSON	Zina	nn	4	SENT_207	[p15l2076t208r2137b365],
4	Dere	NNP	PERSON	Dere	pobj	2	SENT_207	[p15l2076t9r2137b178],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_208	[p15l21t1183r140b1204],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	dep	12	SENT_208	[p15l149t1183r374b1204],
3	&	CC	O	&	_	0	SENT_208	[p15l381t1183r601b1204],
4	THERAPEUT	NNP	O	THERAPEUT	nn	6	SENT_208	[p15l381t1183r601b1204],
5	|	CD	NUMBER	|	num	6	SENT_208	[p15l381t1183r601b1204],
6	CS	NNP	O	CS	conj_and	2	SENT_208	[p15l381t1183r601b1204],
7	|	NNP	O	|	nn	8	SENT_208	[p15l611t1181r613b1211],
8	VOLUME	NNP	O	VOLUME	dep	2	SENT_208	[p15l621t1183r729b1204],
9	95	CD	NUMBER	95	num	10	SENT_208	[p15l737t1183r764b1204],
10	NUMBER	NN	O	number	dep	12	SENT_208	[p15l774t1183r882b1204],
11	1	CD	NUMBER	1	num	12	SENT_208	[p15l892t1184r899b1204],
12	|	CD	NUMBER	|	dep	15	SENT_208	[p15l913t1181r915b1211],
13	JANUARY	NNP	DATE	JANUARY	dep	12	SENT_208	[p15l924t1183r1042b1204],
14	2014	CD	DATE	2014	num	15	SENT_208	[p15l1050t1183r1108b1204],
15	19	CD	DATE	19	_	0	SENT_208	[p15l2111t1183r2140b1204],

1	STATE	NN	O	state	nn	2	SENT_209	[p15l21t1326r163b1363],
2	ART	NN	O	art	_	0	SENT_209	[p15l305t1326r399b1363],

1	ALK	NNP	O	ALK	_	0	SENT_210	[p15l9t1563r186b1622],
2	.	.	O	.	_	0	SENT_210	[p15l9t1563r186b1622],

1	The	DT	O	the	det	5	SENT_211	[p15l209t1559r333b1622],
2	synthesis	NN	O	synthesis	nn	5	SENT_211	[p15l354t1559r660b1643],
3	and	CC	O	and	_	0	SENT_211	[p15l682t1559r807b1622],
4	preclinical	JJ	O	preclinical	conj_and	2	SENT_211	[p15l826t1559r1182b1642],
5	characterization	NN	O	characterization	nsubjpass	12	SENT_211	[p15l1202t1559r1751b1622],
6	of	IN	O	of	_	0	SENT_211	[p15l1772t1559r1845b1622],
7	LDK3	NN	O	ldk3	prep_of	5	SENT_211	[p15l1857t1564r2057b1622],
8	78	CD	NUMBER	78	num	7	SENT_211	[p15l2066t1566r2141b1622],
9	have	VBP	O	have	aux	12	SENT_211	[p15l9t1661r165b1724],
10	been	VBN	O	be	auxpass	12	SENT_211	[p15l185t1661r350b1724],
11	recently	RB	DATE	recently	advmod	12	SENT_211	[p15l373t1661r649b1745],
12	reported	VBN	O	report	_	0	SENT_211	[p15l668t1654r1045b1744],
13	.77	CD	NUMBER	.77	num	14	SENT_211	[p15l668t1654r1045b1744],
14	LDK378	NN	O	ldk378	nsubjpass	16	SENT_211	[p15l1068t1666r1355b1724],
15	was	VBD	O	be	auxpass	16	SENT_211	[p15l1378t1684r1504b1724],
16	synthesized	VBN	O	synthesize	ccomp	12	SENT_211	[p15l1529t1661r1927b1745],
17	based	VBN	O	base	_	0	SENT_211	[p15l1947t1661r2145b1724],
18	on	IN	O	on	prepc_based_on	16	SENT_211	[p15l10t1786r94b1826],
19	the	DT	O	the	det	20	SENT_211	[p15l112t1763r216b1826],
20	structure	NN	O	structure	pobj	16	SENT_211	[p15l237t1775r536b1826],
21	of	IN	O	of	_	0	SENT_211	[p15l556t1763r628b1826],
22	TAE684	NN	O	tae684	prep_of	20	SENT_211	[p15l638t1755r986b1835],
23	,78	CD	NUMBER	,78	num	22	SENT_211	[p15l638t1755r986b1835],
24	a	DT	O	a	det	28	SENT_211	[p15l1007t1786r1041b1826],
25	previously	RB	DATE	previously	advmod	26	SENT_211	[p15l1058t1763r1406b1847],
26	described	VBN	O	describe	amod	28	SENT_211	[p15l1422t1763r1744b1826],
27	ALK	NNP	O	ALK	nn	28	SENT_211	[p15l1762t1767r1921b1825],
28	inhibitor	NN	O	inhibitor	dep	22	SENT_211	[p15l1939t1763r2141b1826, p15l10t1872r133b1929],
29	with	IN	O	with	_	0	SENT_211	[p15l154t1866r311b1929],
30	the	DT	O	the	det	31	SENT_211	[p15l333t1866r442b1929],
31	potential	NN	O	potential	prep_with	28	SENT_211	[p15l465t1866r779b1949],
32	for	IN	O	for	_	0	SENT_211	[p15l802t1866r902b1929],
33	reactive	JJ	O	reactive	amod	35	SENT_211	[p15l925t1872r1196b1929],
34	adduct	NN	O	adduct	nn	35	SENT_211	[p15l1221t1866r1462b1929],
35	formation	NN	O	formation	prep_for	28	SENT_211	[p15l1484t1866r1855b1929],
36	.	.	O	.	_	0	SENT_211	[p15l1484t1866r1855b1929],

1	Using	VBG	O	use	partmod	21	SENT_212	[p15l1881t1871r2085b1950],
2	a	DT	O	a	det	5	SENT_212	[p15l2108t1889r2143b1929],
3	rational	JJ	O	rational	amod	5	SENT_212	[p15l10t1969r268b2032],
4	design	NN	O	design	nn	5	SENT_212	[p15l287t1969r503b2053],
5	strategy	NN	O	strategy	dobj	1	SENT_212	[p15l523t1981r794b2053],
6	,	,	O	,	_	0	SENT_212	[p15l523t1981r794b2053],
7	novel	JJ	O	novel	amod	8	SENT_212	[p15l815t1969r994b2032],
8	derivatives	NNS	O	derivative	nsubjpass	21	SENT_212	[p15l1014t1969r1370b2032],
9	that	WDT	O	that	nsubj	18	SENT_212	[p15l1389t1969r1520b2032],
10	did	VBD	O	do	aux	12	SENT_212	[p15l1538t1969r1647b2032],
11	not	RB	O	not	neg	12	SENT_212	[p15l1665t1981r1776b2032],
12	form	VB	O	form	rcmod	8	SENT_212	[p15l1794t1969r1958b2032],
13	reactive	JJ	O	reactive	amod	14	SENT_212	[p15l1978t1992r2140b2032, p15l9t2078r131b2135],
14	adducts	NNS	O	adduct	dobj	12	SENT_212	[p15l152t2072r416b2135],
15	and	CC	O	and	_	0	SENT_212	[p15l438t2072r564b2135],
16	that	IN	O	that	dep	18	SENT_212	[p15l582t2072r716b2135],
17	potently	RB	O	potently	advmod	18	SENT_212	[p15l735t2072r1020b2156],
18	inhibited	VBD	O	inhibit	conj_and	12	SENT_212	[p15l1037t2072r1348b2135],
19	ALK	NN	O	alk	dobj	18	SENT_212	[p15l1366t2076r1529b2134],
20	were	VBD	O	be	auxpass	21	SENT_212	[p15l1546t2095r1707b2135],
21	synthesized	VBN	O	synthesize	_	0	SENT_212	[p15l1729t2072r2140b2156],
22	.	.	O	.	_	0	SENT_212	[p15l1729t2072r2140b2156],

1	One	CD	NUMBER	one	nsubjpass	5	SENT_213	[p15l11t2178r153b2238],
2	of	IN	O	of	_	0	SENT_213	[p15l176t2174r250b2237],
3	these	DT	O	these	prep_of	1	SENT_213	[p15l261t2174r436b2237],
4	was	VBD	O	be	auxpass	5	SENT_213	[p15l456t2197r582b2237],
5	designated	VBN	O	designate	_	0	SENT_213	[p15l604t2174r971b2258],
6	compound	NN	O	compound	nn	7	SENT_213	[p15l992t2174r1365b2257],
7	15b	NN	O	15b	dobj	5	SENT_213	[p15l1392t2174r1507b2237],
8	or	CC	O	or	_	0	SENT_213	[p15l1530t2197r1602b2237],
9	LDK378	NN	O	ldk378	dobj	5	SENT_213	[p15l1623t2167r1993b2237],
10	.77	CD	NUMBER	.77	num	9	SENT_213	[p15l1623t2167r1993b2237],

1	In	IN	O	in	_	0	SENT_214	[p15l84t2282r157b2339],
2	biochemical	JJ	O	biochemical	amod	5	SENT_214	[p15l180t2277r614b2340],
3	and	CC	O	and	_	0	SENT_214	[p15l639t2277r769b2340],
4	cellular	JJ	O	cellular	amod	5	SENT_214	[p15l794t2277r1053b2340],
5	assays	NNS	O	assay	prep_in	11	SENT_214	[p15l1078t2300r1309b2361],
6	,	,	O	,	_	0	SENT_214	[p15l1078t2300r1309b2361],
7	LDK378	NN	O	ldk378	nsubj	13	SENT_214	[p15l1336t2282r1631b2340],
8	is	VBZ	O	be	cop	11	SENT_214	[p15l1658t2283r1709b2340],
9	both	CC	O	both	preconj	11	SENT_214	[p15l1733t2277r1897b2340],
10	highly	RB	O	highly	advmod	11	SENT_214	[p15l1921t2277r2147b2361],
11	potent	JJ	O	potent	_	0	SENT_214	[p15l8t2392r246b2463],
12	and	CC	O	and	_	0	SENT_214	[p15l277t2380r410b2443],
13	selective	JJ	O	selective	conj_and	11	SENT_214	[p15l442t2380r751b2443],
14	against	IN	O	against	_	0	SENT_214	[p15l783t2386r1040b2464],
15	ALK	NNP	O	ALK	prep_against	11	SENT_214	[p15l1070t2384r1258b2443],
16	.	.	O	.	_	0	SENT_214	[p15l1070t2384r1258b2443],

1	At	IN	O	at	_	0	SENT_215	[p15l1292t2384r1377b2443],
2	the	DT	O	the	det	4	SENT_215	[p15l1406t2380r1519b2443],
3	enzymatic	JJ	O	enzymatic	amod	4	SENT_215	[p15l1552t2386r1926b2464],
4	level	NN	O	level	prep_at	7	SENT_215	[p15l1956t2380r2142b2452],
5	,	,	O	,	_	0	SENT_215	[p15l1956t2380r2142b2452],
6	LDK378	NN	O	ldk378	nsubj	7	SENT_215	[p15l10t2488r296b2546],
7	inhibits	VBZ	O	inhibit	_	0	SENT_215	[p15l320t2483r579b2546],
8	ALK	NN	O	alk	dobj	7	SENT_215	[p15l601t2487r764b2545],
9	with	IN	O	with	_	0	SENT_215	[p15l783t2483r936b2546],
10	a	DT	O	a	det	17	SENT_215	[p15l960t2506r994b2546],
11	half-maximal	JJ	O	half-maximal	amod	17	SENT_215	[p15l1014t2483r1478b2546],
12	inhibitory	JJ	O	inhibitory	amod	17	SENT_215	[p15l1501t2483r1848b2567],
13	concentration	NN	O	concentration	nn	17	SENT_215	[p15l1868t2506r2139b2546, p15l9t2591r240b2648],
14	(	CD	NUMBER	(	num	17	SENT_215	[p15l264t2585r459b2676],
15	IC50	NN	O	ic50	nn	17	SENT_215	[p15l264t2585r459b2676],
16	)	NN	O	)	nn	17	SENT_215	[p15l264t2585r459b2676],
17	value	NN	O	value	prep_with	7	SENT_215	[p15l481t2585r661b2648],
18	of	IN	O	of	_	0	SENT_215	[p15l682t2585r756b2648],
19	200	CD	NUMBER	200	num	20	SENT_215	[p15l766t2592r885b2648],
20	pmol/1	NN	O	pmol/1	prep_of	17	SENT_215	[p15l905t2585r1148b2668],
21	.	.	O	.	_	0	SENT_215	[p15l905t2585r1148b2668],

1	Only	RB	O	only	quantmod	2	SENT_216	[p15l1172t2585r1344b2669],
2	three	CD	NUMBER	three	num	4	SENT_216	[p15l1359t2585r1533b2648],
3	other	JJ	O	other	amod	4	SENT_216	[p15l1554t2585r1734b2648],
4	kinases	NNS	O	kinase	nsubj	10	SENT_216	[p15l1752t2585r2000b2648],
5	in	IN	O	in	_	0	SENT_216	[p15l2021t2591r2087b2647],
6	a	DT	O	a	det	7	SENT_216	[p15l2108t2608r2143b2648],
7	panel	NN	O	panel	prep_in	4	SENT_216	[p15l8t2687r191b2770],
8	of	IN	O	of	_	0	SENT_216	[p15l211t2687r283b2750],
9	30	CD	NUMBER	30	prep_of	7	SENT_216	[p15l295t2694r370b2750],
10	showed	VBD	O	show	_	0	SENT_216	[p15l392t2687r645b2750],
11	IC50	NN	O	ic50	nn	12	SENT_216	[p15l664t2691r805b2778],
12	Values	NNS	O	value	iobj	10	SENT_216	[p15l823t2687r1031b2750],
13	<	JJR	O	<	amod	18	SENT_216	[p15l1054t2705r1092b2748],
14	100	CD	NUMBER	100	num	15	SENT_216	[p15l1105t2694r1215b2750],
15	nmol/l	NN	O	nmol/l	dep	18	SENT_216	[p15l1236t2687r1478b2753],
16	:	:	O	:	_	0	SENT_216	[p15l1236t2687r1478b2753],
17	insulin	NN	O	insulin	nn	18	SENT_216	[p15l1501t2687r1884b2750],
18	—	NN	O	—	dobj	10	SENT_216	[p15l1501t2687r1884b2750],
19	like	IN	O	like	_	0	SENT_216	[p15l1501t2687r1884b2750],
20	growth	NN	O	growth	nn	25	SENT_216	[p15l1904t2687r2143b2771],
21	factor	NN	O	factor	nn	25	SENT_216	[p15l9t2790r285b2853],
22	—	NN	O	—	nn	25	SENT_216	[p15l9t2790r285b2853],
23	1	CD	NUMBER	1	num	25	SENT_216	[p15l9t2790r285b2853],
24	receptor	NN	O	receptor	nn	25	SENT_216	[p15l320t2802r619b2873],
25	(	NN	O	(	prep_like	18	SENT_216	[p15l649t2791r713b2867],
26	8	CD	NUMBER	8	num	28	SENT_216	[p15l649t2791r713b2867],
27	nmol/1	NN	O	nmol/1	nn	28	SENT_216	[p15l743t2790r1036b2867],
28	)	NN	O	)	dep	25	SENT_216	[p15l743t2790r1036b2867],
29	,	,	O	,	_	0	SENT_216	[p15l743t2790r1036b2867],
30	InsR	NN	O	insr	nn	31	SENT_216	[p15l1066t2795r1232b2853],
31	(	NN	O	(	prep_like	18	SENT_216	[p15l1260t2791r1326b2867],
32	7	CD	NUMBER	7	num	34	SENT_216	[p15l1260t2791r1326b2867],
33	nmol/l	NN	O	nmol/l	nn	34	SENT_216	[p15l1355t2790r1647b2867],
34	)	NN	O	)	dep	31	SENT_216	[p15l1355t2790r1647b2867],
35	,	,	O	,	_	0	SENT_216	[p15l1355t2790r1647b2867],
36	and	CC	O	and	_	0	SENT_216	[p15l1677t2790r1809b2853],
37	STK22D	NN	O	stk22d	prep_like	18	SENT_216	[p15l1837t2793r2140b2853],
38	(	CD	NUMBER	(	number	39	SENT_216	[p15l13t2893r115b2970],
39	23	CD	NUMBER	23	num	41	SENT_216	[p15l13t2893r115b2970],
40	nmol/1	NN	O	nmol/1	nn	41	SENT_216	[p15l140t2893r416b2970],
41	)	NN	O	)	dep	37	SENT_216	[p15l140t2893r416b2970],
42	.	.	O	.	_	0	SENT_216	[p15l140t2893r416b2970],

1	At	IN	O	at	_	0	SENT_217	[p15l440t2897r521b2957],
2	the	DT	O	the	det	4	SENT_217	[p15l540t2893r647b2957],
3	cellular	JJ	O	cellular	amod	4	SENT_217	[p15l669t2893r919b2957],
4	level	NN	O	level	prep_at	7	SENT_217	[p15l939t2893r1110b2965],
5	,	,	O	,	_	0	SENT_217	[p15l939t2893r1110b2965],
6	LDK378	NN	O	ldk378	nsubj	7	SENT_217	[p15l1134t2898r1419b2957],
7	inhibits	VBZ	O	inhibit	_	0	SENT_217	[p15l1444t2893r1701b2957],
8	EML4	NN	O	eml4	dobj	7	SENT_217	[p15l1724t2897r2145b2956],
9	.	.	O	.	_	0	SENT_217	[p15l1724t2897r2145b2956],

1	—	NN	O	—	_	0	SENT_218	[p15l1724t2897r2145b2956],
2	.	.	O	.	_	0	SENT_218	[p15l1724t2897r2145b2956],

1	ALK	NN	O	alk	_	0	SENT_219	[p15l1724t2897r2145b2956],
2	with	IN	O	with	_	0	SENT_219	[p15l8t2995r161b3058],
3	an	DT	O	a	det	5	SENT_219	[p15l183t3018r263b3058],
4	IC50	NN	O	ic50	nn	5	SENT_219	[p15l286t2999r429b3086],
5	value	NN	O	value	prep_with	1	SENT_219	[p15l448t2995r629b3058],
6	of	IN	O	of	_	0	SENT_219	[p15l652t2995r726b3058],
7	2.2	CD	NUMBER	2.2	num	8	SENT_219	[p15l738t3002r835b3058],
8	nmol/l	NN	O	nmol/l	prep_of	1	SENT_219	[p15l859t2995r1105b3061],
9	.	.	O	.	_	0	SENT_219	[p15l859t2995r1105b3061],

1	No	DT	O	no	det	3	SENT_220	[p15l1129t3000r1231b3058],
2	other	JJ	O	other	amod	3	SENT_220	[p15l1255t2995r1436b3058],
3	kinases	NNS	O	kinase	nsubjpass	10	SENT_220	[p15l1455t2995r1704b3058],
4	in	IN	O	in	_	0	SENT_220	[p15l1727t3001r1794b3057],
5	a	DT	O	a	det	6	SENT_220	[p15l1816t3018r1851b3058],
6	panel	NN	O	panel	prep_in	3	SENT_220	[p15l1871t2995r2057b3078],
7	of	IN	O	of	_	0	SENT_220	[p15l2078t2995r2152b3058],
8	18	CD	NUMBER	18	prep_of	6	SENT_220	[p15l16t3104r87b3160],
9	were	VBD	O	be	auxpass	10	SENT_220	[p15l108t3120r269b3160],
10	inhibited	VBN	O	inhibit	_	0	SENT_220	[p15l291t3097r601b3160],
11	by	IN	O	by	_	0	SENT_220	[p15l619t3097r704b3181],
12	LDK378	NN	O	ldk378	agent	10	SENT_220	[p15l722t3102r1007b3160],
13	at	IN	O	at	_	0	SENT_220	[p15l1031t3109r1091b3160],
14	levels	NNS	O	level	dep	15	SENT_220	[p15l1110t3097r1295b3160],
15	<	JJR	O	<	prep_at	10	SENT_220	[p15l1319t3104r1484b3160],
16	10O	CD	NUMBER	10o	num	17	SENT_220	[p15l1319t3104r1484b3160],
17	nmol/1	NN	O	nmol/1	dep	15	SENT_220	[p15l1506t3090r1818b3163],
18	.77	CD	NUMBER	.77	dep	17	SENT_220	[p15l1506t3090r1818b3163],

1	LDK378	NN	O	ldk378	nsubj	2	SENT_221	[p15l83t3205r379b3263],
2	has	VBZ	O	have	_	0	SENT_221	[p15l406t3200r521b3263],
3	potent	JJ	O	potent	amod	5	SENT_221	[p15l547t3212r778b3283],
4	antitumor	NN	O	antitumor	nn	5	SENT_221	[p15l803t3206r1162b3263],
5	activity	NN	O	activity	dobj	2	SENT_221	[p15l1188t3206r1451b3284],
6	in	IN	O	in	_	0	SENT_221	[p15l1473t3206r1542b3262],
7	two	CD	NUMBER	two	num	11	SENT_221	[p15l1566t3212r1696b3263],
8	different	JJ	O	different	amod	11	SENT_221	[p15l1724t3200r2025b3263],
9	rat	NN	O	rat	nn	11	SENT_221	[p15l2050t3212r2145b3263],
10	Xenograft	NN	O	xenograft	nn	11	SENT_221	[p15l7t3303r346b3387],
11	models	NNS	O	model	prep_in	5	SENT_221	[p15l369t3303r643b3375],
12	,	,	O	,	_	0	SENT_221	[p15l369t3303r643b3375],
13	including	VBG	O	include	_	0	SENT_221	[p15l669t3303r1007b3387],
14	one	CD	NUMBER	one	prep_including	5	SENT_221	[p15l1031t3326r1156b3366],
15	generated	VBN	O	generate	partmod	14	SENT_221	[p15l1181t3303r1527b3387],
16	from	IN	O	from	_	0	SENT_221	[p15l1550t3303r1723b3366],
17	the	DT	O	the	det	19	SENT_221	[p15l1746t3303r1857b3366],
18	EML4ALK	NN	O	eml4alk	nn	19	SENT_221	[p15l1881t3308r2142b3365, p15l9t3410r485b3489],
19	—	NN	O	—	prep_from	15	SENT_221	[p15l1881t3308r2142b3365, p15l9t3410r485b3489],
20	positive	JJ	O	positive	amod	25	SENT_221	[p15l1881t3308r2142b3365, p15l9t3410r485b3489],
21	H2228	NN	O	h2228	nn	25	SENT_221	[p15l510t3411r742b3469],
22	lung	NN	O	lung	nn	25	SENT_221	[p15l767t3406r925b3490],
23	cancer	NN	O	cancer	nn	25	SENT_221	[p15l948t3429r1178b3469],
24	cell	NN	O	cell	nn	25	SENT_221	[p15l1201t3406r1319b3469],
25	line	NN	O	line	dep	19	SENT_221	[p15l1341t3406r1471b3469],
26	and	CC	O	and	_	0	SENT_221	[p15l1496t3406r1626b3469],
27	one	CD	NUMBER	one	prep_from	15	SENT_221	[p15l1650t3429r1775b3469],
28	generated	VBN	O	generate	partmod	27	SENT_221	[p15l1800t3406r2145b3490],
29	from	IN	O	from	_	0	SENT_221	[p15l9t3509r180b3572],
30	Karpas299	NN	O	karpas299	nn	31	SENT_221	[p15l204t3514r571b3592],
31	cells	NNS	O	cell	prep_from	28	SENT_221	[p15l596t3509r742b3572],
32	harboring	VBG	O	harbor	xcomp	28	SENT_221	[p15l765t3509r1116b3593],
33	the	DT	O	the	det	34	SENT_221	[p15l1136t3509r1244b3572],
34	NPM	NNP	ORGANIZATION	NPM	dobj	32	SENT_221	[p15l1265t3513r1665b3572],
35	.	.	O	.	_	0	SENT_221	[p15l1265t3513r1665b3572],

1	—	NN	O	—	_	0	SENT_222	[p15l1265t3513r1665b3572],
2	.	.	O	.	_	0	SENT_222	[p15l1265t3513r1665b3572],

1	ALK	NN	O	alk	_	0	SENT_223	[p15l1265t3513r1665b3572],
2	fusion	NN	O	fusion	dep	1	SENT_223	[p15l1680t3509r1915b3572],
3	.	.	O	.	_	0	SENT_223	[p15l1680t3509r1915b3572],

1	In	IN	O	in	_	0	SENT_224	[p15l1941t3514r2013b3571],
2	the	DT	O	the	det	4	SENT_224	[p15l2036t3509r2144b3572],
3	H2228	NN	O	h2228	nn	4	SENT_224	[p15l10t3617r245b3675],
4	model	NN	O	model	prep_in	8	SENT_224	[p15l274t3612r517b3684],
5	,	,	O	,	_	0	SENT_224	[p15l274t3612r517b3684],
6	LDK378	NN	O	ldk378	nn	7	SENT_224	[p15l546t3617r843b3675],
7	treatment	NN	O	treatment	nsubj	8	SENT_224	[p15l871t3623r1223b3675],
8	induced	VBD	O	induce	_	0	SENT_224	[p15l1249t3612r1538b3675],
9	dose	NN	O	dose	nn	10	SENT_224	[p15l1565t3612r2143b3695],
10	—	NN	O	—	iobj	8	SENT_224	[p15l1565t3612r2143b3695],
11	dependent	JJ	O	dependent	amod	13	SENT_224	[p15l1565t3612r2143b3695],
12	tumor	NN	O	tumor	nn	13	SENT_224	[p15l9t3727r224b3778],
13	regression	NN	O	regression	dobj	8	SENT_224	[p15l245t3721r613b3799],
14	,	,	O	,	_	0	SENT_224	[p15l245t3721r613b3799],
15	with	IN	O	with	_	0	SENT_224	[p15l635t3715r788b3778],
16	complete	JJ	O	complete	amod	17	SENT_224	[p15l811t3715r1121b3798],
17	regression	NN	O	regression	prep_with	8	SENT_224	[p15l1144t3721r1493b3799],
18	observed	VBN	O	observe	partmod	17	SENT_224	[p15l1516t3715r1827b3778],
19	at	IN	O	at	_	0	SENT_224	[p15l1849t3727r1908b3778],
20	a	DT	O	a	det	21	SENT_224	[p15l1930t3738r1965b3778],
21	dose	NN	O	dose	prep_at	18	SENT_224	[p15l1987t3715r2141b3778],
22	of	IN	O	of	_	0	SENT_224	[p16l10t16r84b79],
23	25	CD	NUMBER	25	num	24	SENT_224	[p16l95t23r171b79],
24	mg/kg	NN	O	mg/kg	prep_of	21	SENT_224	[p16l188t16r424b100],
25	.	.	O	.	_	0	SENT_224	[p16l188t16r424b100],

1	LDK378	NN	O	ldk378	nsubjpass	3	SENT_225	[p16l448t21r733b79],
2	was	VBD	O	be	auxpass	3	SENT_225	[p16l754t39r880b79],
3	noted	VBN	O	note	_	0	SENT_225	[p16l901t16r1097b79],
4	to	TO	O	to	aux	7	SENT_225	[p16l1115t28r1181b79],
5	be	VB	O	be	auxpass	7	SENT_225	[p16l1201t16r1280b79],
6	well	RB	O	well	advmod	7	SENT_225	[p16l1299t16r1437b79],
7	tolerated	VBN	O	tolerate	xcomp	3	SENT_225	[p16l1456t16r1758b79],
8	at	IN	O	at	_	0	SENT_225	[p16l1779t28r1838b79],
9	all	DT	O	all	det	10	SENT_225	[p16l1858t16r1937b79],
10	doses	NNS	O	dose	prep_at	7	SENT_225	[p16l1957t16r2142b79],
11	tested	VBN	O	test	partmod	10	SENT_225	[p16l9t111r290b181],
12	.77	CD	NUMBER	.77	dobj	11	SENT_225	[p16l9t111r290b181],

1	On	IN	O	on	_	0	SENT_226	[p16l84t225r191b284],
2	the	DT	O	the	det	3	SENT_226	[p16l210t221r315b284],
3	basis	NN	O	basis	prep_on	20	SENT_226	[p16l334t221r499b284],
4	of	IN	O	of	_	0	SENT_226	[p16l521t221r594b284],
5	these	DT	O	these	det	7	SENT_226	[p16l604t221r777b284],
6	preclinical	JJ	O	preclinical	amod	7	SENT_226	[p16l798t221r1152b304],
7	data	NNS	O	datum	prep_of	3	SENT_226	[p16l1173t221r1331b293],
8	,	,	O	,	_	0	SENT_226	[p16l1173t221r1331b293],
9	an	DT	O	a	det	13	SENT_226	[p16l1355t244r1434b284],
10	international	JJ	O	international	amod	13	SENT_226	[p16l1455t221r1910b293],
11	,	,	O	,	_	0	SENT_226	[p16l1455t221r1910b293],
12	multicenter	JJ	O	multicenter	amod	13	SENT_226	[p16l1932t221r2140b284, p16l10t336r216b387],
13	phase	NN	O	phase	nsubjpass	20	SENT_226	[p16l233t324r423b407],
14	I	PRP	O	I	dep	13	SENT_226	[p16l443t329r467b386],
15	study	NN	O	study	dep	13	SENT_226	[p16l488t324r671b408],
16	of	IN	O	of	_	0	SENT_226	[p16l687t324r759b387],
17	LDK37	NN	O	ldk37	prep_of	15	SENT_226	[p16l770t329r1011b387],
18	8	CD	NUMBER	8	num	17	SENT_226	[p16l1016t331r1050b387],
19	was	VBD	O	be	auxpass	20	SENT_226	[p16l1069t347r1193b387],
20	conducted	VBN	O	conduct	_	0	SENT_226	[p16l1214t324r1581b396],
21	,	,	O	,	_	0	SENT_226	[p16l1214t324r1581b396],
22	and	CC	O	and	_	0	SENT_226	[p16l1603t324r1727b387],
23	preliminary	JJ	O	preliminary	amod	24	SENT_226	[p16l1744t324r2145b408],
24	results	NNS	O	result	nsubjpass	27	SENT_226	[p16l10t426r229b489],
25	were	VBD	O	be	auxpass	27	SENT_226	[p16l251t449r412b489],
26	recently	RB	DATE	recently	advmod	27	SENT_226	[p16l435t426r710b510],
27	presented	VBN	O	present	conj_and	20	SENT_226	[p16l727t418r1141b509],
28	.79	CD	NUMBER	.79	num	29	SENT_226	[p16l727t418r1141b509],
29	LDK37	NN	O	ldk37	dobj	27	SENT_226	[p16l1165t431r1412b489],
30	8	CD	NUMBER	8	nsubjpass	33	SENT_226	[p16l1417t433r1451b489],
31	has	VBZ	O	have	aux	33	SENT_226	[p16l1475t426r1587b489],
32	been	VBN	O	be	auxpass	33	SENT_226	[p16l1608t426r1773b489],
33	associated	VBN	O	associate	rcmod	29	SENT_226	[p16l1796t426r2144b489],
34	with	IN	O	with	_	0	SENT_226	[p16l8t529r155b592],
35	a	DT	O	a	det	38	SENT_226	[p16l175t552r209b592],
36	high	JJ	O	high	amod	38	SENT_226	[p16l225t529r374b613],
37	response	NN	O	response	nn	38	SENT_226	[p16l393t551r682b612],
38	rate	NN	O	rate	prep_with	33	SENT_226	[p16l701t541r823b592],
39	in	IN	O	in	_	0	SENT_226	[p16l842t535r907b591],
40	patients	NNS	O	patient	prep_in	38	SENT_226	[p16l924t535r1183b612],
41	with	IN	O	with	_	0	SENT_226	[p16l1201t529r1349b592],
42	advanced	JJ	O	advanced	amod	44	SENT_226	[p16l1368t529r1680b592],
43	ALK-positive	JJ	MISC	alk-positive	amod	44	SENT_226	[p16l1697t533r2142b612],
44	NSCLC	NN	MISC	nsclc	prep_with	33	SENT_226	[p16l9t636r282b704],
45	,	,	O	,	_	0	SENT_226	[p16l9t636r282b704],
46	including	VBG	O	include	_	0	SENT_226	[p16l303t632r619b716],
47	those	DT	O	those	prep_including	33	SENT_226	[p16l635t632r813b695],
48	with	IN	O	with	_	0	SENT_226	[p16l830t632r979b695],
49	crizotinib-resistant	JJ	O	crizotinib-resistant	amod	50	SENT_226	[p16l998t632r1629b695],
50	disease	NN	O	disease	prep_with	47	SENT_226	[p16l1647t632r1895b695],
51	.	.	O	.	_	0	SENT_226	[p16l1647t632r1895b695],

1	On	IN	O	on	_	0	SENT_227	[p16l1918t636r2023b695],
2	the	DT	O	the	det	3	SENT_227	[p16l2041t632r2144b695],
3	basis	NN	O	basis	prep_on	8	SENT_227	[p16l8t735r173b798],
4	of	IN	O	of	_	0	SENT_227	[p16l196t735r270b798],
5	the	DT	O	the	det	6	SENT_227	[p16l281t735r387b798],
6	phase	NN	O	phase	prep_of	3	SENT_227	[p16l408t735r602b818],
7	I	PRP	O	I	nsubj	8	SENT_227	[p16l625t740r648b797],
8	results	VBZ	O	result	ccomp	12	SENT_227	[p16l672t735r909b807],
9	,	,	O	,	_	0	SENT_227	[p16l672t735r909b807],
10	LDK378	NN	O	ldk378	nsubjpass	12	SENT_227	[p16l933t740r1218b798],
11	was	VBD	O	be	auxpass	12	SENT_227	[p16l1240t758r1365b798],
12	granted	VBN	O	grant	_	0	SENT_227	[p16l1388t735r1649b819],
13	Breakthrough	NNP	O	Breakthrough	nn	15	SENT_227	[p16l1671t735r2143b819],
14	Therapy	NN	O	therapy	nn	15	SENT_227	[p16l9t838r290b922],
15	designation	NN	O	designation	dobj	12	SENT_227	[p16l309t838r705b922],
16	by	IN	O	by	_	0	SENT_227	[p16l725t838r809b922],
17	the	DT	O	the	det	18	SENT_227	[p16l826t838r932b901],
18	FDA	NNP	ORGANIZATION	FDA	agent	12	SENT_227	[p16l955t842r1117b900],
19	in	IN	O	in	_	0	SENT_227	[p16l1139t844r1205b900],
20	March	NNP	DATE	March	prep_in	18	SENT_227	[p16l1227t838r1449b901],
21	2013	CD	DATE	2013	num	20	SENT_227	[p16l1471t845r1649b901],
22	.	.	O	.	_	0	SENT_227	[p16l1471t845r1649b901],

1	This	DT	O	this	det	3	SENT_228	[p16l1674t838r1817b901],
2	new	JJ	O	new	amod	3	SENT_228	[p16l1840t861r1982b901],
3	designation	NN	O	designation	nsubjpass	5	SENT_228	[p16l2002t838r2139b901, p16l10t947r305b1025],
4	is	VBZ	O	be	auxpass	5	SENT_228	[p16l331t947r383b1004],
5	intended	VBN	O	intend	_	0	SENT_228	[p16l411t941r726b1004],
6	to	TO	O	to	aux	7	SENT_228	[p16l750t953r818b1004],
7	expedite	VB	O	expedite	xcomp	5	SENT_228	[p16l847t941r1144b1024],
8	development	NN	O	development	dobj	7	SENT_228	[p16l1172t941r1633b1024],
9	and	CC	O	and	_	0	SENT_228	[p16l1659t941r1789b1004],
10	review	NN	O	review	dobj	7	SENT_228	[p16l1815t947r2051b1004],
11	of	IN	O	of	_	0	SENT_228	[p16l2075t941r2151b1004],
12	promising	JJ	O	promising	amod	14	SENT_228	[p16l8t1050r353b1128],
13	new	JJ	O	new	amod	14	SENT_228	[p16l371t1067r511b1107],
14	therapies	NNS	O	therapy	prep_of	8	SENT_228	[p16l526t1044r829b1127],
15	by	IN	O	by	_	0	SENT_228	[p16l847t1044r929b1128],
16	olfering	VBG	O	olfer	prepc_by	7	SENT_228	[p16l946t1044r1207b1128],
17	not	RB	O	not	neg	18	SENT_228	[p16l1224t1056r1336b1107],
18	only	RB	O	only	preconj	23	SENT_228	[p16l1355t1044r1502b1128],
19	fast	JJ	O	fast	amod	23	SENT_228	[p16l1518t1044r1837b1107],
20	—	NN	O	—	nn	23	SENT_228	[p16l1518t1044r1837b1107],
21	track	NN	O	track	nn	23	SENT_228	[p16l1518t1044r1837b1107],
22	program	NN	O	program	nn	23	SENT_228	[p16l1851t1066r2143b1128],
23	features	NNS	O	feature	dobj	16	SENT_228	[p16l9t1147r265b1210],
24	but	CC	O	but	_	0	SENT_228	[p16l282t1147r393b1210],
25	also	RB	O	also	_	0	SENT_228	[p16l411t1147r538b1210],
26	more	RBR	O	more	advmod	27	SENT_228	[p16l557t1170r730b1210],
27	intensive	JJ	O	intensive	amod	28	SENT_228	[p16l750t1153r1043b1210],
28	guidance	NN	O	guidance	conj_and	23	SENT_228	[p16l1062t1147r1362b1231],
29	from	IN	O	from	_	0	SENT_228	[p16l1381t1147r1544b1210],
30	the	DT	O	the	det	31	SENT_228	[p16l1561t1147r1664b1210],
31	FDA	NNP	ORGANIZATION	FDA	prep_from	28	SENT_228	[p16l1685t1151r1858b1210],
32	.	.	O	.	_	0	SENT_228	[p16l1685t1151r1858b1210],

1	The	DT	O	the	det	4	SENT_229	[p16l1879t1147r2002b1210],
2	ﬁrst	JJ	O	ﬁrst	amod	4	SENT_229	[p16l2021t1147r2149b1210],
3	regulatory	JJ	O	regulatory	amod	4	SENT_229	[p16l10t1250r362b1334],
4	ﬁling	NN	O	ﬁling	nsubjpass	8	SENT_229	[p16l379t1250r554b1334],
5	of	IN	O	of	_	0	SENT_229	[p16l574t1250r648b1313],
6	LDK378	NN	O	ldk378	prep_of	4	SENT_229	[p16l659t1255r943b1313],
7	is	VBZ	O	be	auxpass	8	SENT_229	[p16l966t1256r1016b1313],
8	anticipated	VBN	O	anticipate	_	0	SENT_229	[p16l1038t1250r1414b1333],
9	in	IN	O	in	_	0	SENT_229	[p16l1433t1256r1499b1312],
10	early	JJ	DATE	early	amod	11	SENT_229	[p16l1521t1250r1686b1334],
11	2014	CD	DATE	2014	prep_in	8	SENT_229	[p16l1703t1257r1880b1313],
12	.	.	O	.	_	0	SENT_229	[p16l1703t1257r1880b1313],

1	Two	CD	NUMBER	two	num	5	SENT_230	[p16l83t1356r230b1416],
2	conﬁrmatory	JJ	O	conﬁrmatory	amod	5	SENT_230	[p16l255t1353r718b1437],
3	phase	NN	O	phase	nn	5	SENT_230	[p16l736t1353r933b1436],
4	II	CD	NUMBER	ii	num	5	SENT_230	[p16l958t1358r1011b1415],
5	studies	NNS	O	study	nsubj	8	SENT_230	[p16l1037t1353r1276b1416],
6	of	IN	O	of	_	0	SENT_230	[p16l1300t1353r1375b1416],
7	LDK378	NN	O	ldk378	prep_of	5	SENT_230	[p16l1389t1358r1679b1416],
8	are	VBP	O	be	_	0	SENT_230	[p16l1705t1376r1807b1416],
9	currently	RB	DATE	currently	advmod	8	SENT_230	[p16l1831t1353r2152b1437],
10	under	IN	O	under	_	0	SENT_230	[p16l9t1456r211b1519],
11	way	NN	O	way	prep_under	8	SENT_230	[p16l228t1479r371b1540],
12	,	,	O	,	_	0	SENT_230	[p16l228t1479r371b1540],
13	one	CD	NUMBER	one	prep_under	8	SENT_230	[p16l393t1479r513b1519],
14	for	IN	O	for	_	0	SENT_230	[p16l533t1456r629b1519],
15	crizotinib-resistant	JJ	O	crizotinib-resistant	amod	16	SENT_230	[p16l649t1456r1291b1519],
16	patients	NNS	O	patient	prep_for	13	SENT_230	[p16l1308t1462r1574b1539],
17	(	IN	O	(	_	0	SENT_230	[p16l1597t1456r2144b1533],
18	NCT01685060	NN	O	nct01685060	nn	19	SENT_230	[p16l1597t1456r2144b1533],
19	)	NN	O	)	prep_(	16	SENT_230	[p16l1597t1456r2144b1533],
20	and	CC	O	and	_	0	SENT_230	[p16l10t1559r142b1622],
21	one	CD	NUMBER	one	conj_and	11	SENT_230	[p16l169t1582r297b1622],
22	for	IN	O	for	_	0	SENT_230	[p16l325t1559r427b1622],
23	crizotinib	JJ	O	crizotinib	amod	26	SENT_230	[p16l454t1559r1032b1622],
24	—	NN	O	—	npadvmod	25	SENT_230	[p16l454t1559r1032b1622],
25	naive	JJ	O	naive	amod	26	SENT_230	[p16l454t1559r1032b1622],
26	patients	NNS	O	patient	prep_for	21	SENT_230	[p16l1059t1565r1343b1642],
27	(	IN	O	(	_	0	SENT_230	[p16l1376t1560r1959b1636],
28	NCTO1685138	NN	O	ncto1685138	nn	29	SENT_230	[p16l1376t1560r1959b1636],
29	)	NN	O	)	prep_(	8	SENT_230	[p16l1376t1560r1959b1636],
30	with	IN	O	with	_	0	SENT_230	[p16l1989t1559r2149b1622],
31	advanced	JJ	O	advanced	amod	34	SENT_230	[p16l10t1662r368b1734],
32	,	,	O	,	_	0	SENT_230	[p16l10t1662r368b1734],
33	ALK-positive	JJ	O	alk-positive	amod	34	SENT_230	[p16l398t1666r885b1745],
34	NSCLC	NN	O	nsclc	prep_with	29	SENT_230	[p16l913t1666r1206b1725],
35	.	.	O	.	_	0	SENT_230	[p16l913t1666r1206b1725],

1	In	IN	O	in	_	0	SENT_231	[p16l1238t1667r1312b1724],
2	addition	NN	O	addition	prep_in	11	SENT_231	[p16l1342t1662r1665b1734],
3	,	,	O	,	_	0	SENT_231	[p16l1342t1662r1665b1734],
4	two	CD	NUMBER	two	num	9	SENT_231	[p16l1694t1674r1825b1725],
5	ongoing	JJ	O	ongoing	amod	9	SENT_231	[p16l1855t1668r2150b1746],
6	phase	NN	O	phase	nn	9	SENT_231	[p16l8t1765r208b1848],
7	III	CD	NUMBER	iii	num	9	SENT_231	[p16l233t1770r317b1827],
8	NSCLC	NN	O	nsclc	nn	9	SENT_231	[p16l341t1769r611b1828],
9	studies	NNS	O	study	nsubj	11	SENT_231	[p16l635t1765r877b1828],
10	are	VBP	O	be	aux	11	SENT_231	[p16l902t1788r1004b1828],
11	comparing	VBG	O	compare	_	0	SENT_231	[p16l1029t1771r1411b1849],
12	LDK37	NN	O	ldk37	dobj	11	SENT_231	[p16l1433t1770r1685b1828],
13	8	CD	NUMBER	8	num	12	SENT_231	[p16l1691t1772r1726b1828],
14	with	IN	O	with	_	0	SENT_231	[p16l1749t1765r1907b1828],
15	standard	JJ	O	standard	amod	16	SENT_231	[p16l1931t1765r2148b1828, p16l10t1869r125b1932],
16	chemotherapy	NN	O	chemotherapy	prep_with	12	SENT_231	[p16l150t1869r672b1953],
17	,	,	O	,	_	0	SENT_231	[p16l150t1869r672b1953],
18	one	CD	NUMBER	one	appos	16	SENT_231	[p16l701t1892r827b1932],
19	on	IN	O	on	_	0	SENT_231	[p16l854t1892r942b1932],
20	ALK-positive	JJ	O	alk-positive	amod	21	SENT_231	[p16l967t1873r1448b1952],
21	patients	NNS	O	patient	prep_on	18	SENT_231	[p16l1473t1875r1754b1952],
22	previously	RB	DATE	previously	advmod	23	SENT_231	[p16l1779t1869r2153b1953],
23	treated	VBN	O	treat	partmod	21	SENT_231	[p16l8t1972r262b2035],
24	with	IN	O	with	_	0	SENT_231	[p16l289t1972r450b2035],
25	platinum-based	JJ	O	platinum-based	amod	26	SENT_231	[p16l478t1972r1054b2055],
26	chemotherapy	NN	O	chemotherapy	prep_with	23	SENT_231	[p16l1084t1972r1606b2056],
27	and	CC	O	and	_	0	SENT_231	[p16l1633t1972r1765b2035],
28	crizotinib	NN	O	crizotinib	nn	31	SENT_231	[p16l1795t1972r2147b2035],
29	(	CD	NUMBER	(	num	31	SENT_231	[p16l13t2076r574b2151],
30	NCT01828112	NN	O	nct01828112	nn	31	SENT_231	[p16l13t2076r574b2151],
31	)	NN	O	)	prep_with	23	SENT_231	[p16l13t2076r574b2151],
32	,	,	O	,	_	0	SENT_231	[p16l13t2076r574b2151],
33	and	CC	O	and	_	0	SENT_231	[p16l596t2075r719b2138],
34	one	CD	NUMBER	one	prep_with	23	SENT_231	[p16l738t2098r857b2138],
35	on	IN	O	on	_	0	SENT_231	[p16l877t2098r961b2138],
36	previously	RB	DATE	previously	advmod	39	SENT_231	[p16l979t2075r1327b2159],
37	untreated	JJ	O	untreated	amod	39	SENT_231	[p16l1343t2075r1679b2147],
38	,	,	O	,	_	0	SENT_231	[p16l1343t2075r1679b2147],
39	ALK-positive	JJ	O	alk-positive	amod	40	SENT_231	[p16l1699t2079r2148b2158],
40	patients	NNS	O	patient	prep_on	34	SENT_231	[p16l8t2184r278b2261],
41	(	IN	O	(	_	0	SENT_231	[p16l303t2179r881b2254],
42	NCT01828099	NN	O	nct01828099	nn	43	SENT_231	[p16l303t2179r881b2254],
43	)	NN	O	)	prep_(	23	SENT_231	[p16l303t2179r881b2254],
44	.	.	O	.	_	0	SENT_231	[p16l303t2179r881b2254],

1	CH5424802	NN	O	ch5424802	_	0	SENT_232	[p16l9t2394r411b2449],

1	CH5424802	NN	O	ch5424802	_	0	SENT_233	[p16l11t2493r419b2552],
2	(	CD	NUMBER	(	num	3	SENT_233	[p16l445t2490r583b2565],
3	RO	NN	O	ro	nsubj	21	SENT_233	[p16l445t2490r583b2565],
4	5424802	CD	NUMBER	5424802	dep	3	SENT_233	[p16l608t2496r912b2561],
5	;	:	O	;	_	0	SENT_233	[p16l608t2496r912b2561],
6	Chugai	NNP	ORGANIZATION	Chugai	nn	7	SENT_233	[p16l936t2489r1181b2573],
7	Pharmaceuticals	NNP	ORGANIZATION	Pharmaceuticals	dep	3	SENT_233	[p16l1202t2489r1767b2552],
8	and	CC	O	and	_	0	SENT_233	[p16l1790t2489r1916b2552],
9	Roche	NNP	ORGANIZATION	Roche	nn	11	SENT_233	[p16l1937t2489r2150b2552],
10	Pharmaceuticals	NNP	ORGANIZATION	Pharmaceuticals	nn	11	SENT_233	[p16l10t2592r609b2669],
11	)	NN	O	)	conj_and	7	SENT_233	[p16l10t2592r609b2669],
12	is	VBZ	O	be	cop	21	SENT_233	[p16l637t2598r687b2656],
13	a	DT	O	a	det	21	SENT_233	[p16l712t2615r747b2656],
14	highly	RB	O	highly	advmod	15	SENT_233	[p16l768t2592r990b2677],
15	potent	JJ	O	potent	amod	21	SENT_233	[p16l1008t2604r1234b2676],
16	(	NN	O	(	nn	21	SENT_233	[p16l1259t2593r1432b2684],
17	IC50	NN	O	ic50	nn	21	SENT_233	[p16l1259t2593r1432b2684],
18	=	JJ	O	=	amod	21	SENT_233	[p16l1457t2622r1500b2642],
19	1.9	CD	NUMBER	1.9	num	21	SENT_233	[p16l1532t2599r1624b2656],
20	nmol/l	NN	O	nmol/l	nn	21	SENT_233	[p16l1648t2592r1931b2669],
21	)	NN	O	)	rcmod	1	SENT_233	[p16l1648t2592r1931b2669],
22	,	,	O	,	_	0	SENT_233	[p16l1648t2592r1931b2669],
23	selective	JJ	O	selective	amod	26	SENT_233	[p16l1956t2592r2147b2656, p16l8t2702r146b2768],
24	,	,	O	,	_	0	SENT_233	[p16l1956t2592r2147b2656, p16l8t2702r146b2768],
25	orally	RB	O	orally	advmod	26	SENT_233	[p16l168t2696r360b2780],
26	available	JJ	O	available	amod	21	SENT_233	[p16l377t2696r666b2759],
27	benzo	NN	O	benzo	dep	31	SENT_233	[p16l683t2696r886b2759],
28	[	NN	O	[	dep	27	SENT_233	[p16l898t2696r978b2772],
29	I9	NN	O	i9	dep	31	SENT_233	[p16l898t2696r978b2772],
30	]	CD	NUMBER	]	num	29	SENT_233	[p16l898t2696r978b2772],
31	carbazole	NN	O	carbazole	dep	35	SENT_233	[p16l991t2696r1307b2759],
32	derivative	JJ	O	derivative	amod	34	SENT_233	[p16l1328t2696r1656b2759],
33	ALK	NN	O	alk	nn	34	SENT_233	[p16l1675t2700r1836b2758],
34	inhibitor	NN	O	inhibitor	dep	31	SENT_233	[p16l1854t2696r2151b2759],
35	with	IN	O	with	dep	1	SENT_233	[p16l8t2799r163b2862],
36	demonstrated	VBN	O	demonstrate	pcomp	35	SENT_233	[p16l187t2799r671b2862],
37	activity	NN	O	activity	dobj	36	SENT_233	[p16l694t2805r952b2883],
38	against	IN	O	against	_	0	SENT_233	[p16l972t2805r1216b2883],
39	both	DT	O	both	preconj	40	SENT_233	[p16l1236t2799r1399b2862],
40	ALK	NN	O	alk	prep_against	37	SENT_233	[p16l1421t2803r1587b2861],
41	and	CC	O	and	_	0	SENT_233	[p16l1609t2799r1738b2862],
42	ALK	NN	O	alk	nn	46	SENT_233	[p16l1759t2803r1925b2861],
43	tyrosine	NN	O	tyrosine	nn	46	SENT_233	[p16l1946t2811r2148b2883, p16l9t2908r110b2965],
44	kinase	NN	O	kinase	nn	46	SENT_233	[p16l129t2902r344b2965],
45	domain	NN	O	domain	nn	46	SENT_233	[p16l365t2902r623b2965],
46	mutations	NNS	O	mutation	prep_against	37	SENT_233	[p16l643t2908r1000b2974],
47	,	,	O	,	_	0	SENT_233	[p16l643t2908r1000b2974],
48	including	VBG	O	include	_	0	SENT_233	[p16l1022t2902r1344b2986],
49	the	DT	O	the	det	52	SENT_233	[p16l1361t2902r1466b2965],
50	L1196M	NN	O	l1196m	nn	52	SENT_233	[p16l1486t2907r1767b2965],
51	gatekeeper	NN	O	gatekeeper	nn	52	SENT_233	[p16l1788t2902r2149b2986],
52	mutation	NN	O	mutation	prep_including	36	SENT_233	[p16l9t3011r324b3068],
53	and	CC	O	and	_	0	SENT_233	[p16l346t3004r472b3068],
54	other	JJ	O	other	amod	55	SENT_233	[p16l494t3004r675b3068],
55	mutations	NNS	O	mutation	prep_including	36	SENT_233	[p16l696t3011r1060b3077],
56	,	,	O	,	_	0	SENT_233	[p16l696t3011r1060b3077],
57	e.g.	FW	O	e.g.	prep_including	36	SENT_233	[p16l1084t3027r1214b3089],
58	,	,	O	,	_	0	SENT_233	[p16l1084t3027r1214b3089],
59	F1174L	NN	O	f1174l	prep_including	36	SENT_233	[p16l1238t3010r1493b3068],
60	and	CC	O	and	_	0	SENT_233	[p16l1514t3004r1641b3068],
61	R1275Q	NN	O	r1275q	prep_including	36	SENT_233	[p16l1662t2996r2094b3081],
62	.8	CD	NUMBER	.8	num	61	SENT_233	[p16l1662t2996r2094b3081],
63	°	CD	NUMBER	°	number	64	SENT_233	[p16l1662t2996r2094b3081],
64	’81	CD	NUMBER	’81	dep	61	SENT_233	[p16l1662t2996r2094b3081],

1	A	DT	O	a	det	4	SENT_234	[p16l82t3112r140b3170],
2	phase	NN	O	phase	nn	4	SENT_234	[p16l168t3108r373b3191],
3	I/II	NN	O	i/ii	nn	4	SENT_234	[p16l403t3112r521b3174],
4	study	NN	O	study	nsubjpass	16	SENT_234	[p16l552t3108r749b3192],
5	of	IN	O	of	_	0	SENT_234	[p16l774t3108r851b3171],
6	CH5424802	NN	O	ch5424802	prep_of	4	SENT_234	[p16l872t3112r1300b3171],
7	conducted	VBN	O	conduct	partmod	6	SENT_234	[p16l1332t3108r1711b3171],
8	in	IN	O	in	_	0	SENT_234	[p16l1739t3114r1809b3170],
9	Japanese	JJ	MISC	japanese	amod	10	SENT_234	[p16l1838t3113r2149b3191],
10	patients	NNS	O	patient	prep_in	7	SENT_234	[p16l8t3218r302b3295],
11	with	IN	O	with	_	0	SENT_234	[p16l335t3211r499b3275],
12	ALK-positive	JJ	O	alk-positive	amod	13	SENT_234	[p16l532t3216r1033b3295],
13	NSCLC	NN	ORGANIZATION	nsclc	prep_with	7	SENT_234	[p16l1066t3215r1345b3275],
14	has	VBZ	O	have	aux	16	SENT_234	[p16l1379t3211r1498b3275],
15	been	VBN	O	be	auxpass	16	SENT_234	[p16l1531t3212r1707b3275],
16	reported	VBN	O	report	_	0	SENT_234	[p16l1741t3203r2149b3295],
17	.82	CD	NUMBER	.82	num	18	SENT_234	[p16l1741t3203r2149b3295],
18	Patients	NNS	O	patient	dobj	16	SENT_234	[p16l10t3320r285b3378],
19	were	VBD	O	be	auxpass	20	SENT_234	[p16l307t3338r471b3378],
20	required	VBN	O	require	rcmod	18	SENT_234	[p16l495t3315r793b3398],
21	to	TO	O	to	aux	23	SENT_234	[p16l814t3327r881b3378],
22	be	VB	O	be	cop	23	SENT_234	[p16l904t3315r985b3378],
23	positive	JJ	O	positive	xcomp	20	SENT_234	[p16l1008t3321r1280b3398],
24	by	IN	O	by	_	0	SENT_234	[p16l1302t3315r1388b3399],
25	both	CC	O	both	dep	26	SENT_234	[p16l1406t3315r1568b3378],
26	FISH	NN	O	fish	prep_by	23	SENT_234	[p16l1592t3319r1771b3378],
27	and	CC	O	and	_	0	SENT_234	[p16l1797t3315r1926b3378],
28	either	CC	O	either	preconj	29	SENT_234	[p16l1949t3315r2151b3378],
29	IHC	NNP	ORGANIZATION	IHC	conj_and	26	SENT_234	[p16l10t3422r158b3481],
30	or	CC	O	or	_	0	SENT_234	[p16l182t3441r254b3481],
31	reverse	JJ	O	reverse	amod	33	SENT_234	[p16l276t3441r519b3481],
32	transcriptase	NN	O	transcriptase	nn	33	SENT_234	[p16l541t3424r985b3501],
33	PCR	NN	O	pcr	conj_or	29	SENT_234	[p16l1010t3422r1168b3481],
34	for	IN	O	for	_	0	SENT_234	[p16l1188t3418r1286b3481],
35	study	NN	O	study	nn	36	SENT_234	[p16l1309t3418r1496b3502],
36	entry	NN	O	entry	prep_for	23	SENT_234	[p16l1516t3430r1707b3502],
37	.	.	O	.	_	0	SENT_234	[p16l1516t3430r1707b3502],

1	In	IN	O	in	_	0	SENT_235	[p16l1733t3423r1805b3480],
2	the	DT	O	the	det	3	SENT_235	[p16l1826t3418r1934b3481],
3	phase	NN	O	phase	prep_in	18	SENT_235	[p16l1955t3418r2151b3501],
4	I	PRP	O	I	amod	3	SENT_235	[p16l10t3526r34b3583],
5	portion	NN	O	portion	dep	4	SENT_235	[p16l58t3527r323b3604],
6	of	IN	O	of	_	0	SENT_235	[p16l347t3521r422b3584],
7	the	DT	O	the	det	8	SENT_235	[p16l434t3521r543b3584],
8	study	NN	O	study	prep_of	5	SENT_235	[p16l568t3521r766b3605],
9	,	,	O	,	_	0	SENT_235	[p16l568t3521r766b3605],
10	no	DT	O	no	det	11	SENT_235	[p16l791t3544r879b3584],
11	dose	NN	O	dose	appos	5	SENT_235	[p16l905t3521r1062b3584],
12	limiting	VBG	O	limit	partmod	11	SENT_235	[p16l1084t3521r1364b3605],
13	toxicities	NNS	O	toxicity	dobj	12	SENT_235	[p16l1385t3527r1698b3584],
14	(	CD	NUMBER	(	num	15	SENT_235	[p16l1726t3521r1960b3598],
15	DLTs	NNS	O	dlt	nsubjpass	18	SENT_235	[p16l1726t3521r1960b3598],
16	)	CD	NUMBER	)	dep	15	SENT_235	[p16l1726t3521r1960b3598],
17	were	VBD	O	be	auxpass	18	SENT_235	[p16l1985t3544r2149b3584],
18	observed	VBN	O	observe	_	0	SENT_235	[p16l10t3624r325b3687],
19	at	IN	O	at	_	0	SENT_235	[p16l348t3636r408b3687],
20	the	DT	O	the	det	23	SENT_235	[p16l428t3624r536b3687],
21	maximally	RB	O	maximally	advmod	22	SENT_235	[p16l559t3624r929b3708],
22	administered	VBN	O	administer	amod	23	SENT_235	[p16l949t3624r1408b3687],
23	dose	NN	O	dose	prep_at	18	SENT_235	[p16l1431t3624r1587b3687],
24	of	IN	O	of	_	0	SENT_235	[p16l1612t3624r1686b3687],
25	300	CD	NUMBER	300	num	26	SENT_235	[p16l1701t3631r1821b3687],
26	mg	NN	O	mg	prep_of	23	SENT_235	[p16l1837t3647r1947b3708],
27	twice	RB	O	twice	advmod	28	SENT_235	[p16l1968t3630r2150b3687],
28	daily	RB	SET	daily	advmod	23	SENT_235	[p16l10t3727r192b3811],
29	,	,	O	,	_	0	SENT_235	[p16l10t3727r192b3811],
30	which	WDT	O	which	nsubjpass	32	SENT_235	[p16l218t3727r436b3790],
31	was	VBD	O	be	auxpass	32	SENT_235	[p16l459t3750r590b3790],
32	chosen	VBN	O	choose	dep	28	SENT_235	[p16l616t3727r863b3790],
33	as	IN	O	as	_	0	SENT_235	[p16l890t3750r956b3790],
34	the	DT	O	the	det	36	SENT_235	[p16l982t3727r1092b3790],
35	recommended	VBN	O	recommend	amod	36	SENT_235	[p16l1118t3727r1635b3790],
36	phase	NN	O	phase	prep_as	32	SENT_235	[p16l1659t3727r1861b3810],
37	II	CD	NUMBER	ii	num	38	SENT_235	[p16l1887t3732r1942b3789],
38	dose	NN	O	dose	dep	36	SENT_235	[p16l1970t3727r2147b3790],
39	.	.	O	.	_	0	SENT_235	[p16l1970t3727r2147b3790],

1	Forty	CD	NUMBER	forty	number	2	SENT_236	[p17l10t16r407b100],
2	—	CD	NUMBER	—	num	3	SENT_236	[p17l10t16r407b100],
3	three	CD	NUMBER	three	nsubj	24	SENT_236	[p17l10t16r407b100],
4	of	IN	O	of	_	0	SENT_236	[p17l431t16r506b79],
5	the	DT	O	the	det	7	SENT_236	[p17l518t16r626b79],
6	46	CD	NUMBER	46	num	7	SENT_236	[p17l649t22r729b79],
7	patients	NNS	O	patient	prep_of	3	SENT_236	[p17l752t22r1026b99],
8	(	IN	O	(	_	0	SENT_236	[p17l1053t16r1315b93],
9	93.5	CD	PERCENT	93.5	num	10	SENT_236	[p17l1053t16r1315b93],
10	%	NN	PERCENT	%	prep_(	24	SENT_236	[p17l1053t16r1315b93],
11	)	CD	NUMBER	)	nsubj	24	SENT_236	[p17l1053t16r1315b93],
12	enrolled	VBN	O	enrol	partmod	11	SENT_236	[p17l1343t16r1630b79],
13	in	IN	O	in	_	0	SENT_236	[p17l1652t22r1720b78],
14	the	DT	O	the	det	17	SENT_236	[p17l1742t16r1850b79],
15	phase	NN	O	phase	nn	17	SENT_236	[p17l1872t16r2070b99],
16	II	CD	NUMBER	ii	num	17	SENT_236	[p17l2094t21r2148b78],
17	portion	NN	O	portion	prep_in	12	SENT_236	[p17l8t125r275b202],
18	of	IN	O	of	_	0	SENT_236	[p17l299t119r375b182],
19	the	DT	O	the	det	20	SENT_236	[p17l388t119r497b182],
20	study	NN	O	study	prep_of	17	SENT_236	[p17l522t119r713b203],
21	had	VBD	O	have	aux	24	SENT_236	[p17l732t119r863b182],
22	an	DT	O	a	dep	23	SENT_236	[p17l886t142r968b182],
23	independently	RB	O	independently	advmod	24	SENT_236	[p17l992t119r1504b203],
24	assessed	VBN	O	assess	_	0	SENT_236	[p17l1525t119r1814b182],
25	objective	JJ	O	objective	amod	29	SENT_236	[p17l1837t119r2150b203],
26	response	NN	O	response	nn	29	SENT_236	[p17l10t244r314b305],
27	(	NN	O	(	nn	29	SENT_236	[p17l340t223r403b298],
28	2	CD	NUMBER	2	num	29	SENT_236	[p17l340t223r403b298],
29	patients	NNS	O	patient	dobj	24	SENT_236	[p17l427t228r700b305],
30	with	IN	O	with	_	0	SENT_236	[p17l722t222r877b285],
31	a	DT	O	a	det	33	SENT_236	[p17l901t245r936b285],
32	complete	JJ	O	complete	amod	33	SENT_236	[p17l958t222r1273b305],
33	response	NN	O	response	prep_with	24	SENT_236	[p17l1296t244r1600b305],
34	and	CC	O	and	_	0	SENT_236	[p17l1624t222r1752b285],
35	41	CD	NUMBER	41	num	36	SENT_236	[p17l1773t229r1848b284],
36	patients	NNS	O	patient	prep_with	24	SENT_236	[p17l1876t228r2150b305],
37	with	IN	O	with	_	0	SENT_236	[p17l8t325r162b388],
38	a	DT	O	a	det	41	SENT_236	[p17l185t348r220b388],
39	partial	JJ	O	partial	amod	41	SENT_236	[p17l241t325r467b408],
40	response	NN	O	response	nn	41	SENT_236	[p17l490t326r839b408],
41	)	NN	O	)	prep_with	24	SENT_236	[p17l490t326r839b408],
42	.	.	O	.	_	0	SENT_236	[p17l490t326r839b408],

1	Responses	NNS	O	response	nsubj	2	SENT_237	[p17l866t330r1223b408],
2	occurred	VBD	O	occur	_	0	SENT_237	[p17l1247t325r1558b388],
3	early	RB	O	early	advmod	2	SENT_237	[p17l1581t325r1757b409],
4	,	,	O	,	_	0	SENT_237	[p17l1581t325r1757b409],
5	with	IN	O	with	_	0	SENT_237	[p17l1779t325r1934b388],
6	30/46	CD	PERCENT	30/46	number	7	SENT_237	[p17l1958t329r2148b391],
7	(	CD	PERCENT	(	nsubj	11	SENT_237	[p17l13t429r218b504],
8	65	CD	PERCENT	65	num	9	SENT_237	[p17l13t429r218b504],
9	%	NN	PERCENT	%	dep	7	SENT_237	[p17l13t429r218b504],
10	)	CD	NUMBER	)	dep	7	SENT_237	[p17l13t429r218b504],
11	achieving	VBG	O	achieve	prepc_with	2	SENT_237	[p17l251t428r596b512],
12	partial	JJ	O	partial	amod	13	SENT_237	[p17l620t428r857b511],
13	response	NN	O	response	dobj	11	SENT_237	[p17l884t450r1198b511],
14	within	IN	O	within	_	0	SENT_237	[p17l1224t428r1457b491],
15	3	CD	DURATION	3	num	16	SENT_237	[p17l1486t435r1520b491],
16	weeks	NNS	NUMBER	week	prep_within	11	SENT_237	[p17l1549t428r1762b491],
17	and	CC	O	and	_	0	SENT_237	[p17l1791t428r1922b491],
18	40/46	CD	PERCENT	40/46	number	19	SENT_237	[p17l1948t432r2147b494],
19	(	CD	PERCENT	(	prep_within	11	SENT_237	[p17l13t531r210b608],
20	87	CD	PERCENT	87	num	21	SENT_237	[p17l13t531r210b608],
21	%	NN	PERCENT	%	dep	19	SENT_237	[p17l13t531r210b608],
22	)	CD	NUMBER	)	tmod	11	SENT_237	[p17l13t531r210b608],
23	within	IN	O	within	_	0	SENT_237	[p17l233t531r456b594],
24	6	CD	DURATION	6	num	25	SENT_237	[p17l478t537r514b594],
25	weeks	NNS	NUMBER	week	prep_within	22	SENT_237	[p17l533t531r755b595],
26	.	.	O	.	_	0	SENT_237	[p17l533t531r755b595],

1	Median	JJ	MISC	median	amod	2	SENT_238	[p17l779t531r1041b594],
2	PFS	NN	MISC	pf	nsubjpass	6	SENT_238	[p17l1063t535r1192b595],
3	had	VBD	O	have	aux	6	SENT_238	[p17l1213t531r1341b594],
4	not	RB	O	not	neg	6	SENT_238	[p17l1360t543r1474b594],
5	been	VBN	O	be	auxpass	6	SENT_238	[p17l1492t531r1656b594],
6	reached	VBN	O	reach	_	0	SENT_238	[p17l1677t531r1945b594],
7	at	IN	O	at	_	0	SENT_238	[p17l1966t543r2025b594],
8	the	DT	O	the	det	9	SENT_238	[p17l2044t531r2150b594],
9	time	NN	O	time	prep_at	6	SENT_238	[p17l8t640r163b697],
10	of	IN	O	of	_	0	SENT_238	[p17l188t634r262b697],
11	the	DT	O	the	det	12	SENT_238	[p17l274t634r381b697],
12	report	NN	O	report	prep_of	9	SENT_238	[p17l404t646r635b717],
13	.	.	O	.	_	0	SENT_238	[p17l404t646r635b717],

1	Responses	NNS	O	response	nsubjpass	3	SENT_239	[p17l662t639r1018b717],
2	were	VBD	O	be	auxpass	3	SENT_239	[p17l1040t657r1202b697],
3	seen	VBN	O	see	_	0	SENT_239	[p17l1226t657r1376b697],
4	in	IN	O	in	_	0	SENT_239	[p17l1399t640r1466b696],
5	brain	NN	O	brain	nn	6	SENT_239	[p17l1487t634r1669b697],
6	metastases	NNS	O	metastase	prep_in	3	SENT_239	[p17l1692t646r2059b697],
7	in	IN	O	in	prep	3	SENT_239	[p17l2083t640r2150b696],

1	Table	NNP	O	Table	_	0	SENT_240	[p17l19t792r106b819],
2	1	CD	NUMBER	1	num	4	SENT_240	[p17l115t794r127b818],
3	ALK	NN	O	alk	nn	4	SENT_240	[p17l157t793r222b818],
4	inhibitors	NNS	O	inhibitor	dep	1	SENT_240	[p17l229t792r384b819],
5	currently	RB	DATE	currently	advmod	4	SENT_240	[p17l391t792r538b826],
6	in	IN	O	in	_	0	SENT_240	[p17l545t792r573b818],
7	the	DT	O	the	det	8	SENT_240	[p17l580t792r633b819],
8	clinic	NN	O	clinic	prep_in	4	SENT_240	[p17l641t792r723b819],
9	or	CC	O	or	_	0	SENT_240	[p17l730t799r763b819],
10	in	IN	O	in	_	0	SENT_240	[p17l771t792r799b818],
11	clinical	JJ	O	clinical	amod	12	SENT_240	[p17l807t792r917b819],
12	development	NN	O	development	prep_in	4	SENT_240	[p17l926t792r1140b826],

1	Activity	NN	O	activity	_	0	SENT_241	[p17l603t852r713b883],
2	against	IN	O	against	_	0	SENT_241	[p17l720t852r824b883],
3	L1196M	NN	O	l1196m	prep_against	1	SENT_241	[p17l627t892r739b916],
4	ALK	NNP	O	ALK	nn	6	SENT_241	[p17l747t892r803b916],
5	Other	JJ	O	other	amod	6	SENT_241	[p17l910t891r992b916],
6	kinases	NNS	O	kinase	dep	1	SENT_241	[p17l1000t891r1104b916],

1	Drug	NN	O	drug	nn	3	SENT_242	[p17l21t931r90b962],
2	Company	NN	O	company	nn	3	SENT_242	[p17l280t931r417b962],
3	mutation	NN	O	mutation	nsubj	4	SENT_242	[p17l649t931r779b955],
4	inhibited	VBD	O	inhibit	_	0	SENT_242	[p17l944t930r1071b955],
5	Status	NNP	O	Status	nn	7	SENT_242	[p17l1229t931r1317b955],
6	Ongoing	JJ	O	ongoing	amod	7	SENT_242	[p17l1526t931r1651b962],
7	studies	NNS	O	study	dobj	4	SENT_242	[p17l1659t930r1761b955],
8	Reference	NNP	MISC	Reference	nn	12	SENT_242	[p17l1847t930r1988b955],
9	Crizotinib	NNP	MISC	Crizotinib	nn	12	SENT_242	[p17l20t1012r152b1036],
10	Pfizer	NNP	MISC	Pfizer	nn	12	SENT_242	[p17l282t1012r356b1036],
11	No	NNP	MISC	No	nn	12	SENT_242	[p17l688t1013r725b1036],
12	ROS1	NN	MISC	ros1	tmod	4	SENT_242	[p17l911t1013r977b1036],
13	Approved	VBN	MISC	approve	partmod	12	SENT_242	[p17l1228t1012r1363b1043],
14	Phase	NN	MISC	phase	dobj	13	SENT_242	[p17l1528t1012r1606b1036],
15	III	CD	NUMBER	iii	num	14	SENT_242	[p17l1615t1013r1635b1036],
16	Camidge	NN	MISC	camidge	dep	12	SENT_242	[p17l1846t1012r1969b1043],
17	etal.	FW	O	etal.	nn	16	SENT_242	[p17l1977t1008r2070b1040],
18	,3	FW	O	,3	nn	16	SENT_242	[p17l1977t1008r2070b1040],
19	°	FW	O	°	dep	16	SENT_242	[p17l1977t1008r2070b1040],

1	T	NN	O	t	_	0	SENT_243	[p17l900t1051r1198b1053],
2	31	CD	NUMBER	31	num	3	SENT_243	[p17l1989t1047r2009b1064],
3	QMEI	NN	O	qmeus	dep	1	SENT_243	[p17l910t1071r995b1095],
4	.	.	O	.	_	0	SENT_243	[p17l910t1071r995b1095],

1	Shaw	NNP	PERSON	Shaw	dep	2	SENT_244	[p17l1846t1051r1920b1075],
2	etal	JJ	O	etal	_	0	SENT_244	[p17l1927t1051r1987b1075],
3	.	.	O	.	_	0	SENT_244	[p17l1927t1051r1987b1075],

1	LDK378	CD	NUMBER	ldk378	num	7	SENT_245	[p17l21t1113r125b1136],
2	Novartis	NNP	O	Novartis	nn	7	SENT_245	[p17l282t1113r394b1137],
3	Yes	NNP	O	Yes	nn	7	SENT_245	[p17l692t1113r735b1137],
4	IGF-1	NN	O	igf-1	nn	7	SENT_245	[p17l911t1113r976b1136],
5	R	NN	O	r	nn	7	SENT_245	[p17l984t1113r999b1136],
6	Investigational	JJ	O	investigational	amod	7	SENT_245	[p17l1230t1112r1430b1143],
7	Phase	NN	O	phase	_	0	SENT_245	[p17l1528t1112r1606b1136],
8	I	PRP	O	I	dep	7	SENT_245	[p17l1615t1113r1627b1140],
9	,	,	O	,	_	0	SENT_245	[p17l1615t1113r1627b1140],
10	phase	NN	O	phase	dep	7	SENT_245	[p17l1636t1112r1716b1143],
11	II	CD	NUMBER	ii	num	10	SENT_245	[p17l1725t1113r1744b1140],
12	,	,	O	,	_	0	SENT_245	[p17l1725t1113r1744b1140],
13	Masilje	NNP	O	Masilje	nn	14	SENT_245	[p17l1847t1112r1941b1143],
14	etaI.	NNP	O	etaI.	dep	7	SENT_245	[p17l1949t1108r2042b1140],
15	,77	CD	NUMBER	,77	number	16	SENT_245	[p17l1949t1108r2042b1140],
16	(	CD	NUMBER	(	num	17	SENT_245	[p17l1229t1152r1426b1183],
17	Breakthrough	NNP	O	Breakthrough	dep	14	SENT_245	[p17l1229t1152r1426b1183],
18	and	CC	O	and	_	0	SENT_245	[p17l1526t1152r1577b1176],
19	phase	NN	O	phase	nn	22	SENT_245	[p17l1586t1152r1667b1183],
20	III	CD	NUMBER	iii	num	22	SENT_245	[p17l1676t1153r1695b1176],
21	Shaw	NNP	O	Shaw	nn	22	SENT_245	[p17l1847t1152r1920b1176],
22	etaI	NNP	O	etaI	conj_and	8	SENT_245	[p17l1927t1148r2013b1176],
23	.79	CD	NUMBER	.79	dep	7	SENT_245	[p17l1927t1148r2013b1176],

1	ROS1	NN	O	ros1	_	0	SENT_246	[p17l911t1171r977b1195],

1	Therapy	NN	O	therapy	nn	2	SENT_247	[p17l1227t1191r1340b1223],
2	designation	NN	O	designation	_	0	SENT_247	[p17l1228t1231r1400b1262],
3	)	CD	NUMBER	)	dep	2	SENT_247	[p17l1228t1231r1400b1262],

1	CH5424802	NN	O	ch5424802	_	0	SENT_248	[p17l20t1290r191b1315],
2	/	:	O	/	punct	18	SENT_248	[p17l20t1290r191b1315],
3	Chugai/Roche	NNP	O	Chugai/Roche	nn	4	SENT_248	[p17l280t1289r475b1320],
4	Yes	NNP	O	Yes	dep	14	SENT_248	[p17l692t1290r735b1314],
5	ROS1	NNP	O	ROS1	nn	10	SENT_248	[p17l911t1290r977b1314],
6	Investigational	NNP	O	Investigational	nn	10	SENT_248	[p17l1230t1289r1430b1320],
7	Phase	NN	O	phase	nn	10	SENT_248	[p17l1528t1289r1606b1314],
8	I/II	NNP	O	I/II	nn	10	SENT_248	[p17l1615t1290r1646b1315],
9	Sakamoto	NNP	PERSON	Sakamoto	nn	10	SENT_248	[p17l1846t1289r1984b1314],
10	etaI.	NNP	O	etaI.	dep	4	SENT_248	[p17l1992t1285r2085b1317],
11	,8	CD	NUMBER	,8	dep	14	SENT_248	[p17l1992t1285r2085b1317],
12	°	CD	NUMBER	°	num	14	SENT_248	[p17l1992t1285r2085b1317],
13	R05424802	NN	O	r05424802	nn	14	SENT_248	[p17l21t1330r178b1353],
14	Kinoshita	NNP	PERSON	Kinoshita	dep	18	SENT_248	[p17l1847t1329r1973b1353],
15	et	FW	O	et	nn	16	SENT_248	[p17l1981t1333r2007b1353],
16	aI.	FW	O	ai.	dep	14	SENT_248	[p17l2012t1325r2071b1357],
17	,8	CD	NUMBER	,8	num	18	SENT_248	[p17l2012t1325r2071b1357],
18	‘	CD	NUMBER	‘	dep	1	SENT_248	[p17l2012t1325r2071b1357],

1	Seto	NNP	PERSON	Seto	nn	2	SENT_249	[p17l1846t1369r1907b1392],
2	etaI	NNP	O	etaI	_	0	SENT_249	[p17l1914t1364r2000b1392],
3	.82	CD	NUMBER	.82	num	7	SENT_249	[p17l1914t1364r2000b1392],
4	AP26113	NNP	O	AP26113	nn	7	SENT_249	[p17l20t1427r141b1451],
5	Ariad	NNP	O	Ariad	nn	7	SENT_249	[p17l280t1426r351b1451],
6	Yes	NNP	O	Yes	nn	7	SENT_249	[p17l692t1427r735b1451],
7	EGFR	NN	O	egfr	dep	2	SENT_249	[p17l911t1427r980b1450],
8	(	CD	NUMBER	(	num	7	SENT_249	[p17l988t1426r1125b1457],
9	including	VBG	O	include	partmod	2	SENT_249	[p17l988t1426r1125b1457],
10	Investigational	JJ	O	investigational	amod	14	SENT_249	[p17l1230t1426r1430b1457],
11	Phase	NN	O	phase	nn	14	SENT_249	[p17l1528t1426r1606b1451],
12	I/II	NN	O	i/ii	nn	14	SENT_249	[p17l1615t1427r1646b1452],
13	Zhang	NNP	PERSON	Zhang	nn	14	SENT_249	[p17l1846t1426r1933b1457],
14	eraI.	NNP	O	eraI.	nsubj	18	SENT_249	[p17l1942t1422r2034b1454],
15	,83	CD	NUMBER	,83	num	14	SENT_249	[p17l1942t1422r2034b1454],
16	T790M	NN	O	t790m	nn	18	SENT_249	[p17l908t1466r1011b1494],
17	)	CD	NUMBER	)	num	18	SENT_249	[p17l908t1466r1011b1494],
18	Rivera	NNP	PERSON	Rivera	xcomp	9	SENT_249	[p17l1847t1467r1929b1490],
19	et	FW	O	et	nn	20	SENT_249	[p17l1937t1470r1962b1490],
20	aI.	FW	O	ai.	dep	18	SENT_249	[p17l1967t1462r2031b1494],
21	,84	CD	NUMBER	,84	num	22	SENT_249	[p17l1967t1462r2031b1494],
22	~	NN	O	~	dep	18	SENT_249	[p17l1910t1536r1914b1540],
23	85	CD	NUMBER	85	num	26	SENT_249	[p17l2039t1531r2062b1548],
24	ROS1	NN	O	ros1	nn	26	SENT_249	[p17l911t1554r977b1578],
25	Camidge	NN	O	camidge	nn	26	SENT_249	[p17l1846t1535r1969b1566],
26	etal	NN	O	etal	dep	22	SENT_249	[p17l1977t1535r2037b1559],
27	.	.	O	.	_	0	SENT_249	[p17l1977t1535r2037b1559],

1	ASP3026	NNP	O	ASP3026	nn	6	SENT_250	[p17l20t1617r141b1640],
2	Astellas	NNP	O	Astellas	nn	6	SENT_250	[p17l280t1616r384b1640],
3	Yes	NNP	O	Yes	nn	6	SENT_250	[p17l692t1617r735b1640],
4	ROS1	NNP	O	ROS1	nn	6	SENT_250	[p17l911t1617r977b1640],
5	Investigational	NNP	O	Investigational	nn	6	SENT_250	[p17l1230t1616r1430b1647],
6	Phase	NN	O	phase	_	0	SENT_250	[p17l1528t1616r1606b1640],
7	I	PRP	O	I	nsubj	8	SENT_250	[p17l1615t1617r1619b1640],
8	Kuromito	VBP	O	kuromito	rcmod	6	SENT_250	[p17l1847t1617r1974b1640],
9	etal.	FW	O	etal.	nn	14	SENT_250	[p17l1982t1612r2075b1644],
10	,87	CD	NUMBER	,87	num	11	SENT_250	[p17l1982t1612r2075b1644],
11	Patnaik	NN	PERSON	patnaik	dep	9	SENT_250	[p17l1847t1655r1947b1680],
12	etal	JJ	O	etal	amod	14	SENT_250	[p17l1954t1651r2040b1680],
13	.83	CD	NUMBER	.83	tmod	12	SENT_250	[p17l1954t1651r2040b1680],
14	X-396	NN	O	x-396	dobj	8	SENT_250	[p17l20t1715r98b1738],
15	Xcovery	NNP	O	Xcovery	nn	19	SENT_250	[p17l280t1715r390b1745],
16	Yes	NNP	O	Yes	nn	19	SENT_250	[p17l692t1715r735b1738],
17	Yes	NNP	O	Yes	nn	19	SENT_250	[p17l909t1715r953b1738],
18	Investigational	NNP	O	Investigational	nn	19	SENT_250	[p17l1230t1714r1430b1745],
19	Phase	NN	O	phase	dep	6	SENT_250	[p17l1528t1714r1606b1738],
20	I	PRP	O	I	nsubj	21	SENT_250	[p17l1615t1715r1619b1738],
21	Lovly	VBP	O	lovly	rcmod	19	SENT_250	[p17l1847t1714r1918b1745],
22	et	FW	O	et	nn	24	SENT_250	[p17l1925t1718r1950b1738],
23	aI	FW	O	ai	nn	24	SENT_250	[p17l1955t1710r2011b1738],
24	.85	FW	NUMBER	.85	dobj	21	SENT_250	[p17l1955t1710r2011b1738],
25	TSR	NN	O	tsr	dep	19	SENT_250	[p17l19t1773r108b1797],
26	.	.	O	.	_	0	SENT_250	[p17l19t1773r108b1797],

1	—	NN	O	—	_	0	SENT_251	[p17l19t1773r108b1797],
2	.	.	O	.	_	0	SENT_251	[p17l19t1773r108b1797],

1	Ol	NN	O	ol	nn	4	SENT_252	[p17l19t1773r108b1797],
2	1	CD	NUMBER	1	num	4	SENT_252	[p17l118t1774r125b1796],
3	Tesaro	NNP	O	Tesaro	nn	4	SENT_252	[p17l279t1773r367b1797],
4	Yes	NNP	O	Yes	nsubj	9	SENT_252	[p17l692t1773r735b1797],
5	Unknown	JJ	O	unknown	amod	7	SENT_252	[p17l911t1772r1042b1797],
6	Investigational	JJ	O	investigational	amod	7	SENT_252	[p17l1230t1772r1430b1803],
7	Phase	NN	O	phase	dep	4	SENT_252	[p17l1528t1772r1606b1797],
8	I	PRP	O	I	dep	4	SENT_252	[p17l1615t1773r1619b1796],
9	Wilcoxen	VBP	O	wilcoxen	_	0	SENT_252	[p17l1846t1772r1969b1797],
10	etal	JJ	O	etal	amod	11	SENT_252	[p17l1978t1768r2063b1797],
11	.85	NN	NUMBER	.85	dobj	9	SENT_252	[p17l1978t1768r2063b1797],

1	ALK	NNP	O	ALK	_	0	SENT_253	[p17l20t1858r72b1882],
2	,	,	O	,	_	0	SENT_253	[p17l20t1858r72b1882],
3	anaplastic	JJ	O	anaplastic	amod	5	SENT_253	[p17l79t1857r200b1884],
4	lymphoma	NN	O	lymphoma	nn	5	SENT_253	[p17l208t1857r336b1885],
5	kinase	NN	O	kinase	appos	1	SENT_253	[p17l345t1857r426b1882],
6	;	:	O	;	_	0	SENT_253	[p17l345t1857r426b1882],
7	EGFR	NN	ORGANIZATION	egfr	dep	1	SENT_253	[p17l438t1858r505b1882],
8	,	,	O	,	_	0	SENT_253	[p17l438t1858r505b1882],
9	epidermal	JJ	O	epidermal	amod	12	SENT_253	[p17l511t1857r633b1884],
10	growth	NN	O	growth	nn	12	SENT_253	[p17l640t1857r726b1885],
11	factor	NN	O	factor	nn	12	SENT_253	[p17l733t1857r804b1879],
12	receptor	NN	O	receptor	appos	7	SENT_253	[p17l811t1861r917b1884],
13	;	:	O	;	_	0	SENT_253	[p17l811t1861r917b1884],
14	IGF-1	NN	O	igf-1	nn	15	SENT_253	[p17l925t1858r982b1879],
15	R	NN	O	r	dep	1	SENT_253	[p17l989t1858r1008b1882],
16	,	,	O	,	_	0	SENT_253	[p17l989t1858r1008b1882],
17	insulin-like	JJ	O	insulin-like	amod	20	SENT_253	[p17l1015t1857r1144b1879],
18	growth	NN	O	growth	nn	20	SENT_253	[p17l1151t1857r1237b1885],
19	factor-1	NN	O	factor-1	nn	20	SENT_253	[p17l1244t1857r1333b1879],
20	receptor	NN	O	receptor	appos	15	SENT_253	[p17l1345t1861r1452b1884],
21	;	:	O	;	_	0	SENT_253	[p17l1345t1861r1452b1884],
22	ROS1	NN	O	ros1	dep	1	SENT_253	[p17l1460t1858r1528b1882],
23	,	,	O	,	_	0	SENT_253	[p17l1460t1858r1528b1882],
24	c-ros	NN	O	c-ro	nn	25	SENT_253	[p17l1535t1864r1592b1879],
25	oncogene	NN	O	oncogene	appos	22	SENT_253	[p17l1599t1864r1720b1885],
26	1	CD	NUMBER	1	dep	25	SENT_253	[p17l1728t1859r1746b1879],
27	.	.	O	.	_	0	SENT_253	[p17l1728t1859r1746b1879],

1	20	CD	NUMBER	20	num	2	SENT_254	[p17l20t1962r51b1983],
2	VOLUME	NN	O	volume	_	0	SENT_254	[p17l1367t1962r1475b1983],
3	95	CD	NUMBER	95	num	4	SENT_254	[p17l1483t1962r1510b1983],
4	NUMBER	NN	O	number	dep	2	SENT_254	[p17l1520t1962r1628b1983],
5	1	CD	NUMBER	1	number	6	SENT_254	[p17l1638t1963r1645b1983],
6	|	CD	NUMBER	|	dep	4	SENT_254	[p17l1659t1960r1661b1990],
7	JANUARY	NNP	DATE	JANUARY	dep	6	SENT_254	[p17l1670t1962r1788b1983],
8	2014	CD	DATE	2014	num	7	SENT_254	[p17l1796t1962r1854b1983],
9	|	CD	NUMBER	|	num	10	SENT_254	[p17l1863t1960r1865b1990],
10	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	2	SENT_254	[p17l1874t1962r2139b1988],

1	S	NN	O	s	_	0	SENT_255	[p17l1761t2105r1783b2142],
2	TAT	NN	O	tat	nn	5	SENT_255	[p17l1790t2105r1873b2142],
3	E	NN	O	e	nn	5	SENT_255	[p17l1882t2105r1902b2142],
4	A	NN	O	a	nn	5	SENT_255	[p17l2045t2105r2073b2142],
5	RT	NN	O	rt	dep	1	SENT_255	[p17l2082t2105r2139b2142],

1	three	CD	NUMBER	three	num	2	SENT_256	[p17l8t2338r182b2401],
2	patients	NNS	O	patient	_	0	SENT_256	[p17l202t2344r488b2421],
3	.	.	O	.	_	0	SENT_256	[p17l202t2344r488b2421],

1	The	DT	O	the	det	2	SENT_257	[p17l512t2338r636b2401],
2	drug	NN	O	drug	nsubjpass	5	SENT_257	[p17l658t2338r820b2422],
3	was	VBD	O	be	auxpass	5	SENT_257	[p17l836t2361r962b2401],
4	well	RB	O	well	advmod	5	SENT_257	[p17l982t2338r1119b2401],
5	tolerated	VBN	O	tolerate	ccomp	31	SENT_257	[p17l1138t2338r1457b2410],
6	,	,	O	,	_	0	SENT_257	[p17l1138t2338r1457b2410],
7	with	IN	O	with	_	0	SENT_257	[p17l1478t2338r1630b2401],
8	the	DT	O	the	det	12	SENT_257	[p17l1650t2338r1756b2401],
9	most	RBS	O	most	advmod	10	SENT_257	[p17l1777t2350r1946b2401],
10	common	JJ	O	common	amod	12	SENT_257	[p17l1966t2361r2140b2401, p17l8t2464r169b2504],
11	adverse	JJ	O	adverse	amod	12	SENT_257	[p17l193t2441r455b2504],
12	events	NNS	O	event	prep_with	5	SENT_257	[p17l480t2453r697b2504],
13	being	VBG	O	be	cop	16	SENT_257	[p17l719t2441r915b2525],
14	grade	NN	O	grade	nn	16	SENT_257	[p17l937t2441r1131b2525],
15	1	CD	NUMBER	1	num	16	SENT_257	[p17l1162t2448r1187b2503],
16	dysgeusia	NN	O	dysgeusium	partmod	12	SENT_257	[p17l1218t2441r1555b2525],
17	(	CD	PERCENT	(	number	18	SENT_257	[p17l1581t2441r1805b2518],
18	30	CD	PERCENT	30	num	19	SENT_257	[p17l1581t2441r1805b2518],
19	%	NN	PERCENT	%	tmod	16	SENT_257	[p17l1581t2441r1805b2518],
20	)	CD	NUMBER	)	dep	19	SENT_257	[p17l1581t2441r1805b2518],
21	,	,	O	,	_	0	SENT_257	[p17l1581t2441r1805b2518],
22	transient	JJ	O	transient	amod	25	SENT_257	[p17l1830t2447r2143b2504],
23	increased	VBN	O	increase	amod	25	SENT_257	[p17l9t2544r328b2607],
24	aspartate	NN	O	aspartate	nn	25	SENT_257	[p17l347t2556r647b2627],
25	aminotransferase	NN	O	aminotransferase	appos	19	SENT_257	[p17l668t2544r1248b2607],
26	(	CD	PERCENT	(	number	27	SENT_257	[p17l1272t2544r1487b2621],
27	28	CD	PERCENT	28	dep	28	SENT_257	[p17l1272t2544r1487b2621],
28	%	NN	PERCENT	%	dep	25	SENT_257	[p17l1272t2544r1487b2621],
29	)	CD	NUMBER	)	dep	19	SENT_257	[p17l1272t2544r1487b2621],
30	,	,	O	,	_	0	SENT_257	[p17l1272t2544r1487b2621],
31	increased	VBD	O	increase	_	0	SENT_257	[p17l1508t2544r1827b2607],
32	bilirubin	NN	O	bilirubin	iobj	31	SENT_257	[p17l1844t2544r2140b2607],
33	(	CD	PERCENT	(	number	34	SENT_257	[p17l12t2647r230b2724],
34	30	CD	PERCENT	30	num	35	SENT_257	[p17l12t2647r230b2724],
35	%	NN	PERCENT	%	dobj	31	SENT_257	[p17l12t2647r230b2724],
36	)	CD	NUMBER	)	dep	35	SENT_257	[p17l12t2647r230b2724],
37	,	,	O	,	_	0	SENT_257	[p17l12t2647r230b2724],
38	and	CC	O	and	_	0	SENT_257	[p17l254t2647r380b2710],
39	rash	JJ	O	rash	amod	40	SENT_257	[p17l401t2647r544b2710],
40	(	NN	O	(	conj_and	35	SENT_257	[p17l568t2648r786b2723],
41	28	CD	PERCENT	28	number	42	SENT_257	[p17l568t2648r786b2723],
42	%	NN	PERCENT	%	amod	40	SENT_257	[p17l568t2648r786b2723],
43	)	CD	NUMBER	)	nsubj	31	SENT_257	[p17l568t2648r786b2723],
44	.	.	O	.	_	0	SENT_257	[p17l568t2648r786b2723],

1	A	DT	O	a	det	4	SENT_258	[p17l808t2651r866b2709],
2	phase	NN	O	phase	nn	4	SENT_258	[p17l885t2647r1079b2730],
3	II	CD	NUMBER	ii	num	4	SENT_258	[p17l1102t2652r1155b2709],
4	study	NN	O	study	nsubj	12	SENT_258	[p17l1178t2647r1364b2731],
5	with	IN	O	with	_	0	SENT_258	[p17l1380t2647r1532b2710],
6	this	DT	O	this	det	7	SENT_258	[p17l1552t2647r1676b2710],
7	compound	NN	O	compound	prep_with	4	SENT_258	[p17l1699t2647r2071b2730],
8	is	VBZ	O	be	cop	12	SENT_258	[p17l2092t2653r2141b2710],
9	ongoing	JJ	O	ongoing	amod	12	SENT_258	[p17l9t2756r289b2834],
10	(	NN	O	(	nn	12	SENT_258	[p17l312t2751r887b2827],
11	NCT01871805	NN	O	nct01871805	nn	12	SENT_258	[p17l312t2751r887b2827],
12	)	NN	O	)	_	0	SENT_258	[p17l312t2751r887b2827],
13	.	.	O	.	_	0	SENT_258	[p17l312t2751r887b2827],

1	AP261	NN	O	ap261	nn	3	SENT_259	[p17l8t2965r224b3020],
2	13	CD	NUMBER	13	num	3	SENT_259	[p17l244t2966r320b3020],
3	AP26113	NN	O	ap26113	_	0	SENT_259	[p17l8t3064r322b3123],
4	(	CD	NUMBER	(	num	7	SENT_259	[p17l351t3060r577b3136],
5	Ariad	NNP	ORGANIZATION	Ariad	nn	7	SENT_259	[p17l351t3060r577b3136],
6	Pharmaceuticals	NNP	ORGANIZATION	Pharmaceuticals	nn	7	SENT_259	[p17l599t3060r1197b3137],
7	)	NN	O	)	nsubj	11	SENT_259	[p17l599t3060r1197b3137],
8	is	VBZ	O	be	cop	11	SENT_259	[p17l1224t3066r1275b3123],
9	a	DT	O	a	det	11	SENT_259	[p17l1299t3083r1334b3123],
10	novel	JJ	O	novel	amod	11	SENT_259	[p17l1355t3060r1542b3123],
11	inhibitor	NN	O	inhibitor	rcmod	3	SENT_259	[p17l1564t3060r1871b3123],
12	of	IN	O	of	_	0	SENT_259	[p17l1893t3060r1968b3123],
13	ALK	NN	O	alk	prep_of	11	SENT_259	[p17l1980t3064r2145b3122],

1	(	NN	O	(	nn	2	SENT_260	[p18l12t20r210b110],
2	IC50	NN	O	ic50	_	0	SENT_260	[p18l12t20r210b110],
3	:	:	O	:	_	0	SENT_260	[p18l12t20r210b110],
4	5-11	CD	NUMBER	5-11	num	6	SENT_260	[p18l244t26r409b82],
5	nmol/1	NN	O	nmol/1	nn	6	SENT_260	[p18l446t19r715b95],
6	)	NN	O	)	dep	2	SENT_260	[p18l446t19r715b95],
7	with	IN	O	with	_	0	SENT_260	[p18l747t19r907b82],
8	activity	NN	O	activity	prep_with	6	SENT_260	[p18l938t25r1206b103],
9	against	IN	O	against	_	0	SENT_260	[p18l1232t25r1485b103],
10	the	DT	O	the	det	18	SENT_260	[p18l1513t19r1624b82],
11	ALK	NNP	O	ALK	nn	18	SENT_260	[p18l1653t23r1822b81],
12	tyrosine	NN	O	tyrosine	nn	18	SENT_260	[p18l1849t25r2142b103],
13	kinase	NN	O	kinase	nn	18	SENT_260	[p18l7t121r226b184],
14	gatekeeper	NN	O	gatekeeper	nn	18	SENT_260	[p18l248t121r616b205],
15	mutation	NN	O	mutation	nn	18	SENT_260	[p18l637t127r953b184],
16	L1196M	NN	O	l1196m	nn	18	SENT_260	[p18l975t126r1261b184],
17	(	CD	NUMBER	(	num	18	SENT_260	[p18l1287t121r1476b212],
18	IC50	NN	O	ic50	prep_against	8	SENT_260	[p18l1287t121r1476b212],
19	:	:	O	:	_	0	SENT_260	[p18l1287t121r1476b212],
20	15-45	CD	NUMBER	15-45	num	22	SENT_260	[p18l1509t128r1707b184],
21	nmol/l	NN	O	nmol/l	nn	22	SENT_260	[p18l1732t121r1988b197],
22	)	NN	O	)	dep	2	SENT_260	[p18l1732t121r1988b197],
23	and	CC	O	and	_	0	SENT_260	[p18l2016t121r2143b184],
24	other	JJ	O	other	amod	27	SENT_260	[p18l9t223r189b286],
25	ALK	NN	O	alk	nn	27	SENT_260	[p18l204t227r369b285],
26	resistance	NN	O	resistance	nn	27	SENT_260	[p18l383t229r712b286],
27	mutations	NNS	O	mutation	conj_and	22	SENT_260	[p18l732t215r1152b286],
28	.	.	O	.	_	0	SENT_260	[p18l732t215r1152b286],

1	“	NN	O	“	dep	103	SENT_261	[p18l732t215r1152b286],
2	This	DT	O	this	dep	103	SENT_261	[p18l1174t223r1316b286],
3	compound	NN	O	compound	dep	103	SENT_261	[p18l1337t223r1707b306],
4	is	VBZ	O	be	dep	103	SENT_261	[p18l1726t229r1776b286],
5	also	RB	O	also	dep	103	SENT_261	[p18l1797t223r1926b286],
6	active	JJ	O	active	dep	103	SENT_261	[p18l1949t229r2142b286],
7	against	IN	O	against	dep	103	SENT_261	[p18l9t332r242b410],
8	ROS1	NN	O	ros1	dep	103	SENT_261	[p18l261t330r446b389],
9	and	CC	O	and	dep	103	SENT_261	[p18l472t326r612b398],
10	,	,	O	,	_	0	SENT_261	[p18l472t326r612b398],
11	to	TO	O	to	dep	103	SENT_261	[p18l632t338r696b389],
12	a	DT	O	a	dep	103	SENT_261	[p18l717t349r751b389],
13	lesser	JJR	O	lesser	dep	103	SENT_261	[p18l768t326r953b389],
14	extent	NN	O	extent	dep	103	SENT_261	[p18l971t338r1191b398],
15	,	,	O	,	_	0	SENT_261	[p18l971t338r1191b398],
16	mutant	JJ	O	mutant	dep	103	SENT_261	[p18l1211t338r1453b389],
17	EGFR	NN	ORGANIZATION	egfr	dep	103	SENT_261	[p18l1469t330r1668b389],
18	harboring	VBG	O	harbor	dep	103	SENT_261	[p18l1685t326r2022b410],
19	the	DT	O	the	dep	103	SENT_261	[p18l2038t326r2142b389],
20	gatekeeper	NN	O	gatekeeper	dep	103	SENT_261	[p18l8t428r379b512],
21	T790M	NN	O	t790m	dep	103	SENT_261	[p18l400t431r653b491],
22	mutation	NN	O	mutation	dep	103	SENT_261	[p18l676t420r1077b491],
23	.84	CD	NUMBER	.84	dep	103	SENT_261	[p18l676t420r1077b491],
24	In	IN	O	in	dep	103	SENT_261	[p18l1099t433r1171b490],
25	an	DT	O	a	dep	103	SENT_261	[p18l1195t451r1275b491],
26	ongoing	JJ	O	ongoing	dep	103	SENT_261	[p18l1298t434r1581b512],
27	phase	NN	O	phase	dep	103	SENT_261	[p18l1600t428r1797b511],
28	I	PRP	O	I	dep	103	SENT_261	[p18l1820t432r1873b494],
29	/	:	O	/	dep	103	SENT_261	[p18l1820t432r1873b494],
30	II	CD	NUMBER	ii	dep	103	SENT_261	[p18l1879t433r1932b490],
31	study	NN	O	study	dep	103	SENT_261	[p18l1957t428r2145b512],
32	(	CD	NUMBER	(	dep	103	SENT_261	[p18l12t532r603b607],
33	NCTO1449461	NN	O	ncto1449461	dep	103	SENT_261	[p18l12t532r603b607],
34	)	NN	O	)	dep	103	SENT_261	[p18l12t532r603b607],
35	,	,	O	,	_	0	SENT_261	[p18l12t532r603b607],
36	the	DT	O	the	dep	103	SENT_261	[p18l629t531r738b594],
37	recommended	VBN	O	recommend	dep	103	SENT_261	[p18l762t531r1273b594],
38	phase	NN	O	phase	dep	103	SENT_261	[p18l1295t531r1494b614],
39	II	CD	NUMBER	ii	dep	103	SENT_261	[p18l1519t536r1574b593],
40	dose	NN	O	dose	dep	103	SENT_261	[p18l1600t531r1758b594],
41	was	VBD	O	be	dep	103	SENT_261	[p18l1781t554r1909b594],
42	determined	VBN	O	determine	dep	103	SENT_261	[p18l1935t531r2139b594, p18l8t634r222b697],
43	to	TO	O	to	dep	103	SENT_261	[p18l238t646r302b697],
44	be	VB	O	be	dep	103	SENT_261	[p18l320t634r397b697],
45	180	CD	NUMBER	180	dep	103	SENT_261	[p18l422t641r531b697],
46	mg	NN	O	mg	dep	103	SENT_261	[p18l545t657r650b718],
47	once	RB	DATE	once	dep	103	SENT_261	[p18l668t657r821b697],
48	daily	RB	SET	daily	dep	103	SENT_261	[p18l840t634r1007b718],
49	,	,	O	,	_	0	SENT_261	[p18l840t634r1007b718],
50	and	CC	O	and	dep	103	SENT_261	[p18l1028t634r1150b697],
51	antitumor	NN	O	antitumor	dep	103	SENT_261	[p18l1168t640r1500b697],
52	activity	NN	O	activity	dep	103	SENT_261	[p18l1518t640r1760b718],
53	was	VBD	O	be	dep	103	SENT_261	[p18l1773t657r1895b697],
54	seen	VBN	O	see	dep	103	SENT_261	[p18l1915t657r2058b697],
55	in	IN	O	in	dep	103	SENT_261	[p18l2077t640r2142b696],
56	patients	NNS	O	patient	dep	103	SENT_261	[p18l7t742r269b819],
57	with	IN	O	with	dep	103	SENT_261	[p18l287t736r436b799],
58	advanced	JJ	O	advanced	dep	103	SENT_261	[p18l457t736r788b808],
59	,	,	O	,	_	0	SENT_261	[p18l457t736r788b808],
60	ALK-positive	JJ	O	alk-positive	dep	103	SENT_261	[p18l807t740r1257b819],
61	NSCLC85	NN	O	nsclc85	dep	103	SENT_261	[p18l1276t728r1611b800],
62	Of	IN	O	of	dep	103	SENT_261	[p18l1633t736r1726b800],
63	the	DT	O	the	dep	103	SENT_261	[p18l1734t736r1838b799],
64	24	CD	NUMBER	24	dep	103	SENT_261	[p18l1858t743r1935b798],
65	ALKpositive	JJ	O	alkpositive	dep	103	SENT_261	[p18l1954t740r2139b798, p18l7t845r267b922],
66	NSCLC	NN	ORGANIZATION	nsclc	dep	103	SENT_261	[p18l286t843r544b902],
67	patients	NNS	O	patient	dep	103	SENT_261	[p18l563t845r825b922],
68	enrolled	VBN	O	enrol	dep	103	SENT_261	[p18l846t839r1122b902],
69	in	IN	O	in	dep	103	SENT_261	[p18l1140t845r1205b901],
70	the	DT	O	the	dep	103	SENT_261	[p18l1223t839r1328b902],
71	study	NN	O	study	dep	103	SENT_261	[p18l1348t839r1538b923],
72	,	,	O	,	_	0	SENT_261	[p18l1348t839r1538b923],
73	15	CD	PERCENT	15	dep	103	SENT_261	[p18l1565t846r1634b902],
74	(	CD	PERCENT	(	dep	103	SENT_261	[p18l1659t839r1852b916],
75	63	CD	PERCENT	63	dep	103	SENT_261	[p18l1659t839r1852b916],
76	%	NN	PERCENT	%	dep	103	SENT_261	[p18l1659t839r1852b916],
77	)	CD	NUMBER	)	dep	103	SENT_261	[p18l1659t839r1852b916],
78	demonstrated	VBD	O	demonstrate	dep	103	SENT_261	[p18l1876t839r2137b902, p18l9t942r238b1005],
79	objective	JJ	O	objective	dep	103	SENT_261	[p18l260t942r561b1026],
80	responses	NNS	O	response	dep	103	SENT_261	[p18l583t964r911b1025],
81	(	VBP	O	(	dep	103	SENT_261	[p18l937t943r995b1018],
82	1	CD	NUMBER	1	dep	103	SENT_261	[p18l937t943r995b1018],
83	complete	JJ	O	complete	dep	103	SENT_261	[p18l1024t942r1331b1025],
84	response	NN	O	response	dep	103	SENT_261	[p18l1353t964r1650b1025],
85	and	CC	O	and	dep	103	SENT_261	[p18l1673t942r1798b1005],
86	14	CD	NUMBER	14	dep	103	SENT_261	[p18l1826t949r1897b1004],
87	partial	JJ	O	partial	dep	103	SENT_261	[p18l1919t942r2140b1025],
88	responses	NNS	O	response	dep	103	SENT_261	[p18l9t1046r396b1128],
89	)	RB	O	)	dep	103	SENT_261	[p18l9t1046r396b1128],
90	,	,	O	,	_	0	SENT_261	[p18l9t1046r396b1128],
91	including	VBG	O	include	dep	103	SENT_261	[p18l420t1045r753b1129],
92	12	CD	TIME	12	dep	103	SENT_261	[p18l781t1052r853b1107],
93	of	IN	TIME	of	dep	103	SENT_261	[p18l879t1045r954b1108],
94	16	CD	TIME	16	dep	103	SENT_261	[p18l974t1051r1047b1108],
95	(	CD	PERCENT	(	dep	103	SENT_261	[p18l1074t1045r1275b1122],
96	75	CD	PERCENT	75	dep	103	SENT_261	[p18l1074t1045r1275b1122],
97	%	NN	PERCENT	%	dep	103	SENT_261	[p18l1074t1045r1275b1122],
98	)	CD	NUMBER	)	dep	103	SENT_261	[p18l1074t1045r1275b1122],
99	with	IN	O	with	dep	103	SENT_261	[p18l1300t1045r1456b1108],
100	crizotinib	JJ	O	crizotinib	dep	103	SENT_261	[p18l1479t1045r2145b1108],
101	—	NN	O	—	dep	103	SENT_261	[p18l1479t1045r2145b1108],
102	resistant	JJ	O	resistant	dep	103	SENT_261	[p18l1479t1045r2145b1108],
103	tumors	NNS	O	tumor	_	0	SENT_261	[p18l8t1160r260b1211],
104	.	.	O	.	_	0	SENT_261	[p18l8t1160r260b1211],

1	Signiﬁcantly	NNP	O	Signiﬁcantly	nsubj	7	SENT_262	[p18l283t1148r702b1232],
2	,	,	O	,	_	0	SENT_262	[p18l283t1148r702b1232],
3	four	CD	NUMBER	four	appos	1	SENT_262	[p18l722t1148r860b1211],
4	of	IN	O	of	_	0	SENT_262	[p18l879t1148r950b1211],
5	ﬁve	NN	O	ﬁve	nn	6	SENT_262	[p18l959t1148r1073b1211],
6	patients	NNS	O	patient	prep_of	3	SENT_262	[p18l1091t1154r1350b1231],
7	had	VBD	O	have	_	0	SENT_262	[p18l1368t1148r1492b1211],
8	objective	JJ	O	objective	amod	9	SENT_262	[p18l1510t1148r1803b1232],
9	responses	NNS	O	response	dobj	7	SENT_262	[p18l1822t1170r2141b1231],
10	in	IN	O	in	_	0	SENT_262	[p18l9t1256r73b1312],
11	CNS	NN	O	cn	nn	12	SENT_262	[p18l93t1254r246b1313],
12	metastases	NNS	O	metastase	prep_in	9	SENT_262	[p18l266t1262r634b1313],
13	.	.	O	.	_	0	SENT_262	[p18l266t1262r634b1313],

1	The	DT	O	the	det	5	SENT_263	[p18l656t1250r779b1313],
2	most	RBS	O	most	advmod	3	SENT_263	[p18l798t1262r962b1313],
3	common	JJ	O	common	amod	5	SENT_263	[p18l981t1273r1279b1313],
4	treatment	NN	O	treatment	nn	5	SENT_263	[p18l1297t1250r1878b1313],
5	—	NN	O	—	nsubj	10	SENT_263	[p18l1297t1250r1878b1313],
6	related	JJ	O	related	amod	5	SENT_263	[p18l1297t1250r1878b1313],
7	adverse	JJ	O	adverse	amod	8	SENT_263	[p18l1896t1250r2143b1313],
8	events	NNS	O	event	dep	6	SENT_263	[p18l9t1365r219b1416],
9	were	VBD	O	be	cop	10	SENT_263	[p18l237t1376r396b1416],
10	nausea	NN	O	nausea	_	0	SENT_263	[p18l416t1376r648b1416],
11	(	CD	PERCENT	(	num	10	SENT_263	[p18l670t1354r886b1430],
12	33	CD	PERCENT	33	number	13	SENT_263	[p18l670t1354r886b1430],
13	%	NN	PERCENT	%	amod	10	SENT_263	[p18l670t1354r886b1430],
14	)	CD	NUMBER	)	dep	10	SENT_263	[p18l670t1354r886b1430],
15	,	,	O	,	_	0	SENT_263	[p18l670t1354r886b1430],
16	fatigue	NN	O	fatigue	conj_and	10	SENT_263	[p18l908t1353r1135b1437],
17	(	CD	PERCENT	(	number	18	SENT_263	[p18l1159t1354r1376b1430],
18	22	CD	PERCENT	22	num	19	SENT_263	[p18l1159t1354r1376b1430],
19	%	NN	PERCENT	%	dep	16	SENT_263	[p18l1159t1354r1376b1430],
20	)	CD	NUMBER	)	dep	16	SENT_263	[p18l1159t1354r1376b1430],
21	,	,	O	,	_	0	SENT_263	[p18l1159t1354r1376b1430],
22	and	CC	O	and	_	0	SENT_263	[p18l1398t1353r1523b1416],
23	diarrhea	NN	O	diarrhea	conj_and	10	SENT_263	[p18l1542t1353r1827b1416],
24	(	CD	PERCENT	(	number	25	SENT_263	[p18l1849t1353r2064b1430],
25	20	CD	PERCENT	20	num	26	SENT_263	[p18l1849t1353r2064b1430],
26	%	NN	PERCENT	%	dep	23	SENT_263	[p18l1849t1353r2064b1430],
27	)	CD	NUMBER	)	dep	23	SENT_263	[p18l1849t1353r2064b1430],
28	.	.	O	.	_	0	SENT_263	[p18l1849t1353r2064b1430],

1	A	DT	O	a	det	5	SENT_264	[p18l2086t1357r2143b1415],
2	conﬁrmatory	JJ	O	conﬁrmatory	amod	5	SENT_264	[p18l9t1456r459b1540],
3	phase	NN	O	phase	nn	5	SENT_264	[p18l475t1456r668b1539],
4	II	CD	NUMBER	ii	num	5	SENT_264	[p18l689t1461r742b1518],
5	study	NN	O	study	nsubjpass	10	SENT_264	[p18l765t1456r949b1540],
6	of	IN	O	of	_	0	SENT_264	[p18l967t1456r1040b1519],
7	AP261	NN	O	ap261	prep_of	5	SENT_264	[p18l1050t1460r1272b1519],
8	13	CD	NUMBER	13	num	7	SENT_264	[p18l1288t1463r1357b1519],
9	is	VBZ	O	be	auxpass	10	SENT_264	[p18l1381t1462r1431b1519],
10	planned	VBN	O	plan	_	0	SENT_264	[p18l1451t1456r1742b1539],
11	.	.	O	.	_	0	SENT_264	[p18l1451t1456r1742b1539],

1	Several	JJ	O	several	amod	4	SENT_265	[p18l83t1559r338b1622],
2	other	JJ	O	other	amod	4	SENT_265	[p18l365t1559r554b1622],
3	ALK	NN	O	alk	nn	4	SENT_265	[p18l578t1563r746b1621],
4	inhibitors	NNS	O	inhibitor	nsubj	5	SENT_265	[p18l772t1559r1120b1622],
5	are	VBP	O	be	_	0	SENT_265	[p18l1148t1582r1252b1622],
6	in	IN	O	in	_	0	SENT_265	[p18l1279t1565r1348b1621],
7	clinical	JJ	O	clinical	amod	8	SENT_265	[p18l1375t1559r1632b1622],
8	development	NN	O	development	prep_in	5	SENT_265	[p18l1659t1559r2140b1642],
9	,	,	O	,	_	0	SENT_265	[p18l1659t1559r2140b1642],
10	including	VBG	O	include	_	0	SENT_265	[p18l9t1661r363b1745],
11	X-396	NN	O	x-396	nn	14	SENT_265	[p18l393t1666r616b1724],
12	(	CD	NUMBER	(	num	14	SENT_265	[p18l655t1653r1087b1745],
13	Xcovery	NN	O	xcovery	nn	14	SENT_265	[p18l655t1653r1087b1745],
14	)	NN	O	)	prep_including	5	SENT_265	[p18l655t1653r1087b1745],
15	86	CD	NUMBER	86	number	16	SENT_265	[p18l655t1653r1087b1745],
16	(	CD	NUMBER	(	num	18	SENT_265	[p18l1124t1662r1747b1738],
17	NCTO1625234	NN	O	ncto1625234	nn	18	SENT_265	[p18l1124t1662r1747b1738],
18	)	NN	O	)	dep	14	SENT_265	[p18l1124t1662r1747b1738],
19	,	,	O	,	_	0	SENT_265	[p18l1124t1662r1747b1738],
20	ASP	NN	O	asp	nn	24	SENT_265	[p18l1782t1665r1933b1724],
21	3026	CD	NUMBER	3026	num	24	SENT_265	[p18l1970t1667r2141b1724],
22	(	CD	NUMBER	(	num	24	SENT_265	[p18l12t1764r293b1841],
23	Astellas	NNP	ORGANIZATION	Astellas	nn	24	SENT_265	[p18l12t1764r293b1841],
24	Pharma	NNP	ORGANIZATION	Pharma	conj_and	14	SENT_265	[p18l315t1756r741b1841],
25	)	CD	NUMBER	)	number	26	SENT_265	[p18l315t1756r741b1841],
26	87	CD	NUMBER	87	dep	24	SENT_265	[p18l315t1756r741b1841],
27	’88	CD	NUMBER	’88	number	28	SENT_265	[p18l315t1756r741b1841],
28	(	CD	NUMBER	(	num	30	SENT_265	[p18l766t1765r1331b1841],
29	NCTO1284192	NN	O	ncto1284192	nn	30	SENT_265	[p18l766t1765r1331b1841],
30	)	NN	O	)	dep	24	SENT_265	[p18l766t1765r1331b1841],
31	,	,	O	,	_	0	SENT_265	[p18l766t1765r1331b1841],
32	and	CC	O	and	_	0	SENT_265	[p18l1354t1764r1477b1828],
33	TSR-011	NN	O	tsr-011	nn	35	SENT_265	[p18l1496t1767r1779b1828],
34	(	CD	NUMBER	(	num	35	SENT_265	[p18l1809t1756r2141b1841],
35	Tesaro	NNP	O	Tesaro	conj_and	14	SENT_265	[p18l1809t1756r2141b1841],
36	)	CD	NUMBER	)	number	37	SENT_265	[p18l1809t1756r2141b1841],
37	89	CD	NUMBER	89	num	38	SENT_265	[p18l1809t1756r2141b1841],
38	(	NN	O	(	dep	35	SENT_265	[p18l12t1867r466b1944],
39	summarized	VBN	O	summarize	partmod	35	SENT_265	[p18l12t1867r466b1944],
40	in	IN	O	in	_	0	SENT_265	[p18l487t1873r553b1930],
41	Table	NNP	O	Table	prep_in	39	SENT_265	[p18l574t1868r766b1930],
42	1	CD	NUMBER	1	number	43	SENT_265	[p18l792t1868r873b1944],
43	)	CD	NUMBER	)	dep	41	SENT_265	[p18l792t1868r873b1944],
44	.	.	O	.	_	0	SENT_265	[p18l792t1868r873b1944],

1	HSP9O	NN	O	hsp9o	nn	2	SENT_266	[p18l12t2082r238b2137],
2	INHIBITORS	NNS	O	inhibitor	_	0	SENT_266	[p18l259t2081r675b2137],

1	Another	DT	O	another	det	2	SENT_267	[p18l8t2177r307b2240],
2	class	NN	O	class	nsubj	20	SENT_267	[p18l332t2177r492b2240],
3	of	IN	O	of	_	0	SENT_267	[p18l519t2177r595b2240],
4	drugs	NNS	O	drug	prep_of	2	SENT_267	[p18l611t2177r810b2261],
5	with	IN	O	with	_	0	SENT_267	[p18l834t2177r992b2240],
6	activity	NN	O	activity	prep_with	4	SENT_267	[p18l1018t2183r1281b2261],
7	in	IN	O	in	_	0	SENT_267	[p18l1303t2183r1371b2239],
8	preclinical	JJ	O	preclinical	amod	9	SENT_267	[p18l1396t2177r1770b2260],
9	models	NNS	O	model	prep_in	6	SENT_267	[p18l1794t2177r2049b2240],
10	of	IN	O	of	_	0	SENT_267	[p18l2076t2177r2152b2240],
11	ALK-driven	JJ	O	alk-driven	amod	12	SENT_267	[p18l8t2280r447b2343],
12	cancers	NNS	O	cancer	prep_of	9	SENT_267	[p18l477t2303r743b2343],
13	and	CC	O	and	_	0	SENT_267	[p18l774t2280r906b2343],
14	in	IN	O	in	_	0	SENT_267	[p18l935t2286r1004b2342],
15	clinical	JJ	O	clinical	amod	16	SENT_267	[p18l1034t2280r1295b2343],
16	trials	NNS	O	trial	prep_in	4	SENT_267	[p18l1322t2280r1505b2343],
17	on	IN	O	on	_	0	SENT_267	[p18l1536t2303r1625b2343],
18	ALK-positive	JJ	O	alk-positive	amod	19	SENT_267	[p18l1653t2284r2141b2363],
19	NSCLCS	NN	O	nsclc	prep_on	16	SENT_267	[p18l8t2386r307b2446],
20	comprises	VBZ	O	comprise	_	0	SENT_267	[p18l332t2388r683b2465],
21	the	DT	O	the	det	23	SENT_267	[p18l706t2382r814b2445],
22	HSP9O	NN	O	hsp9o	nn	23	SENT_267	[p18l839t2386r1075b2446],
23	inhibitors	NNS	O	inhibitor	dobj	20	SENT_267	[p18l1100t2382r1457b2445],
24	.	.	O	.	_	0	SENT_267	[p18l1100t2382r1457b2445],

1	Both	DT	O	both	_	0	SENT_268	[p18l1484t2382r1651b2445],
2	NPM	NNP	O	NPM	dep	1	SENT_268	[p18l1674t2374r2142b2445],
3	.	.	O	.	_	0	SENT_268	[p18l1674t2374r2142b2445],

1	—	NN	O	—	_	0	SENT_269	[p18l1674t2374r2142b2445],
2	.	.	O	.	_	0	SENT_269	[p18l1674t2374r2142b2445],

1	ALK9	NN	O	alk9	_	0	SENT_270	[p18l1674t2374r2142b2445],
2	°	NN	O	°	dep	1	SENT_270	[p18l1674t2374r2142b2445],
3	and	CC	O	and	_	0	SENT_270	[p18l9t2485r142b2548],
4	EML	NN	O	eml	dep	1	SENT_270	[p18l173t2489r571b2547],
5	.	.	O	.	_	0	SENT_270	[p18l173t2489r571b2547],

1	—	NN	O	—	_	0	SENT_271	[p18l173t2489r571b2547],
2	.	.	O	.	_	0	SENT_271	[p18l173t2489r571b2547],

1	ALK	NNP	O	ALK	nsubjpass	4	SENT_272	[p18l173t2489r571b2547],
2	have	VBP	O	have	aux	4	SENT_272	[p18l600t2485r765b2548],
3	been	VBN	O	be	auxpass	4	SENT_272	[p18l794t2485r968b2548],
4	shown	VBN	O	show	_	0	SENT_272	[p18l1000t2485r1235b2548],
5	to	TO	O	to	aux	8	SENT_272	[p18l1265t2497r1334b2548],
6	be	VB	O	be	cop	8	SENT_272	[p18l1365t2485r1448b2548],
7	client	NN	O	client	nn	8	SENT_272	[p18l1480t2485r1681b2548],
8	proteins	NNS	O	protein	xcomp	4	SENT_272	[p18l1710t2491r2009b2568],
9	for	IN	O	for	_	0	SENT_272	[p18l2041t2485r2144b2548],
10	HSP90	NN	O	hsp90	prep_for	8	SENT_272	[p18l9t2579r503b2650],
11	.23	CD	NUMBER	.23	number	12	SENT_272	[p18l9t2579r503b2650],
12	’	CD	NUMBER	’	dep	10	SENT_272	[p18l9t2579r503b2650],
13	91	CD	NUMBER	91	num	14	SENT_272	[p18l9t2579r503b2650],
14	‘	NN	O	‘	dep	12	SENT_272	[p18l9t2579r503b2650],
15	94	CD	NUMBER	94	num	16	SENT_272	[p18l9t2579r503b2650],
16	Treatment	NN	O	treatment	dep	12	SENT_272	[p18l525t2590r883b2650],
17	of	IN	O	of	_	0	SENT_272	[p18l906t2587r980b2650],
18	EML4	NN	O	eml4	prep_of	16	SENT_272	[p18l993t2587r1800b2671],
19	.	.	O	.	_	0	SENT_272	[p18l993t2587r1800b2671],

1	—	NN	O	—	_	0	SENT_273	[p18l993t2587r1800b2671],
2	.	.	O	.	_	0	SENT_273	[p18l993t2587r1800b2671],

1	ALK	NNP	O	ALK	_	0	SENT_274	[p18l993t2587r1800b2671],
2	.	.	O	.	_	0	SENT_274	[p18l993t2587r1800b2671],

1	—	NN	O	—	_	0	SENT_275	[p18l993t2587r1800b2671],
2	.	.	O	.	_	0	SENT_275	[p18l993t2587r1800b2671],

1	harboring	VBG	O	harbor	partmod	25	SENT_276	[p18l993t2587r1800b2671],
2	cells	NNS	O	cell	dobj	1	SENT_276	[p18l1822t2587r1967b2650],
3	with	IN	O	with	_	0	SENT_276	[p18l1989t2587r2143b2650],
4	HSP9O	NN	O	hsp9o	nn	5	SENT_276	[p18l9t2694r245b2753],
5	inhibitors	NNS	O	inhibitor	prep_with	1	SENT_276	[p18l270t2690r627b2762],
6	,	,	O	,	_	0	SENT_276	[p18l270t2690r627b2762],
7	such	JJ	O	such	nsubj	41	SENT_276	[p18l654t2690r811b2753],
8	as	IN	O	as	_	0	SENT_276	[p18l834t2713r900b2753],
9	17	CD	NUMBER	17	prep_as	7	SENT_276	[p18l931t2697r1003b2753],
10	-	:	O	-	_	0	SENT_276	[p18l1011t2694r1236b2762],
11	AAG	NN	ORGANIZATION	aag	dep	7	SENT_276	[p18l1011t2694r1236b2762],
12	,	,	O	,	_	0	SENT_276	[p18l1011t2694r1236b2762],
13	17	CD	NUMBER	17	appos	11	SENT_276	[p18l1267t2697r1340b2753],
14	-	:	O	-	_	0	SENT_276	[p18l1348t2694r1653b2762],
15	DMAG	NN	O	dmag	dep	7	SENT_276	[p18l1348t2694r1653b2762],
16	,	,	O	,	_	0	SENT_276	[p18l1348t2694r1653b2762],
17	or	CC	O	or	_	0	SENT_276	[p18l1679t2713r1752b2753],
18	ganetespib	NN	O	ganetespib	nn	20	SENT_276	[p18l1774t2690r2142b2774],
19	(	CD	NUMBER	(	num	20	SENT_276	[p18l12t2794r404b2869],
20	STA-9090	NN	O	sta-9090	conj_or	15	SENT_276	[p18l12t2794r404b2869],
21	;	:	O	;	_	0	SENT_276	[p18l12t2794r404b2869],
22	Synta	NNP	ORGANIZATION	Synta	nn	23	SENT_276	[p18l432t2793r673b2877],
23	)	NNP	O	)	dep	7	SENT_276	[p18l432t2793r673b2877],
24	,	,	O	,	_	0	SENT_276	[p18l432t2793r673b2877],
25	reduces	VBZ	O	reduce	_	0	SENT_276	[p18l699t2793r966b2856],
26	protein	NN	O	protein	nn	27	SENT_276	[p18l990t2799r1247b2876],
27	levels	NNS	O	level	dobj	25	SENT_276	[p18l1270t2793r1461b2856],
28	of	IN	O	of	_	0	SENT_276	[p18l1487t2793r1563b2856],
29	the	DT	O	the	det	31	SENT_276	[p18l1576t2793r1686b2856],
30	ALK	NNP	O	ALK	nn	31	SENT_276	[p18l1710t2797r1877b2855],
31	fusion	NN	O	fusion	prep_of	27	SENT_276	[p18l1900t2793r2139b2865],
32	,	,	O	,	_	0	SENT_276	[p18l1900t2793r2139b2865],
33	resulting	VBG	O	result	partmod	27	SENT_276	[p18l9t2896r319b2980],
34	in	IN	O	in	_	0	SENT_276	[p18l343t2902r410b2958],
35	cell	NN	O	cell	nn	36	SENT_276	[p18l436t2896r553b2959],
36	death	NN	O	death	prep_in	33	SENT_276	[p18l577t2896r771b2959],
37	in	FW	O	in	nn	38	SENT_276	[p18l798t2902r860b2959],
38	vitro	FW	O	vitro	advmod	33	SENT_276	[p18l887t2902r1065b2968],
39	,	,	O	,	_	0	SENT_276	[p18l887t2902r1065b2968],
40	and	CC	O	and	_	0	SENT_276	[p18l1092t2896r1221b2959],
41	leads	VBZ	O	lead	conj_and	25	SENT_276	[p18l1244t2896r1420b2959],
42	to	TO	O	to	_	0	SENT_276	[p18l1444t2908r1512b2959],
43	tumor	NN	O	tumor	nn	44	SENT_276	[p18l1536t2908r1758b2959],
44	regression	NN	O	regression	prep_to	41	SENT_276	[p18l1781t2902r2142b2980],
45	in	IN	O	in	prep	41	SENT_276	[p18l9t3005r77b3061],
46	in	FW	O	in	dep	45	SENT_276	[p18l104t3005r166b3062],
47	vivo	FW	O	vivo	nn	48	SENT_276	[p18l193t3005r333b3062],
48	models	NNS	O	model	pobj	46	SENT_276	[p18l357t2999r629b3062],
49	.	.	O	.	_	0	SENT_276	[p18l357t2999r629b3062],

1	Consistent	JJ	O	consistent	nsubjpass	11	SENT_277	[p18l658t3003r1035b3062],
2	with	IN	O	with	_	0	SENT_277	[p18l1056t2999r1214b3062],
3	these	DT	O	these	det	5	SENT_277	[p18l1236t2999r1418b3062],
4	preclinical	JJ	O	preclinical	amod	5	SENT_277	[p18l1441t2999r1812b3082],
5	ﬁndings	NNS	O	ﬁndings	prep_with	1	SENT_277	[p18l1836t2999r2140b3083],
6	,	,	O	,	_	0	SENT_277	[p18l1836t2999r2140b3083],
7	antitumor	NN	O	antitumor	nn	8	SENT_277	[p18l9t3108r368b3165],
8	activity	NN	O	activity	appos	5	SENT_277	[p18l393t3108r655b3186],
9	has	VBZ	O	have	aux	11	SENT_277	[p18l676t3102r792b3165],
10	been	VBN	O	be	auxpass	11	SENT_277	[p18l816t3102r985b3165],
11	observed	VBN	O	observe	_	0	SENT_277	[p18l1011t3102r1333b3165],
12	in	IN	O	in	_	0	SENT_277	[p18l1358t3108r1426b3164],
13	single	JJ	O	single	amod	18	SENT_277	[p18l1452t3102r1834b3186],
14	—	NN	O	—	nn	18	SENT_277	[p18l1452t3102r1834b3186],
15	arm	NN	O	arm	nn	18	SENT_277	[p18l1452t3102r1834b3186],
16	phase	NN	O	phase	nn	18	SENT_277	[p18l1858t3102r2060b3185],
17	II	CD	NUMBER	ii	num	18	SENT_277	[p18l2086t3107r2141b3164],
18	studies	NNS	O	study	prep_in	11	SENT_277	[p18l9t3205r249b3268],
19	with	IN	O	with	_	0	SENT_277	[p18l271t3205r426b3268],
20	several	JJ	O	several	amod	22	SENT_277	[p18l451t3205r689b3268],
21	HSP90	NN	O	hsp90	nn	22	SENT_277	[p18l713t3209r949b3268],
22	inhibitors	NNS	O	inhibitor	prep_with	18	SENT_277	[p18l974t3205r1331b3268],
23	.	.	O	.	_	0	SENT_277	[p18l974t3205r1331b3268],

1	Three	CD	NUMBER	three	num	3	SENT_278	[p18l1357t3205r1554b3268],
2	NSCLC	NN	O	nsclc	nn	3	SENT_278	[p18l1577t3209r1844b3268],
3	patients	NNS	O	patient	nsubjpass	8	SENT_278	[p18l1867t3211r2141b3288],
4	with	IN	O	with	_	0	SENT_278	[p18l7t3308r157b3371],
5	ALK	NN	O	alk	nn	6	SENT_278	[p18l173t3312r337b3370],
6	rearrangements	NNS	O	rearrangement	prep_with	3	SENT_278	[p18l350t3320r877b3392],
7	were	VBD	O	be	auxpass	8	SENT_278	[p18l895t3331r1053b3371],
8	enrolled	VBN	O	enrol	_	0	SENT_278	[p18l1074t3308r1351b3371],
9	in	IN	O	in	_	0	SENT_278	[p18l1370t3314r1435b3370],
10	a	DT	O	a	det	13	SENT_278	[p18l1456t3331r1490b3371],
11	phase	NN	O	phase	nn	13	SENT_278	[p18l1507t3308r1698b3391],
12	II	CD	NUMBER	ii	num	13	SENT_278	[p18l1719t3313r1771b3370],
13	study	NN	O	study	prep_in	8	SENT_278	[p18l1793t3308r1976b3392],
14	with	IN	O	with	_	0	SENT_278	[p18l1990t3308r2141b3371],
15	IPI-504	NN	O	ipi-504	nn	19	SENT_278	[p18l9t3416r271b3474],
16	(	CD	NUMBER	(	num	19	SENT_278	[p18l298t3411r586b3495],
17	Inﬁnity	NNP	ORGANIZATION	Inﬁnity	nn	19	SENT_278	[p18l298t3411r586b3495],
18	Pharmaceuticals	NNP	ORGANIZATION	Pharmaceuticals	nn	19	SENT_278	[p18l607t3411r1229b3488],
19	)	NN	O	)	prep_with	13	SENT_278	[p18l607t3411r1229b3488],
20	,	,	O	,	_	0	SENT_278	[p18l607t3411r1229b3488],
21	and	CC	O	and	_	0	SENT_278	[p18l1255t3411r1383b3474],
22	two	CD	NUMBER	two	num	24	SENT_278	[p18l1404t3423r1531b3474],
23	partial	JJ	O	partial	amod	24	SENT_278	[p18l1555t3411r1783b3494],
24	responses	NNS	O	response	nsubjpass	33	SENT_278	[p18l1806t3433r2142b3494],
25	and	CC	O	and	_	0	SENT_278	[p18l9t3513r132b3576],
26	one	CD	NUMBER	one	num	27	SENT_278	[p18l151t3536r270b3576],
27	case	NN	O	case	nsubjpass	33	SENT_278	[p18l291t3536r426b3576],
28	of	IN	O	of	_	0	SENT_278	[p18l446t3513r518b3576],
29	prolonged	JJ	O	prolonged	amod	31	SENT_278	[p18l527t3513r869b3597],
30	stable	JJ	O	stable	amod	31	SENT_278	[p18l888t3513r1075b3576],
31	disease	NN	O	disease	prep_of	27	SENT_278	[p18l1096t3513r1329b3576],
32	were	VBD	O	be	auxpass	33	SENT_278	[p18l1347t3536r1504b3576],
33	noted	VBN	O	note	conj_and	8	SENT_278	[p18l1524t3505r1792b3576],
34	.94	CD	NUMBER	.94	dobj	33	SENT_278	[p18l1524t3505r1792b3576],
35	In	IN	O	in	_	0	SENT_278	[p18l1812t3518r1881b3575],
36	a	DT	O	a	det	39	SENT_278	[p18l1901t3536r1935b3576],
37	phase	NN	O	phase	nn	39	SENT_278	[p18l1953t3513r2142b3596],
38	II	CD	NUMBER	ii	num	39	SENT_278	[p18l9t3620r62b3677],
39	study	NN	O	study	prep_in	51	SENT_278	[p18l85t3615r270b3699],
40	with	IN	O	with	_	0	SENT_278	[p18l285t3615r437b3678],
41	ganetespib	NN	O	ganetespib	prep_with	39	SENT_278	[p18l457t3607r896b3699],
42	,95	CD	NUMBER	,95	number	43	SENT_278	[p18l457t3607r896b3699],
43	four	CD	TIME	four	nsubj	51	SENT_278	[p18l917t3615r1060b3678],
44	of	IN	TIME	of	_	0	SENT_278	[p18l1080t3615r1153b3678],
45	eight	CD	TIME	eight	num	46	SENT_278	[p18l1165t3615r1332b3699],
46	patients	NNS	O	patient	prep_of	43	SENT_278	[p18l1350t3621r1618b3698],
47	with	IN	O	with	_	0	SENT_278	[p18l1637t3615r1789b3678],
48	ALK	NN	O	alk	nn	50	SENT_278	[p18l1806t3619r1972b3677],
49	gene	NN	O	gene	nn	50	SENT_278	[p18l1985t3638r2140b3699],
50	rearrangements	NNS	O	rearrangement	prep_with	46	SENT_278	[p18l9t3730r545b3802],
51	had	VBD	O	have	rcmod	34	SENT_278	[p18l566t3718r694b3781],
52	partial	JJ	O	partial	amod	53	SENT_278	[p18l713t3718r937b3801],
53	responses	NNS	O	response	dobj	51	SENT_278	[p18l958t3740r1288b3801],
54	and	CC	O	and	_	0	SENT_278	[p18l1311t3718r1437b3781],
55	three	CD	NUMBER	three	nsubj	56	SENT_278	[p18l1457t3718r1631b3781],
56	had	VBD	O	have	rcmod	34	SENT_278	[p18l1652t3718r1780b3781],
57	stable	JJ	O	stable	amod	58	SENT_278	[p18l1801t3718r1993b3781],
58	disease	NN	O	disease	dobj	56	SENT_278	[p18l2015t3718r2139b3781, p19l9t53r166b93],
59	.	.	O	.	_	0	SENT_278	[p18l2015t3718r2139b3781, p19l9t53r166b93],

1	An	DT	O	a	det	3	SENT_279	[p19l191t34r295b92],
2	objective	JJ	O	objective	amod	3	SENT_279	[p19l319t30r625b114],
3	response	NN	O	response	nsubjpass	8	SENT_279	[p19l649t52r950b113],
4	to	TO	O	to	_	0	SENT_279	[p19l972t42r1038b93],
5	ganetespib	NN	O	ganetespib	prep_to	3	SENT_279	[p19l1062t30r1426b114],
6	was	VBD	O	be	auxpass	8	SENT_279	[p19l1448t53r1575b93],
7	also	RB	O	also	advmod	8	SENT_279	[p19l1599t30r1730b93],
8	reported	VBN	O	report	_	0	SENT_279	[p19l1755t30r2052b113],
9	in	IN	O	in	_	0	SENT_279	[p19l2074t36r2141b92],
10	one	CD	NUMBER	one	num	11	SENT_279	[p19l9t184r134b224],
11	patient	NN	O	patient	prep_in	8	SENT_279	[p19l156t167r401b244],
12	with	IN	O	with	_	0	SENT_279	[p19l422t161r578b224],
13	crizotinib	JJ	O	crizotinib	amod	21	SENT_279	[p19l603t161r1273b224],
14	—	NN	O	—	npadvmod	15	SENT_279	[p19l603t161r1273b224],
15	resistant	JJ	O	resistant	amod	21	SENT_279	[p19l603t161r1273b224],
16	ALK	NN	O	alk	nn	21	SENT_279	[p19l1294t165r1767b244],
17	—	NN	O	—	nn	21	SENT_279	[p19l1294t165r1767b244],
18	positive	JJ	O	positive	amod	21	SENT_279	[p19l1294t165r1767b244],
19	NSCLC	NN	O	nsclc	dep	18	SENT_279	[p19l1790t153r2140b225],
20	.93	CD	NUMBER	.93	num	19	SENT_279	[p19l1790t153r2140b225],
21	AUY922	NN	O	auy922	prep_with	8	SENT_279	[p19l8t268r309b327],
22	(	CD	NUMBER	(	num	24	SENT_279	[p19l339t265r695b340],
23	Novartis	NNP	ORGANIZATION	Novartis	nn	24	SENT_279	[p19l339t265r695b340],
24	)	NN	O	)	nsubj	25	SENT_279	[p19l339t265r695b340],
25	showed	VBD	O	show	rcmod	21	SENT_279	[p19l724t264r990b327],
26	clinical	JJ	O	clinical	amod	27	SENT_279	[p19l1014t264r1267b327],
27	activity	NN	O	activity	dobj	25	SENT_279	[p19l1291t270r1552b348],
28	as	IN	O	as	_	0	SENT_279	[p19l1574t287r1640b327],
29	a	DT	O	a	det	31	SENT_279	[p19l1666t287r1701b327],
30	single	JJ	O	single	amod	31	SENT_279	[p19l1725t264r1927b348],
31	agent	NN	O	agent	prep_as	25	SENT_279	[p19l1953t276r2141b348],
32	in	IN	O	in	_	0	SENT_279	[p19l9t373r76b429],
33	patients	NNS	O	patient	prep_in	31	SENT_279	[p19l98t373r373b450],
34	with	IN	O	with	_	0	SENT_279	[p19l396t367r551b430],
35	crizotinib-treated	JJ	O	crizotinib-treated	amod	39	SENT_279	[p19l575t367r1191b430],
36	and	CC	O	and	_	0	SENT_279	[p19l1215t367r1343b430],
37	crizotinib-naive	JJ	O	crizotinib-naive	conj_and	35	SENT_279	[p19l1366t367r1922b430],
38	ALKpositive	JJ	MISC	alkpositive	amod	39	SENT_279	[p19l1945t371r2137b429, p19l7t476r269b553],
39	NSCLC	NN	MISC	nsclc	prep_with	25	SENT_279	[p19l288t474r563b533],
40	.	.	O	.	_	0	SENT_279	[p19l288t474r563b533],

1	Objective	NN	O	objective	nn	2	SENT_280	[p19l587t470r906b554],
2	responses	NNS	O	response	nsubjpass	4	SENT_280	[p19l926t492r1251b553],
3	were	VBD	O	be	auxpass	4	SENT_280	[p19l1270t493r1428b533],
4	seen	VBN	O	see	_	0	SENT_280	[p19l1449t493r1595b533],
5	in	IN	O	in	_	0	SENT_280	[p19l1615t476r1680b532],
6	6	CD	TIME	6	prep_in	4	SENT_280	[p19l1701t476r1737b533],
7	of	IN	TIME	of	_	0	SENT_280	[p19l1758t470r1831b533],
8	21	CD	TIME	21	number	9	SENT_280	[p19l1841t477r1913b532],
9	(	CD	PERCENT	(	prep_of	6	SENT_280	[p19l1942t470r2136b547],
10	29	CD	PERCENT	29	num	11	SENT_280	[p19l1942t470r2136b547],
11	%	NN	PERCENT	%	dep	9	SENT_280	[p19l1942t470r2136b547],
12	)	CD	NUMBER	)	num	13	SENT_280	[p19l1942t470r2136b547],
13	patients	NNS	O	patient	dobj	4	SENT_280	[p19l7t579r284b656],
14	enrolled	VBN	O	enrol	partmod	13	SENT_280	[p19l309t573r598b636],
15	in	IN	O	in	_	0	SENT_280	[p19l621t579r688b635],
16	the	DT	O	the	det	21	SENT_280	[p19l711t573r820b636],
17	ALK	NNP	O	ALK	nn	21	SENT_280	[p19l843t577r1316b656],
18	—	CD	NUMBER	—	num	21	SENT_280	[p19l843t577r1316b656],
19	positive	JJ	O	positive	amod	21	SENT_280	[p19l843t577r1316b656],
20	NSCLC	NN	O	nsclc	nn	21	SENT_280	[p19l1339t577r1608b636],
21	cohort	NN	O	cohort	prep_in	14	SENT_280	[p19l1632t573r1880b645],
22	;	:	O	;	_	0	SENT_280	[p19l1632t573r1880b645],
23	four	CD	NUMBER	four	nsubj	30	SENT_280	[p19l1906t573r2053b636],
24	of	IN	O	of	_	0	SENT_280	[p19l2076t573r2151b636],
25	the	DT	O	the	det	27	SENT_280	[p19l8t676r114b739],
26	six	CD	NUMBER	six	num	27	SENT_280	[p19l136t682r229b739],
27	responders	NNS	O	responder	prep_of	23	SENT_280	[p19l247t676r623b759],
28	were	VBD	O	be	cop	30	SENT_280	[p19l643t699r803b739],
29	crizotinib	JJ	O	crizotinib	amod	30	SENT_280	[p19l825t676r1155b739],
30	naive	JJ	O	naive	parataxis	4	SENT_280	[p19l1177t682r1373b748],
31	,	,	O	,	_	0	SENT_280	[p19l1177t682r1373b748],
32	whereas	IN	O	whereas	mark	39	SENT_280	[p19l1394t676r1671b739],
33	two	CD	NUMBER	two	nsubj	39	SENT_280	[p19l1691t688r1816b739],
34	of	IN	O	of	_	0	SENT_280	[p19l1839t676r1913b739],
35	the	DT	O	the	det	37	SENT_280	[p19l1923t676r2029b739],
36	six	CD	NUMBER	six	num	37	SENT_280	[p19l2051t682r2144b739],
37	responders	NNS	O	responder	prep_of	33	SENT_280	[p19l9t778r384b861],
38	had	VBD	O	have	aux	39	SENT_280	[p19l406t778r533b841],
39	received	VBN	O	receive	advcl	30	SENT_280	[p19l554t778r837b841],
40	previous	JJ	O	previous	amod	41	SENT_280	[p19l856t784r1149b861],
41	treatment	NN	O	treatment	dobj	39	SENT_280	[p19l1170t790r1506b841],
42	with	IN	O	with	_	0	SENT_280	[p19l1524t778r1677b841],
43	crizotinib	NN	O	crizotinib	prep_with	41	SENT_280	[p19l1699t770r2109b841],
44	.96	CD	NUMBER	.96	num	43	SENT_280	[p19l1699t770r2109b841],
45	Furthermore	RB	O	furthermore	advmod	39	SENT_280	[p19l83t881r561b953],
46	,	,	O	,	_	0	SENT_280	[p19l83t881r561b953],
47	given	VBN	O	give	prep	39	SENT_280	[p19l589t887r780b965],
48	preclinical	JJ	O	preclinical	amod	49	SENT_280	[p19l805t881r1180b964],
49	studies	NNS	O	study	dep	47	SENT_280	[p19l1207t881r1452b944],
50	indicating	VBG	O	indicate	partmod	49	SENT_280	[p19l1479t881r1841b965],
51	synergy	NN	O	synergy	dobj	50	SENT_280	[p19l1867t904r2146b965],
52	between	IN	O	between	_	0	SENT_280	[p19l7t983r297b1047],
53	ALK	NN	O	alk	nn	54	SENT_280	[p19l320t987r485b1046],
54	inhibitors	NNS	O	inhibitor	prep_between	51	SENT_280	[p19l507t983r846b1047],
55	and	CC	O	and	_	0	SENT_280	[p19l870t983r998b1047],
56	HSP9O	NN	O	hsp9o	nn	57	SENT_280	[p19l1022t987r1257b1047],
57	inhibitors	NNS	O	inhibitor	prep_between	51	SENT_280	[p19l1282t975r1878b1055],
58	,23	CD	NUMBER	,23	number	59	SENT_280	[p19l1282t975r1878b1055],
59	’	CD	NUMBER	’	nsubjpass	68	SENT_280	[p19l1282t975r1878b1055],
60	91	CD	NUMBER	91	num	61	SENT_280	[p19l1282t975r1878b1055],
61	‘	NN	O	‘	dep	59	SENT_280	[p19l1282t975r1878b1055],
62	93	CD	NUMBER	93	num	65	SENT_280	[p19l1282t975r1878b1055],
63	several	JJ	O	several	amod	65	SENT_280	[p19l1904t983r2143b1047],
64	combination	NN	O	combination	nn	65	SENT_280	[p19l9t1087r433b1150],
65	studies	NNS	O	study	dep	59	SENT_280	[p19l454t1087r683b1150],
66	have	VBP	O	have	aux	68	SENT_280	[p19l702t1087r854b1150],
67	been	VBN	O	be	auxpass	68	SENT_280	[p19l872t1087r1032b1150],
68	initiated	VBN	O	initiate	rcmod	51	SENT_280	[p19l1052t1087r1329b1150],
69	including	VBG	O	include	_	0	SENT_280	[p19l1348t1087r1667b1171],
70	combinations	NNS	O	combination	prep_including	68	SENT_280	[p19l1685t1087r2139b1150],
71	of	IN	O	of	_	0	SENT_280	[p19l9t1190r83b1253],
72	crizotinib	NN	O	crizotinib	prep_of	70	SENT_280	[p19l97t1190r431b1253],
73	with	IN	O	with	_	0	SENT_280	[p19l454t1190r608b1253],
74	ganetespib	NN	O	ganetespib	nn	77	SENT_280	[p19l631t1190r996b1274],
75	(	CD	NUMBER	(	num	77	SENT_280	[p19l1024t1190r1607b1267],
76	NCTO1579994	NN	O	ncto1579994	nn	77	SENT_280	[p19l1024t1190r1607b1267],
77	)	NN	O	)	prep_with	72	SENT_280	[p19l1024t1190r1607b1267],
78	,	,	O	,	_	0	SENT_280	[p19l1024t1190r1607b1267],
79	crizotinib	NN	O	crizotinib	conj_and	72	SENT_280	[p19l1632t1190r1966b1253],
80	with	IN	O	with	_	0	SENT_280	[p19l1988t1190r2143b1253],
81	AT13387	NN	O	at13387	nn	84	SENT_280	[p19l7t1296r324b1356],
82	(	CD	NUMBER	(	num	84	SENT_280	[p19l351t1293r938b1370],
83	NCTO1712217	NN	O	ncto1712217	nn	84	SENT_280	[p19l351t1293r938b1370],
84	)	NN	O	)	prep_with	79	SENT_280	[p19l351t1293r938b1370],
85	,	,	O	,	_	0	SENT_280	[p19l351t1293r938b1370],
86	and	CC	O	and	_	0	SENT_280	[p19l965t1293r1093b1356],
87	LDK378	NN	O	ldk378	conj_and	72	SENT_280	[p19l1115t1298r1406b1356],
88	in	IN	O	in	_	0	SENT_280	[p19l1431t1299r1499b1356],
89	combination	NN	O	combination	prep_in	87	SENT_280	[p19l1523t1293r1965b1356],
90	with	IN	O	with	_	0	SENT_280	[p19l1987t1293r2142b1356],
91	AUY922	NN	O	auy922	nn	94	SENT_280	[p19l7t1400r300b1460],
92	(	CD	NUMBER	(	num	94	SENT_280	[p19l327t1396r902b1473],
93	NCTO1772797	NN	O	ncto1772797	nn	94	SENT_280	[p19l327t1396r902b1473],
94	)	NN	O	)	prep_with	89	SENT_280	[p19l327t1396r902b1473],
95	.	.	O	.	_	0	SENT_280	[p19l327t1396r902b1473],

1	CONCLUSION	NN	O	conclusion	_	0	SENT_281	[p19l9t1610r485b1666],

1	The	DT	O	the	det	2	SENT_282	[p19l8t1706r133b1769],
2	identiﬁcation	NN	O	identiﬁcation	nsubj	26	SENT_282	[p19l156t1706r613b1769],
3	of	IN	O	of	_	0	SENT_282	[p19l636t1706r710b1769],
4	ALK	NN	O	alk	nn	6	SENT_282	[p19l719t1710r886b1768],
5	gene	NN	O	gene	nn	6	SENT_282	[p19l902t1729r1058b1790],
6	rearrangements	NNS	O	rearrangement	prep_of	2	SENT_282	[p19l1081t1718r1617b1790],
7	in	IN	O	in	_	0	SENT_282	[p19l1641t1712r1707b1768],
8	NSCLC	NN	ORGANIZATION	nsclc	prep_in	6	SENT_282	[p19l1729t1710r1992b1769],
9	and	CC	O	and	_	0	SENT_282	[p19l2015t1706r2142b1769],
10	their	PRP$	O	they	poss	12	SENT_282	[p19l7t1809r176b1872],
11	subsequent	JJ	O	subsequent	amod	12	SENT_282	[p19l201t1809r598b1892],
12	validation	NN	O	validation	prep_of	2	SENT_282	[p19l619t1809r976b1872],
13	as	IN	O	as	_	0	SENT_282	[p19l1001t1832r1067b1872],
14	therapeutic	JJ	O	therapeutic	amod	15	SENT_282	[p19l1092t1809r1495b1892],
15	targets	NNS	O	target	prep_as	12	SENT_282	[p19l1518t1821r1753b1893],
16	in	IN	O	in	_	0	SENT_282	[p19l1779t1815r1847b1871],
17	NSCLC	NN	O	nsclc	prep_in	15	SENT_282	[p19l1871t1813r2141b1872],
18	through	IN	O	through	_	0	SENT_282	[p19l7t1912r284b1996],
19	clinical	JJ	O	clinical	amod	20	SENT_282	[p19l304t1912r548b1975],
20	trials	NNS	O	trial	prep_through	17	SENT_282	[p19l567t1912r737b1975],
21	with	IN	O	with	_	0	SENT_282	[p19l756t1912r908b1975],
22	crizotinib	NN	O	crizotinib	prep_with	20	SENT_282	[p19l929t1912r1257b1975],
23	is	VBZ	O	be	cop	26	SENT_282	[p19l1279t1918r1329b1975],
24	a	DT	O	a	det	26	SENT_282	[p19l1350t1935r1385b1975],
25	signiﬁcant	JJ	O	signiﬁcant	amod	26	SENT_282	[p19l1405t1912r1758b1996],
26	advance	NN	O	advance	_	0	SENT_282	[p19l1778t1912r2053b1975],
27	in	IN	O	in	_	0	SENT_282	[p19l2073t1918r2140b1974],
28	what	WP	O	what	nsubjpass	31	SENT_282	[p19l7t2015r175b2078],
29	has	VBZ	O	have	aux	31	SENT_282	[p19l195t2015r308b2078],
30	been	VBN	O	be	auxpass	31	SENT_282	[p19l329t2015r494b2078],
31	termed	VBN	O	term	prepc_in	26	SENT_282	[p19l516t2015r764b2078],
32	precision	NN	O	precision	nn	34	SENT_282	[p19l784t2021r1100b2098],
33	cancer	NN	O	cancer	nn	34	SENT_282	[p19l1124t2038r1348b2078],
34	medicine	NN	O	medicine	dobj	31	SENT_282	[p19l1369t2015r1703b2078],
35	.	.	O	.	_	0	SENT_282	[p19l1369t2015r1703b2078],

1	Noteworthy	NNP	O	Noteworthy	nsubj	6	SENT_283	[p19l1729t2015r2145b2099],
2	is	VBZ	O	be	cop	6	SENT_283	[p19l9t2124r60b2181],
3	the	DT	O	the	det	6	SENT_283	[p19l84t2118r194b2181],
4	short	JJ	O	short	amod	6	SENT_283	[p19l220t2118r401b2181],
5	time	NN	O	time	nn	6	SENT_283	[p19l424t2124r583b2181],
6	line	NN	O	line	_	0	SENT_283	[p19l606t2118r737b2181],
7	from	IN	O	from	_	0	SENT_283	[p19l762t2118r934b2181],
8	the	DT	O	the	det	10	SENT_283	[p19l957t2118r1067b2181],
9	original	JJ	O	original	amod	10	SENT_283	[p19l1093t2118r1368b2202],
10	identiﬁcation	NN	O	identiﬁcation	prep_from	6	SENT_283	[p19l1393t2118r1866b2181],
11	of	IN	O	of	_	0	SENT_283	[p19l1891t2118r1967b2181],
12	ALK	NN	O	alk	nn	14	SENT_283	[p19l1978t2122r2149b2180],
13	gene	NN	O	gene	nn	14	SENT_283	[p19l8t2244r164b2305],
14	rearrangements	NNS	O	rearrangement	prep_of	10	SENT_283	[p19l186t2233r723b2305],
15	in	IN	O	in	_	0	SENT_283	[p19l745t2227r812b2283],
16	NSCLC	NNP	O	NSCLC	prep_in	14	SENT_283	[p19l833t2225r1095b2284],
17	(	CD	NUMBER	(	num	16	SENT_283	[p19l1121t2222r1335b2297],
18	2007	CD	DATE	2007	num	19	SENT_283	[p19l1121t2222r1335b2297],
19	)	NN	O	)	advmod	14	SENT_283	[p19l1121t2222r1335b2297],
20	to	TO	O	to	_	0	SENT_283	[p19l1360t2233r1426b2284],
21	the	DT	O	the	det	23	SENT_283	[p19l1448t2221r1554b2284],
22	FDA	NNP	ORGANIZATION	FDA	nn	23	SENT_283	[p19l1577t2225r1739b2283],
23	approval	NN	O	approval	prep_to	19	SENT_283	[p19l1761t2221r2055b2304],
24	of	IN	O	of	_	0	SENT_283	[p19l2077t2221r2151b2284],
25	crizotinib	NN	O	crizotinib	prep_of	23	SENT_283	[p19l9t2324r336b2387],
26	for	IN	O	for	_	0	SENT_283	[p19l357t2324r454b2387],
27	this	DT	O	this	det	28	SENT_283	[p19l472t2324r595b2387],
28	indication	NN	O	indication	prep_for	25	SENT_283	[p19l616t2324r962b2387],
29	(	CD	NUMBER	(	num	31	SENT_283	[p19l986t2325r1219b2400],
30	2011	CD	DATE	2011	num	31	SENT_283	[p19l986t2325r1219b2400],
31	)	NN	O	)	dep	14	SENT_283	[p19l986t2325r1219b2400],
32	.	.	O	.	_	0	SENT_283	[p19l986t2325r1219b2400],

1	Testing	VBG	O	test	nsubjpass	18	SENT_284	[p19l1243t2327r1489b2408],
2	of	IN	O	of	_	0	SENT_284	[p19l1508t2324r1581b2387],
3	NSCLC	NNP	ORGANIZATION	NSCLC	prep_of	1	SENT_284	[p19l1591t2328r1852b2387],
4	for	IN	O	for	_	0	SENT_284	[p19l1872t2324r1969b2387],
5	ALK	NNP	O	ALK	nn	7	SENT_284	[p19l1984t2328r2149b2386],
6	gene	NN	O	gene	nn	7	SENT_284	[p19l8t2450r162b2511],
7	rearrangements	NNS	O	rearrangement	prep_for	3	SENT_284	[p19l182t2439r708b2511],
8	and	CC	O	and	_	0	SENT_284	[p19l729t2427r853b2490],
9	treatment	NN	O	treatment	conj_and	3	SENT_284	[p19l871t2439r1201b2490],
10	of	IN	O	of	_	0	SENT_284	[p19l1220t2427r1292b2490],
11	those	DT	O	those	det	12	SENT_284	[p19l1302t2427r1481b2490],
12	patients	NNS	O	patient	prep_of	9	SENT_284	[p19l1500t2433r1764b2510],
13	with	IN	O	with	_	0	SENT_284	[p19l1783t2427r1933b2490],
14	ALKpositive	JJ	O	alkpositive	amod	15	SENT_284	[p19l1952t2431r2137b2489, p19l7t2536r274b2613],
15	tumors	NNS	O	tumor	prep_with	12	SENT_284	[p19l296t2542r541b2593],
16	is	VBZ	O	be	auxpass	18	SENT_284	[p19l564t2536r614b2593],
17	now	RB	DATE	now	advmod	18	SENT_284	[p19l637t2553r786b2593],
18	established	VBN	O	establish	_	0	SENT_284	[p19l806t2530r1184b2593],
19	as	IN	O	as	_	0	SENT_284	[p19l1206t2553r1270b2593],
20	standard	NN	O	standard	prep_as	18	SENT_284	[p19l1294t2530r1593b2593],
21	of	IN	O	of	_	0	SENT_284	[p19l1616t2530r1689b2593],
22	care	NN	O	care	prep_of	20	SENT_284	[p19l1703t2553r1856b2593],
23	.	.	O	.	_	0	SENT_284	[p19l1703t2553r1856b2593],

1	Despite	IN	O	despite	_	0	SENT_285	[p19l1882t2535r2140b2613],
2	excellent	JJ	O	excellent	amod	4	SENT_285	[p19l9t2633r300b2696],
3	initial	JJ	O	initial	amod	4	SENT_285	[p19l319t2633r513b2696],
4	responses	NNS	O	response	prep_despite	13	SENT_285	[p19l532t2655r854b2716],
5	to	TO	O	to	_	0	SENT_285	[p19l873t2645r938b2696],
6	therapy	NN	O	therapy	prep_to	4	SENT_285	[p19l957t2633r1220b2717],
7	,	,	O	,	_	0	SENT_285	[p19l957t2633r1220b2717],
8	however	RB	O	however	advmod	13	SENT_285	[p19l1241t2633r1535b2705],
9	,	,	O	,	_	0	SENT_285	[p19l1241t2633r1535b2705],
10	most	RBS	O	most	advmod	11	SENT_285	[p19l1556t2645r1722b2696],
11	patients	NNS	O	patient	nsubj	13	SENT_285	[p19l1739t2639r2001b2716],
12	will	MD	O	will	aux	13	SENT_285	[p19l2019t2633r2142b2696],
13	go	VB	O	go	_	0	SENT_285	[p19l8t2759r87b2820],
14	on	IN	O	on	_	0	SENT_285	[p19l112t2759r198b2799],
15	to	TO	O	to	aux	16	SENT_285	[p19l220t2748r286b2799],
16	develop	VB	O	develop	prep_on	13	SENT_285	[p19l311t2736r576b2819],
17	acquired	VBN	O	acquire	amod	18	SENT_285	[p19l601t2736r900b2819],
18	resistance	NN	O	resistance	dobj	16	SENT_285	[p19l921t2742r1275b2808],
19	,	,	O	,	_	0	SENT_285	[p19l921t2742r1275b2808],
20	both	DT	O	both	preconj	13	SENT_285	[p19l1298t2736r1458b2799],
21	to	TO	O	to	_	0	SENT_285	[p19l1479t2748r1546b2799],
22	crizotinib	NN	O	crizotinib	prep_to	13	SENT_285	[p19l1570t2736r1902b2799],
23	and	CC	O	and	_	0	SENT_285	[p19l1927t2736r2054b2799],
24	to	TO	O	to	_	0	SENT_285	[p19l2074t2748r2141b2799],
25	second-generation	JJ	O	second-generation	amod	27	SENT_285	[p19l9t2839r645b2923],
26	ALK	NN	O	alk	nn	27	SENT_285	[p19l665t2843r827b2901],
27	inhibitors	NNS	O	inhibitor	prep_to	13	SENT_285	[p19l847t2839r1196b2902],
28	.	.	O	.	_	0	SENT_285	[p19l847t2839r1196b2902],

1	Elucidating	VBG	O	elucidate	csubj	17	SENT_286	[p19l1220t2839r1612b2923],
2	mechanisms	NNS	O	mechanism	dobj	1	SENT_286	[p19l1630t2839r2056b2902],
3	of	IN	O	of	_	0	SENT_286	[p19l2078t2839r2152b2902],
4	acquired	VBN	O	acquire	amod	5	SENT_286	[p19l9t2942r302b3025],
5	resistance	NN	O	resistance	prep_of	2	SENT_286	[p19l321t2948r649b3005],
6	to	TO	O	to	_	0	SENT_286	[p19l669t2954r733b3005],
7	ALK	NN	O	alk	nn	8	SENT_286	[p19l754t2946r915b3004],
8	inhibitors	NNS	O	inhibitor	prep_to	5	SENT_286	[p19l933t2942r1261b3005],
9	and	CC	O	and	_	0	SENT_286	[p19l1282t2942r1407b3005],
10	developing	VBG	O	develop	csubj	17	SENT_286	[p19l1426t2942r1796b3026],
11	therapeutic	JJ	O	therapeutic	amod	12	SENT_286	[p19l1814t2942r2140b3025, p19l7t3051r91b3108],
12	strategies	NNS	O	strategy	dobj	10	SENT_286	[p19l115t3051r431b3129],
13	that	WDT	O	that	nsubj	15	SENT_286	[p19l453t3045r587b3108],
14	may	MD	O	may	aux	15	SENT_286	[p19l608t3068r755b3129],
15	overcome	VB	O	overcome	rcmod	12	SENT_286	[p19l775t3068r1107b3108],
16	resistance	NN	O	resistance	dobj	15	SENT_286	[p19l1130t3051r1464b3108],
17	represent	VBP	O	represent	_	0	SENT_286	[p19l1487t3057r1805b3128],
18	priorities	NNS	O	priority	dobj	17	SENT_286	[p19l1826t3051r2139b3128],
19	in	IN	O	in	_	0	SENT_286	[p19l9t3154r75b3210],
20	the	DT	O	the	det	21	SENT_286	[p19l97t3148r204b3211],
21	ﬁeld	NN	O	ﬁeld	prep_in	18	SENT_286	[p19l227t3148r392b3211],
22	.	.	O	.	_	0	SENT_286	[p19l227t3148r392b3211],

1	There	EX	O	there	expl	6	SENT_287	[p19l417t3148r612b3211],
2	are	VBP	O	be	aux	6	SENT_287	[p19l636t3171r736b3211],
3	now	RB	DATE	now	advmod	5	SENT_287	[p19l760t3171r909b3211],
4	a	DT	O	a	dep	5	SENT_287	[p19l930t3171r964b3211],
5	rapidly	RB	O	rapidly	advmod	6	SENT_287	[p19l986t3148r1231b3232],
6	expanding	VBG	O	expand	_	0	SENT_287	[p19l1251t3148r1614b3232],
7	range	NN	O	range	dobj	6	SENT_287	[p19l1635t3171r1825b3232],
8	of	IN	O	of	_	0	SENT_287	[p19l1849t3148r1923b3211],
9	novel	JJ	O	novel	amod	14	SENT_287	[p19l1937t3148r2140b3220],
10	,	,	O	,	_	0	SENT_287	[p19l1937t3148r2140b3220],
11	highly	RB	O	highly	advmod	12	SENT_287	[p19l7t3251r226b3335],
12	potent	JJ	O	potent	amod	14	SENT_287	[p19l244t3263r466b3334],
13	ALK	NN	O	alk	nn	14	SENT_287	[p19l487t3255r650b3313],
14	inhibitors	NNS	O	inhibitor	prep_of	7	SENT_287	[p19l671t3251r1003b3314],
15	and	CC	O	and	_	0	SENT_287	[p19l1027t3251r1153b3314],
16	HSP90	NN	O	hsp90	nn	17	SENT_287	[p19l1176t3255r1408b3314],
17	inhibitors	NNS	O	inhibitor	conj_and	14	SENT_287	[p19l1431t3251r1764b3314],
18	with	IN	O	with	_	0	SENT_287	[p19l1786t3251r1938b3314],
19	demonstrated	VBN	O	demonstrate	amod	20	SENT_287	[p19l1961t3251r2138b3314, p19l9t3354r331b3417],
20	activity	NN	O	activity	prep_with	14	SENT_287	[p19l353t3360r606b3438],
21	in	IN	O	in	_	0	SENT_287	[p19l626t3360r692b3416],
22	this	DT	O	this	det	23	SENT_287	[p19l714t3354r838b3417],
23	setting	NN	O	setting	prep_in	20	SENT_287	[p19l863t3360r1107b3438],
24	.	.	O	.	_	0	SENT_287	[p19l863t3360r1107b3438],

1	Key	NN	O	key	nn	2	SENT_288	[p19l1134t3359r1266b3438],
2	questions	NNS	O	question	nsubj	3	SENT_288	[p19l1286t3360r1610b3437],
3	include	VBP	O	include	_	0	SENT_288	[p19l1633t3354r1885b3417],
4	how	WRB	O	how	advmod	6	SENT_288	[p19l1907t3354r2056b3417],
5	to	TO	O	to	aux	6	SENT_288	[p19l2074t3366r2140b3417],
6	choose	VB	O	choose	dep	3	SENT_288	[p19l9t3457r237b3520],
7	between	IN	O	between	_	0	SENT_288	[p19l255t3457r532b3520],
8	these	DT	O	these	det	9	SENT_288	[p19l550t3457r721b3520],
9	drugs	NNS	O	drug	prep_between	6	SENT_288	[p19l741t3457r944b3541],
10	,	,	O	,	_	0	SENT_288	[p19l741t3457r944b3541],
11	how	WRB	O	how	advmod	13	SENT_288	[p19l964t3457r1108b3520],
12	to	TO	O	to	aux	13	SENT_288	[p19l1124t3469r1188b3520],
13	determine	VB	O	determine	dep	6	SENT_288	[p19l1209t3457r1549b3520],
14	optimal	JJ	O	optimal	amod	15	SENT_288	[p19l1569t3457r1825b3540],
15	sequencing	NN	O	sequencing	dobj	13	SENT_288	[p19l1845t3480r2137b3540, p19l8t3566r116b3644],
16	or	CC	O	or	_	0	SENT_288	[p19l135t3583r207b3623],
17	schedules	NNS	O	schedule	conj_or	15	SENT_288	[p19l227t3560r554b3623],
18	for	IN	O	for	_	0	SENT_288	[p19l575t3560r672b3623],
19	treatment	NN	O	treatment	prep_for	13	SENT_288	[p19l690t3572r1042b3632],
20	,	,	O	,	_	0	SENT_288	[p19l690t3572r1042b3632],
21	and	CC	O	and	_	0	SENT_288	[p19l1065t3560r1191b3623],
22	how	WRB	O	how	advmod	25	SENT_288	[p19l1209t3560r1357b3623],
23	to	TO	O	to	aux	25	SENT_288	[p19l1373t3572r1439b3623],
24	best	JJS	O	best	advmod	25	SENT_288	[p19l1459t3560r1597b3623],
25	develop	VB	O	develop	conj_and	6	SENT_288	[p19l1617t3560r1880b3643],
26	combinations	NNS	O	combination	dobj	25	SENT_288	[p19l1902t3560r2140b3623, p19l8t3669r258b3726],
27	that	WDT	O	that	nsubj	33	SENT_288	[p19l278t3663r412b3726],
28	will	MD	O	will	aux	30	SENT_288	[p19l429t3663r555b3726],
29	both	CC	O	both	preconj	30	SENT_288	[p19l573t3663r731b3726],
30	minimize	VB	O	minimize	rcmod	26	SENT_288	[p19l751t3669r1078b3726],
31	toxicity	NN	O	toxicity	dobj	30	SENT_288	[p19l1098t3669r1356b3747],
32	and	CC	O	and	_	0	SENT_288	[p19l1373t3663r1499b3726],
33	achieve	VB	O	achieve	rcmod	26	SENT_288	[p19l1520t3663r1771b3726],
34	the	DT	O	the	det	35	SENT_288	[p19l1791t3663r1897b3726],
35	goal	NN	O	goal	dobj	33	SENT_288	[p19l1918t3663r2059b3747],
36	of	IN	O	of	_	0	SENT_288	[p19l2079t3663r2153b3726],
37	long-term	JJ	O	long-term	amod	39	SENT_288	[p20l7t16r342b100],
38	disease	NN	O	disease	nn	39	SENT_288	[p20l362t16r595b79],
39	control	NN	O	control	prep_of	35	SENT_288	[p20l615t16r852b79],
40	in	IN	O	in	_	0	SENT_288	[p20l871t22r936b78],
41	patients	NNS	O	patient	prep_in	30	SENT_288	[p20l954t22r1215b99],
42	with	IN	O	with	_	0	SENT_288	[p20l1232t16r1381b79],
43	ALK-positive	JJ	MISC	alk-positive	amod	44	SENT_288	[p20l1399t20r1846b99],
44	NSCLC	NN	MISC	nsclc	prep_with	41	SENT_288	[p20l1865t20r2137b79],
45	.	.	O	.	_	0	SENT_288	[p20l1865t20r2137b79],

1	CONFLICT	NN	O	conflict	nsubj	6	SENT_289	[p20l9t194r321b243],
2	OF	IN	O	of	_	0	SENT_289	[p20l335t194r418b243],
3	INTEREST	NN	O	interest	nn	4	SENT_289	[p20l436t194r734b243],
4	A.T.S.	NNP	O	A.T.S.	prep_of	1	SENT_289	[p20l8t279r151b328],
5	has	VBZ	O	have	aux	6	SENT_289	[p20l170t278r260b328],
6	done	VBN	O	do	_	0	SENT_289	[p20l276t278r421b328],
7	consulting	VBG	O	consult	xcomp	6	SENT_289	[p20l436t278r731b341],
8	for	IN	O	for	_	0	SENT_289	[p20l747t277r825b328],
9	Pfizer	NNP	ORGANIZATION	Pfizer	nn	15	SENT_289	[p20l842t277r1003b336],
10	,	,	O	,	_	0	SENT_289	[p20l842t277r1003b336],
11	Novartis	NNP	ORGANIZATION	Novartis	appos	15	SENT_289	[p20l1021t280r1265b335],
12	,	,	O	,	_	0	SENT_289	[p20l1021t280r1265b335],
13	Chugai	NNP	ORGANIZATION	Chugai	appos	15	SENT_289	[p20l1280t278r1492b341],
14	,	,	O	,	_	0	SENT_289	[p20l1280t278r1492b341],
15	Ariad	NNP	ORGANIZATION	Ariad	prep_for	7	SENT_289	[p20l1507t278r1669b335],
16	,	,	O	,	_	0	SENT_289	[p20l1507t278r1669b335],
17	and	CC	O	and	_	0	SENT_289	[p20l1684t278r1787b328],
18	Daiichi	NNP	ORGANIZATION	Daiichi	nn	19	SENT_289	[p20l1808t278r1994b328],
19	Sankyo	NNP	ORGANIZATION	Sankyo	conj_and	15	SENT_289	[p20l9t363r223b427],
20	.	.	O	.	_	0	SENT_289	[p20l9t363r223b427],

1	K.D.W.	NNP	ORGANIZATION	K.D.W.	nsubj	4	SENT_290	[p20l241t365r413b413],
2	is	VBZ	O	be	cop	4	SENT_290	[p20l430t365r466b413],
3	an	DT	O	a	det	4	SENT_290	[p20l482t378r547b413],
4	employee	NN	O	employee	_	0	SENT_290	[p20l565t363r844b427],
5	of	IN	O	of	_	0	SENT_290	[p20l860t362r918b413],
6	Pfizer	NNP	ORGANIZATION	Pfizer	prep_of	4	SENT_290	[p20l931t362r1092b413],
7	.	.	O	.	_	0	SENT_290	[p20l931t362r1092b413],

1	B.S.	NNP	O	B.S.	nsubj	3	SENT_291	[p20l1110t365r1202b413],
2	has	VBZ	O	have	aux	3	SENT_291	[p20l1220t363r1310b413],
3	done	VBN	O	do	_	0	SENT_291	[p20l1327t363r1471b413],
4	consulting	VBG	O	consult	xcomp	3	SENT_291	[p20l1486t363r1781b427],
5	for	IN	O	for	_	0	SENT_291	[p20l1797t362r1875b413],
6	Pfizer	NNP	ORGANIZATION	Pfizer	prep_for	4	SENT_291	[p20l1892t362r2044b413],
7	and	CC	O	and	_	0	SENT_291	[p20l8t448r112b499],
8	Novartis	NNP	ORGANIZATION	Novartis	prep_for	4	SENT_291	[p20l132t451r375b499],
9	.	.	O	.	_	0	SENT_291	[p20l132t451r375b499],

1	©	RB	O	©	dep	2	SENT_292	[p20l8t657r48b698],
2	2014	CD	DATE	2014	dep	4	SENT_292	[p20l63t656r193b700],
3	American	NNP	ORGANIZATION	American	nn	4	SENT_292	[p20l206t655r459b700],
4	Society	NNP	ORGANIZATION	Society	_	0	SENT_292	[p20l477t655r671b714],
5	for	IN	O	for	_	0	SENT_292	[p20l683t653r757b700],
6	Clinical	JJ	O	clinical	amod	7	SENT_292	[p20l771t653r959b700],
7	Pharmacology	NN	O	pharmacology	prep_for	4	SENT_292	[p20l979t653r1364b714],
8	and	CC	O	and	_	0	SENT_292	[p20l1377t653r1475b700],
9	Therapeutics	NNS	O	therapeutics	prep_for	4	SENT_292	[p20l1487t653r1834b712],

1	1	LS	NUMBER	1	_	0	SENT_293	[p20l13t875r50b920],
2	.	.	O	.	_	0	SENT_293	[p20l13t875r50b920],

1	Morris	NNP	PERSON	Morris	_	0	SENT_294	[p20l130t873r305b927],
2	,	,	O	,	_	0	SENT_294	[p20l130t873r305b927],
3	S.W.	NNP	O	S.W.	nn	4	SENT_294	[p20l320t873r423b920],
4	etal	NN	O	etal	appos	1	SENT_294	[p20l437t871r551b920],
5	.	.	O	.	_	0	SENT_294	[p20l437t871r551b920],

1	Fusion	NN	O	fusion	_	0	SENT_295	[p20l568t873r733b920],
2	of	IN	O	of	_	0	SENT_295	[p20l750t870r804b920],
3	a	DT	O	a	det	5	SENT_295	[p20l813t885r839b920],
4	kinase	NN	O	kinase	nn	5	SENT_295	[p20l857t871r1019b920],
5	gene	NN	O	gene	prep_of	1	SENT_295	[p20l1033t885r1176b933],
6	,	,	O	,	_	0	SENT_295	[p20l1033t885r1176b933],
7	ALK	NNP	O	ALK	appos	5	SENT_295	[p20l1190t873r1303b927],
8	,	,	O	,	_	0	SENT_295	[p20l1190t873r1303b927],
9	to	TO	O	to	_	0	SENT_295	[p20l1316t879r1369b920],
10	a	DT	O	a	det	13	SENT_295	[p20l1384t885r1409b920],
11	nucleolar	JJ	O	nucleolar	amod	13	SENT_295	[p20l1427t871r1668b920],
12	protein	NN	O	protein	nn	13	SENT_295	[p20l1683t873r1868b932],
13	gene	NN	O	gene	prep_to	7	SENT_295	[p20l1884t885r2027b933],
14	,	,	O	,	_	0	SENT_295	[p20l1884t885r2027b933],

1	NPM	NNP	ORGANIZATION	NPM	_	0	SENT_296	[p20l133t949r265b1003],
2	,	,	O	,	_	0	SENT_296	[p20l133t949r265b1003],
3	in	IN	O	in	dep	1	SENT_296	[p20l282t949r324b995],
4	non	JJ	O	non	pobj	3	SENT_296	[p20l342t947r720b1009],
5	.	.	O	.	_	0	SENT_296	[p20l342t947r720b1009],

1	—	NN	O	—	_	0	SENT_297	[p20l342t947r720b1009],
2	.	.	O	.	_	0	SENT_297	[p20l342t947r720b1009],

1	Hodgkin	NN	PERSON	hodgkin	poss	3	SENT_298	[p20l342t947r720b1009],
2	’s	POS	O	’s	_	0	SENT_298	[p20l342t947r720b1009],
3	lymphoma	NN	O	lymphoma	_	0	SENT_298	[p20l737t947r1031b1010],
4	.	.	O	.	_	0	SENT_298	[p20l737t947r1031b1010],

1	Science	NNP	O	Science	_	0	SENT_299	[p20l1045t949r1232b996],
2	263	CD	NUMBER	263	num	1	SENT_299	[p20l1245t950r1360b1003],
3	,	,	O	,	_	0	SENT_299	[p20l1245t950r1360b1003],
4	1281-1284	CD	DATE	1281-1284	num	1	SENT_299	[p20l1378t950r1663b996],
5	(	CD	NUMBER	(	num	7	SENT_299	[p20l1678t948r1851b1003],
6	1994	CD	DATE	1994	num	7	SENT_299	[p20l1678t948r1851b1003],
7	)	NN	O	)	dep	1	SENT_299	[p20l1678t948r1851b1003],
8	.	.	O	.	_	0	SENT_299	[p20l1678t948r1851b1003],

1	2	LS	NUMBER	2	_	0	SENT_300	[p20l9t1026r50b1072],
2	.	.	O	.	_	0	SENT_300	[p20l9t1026r50b1072],

1	Soda	NNP	O	Soda	_	0	SENT_301	[p20l129t1023r271b1080],
2	,	,	O	,	_	0	SENT_301	[p20l129t1023r271b1080],
3	M.	NNP	O	M.	nn	4	SENT_301	[p20l287t1025r345b1072],
4	etal	NNP	O	etal	appos	1	SENT_301	[p20l359t1023r474b1072],
5	.	.	O	.	_	0	SENT_301	[p20l359t1023r474b1072],

1	Identiﬁcation	NN	O	identiﬁcation	_	0	SENT_302	[p20l490t1022r832b1072],
2	of	IN	O	of	_	0	SENT_302	[p20l849t1022r903b1072],
3	the	DT	O	the	det	5	SENT_302	[p20l911t1023r996b1072],
4	transforming	VBG	O	transform	amod	5	SENT_302	[p20l1009t1022r1348b1085],
5	EML4	NN	O	eml4	prep_of	1	SENT_302	[p20l1367t1025r1630b1071],
6	.	.	O	.	_	0	SENT_302	[p20l1367t1025r1630b1071],

1	—	NN	O	—	_	0	SENT_303	[p20l1367t1025r1630b1071],
2	.	.	O	.	_	0	SENT_303	[p20l1367t1025r1630b1071],

1	ALK	NN	O	alk	_	0	SENT_304	[p20l1367t1025r1630b1071],
2	fusion	NN	O	fusion	nn	3	SENT_304	[p20l1640t1022r1799b1072],
3	gene	NN	O	gene	dep	1	SENT_304	[p20l1815t1037r1946b1085],
4	in	IN	O	in	_	0	SENT_304	[p20l1962t1025r2004b1071],
5	nonsmall	JJ	O	nonsmall	amod	7	SENT_304	[p20l2022t1037r2142b1072, p20l131t1100r372b1149],
6	—	NN	O	—	nn	7	SENT_304	[p20l2022t1037r2142b1072, p20l131t1100r372b1149],
7	cell	NN	O	cell	prep_in	3	SENT_304	[p20l2022t1037r2142b1072, p20l131t1100r372b1149],

1	lung	NN	O	lung	_	0	SENT_305	[p20l391t1100r504b1162],
2	cancer	NN	O	cancer	dep	1	SENT_305	[p20l520t1114r700b1149],
3	.	.	O	.	_	0	SENT_305	[p20l520t1114r700b1149],

1	Nature	NNP	O	Nature	_	0	SENT_306	[p20l714t1102r887b1149],
2	448	CD	NUMBER	448	num	1	SENT_306	[p20l899t1103r1014b1156],
3	,	,	O	,	_	0	SENT_306	[p20l899t1103r1014b1156],
4	561	CD	NUMBER	561	num	1	SENT_306	[p20l1029t1103r1112b1149],
5	-566	CD	NUMBER	-566	number	6	SENT_306	[p20l1126t1103r1252b1149],
6	(	CD	NUMBER	(	dep	1	SENT_306	[p20l1268t1101r1441b1156],
7	2007	CD	DATE	2007	num	8	SENT_306	[p20l1268t1101r1441b1156],
8	)	NN	O	)	dep	6	SENT_306	[p20l1268t1101r1441b1156],
9	.	.	O	.	_	0	SENT_306	[p20l1268t1101r1441b1156],

1	3	LS	NUMBER	3	_	0	SENT_307	[p20l8t1179r50b1225],
2	.	.	O	.	_	0	SENT_307	[p20l8t1179r50b1225],

1	Rikova	NNP	PERSON	Rikova	_	0	SENT_308	[p20l131t1176r312b1232],
2	,	,	O	,	_	0	SENT_308	[p20l131t1176r312b1232],
3	K.	NNP	O	K.	nn	4	SENT_308	[p20l329t1178r371b1225],
4	etal	NN	O	etal	appos	1	SENT_308	[p20l385t1176r500b1225],
5	.	.	O	.	_	0	SENT_308	[p20l385t1176r500b1225],

1	Global	JJ	O	global	amod	2	SENT_309	[p20l514t1176r680b1225],
2	survey	NN	O	survey	_	0	SENT_309	[p20l697t1190r868b1239],
3	of	IN	O	of	_	0	SENT_309	[p20l881t1175r935b1225],
4	phosphotyrosine	NN	O	phosphotyrosine	nn	6	SENT_309	[p20l946t1176r1391b1239],
5	signaling	NN	O	signaling	nn	6	SENT_309	[p20l1405t1176r1640b1238],
6	identiﬁes	NNS	O	identiﬁes	prep_of	2	SENT_309	[p20l1658t1175r1895b1225],
7	oncogenic	JJ	O	oncogenic	amod	8	SENT_309	[p20l130t1255r405b1315],
8	kinases	NNS	O	kinase	dep	2	SENT_309	[p20l422t1253r608b1302],
9	in	IN	O	in	_	0	SENT_309	[p20l625t1255r667b1301],
10	lung	NN	O	lung	nn	11	SENT_309	[p20l685t1253r798b1315],
11	cancer	NN	O	cancer	prep_in	8	SENT_309	[p20l814t1267r994b1302],
12	.	.	O	.	_	0	SENT_309	[p20l814t1267r994b1302],

1	Cell	NN	O	cell	_	0	SENT_310	[p20l1009t1253r1100b1302],
2	1	CD	NUMBER	1	num	3	SENT_310	[p20l1114t1257r1134b1301],
3	31	CD	NUMBER	31	dep	1	SENT_310	[p20l1147t1256r1226b1310],
4	,	,	O	,	_	0	SENT_310	[p20l1147t1256r1226b1310],
5	1	CD	NUMBER	1	num	6	SENT_310	[p20l1245t1257r1259b1301],
6	190-1	CD	NUMBER	190-1	appos	3	SENT_310	[p20l1277t1256r1421b1302],
7	203	CD	NUMBER	203	num	8	SENT_310	[p20l1435t1256r1527b1302],
8	(	CD	NUMBER	(	dep	1	SENT_310	[p20l1544t1254r1718b1309],
9	2007	CD	DATE	2007	num	10	SENT_310	[p20l1544t1254r1718b1309],
10	)	NN	O	)	dep	8	SENT_310	[p20l1544t1254r1718b1309],
11	.	.	O	.	_	0	SENT_310	[p20l1544t1254r1718b1309],

1	4	LS	NUMBER	4	_	0	SENT_311	[p20l6t1334r50b1379],
2	.	.	O	.	_	0	SENT_311	[p20l6t1334r50b1379],

1	Chiarle	NNP	O	Chiarle	_	0	SENT_312	[p20l129t1330r322b1387],
2	,	,	O	,	_	0	SENT_312	[p20l129t1330r322b1387],
3	R.	NNP	O	R.	conj_and	1	SENT_312	[p20l339t1332r579b1387],
4	,	,	O	,	_	0	SENT_312	[p20l339t1332r579b1387],
5	Voena	NNP	PERSON	Voena	conj_and	1	SENT_312	[p20l339t1332r579b1387],
6	,	,	O	,	_	0	SENT_312	[p20l339t1332r579b1387],
7	C.	NNP	O	C.	conj_and	1	SENT_312	[p20l594t1332r652b1386],
8	,	,	O	,	_	0	SENT_312	[p20l594t1332r652b1386],
9	Ambrogio	NNP	O	Ambrogio	conj_and	1	SENT_312	[p20l666t1330r941b1392],
10	,	,	O	,	_	0	SENT_312	[p20l666t1330r941b1392],
11	C.	NNP	O	C.	conj_and	1	SENT_312	[p20l956t1332r1015b1386],
12	,	,	O	,	_	0	SENT_312	[p20l956t1332r1015b1386],
13	Piva	NNP	PERSON	Piva	conj_and	1	SENT_312	[p20l1032t1332r1146b1386],
14	,	,	O	,	_	0	SENT_312	[p20l1032t1332r1146b1386],
15	R.	NNP	ORGANIZATION	R.	conj_and	1	SENT_312	[p20l1163t1332r1204b1379],
16	&	CC	ORGANIZATION	&	_	0	SENT_312	[p20l1218t1332r1254b1379],
17	Inghirami	NNP	ORGANIZATION	Inghirami	conj_and	1	SENT_312	[p20l1270t1330r1531b1392],
18	,	,	O	,	_	0	SENT_312	[p20l1270t1330r1531b1392],
19	G.	NNP	O	G.	nn	23	SENT_312	[p20l1545t1330r1701b1379],
20	The	NNP	O	The	nn	23	SENT_312	[p20l1545t1330r1701b1379],
21	anaplastic	JJ	O	anaplastic	amod	23	SENT_312	[p20l1716t1330r1979b1392],
22	lymphoma	NN	O	lymphoma	nn	23	SENT_312	[p20l132t1406r412b1469],
23	kinase	NN	O	kinase	appos	1	SENT_312	[p20l431t1406r593b1455],
24	in	IN	O	in	_	0	SENT_312	[p20l608t1408r651b1454],
25	the	DT	O	the	det	26	SENT_312	[p20l666t1406r751b1455],
26	pathogenesis	NN	O	pathogenesis	prep_in	23	SENT_312	[p20l768t1406r1118b1468],
27	of	IN	O	of	_	0	SENT_312	[p20l1133t1405r1187b1455],
28	cancer	NN	O	cancer	prep_of	26	SENT_312	[p20l1196t1420r1376b1455],
29	.	.	O	.	_	0	SENT_312	[p20l1196t1420r1376b1455],

1	Nat	NN	PERSON	nat	_	0	SENT_313	[p20l1390t1408r1491b1455],
2	.	.	O	.	_	0	SENT_313	[p20l1390t1408r1491b1455],

1	Rev.	NNP	O	Rev.	nn	2	SENT_314	[p20l1506t1408r1601b1455],
2	Cancer	NNP	O	Cancer	_	0	SENT_314	[p20l1617t1408r1793b1455],
3	8	CD	NUMBER	8	num	2	SENT_314	[p20l1803t1409r1847b1462],
4	,	,	O	,	_	0	SENT_314	[p20l1803t1409r1847b1462],
5	11-23	CD	NUMBER	11-23	num	2	SENT_314	[p20l1866t1409r2018b1455],
6	(	CD	NUMBER	(	num	8	SENT_314	[p20l132t1484r305b1540],
7	2008	CD	DATE	2008	num	8	SENT_314	[p20l132t1484r305b1540],
8	)	NN	O	)	dep	2	SENT_314	[p20l132t1484r305b1540],
9	.	.	O	.	_	0	SENT_314	[p20l132t1484r305b1540],

1	5	CD	NUMBER	5	_	0	SENT_315	[p20l8t1563r50b1608],
2	.	.	O	.	_	0	SENT_315	[p20l8t1563r50b1608],

1	Englund	NNP	PERSON	Englund	_	0	SENT_316	[p20l131t1559r360b1621],
2	,	,	O	,	_	0	SENT_316	[p20l131t1559r360b1621],
3	C.	NNP	O	C.	nn	4	SENT_316	[p20l374t1561r420b1608],
4	etal	NNP	O	etal	appos	1	SENT_316	[p20l434t1559r548b1608],
5	.	.	O	.	_	0	SENT_316	[p20l434t1559r548b1608],

1	Jeb	NNP	PERSON	Jeb	nn	2	SENT_317	[p20l561t1559r650b1608],
2	signals	NNS	O	signal	_	0	SENT_317	[p20l665t1559r841b1621],
3	through	IN	O	through	_	0	SENT_317	[p20l854t1559r1066b1621],
4	the	DT	O	the	det	8	SENT_317	[p20l1081t1559r1167b1608],
5	Alk	NN	O	alk	nn	8	SENT_317	[p20l1180t1559r1263b1608],
6	receptor	NN	O	receptor	nn	8	SENT_317	[p20l1277t1567r1496b1621],
7	tyrosine	NN	O	tyrosine	nn	8	SENT_317	[p20l1508t1562r1718b1622],
8	kinase	NN	O	kinase	prep_through	2	SENT_317	[p20l1734t1559r1896b1608],
9	to	TO	O	to	aux	10	SENT_317	[p20l1909t1567r1962b1608],
10	drive	VB	O	drive	infmod	2	SENT_317	[p20l1977t1559r2105b1608],
11	visceral	JJ	O	visceral	amod	13	SENT_317	[p20l129t1636r319b1685],
12	muscle	NN	O	muscle	nn	13	SENT_317	[p20l338t1636r520b1685],
13	fusion	NN	O	fusion	dobj	10	SENT_317	[p20l533t1636r707b1685],
14	.	.	O	.	_	0	SENT_317	[p20l533t1636r707b1685],

1	Nature	NNP	O	Nature	_	0	SENT_318	[p20l721t1639r894b1685],
2	425	CD	NUMBER	425	num	1	SENT_318	[p20l906t1639r1021b1693],
3	,	,	O	,	_	0	SENT_318	[p20l906t1639r1021b1693],
4	512-516	CD	NUMBER	512-516	num	1	SENT_318	[p20l1036t1639r1259b1685],
5	(	CD	NUMBER	(	num	7	SENT_318	[p20l1275t1637r1448b1693],
6	2003	CD	DATE	2003	num	7	SENT_318	[p20l1275t1637r1448b1693],
7	)	NN	O	)	dep	1	SENT_318	[p20l1275t1637r1448b1693],
8	.	.	O	.	_	0	SENT_318	[p20l1275t1637r1448b1693],

1	6	CD	NUMBER	6	_	0	SENT_319	[p20l8t1716r50b1761],
2	.	.	O	.	_	0	SENT_319	[p20l8t1716r50b1761],

1	Lee	NNP	PERSON	Lee	nsubj	19	SENT_320	[p20l131t1715r230b1769],
2	,	,	O	,	_	0	SENT_320	[p20l131t1715r230b1769],
3	H.H.	NNP	LOCATION	H.H.	appos	1	SENT_320	[p20l246t1715r362b1769],
4	,	,	O	,	_	0	SENT_320	[p20l246t1715r362b1769],
5	Norris	NNP	PERSON	Norris	appos	1	SENT_320	[p20l379t1715r542b1769],
6	,	,	O	,	_	0	SENT_320	[p20l379t1715r542b1769],
7	A.	NN	O	a.	appos	1	SENT_320	[p20l556t1715r618b1769],
8	,	,	O	,	_	0	SENT_320	[p20l556t1715r618b1769],
9	Weiss	NNP	PERSON	Weiss	appos	1	SENT_320	[p20l629t1715r787b1769],
10	,	,	O	,	_	0	SENT_320	[p20l629t1715r787b1769],
11	J.B.	NNP	ORGANIZATION	J.B.	appos	1	SENT_320	[p20l799t1714r879b1761],
12	&	CC	ORGANIZATION	&	_	0	SENT_320	[p20l893t1714r930b1761],
13	Frasch	NNP	ORGANIZATION	Frasch	appos	1	SENT_320	[p20l945t1712r1120b1769],
14	,	,	O	,	_	0	SENT_320	[p20l945t1712r1120b1769],
15	M.	NNP	PERSON	M.	nn	18	SENT_320	[p20l1136t1715r1195b1761],
16	Jelly	NNP	PERSON	Jelly	nn	18	SENT_320	[p20l1207t1712r1322b1775],
17	belly	NN	O	belly	nn	18	SENT_320	[p20l1337t1712r1460b1775],
18	protein	NN	O	protein	appos	1	SENT_320	[p20l1474t1715r1660b1774],
19	activates	VBZ	O	activate	_	0	SENT_320	[p20l1676t1715r1904b1761],
20	the	DT	O	the	det	24	SENT_320	[p20l1918t1712r2004b1761],
21	receptor	NN	O	receptor	nn	24	SENT_320	[p20l132t1796r351b1850],
22	tyrosine	NN	O	tyrosine	nn	24	SENT_320	[p20l363t1791r573b1851],
23	kinase	NN	O	kinase	nn	24	SENT_320	[p20l590t1788r752b1837],
24	Alk	NN	PERSON	alk	dobj	19	SENT_320	[p20l766t1788r848b1837],
25	to	TO	O	to	aux	26	SENT_320	[p20l859t1796r911b1837],
26	specify	VB	O	specify	xcomp	19	SENT_320	[p20l926t1788r1107b1851],
27	visceral	JJ	O	visceral	amod	29	SENT_320	[p20l1119t1788r1309b1837],
28	muscle	NN	O	muscle	nn	29	SENT_320	[p20l1329t1788r1511b1837],
29	pioneers	NNS	O	pioneer	dobj	26	SENT_320	[p20l1527t1791r1763b1850],
30	.	.	O	.	_	0	SENT_320	[p20l1527t1791r1763b1850],

1	Nature	NNP	O	Nature	_	0	SENT_321	[p20l1778t1791r1950b1837],
2	425	CD	NUMBER	425	num	1	SENT_321	[p20l1962t1791r2077b1845],
3	,	,	O	,	_	0	SENT_321	[p20l1962t1791r2077b1845],
4	507-512	CD	NUMBER	507-512	num	1	SENT_321	[p20l131t1868r352b1914],
5	(	CD	NUMBER	(	num	7	SENT_321	[p20l369t1866r542b1922],
6	2003	CD	DATE	2003	num	7	SENT_321	[p20l369t1866r542b1922],
7	)	NN	O	)	dep	1	SENT_321	[p20l369t1866r542b1922],
8	.	.	O	.	_	0	SENT_321	[p20l369t1866r542b1922],

1	7	CD	NUMBER	7	_	0	SENT_322	[p20l9t1945r49b1990],
2	.	.	O	.	_	0	SENT_322	[p20l9t1945r49b1990],

1	Reiner	NNP	PERSON	Reiner	nsubj	27	SENT_323	[p20l131t1943r303b1998],
2	,	,	O	,	_	0	SENT_323	[p20l131t1943r303b1998],
3	D.J.	NNP	PERSON	D.J.	nsubj	27	SENT_323	[p20l320t1943r415b1998],
4	,	,	O	,	_	0	SENT_323	[p20l320t1943r415b1998],
5	Ailion	NNP	O	Ailion	nsubj	27	SENT_323	[p20l429t1941r591b1998],
6	,	,	O	,	_	0	SENT_323	[p20l429t1941r591b1998],
7	M.	NNP	O	M.	nsubj	27	SENT_323	[p20l607t1941r908b1998],
8	,	,	O	,	_	0	SENT_323	[p20l607t1941r908b1998],
9	Thomas	NNP	PERSON	Thomas	nsubj	27	SENT_323	[p20l607t1941r908b1998],
10	,	,	O	,	_	0	SENT_323	[p20l607t1941r908b1998],
11	J.H.	NNP	ORGANIZATION	J.H.	nsubj	27	SENT_323	[p20l921t1944r1009b1990],
12	&	CC	ORGANIZATION	&	_	0	SENT_323	[p20l1023t1943r1059b1990],
13	Meyer	NNP	ORGANIZATION	Meyer	conj_and	1	SENT_323	[p20l1074t1944r1243b2004],
14	,	,	O	,	_	0	SENT_323	[p20l1074t1944r1243b2004],
15	B.J.	NNP	PERSON	B.J.	nn	17	SENT_323	[p20l1260t1943r1335b1990],
16	C.	NNP	PERSON	C.	nn	17	SENT_323	[p20l1351t1943r1392b1990],
17	elegans	NNS	PERSON	elegan	appos	1	SENT_323	[p20l1407t1941r1600b2003],
18	anaplastic	JJ	O	anaplastic	amod	26	SENT_323	[p20l1613t1941r1876b2003],
19	lymphoma	NN	O	lymphoma	nn	26	SENT_323	[p20l132t2017r412b2080],
20	kinase	NN	O	kinase	nn	26	SENT_323	[p20l430t2017r592b2066],
21	ortholog	NN	O	ortholog	nn	26	SENT_323	[p20l607t2017r834b2079],
22	SCD	NN	O	scd	nn	26	SENT_323	[p20l851t2019r1009b2066],
23	—	NN	O	—	nn	26	SENT_323	[p20l851t2019r1009b2066],
24	2	CD	NUMBER	2	num	26	SENT_323	[p20l851t2019r1009b2066],
25	controls	NNS	O	control	nn	26	SENT_323	[p20l1024t2017r1233b2066],
26	dauer	NN	O	dauer	dep	17	SENT_323	[p20l1248t2017r1399b2066],
27	formation	NN	O	formation	_	0	SENT_323	[p20l1411t2017r1668b2066],
28	by	IN	O	by	_	0	SENT_323	[p20l1687t2017r1748b2080],
29	modulating	VBG	O	modulate	prepc_by	27	SENT_323	[p20l1763t2017r2065b2079],
30	TGF	NN	O	tgf	nn	33	SENT_323	[p20l128t2094r365b2143],
31	—	NN	O	—	nn	33	SENT_323	[p20l128t2094r365b2143],
32	beta	NN	O	beta	nn	33	SENT_323	[p20l128t2094r365b2143],
33	signaling	NN	O	signaling	dobj	29	SENT_323	[p20l381t2094r630b2156],
34	.	.	O	.	_	0	SENT_323	[p20l381t2094r630b2156],

1	Curr	NN	O	curr	_	0	SENT_324	[p20l645t2096r757b2143],
2	.	.	O	.	_	0	SENT_324	[p20l645t2096r757b2143],

1	Biol	NNP	O	Biol	_	0	SENT_325	[p20l772t2094r876b2143],
2	.	.	O	.	_	0	SENT_325	[p20l772t2094r876b2143],

1	18	CD	NUMBER	18	_	0	SENT_326	[p20l893t2097r970b2151],
2	,	,	O	,	_	0	SENT_326	[p20l893t2097r970b2151],
3	1	CD	NUMBER	1	num	4	SENT_326	[p20l989t2098r1003b2143],
4	101-1	CD	NUMBER	101-1	appos	1	SENT_326	[p20l1021t2098r1165b2143],
5	109	CD	NUMBER	109	number	6	SENT_326	[p20l1183t2097r1272b2143],
6	(	CD	NUMBER	(	dep	4	SENT_326	[p20l1288t2095r1462b2151],
7	2008	CD	DATE	2008	num	8	SENT_326	[p20l1288t2095r1462b2151],
8	)	NN	O	)	dep	6	SENT_326	[p20l1288t2095r1462b2151],
9	.	.	O	.	_	0	SENT_326	[p20l1288t2095r1462b2151],

1	8	CD	NUMBER	8	_	0	SENT_327	[p20l8t2175r49b2220],
2	.	.	O	.	_	0	SENT_327	[p20l8t2175r49b2220],

1	Bilsland	NNP	O	Bilsland	_	0	SENT_328	[p20l131t2171r342b2228],
2	,	,	O	,	_	0	SENT_328	[p20l131t2171r342b2228],
3	J.G.	NNP	PERSON	J.G.	nn	4	SENT_328	[p20l355t2173r442b2220],
4	etal	NNP	O	etal	appos	1	SENT_328	[p20l457t2171r571b2220],
5	.	.	O	.	_	0	SENT_328	[p20l457t2171r571b2220],

1	Behavioral	JJ	O	behavioral	amod	4	SENT_329	[p20l587t2171r856b2220],
2	and	CC	O	and	_	0	SENT_329	[p20l873t2171r968b2220],
3	neurochemical	JJ	O	neurochemical	conj_and	1	SENT_329	[p20l987t2171r1372b2220],
4	alterations	NNS	O	alteration	nsubj	12	SENT_329	[p20l1389t2171r1664b2220],
5	in	IN	O	in	_	0	SENT_329	[p20l1680t2174r1722b2220],
6	mice	NNS	O	mouse	prep_in	4	SENT_329	[p20l1741t2174r1862b2220],
7	deﬁcient	JJ	O	deﬁcient	amod	6	SENT_329	[p20l1877t2171r2105b2220],
8	in	IN	O	in	_	0	SENT_329	[p20l132t2250r174b2296],
9	anaplastic	JJ	O	anaplastic	amod	11	SENT_329	[p20l190t2247r454b2309],
10	lymphoma	NN	O	lymphoma	nn	11	SENT_329	[p20l470t2247r750b2310],
11	kinase	NN	O	kinase	prep_in	7	SENT_329	[p20l768t2247r930b2296],
12	suggest	VBP	O	suggest	_	0	SENT_329	[p20l945t2255r1150b2309],
13	therapeutic	JJ	O	therapeutic	amod	14	SENT_329	[p20l1162t2247r1465b2309],
14	potential	NN	O	potential	dobj	12	SENT_329	[p20l1481t2247r1712b2309],
15	for	IN	O	for	_	0	SENT_329	[p20l1727t2247r1800b2296],
16	psychiatric	JJ	O	psychiatric	amod	17	SENT_329	[p20l1814t2247r2092b2310],
17	indications	NNS	O	indication	prep_for	14	SENT_329	[p20l132t2323r428b2372],
18	.	.	O	.	_	0	SENT_329	[p20l132t2323r428b2372],

1	Neuropsychopharmacology	NNP	O	Neuropsychopharmacology	_	0	SENT_330	[p20l442t2323r1148b2386],
2	33	CD	NUMBER	33	num	1	SENT_330	[p20l1159t2326r1238b2380],
3	,	,	O	,	_	0	SENT_330	[p20l1159t2326r1238b2380],
4	685-700	CD	NUMBER	685-700	num	1	SENT_330	[p20l1252t2326r1475b2372],
5	(	CD	NUMBER	(	num	7	SENT_330	[p20l1492t2324r1665b2380],
6	2008	CD	DATE	2008	num	7	SENT_330	[p20l1492t2324r1665b2380],
7	)	NN	O	)	dep	1	SENT_330	[p20l1492t2324r1665b2380],
8	.	.	O	.	_	0	SENT_330	[p20l1492t2324r1665b2380],

1	9	CD	NUMBER	9	_	0	SENT_331	[p20l8t2403r49b2449],
2	.	.	O	.	_	0	SENT_331	[p20l8t2403r49b2449],

1	Grifﬁn	NNP	PERSON	Grifﬁn	nn	17	SENT_332	[p20l128t2400r301b2457],
2	,	,	O	,	_	0	SENT_332	[p20l128t2400r301b2457],
3	C.A.	NNP	LOCATION	C.A.	appos	17	SENT_332	[p20l316t2402r426b2457],
4	,	,	O	,	_	0	SENT_332	[p20l316t2402r426b2457],
5	Hawkins	NNP	PERSON	Hawkins	appos	17	SENT_332	[p20l443t2400r673b2457],
6	,	,	O	,	_	0	SENT_332	[p20l443t2400r673b2457],
7	A.L.	NNP	O	A.L.	appos	17	SENT_332	[p20l687t2403r791b2457],
8	,	,	O	,	_	0	SENT_332	[p20l687t2403r791b2457],
9	Dvorak	NNP	PERSON	Dvorak	appos	17	SENT_332	[p20l808t2400r1004b2457],
10	,	,	O	,	_	0	SENT_332	[p20l808t2400r1004b2457],
11	C.	NNP	O	C.	appos	17	SENT_332	[p20l1018t2402r1077b2457],
12	,	,	O	,	_	0	SENT_332	[p20l1018t2402r1077b2457],
13	Henkle	NNP	PERSON	Henkle	appos	17	SENT_332	[p20l1094t2400r1286b2457],
14	,	,	O	,	_	0	SENT_332	[p20l1094t2400r1286b2457],
15	C.	NNP	O	C.	appos	17	SENT_332	[p20l1300t2402r1359b2457],
16	,	,	O	,	_	0	SENT_332	[p20l1300t2402r1359b2457],
17	E	NNP	O	E	_	0	SENT_332	[p20l1375t2400r1696b2462],
18	|	VBD	O	|	rcmod	17	SENT_332	[p20l1375t2400r1696b2462],
19	lingham	NN	O	lingham	dobj	18	SENT_332	[p20l1375t2400r1696b2462],
20	,	,	O	,	_	0	SENT_332	[p20l1375t2400r1696b2462],
21	T.	NNP	ORGANIZATION	T.	appos	19	SENT_332	[p20l1375t2400r1696b2462],
22	&	CC	ORGANIZATION	&	_	0	SENT_332	[p20l1710t2402r1746b2449],
23	Perlman	NNP	ORGANIZATION	Perlman	appos	19	SENT_332	[p20l1761t2400r1986b2457],
24	,	,	O	,	_	0	SENT_332	[p20l1761t2400r1986b2457],
25	E.J.	NNP	O	E.J.	appos	21	SENT_332	[p20l2004t2403r2076b2449],

1	Recurrent	JJ	O	recurrent	amod	2	SENT_333	[p20l132t2478r385b2525],
2	involvement	NN	O	involvement	_	0	SENT_333	[p20l400t2476r726b2525],
3	of	IN	O	of	_	0	SENT_333	[p20l740t2476r794b2525],
4	2p23	NN	O	2p23	prep_of	2	SENT_333	[p20l804t2479r932b2538],
5	in	IN	O	in	_	0	SENT_333	[p20l949t2479r992b2525],
6	inﬂammatory	JJ	O	inﬂammatory	amod	8	SENT_333	[p20l1010t2476r1363b2539],
7	myoﬁbroblastic	JJ	O	myoﬁbroblastic	amod	8	SENT_333	[p20l1378t2476r1783b2539],
8	tumors	NNS	O	tumor	prep_in	2	SENT_333	[p20l1796t2484r1995b2525],
9	.	.	O	.	_	0	SENT_333	[p20l1796t2484r1995b2525],

1	Cancer	NN	O	cancer	_	0	SENT_334	[p20l131t2555r307b2602],
2	Res	NNP	O	Res	dep	1	SENT_334	[p20l315t2555r410b2602],
3	.	.	O	.	_	0	SENT_334	[p20l315t2555r410b2602],

1	59	CD	NUMBER	59	_	0	SENT_335	[p20l425t2556r504b2610],
2	,	,	O	,	_	0	SENT_335	[p20l425t2556r504b2610],
3	2776-2780	CD	DATE	2776-2780	number	4	SENT_335	[p20l519t2556r806b2602],
4	(	CD	NUMBER	(	appos	1	SENT_335	[p20l823t2554r995b2610],
5	1999	CD	DATE	1999	num	6	SENT_335	[p20l823t2554r995b2610],
6	)	NN	O	)	dep	4	SENT_335	[p20l823t2554r995b2610],
7	.	.	O	.	_	0	SENT_335	[p20l823t2554r995b2610],

1	10	CD	NUMBER	10	_	0	SENT_336	[p20l12t2633r82b2679],
2	.	.	O	.	_	0	SENT_336	[p20l12t2633r82b2679],

1	Debelenko	NNP	PERSON	Debelenko	_	0	SENT_337	[p20l131t2630r425b2687],
2	,	,	O	,	_	0	SENT_337	[p20l131t2630r425b2687],
3	L.V.	NNP	PERSON	L.V.	nn	4	SENT_337	[p20l441t2633r523b2679],
4	etal	NNP	O	etal	appos	1	SENT_337	[p20l537t2630r651b2679],
5	.	.	O	.	_	0	SENT_337	[p20l537t2630r651b2679],

1	Renal	JJ	O	renal	amod	3	SENT_338	[p20l668t2630r806b2679],
2	cell	NN	O	cell	nn	3	SENT_338	[p20l823t2630r906b2679],
3	carcinoma	NN	O	carcinoma	_	0	SENT_338	[p20l923t2633r1192b2679],
4	with	IN	O	with	_	0	SENT_338	[p20l1207t2630r1320b2679],
5	novel	JJ	O	novel	amod	6	SENT_338	[p20l1339t2630r1476b2679],
6	VCL	NNP	O	VCL	prep_with	3	SENT_338	[p20l1489t2630r1895b2679],
7	.	.	O	.	_	0	SENT_338	[p20l1489t2630r1895b2679],

1	—	NN	O	—	_	0	SENT_339	[p20l1489t2630r1895b2679],
2	.	.	O	.	_	0	SENT_339	[p20l1489t2630r1895b2679],

1	ALKfusion	NNP	O	ALKfusion	_	0	SENT_340	[p20l1489t2630r1895b2679],
2	:	:	O	:	_	0	SENT_340	[p20l1489t2630r1895b2679],
3	new	JJ	O	new	amod	4	SENT_340	[p20l1912t2644r2021b2679],
4	representative	NN	O	representative	dep	1	SENT_340	[p20l132t2710r506b2769],
5	of	IN	O	of	_	0	SENT_340	[p20l520t2707r574b2756],
6	ALK	NNP	O	ALK	nn	7	SENT_340	[p20l583t2707r976b2756],
7	—	NN	O	—	prep_of	4	SENT_340	[p20l583t2707r976b2756],
8	associated	VBN	O	associate	partmod	4	SENT_340	[p20l583t2707r976b2756],
9	tumor	NN	O	tumor	nn	10	SENT_340	[p20l991t2715r1155b2756],
10	spectrum	NN	O	spectrum	dobj	8	SENT_340	[p20l1168t2715r1428b2769],
11	.	.	O	.	_	0	SENT_340	[p20l1168t2715r1428b2769],

1	Mod	NN	O	mod	_	0	SENT_341	[p20l1441t2707r1565b2756],
2	.	.	O	.	_	0	SENT_341	[p20l1441t2707r1565b2756],

1	Pathol	NN	PERSON	pathol	_	0	SENT_342	[p20l1580t2707r1754b2756],
2	.	.	O	.	_	0	SENT_342	[p20l1580t2707r1754b2756],

1	24	CD	NUMBER	24	_	0	SENT_343	[p20l1768t2710r1847b2764],
2	,	,	O	,	_	0	SENT_343	[p20l1768t2710r1847b2764],
3	430-442	CD	NUMBER	430-442	num	4	SENT_343	[p20l1860t2710r2084b2756],
4	(	NN	O	(	appos	1	SENT_343	[p20l132t2785r232b2841],
5	201	CD	NUMBER	201	number	6	SENT_343	[p20l132t2785r232b2841],
6	1	CD	NUMBER	1	num	7	SENT_343	[p20l250t2785r305b2841],
7	)	NN	O	)	dep	4	SENT_343	[p20l250t2785r305b2841],
8	.	.	O	.	_	0	SENT_343	[p20l250t2785r305b2841],

1	11	CD	NUMBER	11	_	0	SENT_344	[p20l12t2865r82b2910],
2	.	.	O	.	_	0	SENT_344	[p20l12t2865r82b2910],

1	Lipson	NNP	PERSON	Lipson	_	0	SENT_345	[p20l131t2864r313b2923],
2	,	,	O	,	_	0	SENT_345	[p20l131t2864r313b2923],
3	D.	NNP	O	D.	nn	4	SENT_345	[p20l330t2863r377b2910],
4	etal	NNP	O	etal	appos	1	SENT_345	[p20l391t2861r505b2910],
5	.	.	O	.	_	0	SENT_345	[p20l391t2861r505b2910],

1	Identiﬁcation	NN	O	identiﬁcation	_	0	SENT_346	[p20l522t2861r864b2910],
2	of	IN	O	of	_	0	SENT_346	[p20l881t2861r935b2910],
3	new	JJ	O	new	amod	4	SENT_346	[p20l946t2875r1055b2910],
4	ALK	NNP	O	ALK	prep_of	1	SENT_346	[p20l1068t2864r1170b2910],
5	and	CC	O	and	_	0	SENT_346	[p20l1182t2861r1278b2910],
6	RET	NNP	O	RET	nn	8	SENT_346	[p20l1297t2863r1391b2910],
7	gene	NN	O	gene	nn	8	SENT_346	[p20l1403t2875r1533b2923],
8	fusions	NNS	O	fusion	prep_of	1	SENT_346	[p20l1546t2861r1731b2910],
9	from	IN	O	from	_	0	SENT_346	[p20l1745t2861r1867b2910],
10	colorectal	JJ	O	colorectal	amod	14	SENT_346	[p20l1883t2861r2136b2910],
11	and	CC	O	and	_	0	SENT_346	[p20l130t2938r226b2987],
12	lung	NN	O	lung	amod	14	SENT_346	[p20l244t2938r357b3000],
13	cancer	NN	O	cancer	nn	14	SENT_346	[p20l373t2952r545b2987],
14	biopsies	NNS	O	biopsy	prep_from	1	SENT_346	[p20l560t2938r785b3000],
15	.	.	O	.	_	0	SENT_346	[p20l560t2938r785b3000],

1	Nat	NN	PERSON	nat	_	0	SENT_347	[p20l799t2941r899b2987],
2	.	.	O	.	_	0	SENT_347	[p20l799t2941r899b2987],

1	Med	NNP	O	Med	_	0	SENT_348	[p20l913t2938r1035b2987],
2	.	.	O	.	_	0	SENT_348	[p20l913t2938r1035b2987],

1	18	CD	NUMBER	18	_	0	SENT_349	[p20l1052t2941r1129b2995],
2	,	,	O	,	_	0	SENT_349	[p20l1052t2941r1129b2995],
3	382-384	CD	NUMBER	382-384	number	4	SENT_349	[p20l1143t2941r1367b2987],
4	(	CD	NUMBER	(	appos	1	SENT_349	[p20l1382t2939r1555b2995],
5	2012	CD	DATE	2012	num	6	SENT_349	[p20l1382t2939r1555b2995],
6	)	NN	O	)	dep	4	SENT_349	[p20l1382t2939r1555b2995],
7	.	.	O	.	_	0	SENT_349	[p20l1382t2939r1555b2995],

1	12	CD	NUMBER	12	_	0	SENT_350	[p20l12t3017r82b3063],
2	.	.	O	.	_	0	SENT_350	[p20l12t3017r82b3063],

1	Lin	NNP	PERSON	Lin	_	0	SENT_351	[p20l131t3017r217b3071],
2	,	,	O	,	_	0	SENT_351	[p20l131t3017r217b3071],
3	E.	NNP	O	E.	nn	4	SENT_351	[p20l234t3017r272b3063],
4	etal	NN	O	etal	appos	1	SENT_351	[p20l286t3014r400b3063],
5	.	.	O	.	_	0	SENT_351	[p20l286t3014r400b3063],

1	Exon	NN	O	exon	nn	3	SENT_352	[p20l417t3017r538b3063],
2	array	NN	O	array	nn	3	SENT_352	[p20l554t3028r684b3077],
3	proﬁling	NN	O	proﬁling	nsubj	4	SENT_352	[p20l699t3014r915b3076],
4	detects	VBZ	O	detect	_	0	SENT_352	[p20l932t3014r1122b3063],
5	EML4	NN	O	eml4	dobj	4	SENT_352	[p20l1139t3014r1572b3063],
6	.	.	O	.	_	0	SENT_352	[p20l1139t3014r1572b3063],

1	—	NN	O	—	_	0	SENT_353	[p20l1139t3014r1572b3063],
2	.	.	O	.	_	0	SENT_353	[p20l1139t3014r1572b3063],

1	ALKfusion	NN	O	alkfusion	_	0	SENT_354	[p20l1139t3014r1572b3063],
2	in	IN	O	in	_	0	SENT_354	[p20l1589t3017r1632b3063],
3	breast	NN	O	breast	prep_in	1	SENT_354	[p20l1650t3014r1821b3071],
4	,	,	O	,	_	0	SENT_354	[p20l1650t3014r1821b3071],
5	colorectal	JJ	O	colorectal	appos	3	SENT_354	[p20l1836t3014r2104b3071],
6	,	,	O	,	_	0	SENT_354	[p20l1836t3014r2104b3071],

1	and	CC	O	and	cc	5	SENT_355	[p20l130t3090r225b3139],
2	non	JJ	O	non	amod	5	SENT_355	[p20l244t3090r499b3140],
3	—	JJ	O	—	amod	5	SENT_355	[p20l244t3090r499b3140],
4	small	JJ	O	small	amod	5	SENT_355	[p20l244t3090r499b3140],
5	cell	NN	O	cell	_	0	SENT_355	[p20l515t3090r598b3139],
6	lung	NN	O	lung	nn	7	SENT_355	[p20l617t3090r730b3153],
7	cancers	NNS	O	cancer	dep	5	SENT_355	[p20l746t3105r954b3139],
8	.	.	O	.	_	0	SENT_355	[p20l746t3105r954b3139],

1	Mo	NN	PERSON	mo	nsubj	2	SENT_356	[p20l967t3090r1072b3139],
2	/	:	O	/	_	0	SENT_356	[p20l967t3090r1072b3139],
3	.	.	O	.	_	0	SENT_356	[p20l967t3090r1072b3139],

1	CancerRes	NNS	O	cancerre	_	0	SENT_357	[p20l1087t3092r1367b3140],
2	.	.	O	.	_	0	SENT_357	[p20l1087t3092r1367b3140],

1	7	CD	NUMBER	7	_	0	SENT_358	[p20l1382t3094r1425b3147],
2	,	,	O	,	_	0	SENT_358	[p20l1382t3094r1425b3147],
3	1466-1476	CD	DATE	1466-1476	number	4	SENT_358	[p20l1444t3094r1728b3139],
4	(	CD	NUMBER	(	appos	1	SENT_358	[p20l1744t3091r1917b3147],
5	2009	CD	DATE	2009	num	6	SENT_358	[p20l1744t3091r1917b3147],
6	)	NN	O	)	dep	4	SENT_358	[p20l1744t3091r1917b3147],
7	.	.	O	.	_	0	SENT_358	[p20l1744t3091r1917b3147],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_359	[p20l22t3223r141b3244],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	dep	12	SENT_359	[p20l150t3223r375b3244],
3	&	CC	O	&	_	0	SENT_359	[p20l382t3223r602b3244],
4	THERAPEUT	NNP	O	THERAPEUT	nn	6	SENT_359	[p20l382t3223r602b3244],
5	|	CD	NUMBER	|	num	6	SENT_359	[p20l382t3223r602b3244],
6	CS	NNP	O	CS	conj_and	2	SENT_359	[p20l382t3223r602b3244],
7	|	NNP	O	|	nn	8	SENT_359	[p20l612t3221r614b3251],
8	VOLUME	NNP	O	VOLUME	dep	2	SENT_359	[p20l622t3223r730b3244],
9	95	CD	NUMBER	95	num	10	SENT_359	[p20l738t3223r765b3244],
10	NUMBER	NN	O	number	dep	12	SENT_359	[p20l775t3223r883b3244],
11	1	CD	NUMBER	1	num	12	SENT_359	[p20l893t3224r900b3244],
12	|	CD	NUMBER	|	dep	15	SENT_359	[p20l914t3221r916b3251],
13	JANUARY	NNP	DATE	JANUARY	dep	12	SENT_359	[p20l925t3223r1043b3244],
14	2014	CD	DATE	2014	num	15	SENT_359	[p20l1051t3223r1109b3244],
15	21	CD	DATE	21	_	0	SENT_359	[p20l2111t3223r2137b3244],

1	STATE	NN	O	state	nn	2	SENT_360	[p20l21t3366r163b3403],
2	ART	NN	O	art	_	0	SENT_360	[p20l306t3366r399b3403],

1	13	CD	NUMBER	13	_	0	SENT_361	[p20l14t3604r84b3650],
2	.	.	O	.	_	0	SENT_361	[p20l14t3604r84b3650],

1	Chen	NNP	PERSON	Chen	_	0	SENT_362	[p20l131t3601r330b3658],
2	,	,	O	,	_	0	SENT_362	[p20l131t3601r330b3658],
3	Y.	NNP	O	Y.	nn	4	SENT_362	[p20l131t3601r330b3658],
4	etal	NN	O	etal	appos	1	SENT_362	[p20l344t3601r459b3650],
5	.	.	O	.	_	0	SENT_362	[p20l344t3601r459b3650],

1	Oncogenic	JJ	O	oncogenic	amod	2	SENT_363	[p20l473t3602r759b3664],
2	mutations	NNS	O	mutation	_	0	SENT_363	[p20l776t3603r1041b3650],
3	of	IN	O	of	_	0	SENT_363	[p20l1056t3600r1111b3650],
4	ALK	NN	O	alk	nn	5	SENT_363	[p20l1120t3603r1223b3650],
5	kinase	NN	O	kinase	prep_of	2	SENT_363	[p20l1237t3601r1400b3650],
6	in	IN	O	in	_	0	SENT_363	[p20l1416t3603r1459b3650],
7	neuroblastoma	NN	O	neuroblastoma	prep_in	2	SENT_363	[p20l1478t3601r1890b3650],
8	.	.	O	.	_	0	SENT_363	[p20l1478t3601r1890b3650],

1	Nature	NNP	O	Nature	_	0	SENT_364	[p20l1904t3603r2078b3650],

1	George	NNP	PERSON	George	nn	3	SENT_365	[p21l131t20r336b81],
2	,	,	O	,	_	0	SENT_365	[p21l131t20r336b81],
3	R.E.	NNP	PERSON	R.E.	_	0	SENT_365	[p21l354t20r439b67],
4	et	FW	O	et	nn	5	SENT_365	[p21l453t25r502b67],
5	al.	FW	O	al.	dep	3	SENT_365	[p21l511t18r568b67],
6	.	.	O	.	_	0	SENT_365	[p21l511t18r568b67],

1	Activating	VBG	O	activate	amod	2	SENT_366	[p21l582t20r848b81],
2	mutations	NNS	O	mutation	nsubj	5	SENT_366	[p21l867t20r1132b67],
3	in	IN	O	in	_	0	SENT_366	[p21l1149t20r1192b67],
4	ALK	NNP	O	ALK	prep_in	2	SENT_366	[p21l1207t20r1311b67],
5	provide	VBP	O	provide	_	0	SENT_366	[p21l1325t18r1523b80],
6	a	DT	O	a	det	8	SENT_366	[p21l1538t32r1563b67],
7	therapeutic	JJ	O	therapeutic	amod	8	SENT_366	[p21l1578t18r1884b80],
8	target	NN	O	target	dobj	5	SENT_366	[p21l1897t25r2056b81],
9	in	IN	O	in	_	0	SENT_366	[p21l2071t20r2114b67],
10	neuroblastoma	NN	O	neuroblastoma	prep_in	8	SENT_366	[p21l134t95r547b144],
11	.	.	O	.	_	0	SENT_366	[p21l134t95r547b144],

1	Nature	NNP	O	Nature	_	0	SENT_367	[p21l561t97r735b144],
2	455	CD	NUMBER	455	num	1	SENT_367	[p21l747t99r864b151],
3	,	,	O	,	_	0	SENT_367	[p21l747t99r864b151],
4	975-978	CD	NUMBER	975-978	num	1	SENT_367	[p21l879t98r1103b144],
5	(	CD	NUMBER	(	num	7	SENT_367	[p21l1119t96r1294b151],
6	2008	CD	DATE	2008	num	7	SENT_367	[p21l1119t96r1294b151],
7	)	NN	O	)	dep	1	SENT_367	[p21l1119t96r1294b151],
8	.	.	O	.	_	0	SENT_367	[p21l1119t96r1294b151],

1	Janoueix-Lerosey	NNP	PERSON	Janoueix-Lerosey	_	0	SENT_368	[p21l129t175r597b236],
2	,	,	O	,	_	0	SENT_368	[p21l129t175r597b236],
3	I.	NNP	O	I.	nn	4	SENT_368	[p21l614t175r636b222],
4	etal	NNP	O	etal	appos	1	SENT_368	[p21l650t173r765b222],
5	.	.	O	.	_	0	SENT_368	[p21l650t173r765b222],

1	Somatic	JJ	MISC	somatic	amod	5	SENT_369	[p21l780t174r991b222],
2	and	CC	O	and	_	0	SENT_369	[p21l1006t173r1102b222],
3	germline	NN	O	germline	amod	5	SENT_369	[p21l1119t173r1354b236],
4	activating	NN	O	activating	nn	5	SENT_369	[p21l1369t175r1627b236],
5	mutations	NNS	O	mutation	_	0	SENT_369	[p21l1645t175r1911b222],
6	of	IN	O	of	_	0	SENT_369	[p21l1926t172r1981b222],
7	the	DT	O	the	det	10	SENT_369	[p21l1989t173r2075b222],
8	ALK	NN	O	alk	nn	10	SENT_369	[p21l132t253r235b300],
9	kinase	NN	O	kinase	nn	10	SENT_369	[p21l249t251r413b300],
10	receptor	NN	O	receptor	prep_of	5	SENT_369	[p21l429t258r650b313],
11	in	IN	O	in	_	0	SENT_369	[p21l665t253r707b300],
12	neuroblastoma	NN	O	neuroblastoma	prep_in	5	SENT_369	[p21l726t251r1138b301],
13	.	.	O	.	_	0	SENT_369	[p21l726t251r1138b301],

1	Nature	NNP	O	Nature	_	0	SENT_370	[p21l1152t253r1326b300],
2	455	CD	NUMBER	455	num	1	SENT_370	[p21l1338t255r1455b308],
3	,	,	O	,	_	0	SENT_370	[p21l1338t255r1455b308],
4	967-970	CD	NUMBER	967-970	num	1	SENT_370	[p21l1470t254r1694b300],
5	(	CD	NUMBER	(	num	7	SENT_370	[p21l1710t252r1885b308],
6	2008	CD	DATE	2008	num	7	SENT_370	[p21l1710t252r1885b308],
7	)	NN	O	)	dep	1	SENT_370	[p21l1710t252r1885b308],
8	.	.	O	.	_	0	SENT_370	[p21l1710t252r1885b308],

1	Mossé	NNP	O	Mossé	_	0	SENT_371	[p21l132t330r396b386],
2	,	,	O	,	_	0	SENT_371	[p21l132t330r396b386],
3	Y.P.	NNP	O	Y.P.	nn	4	SENT_371	[p21l132t330r396b386],
4	etal	NN	O	etal	appos	1	SENT_371	[p21l410t329r525b378],
5	.	.	O	.	_	0	SENT_371	[p21l410t329r525b378],

1	Identiﬁcation	NN	O	identiﬁcation	_	0	SENT_372	[p21l543t328r887b378],
2	of	IN	O	of	_	0	SENT_372	[p21l904t328r958b378],
3	ALK	NNP	O	ALK	prep_of	1	SENT_372	[p21l967t331r1071b378],
4	as	IN	O	as	_	0	SENT_372	[p21l1082t343r1134b378],
5	a	DT	O	a	det	9	SENT_372	[p21l1149t343r1174b378],
6	majorfamilial	JJ	O	majorfamilial	amod	9	SENT_372	[p21l1193t328r1543b392],
7	neuroblastoma	NN	O	neuroblastoma	nn	9	SENT_372	[p21l1562t329r1960b378],
8	predisposition	NN	O	predisposition	nn	9	SENT_372	[p21l134t407r509b469],
9	gene	NN	O	gene	prep_as	1	SENT_372	[p21l526t421r669b470],
10	.	.	O	.	_	0	SENT_372	[p21l526t421r669b470],

1	Nature	NNP	O	Nature	_	0	SENT_373	[p21l684t409r858b456],
2	455	CD	NUMBER	455	num	1	SENT_373	[p21l870t411r986b464],
3	,	,	O	,	_	0	SENT_373	[p21l870t411r986b464],
4	930-935	CD	NUMBER	930-935	num	1	SENT_373	[p21l1001t410r1223b456],
5	(	CD	NUMBER	(	num	7	SENT_373	[p21l1242t408r1416b464],
6	2008	CD	DATE	2008	num	7	SENT_373	[p21l1242t408r1416b464],
7	)	NN	O	)	dep	1	SENT_373	[p21l1242t408r1416b464],
8	.	.	O	.	_	0	SENT_373	[p21l1242t408r1416b464],

1	Murugan	NNP	PERSON	Murugan	nsubj	11	SENT_374	[p21l132t487r385b548],
2	,	,	O	,	_	0	SENT_374	[p21l132t487r385b548],
3	A.K.	NNP	ORGANIZATION	A.K.	conj_and	1	SENT_374	[p21l399t487r497b534],
4	&	CC	ORGANIZATION	&	_	0	SENT_374	[p21l511t486r548b534],
5	Xing	NNP	ORGANIZATION	Xing	conj_and	1	SENT_374	[p21l560t487r692b548],
6	,	,	O	,	_	0	SENT_374	[p21l560t487r692b548],
7	M.	NNP	O	M.	nn	10	SENT_374	[p21l707t487r767b534],
8	Anaplastic	NNP	O	Anaplastic	nn	10	SENT_374	[p21l781t485r1054b547],
9	thyroid	NN	O	thyroid	nn	10	SENT_374	[p21l1067t485r1255b548],
10	cancers	NNS	O	cancer	appos	1	SENT_374	[p21l1271t499r1468b534],
11	harbor	VBP	O	harbor	_	0	SENT_374	[p21l1485t485r1660b534],
12	novel	JJ	O	novel	amod	14	SENT_374	[p21l1675t485r1814b534],
13	oncogenic	JJ	O	oncogenic	amod	14	SENT_374	[p21l1831t487r2108b548],
14	mutations	NNS	O	mutation	dobj	11	SENT_374	[p21l134t565r401b612],
15	of	IN	O	of	_	0	SENT_374	[p21l415t562r470b612],
16	the	DT	O	the	det	18	SENT_374	[p21l478t563r564b612],
17	ALK	NN	O	alk	nn	18	SENT_374	[p21l578t565r681b612],
18	gene	NN	O	gene	prep_of	14	SENT_374	[p21l693t577r837b626],
19	.	.	O	.	_	0	SENT_374	[p21l693t577r837b626],

1	Cancer	NN	O	cancer	_	0	SENT_375	[p21l852t564r1029b612],
2	Res	NNP	O	Res	dep	1	SENT_375	[p21l1038t565r1133b612],
3	.	.	O	.	_	0	SENT_375	[p21l1038t565r1133b612],

1	71	CD	NUMBER	71	_	0	SENT_376	[p21l1149t567r1206b612],
2	,	,	O	,	_	0	SENT_376	[p21l1218t603r1228b620],
3	4403-4411	CD	DURATION	4403-4411	number	4	SENT_376	[p21l1241t566r1523b612],
4	(	CD	NUMBER	(	appos	1	SENT_376	[p21l1549t564r1724b620],
5	2011	CD	DATE	2011	num	6	SENT_376	[p21l1549t564r1724b620],
6	)	NN	O	)	dep	4	SENT_376	[p21l1549t564r1724b620],
7	.	.	O	.	_	0	SENT_376	[p21l1549t564r1724b620],

1	Soda	NNP	O	Soda	_	0	SENT_377	[p21l131t641r274b698],
2	,	,	O	,	_	0	SENT_377	[p21l131t641r274b698],
3	M.	NNP	O	M.	nn	4	SENT_377	[p21l290t643r349b690],
4	etal	NNP	O	etal	appos	1	SENT_377	[p21l363t641r478b690],
5	.	.	O	.	_	0	SENT_377	[p21l363t641r478b690],

1	A	DT	O	a	det	3	SENT_378	[p21l493t643r529b690],
2	mouse	NN	O	mouse	nn	3	SENT_378	[p21l545t655r720b690],
3	model	NN	O	model	_	0	SENT_378	[p21l737t641r900b690],
4	for	IN	O	for	_	0	SENT_378	[p21l915t640r988b690],
5	EML4-ALK-positive	JJ	O	eml4-alk-positive	amod	7	SENT_378	[p21l1003t643r1494b703],
6	lung	NN	O	lung	nn	7	SENT_378	[p21l1510t641r1624b704],
7	cancer	NN	O	cancer	prep_for	3	SENT_378	[p21l1641t655r1822b690],
8	.	.	O	.	_	0	SENT_378	[p21l1641t655r1822b690],

1	Proc	NNP	O	Proc	_	0	SENT_379	[p21l1836t643r1955b690],
2	.	.	O	.	_	0	SENT_379	[p21l1836t643r1955b690],

1	Natl.	NNP	O	Natl.	nn	2	SENT_380	[p21l1970t641r2084b690],
2	Acad	NNP	O	Acad	_	0	SENT_380	[p21l129t718r267b767],
3	.	.	O	.	_	0	SENT_380	[p21l129t718r267b767],

1	Sci	NNP	O	Sci	_	0	SENT_381	[p21l281t719r361b767],
2	.	.	O	.	_	0	SENT_381	[p21l281t719r361b767],

1	USA	NNP	LOCATION	USA	_	0	SENT_382	[p21l379t719r477b767],
2	105	CD	NUMBER	105	num	1	SENT_382	[p21l496t721r608b774],
3	,	,	O	,	_	0	SENT_382	[p21l496t721r608b774],
4	19893-19897	CD	NUMBER	19893-19897	num	1	SENT_382	[p21l627t721r978b767],
5	(	CD	NUMBER	(	num	7	SENT_382	[p21l995t719r1169b774],
6	2008	CD	DATE	2008	num	7	SENT_382	[p21l995t719r1169b774],
7	)	NN	O	)	dep	1	SENT_382	[p21l995t719r1169b774],
8	.	.	O	.	_	0	SENT_382	[p21l995t719r1169b774],

1	Sharma	FW	PERSON	sharma	dep	16	SENT_383	[p21l131t796r344b853],
2	,	,	O	,	_	0	SENT_383	[p21l131t796r344b853],
3	S.V.	NNP	ORGANIZATION	S.V.	appos	1	SENT_383	[p21l358t798r444b846],
4	&	CC	ORGANIZATION	&	_	0	SENT_383	[p21l458t798r495b846],
5	Settleman	NNP	ORGANIZATION	Settleman	conj_and	3	SENT_383	[p21l508t796r789b853],
6	,	,	O	,	_	0	SENT_383	[p21l508t796r789b853],
7	J.	NNP	O	J.	nn	9	SENT_383	[p21l802t798r836b846],
8	Oncogene	NN	O	oncogene	nn	9	SENT_383	[p21l850t797r1124b859],
9	addiction	NN	O	addiction	appos	1	SENT_383	[p21l1139t796r1402b846],
10	:	:	O	:	_	0	SENT_383	[p21l1139t796r1402b846],
11	setting	VBG	O	set	csubj	16	SENT_383	[p21l1416t798r1595b859],
12	the	DT	O	the	det	13	SENT_383	[p21l1611t796r1697b846],
13	stage	NN	O	stage	dobj	11	SENT_383	[p21l1711t804r1852b859],
14	for	IN	O	for	prep	11	SENT_383	[p21l1865t795r1938b846],
15	molecularly	RB	O	molecularly	advmod	16	SENT_383	[p21l134t874r441b937],
16	targeted	VBN	O	target	_	0	SENT_383	[p21l453t874r677b937],
17	cancer	NN	O	cancer	nn	18	SENT_383	[p21l693t888r867b923],
18	therapy	NN	O	therapy	dobj	16	SENT_383	[p21l878t874r1092b938],
19	.	.	O	.	_	0	SENT_383	[p21l878t874r1092b938],

1	Genes	NNS	O	gene	_	0	SENT_384	[p21l1107t876r1259b923],
2	Dev	NN	O	dev	dep	1	SENT_384	[p21l1271t876r1381b923],
3	.	.	O	.	_	0	SENT_384	[p21l1271t876r1381b923],

1	21	CD	NUMBER	21	_	0	SENT_385	[p21l1395t877r1475b931],
2	,	,	O	,	_	0	SENT_385	[p21l1395t877r1475b931],
3	3214-3231	CD	DURATION	3214-3231	number	4	SENT_385	[p21l1490t877r1770b923],
4	(	CD	NUMBER	(	appos	1	SENT_385	[p21l1796t875r1971b931],
5	2007	CD	DATE	2007	num	6	SENT_385	[p21l1796t875r1971b931],
6	)	NN	O	)	dep	4	SENT_385	[p21l1796t875r1971b931],
7	.	.	O	.	_	0	SENT_385	[p21l1796t875r1971b931],

1	Katayama	NNP	PERSON	Katayama	_	0	SENT_386	[p21l133t954r403b1015],
2	,	,	O	,	_	0	SENT_386	[p21l133t954r403b1015],
3	R.	NNP	O	R.	nn	4	SENT_386	[p21l419t954r461b1001],
4	etal	NN	O	etal	appos	1	SENT_386	[p21l475t952r590b1001],
5	.	.	O	.	_	0	SENT_386	[p21l475t952r590b1001],

1	Mechanisms	NNS	O	mechanism	_	0	SENT_387	[p21l606t952r933b1002],
2	of	IN	O	of	_	0	SENT_387	[p21l948t951r1003b1001],
3	acquired	VBN	O	acquire	amod	5	SENT_387	[p21l1012t952r1240b1014],
4	crizotinib	JJ	O	crizotinib	amod	5	SENT_387	[p21l1256t952r1501b1002],
5	resistance	NN	O	resistance	prep_of	1	SENT_387	[p21l1518t954r1776b1001],
6	in	IN	O	in	_	0	SENT_387	[p21l1792t954r1835b1001],
7	ALKrearranged	JJ	O	alkrearranged	amod	9	SENT_387	[p21l1851t954r1971b1001, p21l134t1030r421b1093],
8	lung	NN	O	lung	nn	9	SENT_387	[p21l440t1030r553b1093],
9	Cancers	NNS	O	cancer	prep_in	5	SENT_387	[p21l569t1031r787b1080],
10	.	.	O	.	_	0	SENT_387	[p21l569t1031r787b1080],

1	Sci	NNP	O	Sci	_	0	SENT_388	[p21l800t1031r881b1080],
2	.	.	O	.	_	0	SENT_388	[p21l800t1031r881b1080],

1	Transl	NN	O	transl	_	0	SENT_389	[p21l898t1030r1054b1080],
2	.	.	O	.	_	0	SENT_389	[p21l898t1030r1054b1080],

1	Med	NNP	O	Med	_	0	SENT_390	[p21l1068t1030r1191b1080],
2	.	.	O	.	_	0	SENT_390	[p21l1068t1030r1191b1080],

1	4	CD	NUMBER	4	_	0	SENT_391	[p21l1204t1034r1250b1087],
2	,	,	O	,	_	0	SENT_391	[p21l1204t1034r1250b1087],
3	120ra17	CD	NUMBER	120ra17	num	4	SENT_391	[p21l1269t1033r1475b1080],
4	(	CD	NUMBER	(	appos	1	SENT_391	[p21l1492t1031r1666b1087],
5	2012	CD	DATE	2012	num	6	SENT_391	[p21l1492t1031r1666b1087],
6	)	NN	O	)	dep	4	SENT_391	[p21l1492t1031r1666b1087],
7	.	.	O	.	_	0	SENT_391	[p21l1492t1031r1666b1087],

1	Ou	NNP	LOCATION	Ou	_	0	SENT_392	[p21l131t1108r219b1163],
2	,	,	O	,	_	0	SENT_392	[p21l131t1108r219b1163],
3	S.H.	NNP	LOCATION	S.H.	nn	9	SENT_392	[p21l234t1108r342b1163],
4	,	,	O	,	_	0	SENT_392	[p21l234t1108r342b1163],
5	Bartlett	NNP	PERSON	Bartlett	appos	9	SENT_392	[p21l359t1107r563b1163],
6	,	,	O	,	_	0	SENT_392	[p21l359t1107r563b1163],
7	C.H.	NNP	LOCATION	C.H.	appos	9	SENT_392	[p21l578t1108r692b1163],
8	,	,	O	,	_	0	SENT_392	[p21l578t1108r692b1163],
9	Mino	NNP	PERSON	Mino	appos	1	SENT_392	[p21l708t1107r1143b1163],
10	.	.	O	.	_	0	SENT_392	[p21l708t1107r1143b1163],

1	—	NN	O	—	_	0	SENT_393	[p21l708t1107r1143b1163],
2	.	.	O	.	_	0	SENT_393	[p21l708t1107r1143b1163],

1	Kenudson	NNP	PERSON	Kenudson	_	0	SENT_394	[p21l708t1107r1143b1163],
2	,	,	O	,	_	0	SENT_394	[p21l708t1107r1143b1163],
3	M.	NNP	O	M.	conj_and	1	SENT_394	[p21l1159t1109r1231b1163],
4	,	,	O	,	_	0	SENT_394	[p21l1159t1109r1231b1163],
5	Cui	NNP	PERSON	Cui	conj_and	1	SENT_394	[p21l1246t1109r1341b1163],
6	,	,	O	,	_	0	SENT_394	[p21l1246t1109r1341b1163],
7	J.	NNP	ORGANIZATION	J.	conj_and	1	SENT_394	[p21l1354t1109r1387b1156],
8	&	CC	ORGANIZATION	&	_	0	SENT_394	[p21l1402t1109r1439b1156],
9	Iafrate	NNP	ORGANIZATION	Iafrate	conj_and	1	SENT_394	[p21l1454t1106r1628b1163],
10	,	,	O	,	_	0	SENT_394	[p21l1454t1106r1628b1163],
11	A.J.	NNP	PERSON	A.J.	nn	12	SENT_394	[p21l1642t1109r1727b1156],
12	Crizotinib	NNP	PERSON	Crizotinib	appos	1	SENT_394	[p21l1741t1107r1994b1156],
13	for	IN	O	for	_	0	SENT_394	[p21l2007t1106r2080b1156],
14	the	DT	O	the	det	15	SENT_394	[p21l131t1185r217b1235],
15	treatment	NN	O	treatment	prep_for	12	SENT_394	[p21l230t1192r495b1235],
16	of	IN	O	of	_	0	SENT_394	[p21l509t1184r563b1235],
17	ALK	NNP	O	ALK	prep_of	15	SENT_394	[p21l572t1185r984b1248],
18	—	CD	NUMBER	—	num	17	SENT_394	[p21l572t1185r984b1248],
19	rearranged	VBN	O	rearrange	partmod	12	SENT_394	[p21l572t1185r984b1248],
20	non-small	JJ	O	non-small	amod	23	SENT_394	[p21l1002t1185r1259b1235],
21	cell	NN	O	cell	nn	23	SENT_394	[p21l1276t1185r1359b1235],
22	lung	NN	O	lung	nn	23	SENT_394	[p21l1379t1185r1492b1248],
23	cancer	NN	O	cancer	dobj	19	SENT_394	[p21l1508t1200r1694b1235],
24	:	:	O	:	_	0	SENT_394	[p21l1508t1200r1694b1235],
25	a	DT	O	a	det	27	SENT_394	[p21l1709t1200r1734b1235],
26	success	NN	O	success	nn	27	SENT_394	[p21l1750t1200r1945b1235],
27	story	NN	O	story	nsubj	29	SENT_394	[p21l1960t1192r2091b1248],
28	to	TO	O	to	aux	29	SENT_394	[p21l131t1270r184b1312],
29	usher	VB	O	usher	parataxis	19	SENT_394	[p21l201t1263r345b1313],
30	in	IN	O	in	_	0	SENT_394	[p21l360t1265r402b1312],
31	the	DT	O	the	det	33	SENT_394	[p21l418t1263r504b1313],
32	second	JJ	DATE	second	amod	33	SENT_394	[p21l519t1263r704b1313],
33	decade	NN	DATE	decade	prep_in	29	SENT_394	[p21l721t1263r913b1313],
34	of	IN	O	of	_	0	SENT_394	[p21l927t1262r982b1312],
35	moleculartargeted	JJ	O	moleculartargeted	amod	36	SENT_394	[p21l993t1263r1490b1326],
36	therapy	NN	O	therapy	prep_of	33	SENT_394	[p21l1506t1263r1710b1327],
37	in	IN	O	in	_	0	SENT_394	[p21l1725t1265r1768b1312],
38	oncology	NN	O	oncology	prep_in	29	SENT_394	[p21l1784t1263r2040b1326],
39	.	.	O	.	_	0	SENT_394	[p21l1784t1263r2040b1326],

1	Oncologist	NN	O	oncologist	_	0	SENT_395	[p21l133t1341r409b1404],
2	17	CD	NUMBER	17	num	1	SENT_395	[p21l423t1345r500b1398],
3	,	,	O	,	_	0	SENT_395	[p21l423t1345r500b1398],
4	1351-1375	CD	DATE	1351-1375	number	5	SENT_395	[p21l519t1344r802b1391],
5	(	CD	NUMBER	(	appos	1	SENT_395	[p21l821t1342r995b1398],
6	2012	CD	DATE	2012	num	7	SENT_395	[p21l821t1342r995b1398],
7	)	NN	O	)	dep	5	SENT_395	[p21l821t1342r995b1398],
8	.	.	O	.	_	0	SENT_395	[p21l821t1342r995b1398],

1	Majewski	NNP	PERSON	Majewski	_	0	SENT_396	[p21l132t1419r388b1482],
2	,	,	O	,	_	0	SENT_396	[p21l132t1419r388b1482],
3	|	CD	NUMBER	|	appos	1	SENT_396	[p21l405t1421r463b1469],
4	.	.	O	.	_	0	SENT_396	[p21l405t1421r463b1469],

1	J.	NNP	O	J.	nn	2	SENT_397	[p21l405t1421r463b1469],
2	etal	NNP	O	etal	_	0	SENT_397	[p21l477t1419r592b1469],
3	.	.	O	.	_	0	SENT_397	[p21l477t1419r592b1469],

1	Identiﬁcation	NN	O	identiﬁcation	_	0	SENT_398	[p21l609t1418r954b1469],
2	of	IN	O	of	_	0	SENT_398	[p21l970t1418r1025b1469],
3	recurrent	JJ	O	recurrent	amod	6	SENT_398	[p21l1036t1426r1277b1469],
4	FGFR3	NN	O	fgfr3	nn	6	SENT_398	[p21l1293t1421r1455b1469],
5	fusion	NN	O	fusion	nn	6	SENT_398	[p21l1470t1418r1630b1469],
6	genes	NNS	O	gene	prep_of	1	SENT_398	[p21l1647t1434r1803b1482],
7	in	IN	O	in	_	0	SENT_398	[p21l1820t1421r1862b1468],
8	lung	NN	O	lung	nn	9	SENT_398	[p21l1881t1419r1994b1482],
9	cancerthrough	NN	O	cancerthrough	nn	12	SENT_398	[p21l132t1497r531b1560],
10	kinome-centred	JJ	O	kinome-centred	amod	12	SENT_398	[p21l550t1497r971b1547],
11	RNA	NN	O	rna	nn	12	SENT_398	[p21l990t1499r1100b1546],
12	sequencing	NN	O	sequencing	prep_in	1	SENT_398	[p21l1114t1499r1477b1560],
13	.	.	O	.	_	0	SENT_398	[p21l1114t1499r1477b1560],

1	J.	NNP	PERSON	J.	nn	2	SENT_399	[p21l1114t1499r1477b1560],
2	Pathol	NNP	PERSON	Pathol	_	0	SENT_399	[p21l1492t1497r1668b1547],
3	.	.	O	.	_	0	SENT_399	[p21l1492t1497r1668b1547],

1	230	CD	NUMBER	230	_	0	SENT_400	[p21l1682t1500r1798b1554],
2	,	,	O	,	_	0	SENT_400	[p21l1682t1500r1798b1554],
3	270-276	CD	NUMBER	270-276	number	4	SENT_400	[p21l1813t1500r2037b1547],
4	(	CD	NUMBER	(	appos	1	SENT_400	[p21l134t1575r309b1630],
5	2013	CD	DATE	2013	num	6	SENT_400	[p21l134t1575r309b1630],
6	)	NN	O	)	dep	4	SENT_400	[p21l134t1575r309b1630],
7	.	.	O	.	_	0	SENT_400	[p21l134t1575r309b1630],

1	Heuckmann	NNP	PERSON	Heuckmann	_	0	SENT_401	[p21l133t1652r464b1709],
2	,	,	O	,	_	0	SENT_401	[p21l133t1652r464b1709],
3	J.M.	NNP	O	J.M.	nn	4	SENT_401	[p21l476t1654r575b1702],
4	etal	NN	O	etal	appos	1	SENT_401	[p21l589t1652r704b1701],
5	.	.	O	.	_	0	SENT_401	[p21l589t1652r704b1701],

1	Differential	JJ	O	differential	amod	3	SENT_402	[p21l721t1651r1007b1701],
2	protein	NN	O	protein	nn	3	SENT_402	[p21l1026t1654r1213b1714],
3	stability	NN	O	stability	_	0	SENT_402	[p21l1229t1652r1436b1716],
4	and	CC	O	and	_	0	SENT_402	[p21l1449t1652r1546b1701],
5	ALK	NN	O	alk	nn	7	SENT_402	[p21l1562t1654r1665b1701],
6	inhibitor	NN	O	inhibitor	nn	7	SENT_402	[p21l1679t1652r1903b1701],
7	sensitivity	NN	O	sensitivity	conj_and	3	SENT_402	[p21l133t1732r396b1793],
8	of	IN	O	of	_	0	SENT_402	[p21l409t1729r463b1779],
9	EML4	NN	O	eml4	prep_of	3	SENT_402	[p21l475t1732r741b1779],
10	.	.	O	.	_	0	SENT_402	[p21l475t1732r741b1779],

1	—	NN	O	—	_	0	SENT_403	[p21l475t1732r741b1779],
2	.	.	O	.	_	0	SENT_403	[p21l475t1732r741b1779],

1	ALK	NN	O	alk	_	0	SENT_404	[p21l475t1732r741b1779],
2	fusion	NN	O	fusion	nn	3	SENT_404	[p21l751t1729r911b1779],
3	variants	NNS	O	variant	dep	1	SENT_404	[p21l926t1732r1145b1780],
4	.	.	O	.	_	0	SENT_404	[p21l926t1732r1145b1780],

1	Clin	NNP	O	Clin	_	0	SENT_405	[p21l1160t1730r1265b1779],
2	.	.	O	.	_	0	SENT_405	[p21l1160t1730r1265b1779],

1	Cancer	NN	O	cancer	_	0	SENT_406	[p21l1281t1732r1459b1779],
2	Res	NNP	O	Res	dep	1	SENT_406	[p21l1467t1732r1563b1779],
3	.	.	O	.	_	0	SENT_406	[p21l1467t1732r1563b1779],

1	18	CD	NUMBER	18	_	0	SENT_407	[p21l1580t1733r1658b1787],
2	,	,	O	,	_	0	SENT_407	[p21l1580t1733r1658b1787],
3	4682-4690	CD	DURATION	4682-4690	number	4	SENT_407	[p21l1670t1733r1962b1779],
4	(	CD	NUMBER	(	appos	1	SENT_407	[p21l1978t1731r2153b1787],
5	2012	CD	DATE	2012	num	6	SENT_407	[p21l1978t1731r2153b1787],
6	)	NN	O	)	dep	4	SENT_407	[p21l1978t1731r2153b1787],
7	.	.	O	.	_	0	SENT_407	[p21l1978t1731r2153b1787],

1	Kwak	NNP	PERSON	Kwak	_	0	SENT_408	[p21l133t1808r282b1865],
2	,	,	O	,	_	0	SENT_408	[p21l133t1808r282b1865],
3	E.L.	NNP	O	E.L.	nn	4	SENT_408	[p21l299t1810r380b1857],
4	etal	NN	O	etal	appos	1	SENT_408	[p21l394t1808r510b1857],
5	.	.	O	.	_	0	SENT_408	[p21l394t1808r510b1857],

1	Anaplastic	JJ	O	anaplastic	amod	4	SENT_409	[p21l523t1808r797b1870],
2	lymphoma	NN	O	lymphoma	nn	4	SENT_409	[p21l814t1808r1096b1872],
3	kinase	NN	O	kinase	nn	4	SENT_409	[p21l1114t1808r1277b1857],
4	inhibition	NN	O	inhibition	_	0	SENT_409	[p21l1293t1808r1544b1857],
5	in	IN	O	in	_	0	SENT_409	[p21l1562t1810r1605b1857],
6	non-small-cell	JJ	O	non-small-cell	amod	8	SENT_409	[p21l1623t1808r1990b1857],
7	lung	NN	O	lung	nn	8	SENT_409	[p21l2010t1808r2123b1871],
8	cancer	NN	O	cancer	prep_in	4	SENT_409	[p21l132t1900r314b1936],
9	.	.	O	.	_	0	SENT_409	[p21l132t1900r314b1936],

1	N.	NNP	O	N.	nn	2	SENT_410	[p21l328t1888r376b1936],
2	Engl	NNP	O	Engl	_	0	SENT_410	[p21l391t1886r555b1949],
3	.	.	O	.	_	0	SENT_410	[p21l391t1886r555b1949],

1	J.	NNP	O	J.	nn	2	SENT_411	[p21l391t1886r555b1949],
2	Med	NNP	O	Med	_	0	SENT_411	[p21l569t1886r692b1936],
3	.	.	O	.	_	0	SENT_411	[p21l569t1886r692b1936],

1	363	CD	NUMBER	363	_	0	SENT_412	[p21l706t1889r822b1943],
2	,	,	O	,	_	0	SENT_412	[p21l706t1889r822b1943],
3	1693-1703	CD	DATE	1693-1703	number	4	SENT_412	[p21l841t1889r1125b1936],
4	(	CD	NUMBER	(	appos	1	SENT_412	[p21l1143t1887r1317b1943],
5	2010	CD	DATE	2010	num	6	SENT_412	[p21l1143t1887r1317b1943],
6	)	NN	O	)	dep	4	SENT_412	[p21l1143t1887r1317b1943],
7	.	.	O	.	_	0	SENT_412	[p21l1143t1887r1317b1943],

1	Solomon	NNP	PERSON	Solomon	nn	5	SENT_413	[p21l131t1964r381b2021],
2	,	,	O	,	_	0	SENT_413	[p21l131t1964r381b2021],
3	B.	NNP	O	B.	appos	5	SENT_413	[p21l398t1964r838b2021],
4	,	,	O	,	_	0	SENT_413	[p21l398t1964r838b2021],
5	Vare	NNP	O	Vare	nsubj	6	SENT_413	[p21l398t1964r838b2021],
6	|	VBD	O	|	_	0	SENT_413	[p21l398t1964r838b2021],
7	|	CD	NUMBER	|	num	8	SENT_413	[p21l398t1964r838b2021],
8	a-Garcia	NN	O	a-garcium	dobj	6	SENT_413	[p21l398t1964r838b2021],
9	,	,	O	,	_	0	SENT_413	[p21l398t1964r838b2021],
10	M.	NNP	ORGANIZATION	M.	appos	8	SENT_413	[p21l853t1966r912b2014],
11	&	CC	ORGANIZATION	&	_	0	SENT_413	[p21l926t1965r963b2014],
12	Camidge	NNP	ORGANIZATION	Camidge	conj_and	10	SENT_413	[p21l976t1964r1224b2027],
13	,	,	O	,	_	0	SENT_413	[p21l976t1964r1224b2027],
14	D.R.	NNP	ORGANIZATION	D.R.	nn	17	SENT_413	[p21l1241t1966r1336b2014],
15	ALK	NNP	ORGANIZATION	ALK	nn	17	SENT_413	[p21l1349t1966r1453b2013],
16	gene	NN	O	gene	nn	17	SENT_413	[p21l1465t1978r1596b2027],
17	rearrangements	NNS	O	rearrangement	appos	8	SENT_413	[p21l1613t1971r2045b2027],
18	:	:	O	:	_	0	SENT_413	[p21l1613t1971r2045b2027],
19	a	DT	O	a	det	22	SENT_413	[p21l2060t1978r2085b2014],
20	new	JJ	O	new	amod	22	SENT_413	[p21l134t2057r244b2091],
21	therapeutic	JJ	O	therapeutic	amod	22	SENT_413	[p21l256t2042r562b2104],
22	target	NN	O	target	nsubj	35	SENT_413	[p21l574t2049r733b2105],
23	in	IN	O	in	_	0	SENT_413	[p21l749t2044r792b2091],
24	a	DT	O	a	prep_in	22	SENT_413	[p21l808t2057r834b2091],
25	molecularly	RB	O	molecularly	advmod	26	SENT_413	[p21l852t2042r1158b2106],
26	deﬁned	VBN	O	deﬁned	partmod	24	SENT_413	[p21l1171t2041r1370b2091],
27	subset	NN	O	subset	dobj	26	SENT_413	[p21l1387t2042r1559b2092],
28	of	IN	O	of	_	0	SENT_413	[p21l1573t2041r1627b2091],
29	non	JJ	O	non	amod	33	SENT_413	[p21l1639t2042r1895b2092],
30	—	JJ	O	—	amod	33	SENT_413	[p21l1639t2042r1895b2092],
31	small	JJ	O	small	amod	33	SENT_413	[p21l1639t2042r1895b2092],
32	cell	NN	O	cell	nn	33	SENT_413	[p21l1912t2042r1996b2091],
33	lung	NN	O	lung	prep_of	27	SENT_413	[p21l2015t2042r2128b2105],
34	ca	MD	O	can	aux	35	SENT_413	[p21l132t2133r186b2168],
35	ncer	VB	O	ncer	parataxis	6	SENT_413	[p21l194t2133r314b2168],
36	.	.	O	.	_	0	SENT_413	[p21l194t2133r314b2168],

1	J.	NNP	PERSON	J.	nn	2	SENT_414	[p21l324t2121r358b2168],
2	Thorac	NNP	PERSON	Thorac	_	0	SENT_414	[p21l376t2119r558b2168],
3	.	.	O	.	_	0	SENT_414	[p21l376t2119r558b2168],

1	Oncol	NN	O	oncol	_	0	SENT_415	[p21l573t2119r733b2168],
2	.	.	O	.	_	0	SENT_415	[p21l573t2119r733b2168],

1	4	CD	NUMBER	4	_	0	SENT_416	[p21l747t2123r793b2175],
2	,	,	O	,	_	0	SENT_416	[p21l747t2123r793b2175],
3	1450-1454	CD	DATE	1450-1454	number	4	SENT_416	[p21l811t2122r1098b2168],
4	(	CD	NUMBER	(	appos	1	SENT_416	[p21l1113t2120r1288b2175],
5	2009	CD	DATE	2009	num	6	SENT_416	[p21l1113t2120r1288b2175],
6	)	NN	O	)	dep	4	SENT_416	[p21l1113t2120r1288b2175],
7	.	.	O	.	_	0	SENT_416	[p21l1113t2120r1288b2175],

1	Rodig	NNP	O	Rodig	nn	3	SENT_417	[p21l133t2197r295b2260],
2	,	,	O	,	_	0	SENT_417	[p21l133t2197r295b2260],
3	S.J.	NNP	O	S.J.	dep	4	SENT_417	[p21l310t2198r386b2247],
4	etal	JJ	O	etal	_	0	SENT_417	[p21l401t2197r515b2247],
5	.	.	O	.	_	0	SENT_417	[p21l401t2197r515b2247],

1	Unique	JJ	O	unique	amod	3	SENT_418	[p21l532t2199r721b2259],
2	clinicopathologic	JJ	O	clinicopathologic	amod	3	SENT_418	[p21l735t2197r1191b2260],
3	features	NNS	O	feature	nsubj	4	SENT_418	[p21l1203t2196r1415b2247],
4	characterize	VBP	O	characterize	_	0	SENT_418	[p21l1430t2197r1749b2247],
5	ALKrearranged	JJ	O	alkrearranged	amod	7	SENT_418	[p21l1762t2199r1882b2246, p21l134t2275r421b2338],
6	lung	NN	O	lung	nn	7	SENT_418	[p21l439t2275r553b2338],
7	adenocarcinoma	NN	O	adenocarcinoma	dobj	4	SENT_418	[p21l569t2275r1011b2325],
8	in	IN	O	in	_	0	SENT_418	[p21l1029t2277r1071b2324],
9	the	DT	O	the	det	11	SENT_418	[p21l1087t2275r1172b2325],
10	western	JJ	O	western	amod	11	SENT_418	[p21l1186t2282r1394b2325],
11	population	NN	O	population	prep_in	7	SENT_418	[p21l1413t2275r1714b2337],
12	.	.	O	.	_	0	SENT_418	[p21l1413t2275r1714b2337],

1	Clin	NNP	O	Clin	_	0	SENT_419	[p21l1730t2275r1835b2325],
2	.	.	O	.	_	0	SENT_419	[p21l1730t2275r1835b2325],

1	CancerRes	NNS	O	cancerre	_	0	SENT_420	[p21l1851t2276r2132b2325],
2	.	.	O	.	_	0	SENT_420	[p21l1851t2276r2132b2325],

1	15	CD	NUMBER	15	_	0	SENT_421	[p21l135t2355r212b2407],
2	,	,	O	,	_	0	SENT_421	[p21l135t2355r212b2407],
3	5216-5223	CD	DURATION	5216-5223	number	4	SENT_421	[p21l227t2354r515b2400],
4	(	CD	NUMBER	(	appos	1	SENT_421	[p21l533t2352r708b2408],
5	2009	CD	DATE	2009	num	6	SENT_421	[p21l533t2352r708b2408],
6	)	NN	O	)	dep	4	SENT_421	[p21l533t2352r708b2408],
7	.	.	O	.	_	0	SENT_421	[p21l533t2352r708b2408],

1	Yoshida	NNP	PERSON	Yoshida	_	0	SENT_422	[p21l129t2429r347b2486],
2	,	,	O	,	_	0	SENT_422	[p21l129t2429r347b2486],
3	A.	NNP	O	A.	nn	4	SENT_422	[p21l361t2431r410b2479],
4	et	NNP	O	et	appos	1	SENT_422	[p21l424t2437r473b2479],
5	al.	FW	O	al.	dep	4	SENT_422	[p21l482t2429r539b2479],
6	.	.	O	.	_	0	SENT_422	[p21l482t2429r539b2479],

1	Comprehensive	NNP	O	Comprehensive	nn	3	SENT_423	[p21l553t2429r968b2491],
2	histologic	JJ	O	histologic	amod	3	SENT_423	[p21l985t2429r1239b2492],
3	analysis	NN	O	analysis	nsubj	7	SENT_423	[p21l1253t2429r1456b2493],
4	of	IN	O	of	_	0	SENT_423	[p21l1471t2428r1525b2479],
5	ALK	NNP	O	ALK	prep_of	3	SENT_423	[p21l1534t2429r1946b2492],
6	—	CD	NUMBER	—	num	5	SENT_423	[p21l1534t2429r1946b2492],
7	rearranged	VBN	O	rearrange	_	0	SENT_423	[p21l1534t2429r1946b2492],
8	lung	NN	O	lung	nn	9	SENT_423	[p21l1965t2429r2078b2492],
9	carcinomas	NNS	O	carcinoma	dobj	7	SENT_423	[p21l132t2509r554b2557],
10	.	.	O	.	_	0	SENT_423	[p21l132t2509r554b2557],

1	Am	NNP	O	Am	_	0	SENT_424	[p21l132t2509r554b2557],
2	.	.	O	.	_	0	SENT_424	[p21l132t2509r554b2557],

1	J.	NNP	O	J.	nn	2	SENT_425	[p21l565t2509r599b2557],
2	Surg	NNP	O	Surg	_	0	SENT_425	[p21l613t2509r737b2570],
3	.	.	O	.	_	0	SENT_425	[p21l613t2509r737b2570],

1	Pathol	NN	PERSON	pathol	_	0	SENT_426	[p21l752t2507r928b2557],
2	.	.	O	.	_	0	SENT_426	[p21l752t2507r928b2557],

1	35	CD	NUMBER	35	_	0	SENT_427	[p21l943t2510r1023b2564],
2	,	,	O	,	_	0	SENT_427	[p21l943t2510r1023b2564],
3	1226-1234	CD	DATE	1226-1234	num	4	SENT_427	[p21l1041t2510r1328b2557],
4	(	NN	O	(	appos	1	SENT_427	[p21l1343t2508r1444b2564],
5	201	CD	NUMBER	201	number	6	SENT_427	[p21l1343t2508r1444b2564],
6	1	CD	NUMBER	1	num	7	SENT_427	[p21l1462t2508r1518b2564],
7	)	NN	O	)	dep	4	SENT_427	[p21l1462t2508r1518b2564],
8	.	.	O	.	_	0	SENT_427	[p21l1462t2508r1518b2564],

1	Zhang	NNP	PERSON	Zhang	_	0	SENT_428	[p21l130t2585r415b2648],
2	,	,	O	,	_	0	SENT_428	[p21l130t2585r415b2648],
3	Y.G.	NNP	O	Y.G.	nn	4	SENT_428	[p21l130t2585r415b2648],
4	etal	NN	O	etal	appos	1	SENT_428	[p21l429t2585r544b2635],
5	.	.	O	.	_	0	SENT_428	[p21l429t2585r544b2635],

1	Evaluation	NN	O	evaluation	nn	3	SENT_429	[p21l562t2585r832b2635],
2	ofALK	NN	O	ofalk	nn	3	SENT_429	[p21l849t2584r1016b2635],
3	rearrangement	NN	O	rearrangement	_	0	SENT_429	[p21l1030t2593r1425b2648],
4	in	IN	O	in	_	0	SENT_429	[p21l1440t2587r1483b2634],
5	Chinese	JJ	MISC	chinese	amod	7	SENT_429	[p21l1499t2585r1708b2635],
6	non	JJ	O	non	amod	7	SENT_429	[p21l1724t2585r1981b2635],
7	—	NN	O	—	prep_in	3	SENT_429	[p21l1724t2585r1981b2635],
8	small	JJ	O	small	amod	11	SENT_429	[p21l1724t2585r1981b2635],
9	cell	NN	O	cell	nn	11	SENT_429	[p21l1998t2585r2081b2635],
10	lung	NN	O	lung	nn	11	SENT_429	[p21l134t2663r248b2726],
11	cancer	NN	O	cancer	dep	3	SENT_429	[p21l264t2678r438b2713],
12	using	VBG	O	use	partmod	3	SENT_429	[p21l453t2665r591b2726],
13	FISH	NN	O	fish	dobj	12	SENT_429	[p21l610t2665r736b2720],
14	,	,	O	,	_	0	SENT_429	[p21l610t2665r736b2720],
15	immunohistochemistry	NN	O	immunohistochemistry	appos	13	SENT_429	[p21l753t2663r1379b2727],
16	,	,	O	,	_	0	SENT_429	[p21l753t2663r1379b2727],
17	and	CC	O	and	_	0	SENT_429	[p21l1394t2663r1490b2713],
18	real	JJ	O	real	amod	22	SENT_429	[p21l1509t2663r1742b2713],
19	—	JJ	O	—	amod	20	SENT_429	[p21l1509t2663r1742b2713],
20	time	NN	O	time	tmod	18	SENT_429	[p21l1509t2663r1742b2713],
21	quantitative	JJ	O	quantitative	amod	22	SENT_429	[p21l1756t2665r2075b2726],
22	RT	NN	O	rt	conj_and	13	SENT_429	[p21l134t2743r212b2790],
23	—	CD	NUMBER	—	num	24	SENT_429	[p21l134t2743r212b2790],
24	PCR	NN	O	pcr	dep	13	SENT_429	[p21l228t2743r328b2791],
25	on	IN	O	on	_	0	SENT_429	[p21l342t2756r406b2791],
26	parafﬁn	NN	O	parafﬁn	prep_on	24	SENT_429	[p21l425t2740r938b2804],
27	—	CD	NUMBER	—	num	29	SENT_429	[p21l425t2740r938b2804],
28	embedded	JJ	O	embedded	amod	29	SENT_429	[p21l425t2740r938b2804],
29	tissues	NNS	O	tissue	dep	24	SENT_429	[p21l953t2743r1142b2791],
30	.	.	O	.	_	0	SENT_429	[p21l953t2743r1142b2791],

1	PLoS	NN	O	plo	_	0	SENT_430	[p21l1156t2743r1276b2791],
2	ONE	CD	NUMBER	one	number	3	SENT_430	[p21l1288t2743r1401b2791],
3	8	CD	NUMBER	8	amod	1	SENT_430	[p21l1411t2744r1456b2798],
4	,	,	O	,	_	0	SENT_430	[p21l1411t2744r1456b2798],
5	e64821	NN	O	e64821	appos	1	SENT_430	[p21l1470t2744r1652b2791],
6	(	CD	NUMBER	(	num	5	SENT_430	[p21l1678t2742r1853b2798],
7	2013	CD	DATE	2013	num	8	SENT_430	[p21l1678t2742r1853b2798],
8	)	NN	O	)	dep	5	SENT_430	[p21l1678t2742r1853b2798],
9	.	.	O	.	_	0	SENT_430	[p21l1678t2742r1853b2798],

1	Shaw	NNP	PERSON	Shaw	nn	3	SENT_431	[p21l131t2819r282b2876],
2	,	,	O	,	_	0	SENT_431	[p21l131t2819r282b2876],
3	A.T.	NNP	O	A.T.	_	0	SENT_431	[p21l296t2821r385b2869],
4	et	FW	O	et	nn	5	SENT_431	[p21l400t2827r449b2869],
5	al.	FW	O	al.	dep	3	SENT_431	[p21l457t2819r515b2869],
6	.	.	O	.	_	0	SENT_431	[p21l457t2819r515b2869],

1	Effect	NN	O	effect	_	0	SENT_432	[p21l531t2818r677b2869],
2	of	IN	O	of	_	0	SENT_432	[p21l690t2818r745b2869],
3	crizotinib	NN	O	crizotinib	prep_of	1	SENT_432	[p21l755t2819r1000b2869],
4	on	IN	O	on	_	0	SENT_432	[p21l1014t2834r1079b2869],
5	overall	JJ	O	overall	amod	6	SENT_432	[p21l1095t2819r1267b2869],
6	survival	NN	O	survival	prep_on	3	SENT_432	[p21l1284t2819r1482b2869],
7	in	IN	O	in	_	0	SENT_432	[p21l1500t2821r1543b2868],
8	patients	NNS	O	patient	prep_in	6	SENT_432	[p21l1561t2821r1772b2881],
9	with	IN	O	with	_	0	SENT_432	[p21l1785t2819r1899b2869],
10	advanced	JJ	O	advanced	amod	12	SENT_432	[p21l132t2897r386b2947],
11	non	JJ	O	non	amod	12	SENT_432	[p21l405t2897r772b2947],
12	—	NN	O	—	prep_with	8	SENT_432	[p21l405t2897r772b2947],
13	small	JJ	O	small	amod	17	SENT_432	[p21l405t2897r772b2947],
14	—	NN	O	—	nn	17	SENT_432	[p21l405t2897r772b2947],
15	cell	NN	O	cell	nn	17	SENT_432	[p21l405t2897r772b2947],
16	lung	NN	O	lung	nn	17	SENT_432	[p21l791t2897r904b2960],
17	cancer	NN	O	cancer	dep	1	SENT_432	[p21l921t2912r1094b2947],
18	harbouring	VBG	O	harbour	partmod	1	SENT_432	[p21l1109t2897r1402b2960],
19	ALK	NN	O	alk	nn	21	SENT_432	[p21l1418t2899r1521b2946],
20	gene	NN	O	gene	nn	21	SENT_432	[p21l1533t2912r1665b2960],
21	rearrangement	NN	O	rearrangement	dobj	18	SENT_432	[p21l1681t2905r2088b2960],
22	:	:	O	:	_	0	SENT_432	[p21l1681t2905r2088b2960],
23	a	DT	O	a	det	25	SENT_432	[p21l2103t2912r2128b2947],
24	retrospective	JJ	O	retrospective	amod	25	SENT_432	[p21l134t2977r477b3037],
25	analysis	NN	O	analysis	dep	21	SENT_432	[p21l492t2975r707b3039],
26	.	.	O	.	_	0	SENT_432	[p21l492t2975r707b3039],

1	Lancet	NNP	O	Lancet	nn	2	SENT_433	[p21l721t2977r892b3025],
2	Oncol	NNP	O	Oncol	_	0	SENT_433	[p21l902t2975r1062b3025],
3	.	.	O	.	_	0	SENT_433	[p21l902t2975r1062b3025],

1	12	CD	NUMBER	12	_	0	SENT_434	[p21l1080t2978r1157b3032],
2	,	,	O	,	_	0	SENT_434	[p21l1080t2978r1157b3032],
3	1004-1012	CD	DATE	1004-1012	num	4	SENT_434	[p21l1176t2978r1460b3025],
4	(	NN	O	(	appos	1	SENT_434	[p21l1478t2976r1579b3032],
5	201	CD	NUMBER	201	number	6	SENT_434	[p21l1478t2976r1579b3032],
6	1	CD	NUMBER	1	num	7	SENT_434	[p21l1597t2976r1652b3032],
7	)	NN	O	)	dep	4	SENT_434	[p21l1597t2976r1652b3032],
8	.	.	O	.	_	0	SENT_434	[p21l1597t2976r1652b3032],

1	Camidge	NNP	O	Camidge	_	0	SENT_435	[p21l130t3053r379b3116],
2	,	,	O	,	_	0	SENT_435	[p21l130t3053r379b3116],
3	D.R.	NNP	PERSON	D.R.	nn	4	SENT_435	[p21l395t3055r490b3103],
4	etal	NNP	O	etal	appos	1	SENT_435	[p21l504t3053r619b3103],
5	.	.	O	.	_	0	SENT_435	[p21l504t3053r619b3103],

1	Activity	NN	O	activity	_	0	SENT_436	[p21l634t3055r833b3117],
2	and	CC	O	and	_	0	SENT_436	[p21l845t3053r942b3103],
3	safety	NN	O	safety	conj_and	1	SENT_436	[p21l959t3052r1114b3117],
4	of	IN	O	of	_	0	SENT_436	[p21l1126t3052r1181b3103],
5	crizotinib	NN	O	crizotinib	prep_of	1	SENT_436	[p21l1191t3053r1435b3103],
6	in	IN	O	in	_	0	SENT_436	[p21l1452t3055r1494b3102],
7	patients	NNS	O	patient	prep_in	5	SENT_436	[p21l1513t3055r1723b3115],
8	with	IN	O	with	_	0	SENT_436	[p21l1736t3053r1850b3103],
9	ALKpositive	JJ	O	alkpositive	amod	11	SENT_436	[p21l1866t3055r1986b3102, p21l134t3133r337b3193],
10	non	JJ	O	non	amod	11	SENT_436	[p21l354t3131r721b3181],
11	—	NN	O	—	prep_with	7	SENT_436	[p21l354t3131r721b3181],
12	small	JJ	O	small	amod	16	SENT_436	[p21l354t3131r721b3181],
13	—	NN	O	—	nn	16	SENT_436	[p21l354t3131r721b3181],
14	cell	NN	O	cell	nn	16	SENT_436	[p21l354t3131r721b3181],
15	lung	NN	O	lung	nn	16	SENT_436	[p21l740t3131r854b3194],
16	cancer	NN	O	cancer	dep	1	SENT_436	[p21l870t3146r1056b3181],
17	:	:	O	:	_	0	SENT_436	[p21l870t3146r1056b3181],
18	updated	VBN	O	update	amod	19	SENT_436	[p21l1072t3131r1291b3193],
19	results	NNS	O	result	dep	1	SENT_436	[p21l1310t3131r1477b3181],
20	from	IN	O	from	_	0	SENT_436	[p21l1490t3130r1613b3181],
21	a	DT	O	a	det	24	SENT_436	[p21l1630t3146r1655b3181],
22	phase	NN	O	phase	nn	24	SENT_436	[p21l1673t3131r1827b3193],
23	1	CD	NUMBER	1	num	24	SENT_436	[p21l1847t3135r1861b3180],
24	study	NN	O	study	prep_from	19	SENT_436	[p21l1885t3131r2040b3195],
25	.	.	O	.	_	0	SENT_436	[p21l1885t3131r2040b3195],

1	LancetOncol	NN	O	lancetoncol	_	0	SENT_437	[p21l132t3208r472b3257],
2	.	.	O	.	_	0	SENT_437	[p21l132t3208r472b3257],

1	13	CD	NUMBER	13	_	0	SENT_438	[p21l490t3211r567b3265],
2	,	,	O	,	_	0	SENT_438	[p21l490t3211r567b3265],
3	101	CD	NUMBER	101	number	4	SENT_438	[p21l586t3211r666b3257],
4	1-1019	CD	NUMBER	1-1019	appos	1	SENT_438	[p21l684t3211r872b3257],
5	(	CD	NUMBER	(	num	7	SENT_438	[p21l888t3209r1062b3265],
6	2012	CD	DATE	2012	num	7	SENT_438	[p21l888t3209r1062b3265],
7	)	NN	O	)	dep	4	SENT_438	[p21l888t3209r1062b3265],
8	.	.	O	.	_	0	SENT_438	[p21l888t3209r1062b3265],

1	Shaw	NNP	PERSON	Shaw	_	0	SENT_439	[p22l131t17r282b74],
2	,	,	O	,	_	0	SENT_439	[p22l131t17r282b74],
3	A.T.	NNP	O	A.T.	nn	4	SENT_439	[p22l295t19r385b67],
4	etal	NNP	O	etal	appos	1	SENT_439	[p22l400t17r515b67],
5	.	.	O	.	_	0	SENT_439	[p22l400t17r515b67],

1	Crizotinib	NNP	O	Crizotinib	_	0	SENT_440	[p22l529t17r782b67],
2	versus	CC	O	versus	prep	1	SENT_440	[p22l796t32r961b67],
3	chemotherapy	NN	O	chemotherapy	dep	2	SENT_440	[p22l976t17r1364b81],
4	in	IN	O	in	_	0	SENT_440	[p22l1379t19r1421b66],
5	advanced	JJ	O	advanced	amod	10	SENT_440	[p22l1438t17r1692b67],
6	ALK	NNP	O	ALK	dep	5	SENT_440	[p22l1708t19r2036b79],
7	—	CD	NUMBER	—	num	6	SENT_440	[p22l1708t19r2036b79],
8	positive	JJ	O	positive	amod	10	SENT_440	[p22l1708t19r2036b79],
9	lung	NN	O	lung	nn	10	SENT_440	[p22l134t95r247b158],
10	cancer	NN	O	cancer	prep_in	1	SENT_440	[p22l264t110r446b145],
11	.	.	O	.	_	0	SENT_440	[p22l264t110r446b145],

1	N.	NNP	O	N.	nn	2	SENT_441	[p22l460t97r508b145],
2	Engl	NNP	O	Engl	_	0	SENT_441	[p22l523t95r641b158],
3	.	.	O	.	_	0	SENT_441	[p22l523t95r641b158],

1	J.	NNP	O	J.	nn	2	SENT_442	[p22l652t97r686b145],
2	Med	NNP	O	Med	_	0	SENT_442	[p22l701t95r824b145],
3	.	.	O	.	_	0	SENT_442	[p22l701t95r824b145],

1	368	CD	NUMBER	368	_	0	SENT_443	[p22l838t98r954b152],
2	,	,	O	,	_	0	SENT_443	[p22l838t98r954b152],
3	2385-2394	CD	DATE	2385-2394	num	4	SENT_443	[p22l968t98r1259b145],
4	(	NN	O	(	appos	1	SENT_443	[p22l1274t96r1375b152],
5	201	CD	NUMBER	201	number	6	SENT_443	[p22l1274t96r1375b152],
6	3	CD	NUMBER	3	num	7	SENT_443	[p22l1390t96r1449b152],
7	)	NN	O	)	dep	4	SENT_443	[p22l1390t96r1449b152],
8	.	.	O	.	_	0	SENT_443	[p22l1390t96r1449b152],

1	Shaw	NNP	PERSON	Shaw	_	0	SENT_444	[p22l131t173r282b230],
2	,	,	O	,	_	0	SENT_444	[p22l131t173r282b230],
3	A.T.	NNP	O	A.T.	nn	4	SENT_444	[p22l295t175r385b223],
4	etal	NNP	O	etal	appos	1	SENT_444	[p22l400t173r515b223],
5	.	.	O	.	_	0	SENT_444	[p22l400t173r515b223],

1	Clinical	JJ	O	clinical	amod	2	SENT_445	[p22l529t173r714b223],
2	features	NNS	O	feature	_	0	SENT_445	[p22l730t172r941b223],
3	and	CC	O	and	_	0	SENT_445	[p22l955t173r1052b223],
4	outcome	NN	O	outcome	conj_and	2	SENT_445	[p22l1068t181r1305b223],
5	of	IN	O	of	_	0	SENT_445	[p22l1319t172r1373b223],
6	patients	NNS	O	patient	prep_of	2	SENT_445	[p22l1385t175r1595b235],
7	with	IN	O	with	_	0	SENT_445	[p22l1609t173r1723b223],
8	non	JJ	O	non	amod	14	SENT_445	[p22l1741t173r2108b223],
9	—	JJ	O	—	amod	14	SENT_445	[p22l1741t173r2108b223],
10	small	JJ	O	small	amod	14	SENT_445	[p22l1741t173r2108b223],
11	—	NN	O	—	nn	14	SENT_445	[p22l1741t173r2108b223],
12	cell	NN	O	cell	nn	14	SENT_445	[p22l1741t173r2108b223],
13	lung	NN	O	lung	nn	14	SENT_445	[p22l134t251r247b314],
14	cancer	NN	O	cancer	prep_with	6	SENT_445	[p22l264t266r437b301],
15	who	WP	O	who	nsubj	16	SENT_445	[p22l449t251r564b301],
16	harbor	VBP	O	harbor	rcmod	6	SENT_445	[p22l581t251r756b301],
17	EML4	NN	O	eml4	dobj	16	SENT_445	[p22l771t253r1093b301],
18	.	.	O	.	_	0	SENT_445	[p22l771t253r1093b301],

1	—	NN	O	—	_	0	SENT_446	[p22l771t253r1093b301],
2	.	.	O	.	_	0	SENT_446	[p22l771t253r1093b301],

1	ALK	NNP	O	ALK	_	0	SENT_447	[p22l771t253r1093b301],
2	.	.	O	.	_	0	SENT_447	[p22l771t253r1093b301],

1	J.	NNP	PERSON	J.	nn	2	SENT_448	[p22l771t253r1093b301],
2	Clin	NNP	PERSON	Clin	_	0	SENT_448	[p22l1109t251r1214b301],
3	.	.	O	.	_	0	SENT_448	[p22l1109t251r1214b301],

1	Oncol	NN	O	oncol	_	0	SENT_449	[p22l1230t251r1390b301],
2	.	.	O	.	_	0	SENT_449	[p22l1230t251r1390b301],

1	27	CD	NUMBER	27	_	0	SENT_450	[p22l1405t254r1484b308],
2	,	,	O	,	_	0	SENT_450	[p22l1405t254r1484b308],
3	4247-4253	CD	DURATION	4247-4253	number	4	SENT_450	[p22l1497t254r1787b301],
4	(	CD	NUMBER	(	appos	1	SENT_450	[p22l1805t252r1980b308],
5	2009	CD	DATE	2009	num	6	SENT_450	[p22l1805t252r1980b308],
6	)	NN	O	)	dep	4	SENT_450	[p22l1805t252r1980b308],
7	.	.	O	.	_	0	SENT_450	[p22l1805t252r1980b308],

1	Wong	NNP	PERSON	Wong	nn	4	SENT_451	[p22l129t331r295b392],
2	,	,	O	,	_	0	SENT_451	[p22l129t331r295b392],
3	D.W.	NNP	O	D.W.	appos	4	SENT_451	[p22l310t331r419b379],
4	etal.	NNP	O	etal.	_	0	SENT_451	[p22l432t329r557b386],
5	;	:	O	;	_	0	SENT_451	[p22l432t329r557b386],
6	University	NNP	ORGANIZATION	University	dep	4	SENT_451	[p22l572t331r828b393],
7	of	IN	ORGANIZATION	of	_	0	SENT_451	[p22l839t328r893b379],
8	Hong	NNP	ORGANIZATION	Hong	nn	13	SENT_451	[p22l904t331r1042b392],
9	Kong	NNP	ORGANIZATION	Kong	nn	13	SENT_451	[p22l1059t331r1190b392],
10	Lung	NN	ORGANIZATION	lung	nn	13	SENT_451	[p22l1208t331r1333b392],
11	Cancer	NN	ORGANIZATION	cancer	nn	13	SENT_451	[p22l1348t331r1526b379],
12	Study	NNP	ORGANIZATION	Study	nn	13	SENT_451	[p22l1539t329r1687b393],
13	Group	NNP	ORGANIZATION	Group	prep_of	6	SENT_451	[p22l1699t329r1976b391],
14	.	.	O	.	_	0	SENT_451	[p22l1699t329r1976b391],

1	The	DT	O	the	det	4	SENT_452	[p22l1699t329r1976b391],
2	EML4ALK	NN	O	eml4alk	nn	4	SENT_452	[p22l1991t331r2148b378, p22l131t409r233b456],
3	fusion	NN	O	fusion	nn	4	SENT_452	[p22l242t406r399b457],
4	gene	NN	O	gene	nsubjpass	6	SENT_452	[p22l414t422r544b470],
5	is	VBZ	O	be	auxpass	6	SENT_452	[p22l559t409r592b457],
6	involved	VBN	O	involve	_	0	SENT_452	[p22l607t407r823b457],
7	in	IN	O	in	_	0	SENT_452	[p22l840t409r882b456],
8	various	JJ	O	various	amod	10	SENT_452	[p22l896t409r1082b457],
9	histologic	JJ	O	histologic	amod	10	SENT_452	[p22l1097t407r1346b470],
10	types	NNS	O	type	prep_in	6	SENT_452	[p22l1357t415r1497b471],
11	of	IN	O	of	_	0	SENT_452	[p22l1511t406r1565b457],
12	lung	NN	O	lung	nn	13	SENT_452	[p22l1575t407r1686b470],
13	cancers	NNS	O	cancer	prep_of	10	SENT_452	[p22l1702t422r1895b457],
14	from	IN	O	from	_	0	SENT_452	[p22l1907t406r2028b457],
15	nonsmokers	NNS	O	nonsmoker	prep_from	6	SENT_452	[p22l134t485r450b535],
16	with	IN	O	with	_	0	SENT_452	[p22l462t485r574b535],
17	wild	JJ	O	wild	amod	20	SENT_452	[p22l588t485r833b549],
18	—	NN	O	—	nn	20	SENT_452	[p22l588t485r833b549],
19	type	NN	O	type	nn	20	SENT_452	[p22l588t485r833b549],
20	EGFR	NN	ORGANIZATION	egfr	prep_with	15	SENT_452	[p22l848t487r979b534],
21	and	CC	O	and	_	0	SENT_452	[p22l991t485r1086b535],
22	KRAS	NNP	ORGANIZATION	KRAS	conj_and	20	SENT_452	[p22l1104t487r1248b535],
23	.	.	O	.	_	0	SENT_452	[p22l1104t487r1248b535],

1	Cancer	NN	O	cancer	_	0	SENT_453	[p22l1263t487r1436b535],
2	1	CD	NUMBER	1	number	3	SENT_453	[p22l1449t489r1469b534],
3	15	CD	NUMBER	15	dep	1	SENT_453	[p22l1484t489r1559b542],
4	,	,	O	,	_	0	SENT_453	[p22l1484t489r1559b542],
5	1723-1733	CD	DATE	1723-1733	number	6	SENT_453	[p22l1577t488r1855b535],
6	(	CD	NUMBER	(	appos	1	SENT_453	[p22l1873t486r2043b542],
7	2009	CD	DATE	2009	num	8	SENT_453	[p22l1873t486r2043b542],
8	)	NN	O	)	dep	6	SENT_453	[p22l1873t486r2043b542],
9	.	.	O	.	_	0	SENT_453	[p22l1873t486r2043b542],

1	Paik	NNP	PERSON	Paik	_	0	SENT_454	[p22l133t563r248b620],
2	,	,	O	,	_	0	SENT_454	[p22l133t563r248b620],
3	J.H.	NNP	PERSON	J.H.	nn	4	SENT_454	[p22l261t565r350b613],
4	etal	NNP	O	etal	appos	1	SENT_454	[p22l364t563r479b613],
5	.	.	O	.	_	0	SENT_454	[p22l364t563r479b613],

1	Screening	VBG	O	screen	amod	5	SENT_455	[p22l494t565r753b626],
2	ofanaplastic	JJ	O	ofanaplastic	amod	5	SENT_455	[p22l770t562r1100b625],
3	lymphoma	NN	O	lymphoma	nn	5	SENT_455	[p22l1116t563r1398b627],
4	kinase	NN	O	kinase	nn	5	SENT_455	[p22l1416t563r1579b613],
5	rearrangement	NN	O	rearrangement	_	0	SENT_455	[p22l1596t571r1991b626],
6	by	IN	O	by	_	0	SENT_455	[p22l134t641r195b705],
7	immunohistochemistry	NN	O	immunohistochemistry	prep_by	5	SENT_455	[p22l210t641r828b705],
8	in	IN	O	in	_	0	SENT_455	[p22l843t644r885b690],
9	non	JJ	O	non	amod	14	SENT_455	[p22l904t641r1160b691],
10	—	JJ	O	—	amod	14	SENT_455	[p22l904t641r1160b691],
11	small	JJ	O	small	amod	14	SENT_455	[p22l904t641r1160b691],
12	cell	NN	O	cell	nn	14	SENT_455	[p22l1177t641r1261b691],
13	lung	NN	O	lung	nn	14	SENT_455	[p22l1280t641r1393b704],
14	cancer	NN	O	cancer	prep_in	5	SENT_455	[p22l1410t656r1595b691],
15	:	:	O	:	_	0	SENT_455	[p22l1410t656r1595b691],
16	correlation	NN	O	correlation	dep	5	SENT_455	[p22l1610t641r1892b691],
17	with	IN	O	with	_	0	SENT_455	[p22l1908t641r2021b691],
18	ﬂuorescence	NN	O	ﬂuorescence	prep_with	16	SENT_455	[p22l130t719r465b769],
19	in	FW	O	in	nn	20	SENT_455	[p22l481t722r523b768],
20	situ	FW	O	situ	advmod	21	SENT_455	[p22l541t722r631b769],
21	hybridization	NN	O	hybridization	rcmod	18	SENT_455	[p22l649t719r1053b783],
22	.	.	O	.	_	0	SENT_455	[p22l649t719r1053b783],

1	J.	NNP	PERSON	J.	nn	2	SENT_456	[p22l649t719r1053b783],
2	Thorac	NNP	PERSON	Thorac	_	0	SENT_456	[p22l1070t719r1252b769],
3	.	.	O	.	_	0	SENT_456	[p22l1070t719r1252b769],

1	Oncol	NN	O	oncol	_	0	SENT_457	[p22l1268t719r1428b769],
2	.	.	O	.	_	0	SENT_457	[p22l1268t719r1428b769],

1	6	CD	NUMBER	6	_	0	SENT_458	[p22l1442t723r1487b777],
2	,	,	O	,	_	0	SENT_458	[p22l1442t723r1487b777],
3	466-472	CD	NUMBER	466-472	num	4	SENT_458	[p22l1500t722r1725b769],
4	(	NN	O	(	appos	1	SENT_458	[p22l1742t720r1843b777],
5	201	CD	NUMBER	201	number	6	SENT_458	[p22l1742t720r1843b777],
6	1	CD	NUMBER	1	num	7	SENT_458	[p22l1861t720r1917b777],
7	)	NN	O	)	dep	4	SENT_458	[p22l1861t720r1917b777],
8	.	.	O	.	_	0	SENT_458	[p22l1861t720r1917b777],

1	Gainor	NNP	PERSON	Gainor	_	0	SENT_459	[p22l130t799r315b855],
2	,	,	O	,	_	0	SENT_459	[p22l130t799r315b855],
3	J.F.	NNP	PERSON	J.F.	nn	4	SENT_459	[p22l327t800r399b847],
4	etal	NNP	O	etal	appos	1	SENT_459	[p22l413t797r529b847],
5	.	.	O	.	_	0	SENT_459	[p22l413t797r529b847],

1	ALK	NN	O	alk	nn	2	SENT_460	[p22l543t800r645b846],
2	rearrangements	NNS	O	rearrangement	nsubj	5	SENT_460	[p22l660t805r1079b860],
3	are	VBP	O	be	cop	5	SENT_460	[p22l1093t812r1172b847],
4	mutually	RB	O	mutually	advmod	5	SENT_460	[p22l1189t797r1421b861],
5	exclusive	JJ	O	exclusive	_	0	SENT_460	[p22l1433t797r1671b847],
6	with	IN	O	with	_	0	SENT_460	[p22l1684t797r1798b847],
7	mutations	NNS	O	mutation	prep_with	5	SENT_460	[p22l1816t800r2082b847],
8	in	IN	O	in	_	0	SENT_460	[p22l133t878r176b924],
9	EGFR	NN	ORGANIZATION	egfr	prep_in	7	SENT_460	[p22l195t877r328b925],
10	or	CC	O	or	_	0	SENT_460	[p22l341t890r395b925],
11	KRAS	NNP	ORGANIZATION	KRAS	prep_with	5	SENT_460	[p22l410t877r557b925],
12	:	:	O	:	_	0	SENT_460	[p22l410t877r557b925],
13	an	DT	O	a	det	14	SENT_460	[p22l572t890r632b925],
14	analysis	NN	O	analysis	dep	11	SENT_460	[p22l648t875r851b939],
15	of	IN	O	of	_	0	SENT_460	[p22l866t875r920b925],
16	1,683	CD	NUMBER	1,683	num	17	SENT_460	[p22l935t878r1069b933],
17	patients	NNS	O	patient	prep_of	14	SENT_460	[p22l1087t878r1297b938],
18	with	IN	O	with	_	0	SENT_460	[p22l1311t875r1424b925],
19	non	JJ	O	non	amod	24	SENT_460	[p22l1443t875r1700b925],
20	—	JJ	O	—	amod	24	SENT_460	[p22l1443t875r1700b925],
21	small	JJ	O	small	amod	24	SENT_460	[p22l1443t875r1700b925],
22	cell	NN	O	cell	nn	24	SENT_460	[p22l1716t875r1800b925],
23	lung	NN	O	lung	nn	24	SENT_460	[p22l1820t875r1933b938],
24	cancer	NN	O	cancer	prep_with	17	SENT_460	[p22l1949t890r2131b925],
25	.	.	O	.	_	0	SENT_460	[p22l1949t890r2131b925],

1	Clin	NNP	O	Clin	_	0	SENT_461	[p22l132t952r237b1001],
2	.	.	O	.	_	0	SENT_461	[p22l132t952r237b1001],

1	Cancer	NN	O	cancer	_	0	SENT_462	[p22l253t954r430b1001],
2	Res	NNP	O	Res	dep	1	SENT_462	[p22l439t954r535b1001],
3	.	.	O	.	_	0	SENT_462	[p22l439t954r535b1001],

1	19	CD	NUMBER	19	_	0	SENT_463	[p22l552t955r630b1009],
2	,	,	O	,	_	0	SENT_463	[p22l552t955r630b1009],
3	4273-4281	CD	DURATION	4273-4281	number	4	SENT_463	[p22l642t955r924b1001],
4	(	CD	NUMBER	(	appos	1	SENT_463	[p22l950t953r1125b1009],
5	2013	CD	DATE	2013	num	6	SENT_463	[p22l950t953r1125b1009],
6	)	NN	O	)	dep	4	SENT_463	[p22l950t953r1125b1009],
7	.	.	O	.	_	0	SENT_463	[p22l950t953r1125b1009],

1	Johnson	NNP	PERSON	Johnson	_	0	SENT_464	[p22l128t1030r365b1088],
2	,	,	O	,	_	0	SENT_464	[p22l128t1030r365b1088],
3	B.E.	NNP	LOCATION	B.E.	conj_and	1	SENT_464	[p22l382t1032r479b1088],
4	,	,	O	,	_	0	SENT_464	[p22l382t1032r479b1088],
5	Kris	NNP	PERSON	Kris	conj_and	1	SENT_464	[p22l497t1033r599b1088],
6	,	,	O	,	_	0	SENT_464	[p22l497t1033r599b1088],
7	M.G.	NNP	ORGANIZATION	M.G.	conj_and	1	SENT_464	[p22l615t1032r729b1080],
8	&	CC	ORGANIZATION	&	_	0	SENT_464	[p22l742t1032r779b1080],
9	Lynne	NNP	ORGANIZATION	Lynne	conj_and	1	SENT_464	[p22l795t1033r962b1094],
10	,	,	O	,	_	0	SENT_464	[p22l795t1033r962b1094],
11	D.B.	NNP	PERSON	D.B.	appos	1	SENT_464	[p22l979t1032r1073b1080],
12	.	.	O	.	_	0	SENT_464	[p22l979t1032r1073b1080],

1	A	DT	O	a	det	3	SENT_465	[p22l1087t1033r1123b1079],
2	multicenter	JJ	O	multicenter	amod	3	SENT_465	[p22l1139t1030r1443b1080],
3	effort	NN	O	effort	_	0	SENT_465	[p22l1456t1030r1600b1080],
4	to	TO	O	to	aux	5	SENT_465	[p22l1613t1038r1666b1080],
5	identify	VB	O	identify	infmod	3	SENT_465	[p22l1682t1030r1880b1094],
6	driver	NN	O	driver	nn	7	SENT_465	[p22l132t1108r284b1158],
7	mutations	NNS	O	mutation	dobj	5	SENT_465	[p22l299t1111r565b1158],
8	and	CC	O	and	_	0	SENT_465	[p22l579t1108r676b1158],
9	employ	VB	O	employ	infmod	3	SENT_465	[p22l693t1108r892b1172],
10	targeted	VBN	O	target	dep	9	SENT_465	[p22l903t1108r1127b1171],
11	therapy	NN	O	therapy	dobj	10	SENT_465	[p22l1143t1108r1348b1172],
12	in	IN	O	in	_	0	SENT_465	[p22l1362t1111r1405b1157],
13	patients	NNS	O	patient	prep_in	11	SENT_465	[p22l1423t1111r1633b1171],
14	with	IN	O	with	_	0	SENT_465	[p22l1647t1108r1760b1158],
15	lung	NN	O	lung	nn	16	SENT_465	[p22l1779t1108r1893b1171],
16	adenocarcinomas	NNS	O	adenocarcinoma	prep_with	10	SENT_465	[p22l131t1186r720b1236],
17	:	:	O	:	_	0	SENT_465	[p22l131t1186r720b1236],
18	The	DT	O	the	det	21	SENT_465	[p22l131t1186r720b1236],
19	Lung	NN	O	lung	nn	21	SENT_465	[p22l737t1189r864b1249],
20	Cancer	NN	O	cancer	nn	21	SENT_465	[p22l880t1188r1062b1236],
21	Mutation	NN	O	mutation	dep	3	SENT_465	[p22l1077t1189r1314b1236],
22	Consortium	NNP	O	Consortium	dep	21	SENT_465	[p22l1331t1188r1639b1236],
23	(	CD	NUMBER	(	num	22	SENT_465	[p22l1658t1187r1900b1244],
24	LCMC	NNP	O	LCMC	dep	21	SENT_465	[p22l1658t1187r1900b1244],
25	)	CD	NUMBER	)	num	24	SENT_465	[p22l1658t1187r1900b1244],
26	.	.	O	.	_	0	SENT_465	[p22l1658t1187r1900b1244],

1	J.	NNP	PERSON	J.	nn	2	SENT_466	[p22l1658t1187r1900b1244],
2	Clin	NNP	PERSON	Clin	_	0	SENT_466	[p22l1916t1186r2021b1236],
3	.	.	O	.	_	0	SENT_466	[p22l1916t1186r2021b1236],

1	Oncol	NN	O	oncol	_	0	SENT_467	[p22l132t1264r292b1314],
2	.	.	O	.	_	0	SENT_467	[p22l132t1264r292b1314],

1	31	CD	NUMBER	31	num	2	SENT_468	[p22l307t1267r365b1314],
2	(	CD	NUMBER	(	_	0	SENT_468	[p22l390t1264r889b1327],
3	supp	NN	O	supp	nn	4	SENT_468	[p22l390t1264r889b1327],
4	|	NN	O	|	dep	2	SENT_468	[p22l390t1264r889b1327],
5	.	.	O	.	_	0	SENT_468	[p22l390t1264r889b1327],

1	;	:	O	;	_	0	SENT_469	[p22l390t1264r889b1327],
2	abstr	NN	O	abstr	_	0	SENT_469	[p22l390t1264r889b1327],
3	.8019	CD	NUMBER	.8019	num	4	SENT_469	[p22l390t1264r889b1327],
4	)	CD	NUMBER	)	dep	2	SENT_469	[p22l390t1264r889b1327],
5	(	CD	NUMBER	(	number	6	SENT_469	[p22l907t1265r1081b1322],
6	2013	CD	DATE	2013	num	7	SENT_469	[p22l907t1265r1081b1322],
7	)	NN	O	)	dep	4	SENT_469	[p22l907t1265r1081b1322],
8	.	.	O	.	_	0	SENT_469	[p22l907t1265r1081b1322],

1	Wu	NNP	O	Wu	_	0	SENT_470	[p22l129t1345r227b1400],
2	,	,	O	,	_	0	SENT_470	[p22l129t1345r227b1400],
3	S.G.	NNP	O	S.G.	nn	4	SENT_470	[p22l242t1344r337b1392],
4	etal	NN	O	etal	appos	1	SENT_470	[p22l351t1342r466b1392],
5	.	.	O	.	_	0	SENT_470	[p22l351t1342r466b1392],

1	EML4	NN	O	eml4	_	0	SENT_471	[p22l483t1345r748b1391],
2	.	.	O	.	_	0	SENT_471	[p22l483t1345r748b1391],

1	—	NN	O	—	_	0	SENT_472	[p22l483t1345r748b1391],
2	.	.	O	.	_	0	SENT_472	[p22l483t1345r748b1391],

1	ALK	NN	O	alk	nn	2	SENT_473	[p22l483t1345r748b1391],
2	translocation	NN	O	translocation	nsubj	3	SENT_473	[p22l759t1342r1103b1392],
3	predicts	VBZ	O	predict	_	0	SENT_473	[p22l1122t1342r1330b1405],
4	better	JJR	O	better	amod	5	SENT_473	[p22l1347t1342r1505b1392],
5	outcome	NN	O	outcome	dobj	3	SENT_473	[p22l1519t1350r1754b1392],
6	in	IN	O	in	_	0	SENT_473	[p22l1771t1345r1813b1391],
7	lung	NN	O	lung	nn	9	SENT_473	[p22l1832t1342r1945b1405],
8	adenocarcinoma	NN	O	adenocarcinoma	nn	9	SENT_473	[p22l131t1420r573b1470],
9	patients	NNS	O	patient	prep_in	3	SENT_473	[p22l591t1423r801b1483],
10	with	IN	O	with	_	0	SENT_473	[p22l815t1420r929b1470],
11	wild	JJ	O	wild	amod	14	SENT_473	[p22l944t1420r1194b1484],
12	—	NN	O	—	nn	14	SENT_473	[p22l944t1420r1194b1484],
13	type	NN	O	type	nn	14	SENT_473	[p22l944t1420r1194b1484],
14	EGFR	NN	ORGANIZATION	egfr	prep_with	9	SENT_473	[p22l1211t1422r1401b1470],
15	.	.	O	.	_	0	SENT_473	[p22l1211t1422r1401b1470],

1	J.	NNP	PERSON	J.	nn	2	SENT_474	[p22l1211t1422r1401b1470],
2	Thorac	NNP	PERSON	Thorac	_	0	SENT_474	[p22l1418t1420r1599b1470],
3	.	.	O	.	_	0	SENT_474	[p22l1418t1420r1599b1470],

1	Oncol	NN	O	oncol	_	0	SENT_475	[p22l1616t1420r1775b1470],
2	.	.	O	.	_	0	SENT_475	[p22l1616t1420r1775b1470],

1	7	CD	NUMBER	7	_	0	SENT_476	[p22l1790t1424r1834b1478],
2	,	,	O	,	_	0	SENT_476	[p22l1790t1424r1834b1478],
3	98-104	CD	NUMBER	98-104	number	4	SENT_476	[p22l1849t1423r2042b1470],
4	(	CD	NUMBER	(	appos	1	SENT_476	[p22l133t1498r308b1554],
5	2012	CD	DATE	2012	num	6	SENT_476	[p22l133t1498r308b1554],
6	)	NN	O	)	dep	4	SENT_476	[p22l133t1498r308b1554],
7	.	.	O	.	_	0	SENT_476	[p22l133t1498r308b1554],

1	Yang	NNP	PERSON	Yang	_	0	SENT_477	[p22l129t1578r270b1638],
2	,	,	O	,	_	0	SENT_477	[p22l129t1578r270b1638],
3	P.	NNP	O	P.	nn	4	SENT_477	[p22l287t1577r319b1625],
4	etal	NN	O	etal	appos	1	SENT_477	[p22l333t1575r448b1625],
5	.	.	O	.	_	0	SENT_477	[p22l333t1575r448b1625],

1	Worse	JJR	O	worse	advmod	2	SENT_478	[p22l459t1578r622b1625],
2	disease	NN	O	disease	_	0	SENT_478	[p22l637t1575r953b1625],
3	—	CD	NUMBER	—	num	5	SENT_478	[p22l637t1575r953b1625],
4	free	JJ	O	free	amod	5	SENT_478	[p22l637t1575r953b1625],
5	survival	NN	O	survival	dep	2	SENT_478	[p22l967t1575r1165b1625],
6	in	IN	O	in	_	0	SENT_478	[p22l1184t1578r1226b1624],
7	never	RB	O	never	advmod	5	SENT_478	[p22l1245t1575r1630b1625],
8	—	CD	NUMBER	—	num	9	SENT_478	[p22l1245t1575r1630b1625],
9	smokers	NNS	O	smoker	prep_in	5	SENT_478	[p22l1245t1575r1630b1625],
10	with	IN	O	with	_	0	SENT_478	[p22l1644t1575r1757b1625],
11	ALK	NN	O	alk	prep_with	9	SENT_478	[p22l1774t1578r1912b1624],
12	+	CC	O	+	_	0	SENT_478	[p22l1774t1578r1912b1624],
13	lung	NN	O	lung	nn	14	SENT_478	[p22l1929t1575r2042b1638],
14	adenocarcinoma	NN	O	adenocarcinoma	prep_with	9	SENT_478	[p22l132t1652r633b1701],
15	.	.	O	.	_	0	SENT_478	[p22l132t1652r633b1701],

1	J.	NNP	PERSON	J.	nn	2	SENT_479	[p22l132t1652r633b1701],
2	Thorac	NNP	PERSON	Thorac	_	0	SENT_479	[p22l650t1652r832b1701],
3	.	.	O	.	_	0	SENT_479	[p22l650t1652r832b1701],

1	Oncol	NN	O	oncol	_	0	SENT_480	[p22l848t1652r1007b1701],
2	.	.	O	.	_	0	SENT_480	[p22l848t1652r1007b1701],

1	7	CD	NUMBER	7	_	0	SENT_481	[p22l1022t1656r1066b1709],
2	,	,	O	,	_	0	SENT_481	[p22l1022t1656r1066b1709],
3	90-97	CD	NUMBER	90-97	number	4	SENT_481	[p22l1081t1655r1240b1701],
4	(	CD	NUMBER	(	appos	1	SENT_481	[p22l1256t1653r1431b1709],
5	2012	CD	DATE	2012	num	6	SENT_481	[p22l1256t1653r1431b1709],
6	)	NN	O	)	dep	4	SENT_481	[p22l1256t1653r1431b1709],
7	.	.	O	.	_	0	SENT_481	[p22l1256t1653r1431b1709],

1	Doebele	NNP	O	Doebele	_	0	SENT_482	[p22l132t1730r364b1788],
2	,	,	O	,	_	0	SENT_482	[p22l132t1730r364b1788],
3	R.C.	NNP	O	R.C.	nn	4	SENT_482	[p22l381t1732r472b1780],
4	etal	NN	O	etal	appos	1	SENT_482	[p22l486t1730r601b1780],
5	.	.	O	.	_	0	SENT_482	[p22l486t1730r601b1780],

1	Oncogene	NN	O	oncogene	nn	2	SENT_483	[p22l616t1732r890b1793],
2	status	NN	O	status	nsubj	3	SENT_483	[p22l905t1738r1059b1780],
3	predicts	VBZ	O	predict	_	0	SENT_483	[p22l1076t1730r1284b1793],
4	patterns	NNS	O	pattern	dobj	3	SENT_483	[p22l1301t1738r1517b1793],
5	of	IN	O	of	_	0	SENT_483	[p22l1532t1730r1587b1780],
6	metastatic	JJ	O	metastatic	amod	7	SENT_483	[p22l1598t1733r1871b1780],
7	spread	NN	O	spread	prep_of	4	SENT_483	[p22l1886t1730r2060b1793],
8	in	IN	O	in	_	0	SENT_483	[p22l2079t1733r2121b1779],
9	treatment	NN	O	treatment	prep_in	3	SENT_483	[p22l130t1811r557b1858],
10	—	CD	NUMBER	—	num	15	SENT_483	[p22l130t1811r557b1858],
11	naive	JJ	O	naive	amod	15	SENT_483	[p22l130t1811r557b1858],
12	nonsmall	JJ	O	nonsmall	amod	15	SENT_483	[p22l573t1808r810b1858],
13	cell	NN	O	cell	nn	15	SENT_483	[p22l827t1808r911b1858],
14	lung	NN	O	lung	nn	15	SENT_483	[p22l930t1808r1043b1871],
15	cancer	NN	O	cancer	dep	9	SENT_483	[p22l1060t1823r1241b1858],
16	.	.	O	.	_	0	SENT_483	[p22l1060t1823r1241b1858],

1	Cancer	NN	O	cancer	_	0	SENT_484	[p22l1256t1810r1433b1858],
2	1	CD	NUMBER	1	number	3	SENT_484	[p22l1447t1812r1467b1857],
3	18	CD	NUMBER	18	dep	1	SENT_484	[p22l1483t1812r1560b1866],
4	,	,	O	,	_	0	SENT_484	[p22l1483t1812r1560b1866],
5	4502-4511	CD	DURATION	4502-4511	number	6	SENT_484	[p22l1573t1811r1854b1858],
6	(	CD	NUMBER	(	appos	1	SENT_484	[p22l1880t1809r2055b1866],
7	2012	CD	DATE	2012	num	8	SENT_484	[p22l1880t1809r2055b1866],
8	)	NN	O	)	dep	6	SENT_484	[p22l1880t1809r2055b1866],
9	.	.	O	.	_	0	SENT_484	[p22l1880t1809r2055b1866],

1	Hanna	NNP	PERSON	Hanna	_	0	SENT_485	[p22l132t1889r313b1944],
2	,	,	O	,	_	0	SENT_485	[p22l132t1889r313b1944],
3	N.	NNP	O	N.	nn	4	SENT_485	[p22l331t1889r379b1936],
4	etal	NN	O	etal	appos	1	SENT_485	[p22l393t1886r509b1936],
5	.	.	O	.	_	0	SENT_485	[p22l393t1886r509b1936],

1	Randomized	VBN	O	randomize	csubj	20	SENT_486	[p22l526t1886r853b1936],
2	phase	NN	O	phase	nn	4	SENT_486	[p22l872t1886r1026b1949],
3	III	CD	NUMBER	iii	num	4	SENT_486	[p22l1042t1889r1079b1935],
4	trial	NN	O	trial	dobj	1	SENT_486	[p22l1094t1886r1192b1936],
5	of	IN	O	of	_	0	SENT_486	[p22l1209t1886r1264b1936],
6	pemetrexed	JJ	O	pemetrexed	prep_of	4	SENT_486	[p22l1275t1886r1591b1949],
7	versus	CC	O	versus	prep	6	SENT_486	[p22l1606t1901r1772b1936],
8	docetaxel	NN	O	docetaxel	dep	7	SENT_486	[p22l1787t1886r2039b1936],
9	in	IN	O	in	_	0	SENT_486	[p22l133t1967r176b2013],
10	patients	NNS	O	patient	prep_in	1	SENT_486	[p22l194t1967r404b2027],
11	with	IN	O	with	_	0	SENT_486	[p22l418t1964r532b2014],
12	non	JJ	O	non	amod	18	SENT_486	[p22l550t1964r917b2014],
13	—	JJ	O	—	amod	18	SENT_486	[p22l550t1964r917b2014],
14	small	JJ	O	small	amod	18	SENT_486	[p22l550t1964r917b2014],
15	—	NN	O	—	nn	18	SENT_486	[p22l550t1964r917b2014],
16	cell	NN	O	cell	nn	18	SENT_486	[p22l550t1964r917b2014],
17	lung	NN	O	lung	nn	18	SENT_486	[p22l937t1964r1050b2027],
18	cancer	NN	O	cancer	prep_with	10	SENT_486	[p22l1066t1979r1240b2014],
19	previously	RB	DATE	previously	advmod	1	SENT_486	[p22l1255t1964r1525b2028],
20	treated	VBN	O	treat	_	0	SENT_486	[p22l1537t1964r1725b2014],
21	with	IN	O	with	_	0	SENT_486	[p22l1740t1964r1853b2014],
22	chemotherapy	NN	O	chemotherapy	prep_with	20	SENT_486	[p22l131t2042r529b2106],
23	.	.	O	.	_	0	SENT_486	[p22l131t2042r529b2106],

1	J.	NNP	PERSON	J.	nn	2	SENT_487	[p22l539t2045r573b2092],
2	Clin	NNP	PERSON	Clin	_	0	SENT_487	[p22l589t2042r694b2092],
3	.	.	O	.	_	0	SENT_487	[p22l589t2042r694b2092],

1	Oncol	NN	O	oncol	_	0	SENT_488	[p22l710t2042r870b2092],
2	.	.	O	.	_	0	SENT_488	[p22l710t2042r870b2092],

1	22	CD	NUMBER	22	_	0	SENT_489	[p22l885t2045r965b2100],
2	,	,	O	,	_	0	SENT_489	[p22l885t2045r965b2100],
3	1589-1597	CD	DATE	1589-1597	number	4	SENT_489	[p22l984t2045r1269b2092],
4	(	CD	NUMBER	(	appos	1	SENT_489	[p22l1286t2043r1460b2100],
5	2004	CD	DATE	2004	num	6	SENT_489	[p22l1286t2043r1460b2100],
6	)	NN	O	)	dep	4	SENT_489	[p22l1286t2043r1460b2100],
7	.	.	O	.	_	0	SENT_489	[p22l1286t2043r1460b2100],

1	Camidge	NNP	O	Camidge	_	0	SENT_490	[p22l130t2120r378b2183],
2	,	,	O	,	_	0	SENT_490	[p22l130t2120r378b2183],
3	D.R.	NNP	PERSON	D.R.	nn	4	SENT_490	[p22l395t2122r490b2170],
4	etal	NNP	O	etal	appos	1	SENT_490	[p22l504t2120r619b2170],
5	.	.	O	.	_	0	SENT_490	[p22l504t2120r619b2170],

1	Anaplastic	JJ	O	anaplastic	amod	5	SENT_491	[p22l633t2120r907b2183],
2	lymphoma	NN	O	lymphoma	nn	5	SENT_491	[p22l923t2120r1205b2184],
3	kinase	NN	O	kinase	nn	5	SENT_491	[p22l1224t2120r1387b2170],
4	gene	NN	O	gene	nn	5	SENT_491	[p22l1401t2135r1533b2183],
5	rearrangements	NNS	O	rearrangement	nsubjpass	14	SENT_491	[p22l1549t2128r1968b2183],
6	in	IN	O	in	_	0	SENT_491	[p22l1985t2123r2027b2169],
7	non	JJ	O	non	amod	12	SENT_491	[p22l133t2198r390b2248],
8	—	JJ	O	—	amod	12	SENT_491	[p22l133t2198r390b2248],
9	small	JJ	O	small	amod	12	SENT_491	[p22l133t2198r390b2248],
10	cell	NN	O	cell	nn	12	SENT_491	[p22l407t2198r491b2248],
11	lung	NN	O	lung	nn	12	SENT_491	[p22l510t2198r623b2262],
12	cancer	NN	O	cancer	prep_in	5	SENT_491	[p22l640t2213r813b2248],
13	are	VBP	O	be	auxpass	14	SENT_491	[p22l826t2213r905b2248],
14	associated	VBN	O	associate	_	0	SENT_491	[p22l920t2198r1193b2248],
15	with	IN	O	with	_	0	SENT_491	[p22l1208t2198r1322b2248],
16	prolonged	JJ	O	prolonged	amod	17	SENT_491	[p22l1340t2198r1613b2262],
17	progression	NN	O	progression	prep_with	14	SENT_491	[p22l1632t2198r2063b2262],
18	—	CD	NUMBER	—	num	20	SENT_491	[p22l1632t2198r2063b2262],
19	free	JJ	O	free	amod	20	SENT_491	[p22l1632t2198r2063b2262],
20	survival	NN	O	survival	npadvmod	14	SENT_491	[p22l132t2276r330b2326],
21	on	IN	O	on	_	0	SENT_491	[p22l347t2291r411b2326],
22	pemetrexed	JJ	O	pemetrexed	prep_on	14	SENT_491	[p22l430t2276r805b2339],
23	.	.	O	.	_	0	SENT_491	[p22l430t2276r805b2339],

1	J.	NNP	PERSON	J.	nn	2	SENT_492	[p22l430t2276r805b2339],
2	Thorac	NNP	PERSON	Thorac	_	0	SENT_492	[p22l822t2276r1004b2326],
3	.	.	O	.	_	0	SENT_492	[p22l822t2276r1004b2326],

1	Oncol	NN	O	oncol	_	0	SENT_493	[p22l1019t2276r1179b2326],
2	.	.	O	.	_	0	SENT_493	[p22l1019t2276r1179b2326],

1	6	CD	NUMBER	6	_	0	SENT_494	[p22l1193t2280r1238b2334],
2	,	,	O	,	_	0	SENT_494	[p22l1193t2280r1238b2334],
3	774-780	CD	NUMBER	774-780	num	4	SENT_494	[p22l1254t2280r1477b2326],
4	(	NN	O	(	appos	1	SENT_494	[p22l1494t2277r1594b2334],
5	201	CD	NUMBER	201	number	6	SENT_494	[p22l1494t2277r1594b2334],
6	1	CD	NUMBER	1	num	7	SENT_494	[p22l1613t2277r1668b2334],
7	)	NN	O	)	dep	4	SENT_494	[p22l1613t2277r1668b2334],
8	.	.	O	.	_	0	SENT_494	[p22l1613t2277r1668b2334],

1	Shaw	NNP	PERSON	Shaw	_	0	SENT_495	[p22l130t2566r280b2624],
2	,	,	O	,	_	0	SENT_495	[p22l130t2566r280b2624],
3	A.T.	NNP	O	A.T.	nn	4	SENT_495	[p22l294t2569r383b2616],
4	etal	NNP	O	etal	appos	1	SENT_495	[p22l398t2566r512b2616],
5	.	.	O	.	_	0	SENT_495	[p22l398t2566r512b2616],

1	Pemetrexed	JJ	O	pemetrexed	amod	2	SENT_496	[p22l529t2566r1019b2616],
2	—	NN	O	—	nsubj	3	SENT_496	[p22l529t2566r1019b2616],
3	based	VBN	O	base	_	0	SENT_496	[p22l529t2566r1019b2616],
4	chemotherapy	NN	O	chemotherapy	dobj	3	SENT_496	[p22l1035t2566r1423b2630],
5	in	IN	O	in	_	0	SENT_496	[p22l1437t2569r1479b2615],
6	patients	NNS	O	patient	prep_in	3	SENT_496	[p22l1498t2569r1707b2629],
7	with	IN	O	with	_	0	SENT_496	[p22l1721t2566r1834b2616],
8	advanced	JJ	O	advanced	amod	14	SENT_496	[p22l1851t2566r2119b2624],
9	,	,	O	,	_	0	SENT_496	[p22l1851t2566r2119b2624],
10	ALK	NNP	O	ALK	dep	14	SENT_496	[p22l130t2647r458b2707],
11	—	CD	NUMBER	—	num	14	SENT_496	[p22l130t2647r458b2707],
12	positive	JJ	O	positive	amod	13	SENT_496	[p22l130t2647r458b2707],
13	non	JJ	O	non	amod	14	SENT_496	[p22l474t2644r730b2694],
14	—	NN	O	—	prep_with	3	SENT_496	[p22l474t2644r730b2694],
15	small	JJ	O	small	amod	18	SENT_496	[p22l474t2644r730b2694],
16	cell	NN	O	cell	nn	18	SENT_496	[p22l747t2644r830b2694],
17	lung	NN	O	lung	nn	18	SENT_496	[p22l849t2644r962b2708],
18	cancer	NN	O	cancer	dep	14	SENT_496	[p22l979t2647r1286b2694],
19	.	.	O	.	_	0	SENT_496	[p22l979t2647r1286b2694],

1	Ann	NNP	PERSON	Ann	_	0	SENT_497	[p22l979t2647r1286b2694],
2	.	.	O	.	_	0	SENT_497	[p22l979t2647r1286b2694],

1	Oncol	NN	O	oncol	_	0	SENT_498	[p22l1302t2644r1461b2694],
2	.	.	O	.	_	0	SENT_498	[p22l1302t2644r1461b2694],

1	24	CD	NUMBER	24	_	0	SENT_499	[p22l1476t2648r1556b2702],
2	,	,	O	,	_	0	SENT_499	[p22l1476t2648r1556b2702],
3	59-66	CD	NUMBER	59-66	num	4	SENT_499	[p22l1570t2648r1729b2694],
4	(	NN	O	(	appos	1	SENT_499	[p22l1745t2645r1846b2702],
5	201	CD	NUMBER	201	number	6	SENT_499	[p22l1745t2645r1846b2702],
6	3	CD	NUMBER	3	num	7	SENT_499	[p22l1860t2645r1919b2702],
7	)	NN	O	)	dep	4	SENT_499	[p22l1860t2645r1919b2702],
8	.	.	O	.	_	0	SENT_499	[p22l1860t2645r1919b2702],

1	Lee	NNP	PERSON	Lee	_	0	SENT_500	[p22l132t2725r231b2780],
2	,	,	O	,	_	0	SENT_500	[p22l132t2725r231b2780],
3	J.K.	NNP	PERSON	J.K.	nn	4	SENT_500	[p22l243t2725r326b2772],
4	etal	NNP	O	etal	appos	1	SENT_500	[p22l340t2722r455b2772],
5	.	.	O	.	_	0	SENT_500	[p22l340t2722r455b2772],

1	Comparative	JJ	O	comparative	amod	2	SENT_501	[p22l469t2724r805b2785],
2	analyses	NNS	O	analysis	nsubj	21	SENT_501	[p22l819t2722r1039b2786],
3	of	IN	O	of	_	0	SENT_501	[p22l1054t2722r1108b2772],
4	overall	JJ	O	overall	amod	5	SENT_501	[p22l1118t2722r1289b2772],
5	survival	NN	O	survival	prep_of	2	SENT_501	[p22l1306t2722r1503b2772],
6	in	IN	O	in	_	0	SENT_501	[p22l1522t2725r1564b2771],
7	patients	NNS	O	patient	prep_in	5	SENT_501	[p22l1583t2725r1792b2785],
8	with	IN	O	with	_	0	SENT_501	[p22l1806t2722r1919b2772],
9	anaplastic	JJ	O	anaplastic	amod	12	SENT_501	[p22l131t2800r395b2863],
10	lymphoma	NN	O	lymphoma	nn	12	SENT_501	[p22l412t2800r693b2864],
11	kinase	NN	O	kinase	nn	12	SENT_501	[p22l711t2800r1104b2863],
12	—	NN	O	—	prep_with	7	SENT_501	[p22l711t2800r1104b2863],
13	positive	JJ	O	positive	amod	12	SENT_501	[p22l711t2800r1104b2863],
14	and	CC	O	and	_	0	SENT_501	[p22l1118t2800r1214b2850],
15	matched	VBN	O	match	amod	17	SENT_501	[p22l1233t2800r1461b2850],
16	wi	NN	O	wus	nn	17	SENT_501	[p22l1477t2800r1725b2864],
17	|	NN	O	|	conj_and	5	SENT_501	[p22l1477t2800r1725b2864],
18	d	NN	O	d	prep	17	SENT_501	[p22l1477t2800r1725b2864],
19	—	CD	NUMBER	—	num	20	SENT_501	[p22l1477t2800r1725b2864],
20	type	NN	O	type	dep	18	SENT_501	[p22l1477t2800r1725b2864],
21	advanced	VBD	O	advance	_	0	SENT_501	[p22l1740t2800r1993b2850],
22	nonsmall	JJ	O	nonsmall	amod	25	SENT_501	[p22l133t2878r369b2928],
23	cell	NN	O	cell	nn	25	SENT_501	[p22l386t2878r470b2928],
24	lung	NN	O	lung	nn	25	SENT_501	[p22l489t2878r601b2942],
25	cancer	NN	O	cancer	dobj	21	SENT_501	[p22l618t2893r799b2928],
26	.	.	O	.	_	0	SENT_501	[p22l618t2893r799b2928],

1	Cancer	NN	O	cancer	_	0	SENT_502	[p22l814t2880r991b2928],
2	1	CD	NUMBER	1	number	3	SENT_502	[p22l1005t2882r1024b2927],
3	18	CD	NUMBER	18	dep	1	SENT_502	[p22l1040t2882r1117b2936],
4	,	,	O	,	_	0	SENT_502	[p22l1040t2882r1117b2936],
5	3579-3586	CD	DURATION	3579-3586	number	6	SENT_502	[p22l1132t2882r1421b2928],
6	(	CD	NUMBER	(	appos	1	SENT_502	[p22l1437t2879r1611b2936],
7	2012	CD	DATE	2012	num	8	SENT_502	[p22l1437t2879r1611b2936],
8	)	NN	O	)	dep	6	SENT_502	[p22l1437t2879r1611b2936],
9	.	.	O	.	_	0	SENT_502	[p22l1437t2879r1611b2936],

1	Kim	NNP	PERSON	Kim	_	0	SENT_503	[p22l132t2958r242b3012],
2	,	,	O	,	_	0	SENT_503	[p22l132t2958r242b3012],
3	H.R.	NNP	O	H.R.	nn	4	SENT_503	[p22l259t2957r354b3005],
4	etal	NN	O	etal	appos	1	SENT_503	[p22l368t2955r483b3005],
5	.	.	O	.	_	0	SENT_503	[p22l368t2955r483b3005],

1	Distinct	JJ	O	distinct	amod	3	SENT_504	[p22l500t2957r698b3005],
2	clinical	JJ	O	clinical	amod	3	SENT_504	[p22l712t2955r888b3005],
3	features	NNS	O	feature	_	0	SENT_504	[p22l903t2955r1114b3005],
4	and	CC	O	and	_	0	SENT_504	[p22l1129t2955r1225b3005],
5	outcomes	NNS	O	outcome	conj_and	3	SENT_504	[p22l1241t2963r1501b3005],
6	in	IN	O	in	_	0	SENT_504	[p22l1518t2958r1560b3004],
7	never	RB	O	never	advmod	14	SENT_504	[p22l1579t2955r1963b3005],
8	—	CD	NUMBER	—	num	9	SENT_504	[p22l1579t2955r1963b3005],
9	smokers	NNS	O	smoker	pobj	7	SENT_504	[p22l1579t2955r1963b3005],
10	with	IN	O	with	_	0	SENT_504	[p22l130t3033r243b3083],
11	nonsmall	JJ	O	nonsmall	amod	12	SENT_504	[p22l262t3033r498b3083],
12	cell	NN	O	cell	prep_with	7	SENT_504	[p22l515t3033r598b3083],
13	lung	NN	O	lung	nn	14	SENT_504	[p22l617t3033r730b3097],
14	cancer	NN	O	cancer	prep_in	3	SENT_504	[p22l747t3048r920b3083],
15	who	WP	O	who	nsubj	16	SENT_504	[p22l932t3033r1046b3083],
16	harbor	VBP	O	harbor	rcmod	3	SENT_504	[p22l1063t3033r1237b3083],
17	EGFR	NN	ORGANIZATION	egfr	nn	20	SENT_504	[p22l1253t3035r1385b3083],
18	or	CC	O	or	_	0	SENT_504	[p22l1399t3048r1452b3083],
19	KRAS	NN	ORGANIZATION	kra	nn	20	SENT_504	[p22l1467t3035r1600b3083],
20	mutations	NNS	O	mutation	dobj	16	SENT_504	[p22l1617t3036r1882b3083],
21	or	CC	O	or	_	0	SENT_504	[p22l1897t3048r1950b3083],
22	ALK	NN	O	alk	nn	23	SENT_504	[p22l1962t3036r2066b3082],
23	rearrangement	NN	O	rearrangement	conj_or	20	SENT_504	[p22l133t3119r539b3175],
24	.	.	O	.	_	0	SENT_504	[p22l133t3119r539b3175],

1	Cancer	NN	O	cancer	_	0	SENT_505	[p22l554t3113r731b3161],
2	1	CD	NUMBER	1	number	3	SENT_505	[p22l744t3115r764b3160],
3	18	CD	NUMBER	18	dep	1	SENT_505	[p22l780t3115r856b3169],
4	,	,	O	,	_	0	SENT_505	[p22l780t3115r856b3169],
5	729-739	CD	NUMBER	729-739	num	6	SENT_505	[p22l872t3115r1095b3161],
6	(	NN	O	(	appos	1	SENT_505	[p22l1111t3112r1211b3169],
7	201	CD	NUMBER	201	number	8	SENT_505	[p22l1111t3112r1211b3169],
8	2	CD	NUMBER	2	num	9	SENT_505	[p22l1226t3112r1285b3169],
9	)	NN	O	)	dep	6	SENT_505	[p22l1226t3112r1285b3169],
10	.	.	O	.	_	0	SENT_505	[p22l1226t3112r1285b3169],

1	Shaw	NNP	PERSON	Shaw	_	0	SENT_506	[p22l130t3189r280b3247],
2	,	,	O	,	_	0	SENT_506	[p22l130t3189r280b3247],
3	A.T.	NNP	LOCATION	A.T.	conj_and	1	SENT_506	[p22l294t3192r397b3247],
4	,	,	O	,	_	0	SENT_506	[p22l294t3192r397b3247],
5	Solomon	NNP	PERSON	Solomon	conj_and	1	SENT_506	[p22l411t3189r660b3247],
6	,	,	O	,	_	0	SENT_506	[p22l411t3189r660b3247],
7	B.	NNP	ORGANIZATION	B.	conj_and	1	SENT_506	[p22l677t3192r718b3239],
8	&	CC	ORGANIZATION	&	_	0	SENT_506	[p22l732t3191r769b3239],
9	Kenudson	NNP	ORGANIZATION	Kenudson	conj_and	1	SENT_506	[p22l784t3189r1059b3247],
10	,	,	O	,	_	0	SENT_506	[p22l784t3189r1059b3247],
11	M.M.	NNP	PERSON	M.M.	nn	12	SENT_506	[p22l1075t3192r1198b3239],
12	Crizotinib	NNP	PERSON	Crizotinib	appos	1	SENT_506	[p22l1212t3189r1465b3239],
13	and	CC	O	and	_	0	SENT_506	[p22l1480t3189r1576b3239],
14	testing	NN	O	testing	conj_and	12	SENT_506	[p22l1591t3192r1771b3253],
15	for	IN	O	for	_	0	SENT_506	[p22l1786t3189r1858b3239],
16	ALK	NNP	O	ALK	prep_for	14	SENT_506	[p22l1871t3192r1985b3239],
17	.	.	O	.	_	0	SENT_506	[p22l1871t3192r1985b3239],

1	J.	NNP	O	J.	nn	3	SENT_507	[p22l127t3270r161b3317],
2	Natl.	NNP	O	Natl.	nn	3	SENT_507	[p22l176t3267r290b3317],
3	Compr	NNP	O	Compr	_	0	SENT_507	[p22l306t3269r483b3330],
4	.	.	O	.	_	0	SENT_507	[p22l306t3269r483b3330],

1	Canc	NN	O	canc	_	0	SENT_508	[p22l500t3269r634b3317],
2	.	.	O	.	_	0	SENT_508	[p22l500t3269r634b3317],

1	Netw	NNP	O	Netw	_	0	SENT_509	[p22l649t3270r794b3317],
2	.	.	O	.	_	0	SENT_509	[p22l649t3270r794b3317],

1	9	CD	NUMBER	9	_	0	SENT_510	[p22l807t3271r852b3325],
2	,	,	O	,	_	0	SENT_510	[p22l807t3271r852b3325],
3	1335-1341	CD	DATE	1335-1341	num	4	SENT_510	[p22l871t3271r1146b3317],
4	(	NN	O	(	appos	1	SENT_510	[p22l1173t3268r1273b3325],
5	201	CD	NUMBER	201	number	6	SENT_510	[p22l1173t3268r1273b3325],
6	1	CD	NUMBER	1	num	7	SENT_510	[p22l1291t3268r1347b3325],
7	)	NN	O	)	dep	4	SENT_510	[p22l1291t3268r1347b3325],
8	.	.	O	.	_	0	SENT_510	[p22l1291t3268r1347b3325],

1	Kim	NNP	PERSON	Kim	_	0	SENT_511	[p22l132t3348r242b3403],
2	,	,	O	,	_	0	SENT_511	[p22l132t3348r242b3403],
3	H.	NNP	O	H.	nn	4	SENT_511	[p22l259t3348r307b3395],
4	etal	NN	O	etal	appos	1	SENT_511	[p22l321t3345r436b3395],
5	.	.	O	.	_	0	SENT_511	[p22l321t3345r436b3395],

1	Detection	NN	O	detection	_	0	SENT_512	[p22l453t3347r707b3395],
2	of	IN	O	of	_	0	SENT_512	[p22l724t3345r778b3395],
3	ALK	NN	O	alk	nn	5	SENT_512	[p22l787t3348r890b3394],
4	gene	NN	O	gene	nn	5	SENT_512	[p22l902t3360r1033b3409],
5	rearrangement	NN	O	rearrangement	prep_of	1	SENT_512	[p22l1050t3353r1443b3409],
6	in	IN	O	in	_	0	SENT_512	[p22l1459t3348r1501b3394],
7	non	JJ	O	non	amod	12	SENT_512	[p22l1520t3345r1775b3395],
8	—	JJ	O	—	amod	12	SENT_512	[p22l1520t3345r1775b3395],
9	small	JJ	O	small	amod	12	SENT_512	[p22l1520t3345r1775b3395],
10	cell	NN	O	cell	nn	12	SENT_512	[p22l1792t3345r1876b3395],
11	lung	NN	O	lung	nn	12	SENT_512	[p22l1895t3345r2008b3409],
12	cancer	NN	O	cancer	prep_in	5	SENT_512	[p22l131t3438r316b3473],
13	:	:	O	:	_	0	SENT_512	[p22l131t3438r316b3473],
14	a	DT	O	a	det	15	SENT_512	[p22l330t3438r355b3473],
15	comparison	NN	O	comparison	dep	1	SENT_512	[p22l372t3426r680b3486],
16	of	IN	O	of	_	0	SENT_512	[p22l697t3423r751b3473],
17	ﬂuorescence	NN	O	ﬂuorescence	prep_of	15	SENT_512	[p22l759t3423r1093b3473],
18	in	FW	O	in	prep	17	SENT_512	[p22l1109t3426r1152b3473],
19	situ	FW	O	situ	pobj	18	SENT_512	[p22l1168t3426r1258b3473],
20	hybridization	NN	O	hybridization	amod	19	SENT_512	[p22l1277t3423r1620b3487],
21	and	CC	O	and	_	0	SENT_512	[p22l1636t3423r1732b3473],
22	chromogenic	JJ	O	chromogenic	conj_and	20	SENT_512	[p22l1749t3423r2099b3487],
23	in	FW	O	in	nn	24	SENT_512	[p22l132t3504r175b3550],
24	situ	FW	O	situ	advmod	25	SENT_512	[p22l192t3504r281b3551],
25	hybridization	NN	O	hybridization	rcmod	19	SENT_512	[p22l301t3501r643b3565],
26	with	IN	O	with	_	0	SENT_512	[p22l659t3501r772b3551],
27	correlation	NN	O	correlation	prep_with	25	SENT_512	[p22l788t3501r1070b3551],
28	of	IN	O	of	_	0	SENT_512	[p22l1086t3501r1141b3551],
29	ALK	NN	O	alk	nn	31	SENT_512	[p22l1150t3504r1253b3550],
30	protein	NN	O	protein	nn	31	SENT_512	[p22l1267t3504r1453b3564],
31	expression	NN	O	expression	prep_of	27	SENT_512	[p22l1469t3504r1808b3564],
32	.	.	O	.	_	0	SENT_512	[p22l1469t3504r1808b3564],

1	J.	NNP	PERSON	J.	nn	2	SENT_513	[p22l1469t3504r1808b3564],
2	Thorac	NNP	PERSON	Thorac	_	0	SENT_513	[p22l1825t3501r2006b3551],
3	.	.	O	.	_	0	SENT_513	[p22l1825t3501r2006b3551],

1	Oncol	NN	O	oncol	_	0	SENT_514	[p22l132t3578r350b3635],
2	.6	CD	NUMBER	.6	num	1	SENT_514	[p22l132t3578r350b3635],
3	,	,	O	,	_	0	SENT_514	[p22l132t3578r350b3635],
4	1359-1366	CD	DATE	1359-1366	num	5	SENT_514	[p22l369t3582r654b3628],
5	(	NN	O	(	appos	1	SENT_514	[p22l670t3579r771b3635],
6	201	CD	NUMBER	201	number	7	SENT_514	[p22l670t3579r771b3635],
7	1	CD	NUMBER	1	num	8	SENT_514	[p22l789t3579r844b3635],
8	)	NN	O	)	dep	5	SENT_514	[p22l789t3579r844b3635],
9	.	.	O	.	_	0	SENT_514	[p22l789t3579r844b3635],

1	Yi	NNP	PERSON	Yi	_	0	SENT_515	[p23l128t20r185b75],
2	,	,	O	,	_	0	SENT_515	[p23l128t20r185b75],
3	E.S.	NNP	LOCATION	E.S.	conj_and	1	SENT_515	[p23l200t19r291b75],
4	,	,	O	,	_	0	SENT_515	[p23l200t19r291b75],
5	Chung	NNP	PERSON	Chung	conj_and	1	SENT_515	[p23l304t17r486b81],
6	,	,	O	,	_	0	SENT_515	[p23l304t17r486b81],
7	J.H.	NNP	LOCATION	J.H.	conj_and	1	SENT_515	[p23l496t20r594b75],
8	,	,	O	,	_	0	SENT_515	[p23l496t20r594b75],
9	Kulig	NNP	PERSON	Kulig	conj_and	1	SENT_515	[p23l609t17r744b81],
10	,	,	O	,	_	0	SENT_515	[p23l609t17r744b81],
11	K.	NNP	ORGANIZATION	K.	conj_and	1	SENT_515	[p23l759t20r800b67],
12	&	CC	ORGANIZATION	&	_	0	SENT_515	[p23l812t19r849b67],
13	Kerr	NNP	ORGANIZATION	Kerr	conj_and	1	SENT_515	[p23l863t20r970b75],
14	,	,	O	,	_	0	SENT_515	[p23l863t20r970b75],
15	K.M.	NNP	O	K.M.	nn	16	SENT_515	[p23l985t20r1089b67],
16	Detection	NN	O	detection	appos	1	SENT_515	[p23l1104t20r1351b67],
17	of	IN	O	of	_	0	SENT_515	[p23l1365t17r1419b67],
18	anaplastic	JJ	O	anaplastic	amod	25	SENT_515	[p23l1426t17r1682b80],
19	lymphoma	NN	O	lymphoma	nn	25	SENT_515	[p23l1697t17r1971b81],
20	kinase	NN	O	kinase	nn	25	SENT_515	[p23l1987t17r2145b67],
21	(	NN	O	(	nn	25	SENT_515	[p23l133t96r267b153],
22	ALK	NN	O	alk	nn	25	SENT_515	[p23l133t96r267b153],
23	)	NN	O	)	nn	25	SENT_515	[p23l133t96r267b153],
24	gene	NN	O	gene	nn	25	SENT_515	[p23l284t110r416b159],
25	rearrangement	NN	O	rearrangement	prep_of	16	SENT_515	[p23l433t103r830b159],
26	in	IN	O	in	_	0	SENT_515	[p23l846t98r889b144],
27	non	JJ	O	non	amod	32	SENT_515	[p23l909t95r1167b145],
28	—	JJ	O	—	amod	32	SENT_515	[p23l909t95r1167b145],
29	small	JJ	O	small	amod	32	SENT_515	[p23l909t95r1167b145],
30	cell	NN	O	cell	nn	32	SENT_515	[p23l1184t95r1269b145],
31	lung	NN	O	lung	nn	32	SENT_515	[p23l1288t95r1402b159],
32	cancer	NN	O	cancer	prep_in	25	SENT_515	[p23l1419t110r1594b145],
33	and	CC	O	and	_	0	SENT_515	[p23l1607t95r1704b145],
34	related	JJ	O	related	amod	35	SENT_515	[p23l1724t95r1903b145],
35	issues	NNS	O	issue	prep_of	16	SENT_515	[p23l1922t98r2075b145],
36	in	IN	O	in	_	0	SENT_515	[p23l2092t98r2135b145],
37	ALK	NNP	O	ALK	nn	39	SENT_515	[p23l130t176r233b223],
38	inhibitor	NN	O	inhibitor	nn	39	SENT_515	[p23l247t173r470b223],
39	therapy	NN	O	therapy	prep_in	35	SENT_515	[p23l482t173r699b237],
40	:	:	O	:	_	0	SENT_515	[p23l482t173r699b237],
41	a	DT	O	a	det	43	SENT_515	[p23l713t188r739b223],
42	literature	NN	O	literature	nn	43	SENT_515	[p23l757t173r992b223],
43	review	NN	O	review	dep	1	SENT_515	[p23l1008t176r1189b223],
44	.	.	O	.	_	0	SENT_515	[p23l1008t176r1189b223],

1	Mol	NNP	O	Mol	_	0	SENT_516	[p23l1203t173r1307b223],
2	.	.	O	.	_	0	SENT_516	[p23l1203t173r1307b223],

1	Diagn	NN	O	diagn	_	0	SENT_517	[p23l1323t176r1486b237],
2	.	.	O	.	_	0	SENT_517	[p23l1323t176r1486b237],

1	Ther	NNP	O	Ther	_	0	SENT_518	[p23l1504t173r1624b223],
2	.	.	O	.	_	0	SENT_518	[p23l1504t173r1624b223],

1	16	CD	NUMBER	16	_	0	SENT_519	[p23l1641t177r1718b231],
2	,	,	O	,	_	0	SENT_519	[p23l1641t177r1718b231],
3	143-150	CD	NUMBER	143-150	number	4	SENT_519	[p23l1737t177r1956b223],
4	(	CD	NUMBER	(	appos	1	SENT_519	[p23l1973t174r2147b231],
5	2012	CD	DATE	2012	num	6	SENT_519	[p23l1973t174r2147b231],
6	)	NN	O	)	dep	4	SENT_519	[p23l1973t174r2147b231],
7	.	.	O	.	_	0	SENT_519	[p23l1973t174r2147b231],

1	Yi	NNP	O	Yi	_	0	SENT_520	[p23l128t254r187b309],
2	,	,	O	,	_	0	SENT_520	[p23l128t254r187b309],
3	E.S.	NNP	LOCATION	E.S.	nn	4	SENT_520	[p23l204t253r286b301],
4	etal	NNP	O	etal	appos	1	SENT_520	[p23l300t251r415b301],
5	.	.	O	.	_	0	SENT_520	[p23l300t251r415b301],

1	Correlation	NN	O	correlation	_	0	SENT_521	[p23l429t251r719b301],
2	of	IN	O	of	_	0	SENT_521	[p23l735t251r790b301],
3	IHC	NNP	ORGANIZATION	IHC	prep_of	1	SENT_521	[p23l802t253r890b301],
4	and	CC	O	and	_	0	SENT_521	[p23l904t251r1000b301],
5	FISH	NN	O	fish	conj_and	1	SENT_521	[p23l1019t253r1129b301],
6	for	IN	O	for	_	0	SENT_521	[p23l1144t251r1217b301],
7	ALK	NN	O	alk	nn	9	SENT_521	[p23l1230t254r1332b301],
8	gene	NN	O	gene	nn	9	SENT_521	[p23l1344t266r1475b315],
9	rearrangement	NN	O	rearrangement	prep_for	5	SENT_521	[p23l1492t259r1886b315],
10	in	IN	O	in	_	0	SENT_521	[p23l1901t254r1944b301],
11	nonsmall	JJ	O	nonsmall	amod	14	SENT_521	[p23l1962t266r2082b301, p23l131t329r263b379],
12	cell	NN	O	cell	nn	14	SENT_521	[p23l280t329r364b379],
13	lung	NN	O	lung	nn	14	SENT_521	[p23l383t329r496b393],
14	carcinoma	NN	O	carcinoma	prep_in	9	SENT_521	[p23l512t332r798b379],
15	:	:	O	:	_	0	SENT_521	[p23l512t332r798b379],
16	IHC	NNP	ORGANIZATION	IHC	nn	18	SENT_521	[p23l815t331r903b379],
17	score	NN	NUMBER	score	nn	18	SENT_521	[p23l917t344r1053b379],
18	algorithm	NN	O	algorithm	dep	1	SENT_521	[p23l1067t329r1324b393],
19	for	IN	O	for	_	0	SENT_521	[p23l1338t329r1411b379],
20	F	NN	O	f	nn	22	SENT_521	[p23l1426t331r1597b379],
21	|	CD	NUMBER	|	num	22	SENT_521	[p23l1426t331r1597b379],
22	SH	NN	O	sh	prep_for	18	SENT_521	[p23l1426t331r1597b379],
23	.	.	O	.	_	0	SENT_521	[p23l1426t331r1597b379],

1	J.	NNP	PERSON	J.	nn	2	SENT_522	[p23l1426t331r1597b379],
2	Thorac	NNP	PERSON	Thorac	_	0	SENT_522	[p23l1614t329r1795b379],
3	.	.	O	.	_	0	SENT_522	[p23l1614t329r1795b379],

1	Oncol	NN	O	oncol	_	0	SENT_523	[p23l1811t329r1971b379],
2	.	.	O	.	_	0	SENT_523	[p23l1811t329r1971b379],

1	6	CD	NUMBER	6	_	0	SENT_524	[p23l1984t333r2029b387],
2	,	,	O	,	_	0	SENT_524	[p23l1984t333r2029b387],
3	459-465	CD	NUMBER	459-465	num	4	SENT_524	[p23l129t410r353b456],
4	(	NN	O	(	appos	1	SENT_524	[p23l371t407r471b463],
5	201	CD	NUMBER	201	number	6	SENT_524	[p23l371t407r471b463],
6	1	CD	NUMBER	1	num	7	SENT_524	[p23l490t407r545b463],
7	)	NN	O	)	dep	4	SENT_524	[p23l490t407r545b463],
8	.	.	O	.	_	0	SENT_524	[p23l490t407r545b463],

1	Selinger	NNP	PERSON	Selinger	_	0	SENT_525	[p23l130t485r352b548],
2	,	,	O	,	_	0	SENT_525	[p23l130t485r352b548],
3	C.	NNP	O	C.	nn	4	SENT_525	[p23l366t486r440b534],
4	|	NNP	O	|	appos	1	SENT_525	[p23l366t486r440b534],
5	.	.	O	.	_	0	SENT_525	[p23l366t486r440b534],

1	etal	NN	O	etal	_	0	SENT_526	[p23l455t485r766b548],
2	.	.	O	.	_	0	SENT_526	[p23l455t485r766b548],

1	Testing	VBG	O	test	_	0	SENT_527	[p23l455t485r766b548],
2	for	IN	O	for	_	0	SENT_527	[p23l781t484r854b534],
3	ALK	NNP	O	ALK	nn	4	SENT_527	[p23l866t487r969b534],
4	rearrangement	NN	O	rearrangement	prep_for	1	SENT_527	[p23l983t492r1377b548],
5	in	IN	O	in	_	0	SENT_527	[p23l1392t487r1435b534],
6	lung	NN	O	lung	nn	7	SENT_527	[p23l1454t485r1566b548],
7	adenocarcinoma	NN	O	adenocarcinoma	prep_in	1	SENT_527	[p23l1583t485r2038b534],
8	:	:	O	:	_	0	SENT_527	[p23l1583t485r2038b534],
9	a	DT	O	a	det	11	SENT_527	[p23l131t577r156b612],
10	multicenter	JJ	O	multicenter	amod	11	SENT_527	[p23l174t563r477b612],
11	comparison	NN	O	comparison	dep	1	SENT_527	[p23l490t565r799b625],
12	of	IN	O	of	_	0	SENT_527	[p23l815t562r870b612],
13	immunohistochemistry	NN	O	immunohistochemistry	prep_of	11	SENT_527	[p23l881t563r1497b626],
14	and	CC	O	and	_	0	SENT_527	[p23l1510t563r1606b612],
15	ﬂuorescent	NN	O	ﬂuorescent	conj_and	13	SENT_527	[p23l1621t562r1916b612],
16	in	FW	O	in	nn	17	SENT_527	[p23l132t643r175b690],
17	situ	FW	O	situ	advmod	18	SENT_527	[p23l192t643r281b690],
18	hybridization	NN	O	hybridization	rcmod	13	SENT_527	[p23l300t641r658b704],
19	.	.	O	.	_	0	SENT_527	[p23l300t641r658b704],

1	Mod	NN	O	mod	_	0	SENT_528	[p23l671t641r796b690],
2	.	.	O	.	_	0	SENT_528	[p23l671t641r796b690],

1	Pathol	NN	PERSON	pathol	_	0	SENT_529	[p23l810t641r985b690],
2	.	.	O	.	_	0	SENT_529	[p23l810t641r985b690],

1	(	NN	O	(	_	0	SENT_530	[p23l1002t642r1102b698],
2	201	CD	NUMBER	201	number	3	SENT_530	[p23l1002t642r1102b698],
3	3	CD	NUMBER	3	dep	1	SENT_530	[p23l1116t642r1161b698],
4	)	NN	O	)	dep	3	SENT_530	[p23l1116t642r1161b698],
5	201	CD	NUMBER	201	number	6	SENT_530	[p23l1178t644r1261b690],
6	3	CD	DATE	3	dep	1	SENT_530	[p23l1276t644r1302b690],
7	Jun	NN	DATE	jun	dep	6	SENT_530	[p23l1316t643r1406b690],
8	7	CD	DATE	7	num	7	SENT_530	[p23l1424t645r1465b690],
9	.	.	O	.	_	0	SENT_530	[p23l1424t645r1465b690],

1	doi	FW	O	doi	_	0	SENT_531	[p23l1479t641r1574b690],
2	:	:	O	:	_	0	SENT_531	[p23l1479t641r1574b690],
3	10.1038	CD	NUMBER	10.1038	dep	1	SENT_531	[p23l1593t642r1818b693],
4	/	:	O	/	punct	6	SENT_531	[p23l1593t642r1818b693],
5	modpatho	FW	O	modpatho	nn	6	SENT_531	[p23l133t719r658b781],
6	|	FW	O	|	dep	3	SENT_531	[p23l133t719r658b781],
7	.2013.87	CD	NUMBER	.2013.87	dep	6	SENT_531	[p23l133t719r658b781],
8	.	.	O	.	_	0	SENT_531	[p23l133t719r658b781],

1	[	NN	O	[	nn	2	SENT_532	[p23l676t719r826b781],
2	Epub	NN	O	epub	_	0	SENT_532	[p23l676t719r826b781],
3	ahead	RB	O	ahead	_	0	SENT_532	[p23l840t719r999b768],
4	of	IN	O	of	_	0	SENT_532	[p23l1016t718r1070b768],
5	print	NN	O	print	nn	6	SENT_532	[p23l1082t720r1235b781],
6	]	NN	O	]	prep_ahead_of	2	SENT_532	[p23l1082t720r1235b781],
7	.	.	O	.	_	0	SENT_532	[p23l1082t720r1235b781],

1	Sakai	NNP	LOCATION	Sakai	_	0	SENT_533	[p23l130t797r326b854],
2	,	,	O	,	_	0	SENT_533	[p23l130t797r326b854],
3	Y.	NNP	O	Y.	nn	4	SENT_533	[p23l130t797r326b854],
4	etal	NN	O	etal	appos	1	SENT_533	[p23l340t797r455b846],
5	.	.	O	.	_	0	SENT_533	[p23l340t797r455b846],

1	lmmunohistochemical	JJ	O	lmmunohistochemical	amod	2	SENT_534	[p23l472t797r1060b846],
2	proﬁling	NN	O	proﬁling	_	0	SENT_534	[p23l1079t796r1296b860],
3	of	IN	O	of	_	0	SENT_534	[p23l1312t796r1367b846],
4	ALK	NNP	O	ALK	nn	7	SENT_534	[p23l1376t799r1479b846],
5	fusion	NN	O	fusion	nn	7	SENT_534	[p23l1489t796r1649b846],
6	gene-positive	JJ	O	gene-positive	amod	7	SENT_534	[p23l1665t799r2026b860],
7	adenocarcinomas	NNS	O	adenocarcinoma	prep_of	2	SENT_534	[p23l131t875r598b924],
8	of	IN	O	of	_	0	SENT_534	[p23l612t874r667b924],
9	the	DT	O	the	det	10	SENT_534	[p23l675t875r761b924],
10	lung	NN	O	lung	prep_of	2	SENT_534	[p23l778t875r904b938],
11	.	.	O	.	_	0	SENT_534	[p23l778t875r904b938],

1	Int	NN	O	int	_	0	SENT_535	[p23l918t877r995b924],
2	.	.	O	.	_	0	SENT_535	[p23l918t877r995b924],

1	J.	NNP	O	J.	nn	2	SENT_536	[p23l1005t877r1040b924],
2	Surg	NNP	O	Surg	_	0	SENT_536	[p23l1053t876r1177b938],
3	.	.	O	.	_	0	SENT_536	[p23l1053t876r1177b938],

1	Pathol	NN	PERSON	pathol	_	0	SENT_537	[p23l1192t875r1367b924],
2	.	.	O	.	_	0	SENT_537	[p23l1192t875r1367b924],

1	21	CD	NUMBER	21	_	0	SENT_538	[p23l1382t878r1440b924],
2	,	,	O	,	_	0	SENT_538	[p23l1451t915r1462b932],
3	476-482	CD	NUMBER	476-482	number	4	SENT_538	[p23l1475t878r1699b924],
4	(	CD	NUMBER	(	appos	1	SENT_538	[p23l1716t876r1890b932],
5	2013	CD	DATE	2013	num	6	SENT_538	[p23l1716t876r1890b932],
6	)	NN	O	)	dep	4	SENT_538	[p23l1716t876r1890b932],
7	.	.	O	.	_	0	SENT_538	[p23l1716t876r1890b932],

1	Park	NNP	O	Park	_	0	SENT_539	[p23l132t953r253b1010],
2	,	,	O	,	_	0	SENT_539	[p23l132t953r253b1010],
3	H.S.	NNP	LOCATION	H.S.	nn	4	SENT_539	[p23l270t954r362b1002],
4	etal	NNP	O	etal	appos	1	SENT_539	[p23l377t953r492b1002],
5	.	.	O	.	_	0	SENT_539	[p23l377t953r492b1002],

1	lmmunohistochemical	JJ	O	lmmunohistochemical	amod	2	SENT_540	[p23l508t953r1096b1002],
2	screening	NN	O	screening	_	0	SENT_540	[p23l1113t955r1366b1016],
3	for	IN	O	for	_	0	SENT_540	[p23l1381t952r1453b1002],
4	anaplastic	JJ	O	anaplastic	amod	10	SENT_540	[p23l1466t953r1731b1015],
5	lymphoma	NN	O	lymphoma	nn	10	SENT_540	[p23l1747t953r2028b1016],
6	kinase	NN	O	kinase	nn	10	SENT_540	[p23l133t1031r296b1080],
7	(	NN	O	(	nn	10	SENT_540	[p23l312t1032r445b1088],
8	ALK	NN	O	alk	nn	10	SENT_540	[p23l312t1032r445b1088],
9	)	CD	NUMBER	)	num	10	SENT_540	[p23l312t1032r445b1088],
10	rearrangement	NN	O	rearrangement	prep_for	2	SENT_540	[p23l463t1038r857b1094],
11	in	IN	O	in	_	0	SENT_540	[p23l872t1033r915b1080],
12	advanced	JJ	O	advanced	amod	17	SENT_540	[p23l931t1031r1184b1080],
13	non-small	JJ	O	non-small	amod	17	SENT_540	[p23l1203t1031r1459b1080],
14	cell	NN	O	cell	nn	17	SENT_540	[p23l1476t1031r1559b1080],
15	lung	NN	O	lung	nn	17	SENT_540	[p23l1578t1031r1691b1094],
16	cancer	NN	O	cancer	nn	17	SENT_540	[p23l1708t1045r1880b1080],
17	patients	NNS	O	patient	prep_in	2	SENT_540	[p23l1895t1033r2118b1093],
18	.	.	O	.	_	0	SENT_540	[p23l1895t1033r2118b1093],

1	Lung	NN	O	lung	nn	2	SENT_541	[p23l130t1111r255b1171],
2	Cancer	NN	O	cancer	_	0	SENT_541	[p23l269t1110r446b1158],
3	77	CD	NUMBER	77	dep	2	SENT_541	[p23l457t1113r536b1165],
4	,	,	O	,	_	0	SENT_541	[p23l457t1113r536b1165],
5	288-292	CD	NUMBER	288-292	number	6	SENT_541	[p23l551t1112r773b1158],
6	(	CD	NUMBER	(	appos	3	SENT_541	[p23l790t1110r964b1165],
7	2012	CD	DATE	2012	num	8	SENT_541	[p23l790t1110r964b1165],
8	)	NN	O	)	dep	6	SENT_541	[p23l790t1110r964b1165],
9	.	.	O	.	_	0	SENT_541	[p23l790t1110r964b1165],

1	Martinez	NNP	PERSON	Martinez	_	0	SENT_542	[p23l131t1188r373b1243],
2	,	,	O	,	_	0	SENT_542	[p23l131t1188r373b1243],
3	P.	NNP	O	P.	nn	4	SENT_542	[p23l390t1188r422b1235],
4	etal	NN	O	etal	appos	1	SENT_542	[p23l436t1186r551b1235],
5	.	.	O	.	_	0	SENT_542	[p23l436t1186r551b1235],

1	Fluorescence	NN	O	fluorescence	_	0	SENT_543	[p23l567t1186r909b1235],
2	in	FW	O	in	nn	3	SENT_543	[p23l925t1188r967b1235],
3	situ	FW	O	situ	advmod	4	SENT_543	[p23l984t1188r1074b1235],
4	hybridization	NN	O	hybridization	rcmod	1	SENT_543	[p23l1092t1186r1435b1249],
5	and	CC	O	and	_	0	SENT_543	[p23l1452t1186r1548b1235],
6	immunohistochemistry	NN	O	immunohistochemistry	rcmod	1	SENT_543	[p23l132t1264r748b1327],
7	as	IN	O	as	_	0	SENT_543	[p23l761t1278r813b1313],
8	diagnostic	JJ	O	diagnostic	amod	9	SENT_543	[p23l828t1264r1100b1327],
9	methods	NNS	O	method	prep_as	4	SENT_543	[p23l1117t1264r1348b1313],
10	for	IN	O	for	_	0	SENT_543	[p23l1361t1263r1434b1313],
11	ALK	NNP	O	ALK	prep_for	9	SENT_543	[p23l1446t1266r1549b1313],
12	positive	JJ	O	positive	amod	15	SENT_543	[p23l1563t1266r1766b1326],
13	non-small	JJ	O	non-small	amod	15	SENT_543	[p23l1782t1264r2038b1313],
14	cell	NN	O	cell	nn	15	SENT_543	[p23l2055t1264r2139b1313],
15	lung	NN	O	lung	dep	1	SENT_543	[p23l133t1342r246b1405],
16	cancer	NN	O	cancer	nn	17	SENT_543	[p23l262t1356r435b1391],
17	patients	NNS	O	patient	dep	15	SENT_543	[p23l450t1344r672b1404],
18	.	.	O	.	_	0	SENT_543	[p23l450t1344r672b1404],

1	PLoS	NN	O	plo	_	0	SENT_544	[p23l686t1343r806b1391],
2	ONE	CD	NUMBER	one	number	3	SENT_544	[p23l818t1343r931b1391],
3	8	CD	NUMBER	8	amod	1	SENT_544	[p23l940t1345r985b1399],
4	,	,	O	,	_	0	SENT_544	[p23l940t1345r985b1399],
5	e52261	NN	O	e52261	appos	1	SENT_544	[p23l1000t1345r1181b1391],
6	(	CD	NUMBER	(	num	5	SENT_544	[p23l1207t1343r1381b1399],
7	2013	CD	DATE	2013	num	8	SENT_544	[p23l1207t1343r1381b1399],
8	)	NN	O	)	dep	5	SENT_544	[p23l1207t1343r1381b1399],
9	.	.	O	.	_	0	SENT_544	[p23l1207t1343r1381b1399],

1	Conklin	NNP	PERSON	Conklin	nn	7	SENT_545	[p23l129t1419r341b1475],
2	,	,	O	,	_	0	SENT_545	[p23l129t1419r341b1475],
3	C.M.	NNP	PERSON	C.M.	appos	7	SENT_545	[p23l355t1420r479b1475],
4	,	,	O	,	_	0	SENT_545	[p23l355t1420r479b1475],
5	Craddock	NNP	PERSON	Craddock	appos	7	SENT_545	[p23l493t1419r756b1475],
6	,	,	O	,	_	0	SENT_545	[p23l493t1419r756b1475],
7	K.J.	NNP	LOCATION	K.J.	nsubj	29	SENT_545	[p23l773t1421r864b1475],
8	,	,	O	,	_	0	SENT_545	[p23l773t1421r864b1475],
9	Have	VBP	O	have	rcmod	7	SENT_545	[p23l881t1421r1021b1475],
10	,	,	O	,	_	0	SENT_545	[p23l881t1421r1021b1475],
11	C.	NNP	O	C.	appos	7	SENT_545	[p23l1035t1420r1094b1475],
12	,	,	O	,	_	0	SENT_545	[p23l1035t1420r1094b1475],
13	Laskin	NNP	PERSON	Laskin	appos	7	SENT_545	[p23l1111t1419r1285b1475],
14	,	,	O	,	_	0	SENT_545	[p23l1111t1419r1285b1475],
15	J.	NNP	O	J.	conj_and	11	SENT_545	[p23l1298t1421r1344b1475],
16	,	,	O	,	_	0	SENT_545	[p23l1298t1421r1344b1475],
17	Couture	NNP	O	Couture	conj_and	11	SENT_545	[p23l1359t1420r1581b1475],
18	,	,	O	,	_	0	SENT_545	[p23l1359t1420r1581b1475],
19	C.	NNP	ORGANIZATION	C.	conj_and	11	SENT_545	[p23l1596t1420r1642b1468],
20	&	CC	ORGANIZATION	&	_	0	SENT_545	[p23l1656t1420r1693b1468],
21	Ionescu	NNP	ORGANIZATION	Ionescu	conj_and	11	SENT_545	[p23l1708t1421r1921b1475],
22	,	,	O	,	_	0	SENT_545	[p23l1708t1421r1921b1475],
23	D.N.	NNP	O	D.N.	nn	24	SENT_545	[p23l1937t1421r2040b1468],
24	immunohistochemistry	NN	O	immunohistochemistry	nsubj	29	SENT_545	[p23l133t1497r749b1560],
25	is	VBZ	O	be	cop	29	SENT_545	[p23l764t1499r798b1546],
26	a	DT	O	a	det	29	SENT_545	[p23l812t1511r838b1546],
27	reliable	JJ	O	reliable	amod	29	SENT_545	[p23l856t1497r1046b1546],
28	screening	NN	O	screening	nn	29	SENT_545	[p23l1060t1499r1312b1560],
29	tool	NN	O	tool	_	0	SENT_545	[p23l1328t1497r1428b1546],
30	for	IN	O	for	_	0	SENT_545	[p23l1443t1496r1516b1546],
31	identiﬁcation	NN	O	identiﬁcation	prep_for	29	SENT_545	[p23l1531t1496r1875b1546],
32	of	IN	O	of	_	0	SENT_545	[p23l1891t1496r1946b1546],
33	ALK	NNP	O	ALK	nn	34	SENT_545	[p23l1955t1499r2058b1546],
34	rearrangement	NN	O	rearrangement	prep_of	31	SENT_545	[p23l133t1582r526b1638],
35	in	IN	O	in	_	0	SENT_545	[p23l541t1577r584b1624],
36	non	JJ	O	non	amod	40	SENT_545	[p23l603t1575r969b1624],
37	—	JJ	O	—	amod	40	SENT_545	[p23l603t1575r969b1624],
38	small-cell	NN	O	small-cell	nn	40	SENT_545	[p23l603t1575r969b1624],
39	lung	NN	O	lung	nn	40	SENT_545	[p23l988t1575r1101b1638],
40	carcinoma	NN	O	carcinoma	prep_in	29	SENT_545	[p23l1117t1577r1389b1624],
41	and	CC	O	and	_	0	SENT_545	[p23l1405t1575r1501b1624],
42	is	VBZ	O	be	cop	44	SENT_545	[p23l1519t1577r1553b1624],
43	antibody	NN	O	antibody	npadvmod	44	SENT_545	[p23l1568t1575r1804b1638],
44	dependent	JJ	O	dependent	conj_and	29	SENT_545	[p23l1817t1575r2122b1637],
45	.	.	O	.	_	0	SENT_545	[p23l1817t1575r2122b1637],

1	J.	NNP	PERSON	J.	nn	2	SENT_546	[p23l127t1654r160b1701],
2	Thorac	NNP	PERSON	Thorac	_	0	SENT_546	[p23l178t1652r359b1701],
3	.	.	O	.	_	0	SENT_546	[p23l178t1652r359b1701],

1	Oncol	NN	O	oncol	_	0	SENT_547	[p23l375t1652r534b1701],
2	.	.	O	.	_	0	SENT_547	[p23l375t1652r534b1701],

1	8	CD	NUMBER	8	_	0	SENT_548	[p23l549t1655r593b1708],
2	,	,	O	,	_	0	SENT_548	[p23l549t1655r593b1708],
3	45-51	CD	NUMBER	45-51	number	4	SENT_548	[p23l606t1656r756b1701],
4	(	CD	NUMBER	(	appos	1	SENT_548	[p23l783t1653r957b1708],
5	2013	CD	DATE	2013	num	6	SENT_548	[p23l783t1653r957b1708],
6	)	NN	O	)	dep	4	SENT_548	[p23l783t1653r957b1708],
7	.	.	O	.	_	0	SENT_548	[p23l783t1653r957b1708],

1	Boland	NNP	PERSON	Boland	_	0	SENT_549	[p23l132t1730r324b1787],
2	,	,	O	,	_	0	SENT_549	[p23l132t1730r324b1787],
3	J.M.	NNP	O	J.M.	nn	4	SENT_549	[p23l337t1732r435b1779],
4	etal	NN	O	etal	appos	1	SENT_549	[p23l449t1730r564b1779],
5	.	.	O	.	_	0	SENT_549	[p23l449t1730r564b1779],

1	Anaplastic	JJ	O	anaplastic	amod	4	SENT_550	[p23l578t1730r851b1792],
2	lymphoma	NN	O	lymphoma	nn	4	SENT_550	[p23l867t1730r1148b1793],
3	kinase	NN	O	kinase	nn	4	SENT_550	[p23l1166t1730r1329b1779],
4	immunoreactivity	NN	O	immunoreactivity	nsubj	5	SENT_550	[p23l1346t1732r1813b1793],
5	correlates	VBZ	O	correlate	_	0	SENT_550	[p23l1826t1730r2081b1779],
6	with	IN	O	with	_	0	SENT_550	[p23l130t1808r243b1857],
7	ALK	NN	O	alk	nn	9	SENT_550	[p23l259t1810r362b1857],
8	gene	NN	O	gene	nn	9	SENT_550	[p23l374t1822r504b1871],
9	rearrangement	NN	O	rearrangement	prep_with	5	SENT_550	[p23l521t1815r915b1871],
10	and	CC	O	and	_	0	SENT_550	[p23l929t1808r1025b1857],
11	transcriptional	JJ	O	transcriptional	amod	23	SENT_550	[p23l1040t1808r1420b1870],
12	up	IN	O	up	_	0	SENT_550	[p23l1438t1808r1796b1871],
13	—	CD	NUMBER	—	num	16	SENT_550	[p23l1438t1808r1796b1871],
14	regu	NN	O	regu	nn	16	SENT_550	[p23l1438t1808r1796b1871],
15	|	NN	O	|	nn	16	SENT_550	[p23l1438t1808r1796b1871],
16	ation	NN	O	ation	prep_up	11	SENT_550	[p23l1438t1808r1796b1871],
17	in	IN	O	in	_	0	SENT_550	[p23l1814t1810r1857b1857],
18	non	JJ	O	non	amod	21	SENT_550	[p23l1876t1808r2131b1857],
19	—	JJ	O	—	amod	21	SENT_550	[p23l1876t1808r2131b1857],
20	small	JJ	O	small	amod	21	SENT_550	[p23l1876t1808r2131b1857],
21	cell	NN	O	cell	prep_in	16	SENT_550	[p23l131t1886r214b1935],
22	lung	NN	O	lung	nn	23	SENT_550	[p23l233t1886r346b1949],
23	carcinomas	NNS	O	carcinoma	prep_with	5	SENT_550	[p23l362t1888r673b1935],
24	.	.	O	.	_	0	SENT_550	[p23l362t1888r673b1935],

1	Hum	NNP	O	Hum	_	0	SENT_551	[p23l687t1888r820b1935],
2	.	.	O	.	_	0	SENT_551	[p23l687t1888r820b1935],

1	Pathol	NN	PERSON	pathol	_	0	SENT_552	[p23l834t1886r1010b1935],
2	.	.	O	.	_	0	SENT_552	[p23l834t1886r1010b1935],

1	40	CD	NUMBER	40	_	0	SENT_553	[p23l1023t1889r1104b1943],
2	,	,	O	,	_	0	SENT_553	[p23l1023t1889r1104b1943],
3	1	CD	NUMBER	1	number	4	SENT_553	[p23l1123t1890r1137b1935],
4	152-1	CD	NUMBER	152-1	appos	1	SENT_553	[p23l1156t1889r1300b1935],
5	158	CD	NUMBER	158	num	6	SENT_553	[p23l1318t1889r1408b1935],
6	(	CD	NUMBER	(	dep	4	SENT_553	[p23l1424t1887r1598b1943],
7	2009	CD	DATE	2009	num	8	SENT_553	[p23l1424t1887r1598b1943],
8	)	NN	O	)	dep	4	SENT_553	[p23l1424t1887r1598b1943],
9	.	.	O	.	_	0	SENT_553	[p23l1424t1887r1598b1943],

1	Pailler	NNP	PERSON	Pailler	_	0	SENT_554	[p23l132t1964r295b2021],
2	,	,	O	,	_	0	SENT_554	[p23l132t1964r295b2021],
3	E.	NNP	O	E.	nn	4	SENT_554	[p23l312t1966r349b2013],
4	etal	NN	O	etal	appos	1	SENT_554	[p23l364t1964r478b2013],
5	.	.	O	.	_	0	SENT_554	[p23l364t1964r478b2013],

1	Detection	NN	O	detection	_	0	SENT_555	[p23l495t1966r750b2013],
2	of	IN	O	of	_	0	SENT_555	[p23l766t1963r821b2013],
3	circulating	VBG	O	circulate	prepc_of	1	SENT_555	[p23l830t1964r1103b2027],
4	tumor	NN	O	tumor	nn	5	SENT_555	[p23l1118t1971r1282b2013],
5	cells	NNS	O	cell	dobj	3	SENT_555	[p23l1295t1964r1406b2013],
6	harboring	VBG	O	harbor	xcomp	3	SENT_555	[p23l1423t1964r1680b2027],
7	a	DT	O	a	det	10	SENT_555	[p23l1696t1978r1722b2013],
8	unique	JJ	O	unique	amod	10	SENT_555	[p23l1740t1966r1922b2026],
9	ALK	NN	O	alk	nn	10	SENT_555	[p23l1936t1966r2039b2013],
10	rearrangement	NN	O	rearrangement	dobj	6	SENT_555	[p23l133t2049r526b2105],
11	in	IN	O	in	_	0	SENT_555	[p23l541t2044r584b2091],
12	ALK-positive	JJ	O	alk-positive	amod	15	SENT_555	[p23l600t2044r928b2104],
13	non-small-cell	JJ	O	non-small-cell	amod	15	SENT_555	[p23l944t2042r1310b2092],
14	lung	NN	O	lung	nn	15	SENT_555	[p23l1329t2042r1442b2105],
15	cancer	NN	O	cancer	prep_in	6	SENT_555	[p23l1459t2056r1640b2092],
16	.	.	O	.	_	0	SENT_555	[p23l1459t2056r1640b2092],

1	J.	NNP	PERSON	J.	nn	2	SENT_556	[p23l1650t2044r1684b2092],
2	Clin	NNP	PERSON	Clin	_	0	SENT_556	[p23l1701t2042r1805b2092],
3	.	.	O	.	_	0	SENT_556	[p23l1701t2042r1805b2092],

1	Oncol	NN	O	oncol	_	0	SENT_557	[p23l1821t2042r1980b2092],
2	.	.	O	.	_	0	SENT_557	[p23l1821t2042r1980b2092],

1	31	CD	NUMBER	31	_	0	SENT_558	[p23l1995t2045r2075b2099],
2	,	,	O	,	_	0	SENT_558	[p23l1995t2045r2075b2099],
3	2273-2281	CD	DATE	2273-2281	number	4	SENT_558	[p23l131t2122r410b2168],
4	(	CD	NUMBER	(	appos	1	SENT_558	[p23l436t2120r610b2175],
5	2013	CD	DATE	2013	num	6	SENT_558	[p23l436t2120r610b2175],
6	)	NN	O	)	dep	4	SENT_558	[p23l436t2120r610b2175],
7	.	.	O	.	_	0	SENT_558	[p23l436t2120r610b2175],

1	Jung	NNP	PERSON	Jung	_	0	SENT_559	[p23l127t2199r267b2260],
2	,	,	O	,	_	0	SENT_559	[p23l127t2199r267b2260],
3	Y.	NNP	O	Y.	nn	4	SENT_559	[p23l277t2199r316b2246],
4	etal	NN	O	etal	appos	1	SENT_559	[p23l330t2197r445b2246],
5	.	.	O	.	_	0	SENT_559	[p23l330t2197r445b2246],

1	Discovery	NNP	O	Discovery	nn	4	SENT_560	[p23l462t2199r716b2260],
2	ofALK-PTPN3	NN	O	ofalk-ptpn3	nn	4	SENT_560	[p23l729t2196r1083b2246],
3	gene	NN	O	gene	nn	4	SENT_560	[p23l1100t2212r1231b2260],
4	fusion	NN	O	fusion	_	0	SENT_560	[p23l1243t2196r1403b2247],
5	from	IN	O	from	_	0	SENT_560	[p23l1418t2196r1541b2247],
6	human	JJ	O	human	amod	12	SENT_560	[p23l1559t2197r1741b2247],
7	non-small	JJ	O	non-small	amod	12	SENT_560	[p23l1760t2197r2016b2246],
8	cell	NN	O	cell	nn	12	SENT_560	[p23l131t2275r214b2325],
9	lung	NN	O	lung	nn	12	SENT_560	[p23l233t2275r346b2338],
10	carcinoma	NN	O	carcinoma	nn	12	SENT_560	[p23l362t2277r634b2325],
11	cell	NN	O	cell	nn	12	SENT_560	[p23l650t2275r733b2325],
12	line	NN	O	line	prep_from	4	SENT_560	[p23l753t2275r843b2325],
13	using	VBG	O	use	partmod	4	SENT_560	[p23l860t2277r998b2338],
14	next	JJ	O	next	amod	17	SENT_560	[p23l1016t2282r1130b2325],
15	generation	NN	O	generation	nn	17	SENT_560	[p23l1143t2277r1429b2338],
16	RNA	NN	O	rna	nn	17	SENT_560	[p23l1448t2277r1558b2324],
17	sequencing	NN	O	sequencing	dobj	13	SENT_560	[p23l1572t2277r1890b2338],
18	.	.	O	.	_	0	SENT_560	[p23l1572t2277r1890b2338],

1	Genes	NNS	O	gene	_	0	SENT_561	[p23l1905t2277r2066b2325],
2	.	.	O	.	_	0	SENT_561	[p23l1905t2277r2066b2325],

1	Chromosomes	NNS	O	chromosome	_	0	SENT_562	[p23l131t2352r496b2401],
2	Cancer	NNP	O	Cancer	dep	1	SENT_562	[p23l509t2353r685b2401],
3	51	CD	NUMBER	51	num	2	SENT_562	[p23l697t2356r776b2408],
4	,	,	O	,	_	0	SENT_562	[p23l697t2356r776b2408],
5	590-597	CD	NUMBER	590-597	num	2	SENT_562	[p23l791t2355r1014b2401],
6	(	CD	NUMBER	(	num	8	SENT_562	[p23l1031t2353r1204b2408],
7	2012	CD	DATE	2012	num	8	SENT_562	[p23l1031t2353r1204b2408],
8	)	NN	O	)	dep	2	SENT_562	[p23l1031t2353r1204b2408],
9	.	.	O	.	_	0	SENT_562	[p23l1031t2353r1204b2408],

1	Ou	NNP	LOCATION	Ou	_	0	SENT_563	[p23l129t2432r217b2487],
2	,	,	O	,	_	0	SENT_563	[p23l129t2432r217b2487],
3	S.H.	NNP	PERSON	S.H.	nn	4	SENT_563	[p23l232t2432r327b2479],
4	etal	NNP	O	etal	appos	1	SENT_563	[p23l341t2430r455b2480],
5	.	.	O	.	_	0	SENT_563	[p23l341t2430r455b2480],

1	Activity	NN	O	activity	nsubj	5	SENT_564	[p23l469t2432r668b2493],
2	of	IN	O	of	_	0	SENT_564	[p23l681t2429r735b2479],
3	crizotinib	NN	O	crizotinib	prep_of	1	SENT_564	[p23l745t2430r989b2479],
4	(	CD	NUMBER	(	num	5	SENT_564	[p23l1005t2431r1236b2487],
5	PF02341	NN	O	pf02341	_	0	SENT_564	[p23l1005t2431r1236b2487],
6	066	CD	NUMBER	066	num	7	SENT_564	[p23l1250t2431r1375b2487],
7	)	NN	O	)	dobj	5	SENT_564	[p23l1250t2431r1375b2487],
8	,	,	O	,	_	0	SENT_564	[p23l1250t2431r1375b2487],
9	a	DT	O	a	det	14	SENT_564	[p23l1389t2445r1415b2479],
10	dual	JJ	O	dual	amod	14	SENT_564	[p23l1431t2430r1541b2479],
11	mesenchyma	NN	O	mesenchyma	nn	14	SENT_564	[p23l1560t2430r1944b2494, p23l131t2508r371b2570],
12	|	NN	O	|	nn	14	SENT_564	[p23l1560t2430r1944b2494, p23l131t2508r371b2570],
13	epithelial	JJ	O	epithelial	amod	14	SENT_564	[p23l1560t2430r1944b2494, p23l131t2508r371b2570],
14	transition	NN	O	transition	appos	7	SENT_564	[p23l386t2510r635b2557],
15	(	CD	NUMBER	(	num	17	SENT_564	[p23l653t2509r801b2565],
16	MET	NN	O	met	nn	17	SENT_564	[p23l653t2509r801b2565],
17	)	NN	O	)	dep	14	SENT_564	[p23l653t2509r801b2565],
18	and	CC	O	and	_	0	SENT_564	[p23l817t2508r913b2557],
19	anaplastic	JJ	O	anaplastic	amod	23	SENT_564	[p23l930t2508r1194b2570],
20	lymphoma	NN	O	lymphoma	nn	23	SENT_564	[p23l1211t2508r1492b2572],
21	kinase	NN	O	kinase	nn	23	SENT_564	[p23l1510t2508r1673b2557],
22	(	NN	O	(	nn	23	SENT_564	[p23l1689t2509r1822b2565],
23	ALK	NN	O	alk	conj_and	14	SENT_564	[p23l1689t2509r1822b2565],
24	)	CD	NUMBER	)	num	25	SENT_564	[p23l1689t2509r1822b2565],
25	inhibitor	NN	O	inhibitor	dep	23	SENT_564	[p23l1839t2508r2072b2565],
26	,	,	O	,	_	0	SENT_564	[p23l1839t2508r2072b2565],
27	in	IN	O	in	_	0	SENT_564	[p23l2087t2510r2130b2557],
28	a	DT	O	a	det	33	SENT_564	[p23l130t2601r156b2636],
29	non-small	JJ	O	non-small	amod	33	SENT_564	[p23l174t2586r430b2636],
30	cell	NN	O	cell	nn	33	SENT_564	[p23l447t2586r530b2636],
31	lung	NN	O	lung	nn	33	SENT_564	[p23l549t2586r662b2649],
32	cancer	NN	O	cancer	nn	33	SENT_564	[p23l679t2601r851b2636],
33	patient	NN	O	patient	prep_in	7	SENT_564	[p23l866t2588r1052b2648],
34	with	IN	O	with	_	0	SENT_564	[p23l1064t2586r1177b2636],
35	de	FW	O	de	nn	38	SENT_564	[p23l1194t2586r1258b2636],
36	novo	FW	O	novo	nn	38	SENT_564	[p23l1275t2601r1403b2636],
37	MET	NN	O	met	nn	38	SENT_564	[p23l1419t2588r1532b2635],
38	amp	NN	O	amp	prep_with	5	SENT_564	[p23l1544t2585r1946b2648],
39	|	NN	O	|	nn	40	SENT_564	[p23l1544t2585r1946b2648],
40	iﬁcation	NN	O	iﬁcation	dep	38	SENT_564	[p23l1544t2585r1946b2648],
41	.	.	O	.	_	0	SENT_564	[p23l1544t2585r1946b2648],

1	J.	NNP	PERSON	J.	nn	2	SENT_565	[p23l1544t2585r1946b2648],
2	Thorac	NNP	PERSON	Thorac	_	0	SENT_565	[p23l1963t2586r2144b2636],
3	.	.	O	.	_	0	SENT_565	[p23l1963t2586r2144b2636],

1	Oncol	NN	O	oncol	_	0	SENT_566	[p23l131t2663r291b2712],
2	.	.	O	.	_	0	SENT_566	[p23l131t2663r291b2712],

1	6	CD	NUMBER	6	_	0	SENT_567	[p23l305t2666r350b2719],
2	,	,	O	,	_	0	SENT_567	[p23l305t2666r350b2719],
3	942-946	CD	NUMBER	942-946	num	4	SENT_567	[p23l364t2666r588b2712],
4	(	NN	O	(	appos	1	SENT_567	[p23l605t2664r705b2719],
5	201	CD	NUMBER	201	number	6	SENT_567	[p23l605t2664r705b2719],
6	1	CD	NUMBER	1	num	7	SENT_567	[p23l723t2664r778b2719],
7	)	NN	O	)	dep	4	SENT_567	[p23l723t2664r778b2719],
8	.	.	O	.	_	0	SENT_567	[p23l723t2664r778b2719],

1	Bergethon	NNP	PERSON	Bergethon	_	0	SENT_568	[p23l131t2741r420b2804],
2	,	,	O	,	_	0	SENT_568	[p23l131t2741r420b2804],
3	K.	NNP	O	K.	nn	4	SENT_568	[p23l436t2743r478b2791],
4	etal	NN	O	etal	appos	1	SENT_568	[p23l492t2741r607b2791],
5	.	.	O	.	_	0	SENT_568	[p23l492t2741r607b2791],

1	ROS1	NN	O	ros1	nn	2	SENT_569	[p23l625t2743r751b2791],
2	rearrangements	NNS	O	rearrangement	nsubj	3	SENT_569	[p23l777t2748r1195b2804],
3	deﬁne	VBP	O	deﬁne	_	0	SENT_569	[p23l1210t2740r1375b2791],
4	a	DT	O	a	det	7	SENT_569	[p23l1389t2756r1414b2791],
5	unique	JJ	O	unique	amod	7	SENT_569	[p23l1432t2743r1615b2803],
6	molecular	JJ	O	molecular	amod	7	SENT_569	[p23l1631t2741r1892b2791],
7	class	NN	O	class	dobj	3	SENT_569	[p23l1905t2741r2025b2791],
8	of	IN	O	of	_	0	SENT_569	[p23l2039t2740r2094b2791],
9	lung	NN	O	lung	nn	10	SENT_569	[p23l133t2819r246b2882],
10	cancers	NNS	O	cancer	prep_of	7	SENT_569	[p23l262t2821r516b2869],
11	.	.	O	.	_	0	SENT_569	[p23l262t2821r516b2869],

1	J.	NNP	PERSON	J.	nn	2	SENT_570	[p23l262t2821r516b2869],
2	Clin	NNP	PERSON	Clin	_	0	SENT_570	[p23l532t2819r636b2869],
3	.	.	O	.	_	0	SENT_570	[p23l532t2819r636b2869],

1	Oncol	NN	O	oncol	_	0	SENT_571	[p23l652t2819r812b2869],
2	.	.	O	.	_	0	SENT_571	[p23l652t2819r812b2869],

1	30	CD	NUMBER	30	_	0	SENT_572	[p23l826t2822r906b2876],
2	,	,	O	,	_	0	SENT_572	[p23l826t2822r906b2876],
3	863-870	CD	NUMBER	863-870	num	4	SENT_572	[p23l920t2822r1144b2869],
4	(	NN	O	(	appos	1	SENT_572	[p23l1160t2820r1261b2876],
5	201	CD	NUMBER	201	number	6	SENT_572	[p23l1160t2820r1261b2876],
6	2	CD	NUMBER	2	num	7	SENT_572	[p23l1275t2820r1334b2876],
7	)	NN	O	)	dep	4	SENT_572	[p23l1275t2820r1334b2876],
8	.	.	O	.	_	0	SENT_572	[p23l1275t2820r1334b2876],

1	XALKORI	NNP	O	XALKORI	_	0	SENT_573	[p23l129t2899r354b2947],
2	[	CD	NUMBER	[	num	1	SENT_573	[p23l374t2897r610b2960],
3	package	NN	O	package	nn	5	SENT_573	[p23l374t2897r610b2960],
4	insert	NN	O	insert	nn	5	SENT_573	[p23l626t2898r802b2954],
5	]	NN	O	]	dep	1	SENT_573	[p23l626t2898r802b2954],
6	,	,	O	,	_	0	SENT_573	[p23l626t2898r802b2954],
7	Pﬁzer	NNP	O	Pﬁzer	appos	5	SENT_573	[p23l819t2896r1059b2954],
8	:	:	O	:	_	0	SENT_573	[p23l819t2896r1059b2954],
9	US	NNP	LOCATION	US	dep	1	SENT_573	[p23l819t2896r1059b2954],
10	,	,	O	,	_	0	SENT_573	[p23l819t2896r1059b2954],
11	2013	CD	DATE	2013	appos	9	SENT_573	[p23l1074t2900r1213b2947],
12	.	.	O	.	_	0	SENT_573	[p23l1074t2900r1213b2947],

1	Kim	NNP	PERSON	Kim	nn	3	SENT_574	[p23l131t2977r244b3032],
2	,	,	O	,	_	0	SENT_574	[p23l131t2977r244b3032],
3	D.K.	NNP	O	D.K.	_	0	SENT_574	[p23l261t2977r359b3025],
4	et	FW	O	et	nn	5	SENT_574	[p23l375t2982r424b3025],
5	al.	FW	O	al.	dep	3	SENT_574	[p23l434t2975r493b3025],
6	.	.	O	.	_	0	SENT_574	[p23l434t2975r493b3025],

1	Updated	VBN	O	update	_	0	SENT_575	[p23l511t2975r739b3037],
2	results	NNS	O	result	nsubj	19	SENT_575	[p23l758t2975r929b3025],
3	ofa	NN	O	ofa	nn	5	SENT_575	[p23l945t2974r1037b3025],
4	global	JJ	O	global	amod	5	SENT_575	[p23l1054t2975r1218b3038],
5	phase	NN	O	phase	dep	2	SENT_575	[p23l1238t2975r1395b3037],
6	II	CD	NUMBER	ii	num	7	SENT_575	[p23l1413t2977r1435b3024],
7	study	NN	O	study	dep	2	SENT_575	[p23l1453t2975r1601b3038],
8	with	IN	O	with	_	0	SENT_575	[p23l1613t2975r1729b3025],
9	crizotinib	NN	O	crizotinib	prep_with	7	SENT_575	[p23l1747t2975r1996b3025],
10	in	IN	O	in	_	0	SENT_575	[p23l2014t2977r2057b3024],
11	advanced	JJ	O	advanced	amod	16	SENT_575	[p23l130t3053r388b3103],
12	ALK-positive	JJ	O	alk-positive	amod	16	SENT_575	[p23l405t3055r740b3115],
13	non-small	JJ	O	non-small	amod	16	SENT_575	[p23l757t3053r1019b3103],
14	cell	NN	O	cell	nn	16	SENT_575	[p23l1036t3053r1122b3103],
15	lung	NN	O	lung	nn	16	SENT_575	[p23l1142t3053r1257b3116],
16	cancer	NN	O	cancer	prep_in	9	SENT_575	[p23l1275t3068r1451b3103],
17	(	CD	NUMBER	(	num	19	SENT_575	[p23l1467t3054r1737b3110],
18	NSCLC	NN	O	nsclc	nn	19	SENT_575	[p23l1467t3054r1737b3110],
19	)	NN	O	)	xcomp	1	SENT_575	[p23l1467t3054r1737b3110],
20	.	.	O	.	_	0	SENT_575	[p23l1467t3054r1737b3110],

1	J.	NNP	PERSON	J.	nn	2	SENT_576	[p23l1467t3054r1737b3110],
2	Clin	NNP	PERSON	Clin	_	0	SENT_576	[p23l1755t3053r1862b3103],
3	.	.	O	.	_	0	SENT_576	[p23l1755t3053r1862b3103],

1	Oncol	NN	O	oncol	_	0	SENT_577	[p23l1879t3053r2042b3103],
2	.	.	O	.	_	0	SENT_577	[p23l1879t3053r2042b3103],

1	30	CD	NUMBER	30	_	0	SENT_578	[p23l2057t3056r2139b3110],
2	,	,	O	,	_	0	SENT_578	[p23l2057t3056r2139b3110],
3	(	CD	NUMBER	(	num	4	SENT_578	[p23l132t3130r467b3191],
4	suppl	NN	O	suppl	dep	1	SENT_578	[p23l132t3130r467b3191],
5	;	:	O	;	_	0	SENT_578	[p23l132t3130r467b3191],
6	abstr	NN	O	abstr	dep	4	SENT_578	[p23l132t3130r467b3191],
7	.	.	O	.	_	0	SENT_578	[p23l132t3130r467b3191],

1	7533	CD	NUMBER	7533	_	0	SENT_579	[p23l484t3131r628b3186],
2	)	CD	NUMBER	)	number	3	SENT_579	[p23l484t3131r628b3186],
3	(	CD	NUMBER	(	dep	1	SENT_579	[p23l647t3131r825b3186],
4	2012	CD	DATE	2012	num	5	SENT_579	[p23l647t3131r825b3186],
5	)	NN	O	)	dep	3	SENT_579	[p23l647t3131r825b3186],
6	.	.	O	.	_	0	SENT_579	[p23l647t3131r825b3186],

1	Ou	NNP	LOCATION	Ou	_	0	SENT_580	[p23l129t3210r217b3265],
2	,	,	O	,	_	0	SENT_580	[p23l129t3210r217b3265],
3	S.H.	NNP	PERSON	S.H.	nn	4	SENT_580	[p23l232t3210r326b3257],
4	etal	NNP	O	etal	appos	1	SENT_580	[p23l341t3208r455b3258],
5	.	.	O	.	_	0	SENT_580	[p23l341t3208r455b3258],

1	Efﬁcacy	NN	O	efﬁcacy	_	0	SENT_581	[p23l472t3207r670b3271],
2	and	CC	O	and	_	0	SENT_581	[p23l683t3208r779b3258],
3	safety	NN	O	safety	conj_and	1	SENT_581	[p23l796t3207r950b3272],
4	of	IN	O	of	_	0	SENT_581	[p23l963t3207r1018b3258],
5	crizotinib	NN	O	crizotinib	prep_of	1	SENT_581	[p23l1027t3208r1271b3257],
6	in	IN	O	in	_	0	SENT_581	[p23l1287t3210r1330b3257],
7	patients	NNS	O	patient	prep_in	1	SENT_581	[p23l1348t3210r1558b3270],
8	with	IN	O	with	_	0	SENT_581	[p23l1572t3208r1685b3258],
9	advanced	JJ	O	advanced	amod	13	SENT_581	[p23l1701t3208r1954b3257],
10	ROS1rearranged	JJ	O	ros1rearranged	amod	13	SENT_581	[p23l1973t3210r2129b3257, p23l132t3286r418b3349],
11	non-small	JJ	O	non-small	amod	13	SENT_581	[p23l437t3286r693b3336],
12	cell	NN	O	cell	nn	13	SENT_581	[p23l709t3286r793b3336],
13	lung	NN	O	lung	prep_with	7	SENT_581	[p23l812t3286r925b3349],
14	cancer	NN	O	cancer	nn	17	SENT_581	[p23l941t3300r1114b3336],
15	(	CD	NUMBER	(	num	17	SENT_581	[p23l1129t3287r1393b3343],
16	NSCLC	NN	O	nsclc	nn	17	SENT_581	[p23l1129t3287r1393b3343],
17	)	NN	O	)	dep	13	SENT_581	[p23l1129t3287r1393b3343],
18	.	.	O	.	_	0	SENT_581	[p23l1129t3287r1393b3343],

1	J.	NNP	PERSON	J.	nn	2	SENT_582	[p23l1129t3287r1393b3343],
2	Clin	NNP	PERSON	Clin	_	0	SENT_582	[p23l1409t3286r1514b3336],
3	.	.	O	.	_	0	SENT_582	[p23l1409t3286r1514b3336],

1	Oncol	NN	O	oncol	_	0	SENT_583	[p23l1529t3286r1689b3336],
2	.	.	O	.	_	0	SENT_583	[p23l1529t3286r1689b3336],

1	31	CD	NUMBER	31	num	2	SENT_584	[p23l1703t3289r1761b3336],
2	(	CD	NUMBER	(	_	0	SENT_584	[p23l1786t3286r1972b3348],
3	suppl.	VBN	O	suppl.	partmod	2	SENT_584	[p23l1786t3286r1972b3348],
4	;	:	O	;	_	0	SENT_584	[p23l1786t3286r1972b3348],
5	abstr	NN	O	abstr	dep	2	SENT_584	[p23l1986t3286r2125b3336],
6	.	.	O	.	_	0	SENT_584	[p23l1986t3286r2125b3336],

1	8032	CD	NUMBER	8032	_	0	SENT_585	[p23l130t3364r273b3419],
2	)	CD	NUMBER	)	number	3	SENT_585	[p23l130t3364r273b3419],
3	(	CD	NUMBER	(	dep	1	SENT_585	[p23l291t3364r465b3419],
4	2013	CD	DATE	2013	num	5	SENT_585	[p23l291t3364r465b3419],
5	)	NN	O	)	dep	3	SENT_585	[p23l291t3364r465b3419],
6	.	.	O	.	_	0	SENT_585	[p23l291t3364r465b3419],

1	Chu	NNP	PERSON	Chu	_	0	SENT_586	[p24l129t18r245b75],
2	,	,	O	,	_	0	SENT_586	[p24l129t18r245b75],
3	A.S.	NNP	O	A.S.	nn	4	SENT_586	[p24l259t19r352b68],
4	etal	NN	O	etal	appos	1	SENT_586	[p24l366t18r481b68],
5	.	.	O	.	_	0	SENT_586	[p24l366t18r481b68],

1	Clinical	JJ	O	clinical	amod	2	SENT_587	[p24l495t18r680b68],
2	improvement	NN	O	improvement	nsubj	7	SENT_587	[p24l698t20r1056b80],
3	and	CC	O	and	_	0	SENT_587	[p24l1069t18r1166b68],
4	rapid	JJ	O	rapid	amod	6	SENT_587	[p24l1184t18r1314b80],
5	radiographic	JJ	O	radiographic	amod	6	SENT_587	[p24l1333t18r1665b81],
6	regression	NN	O	regression	conj_and	2	SENT_587	[p24l1681t20r1948b81],
7	induced	VBD	O	induce	_	0	SENT_587	[p24l132t96r342b145],
8	bya	NN	O	bya	nn	10	SENT_587	[p24l360t96r460b159],
9	MET	NN	O	met	nn	10	SENT_587	[p24l477t98r590b145],
10	inhibitor	NN	O	inhibitor	nsubj	19	SENT_587	[p24l604t96r827b145],
11	in	IN	O	in	_	0	SENT_587	[p24l842t98r884b145],
12	a	DT	O	a	det	13	SENT_587	[p24l901t111r926b145],
13	patient	NN	O	patient	prep_in	10	SENT_587	[p24l944t98r1129b158],
14	with	IN	O	with	_	0	SENT_587	[p24l1142t96r1255b145],
15	MET	NN	O	met	nn	18	SENT_587	[p24l1273t95r1649b158],
16	—	CD	NUMBER	—	num	18	SENT_587	[p24l1273t95r1649b158],
17	amp	NN	O	amp	nn	18	SENT_587	[p24l1273t95r1649b158],
18	|	NN	O	|	prep_with	13	SENT_587	[p24l1273t95r1649b158],
19	iﬁed	VBD	O	iﬁed	ccomp	7	SENT_587	[p24l1273t95r1649b158],
20	glioblastoma	NN	O	glioblastoma	dobj	19	SENT_587	[p24l1665t96r2021b159],
21	.	.	O	.	_	0	SENT_587	[p24l1665t96r2021b159],

1	J.	NNP	PERSON	J.	nn	2	SENT_588	[p24l126t176r160b223],
2	Clin	NNP	PERSON	Clin	_	0	SENT_588	[p24l177t174r281b223],
3	.	.	O	.	_	0	SENT_588	[p24l177t174r281b223],

1	Oncol	NN	O	oncol	_	0	SENT_589	[p24l297t174r458b223],
2	.	.	O	.	_	0	SENT_589	[p24l297t174r458b223],

1	29	CD	NUMBER	29	num	2	SENT_590	[p24l473t176r540b222],
2	(	CD	NUMBER	(	_	0	SENT_590	[p24l556t173r742b234],
3	suppl.	VBN	O	suppl.	partmod	2	SENT_590	[p24l556t173r742b234],
4	;	:	O	;	_	0	SENT_590	[p24l556t173r742b234],
5	abstr	NN	O	abstr	dep	2	SENT_590	[p24l756t173r895b222],
6	.	.	O	.	_	0	SENT_590	[p24l756t173r895b222],

1	2072	CD	DATE	2072	_	0	SENT_591	[p24l910t174r1053b229],
2	)	CD	NUMBER	)	number	3	SENT_591	[p24l910t174r1053b229],
3	(	CD	NUMBER	(	dep	1	SENT_591	[p24l1071t174r1245b229],
4	2012	CD	DATE	2012	num	5	SENT_591	[p24l1071t174r1245b229],
5	)	NN	O	)	dep	3	SENT_591	[p24l1071t174r1245b229],
6	.	.	O	.	_	0	SENT_591	[p24l1071t174r1245b229],

1	Lennerz	NNP	PERSON	Lennerz	_	0	SENT_592	[p24l133t253r352b308],
2	,	,	O	,	_	0	SENT_592	[p24l133t253r352b308],
3	J.K.	NNP	PERSON	J.K.	nn	4	SENT_592	[p24l364t253r447b300],
4	etal	NNP	O	etal	appos	1	SENT_592	[p24l461t251r576b300],
5	.	.	O	.	_	0	SENT_592	[p24l461t251r576b300],

1	MET	NN	O	met	nn	2	SENT_593	[p24l592t253r704b300],
2	ampliﬁcation	NN	O	ampliﬁcation	nsubj	3	SENT_593	[p24l716t250r1058b313],
3	identiﬁes	VBZ	O	identiﬁes	_	0	SENT_593	[p24l1077t250r1315b300],
4	a	DT	O	a	det	8	SENT_593	[p24l1330t265r1355b300],
5	small	JJ	O	small	amod	8	SENT_593	[p24l1371t251r1504b300],
6	and	CC	O	and	_	0	SENT_593	[p24l1520t251r1617b300],
7	aggressive	JJ	O	aggressive	conj_and	5	SENT_593	[p24l1633t253r1909b314],
8	subgroup	NN	O	subgroup	dobj	3	SENT_593	[p24l132t329r386b392],
9	of	IN	O	of	_	0	SENT_593	[p24l401t328r455b378],
10	esophagogastric	JJ	O	esophagogastric	amod	11	SENT_593	[p24l465t329r903b392],
11	adenocarcinoma	NN	O	adenocarcinoma	prep_of	8	SENT_593	[p24l917t329r1358b378],
12	with	IN	O	with	_	0	SENT_593	[p24l1373t329r1486b378],
13	evidence	NN	O	evidence	prep_with	11	SENT_593	[p24l1503t329r1739b378],
14	of	IN	O	of	_	0	SENT_593	[p24l1754t328r1808b378],
15	responsiveness	NN	O	responsiveness	prep_of	13	SENT_593	[p24l134t408r531b467],
16	to	TO	O	to	_	0	SENT_593	[p24l544t413r598b455],
17	crizotinib	NN	O	crizotinib	prep_to	3	SENT_593	[p24l612t406r912b455],
18	.	.	O	.	_	0	SENT_593	[p24l612t406r912b455],

1	J.	NNP	PERSON	J.	nn	2	SENT_594	[p24l612t406r912b455],
2	Clin	NNP	PERSON	Clin	_	0	SENT_594	[p24l928t406r1033b455],
3	.	.	O	.	_	0	SENT_594	[p24l928t406r1033b455],

1	Oncol	NN	O	oncol	_	0	SENT_595	[p24l1049t406r1208b455],
2	.	.	O	.	_	0	SENT_595	[p24l1049t406r1208b455],

1	29	CD	NUMBER	29	_	0	SENT_596	[p24l1223t409r1303b462],
2	,	,	O	,	_	0	SENT_596	[p24l1223t409r1303b462],
3	4803-4810	CD	DURATION	4803-4810	num	4	SENT_596	[p24l1315t409r1606b455],
4	(	NN	O	(	appos	1	SENT_596	[p24l1623t407r1723b462],
5	201	CD	NUMBER	201	number	6	SENT_596	[p24l1623t407r1723b462],
6	1	CD	NUMBER	1	num	7	SENT_596	[p24l1741t407r1797b462],
7	)	NN	O	)	dep	4	SENT_596	[p24l1741t407r1797b462],
8	.	.	O	.	_	0	SENT_596	[p24l1741t407r1797b462],

1	Butrynski	NNP	PERSON	Butrynski	_	0	SENT_597	[p24l133t484r389b547],
2	,	,	O	,	_	0	SENT_597	[p24l133t484r389b547],
3	J.E.	NNP	PERSON	J.E.	nn	4	SENT_597	[p24l401t486r479b533],
4	etal	NNP	O	etal	appos	1	SENT_597	[p24l493t484r607b533],
5	.	.	O	.	_	0	SENT_597	[p24l493t484r607b533],

1	Crizotinib	NNP	O	Crizotinib	_	0	SENT_598	[p24l621t484r874b533],
2	in	IN	O	in	_	0	SENT_598	[p24l890t486r932b533],
3	ALK-rearranged	JJ	O	alk-rearranged	amod	6	SENT_598	[p24l948t484r1358b547],
4	inﬂammatory	JJ	O	inﬂammatory	amod	6	SENT_598	[p24l1376t483r1731b547],
5	myoﬁbroblastic	JJ	O	myoﬁbroblastic	amod	6	SENT_598	[p24l1746t483r2153b547],
6	tumor	NN	O	tumor	prep_in	1	SENT_598	[p24l131t569r303b611],
7	.	.	O	.	_	0	SENT_598	[p24l131t569r303b611],

1	N.	NNP	O	N.	nn	2	SENT_599	[p24l317t564r365b611],
2	Engl	NNP	O	Engl	_	0	SENT_599	[p24l380t562r498b625],
3	.	.	O	.	_	0	SENT_599	[p24l380t562r498b625],

1	J.	NNP	O	J.	nn	2	SENT_600	[p24l509t564r544b611],
2	Med	NNP	O	Med	_	0	SENT_600	[p24l557t562r680b611],
3	.	.	O	.	_	0	SENT_600	[p24l557t562r680b611],

1	363	CD	NUMBER	363	_	0	SENT_601	[p24l694t565r809b619],
2	,	,	O	,	_	0	SENT_601	[p24l694t565r809b619],
3	1727-1733	CD	DATE	1727-1733	number	4	SENT_601	[p24l829t565r1111b611],
4	(	CD	NUMBER	(	appos	1	SENT_601	[p24l1130t563r1304b619],
5	2010	CD	DATE	2010	num	6	SENT_601	[p24l1130t563r1304b619],
6	)	NN	O	)	dep	4	SENT_601	[p24l1130t563r1304b619],
7	.	.	O	.	_	0	SENT_601	[p24l1130t563r1304b619],

1	Stasia	NNP	PERSON	Stasia	_	0	SENT_602	[p24l131t640r289b695],
2	,	,	O	,	_	0	SENT_602	[p24l131t640r289b695],
3	A.	NNP	O	A.	nn	4	SENT_602	[p24l302t641r350b688],
4	etal	NNP	O	etal	appos	1	SENT_602	[p24l363t639r474b688],
5	.	.	O	.	_	0	SENT_602	[p24l363t639r474b688],

1	Crizotinib	NNP	O	Crizotinib	nsubj	2	SENT_603	[p24l487t639r734b688],
2	obtains	VBZ	O	obtain	_	0	SENT_603	[p24l748t639r938b688],
3	durable	JJ	O	durable	amod	4	SENT_603	[p24l951t639r1149b688],
4	responses	NNS	O	response	dobj	2	SENT_603	[p24l1164t653r1419b700],
5	in	IN	O	in	_	0	SENT_603	[p24l1434t641r1476b687],
6	advanced	JJ	O	advanced	amod	8	SENT_603	[p24l1490t639r1739b688],
7	chemoresistant	JJ	O	chemoresistant	amod	8	SENT_603	[p24l1755t639r2152b688],
8	ALK	NN	O	alk	prep_in	2	SENT_603	[p24l132t719r268b766],
9	+	CC	O	+	_	0	SENT_603	[p24l132t719r268b766],
10	lymphoma	NN	O	lymphoma	nn	11	SENT_603	[p24l283t717r560b780],
11	patients	NNS	O	patient	conj_+	8	SENT_603	[p24l577t719r794b779],
12	.	.	O	.	_	0	SENT_603	[p24l577t719r794b779],

1	Haematologica	NNP	O	Haematologica	_	0	SENT_604	[p24l806t717r1191b780],
2	97	CD	NUMBER	97	num	1	SENT_604	[p24l1203t720r1269b766],
3	(	CD	NUMBER	(	num	4	SENT_604	[p24l1284t717r1453b779],
4	suppl	NN	O	suppl	dep	1	SENT_604	[p24l1284t717r1453b779],
5	.	.	O	.	_	0	SENT_604	[p24l1284t717r1453b779],

1	1	CD	NUMBER	1	num	2	SENT_605	[p24l1470t718r1524b774],
2	)	NN	O	)	_	0	SENT_605	[p24l1470t718r1524b774],
3	,	,	O	,	_	0	SENT_605	[p24l1470t718r1524b774],
4	488	CD	NUMBER	488	number	5	SENT_605	[p24l1536t720r1630b766],
5	(	CD	NUMBER	(	appos	2	SENT_605	[p24l1645t718r1816b774],
6	2012	CD	DATE	2012	num	7	SENT_605	[p24l1645t718r1816b774],
7	)	NN	O	)	dep	5	SENT_605	[p24l1645t718r1816b774],
8	.	.	O	.	_	0	SENT_605	[p24l1645t718r1816b774],

1	Mossé	NNP	O	Mossé	_	0	SENT_606	[p24l132t796r308b852],
2	,	,	O	,	_	0	SENT_606	[p24l132t796r308b852],
3	Y.P.	NNP	O	Y.P.	nn	4	SENT_606	[p24l318t797r395b844],
4	etal	NN	O	etal	appos	1	SENT_606	[p24l409t795r524b844],
5	.	.	O	.	_	0	SENT_606	[p24l409t795r524b844],

1	Safety	NN	O	safety	_	0	SENT_607	[p24l538t794r699b858],
2	and	CC	O	and	_	0	SENT_607	[p24l712t795r808b844],
3	activity	NN	O	activity	conj_and	1	SENT_607	[p24l825t797r1015b858],
4	of	IN	O	of	_	0	SENT_607	[p24l1028t794r1082b844],
5	crizotinib	NN	O	crizotinib	prep_of	1	SENT_607	[p24l1092t795r1336b844],
6	for	IN	O	for	_	0	SENT_607	[p24l1349t794r1422b844],
7	paediatric	JJ	O	paediatric	amod	8	SENT_607	[p24l1437t795r1696b857],
8	patients	NNS	O	patient	prep_for	5	SENT_607	[p24l1712t797r1922b857],
9	with	IN	O	with	_	0	SENT_607	[p24l1935t795r2049b844],
10	refractory	JJ	O	refractory	amod	12	SENT_607	[p24l134t872r388b936],
11	solid	JJ	O	solid	amod	12	SENT_607	[p24l402t873r521b922],
12	tumours	NNS	O	tumour	prep_with	8	SENT_607	[p24l536t880r759b922],
13	or	CC	O	or	_	0	SENT_607	[p24l774t887r827b922],
14	anaplastic	JJ	O	anaplastic	amod	16	SENT_607	[p24l840t873r1104b935],
15	large-cell	JJ	O	large-cell	amod	16	SENT_607	[p24l1121t873r1357b936],
16	lymphoma	NN	O	lymphoma	conj_or	12	SENT_607	[p24l1377t873r1673b936],
17	:	:	O	:	_	0	SENT_607	[p24l1377t873r1673b936],
18	a	DT	O	a	det	19	SENT_607	[p24l1687t887r1712b922],
19	Children	NNP	ORGANIZATION	Children	poss	23	SENT_607	[p24l1728t873r1981b922],
20	's	POS	ORGANIZATION	's	_	0	SENT_607	[p24l1728t873r1981b922],
21	Oncology	NNP	ORGANIZATION	Oncology	nn	23	SENT_607	[p24l132t951r388b1014],
22	Group	NNP	ORGANIZATION	Group	nn	23	SENT_607	[p24l401t953r564b1013],
23	phase	NN	O	phase	dep	1	SENT_607	[p24l581t951r734b1013],
24	1	CD	NUMBER	1	num	26	SENT_607	[p24l754t955r768b1000],
25	consortium	NN	O	consortium	nn	26	SENT_607	[p24l792t953r1092b1000],
26	study	NN	O	study	dep	23	SENT_607	[p24l1108t951r1262b1014],
27	.	.	O	.	_	0	SENT_607	[p24l1108t951r1262b1014],

1	Lancet	NNP	O	Lancet	nn	2	SENT_608	[p24l1276t953r1446b1000],
2	Oncol	NNP	O	Oncol	_	0	SENT_608	[p24l1456t951r1616b1000],
3	.	.	O	.	_	0	SENT_608	[p24l1456t951r1616b1000],

1	14	CD	NUMBER	14	_	0	SENT_609	[p24l1633t955r1710b1008],
2	,	,	O	,	_	0	SENT_609	[p24l1633t955r1710b1008],
3	472-480	CD	NUMBER	472-480	num	4	SENT_609	[p24l1723t954r1948b1000],
4	(	NN	O	(	appos	1	SENT_609	[p24l1964t952r2065b1008],
5	201	CD	NUMBER	201	number	6	SENT_609	[p24l1964t952r2065b1008],
6	3	CD	NUMBER	3	num	7	SENT_609	[p24l2079t952r2139b1008],
7	)	NN	O	)	dep	4	SENT_609	[p24l2079t952r2139b1008],
8	.	.	O	.	_	0	SENT_609	[p24l2079t952r2139b1008],

1	Ou	NNP	LOCATION	Ou	nsubj	26	SENT_610	[p24l130t1030r219b1086],
2	,	,	O	,	_	0	SENT_610	[p24l130t1030r219b1086],
3	S.H.	NNP	LOCATION	S.H.	conj_and	1	SENT_610	[p24l233t1030r341b1086],
4	,	,	O	,	_	0	SENT_610	[p24l233t1030r341b1086],
5	Tong	NNP	PERSON	Tong	conj_and	1	SENT_610	[p24l351t1031r494b1092],
6	,	,	O	,	_	0	SENT_610	[p24l351t1031r494b1092],
7	W.P.	NNP	LOCATION	W.P.	conj_and	1	SENT_610	[p24l505t1031r617b1086],
8	,	,	O	,	_	0	SENT_610	[p24l505t1031r617b1086],
9	Azada	NNP	PERSON	Azada	nsubj	26	SENT_610	[p24l631t1029r805b1086],
10	,	,	O	,	_	0	SENT_610	[p24l631t1029r805b1086],
11	M.	NNP	O	M.	nsubj	26	SENT_610	[p24l821t1031r893b1086],
12	,	,	O	,	_	0	SENT_610	[p24l821t1031r893b1086],
13	Siwak-Tapp	NNP	PERSON	Siwak-Tapp	nsubj	26	SENT_610	[p24l908t1029r1215b1091],
14	,	,	O	,	_	0	SENT_610	[p24l908t1029r1215b1091],
15	C.	NNP	O	C.	nsubj	26	SENT_610	[p24l1229t1030r1289b1086],
16	,	,	O	,	_	0	SENT_610	[p24l1229t1030r1289b1086],
17	Dy	NNP	O	Dy	nsubj	26	SENT_610	[p24l1305t1031r1383b1092],
18	,	,	O	,	_	0	SENT_610	[p24l1305t1031r1383b1092],
19	J.	NNP	ORGANIZATION	J.	nsubj	26	SENT_610	[p24l1395t1031r1429b1078],
20	&	CC	ORGANIZATION	&	_	0	SENT_610	[p24l1443t1030r1480b1078],
21	Stiber	NNP	ORGANIZATION	Stiber	nsubj	26	SENT_610	[p24l1493t1029r1654b1086],
22	,	,	O	,	_	0	SENT_610	[p24l1493t1029r1654b1086],
23	J.A.	NNP	PERSON	J.A.	nn	24	SENT_610	[p24l1667t1031r1753b1078],
24	Heart	NNP	PERSON	Heart	appos	1	SENT_610	[p24l1769t1031r1912b1078],
25	rate	NN	O	rate	dep	24	SENT_610	[p24l1927t1036r2025b1078],
26	decrease	VB	O	decrease	_	0	SENT_610	[p24l132t1107r364b1157],
27	during	IN	O	during	_	0	SENT_610	[p24l379t1107r551b1170],
28	crizotinib	NN	O	crizotinib	nn	29	SENT_610	[p24l567t1107r811b1157],
29	treatment	NN	O	treatment	prep_during	26	SENT_610	[p24l824t1114r1088b1157],
30	and	CC	O	and	_	0	SENT_610	[p24l1102t1107r1198b1157],
31	potential	JJ	O	potential	amod	32	SENT_610	[p24l1216t1107r1449b1169],
32	correlation	NN	O	correlation	prep_during	26	SENT_610	[p24l1465t1107r1747b1157],
33	to	TO	O	to	_	0	SENT_610	[p24l1762t1114r1815b1157],
34	clinical	JJ	O	clinical	amod	35	SENT_610	[p24l1830t1107r2005b1157],
35	response	NN	O	response	prep_to	26	SENT_610	[p24l134t1198r381b1245],
36	.	.	O	.	_	0	SENT_610	[p24l134t1198r381b1245],

1	Cancer	NN	O	cancer	_	0	SENT_611	[p24l396t1185r573b1233],
2	1	CD	NUMBER	1	number	3	SENT_611	[p24l587t1188r606b1232],
3	19	CD	NUMBER	19	dep	1	SENT_611	[p24l622t1187r699b1240],
4	,	,	O	,	_	0	SENT_611	[p24l622t1187r699b1240],
5	1969-1975	CD	DATE	1969-1975	number	6	SENT_611	[p24l718t1187r1001b1233],
6	(	CD	NUMBER	(	appos	1	SENT_611	[p24l1019t1185r1193b1240],
7	2013	CD	DATE	2013	num	8	SENT_611	[p24l1019t1185r1193b1240],
8	)	NN	O	)	dep	6	SENT_611	[p24l1019t1185r1193b1240],
9	.	.	O	.	_	0	SENT_611	[p24l1019t1185r1193b1240],

1	VOLUME	NN	O	volume	nn	3	SENT_612	[p24l545t1405r769b1447],
2	95	CD	NUMBER	95	num	3	SENT_612	[p24l787t1406r843b1447],
3	NUMBER	NN	O	number	_	0	SENT_612	[p24l864t1405r1088b1447],
4	1	CD	NUMBER	1	number	5	SENT_612	[p24l1110t1407r1123b1447],
5	|	CD	NUMBER	|	dep	3	SENT_612	[p24l1153t1401r1157b1462],
6	JANUARY	NNP	DATE	JANUARY	dep	5	SENT_612	[p24l1176t1405r1422b1447],
7	2014	CD	DATE	2014	num	6	SENT_612	[p24l1438t1406r1559b1447],
8	|	CD	NUMBER	|	num	9	SENT_612	[p24l1578t1401r1582b1462],
9	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	3	SENT_612	[p24l1601t1405r2153b1458],

1	STATE	NN	O	state	nn	2	SENT_613	[p24l1761t1577r1902b1614],
2	ART	NN	O	art	_	0	SENT_613	[p24l2045t1577r2139b1614],

1	Weickhardt	NNP	PERSON	Weickhardt	_	0	SENT_614	[p24l127t1811r440b1869],
2	,	,	O	,	_	0	SENT_614	[p24l127t1811r440b1869],
3	A.J.	NNP	PERSON	A.J.	nn	4	SENT_614	[p24l454t1814r540b1861],
4	etal	NNP	O	etal	appos	1	SENT_614	[p24l554t1811r669b1861],
5	.	.	O	.	_	0	SENT_614	[p24l554t1811r669b1861],

1	Rapid	JJ	O	rapid	amod	4	SENT_615	[p24l686t1811r1004b1874],
2	—	NN	O	—	nn	4	SENT_615	[p24l686t1811r1004b1874],
3	onset	NN	O	onset	nn	4	SENT_615	[p24l686t1811r1004b1874],
4	hypogonadism	NN	O	hypogonadism	_	0	SENT_615	[p24l1020t1811r1416b1875],
5	secondary	JJ	O	secondary	amod	7	SENT_615	[p24l1433t1811r1707b1875],
6	to	TO	O	to	dep	7	SENT_615	[p24l1719t1819r1772b1861],
7	crizotinib	JJ	O	crizotinib	amod	8	SENT_615	[p24l1787t1811r2032b1861],
8	use	NN	O	use	dep	4	SENT_615	[p24l2049t1826r2136b1861],
9	in	IN	O	in	_	0	SENT_615	[p24l132t1892r174b1939],
10	men	NNS	O	man	prep_in	8	SENT_615	[p24l193t1904r306b1939],
11	with	IN	O	with	_	0	SENT_615	[p24l322t1889r436b1939],
12	metastatic	JJ	O	metastatic	amod	16	SENT_615	[p24l455t1892r729b1939],
13	nonsmall	JJ	O	nonsmall	amod	16	SENT_615	[p24l745t1889r982b1939],
14	cell	NN	O	cell	nn	16	SENT_615	[p24l1000t1889r1084b1939],
15	lung	NN	O	lung	nn	16	SENT_615	[p24l1103t1889r1216b1953],
16	cancer	NN	O	cancer	prep_with	10	SENT_615	[p24l1233t1904r1415b1939],
17	.	.	O	.	_	0	SENT_615	[p24l1233t1904r1415b1939],

1	Cancer	NN	O	cancer	_	0	SENT_616	[p24l1430t1891r1608b1939],
2	1	CD	NUMBER	1	number	3	SENT_616	[p24l1622t1893r1642b1938],
3	18	CD	NUMBER	18	dep	1	SENT_616	[p24l1657t1893r1735b1947],
4	,	,	O	,	_	0	SENT_616	[p24l1657t1893r1735b1947],
5	5302-5309	CD	DURATION	5302-5309	number	6	SENT_616	[p24l1749t1893r2041b1939],
6	(	CD	NUMBER	(	appos	1	SENT_616	[p24l132t1967r307b2024],
7	2012	CD	DATE	2012	num	8	SENT_616	[p24l132t1967r307b2024],
8	)	NN	O	)	dep	6	SENT_616	[p24l132t1967r307b2024],
9	.	.	O	.	_	0	SENT_616	[p24l132t1967r307b2024],

1	Li	NNP	PERSON	Li	nn	9	SENT_617	[p24l131t2048r182b2103],
2	,	,	O	,	_	0	SENT_617	[p24l131t2048r182b2103],
3	C.	NNP	O	C.	appos	9	SENT_617	[p24l197t2047r257b2103],
4	,	,	O	,	_	0	SENT_617	[p24l197t2047r257b2103],
5	Alvey	NNP	PERSON	Alvey	appos	9	SENT_617	[p24l271t2045r424b2109],
6	,	,	O	,	_	0	SENT_617	[p24l271t2045r424b2109],
7	C.	NNP	O	C.	appos	9	SENT_617	[p24l439t2047r499b2103],
8	,	,	O	,	_	0	SENT_617	[p24l439t2047r499b2103],
9	Bello	NNP	PERSON	Bello	_	0	SENT_617	[p24l515t2045r653b2103],
10	,	,	O	,	_	0	SENT_617	[p24l515t2045r653b2103],
11	A.	NN	O	a.	appos	9	SENT_617	[p24l667t2048r729b2103],
12	,	,	O	,	_	0	SENT_617	[p24l667t2048r729b2103],
13	Wilner	NNP	PERSON	Wilner	appos	9	SENT_617	[p24l740t2045r919b2103],
14	,	,	O	,	_	0	SENT_617	[p24l740t2045r919b2103],
15	K.	NNP	ORGANIZATION	K.	appos	9	SENT_617	[p24l936t2048r978b2095],
16	&	CC	ORGANIZATION	&	_	0	SENT_617	[p24l992t2047r1143b2103],
17	Tan	NNP	ORGANIZATION	Tan	appos	9	SENT_617	[p24l992t2047r1143b2103],
18	,	,	O	,	_	0	SENT_617	[p24l992t2047r1143b2103],
19	W.	NNP	PERSON	W.	nn	20	SENT_617	[p24l1154t2048r1216b2095],
20	Pharmacokinetics	NNP	PERSON	Pharmacokinetics	appos	13	SENT_617	[p24l1232t2045r1699b2095],
21	(	CD	NUMBER	(	num	23	SENT_617	[p24l1716t2046r1815b2103],
22	PK	NN	O	pk	nn	23	SENT_617	[p24l1716t2046r1815b2103],
23	)	NN	O	)	dep	9	SENT_617	[p24l1716t2046r1815b2103],
24	of	IN	O	of	_	0	SENT_617	[p24l1831t2045r1886b2095],
25	crizotinib	NN	O	crizotinib	nn	27	SENT_617	[p24l1895t2045r2141b2095],
26	(	CD	NUMBER	(	num	27	SENT_617	[p24l132t2124r508b2181],
27	PF	NN	O	pf	prep_of	23	SENT_617	[p24l132t2124r508b2181],
28	—	CD	NUMBER	—	num	27	SENT_617	[p24l132t2124r508b2181],
29	02341066	CD	NUMBER	02341066	num	30	SENT_617	[p24l132t2124r508b2181],
30	)	NN	O	)	dep	9	SENT_617	[p24l132t2124r508b2181],
31	in	IN	O	in	_	0	SENT_617	[p24l526t2126r569b2173],
32	patients	NNS	O	patient	prep_in	30	SENT_617	[p24l588t2126r799b2186],
33	with	IN	O	with	_	0	SENT_617	[p24l812t2123r926b2173],
34	advanced	JJ	O	advanced	amod	36	SENT_617	[p24l943t2123r1198b2173],
35	non	JJ	O	non	amod	36	SENT_617	[p24l1216t2123r1474b2173],
36	—	NN	O	—	prep_with	32	SENT_617	[p24l1216t2123r1474b2173],
37	small	JJ	O	small	amod	43	SENT_617	[p24l1216t2123r1474b2173],
38	cell	NN	O	cell	nn	43	SENT_617	[p24l1491t2123r1575b2173],
39	lung	NN	O	lung	nn	43	SENT_617	[p24l1594t2123r1708b2187],
40	cancer	NN	O	cancer	nn	43	SENT_617	[p24l1724t2138r1898b2173],
41	(	CD	NUMBER	(	num	43	SENT_617	[p24l1913t2124r2119b2181],
42	NSCLC	NN	O	nsclc	nn	43	SENT_617	[p24l1913t2124r2119b2181],
43	)	NN	O	)	dep	9	SENT_617	[p24l1913t2124r2119b2181],
44	and	CC	O	and	_	0	SENT_617	[p24l130t2201r226b2251],
45	other	JJ	O	other	amod	47	SENT_617	[p24l243t2201r386b2251],
46	solid	JJ	O	solid	amod	47	SENT_617	[p24l399t2201r519b2251],
47	tumors	NNS	O	tumor	conj_and	43	SENT_617	[p24l534t2204r781b2251],
48	.	.	O	.	_	0	SENT_617	[p24l534t2204r781b2251],

1	J.	NNP	O	J.	nn	2	SENT_618	[p24l534t2204r781b2251],
2	C/in	NNP	O	C/in	_	0	SENT_618	[p24l797t2201r902b2251],
3	.	.	O	.	_	0	SENT_618	[p24l797t2201r902b2251],

1	Oncol	NN	O	oncol	_	0	SENT_619	[p24l918t2201r1160b2251],
2	.29	CD	NUMBER	.29	number	3	SENT_619	[p24l918t2201r1160b2251],
3	(	CD	NUMBER	(	dep	1	SENT_619	[p24l1177t2201r1518b2264],
4	supp	NN	O	supp	nn	5	SENT_619	[p24l1177t2201r1518b2264],
5	|	NN	O	|	dep	3	SENT_619	[p24l1177t2201r1518b2264],
6	.	.	O	.	_	0	SENT_619	[p24l1177t2201r1518b2264],

1	;	:	O	;	_	0	SENT_620	[p24l1177t2201r1518b2264],
2	abstr	NN	O	abstr	_	0	SENT_620	[p24l1177t2201r1518b2264],
3	.	.	O	.	_	0	SENT_620	[p24l1177t2201r1518b2264],

1	e13065	NN	O	e13065	_	0	SENT_621	[p24l1533t2202r1742b2259],
2	)	CD	NUMBER	)	num	3	SENT_621	[p24l1533t2202r1742b2259],
3	(	NN	O	(	dep	1	SENT_621	[p24l1760t2202r1861b2259],
4	201	CD	NUMBER	201	number	5	SENT_621	[p24l1760t2202r1861b2259],
5	1	CD	NUMBER	1	num	6	SENT_621	[p24l1879t2202r1935b2259],
6	)	NN	O	)	dep	3	SENT_621	[p24l1879t2202r1935b2259],
7	.	.	O	.	_	0	SENT_621	[p24l1879t2202r1935b2259],

1	Choi	NNP	PERSON	Choi	nn	4	SENT_622	[p24l128t2279r353b2337],
2	,	,	O	,	_	0	SENT_622	[p24l128t2279r353b2337],
3	Y.L.	NNP	O	Y.L.	appos	4	SENT_622	[p24l128t2279r353b2337],
4	etal.	NNP	O	etal.	_	0	SENT_622	[p24l367t2279r496b2337],
5	;	:	O	;	_	0	SENT_622	[p24l367t2279r496b2337],
6	ALK	NNP	O	ALK	nn	10	SENT_622	[p24l510t2282r613b2328],
7	Lung	NN	O	lung	nn	10	SENT_622	[p24l628t2282r756b2343],
8	Cancer	NN	O	cancer	nn	10	SENT_622	[p24l772t2281r954b2329],
9	Study	NNP	O	Study	nn	10	SENT_622	[p24l968t2279r1119b2343],
10	Group	NNP	O	Group	dep	4	SENT_622	[p24l1132t2281r1309b2342],
11	.	.	O	.	_	0	SENT_622	[p24l1132t2281r1309b2342],

1	EML4	NN	O	eml4	_	0	SENT_623	[p24l1326t2282r1592b2329],
2	.	.	O	.	_	0	SENT_623	[p24l1326t2282r1592b2329],

1	—	NN	O	—	_	0	SENT_624	[p24l1326t2282r1592b2329],
2	.	.	O	.	_	0	SENT_624	[p24l1326t2282r1592b2329],

1	ALK	NN	O	alk	nn	2	SENT_625	[p24l1326t2282r1592b2329],
2	mutations	NNS	O	mutation	_	0	SENT_625	[p24l1606t2282r1872b2329],
3	in	IN	O	in	_	0	SENT_625	[p24l1889t2282r1932b2328],
4	lung	NN	O	lung	nn	5	SENT_625	[p24l1951t2279r2064b2343],
5	cancer	NN	O	cancer	prep_in	2	SENT_625	[p24l130t2372r304b2407],
6	that	WDT	O	that	nsubj	7	SENT_625	[p24l316t2357r422b2407],
7	confer	VBP	O	confer	rcmod	5	SENT_625	[p24l436t2357r604b2407],
8	resistance	NN	O	resistance	dobj	7	SENT_625	[p24l619t2360r878b2407],
9	to	TO	O	to	_	0	SENT_625	[p24l892t2365r945b2407],
10	ALK	NN	O	alk	nn	11	SENT_625	[p24l959t2360r1063b2406],
11	inhibitors	NNS	O	inhibitor	prep_to	7	SENT_625	[p24l1076t2357r1337b2407],
12	.	.	O	.	_	0	SENT_625	[p24l1076t2357r1337b2407],

1	N.	NNP	O	N.	nn	2	SENT_626	[p24l1352t2360r1399b2407],
2	Engl	NNP	O	Engl	_	0	SENT_626	[p24l1415t2357r1534b2421],
3	.	.	O	.	_	0	SENT_626	[p24l1415t2357r1534b2421],

1	J.	NNP	O	J.	nn	2	SENT_627	[p24l1545t2360r1579b2407],
2	Med	NNP	O	Med	_	0	SENT_627	[p24l1593t2357r1716b2407],
3	.	.	O	.	_	0	SENT_627	[p24l1593t2357r1716b2407],

1	363	CD	NUMBER	363	_	0	SENT_628	[p24l1731t2361r1847b2415],
2	,	,	O	,	_	0	SENT_628	[p24l1731t2361r1847b2415],
3	1734-1739	CD	DATE	1734-1739	number	4	SENT_628	[p24l1866t2361r2153b2407],
4	(	CD	NUMBER	(	appos	1	SENT_628	[p24l132t2435r307b2492],
5	2010	CD	DATE	2010	num	6	SENT_628	[p24l132t2435r307b2492],
6	)	NN	O	)	dep	4	SENT_628	[p24l132t2435r307b2492],
7	.	.	O	.	_	0	SENT_628	[p24l132t2435r307b2492],

1	Doebele	NNP	O	Doebele	nn	3	SENT_629	[p24l131t2513r363b2571],
2	,	,	O	,	_	0	SENT_629	[p24l131t2513r363b2571],
3	R.C.	NNP	O	R.C.	_	0	SENT_629	[p24l380t2515r471b2563],
4	et	FW	O	et	nn	5	SENT_629	[p24l485t2521r535b2563],
5	al.	FW	O	al.	dep	3	SENT_629	[p24l544t2513r601b2563],
6	.	.	O	.	_	0	SENT_629	[p24l544t2513r601b2563],

1	Mechanisms	NNS	O	mechanism	_	0	SENT_630	[p24l617t2513r946b2563],
2	of	IN	O	of	_	0	SENT_630	[p24l961t2513r1015b2563],
3	resistance	NN	O	resistance	prep_of	1	SENT_630	[p24l1027t2516r1287b2563],
4	to	TO	O	to	_	0	SENT_630	[p24l1300t2521r1353b2563],
5	crizotinib	NN	O	crizotinib	prep_to	1	SENT_630	[p24l1368t2513r1613b2563],
6	in	IN	O	in	_	0	SENT_630	[p24l1630t2516r1673b2563],
7	patients	NNS	O	patient	prep_in	1	SENT_630	[p24l1691t2516r1902b2576],
8	with	IN	O	with	_	0	SENT_630	[p24l1916t2513r2030b2563],
9	ALK	NN	O	alk	nn	10	SENT_630	[p24l2046t2516r2149b2563],
10	gene	NN	O	gene	prep_with	1	SENT_630	[p24l130t2606r262b2655],
11	rearranged	VBN	O	rearrange	partmod	1	SENT_630	[p24l278t2591r566b2655],
12	non	JJ	O	non	amod	17	SENT_630	[p24l584t2591r842b2641],
13	—	NN	O	—	nn	17	SENT_630	[p24l584t2591r842b2641],
14	small	JJ	O	small	amod	17	SENT_630	[p24l584t2591r842b2641],
15	cell	NN	O	cell	nn	17	SENT_630	[p24l859t2591r942b2641],
16	lung	NN	O	lung	nn	17	SENT_630	[p24l962t2591r1075b2655],
17	cancer	NN	O	cancer	dep	11	SENT_630	[p24l1092t2606r1274b2641],
18	.	.	O	.	_	0	SENT_630	[p24l1092t2606r1274b2641],

1	Clin	NNP	O	Clin	_	0	SENT_631	[p24l1289t2591r1395b2641],
2	.	.	O	.	_	0	SENT_631	[p24l1289t2591r1395b2641],

1	CancerRes	NNS	O	cancerre	_	0	SENT_632	[p24l1411t2593r1693b2641],
2	.	.	O	.	_	0	SENT_632	[p24l1411t2593r1693b2641],

1	18	CD	NUMBER	18	_	0	SENT_633	[p24l1711t2595r1788b2649],
2	,	,	O	,	_	0	SENT_633	[p24l1711t2595r1788b2649],
3	1472-1482	CD	DATE	1472-1482	number	4	SENT_633	[p24l1807t2595r2093b2641],
4	(	CD	NUMBER	(	appos	1	SENT_633	[p24l132t2669r307b2726],
5	2012	CD	DATE	2012	num	6	SENT_633	[p24l132t2669r307b2726],
6	)	NN	O	)	dep	4	SENT_633	[p24l132t2669r307b2726],
7	.	.	O	.	_	0	SENT_633	[p24l132t2669r307b2726],

1	Sasaki	NNP	PERSON	Sasaki	_	0	SENT_634	[p24l129t2747r351b2805],
2	,	,	O	,	_	0	SENT_634	[p24l129t2747r351b2805],
3	T.	NNP	O	T.	nn	4	SENT_634	[p24l129t2747r351b2805],
4	etal	NNP	O	etal	appos	1	SENT_634	[p24l365t2747r481b2797],
5	.	.	O	.	_	0	SENT_634	[p24l365t2747r481b2797],

1	A	DT	O	a	det	3	SENT_635	[p24l495t2750r532b2796],
2	novel	JJ	O	novel	amod	3	SENT_635	[p24l548t2747r687b2797],
3	ALK	NN	O	alk	_	0	SENT_635	[p24l703t2750r807b2796],
4	secondary	JJ	O	secondary	amod	5	SENT_635	[p24l819t2747r1093b2811],
5	mutation	NN	O	mutation	dep	3	SENT_635	[p24l1108t2750r1347b2797],
6	and	CC	O	and	_	0	SENT_635	[p24l1364t2747r1460b2797],
7	EGFR	NN	ORGANIZATION	egfr	nn	8	SENT_635	[p24l1480t2749r1613b2797],
8	signaling	NN	O	signaling	dep	3	SENT_635	[p24l1627t2747r1864b2811],
9	cause	NN	O	cause	nn	10	SENT_635	[p24l1881t2762r2029b2797],
10	resistance	NN	O	resistance	dep	3	SENT_635	[p24l132t2827r392b2875],
11	to	TO	O	to	_	0	SENT_635	[p24l405t2832r458b2875],
12	ALK	NN	O	alk	nn	14	SENT_635	[p24l472t2827r575b2874],
13	kinase	NN	O	kinase	nn	14	SENT_635	[p24l590t2824r754b2875],
14	inhibitors	NNS	O	inhibitor	prep_to	10	SENT_635	[p24l770t2824r1031b2875],
15	.	.	O	.	_	0	SENT_635	[p24l770t2824r1031b2875],

1	Cancer	NN	O	cancer	_	0	SENT_636	[p24l1046t2826r1224b2875],
2	Res	NNP	O	Res	dep	1	SENT_636	[p24l1233t2827r1329b2875],
3	.	.	O	.	_	0	SENT_636	[p24l1233t2827r1329b2875],

1	71	CD	NUMBER	71	_	0	SENT_637	[p24l1344t2828r1402b2874],
2	,	,	O	,	_	0	SENT_637	[p24l1413t2864r1424b2882],
3	6051-6060	CD	DURATION	6051-6060	num	4	SENT_637	[p24l1438t2828r1730b2875],
4	(	NN	O	(	appos	1	SENT_637	[p24l1746t2825r1847b2882],
5	201	CD	NUMBER	201	number	6	SENT_637	[p24l1746t2825r1847b2882],
6	1	CD	NUMBER	1	num	7	SENT_637	[p24l1865t2825r1921b2882],
7	)	NN	O	)	dep	4	SENT_637	[p24l1865t2825r1921b2882],
8	.	.	O	.	_	0	SENT_637	[p24l1865t2825r1921b2882],

1	Huang	NNP	PERSON	Huang	_	0	SENT_638	[p24l131t2906r316b2967],
2	,	,	O	,	_	0	SENT_638	[p24l131t2906r316b2967],
3	D.	NNP	O	D.	nn	4	SENT_638	[p24l333t2906r380b2953],
4	etal	NNP	O	etal	appos	1	SENT_638	[p24l395t2903r510b2953],
5	.	.	O	.	_	0	SENT_638	[p24l395t2903r510b2953],

1	Multiplexed	JJ	O	multiplexed	amod	4	SENT_639	[p24l526t2903r837b2966],
2	deep	JJ	O	deep	amod	4	SENT_639	[p24l854t2903r987b2966],
3	sequencing	NN	O	sequencing	nn	4	SENT_639	[p24l1002t2906r1307b2967],
4	analysis	NN	O	analysis	_	0	SENT_639	[p24l1324t2903r1527b2967],
5	of	IN	O	of	_	0	SENT_639	[p24l1542t2903r1597b2953],
6	ALK	NN	O	alk	nn	9	SENT_639	[p24l1606t2906r1709b2952],
7	kinase	NN	O	kinase	nn	9	SENT_639	[p24l1724t2903r1887b2953],
8	domain	NN	O	domain	nn	9	SENT_639	[p24l1902t2903r2102b2953],
9	identiﬁes	NNS	O	identiﬁes	prep_of	4	SENT_639	[p24l131t2981r371b3031],
10	resistance	NN	O	resistance	nn	11	SENT_639	[p24l388t2984r648b3031],
11	mutations	NNS	O	mutation	dep	4	SENT_639	[p24l664t2984r931b3031],
12	in	IN	O	in	_	0	SENT_639	[p24l947t2984r990b3030],
13	relapsed	JJ	O	relapsed	amod	14	SENT_639	[p24l1009t2981r1229b3044],
14	patients	NNS	O	patient	prep_in	11	SENT_639	[p24l1248t2984r1458b3044],
15	following	VBG	O	follow	_	0	SENT_639	[p24l1472t2981r1718b3045],
16	crizotinib	JJ	O	crizotinib	amod	17	SENT_639	[p24l1735t2981r1981b3031],
17	treatment	NN	O	treatment	prep_following	14	SENT_639	[p24l128t3066r406b3109],
18	.	.	O	.	_	0	SENT_639	[p24l128t3066r406b3109],

1	Genomics	NN	O	genomic	_	0	SENT_640	[p24l421t3060r672b3109],
2	102	CD	NUMBER	102	num	1	SENT_640	[p24l689t3062r802b3116],
3	,	,	O	,	_	0	SENT_640	[p24l689t3062r802b3116],
4	157-162	CD	NUMBER	157-162	number	5	SENT_640	[p24l821t3062r1041b3109],
5	(	CD	NUMBER	(	appos	1	SENT_640	[p24l1058t3059r1233b3116],
6	2013	CD	DATE	2013	num	7	SENT_640	[p24l1058t3059r1233b3116],
7	)	NN	O	)	dep	5	SENT_640	[p24l1058t3059r1233b3116],
8	.	.	O	.	_	0	SENT_640	[p24l1058t3059r1233b3116],

1	Kim	NNP	PERSON	Kim	nn	3	SENT_641	[p24l131t3140r241b3195],
2	,	,	O	,	_	0	SENT_641	[p24l131t3140r241b3195],
3	S.	NNP	O	S.	_	0	SENT_641	[p24l256t3139r297b3187],
4	et	FW	O	et	nn	5	SENT_641	[p24l311t3145r360b3187],
5	al.	FW	O	al.	dep	3	SENT_641	[p24l369t3137r426b3187],
6	.	.	O	.	_	0	SENT_641	[p24l369t3137r426b3187],

1	Heterogeneity	NN	O	heterogeneity	nsubj	5	SENT_642	[p24l443t3140r823b3201],
2	of	IN	O	of	_	0	SENT_642	[p24l836t3137r891b3187],
3	genetic	JJ	O	genetic	amod	4	SENT_642	[p24l901t3140r1097b3201],
4	changes	NNS	O	change	prep_of	1	SENT_642	[p24l1112t3137r1331b3201],
5	associated	VBN	O	associate	_	0	SENT_642	[p24l1346t3137r1620b3187],
6	with	IN	O	with	_	0	SENT_642	[p24l1636t3137r1750b3187],
7	acquired	VBN	O	acquire	amod	9	SENT_642	[p24l1766t3137r1994b3200],
8	crizotinib	JJ	O	crizotinib	amod	9	SENT_642	[p24l130t3216r375b3265],
9	resistance	NN	O	resistance	prep_with	5	SENT_642	[p24l392t3218r652b3265],
10	in	IN	O	in	_	0	SENT_642	[p24l668t3218r711b3265],
11	ALK-rearranged	JJ	O	alk-rearranged	amod	13	SENT_642	[p24l727t3216r1139b3279],
12	lung	NN	O	lung	nn	13	SENT_642	[p24l1158t3216r1272b3279],
13	cancer	NN	O	cancer	prep_in	9	SENT_642	[p24l1289t3230r1471b3265],
14	.	.	O	.	_	0	SENT_642	[p24l1289t3230r1471b3265],

1	J.	NNP	PERSON	J.	nn	2	SENT_643	[p24l1481t3218r1516b3265],
2	Thorac	NNP	PERSON	Thorac	_	0	SENT_643	[p24l1533t3216r1715b3265],
3	.	.	O	.	_	0	SENT_643	[p24l1533t3216r1715b3265],

1	Oncol	NN	O	oncol	_	0	SENT_644	[p24l1731t3216r1892b3265],
2	.	.	O	.	_	0	SENT_644	[p24l1731t3216r1892b3265],

1	8	CD	NUMBER	8	_	0	SENT_645	[p24l1906t3219r1951b3273],
2	,	,	O	,	_	0	SENT_645	[p24l1906t3219r1951b3273],
3	415-422	CD	NUMBER	415-422	number	4	SENT_645	[p24l128t3297r354b3344],
4	(	CD	NUMBER	(	appos	1	SENT_645	[p24l371t3295r546b3351],
5	2013	CD	DATE	2013	num	6	SENT_645	[p24l371t3295r546b3351],
6	)	NN	O	)	dep	4	SENT_645	[p24l371t3295r546b3351],
7	.	.	O	.	_	0	SENT_645	[p24l371t3295r546b3351],

1	Weickhardt	NNP	PERSON	Weickhardt	_	0	SENT_646	[p24l127t3372r440b3429],
2	,	,	O	,	_	0	SENT_646	[p24l127t3372r440b3429],
3	A.J.	NNP	PERSON	A.J.	nn	4	SENT_646	[p24l454t3374r539b3421],
4	etal	NNP	O	etal	appos	1	SENT_646	[p24l553t3372r669b3421],
5	.	.	O	.	_	0	SENT_646	[p24l553t3372r669b3421],

1	Continuation	NN	O	continuation	_	0	SENT_647	[p24l683t3373r1028b3421],
2	of	IN	O	of	_	0	SENT_647	[p24l1046t3371r1100b3421],
3	EGFR/ALK	NN	O	egfr/alk	nn	4	SENT_647	[p24l1112t3373r1373b3424],
4	inhibition	NN	O	inhibition	prep_of	1	SENT_647	[p24l1387t3372r1638b3421],
5	after	IN	O	after	_	0	SENT_647	[p24l1655t3371r1777b3421],
6	local	JJ	O	local	amod	7	SENT_647	[p24l1792t3372r1908b3421],
7	therapy	NN	O	therapy	prep_after	1	SENT_647	[p24l1923t3372r2129b3435],
8	of	IN	O	of	_	0	SENT_647	[p24l130t3449r184b3499],
9	oligoprogressive	JJ	O	oligoprogressive	amod	10	SENT_647	[p24l194t3450r633b3513],
10	disease	NN	O	disease	prep_of	1	SENT_647	[p24l648t3450r841b3499],
11	in	IN	O	in	_	0	SENT_647	[p24l857t3452r900b3499],
12	EGFR	NN	ORGANIZATION	egfr	prep_in	10	SENT_647	[p24l919t3452r1052b3499],
13	mutant	JJ	O	mutant	amod	16	SENT_647	[p24l1068t3457r1260b3499],
14	(	NN	O	(	nn	16	SENT_647	[p24l1276t3451r1377b3507],
15	Mt	NN	O	mt	nn	16	SENT_647	[p24l1276t3451r1377b3507],
16	)	NN	O	)	dep	12	SENT_647	[p24l1276t3451r1377b3507],
17	and	CC	O	and	_	0	SENT_647	[p24l1394t3450r1491b3499],
18	ALK	NN	O	alk	conj_and	12	SENT_647	[p24l1507t3452r1646b3499],
19	+	CC	O	+	_	0	SENT_647	[p24l1507t3452r1646b3499],
20	non-small	JJ	O	non-small	amod	26	SENT_647	[p24l1662t3450r1920b3499],
21	cell	NN	O	cell	nn	26	SENT_647	[p24l1937t3450r2021b3499],
22	lung	NN	O	lung	nn	26	SENT_647	[p24l2040t3450r2153b3513],
23	cancer	NN	O	cancer	nn	26	SENT_647	[p24l130t3542r304b3577],
24	(	CD	NUMBER	(	num	26	SENT_647	[p24l318t3529r584b3585],
25	NSCLC	NN	O	nsclc	nn	26	SENT_647	[p24l318t3529r584b3585],
26	)	NN	O	)	conj_and	12	SENT_647	[p24l318t3529r584b3585],
27	.	.	O	.	_	0	SENT_647	[p24l318t3529r584b3585],

1	J.	NNP	PERSON	J.	nn	2	SENT_648	[p24l318t3529r584b3585],
2	Clin	NNP	PERSON	Clin	_	0	SENT_648	[p24l600t3528r705b3577],
3	.	.	O	.	_	0	SENT_648	[p24l600t3528r705b3577],

1	Oncol	NN	O	oncol	_	0	SENT_649	[p24l721t3528r882b3577],
2	.	.	O	.	_	0	SENT_649	[p24l721t3528r882b3577],

1	30	CD	NUMBER	30	num	2	SENT_650	[p24l896t3531r964b3577],
2	(	CD	NUMBER	(	_	0	SENT_650	[p24l980t3528r1167b3590],
3	suppl.	VBN	O	suppl.	partmod	2	SENT_650	[p24l980t3528r1167b3590],
4	;	:	O	;	_	0	SENT_650	[p24l980t3528r1167b3590],
5	abstr	NN	O	abstr	dep	2	SENT_650	[p24l1181t3528r1322b3577],
6	.	.	O	.	_	0	SENT_650	[p24l1181t3528r1322b3577],

1	7526	CD	NUMBER	7526	_	0	SENT_651	[p24l1337t3529r1480b3585],
2	)	CD	NUMBER	)	number	3	SENT_651	[p24l1337t3529r1480b3585],
3	(	CD	NUMBER	(	dep	1	SENT_651	[p24l1498t3529r1673b3585],
4	2012	CD	DATE	2012	num	5	SENT_651	[p24l1498t3529r1673b3585],
5	)	NN	O	)	dep	3	SENT_651	[p24l1498t3529r1673b3585],
6	.	.	O	.	_	0	SENT_651	[p24l1498t3529r1673b3585],

1	Costa	NNP	O	Costa	_	0	SENT_652	[p24l128t3607r286b3663],
2	,	,	O	,	_	0	SENT_652	[p24l128t3607r286b3663],
3	D.B.	NNP	PERSON	D.B.	nn	4	SENT_652	[p24l303t3608r398b3655],
4	etal	NNP	O	etal	appos	1	SENT_652	[p24l412t3606r527b3655],
5	.	.	O	.	_	0	SENT_652	[p24l412t3606r527b3655],

1	CSF	NN	O	csf	nn	2	SENT_653	[p24l542t3607r637b3655],
2	concentration	NN	O	concentration	_	0	SENT_653	[p24l653t3608r1021b3655],
3	of	IN	O	of	_	0	SENT_653	[p24l1037t3605r1092b3655],
4	the	DT	O	the	det	9	SENT_653	[p24l1100t3606r1187b3655],
5	anaplastic	JJ	O	anaplastic	amod	9	SENT_653	[p24l1201t3606r1467b3668],
6	lymphoma	NN	O	lymphoma	nn	9	SENT_653	[p24l1484t3606r1766b3669],
7	kinase	NN	O	kinase	nn	9	SENT_653	[p24l1785t3606r1949b3655],
8	inhibitor	NN	O	inhibitor	nn	9	SENT_653	[p24l131t3683r356b3733],
9	crizotinib	NN	O	crizotinib	prep_of	2	SENT_653	[p24l369t3683r671b3733],
10	.	.	O	.	_	0	SENT_653	[p24l369t3683r671b3733],

1	J.	NNP	PERSON	J.	nn	2	SENT_654	[p24l369t3683r671b3733],
2	Clin	NNP	PERSON	Clin	_	0	SENT_654	[p24l687t3683r792b3733],
3	.	.	O	.	_	0	SENT_654	[p24l687t3683r792b3733],

1	Oncol	NN	O	oncol	_	0	SENT_655	[p24l809t3683r969b3733],
2	.	.	O	.	_	0	SENT_655	[p24l809t3683r969b3733],

1	29	CD	NUMBER	29	_	0	SENT_656	[p24l984t3686r1064b3740],
2	,	,	O	,	_	0	SENT_656	[p24l984t3686r1064b3740],
3	e443	NN	O	e443	nn	6	SENT_656	[p24l1078t3686r1367b3733],
4	—	CD	NUMBER	—	num	6	SENT_656	[p24l1078t3686r1367b3733],
5	e445	NN	O	e445	nn	6	SENT_656	[p24l1078t3686r1367b3733],
6	(	NN	O	(	appos	1	SENT_656	[p24l1386t3684r1487b3740],
7	201	CD	NUMBER	201	number	8	SENT_656	[p24l1386t3684r1487b3740],
8	1	CD	NUMBER	1	num	9	SENT_656	[p24l1505t3684r1561b3740],
9	)	NN	O	)	dep	6	SENT_656	[p24l1505t3684r1561b3740],
10	.	.	O	.	_	0	SENT_656	[p24l1505t3684r1561b3740],

1	Marsi	NNP	PERSON	Marsi	nn	3	SENT_657	[p25l129t18r447b81],
2	|	CD	NUMBER	|	num	3	SENT_657	[p25l129t18r447b81],
3	je	NN	O	je	_	0	SENT_657	[p25l129t18r447b81],
4	,	,	O	,	_	0	SENT_657	[p25l129t18r447b81],
5	T.H.	NNP	PERSON	T.H.	nn	6	SENT_657	[p25l129t18r447b81],
6	etal	NNP	O	etal	appos	3	SENT_657	[p25l461t18r577b67],
7	.	.	O	.	_	0	SENT_657	[p25l461t18r577b67],

1	Synthesis	NN	O	synthesis	_	0	SENT_658	[p25l592t18r851b81],
2	,	,	O	,	_	0	SENT_658	[p25l592t18r851b81],
3	Structure	NN	O	structure	appos	1	SENT_658	[p25l865t19r1332b81],
4	.	.	O	.	_	0	SENT_658	[p25l865t19r1332b81],

1	—	NN	O	—	_	0	SENT_659	[p25l865t19r1332b81],
2	.	.	O	.	_	0	SENT_659	[p25l865t19r1332b81],

1	Activity	NN	O	activity	_	0	SENT_660	[p25l865t19r1332b81],
2	Relationships	NNPS	O	Relationships	dep	1	SENT_660	[p25l1348t18r1711b80],
3	,	,	O	,	_	0	SENT_660	[p25l1348t18r1711b80],
4	and	CC	O	and	_	0	SENT_660	[p25l1725t18r1822b67],
5	in	IN	O	in	conj_and	1	SENT_660	[p25l1838t20r1883b67],
6	Vivo	NNP	O	Vivo	nn	7	SENT_660	[p25l1899t20r2003b67],
7	Efﬁcacy	NNP	O	Efﬁcacy	pobj	5	SENT_660	[p25l132t95r331b159],
8	of	IN	O	of	_	0	SENT_660	[p25l344t95r398b145],
9	the	DT	O	the	det	11	SENT_660	[p25l407t96r493b145],
10	Novel	JJ	O	novel	amod	11	SENT_660	[p25l510t96r656b145],
11	Potent	NN	O	potent	prep_of	7	SENT_660	[p25l675t98r847b145],
12	and	CC	O	and	_	0	SENT_660	[p25l860t96r957b145],
13	Selective	JJ	O	selective	amod	16	SENT_660	[p25l974t96r1209b145],
14	Anaplastic	JJ	O	anaplastic	amod	16	SENT_660	[p25l1223t96r1498b158],
15	Lymphoma	NN	O	lymphoma	nn	16	SENT_660	[p25l1514t96r1810b159],
16	Kinase	NN	O	kinase	conj_and	11	SENT_660	[p25l1829t98r1997b145],
17	(	CD	NUMBER	(	num	18	SENT_660	[p25l2013t97r2147b153],
18	ALK	NNP	O	ALK	dep	1	SENT_660	[p25l2013t97r2147b153],
19	)	CD	NUMBER	)	num	18	SENT_660	[p25l2013t97r2147b153],
20	Inhibitor	NNP	O	Inhibitor	dep	18	SENT_660	[p25l132t174r357b223],
21	5	CD	NUMBER	5	num	20	SENT_660	[p25l371t174r2125b237, p25l131t251r1520b315],
22	.	.	O	.	_	0	SENT_660	[p25l371t174r2125b237, p25l131t251r1520b315],

1	—	NN	O	—	_	0	SENT_661	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_661	[p25l371t174r2125b237, p25l131t251r1520b315],

1	Chloro	NNP	O	Chloro	_	0	SENT_662	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_662	[p25l371t174r2125b237, p25l131t251r1520b315],

1	—	NN	O	—	_	0	SENT_663	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_663	[p25l371t174r2125b237, p25l131t251r1520b315],

1	N2	NN	O	n2	_	0	SENT_664	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_664	[p25l371t174r2125b237, p25l131t251r1520b315],

1	—	NN	O	—	_	0	SENT_665	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_665	[p25l371t174r2125b237, p25l131t251r1520b315],

1	(	NN	O	(	_	0	SENT_666	[p25l371t174r2125b237, p25l131t251r1520b315],
2	2	CD	NUMBER	2	dep	1	SENT_666	[p25l371t174r2125b237, p25l131t251r1520b315],
3	.	.	O	.	_	0	SENT_666	[p25l371t174r2125b237, p25l131t251r1520b315],

1	—	NN	O	—	_	0	SENT_667	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_667	[p25l371t174r2125b237, p25l131t251r1520b315],

1	isopropoxy	NN	O	isopropoxy	_	0	SENT_668	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_668	[p25l371t174r2125b237, p25l131t251r1520b315],

1	—	NN	O	—	_	0	SENT_669	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_669	[p25l371t174r2125b237, p25l131t251r1520b315],

1	5	CD	NUMBER	5	_	0	SENT_670	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_670	[p25l371t174r2125b237, p25l131t251r1520b315],

1	—	NN	O	—	_	0	SENT_671	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_671	[p25l371t174r2125b237, p25l131t251r1520b315],

1	methy	NN	O	methy	nn	2	SENT_672	[p25l371t174r2125b237, p25l131t251r1520b315],
2	|	NN	O	|	_	0	SENT_672	[p25l371t174r2125b237, p25l131t251r1520b315],
3	4	CD	NUMBER	4	dep	2	SENT_672	[p25l371t174r2125b237, p25l131t251r1520b315],
4	.	.	O	.	_	0	SENT_672	[p25l371t174r2125b237, p25l131t251r1520b315],

1	—	NN	O	—	_	0	SENT_673	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_673	[p25l371t174r2125b237, p25l131t251r1520b315],

1	(	NN	O	(	_	0	SENT_674	[p25l371t174r2125b237, p25l131t251r1520b315],
2	piperidin	NN	O	piperidin	dep	1	SENT_674	[p25l371t174r2125b237, p25l131t251r1520b315],
3	.	.	O	.	_	0	SENT_674	[p25l371t174r2125b237, p25l131t251r1520b315],

1	—	NN	O	—	_	0	SENT_675	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_675	[p25l371t174r2125b237, p25l131t251r1520b315],

1	4	LS	NUMBER	4	_	0	SENT_676	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_676	[p25l371t174r2125b237, p25l131t251r1520b315],

1	—	NN	O	—	_	0	SENT_677	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_677	[p25l371t174r2125b237, p25l131t251r1520b315],

1	y	NN	O	y	nn	4	SENT_678	[p25l371t174r2125b237, p25l131t251r1520b315],
2	|	CD	NUMBER	|	num	4	SENT_678	[p25l371t174r2125b237, p25l131t251r1520b315],
3	)	NN	O	)	nn	4	SENT_678	[p25l371t174r2125b237, p25l131t251r1520b315],
4	pheny	NN	O	pheny	_	0	SENT_678	[p25l371t174r2125b237, p25l131t251r1520b315],
5	|	CD	NUMBER	|	num	6	SENT_678	[p25l371t174r2125b237, p25l131t251r1520b315],
6	)	NN	O	)	dep	4	SENT_678	[p25l371t174r2125b237, p25l131t251r1520b315],
7	.	.	O	.	_	0	SENT_678	[p25l371t174r2125b237, p25l131t251r1520b315],

1	—	NN	O	—	_	0	SENT_679	[p25l371t174r2125b237, p25l131t251r1520b315],
2	.	.	O	.	_	0	SENT_679	[p25l371t174r2125b237, p25l131t251r1520b315],

1	N4	NN	O	n4	nn	2	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
2	(	NN	O	(	_	0	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
3	2	CD	NUMBER	2	dep	2	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
4	-	:	O	-	_	0	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
5	(	CD	NUMBER	(	num	8	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
6	isopropylsulfonyl	NN	O	isopropylsulfonyl	nn	8	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
7	)	NN	O	)	nn	8	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
8	phenyl	NN	O	phenyl	dep	2	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
9	)	CD	NUMBER	)	num	10	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
10	pyrimidine-2	NN	O	pyrimidine-2	dep	8	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
11	,4	CD	NUMBER	,4	dep	8	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
12	-	:	O	-	_	0	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
13	diamine	NN	O	diamine	nn	15	SENT_680	[p25l371t174r2125b237, p25l131t251r1520b315],
14	(	CD	NUMBER	(	num	15	SENT_680	[p25l1536t253r1771b309],
15	LDK378	NN	O	ldk378	dep	2	SENT_680	[p25l1536t253r1771b309],
16	)	CD	NUMBER	)	num	25	SENT_680	[p25l1536t253r1771b309],
17	Currently	NNP	DATE	Currently	dep	25	SENT_680	[p25l1787t252r2032b315],
18	in	IN	O	in	_	0	SENT_680	[p25l2047t254r2089b301],
19	Phase	NN	O	phase	prep_in	17	SENT_680	[p25l132t329r283b379],
20	1	CD	NUMBER	1	num	19	SENT_680	[p25l302t333r317b378],
21	and	CC	O	and	_	0	SENT_680	[p25l341t329r438b379],
22	Phase	NN	O	phase	conj_and	19	SENT_680	[p25l458t329r609b379],
23	2	CD	NUMBER	2	num	22	SENT_680	[p25l624t332r651b378],
24	Clinical	JJ	O	clinical	amod	25	SENT_680	[p25l666t329r852b379],
25	Trials	NNS	O	trial	dep	15	SENT_680	[p25l864t329r1011b379],
26	.	.	O	.	_	0	SENT_680	[p25l864t329r1011b379],

1	J.	NNP	O	J.	nn	2	SENT_681	[p25l1022t331r1056b379],
2	Med	NNP	O	Med	_	0	SENT_681	[p25l1070t329r1191b379],
3	.	.	O	.	_	0	SENT_681	[p25l1070t329r1191b379],

1	Chem	NNP	O	Chem	_	0	SENT_682	[p25l1206t329r1366b379],
2	.	.	O	.	_	0	SENT_682	[p25l1206t329r1366b379],

1	(	NN	O	(	_	0	SENT_683	[p25l1382t330r1483b386],
2	201	CD	NUMBER	201	number	3	SENT_683	[p25l1382t330r1483b386],
3	3	CD	NUMBER	3	dep	1	SENT_683	[p25l1498t330r1557b386],
4	)	NN	O	)	dep	3	SENT_683	[p25l1498t330r1557b386],
5	.	.	O	.	_	0	SENT_683	[p25l1498t330r1557b386],

1	Galkin	NNP	PERSON	Galkin	nn	3	SENT_684	[p25l128t408r318b465],
2	,	,	O	,	_	0	SENT_684	[p25l128t408r318b465],
3	A.V.	NNP	O	A.V.	dep	4	SENT_684	[p25l336t410r436b457],
4	etal	JJ	O	etal	_	0	SENT_684	[p25l454t408r580b457],
5	.	.	O	.	_	0	SENT_684	[p25l454t408r580b457],

1	Identification	NN	O	identification	_	0	SENT_685	[p25l600t407r972b457],
2	of	IN	O	of	_	0	SENT_685	[p25l992t407r1049b457],
3	NVP-TAE684	NN	O	nvp-tae684	prep_of	1	SENT_685	[p25l1065t410r1415b465],
4	,	,	O	,	_	0	SENT_685	[p25l1065t410r1415b465],
5	a	DT	O	a	det	12	SENT_685	[p25l1433t422r1459b457],
6	potent	JJ	O	potent	amod	12	SENT_685	[p25l1481t415r1680b470],
7	,	,	O	,	_	0	SENT_685	[p25l1481t415r1680b470],
8	selective	JJ	O	selective	amod	12	SENT_685	[p25l1699t408r1957b465],
9	,	,	O	,	_	0	SENT_685	[p25l1699t408r1957b465],
10	and	CC	O	and	_	0	SENT_685	[p25l1975t408r2076b457],
11	efﬁcacious	JJ	O	efﬁcacious	amod	12	SENT_685	[p25l130t484r417b535],
12	inhibitor	NN	O	inhibitor	appos	1	SENT_685	[p25l435t485r668b535],
13	of	IN	O	of	_	0	SENT_685	[p25l683t484r739b535],
14	NPM-ALK	NN	O	npm-alk	prep_of	12	SENT_685	[p25l752t487r1019b535],
15	.	.	O	.	_	0	SENT_685	[p25l752t487r1019b535],

1	Proc	NNP	O	Proc	_	0	SENT_686	[p25l1035t487r1158b535],
2	.	.	O	.	_	0	SENT_686	[p25l1035t487r1158b535],

1	Natl.	NNP	O	Natl.	nn	2	SENT_687	[p25l1175t485r1294b535],
2	Acad	NNP	O	Acad	_	0	SENT_687	[p25l1307t485r1450b535],
3	.	.	O	.	_	0	SENT_687	[p25l1307t485r1450b535],

1	Sci	NNP	O	Sci	_	0	SENT_688	[p25l1466t486r1549b535],
2	.	.	O	.	_	0	SENT_688	[p25l1466t486r1549b535],

1	USA	NNP	LOCATION	USA	_	0	SENT_689	[p25l1569t486r1669b535],
2	104	CD	NUMBER	104	num	1	SENT_689	[p25l1690t488r1805b542],
3	,	,	O	,	_	0	SENT_689	[p25l1690t488r1805b542],
4	270-275	CD	NUMBER	270-275	num	1	SENT_689	[p25l1822t488r2051b535],
5	(	CD	NUMBER	(	num	7	SENT_689	[p25l131t565r312b621],
6	2007	CD	DATE	2007	num	7	SENT_689	[p25l131t565r312b621],
7	)	NN	O	)	dep	1	SENT_689	[p25l131t565r312b621],
8	.	.	O	.	_	0	SENT_689	[p25l131t565r312b621],

1	Shaw	NNP	ORGANIZATION	Shaw	_	0	SENT_690	[p25l128t642r280b699],
2	,	,	O	,	_	0	SENT_690	[p25l128t642r280b699],
3	A.T.	NNP	ORGANIZATION	A.T.	conj_and	1	SENT_690	[p25l293t644r384b691],
4	&	CC	ORGANIZATION	&	_	0	SENT_690	[p25l398t643r435b691],
5	Engelman	NNP	ORGANIZATION	Engelman	conj_and	1	SENT_690	[p25l450t642r727b705],
6	,	,	O	,	_	0	SENT_690	[p25l450t642r727b705],
7	J.A.	NNP	PERSON	J.A.	nn	8	SENT_690	[p25l740t644r826b691],
8	ALK	NNP	PERSON	ALK	appos	1	SENT_690	[p25l840t644r944b691],
9	in	IN	O	in	_	0	SENT_690	[p25l957t644r1000b691],
10	lung	NN	O	lung	nn	11	SENT_690	[p25l1019t642r1132b705],
11	cancer	NN	O	cancer	prep_in	8	SENT_690	[p25l1149t656r1335b691],
12	:	:	O	:	_	0	SENT_690	[p25l1149t656r1335b691],
13	past	NN	DATE	past	dep	1	SENT_690	[p25l1352t649r1473b704],
14	,	,	DATE	,	_	0	SENT_690	[p25l1352t649r1473b704],
15	present	JJ	DATE	present	conj_and	13	SENT_690	[p25l1489t649r1699b704],
16	,	,	O	,	_	0	SENT_690	[p25l1489t649r1699b704],
17	and	CC	O	and	_	0	SENT_690	[p25l1714t642r1810b691],
18	future	NN	DATE	future	dep	1	SENT_690	[p25l1825t641r1998b691],
19	.	.	O	.	_	0	SENT_690	[p25l1825t641r1998b691],

1	J.CIin.OncoI.31,1105-1111	NN	DURATION	j.ciin.oncoi.31,1105-1111	_	0	SENT_691	[p25l125t719r848b776],
2	(	CD	NUMBER	(	num	1	SENT_691	[p25l875t720r1050b776],
3	2013	CD	DATE	2013	num	4	SENT_691	[p25l875t720r1050b776],
4	)	NN	O	)	dep	1	SENT_691	[p25l875t720r1050b776],
5	.	.	O	.	_	0	SENT_691	[p25l875t720r1050b776],

1	Sakamoto	NNP	PERSON	Sakamoto	nn	3	SENT_692	[p25l128t798r406b855],
2	,	,	O	,	_	0	SENT_692	[p25l128t798r406b855],
3	H.	NNP	O	H.	_	0	SENT_692	[p25l422t800r471b847],
4	et	FW	O	et	nn	5	SENT_692	[p25l485t805r534b847],
5	al.	FW	O	al.	dep	3	SENT_692	[p25l543t798r601b847],
6	.	.	O	.	_	0	SENT_692	[p25l543t798r601b847],

1	CH5424802	NN	O	ch5424802	_	0	SENT_693	[p25l615t799r934b855],
2	,	,	O	,	_	0	SENT_693	[p25l615t799r934b855],
3	a	DT	O	a	det	6	SENT_693	[p25l948t812r974b847],
4	selective	JJ	O	selective	amod	6	SENT_693	[p25l990t798r1218b847],
5	ALK	NN	O	alk	nn	6	SENT_693	[p25l1232t800r1336b847],
6	inhibitor	NN	O	inhibitor	appos	1	SENT_693	[p25l1349t798r1574b847],
7	capable	JJ	O	capable	amod	6	SENT_693	[p25l1588t798r1794b860],
8	of	IN	O	of	_	0	SENT_693	[p25l1809t797r1863b847],
9	blocking	VBG	O	block	prepc_of	7	SENT_693	[p25l1875t798r2100b861],
10	the	DT	O	the	det	13	SENT_693	[p25l128t876r215b925],
11	resistant	JJ	O	resistant	amod	13	SENT_693	[p25l231t878r452b925],
12	gatekeeper	NN	O	gatekeeper	nn	13	SENT_693	[p25l466t876r766b939],
13	mutant	NN	O	mutant	dobj	9	SENT_693	[p25l782t883r986b925],
14	.	.	O	.	_	0	SENT_693	[p25l782t883r986b925],

1	Cancer	NN	O	cancer	nn	2	SENT_694	[p25l1001t877r1179b925],
2	Cell	NN	O	cell	_	0	SENT_694	[p25l1189t876r1281b925],
3	1	CD	NUMBER	1	number	4	SENT_694	[p25l1295t880r1315b925],
4	9	CD	NUMBER	9	dep	2	SENT_694	[p25l1327t879r1372b933],
5	,	,	O	,	_	0	SENT_694	[p25l1327t879r1372b933],
6	679-690	CD	NUMBER	679-690	num	7	SENT_694	[p25l1386t879r1612b925],
7	(	NN	O	(	appos	2	SENT_694	[p25l1629t877r1730b933],
8	201	CD	NUMBER	201	number	9	SENT_694	[p25l1629t877r1730b933],
9	1	CD	NUMBER	1	num	10	SENT_694	[p25l1748t877r1804b933],
10	)	NN	O	)	dep	7	SENT_694	[p25l1748t877r1804b933],
11	.	.	O	.	_	0	SENT_694	[p25l1748t877r1804b933],

1	Kinoshita	NNP	PERSON	Kinoshita	nn	3	SENT_695	[p25l130t954r386b1011],
2	,	,	O	,	_	0	SENT_695	[p25l130t954r386b1011],
3	K.	NNP	O	K.	_	0	SENT_695	[p25l403t956r445b1003],
4	et	FW	O	et	nn	5	SENT_695	[p25l460t961r509b1003],
5	al.	FW	O	al.	dep	3	SENT_695	[p25l518t954r575b1003],
6	.	.	O	.	_	0	SENT_695	[p25l518t954r575b1003],

1	Design	NN	O	design	_	0	SENT_696	[p25l592t956r770b1017],
2	and	CC	O	and	_	0	SENT_696	[p25l787t954r884b1003],
3	synthesis	NN	O	synthesis	conj_and	1	SENT_696	[p25l901t954r1141b1017],
4	of	IN	O	of	_	0	SENT_696	[p25l1156t953r1211b1003],
5	a	DT	O	a	det	19	SENT_696	[p25l1220t968r1246b1003],
6	highly	RB	O	highly	advmod	7	SENT_696	[p25l1264t954r1427b1017],
7	selective	JJ	O	selective	amod	19	SENT_696	[p25l1440t954r1680b1011],
8	,	,	O	,	_	0	SENT_696	[p25l1440t954r1680b1011],
9	orally	RB	O	orally	advmod	10	SENT_696	[p25l1695t954r1839b1017],
10	active	JJ	O	active	amod	19	SENT_696	[p25l1852t956r2007b1003],
11	and	CC	O	and	_	0	SENT_696	[p25l129t1032r226b1081],
12	potent	JJ	O	potent	amod	13	SENT_696	[p25l245t1039r420b1094],
13	anaplastic	JJ	O	anaplastic	amod	19	SENT_696	[p25l434t1032r700b1094],
14	lymphoma	NN	O	lymphoma	nn	19	SENT_696	[p25l717t1032r1000b1095],
15	kinase	NN	O	kinase	nn	19	SENT_696	[p25l1018t1032r1182b1081],
16	inhibitor	NN	O	inhibitor	nn	19	SENT_696	[p25l1198t1032r1423b1081],
17	(	NN	O	(	nn	19	SENT_696	[p25l1438t1033r1790b1089],
18	CH5424802	NN	O	ch5424802	nn	19	SENT_696	[p25l1438t1033r1790b1089],
19	)	NN	O	)	prep_of	1	SENT_696	[p25l1438t1033r1790b1089],
20	.	.	O	.	_	0	SENT_696	[p25l1438t1033r1790b1089],

1	Bioorg	NNP	PERSON	Bioorg	_	0	SENT_697	[p25l1804t1034r1979b1095],
2	.	.	O	.	_	0	SENT_697	[p25l1804t1034r1979b1095],

1	Med	NNP	O	Med	_	0	SENT_698	[p25l1993t1032r2113b1081],
2	.	.	O	.	_	0	SENT_698	[p25l1993t1032r2113b1081],

1	Chem	NNP	ORGANIZATION	Chem	_	0	SENT_699	[p25l130t1109r385b1166],
2	.20	CD	NUMBER	.20	num	1	SENT_699	[p25l130t1109r385b1166],
3	,	,	O	,	_	0	SENT_699	[p25l130t1109r385b1166],
4	1271-1280	CD	DATE	1271-1280	num	1	SENT_699	[p25l403t1112r690b1159],
5	(	CD	NUMBER	(	num	7	SENT_699	[p25l706t1110r882b1166],
6	2012	CD	DATE	2012	num	7	SENT_699	[p25l706t1110r882b1166],
7	)	NN	O	)	dep	1	SENT_699	[p25l706t1110r882b1166],
8	.	.	O	.	_	0	SENT_699	[p25l706t1110r882b1166],

1	Seto	NNP	PERSON	Seto	nn	3	SENT_700	[p25l128t1190r256b1245],
2	,	,	O	,	_	0	SENT_700	[p25l128t1190r256b1245],
3	T.	NNP	O	T.	_	0	SENT_700	[p25l265t1190r305b1238],
4	et	FW	O	et	nn	5	SENT_700	[p25l319t1195r368b1238],
5	al.	FW	O	al.	dep	3	SENT_700	[p25l377t1188r434b1238],
6	.	.	O	.	_	0	SENT_700	[p25l377t1188r434b1238],

1	CH5424802	NN	O	ch5424802	nn	4	SENT_701	[p25l449t1190r754b1238],
2	(	CD	NUMBER	(	num	4	SENT_701	[p25l770t1189r1108b1245],
3	RO5424802	NN	O	ro5424802	nn	4	SENT_701	[p25l770t1189r1108b1245],
4	)	NN	O	)	dep	15	SENT_701	[p25l770t1189r1108b1245],
5	for	IN	O	for	_	0	SENT_701	[p25l1123t1187r1196b1238],
6	patients	NNS	O	patient	prep_for	4	SENT_701	[p25l1211t1190r1422b1250],
7	with	IN	O	with	_	0	SENT_701	[p25l1436t1188r1550b1238],
8	ALK-rearranged	JJ	MISC	alk-rearranged	amod	12	SENT_701	[p25l1566t1188r1979b1251],
9	advanced	JJ	O	advanced	amod	12	SENT_701	[p25l129t1266r384b1315],
10	non-small-cell	JJ	O	non-small-cell	amod	12	SENT_701	[p25l403t1266r771b1315],
11	lung	NN	O	lung	nn	12	SENT_701	[p25l790t1266r904b1329],
12	cancer	NN	O	cancer	prep_with	6	SENT_701	[p25l921t1280r1094b1315],
13	(	CD	NUMBER	(	num	14	SENT_701	[p25l1109t1267r1300b1323],
14	AF-001	NN	O	af-001	dep	15	SENT_701	[p25l1109t1267r1300b1323],
15	JP	NNP	O	JP	dep	20	SENT_701	[p25l1312t1268r1367b1315],
16	study	NN	O	study	dep	15	SENT_701	[p25l1382t1266r1558b1330],
17	)	CD	NUMBER	)	num	16	SENT_701	[p25l1382t1266r1558b1330],
18	:	:	O	:	_	0	SENT_701	[p25l1382t1266r1558b1330],
19	a	DT	O	a	det	20	SENT_701	[p25l1572t1280r1598b1315],
20	single-arm	JJ	O	single-arm	_	0	SENT_701	[p25l1614t1266r1909b1329],
21	,	,	O	,	_	0	SENT_701	[p25l1614t1266r1909b1329],
22	openlabel	NN	O	openlabel	appos	20	SENT_701	[p25l1923t1280r2079b1328, p25l132t1344r267b1401],
23	,	,	O	,	_	0	SENT_701	[p25l1923t1280r2079b1328, p25l132t1344r267b1401],
24	phase	NN	O	phase	appos	20	SENT_701	[p25l284t1344r438b1406],
25	1-2	CD	NUMBER	1-2	num	26	SENT_701	[p25l458t1347r533b1393],
26	study	NN	O	study	dep	24	SENT_701	[p25l549t1344r704b1407],
27	.	.	O	.	_	0	SENT_701	[p25l549t1344r704b1407],

1	Lancet	NNP	O	Lancet	nn	2	SENT_702	[p25l718t1346r890b1394],
2	Oncol	NNP	O	Oncol	_	0	SENT_702	[p25l899t1344r1060b1394],
3	.	.	O	.	_	0	SENT_702	[p25l899t1344r1060b1394],

1	14	CD	NUMBER	14	_	0	SENT_703	[p25l1077t1348r1155b1401],
2	,	,	O	,	_	0	SENT_703	[p25l1077t1348r1155b1401],
3	590-598	CD	NUMBER	590-598	number	4	SENT_703	[p25l1170t1347r1395b1394],
4	(	CD	NUMBER	(	appos	1	SENT_703	[p25l1411t1345r1586b1401],
5	2013	CD	DATE	2013	num	6	SENT_703	[p25l1411t1345r1586b1401],
6	)	NN	O	)	dep	4	SENT_703	[p25l1411t1345r1586b1401],
7	.	.	O	.	_	0	SENT_703	[p25l1411t1345r1586b1401],

1	Zhang	NNP	PERSON	Zhang	_	0	SENT_704	[p25l128t1422r310b1485],
2	,	,	O	,	_	0	SENT_704	[p25l128t1422r310b1485],
3	S.	NNP	O	S.	nn	4	SENT_704	[p25l325t1423r365b1472],
4	etal	NNP	O	etal	appos	1	SENT_704	[p25l380t1422r495b1472],
5	.	.	O	.	_	0	SENT_704	[p25l380t1422r495b1472],

1	Proceedings	NNP	O	Proceedings	_	0	SENT_705	[p25l511t1422r846b1485],
2	:	:	O	:	_	0	SENT_705	[p25l511t1422r846b1485],
3	AACR	NN	O	aacr	nn	5	SENT_705	[p25l860t1423r1006b1472],
4	101	CD	NUMBER	101	num	5	SENT_705	[p25l1025t1425r1104b1472],
5	st	NN	O	st	nsubj	7	SENT_705	[p25l1118t1429r1162b1472],
6	Annual	JJ	SET	annual	amod	5	SENT_705	[p25l1175t1422r1360b1472],
7	Meeting	VBG	O	meet	dep	1	SENT_705	[p25l1378t1424r1594b1485],
8	2010,15	CD	NUMBER	2010,15	dobj	7	SENT_705	[p25l1611t1425r1825b1479],
9	April	NNP	DATE	April	tmod	7	SENT_705	[p25l1841t1422r1961b1484],
10	2010	CD	DATE	2010	num	9	SENT_705	[p25l1978t1425r2118b1472],
11	.	.	O	.	_	0	SENT_705	[p25l1978t1425r2118b1472],

1	CancerRes	NNS	O	cancerre	_	0	SENT_706	[p25l131t1501r413b1550],
2	.	.	O	.	_	0	SENT_706	[p25l131t1501r413b1550],

1	70	CD	NUMBER	70	number	2	SENT_707	[p25l428t1503r495b1550],
2	(	CD	NUMBER	(	num	3	SENT_707	[p25l511t1501r569b1557],
3	8	CD	NUMBER	8	_	0	SENT_707	[p25l511t1501r569b1557],
4	;	:	O	;	_	0	SENT_707	[p25l511t1501r569b1557],
5	70	CD	NUMBER	70	num	6	SENT_707	[p25l584t1503r651b1550],
6	suppl	NN	O	suppl	dep	3	SENT_707	[p25l665t1500r822b1562],
7	.	.	O	.	_	0	SENT_707	[p25l665t1500r822b1562],

1	1	CD	NUMBER	1	_	0	SENT_708	[p25l841t1504r879b1557],
2	;	:	O	;	_	0	SENT_708	[p25l841t1504r879b1557],
3	abstr	NN	O	abstr	dep	1	SENT_708	[p25l893t1500r1032b1550],
4	.	.	O	.	_	0	SENT_708	[p25l893t1500r1032b1550],

1	LB-298	NN	O	lb-298	_	0	SENT_709	[p25l1049t1501r1242b1557],
2	)	CD	NUMBER	)	number	3	SENT_709	[p25l1049t1501r1242b1557],
3	(	CD	NUMBER	(	dep	1	SENT_709	[p25l1261t1501r1435b1557],
4	2010	CD	DATE	2010	num	5	SENT_709	[p25l1261t1501r1435b1557],
5	)	NN	O	)	dep	3	SENT_709	[p25l1261t1501r1435b1557],
6	.	.	O	.	_	0	SENT_709	[p25l1261t1501r1435b1557],

1	Rivera	NNP	PERSON	Rivera	_	0	SENT_710	[p25l131t1577r721b1633],
2	,	,	O	,	_	0	SENT_710	[p25l131t1577r721b1633],
3	V.M.	NNP	O	V.M.	nn	4	SENT_710	[p25l131t1577r721b1633],
4	etaI	NNP	O	etaI	appos	1	SENT_710	[p25l131t1577r721b1633],
5	.	.	O	.	_	0	SENT_710	[p25l131t1577r721b1633],

1	AP261	NN	O	ap261	nsubj	7	SENT_711	[p25l131t1577r721b1633],
2	13	CD	NUMBER	13	num	1	SENT_711	[p25l739t1580r795b1626],
3	is	VBZ	O	be	cop	7	SENT_711	[p25l812t1579r847b1626],
4	a	DT	O	a	det	7	SENT_711	[p25l861t1591r887b1626],
5	dual	JJ	O	dual	amod	7	SENT_711	[p25l903t1577r1013b1626],
6	ALK/EGFR	NN	O	alk/egfr	nn	7	SENT_711	[p25l1030t1578r1291b1628],
7	inhibitor	NN	O	inhibitor	_	0	SENT_711	[p25l1307t1577r1543b1626],
8	:	:	O	:	_	0	SENT_711	[p25l1307t1577r1543b1626],
9	characterization	NN	O	characterization	dep	7	SENT_711	[p25l1558t1577r1980b1626],
10	against	IN	O	against	_	0	SENT_711	[p25l130t1657r321b1718],
11	EGFRT790M	NN	O	egfrt790m	prep_against	9	SENT_711	[p25l337t1657r658b1705],
12	in	IN	O	in	_	0	SENT_711	[p25l675t1657r718b1704],
13	cell	NN	O	cell	nn	16	SENT_711	[p25l734t1655r818b1705],
14	and	CC	O	and	_	0	SENT_711	[p25l835t1655r932b1705],
15	mouse	NN	O	mouse	nn	16	SENT_711	[p25l950t1670r1125b1705],
16	models	NNS	O	model	prep_in	11	SENT_711	[p25l1142t1655r1332b1705],
17	of	IN	O	of	_	0	SENT_711	[p25l1347t1654r1402b1705],
18	NSCLC	NNP	O	NSCLC	nn	19	SENT_711	[p25l1414t1657r1583b1705],
19	Proceedings	NNP	O	Proceedings	prep_of	16	SENT_711	[p25l1600t1655r1934b1718],
20	:	:	O	:	_	0	SENT_711	[p25l1600t1655r1934b1718],
21	AACR	NN	O	aacr	dep	9	SENT_711	[p25l1948t1656r2094b1705],
22	103rd	CD	NUMBER	103rd	num	21	SENT_711	[p25l135t1733r279b1783],
23	Annual	JJ	SET	annual	tmod	21	SENT_711	[p25l295t1733r480b1783],
24	Meeting	VBG	O	meet	partmod	21	SENT_711	[p25l499t1735r728b1796],
25	,	,	O	,	_	0	SENT_711	[p25l499t1735r728b1796],
26	AACR	NNP	O	AACR	appos	21	SENT_711	[p25l742t1734r888b1783],
27	2012	CD	DATE	2012	num	26	SENT_711	[p25l903t1736r1043b1790],
28	,	,	O	,	_	0	SENT_711	[p25l903t1736r1043b1790],
29	Chicago	NNP	LOCATION	Chicago	appos	26	SENT_711	[p25l1057t1733r1283b1796],
30	,	,	O	,	_	0	SENT_711	[p25l1057t1733r1283b1796],
31	USA	NNP	LOCATION	USA	appos	26	SENT_711	[p25l1299t1734r1418b1790],
32	,	,	O	,	_	0	SENT_711	[p25l1299t1734r1418b1790],
33	2	CD	DATE	2	appos	26	SENT_711	[p25l1433t1736r1460b1782],
34	April	NNP	DATE	April	tmod	33	SENT_711	[p25l1476t1733r1611b1795],
35	,	,	DATE	,	_	0	SENT_711	[p25l1476t1733r1611b1795],
36	2012	CD	DATE	2012	num	37	SENT_711	[p25l1625t1736r1751b1783],
37	(	CD	DATE	(	appos	26	SENT_711	[p25l1768t1734r1943b1790],
38	2012	CD	DATE	2012	num	39	SENT_711	[p25l1768t1734r1943b1790],
39	)	NN	O	)	dep	37	SENT_711	[p25l1768t1734r1943b1790],
40	.	.	O	.	_	0	SENT_711	[p25l1768t1734r1943b1790],

1	Camidge	NNP	O	Camidge	_	0	SENT_712	[p25l129t1811r377b1874],
2	,	,	O	,	_	0	SENT_712	[p25l129t1811r377b1874],
3	D.R.	NNP	PERSON	D.R.	nn	4	SENT_712	[p25l394t1813r489b1860],
4	etal	NNP	O	etal	appos	1	SENT_712	[p25l503t1811r618b1861],
5	.	.	O	.	_	0	SENT_712	[p25l503t1811r618b1861],

1	First-in-human	JJ	O	first-in-human	amod	3	SENT_713	[p25l635t1811r1017b1860],
2	dose-ﬁnding	JJ	O	dose-ﬁnding	amod	3	SENT_713	[p25l1034t1810r1368b1874],
3	study	NN	O	study	dep	9	SENT_713	[p25l1385t1811r1530b1874],
4	of	IN	O	of	_	0	SENT_713	[p25l1543t1810r1598b1860],
5	the	DT	O	the	det	7	SENT_713	[p25l1606t1811r1692b1861],
6	ALK/EGFR	NN	O	alk/egfr	nn	7	SENT_713	[p25l1706t1812r1967b1863],
7	inhibitor	NN	O	inhibitor	prep_of	3	SENT_713	[p25l132t1889r356b1939],
8	AP261	NN	O	ap261	dep	9	SENT_713	[p25l369t1891r527b1939],
9	13	CD	NUMBER	13	dep	16	SENT_713	[p25l545t1892r601b1939],
10	in	IN	O	in	_	0	SENT_713	[p25l619t1891r661b1938],
11	patients	NNS	O	patient	prep_in	9	SENT_713	[p25l680t1891r890b1951],
12	with	IN	O	with	_	0	SENT_713	[p25l904t1889r1017b1939],
13	advanced	JJ	O	advanced	amod	14	SENT_713	[p25l1034t1889r1288b1939],
14	malignancies	NNS	O	malignancy	prep_with	11	SENT_713	[p25l1306t1889r1665b1952],
15	:	:	O	:	_	0	SENT_713	[p25l1306t1889r1665b1952],
16	Updated	VBN	O	update	_	0	SENT_713	[p25l1682t1889r1907b1951],
17	results	NNS	O	result	dobj	16	SENT_713	[p25l1925t1889r2105b1939],
18	.	.	O	.	_	0	SENT_713	[p25l1925t1889r2105b1939],

1	J.	NNP	PERSON	J.	nn	2	SENT_714	[p25l126t1969r161b2017],
2	Clin	NNP	PERSON	Clin	_	0	SENT_714	[p25l177t1967r282b2017],
3	.	.	O	.	_	0	SENT_714	[p25l177t1967r282b2017],

1	Oncol	NN	O	oncol	_	0	SENT_715	[p25l297t1967r457b2017],
2	.	.	O	.	_	0	SENT_715	[p25l297t1967r457b2017],

1	31	CD	NUMBER	31	num	2	SENT_716	[p25l472t1970r531b2017],
2	(	CD	NUMBER	(	_	0	SENT_716	[p25l555t1967r742b2029],
3	suppl.	VBN	O	suppl.	partmod	2	SENT_716	[p25l555t1967r742b2029],
4	;	:	O	;	_	0	SENT_716	[p25l555t1967r742b2029],
5	abstr	NN	O	abstr	dep	2	SENT_716	[p25l756t1967r896b2017],
6	.	.	O	.	_	0	SENT_716	[p25l756t1967r896b2017],

1	8031	CD	NUMBER	8031	_	0	SENT_717	[p25l910t1968r1054b2024],
2	)	CD	NUMBER	)	number	3	SENT_717	[p25l910t1968r1054b2024],
3	(	CD	NUMBER	(	dep	1	SENT_717	[p25l1072t1968r1246b2024],
4	2013	CD	DATE	2013	num	5	SENT_717	[p25l1072t1968r1246b2024],
5	)	NN	O	)	dep	3	SENT_717	[p25l1072t1968r1246b2024],
6	.	.	O	.	_	0	SENT_717	[p25l1072t1968r1246b2024],

1	Lovly	NNP	O	Lovly	nn	3	SENT_718	[p25l131t2045r276b2109],
2	,	,	O	,	_	0	SENT_718	[p25l131t2045r276b2109],
3	C.M.	NNP	O	C.M.	_	0	SENT_718	[p25l290t2046r400b2094],
4	et	FW	O	et	nn	5	SENT_718	[p25l415t2052r464b2094],
5	al.	FW	O	al.	dep	3	SENT_718	[p25l473t2045r530b2094],
6	.	.	O	.	_	0	SENT_718	[p25l473t2045r530b2094],

1	Insights	NNPS	O	Insights	nsubj	5	SENT_719	[p25l547t2045r749b2108],
2	into	IN	O	into	_	0	SENT_719	[p25l765t2047r865b2094],
3	ALK-driven	JJ	MISC	alk-driven	amod	4	SENT_719	[p25l879t2045r1167b2094],
4	cancers	NNS	O	cancer	prep_into	1	SENT_719	[p25l1183t2059r1380b2094],
5	revealed	VBD	O	reveal	_	0	SENT_719	[p25l1397t2045r1617b2094],
6	through	IN	O	through	_	0	SENT_719	[p25l1632t2045r1846b2108],
7	development	NN	O	development	prep_through	5	SENT_719	[p25l130t2123r486b2185],
8	of	IN	O	of	_	0	SENT_719	[p25l499t2122r554b2173],
9	novel	JJ	O	novel	amod	13	SENT_719	[p25l566t2123r704b2173],
10	ALK	NN	O	alk	nn	13	SENT_719	[p25l721t2125r824b2172],
11	tyrosine	NN	O	tyrosine	nn	13	SENT_719	[p25l834t2125r1047b2186],
12	kinase	NN	O	kinase	nn	13	SENT_719	[p25l1063t2123r1226b2173],
13	inhibitors	NNS	O	inhibitor	prep_of	7	SENT_719	[p25l1243t2123r1503b2173],
14	.	.	O	.	_	0	SENT_719	[p25l1243t2123r1503b2173],

1	CancerRes	NNS	O	cancerre	_	0	SENT_720	[p25l1518t2125r1800b2173],
2	.	.	O	.	_	0	SENT_720	[p25l1518t2125r1800b2173],

1	71	CD	NUMBER	71	_	0	SENT_721	[p25l1814t2127r1894b2180],
2	,	,	O	,	_	0	SENT_721	[p25l1814t2127r1894b2180],
3	4920-4931	CD	DURATION	4920-4931	number	4	SENT_721	[p25l129t2203r411b2249],
4	(	CD	NUMBER	(	appos	1	SENT_721	[p25l437t2201r611b2256],
5	2011	CD	DATE	2011	num	6	SENT_721	[p25l437t2201r611b2256],
6	)	NN	O	)	dep	4	SENT_721	[p25l437t2201r611b2256],
7	.	.	O	.	_	0	SENT_721	[p25l437t2201r611b2256],

1	Kuromitsu	NNP	PERSON	Kuromitsu	_	0	SENT_722	[p25l131t2280r415b2335],
2	,	,	O	,	_	0	SENT_722	[p25l131t2280r415b2335],
3	S.	NNP	O	S.	nn	4	SENT_722	[p25l431t2280r471b2328],
4	etal	NNP	O	etal	appos	1	SENT_722	[p25l486t2278r603b2328],
5	.	.	O	.	_	0	SENT_722	[p25l486t2278r603b2328],

1	Proceedings	NNP	O	Proceedings	_	0	SENT_723	[p25l620t2278r945b2341],
2	of	IN	O	of	_	0	SENT_723	[p25l960t2277r1015b2328],
3	the	DT	O	the	det	6	SENT_723	[p25l1024t2278r1110b2328],
4	AACR-NCI-EORTC	NNP	MISC	AACR-NCI-EORTC	nn	6	SENT_723	[p25l1125t2280r1586b2328],
5	International	NNP	MISC	International	nn	6	SENT_723	[p25l1603t2278r1941b2328],
6	Conference	NNP	MISC	Conference	prep_of	1	SENT_723	[p25l130t2355r447b2406],
7	:	:	MISC	:	_	0	SENT_723	[p25l130t2355r447b2406],
8	Mo	NNP	DURATION	Mo	nn	9	SENT_723	[p25l464t2356r929b2419],
9	|	NNP	O	|	dep	1	SENT_723	[p25l464t2356r929b2419],
10	ecu	FW	O	ecu	nn	12	SENT_723	[p25l464t2356r929b2419],
11	|	FW	O	|	nn	12	SENT_723	[p25l464t2356r929b2419],
12	arTargets	NNS	O	artarget	dep	9	SENT_723	[p25l464t2356r929b2419],
13	and	CC	O	and	_	0	SENT_723	[p25l944t2356r1041b2406],
14	CancerTherapeutics	NNS	O	cancertherapeutic	dep	1	SENT_723	[p25l1058t2356r1608b2418],
15	,	,	O	,	_	0	SENT_723	[p25l1058t2356r1608b2418],
16	San	NNP	LOCATION	San	nn	17	SENT_723	[p25l1623t2357r1715b2406],
17	Francisco	NNP	LOCATION	Francisco	appos	14	SENT_723	[p25l1735t2358r1991b2413],
18	,	,	O	,	_	0	SENT_723	[p25l1735t2358r1991b2413],
19	CA	NNP	LOCATION	CA	appos	14	SENT_723	[p25l2006t2358r2093b2413],
20	,	,	O	,	_	0	SENT_723	[p25l2006t2358r2093b2413],
21	12-16	CD	DATE	12-16	num	22	SENT_723	[p25l135t2437r291b2484],
22	November	NNP	DATE	November	appos	14	SENT_723	[p25l309t2434r587b2484],
23	201	CD	NUMBER	201	number	24	SENT_723	[p25l601t2437r686b2484],
24	1	CD	NUMBER	1	dep	22	SENT_723	[p25l705t2434r863b2484],
25	.	.	O	.	_	0	SENT_723	[p25l705t2434r863b2484],

1	MoI	NN	O	mous	_	0	SENT_724	[p25l705t2434r863b2484],
2	.	.	O	.	_	0	SENT_724	[p25l705t2434r863b2484],

1	Cancer	NN	O	cancer	_	0	SENT_725	[p25l879t2435r1063b2484],
2	.	.	O	.	_	0	SENT_725	[p25l879t2435r1063b2484],

1	Ther	NNP	O	Ther	_	0	SENT_726	[p25l1081t2434r1203b2484],
2	.	.	O	.	_	0	SENT_726	[p25l1081t2434r1203b2484],

1	10	CD	NUMBER	10	num	2	SENT_727	[p25l1221t2437r1286b2484],
2	(	CD	NUMBER	(	_	0	SENT_727	[p25l1302t2434r1477b2496],
3	suppl	NN	O	suppl	dep	2	SENT_727	[p25l1302t2434r1477b2496],
4	.	.	O	.	_	0	SENT_727	[p25l1302t2434r1477b2496],

1	1	CD	NUMBER	1	num	2	SENT_728	[p25l1497t2438r1511b2483],
2	1	CD	NUMBER	1	_	0	SENT_728	[p25l1530t2434r1724b2491],
3	;	:	O	;	_	0	SENT_728	[p25l1530t2434r1724b2491],
4	abstr	NN	O	abstr	dep	2	SENT_728	[p25l1530t2434r1724b2491],
5	.	.	O	.	_	0	SENT_728	[p25l1530t2434r1724b2491],

1	nr	NN	O	nr	nn	2	SENT_729	[p25l1741t2449r1794b2483],
2	A227	NN	O	a227	_	0	SENT_729	[p25l1807t2435r1959b2491],
3	)	CD	NUMBER	)	num	4	SENT_729	[p25l1807t2435r1959b2491],
4	(	NN	O	(	dep	2	SENT_729	[p25l1977t2435r2079b2491],
5	201	CD	NUMBER	201	number	6	SENT_729	[p25l1977t2435r2079b2491],
6	1	CD	NUMBER	1	num	7	SENT_729	[p25l2097t2435r2153b2491],
7	)	NN	O	)	dep	4	SENT_729	[p25l2097t2435r2153b2491],
8	.	.	O	.	_	0	SENT_729	[p25l2097t2435r2153b2491],

1	Patnaik	NNP	PERSON	Patnaik	_	0	SENT_730	[p25l131t2512r334b2569],
2	,	,	O	,	_	0	SENT_730	[p25l131t2512r334b2569],
3	A.	NNP	O	A.	nn	4	SENT_730	[p25l348t2514r397b2562],
4	et	NNP	O	et	appos	1	SENT_730	[p25l411t2519r460b2562],
5	al.	FW	O	al.	dep	4	SENT_730	[p25l469t2512r526b2562],
6	.	.	O	.	_	0	SENT_730	[p25l469t2512r526b2562],

1	Pharmacokinetics	NNS	O	pharmacokinetic	nsubj	12	SENT_731	[p25l543t2512r1008b2562],
2	and	CC	O	and	_	0	SENT_731	[p25l1022t2512r1119b2562],
3	safety	NN	O	safety	conj_and	1	SENT_731	[p25l1136t2511r1291b2575],
4	of	IN	O	of	_	0	SENT_731	[p25l1304t2511r1358b2562],
5	an	DT	O	a	det	8	SENT_731	[p25l1367t2527r1428b2562],
6	oral	JJ	O	oral	amod	8	SENT_731	[p25l1445t2512r1540b2562],
7	ALK	NN	O	alk	nn	8	SENT_731	[p25l1556t2514r1659b2561],
8	inhibitor	NN	O	inhibitor	prep_of	1	SENT_731	[p25l1673t2512r1905b2569],
9	,	,	O	,	_	0	SENT_731	[p25l1673t2512r1905b2569],
10	ASP3026	NN	O	asp3026	appos	8	SENT_731	[p25l130t2591r375b2647],
11	,	,	O	,	_	0	SENT_731	[p25l130t2591r375b2647],
12	observed	VBN	O	observe	_	0	SENT_731	[p25l390t2590r633b2640],
13	in	IN	O	in	_	0	SENT_731	[p25l651t2592r694b2639],
14	a	DT	O	a	det	15	SENT_731	[p25l710t2605r736b2640],
15	phase	NN	O	phase	prep_in	12	SENT_731	[p25l754t2590r908b2652],
16	I	PRP	O	I	dep	15	SENT_731	[p25l925t2592r931b2639],
17	dose	NN	O	dose	nn	19	SENT_731	[p25l948t2590r1073b2640],
18	escalation	NN	O	escalation	nn	19	SENT_731	[p25l1087t2590r1350b2640],
19	trial	NN	O	trial	dep	16	SENT_731	[p25l1365t2590r1522b2640],
20	.	.	O	.	_	0	SENT_731	[p25l1365t2590r1522b2640],

1	J.	NNP	PERSON	J.	nn	2	SENT_732	[p25l1365t2590r1522b2640],
2	Clin	NNP	PERSON	Clin	_	0	SENT_732	[p25l1538t2590r1643b2640],
3	.	.	O	.	_	0	SENT_732	[p25l1538t2590r1643b2640],

1	Oncol	NN	O	oncol	_	0	SENT_733	[p25l1659t2590r1819b2640],
2	.	.	O	.	_	0	SENT_733	[p25l1659t2590r1819b2640],

1	31	CD	NUMBER	31	num	2	SENT_734	[p25l1833t2593r1892b2640],
2	(	CD	NUMBER	(	_	0	SENT_734	[p25l132t2668r319b2730],
3	suppl.	VBN	O	suppl.	partmod	2	SENT_734	[p25l132t2668r319b2730],
4	;	:	O	;	_	0	SENT_734	[p25l132t2668r319b2730],
5	abstr	NN	O	abstr	dep	2	SENT_734	[p25l333t2668r472b2718],
6	.	.	O	.	_	0	SENT_734	[p25l333t2668r472b2718],

1	2602	CD	DATE	2602	_	0	SENT_735	[p25l487t2669r630b2725],
2	)	CD	NUMBER	)	number	3	SENT_735	[p25l487t2669r630b2725],
3	(	CD	NUMBER	(	dep	1	SENT_735	[p25l648t2669r823b2725],
4	2013	CD	DATE	2013	num	5	SENT_735	[p25l648t2669r823b2725],
5	)	NN	O	)	dep	3	SENT_735	[p25l648t2669r823b2725],
6	.	.	O	.	_	0	SENT_735	[p25l648t2669r823b2725],

1	Wilcoxen	NNP	PERSON	Wilcoxen	nn	3	SENT_736	[p25l128t2746r379b2803],
2	,	,	O	,	_	0	SENT_736	[p25l128t2746r379b2803],
3	K.M.	NNP	O	K.M.	_	0	SENT_736	[p25l396t2748r503b2796],
4	et	FW	O	et	nn	5	SENT_736	[p25l518t2753r566b2796],
5	al.	FW	O	al.	dep	3	SENT_736	[p25l575t2746r633b2796],
6	.	.	O	.	_	0	SENT_736	[p25l575t2746r633b2796],

1	Proceedings	NNP	O	Proceedings	_	0	SENT_737	[p25l649t2746r971b2809],
2	of	IN	O	of	_	0	SENT_737	[p25l986t2745r1040b2796],
3	AACR	NNP	O	AACR	prep_of	1	SENT_737	[p25l1049t2747r1208b2803],
4	,	,	O	,	_	0	SENT_737	[p25l1049t2747r1208b2803],
5	15	CD	DATE	15	num	6	SENT_737	[p25l1227t2750r1282b2796],
6	April	NNP	DATE	April	appos	1	SENT_737	[p25l1298t2746r1418b2808],
7	201	CD	NUMBER	201	num	6	SENT_737	[p25l1435t2749r1520b2796],
8	2	CD	NUMBER	2	dep	6	SENT_737	[p25l1534t2749r1575b2796],
9	.	.	O	.	_	0	SENT_737	[p25l1534t2749r1575b2796],

1	Cancer	NN	O	cancer	_	0	SENT_738	[p25l1591t2747r1768b2796],
2	Res	NNP	O	Res	dep	1	SENT_738	[p25l1777t2748r1872b2796],
3	.	.	O	.	_	0	SENT_738	[p25l1777t2748r1872b2796],

1	71	CD	NUMBER	71	number	2	SENT_739	[p25l1887t2750r1945b2795],
2	(	CD	NUMBER	(	num	3	SENT_739	[p25l132t2825r191b2881],
3	8	CD	NUMBER	8	_	0	SENT_739	[p25l132t2825r191b2881],
4	;	:	O	;	_	0	SENT_739	[p25l132t2825r191b2881],
5	suppl	NN	O	suppl	dep	3	SENT_739	[p25l205t2824r361b2886],
6	.	.	O	.	_	0	SENT_739	[p25l205t2824r361b2886],

1	1	CD	NUMBER	1	_	0	SENT_740	[p25l381t2824r572b2881],
2	;	:	O	;	_	0	SENT_740	[p25l381t2824r572b2881],
3	abstr	NN	O	abstr	dep	1	SENT_740	[p25l381t2824r572b2881],
4	.	.	O	.	_	0	SENT_740	[p25l381t2824r572b2881],

1	1795	CD	DATE	1795	_	0	SENT_741	[p25l591t2825r730b2881],
2	)	CD	NUMBER	)	number	3	SENT_741	[p25l591t2825r730b2881],
3	(	CD	NUMBER	(	dep	1	SENT_741	[p25l748t2825r923b2881],
4	2012	CD	DATE	2012	num	5	SENT_741	[p25l748t2825r923b2881],
5	)	NN	O	)	dep	3	SENT_741	[p25l748t2825r923b2881],
6	.	.	O	.	_	0	SENT_741	[p25l748t2825r923b2881],

1	Bonvini	NNP	PERSON	Bonvini	nn	5	SENT_742	[p25l131t2903r348b2958],
2	,	,	O	,	_	0	SENT_742	[p25l131t2903r348b2958],
3	P.	NNP	O	P.	appos	5	SENT_742	[p25l367t2903r414b2958],
4	,	,	O	,	_	0	SENT_742	[p25l367t2903r414b2958],
5	Gasta	NNP	O	Gasta	_	0	SENT_742	[p25l431t2901r733b2958],
6	|	CD	NUMBER	|	num	5	SENT_742	[p25l431t2901r733b2958],
7	di	FW	O	di	dep	5	SENT_742	[p25l431t2901r733b2958],
8	,	,	O	,	_	0	SENT_742	[p25l431t2901r733b2958],
9	T.	FW	O	t.	appos	7	SENT_742	[p25l431t2901r733b2958],
10	,	,	O	,	_	0	SENT_742	[p25l431t2901r733b2958],
11	Falini	NNP	LOCATION	Falini	appos	7	SENT_742	[p25l753t2901r906b2958],
12	,	,	O	,	_	0	SENT_742	[p25l753t2901r906b2958],
13	B.	NNP	ORGANIZATION	B.	conj_and	11	SENT_742	[p25l926t2903r967b2951],
14	&	CC	ORGANIZATION	&	_	0	SENT_742	[p25l984t2903r1021b2951],
15	Rosolen	NNP	ORGANIZATION	Rosolen	conj_and	11	SENT_742	[p25l1039t2901r1267b2958],
16	,	,	O	,	_	0	SENT_742	[p25l1039t2901r1267b2958],
17	A.	NN	O	a.	appos	7	SENT_742	[p25l1284t2903r1334b2951],
18	Nuc	NNP	O	Nuc	dep	5	SENT_742	[p25l1354t2901r1808b2963],
19	|	CD	NUMBER	|	num	18	SENT_742	[p25l1354t2901r1808b2963],
20	eophosmin	JJ	O	eophosmin	amod	21	SENT_742	[p25l1354t2901r1808b2963],
21	—	NN	O	—	dep	18	SENT_742	[p25l1354t2901r1808b2963],
22	anaplastic	JJ	O	anaplastic	amod	23	SENT_742	[p25l130t2979r407b3041],
23	lymphoma	NN	O	lymphoma	dep	5	SENT_742	[p25l426t2979r717b3043],
24	kinase	NN	O	kinase	nn	26	SENT_742	[p25l738t2979r908b3029],
25	(	CD	NUMBER	(	num	26	SENT_742	[p25l926t2980r1234b3036],
26	NPM	NNP	O	NPM	dep	23	SENT_742	[p25l926t2980r1234b3036],
27	.	.	O	.	_	0	SENT_742	[p25l926t2980r1234b3036],

1	—	NN	O	—	_	0	SENT_743	[p25l926t2980r1234b3036],
2	.	.	O	.	_	0	SENT_743	[p25l926t2980r1234b3036],

1	ALK	NNP	O	ALK	_	0	SENT_744	[p25l926t2980r1234b3036],
2	)	CD	NUMBER	)	num	1	SENT_744	[p25l926t2980r1234b3036],
3	,	,	O	,	_	0	SENT_744	[p25l926t2980r1234b3036],
4	a	DT	O	a	det	12	SENT_744	[p25l1250t2994r1276b3029],
5	novel	JJ	O	novel	amod	12	SENT_744	[p25l1297t2979r1441b3029],
6	Hsp90	NN	O	hsp90	nn	12	SENT_744	[p25l1462t2979r1807b3041],
7	—	NN	O	—	nn	12	SENT_744	[p25l1462t2979r1807b3041],
8	c	NN	O	c	nn	12	SENT_744	[p25l1462t2979r1807b3041],
9	|	CD	NUMBER	|	num	12	SENT_744	[p25l1462t2979r1807b3041],
10	ient	JJ	O	ient	amod	12	SENT_744	[p25l1462t2979r1807b3041],
11	tyrosine	NN	O	tyrosine	nn	12	SENT_744	[p25l129t3059r350b3121],
12	kinase	NN	O	kinase	appos	1	SENT_744	[p25l369t3057r553b3107],
13	:	:	O	:	_	0	SENT_744	[p25l369t3057r553b3107],
14	down	IN	O	down	advmod	16	SENT_744	[p25l570t3057r1030b3120],
15	—	CD	NUMBER	—	pobj	14	SENT_744	[p25l570t3057r1030b3120],
16	regulation	NN	O	regulation	dep	1	SENT_744	[p25l570t3057r1030b3120],
17	of	IN	O	of	_	0	SENT_744	[p25l1049t3056r1105b3107],
18	NPM	NNP	O	NPM	prep_of	16	SENT_744	[p25l1120t3059r1374b3106],
19	.	.	O	.	_	0	SENT_744	[p25l1120t3059r1374b3106],

1	—	NN	O	—	_	0	SENT_745	[p25l1120t3059r1374b3106],
2	.	.	O	.	_	0	SENT_745	[p25l1120t3059r1374b3106],

1	ALK	NN	O	alk	_	0	SENT_746	[p25l1120t3059r1374b3106],
2	expression	NN	O	expression	nn	5	SENT_746	[p25l1389t3059r1680b3119],
3	and	CC	O	and	_	0	SENT_746	[p25l1699t3057r1798b3107],
4	tyrosine	NN	O	tyrosine	conj_and	2	SENT_746	[p25l1816t3059r2037b3121],
5	phosphorylation	NN	O	phosphorylation	dep	1	SENT_746	[p25l132t3135r586b3199],
6	in	IN	O	in	_	0	SENT_746	[p25l607t3137r651b3184],
7	ALK	NNP	O	ALK	prep_in	5	SENT_746	[p25l669t3136r849b3192],
8	(	CD	NUMBER	(	num	7	SENT_746	[p25l669t3136r849b3192],
9	+	CC	O	+	_	0	SENT_746	[p25l669t3136r849b3192],
10	)	CD	NUMBER	)	num	12	SENT_746	[p25l669t3136r849b3192],
11	CD30	NN	O	cd30	nn	12	SENT_746	[p25l868t3136r1089b3192],
12	(	NN	O	(	conj_+	5	SENT_746	[p25l868t3136r1089b3192],
13	+	CC	O	+	_	0	SENT_746	[p25l868t3136r1089b3192],
14	)	NN	O	)	nn	16	SENT_746	[p25l868t3136r1089b3192],
15	lymphoma	NN	O	lymphoma	nn	16	SENT_746	[p25l1110t3135r1401b3199],
16	cells	NNS	O	cell	conj_+	12	SENT_746	[p25l1420t3135r1536b3185],
17	by	IN	O	by	_	0	SENT_746	[p25l1555t3135r1618b3199],
18	the	DT	O	the	det	20	SENT_746	[p25l1632t3135r1721b3185],
19	Hsp90	NN	O	hsp90	nn	20	SENT_746	[p25l1741t3137r1909b3197],
20	antagonist	NN	O	antagonist	prep_by	16	SENT_746	[p25l130t3215r424b3276],
21	17	CD	NUMBER	17	number	22	SENT_746	[p25l445t3213r849b3277],
22	—	CD	NUMBER	—	dep	1	SENT_746	[p25l445t3213r849b3277],
23	a	DT	O	a	det	24	SENT_746	[p25l445t3213r849b3277],
24	|	NN	O	|	dep	22	SENT_746	[p25l445t3213r849b3277],
25	|	NN	O	|	nn	26	SENT_746	[p25l445t3213r849b3277],
26	yIamino	NN	O	yiamino	dep	1	SENT_746	[p25l445t3213r849b3277],
27	,1	CD	NUMBER	,1	number	28	SENT_746	[p25l445t3213r849b3277],
28	7	CD	NUMBER	7	num	32	SENT_746	[p25l866t3213r1637b3277],
29	—	NN	O	—	nn	32	SENT_746	[p25l866t3213r1637b3277],
30	demethoxyge	NN	O	demethoxyge	nn	32	SENT_746	[p25l866t3213r1637b3277],
31	|	NN	O	|	nn	32	SENT_746	[p25l866t3213r1637b3277],
32	danamycin	NN	O	danamycin	dep	26	SENT_746	[p25l866t3213r1637b3277],
33	.	.	O	.	_	0	SENT_746	[p25l866t3213r1637b3277],

1	Cancer	NN	O	cancer	_	0	SENT_747	[p25l1655t3215r1839b3263],
2	Res	NNP	O	Res	dep	1	SENT_747	[p25l1850t3215r1949b3263],
3	.	.	O	.	_	0	SENT_747	[p25l1850t3215r1949b3263],

1	62	CD	NUMBER	62	_	0	SENT_748	[p25l1966t3216r2049b3270],
2	,	,	O	,	_	0	SENT_748	[p25l1966t3216r2049b3270],
3	1559-1566	CD	DATE	1559-1566	number	4	SENT_748	[p25l135t3293r431b3339],
4	(	CD	NUMBER	(	appos	1	SENT_748	[p25l450t3291r632b3346],
5	2002	CD	DATE	2002	num	6	SENT_748	[p25l450t3291r632b3346],
6	)	NN	O	)	dep	4	SENT_748	[p25l450t3291r632b3346],
7	.	.	O	.	_	0	SENT_748	[p25l450t3291r632b3346],

1	Katayama	NNP	PERSON	Katayama	_	0	SENT_749	[p25l131t3370r400b3432],
2	,	,	O	,	_	0	SENT_749	[p25l131t3370r400b3432],
3	R.	NNP	O	R.	nn	4	SENT_749	[p25l417t3370r458b3418],
4	etal	NN	O	etal	appos	1	SENT_749	[p25l473t3368r587b3418],
5	.	.	O	.	_	0	SENT_749	[p25l473t3368r587b3418],

1	Therapeutic	JJ	O	therapeutic	amod	2	SENT_750	[p25l597t3368r914b3430],
2	strategies	NNS	O	strategy	nsubj	4	SENT_750	[p25l928t3370r1181b3431],
3	to	TO	O	to	aux	4	SENT_750	[p25l1195t3376r1248b3418],
4	overcome	VB	O	overcome	_	0	SENT_750	[p25l1263t3383r1524b3418],
5	crizotinib	JJ	O	crizotinib	amod	6	SENT_750	[p25l1539t3368r1783b3418],
6	resistance	NN	O	resistance	dobj	4	SENT_750	[p25l1800t3370r2059b3418],
7	in	IN	O	in	_	0	SENT_750	[p25l2075t3370r2118b3417],
8	non	JJ	O	non	amod	13	SENT_750	[p25l132t3446r389b3496],
9	—	JJ	O	—	amod	13	SENT_750	[p25l132t3446r389b3496],
10	small	JJ	O	small	amod	13	SENT_750	[p25l132t3446r389b3496],
11	cell	NN	O	cell	nn	13	SENT_750	[p25l406t3446r489b3496],
12	lung	NN	O	lung	nn	13	SENT_750	[p25l509t3446r622b3509],
13	cancers	NNS	O	cancer	prep_in	4	SENT_750	[p25l638t3461r836b3496],
14	harboring	VBG	O	harbor	partmod	13	SENT_750	[p25l852t3446r1110b3509],
15	the	DT	O	the	det	18	SENT_750	[p25l1125t3446r1211b3496],
16	fusion	NN	O	fusion	nn	18	SENT_750	[p25l1224t3445r1384b3496],
17	oncogene	NN	O	oncogene	nn	18	SENT_750	[p25l1401t3461r1666b3509],
18	EML4	NN	O	eml4	dobj	14	SENT_750	[p25l1683t3448r1960b3496],
19	.	.	O	.	_	0	SENT_750	[p25l1683t3448r1960b3496],

1	—	NN	O	—	_	0	SENT_751	[p25l1683t3448r1960b3496],
2	.	.	O	.	_	0	SENT_751	[p25l1683t3448r1960b3496],

1	ALK	NNP	O	ALK	_	0	SENT_752	[p25l1683t3448r1960b3496],
2	.	.	O	.	_	0	SENT_752	[p25l1683t3448r1960b3496],

1	Proc	NNP	O	Proc	_	0	SENT_753	[p25l1974t3448r2093b3496],
2	.	.	O	.	_	0	SENT_753	[p25l1974t3448r2093b3496],

1	Natl.	NNP	O	Natl.	nn	2	SENT_754	[p25l130t3523r244b3572],
2	Acad	NNP	O	Acad	_	0	SENT_754	[p25l256t3523r395b3572],
3	.	.	O	.	_	0	SENT_754	[p25l256t3523r395b3572],

1	Sci	NNP	O	Sci	_	0	SENT_755	[p25l408t3525r489b3572],
2	.	.	O	.	_	0	SENT_755	[p25l408t3525r489b3572],

1	USA	NNP	LOCATION	USA	_	0	SENT_756	[p25l506t3525r604b3572],
2	108	CD	NUMBER	108	num	1	SENT_756	[p25l623t3526r735b3580],
3	,	,	O	,	_	0	SENT_756	[p25l623t3526r735b3580],
4	7535-7540	CD	DURATION	7535-7540	num	1	SENT_756	[p25l751t3526r1040b3572],
5	(	NN	O	(	dep	1	SENT_756	[p25l1056t3524r1157b3579],
6	201	CD	NUMBER	201	number	7	SENT_756	[p25l1056t3524r1157b3579],
7	1	CD	NUMBER	1	num	8	SENT_756	[p25l1175t3524r1231b3579],
8	)	NN	O	)	dep	5	SENT_756	[p25l1175t3524r1231b3579],
9	.	.	O	.	_	0	SENT_756	[p25l1175t3524r1231b3579],

1	Normant	NNP	PERSON	Normant	_	0	SENT_757	[p26l131t19r377b74],
2	,	,	O	,	_	0	SENT_757	[p26l131t19r377b74],
3	E.	NNP	O	E.	nn	4	SENT_757	[p26l393t19r431b67],
4	etaI	NNP	O	etaI	appos	1	SENT_757	[p26l446t17r667b67],
5	.	.	O	.	_	0	SENT_757	[p26l446t17r667b67],

1	The	DT	O	the	det	2	SENT_758	[p26l446t17r667b67],
2	Hsp9O	NN	O	hsp9o	_	0	SENT_758	[p26l684t19r847b79],
3	inhibitor	NN	O	inhibitor	nn	6	SENT_758	[p26l863t17r1087b67],
4	|	NN	O	|	nn	6	SENT_758	[p26l1103t19r1280b67],
5	P	NN	O	p	nn	6	SENT_758	[p26l1103t19r1280b67],
6	|	NN	O	|	dep	2	SENT_758	[p26l1103t19r1280b67],
7	.	.	O	.	_	0	SENT_758	[p26l1103t19r1280b67],

1	—	NN	O	—	_	0	SENT_759	[p26l1103t19r1280b67],
2	.	.	O	.	_	0	SENT_759	[p26l1103t19r1280b67],

1	504	CD	NUMBER	504	nsubj	3	SENT_760	[p26l1103t19r1280b67],
2	rapidly	RB	O	rapidly	advmod	3	SENT_760	[p26l1295t17r1474b81],
3	lowers	VBZ	O	lower	_	0	SENT_760	[p26l1489t17r1657b67],
4	EML4	NN	O	eml4	dobj	3	SENT_760	[p26l1674t19r1939b66],
5	.	.	O	.	_	0	SENT_760	[p26l1674t19r1939b66],

1	—	NN	O	—	_	0	SENT_761	[p26l1674t19r1939b66],
2	.	.	O	.	_	0	SENT_761	[p26l1674t19r1939b66],

1	ALK	NN	O	alk	nn	2	SENT_762	[p26l1674t19r1939b66],
2	levels	NNS	O	level	_	0	SENT_762	[p26l1953t17r2097b67],
3	and	CC	O	and	_	0	SENT_762	[p26l130t95r227b145],
4	induces	VBZ	O	induce	conj_and	2	SENT_762	[p26l245t95r446b145],
5	tumor	NN	O	tumor	nn	6	SENT_762	[p26l459t103r624b145],
6	regression	NN	O	regression	dobj	4	SENT_762	[p26l639t97r907b158],
7	in	IN	O	in	_	0	SENT_762	[p26l925t97r967b144],
8	ALK	NNP	O	ALK	prep_in	6	SENT_762	[p26l984t95r1271b145],
9	—	CD	NUMBER	—	num	8	SENT_762	[p26l984t95r1271b145],
10	driven	VBN	O	drive	partmod	2	SENT_762	[p26l984t95r1271b145],
11	NSCLC	NNP	O	NSCLC	nn	12	SENT_762	[p26l1290t97r1459b145],
12	models	NNS	O	model	dobj	10	SENT_762	[p26l1476t95r1679b145],
13	.	.	O	.	_	0	SENT_762	[p26l1476t95r1679b145],

1	Oncogene	NN	ORGANIZATION	oncogene	_	0	SENT_763	[p26l1694t97r1954b158],
2	30	CD	NUMBER	30	num	1	SENT_763	[p26l1967t98r2047b152],
3	,	,	O	,	_	0	SENT_763	[p26l1967t98r2047b152],
4	2581-2586	CD	DATE	2581-2586	num	5	SENT_763	[p26l130t175r421b221],
5	(	NN	O	(	appos	1	SENT_763	[p26l437t173r538b228],
6	201	CD	NUMBER	201	number	7	SENT_763	[p26l437t173r538b228],
7	1	CD	NUMBER	1	num	8	SENT_763	[p26l556t173r611b228],
8	)	NN	O	)	dep	5	SENT_763	[p26l556t173r611b228],
9	.	.	O	.	_	0	SENT_763	[p26l556t173r611b228],

1	Sang	NNP	O	Sang	_	0	SENT_764	[p26l129t252r270b313],
2	,	,	O	,	_	0	SENT_764	[p26l129t252r270b313],
3	J.	NNP	O	J.	nn	4	SENT_764	[p26l283t252r317b300],
4	etal	NNP	O	etal	appos	1	SENT_764	[p26l331t250r446b300],
5	.	.	O	.	_	0	SENT_764	[p26l331t250r446b300],

1	Targeted	VBN	O	target	_	0	SENT_765	[p26l456t250r687b313],
2	inhibition	NN	O	inhibition	dobj	1	SENT_765	[p26l706t250r956b300],
3	of	IN	O	of	_	0	SENT_765	[p26l973t249r1027b300],
4	the	DT	O	the	det	7	SENT_765	[p26l1035t250r1122b300],
5	molecular	JJ	O	molecular	amod	7	SENT_765	[p26l1138t250r1399b300],
6	chaperone	NN	O	chaperone	nn	7	SENT_765	[p26l1412t250r1694b312],
7	Hsp9O	NN	O	hsp9o	prep_of	2	SENT_765	[p26l1711t252r1874b313],
8	overcomes	VBZ	O	overcome	dep	1	SENT_765	[p26l130t343r417b378],
9	ALK	NNP	O	ALK	nn	11	SENT_765	[p26l431t330r534b377],
10	inhibitor	NN	O	inhibitor	nn	11	SENT_765	[p26l548t328r772b378],
11	resistance	NN	O	resistance	nsubj	1	SENT_765	[p26l787t330r1046b378],
12	in	IN	O	in	_	0	SENT_765	[p26l1062t330r1105b377],
13	non	JJ	O	non	amod	18	SENT_765	[p26l1124t328r1380b378],
14	—	JJ	O	—	amod	18	SENT_765	[p26l1124t328r1380b378],
15	small	JJ	O	small	amod	18	SENT_765	[p26l1124t328r1380b378],
16	cell	NN	O	cell	nn	18	SENT_765	[p26l1397t328r1480b378],
17	lung	NN	O	lung	nn	18	SENT_765	[p26l1500t328r1613b391],
18	cancer	NN	O	cancer	prep_in	11	SENT_765	[p26l1629t343r1811b378],
19	.	.	O	.	_	0	SENT_765	[p26l1629t343r1811b378],

1	Cancer	NNP	O	Cancer	nn	2	SENT_766	[p26l1826t330r2004b378],
2	Discov	NNP	O	Discov	_	0	SENT_766	[p26l130t407r308b454],
3	.	.	O	.	_	0	SENT_766	[p26l130t407r308b454],

1	3	CD	NUMBER	3	_	0	SENT_767	[p26l322t408r367b462],
2	,	,	O	,	_	0	SENT_767	[p26l322t408r367b462],
3	430-443	CD	NUMBER	430-443	num	4	SENT_767	[p26l380t408r604b454],
4	(	NN	O	(	appos	1	SENT_767	[p26l622t406r723b461],
5	201	CD	NUMBER	201	number	6	SENT_767	[p26l622t406r723b461],
6	3	CD	NUMBER	3	num	7	SENT_767	[p26l737t406r797b461],
7	)	NN	O	)	dep	4	SENT_767	[p26l737t406r797b461],
8	.	.	O	.	_	0	SENT_767	[p26l737t406r797b461],

1	Sequist	NNP	O	Sequist	_	0	SENT_768	[p26l129t485r334b545],
2	,	,	O	,	_	0	SENT_768	[p26l129t485r334b545],
3	L.V.	NNP	PERSON	L.V.	nn	4	SENT_768	[p26l351t485r432b533],
4	etal	NNP	O	etal	appos	1	SENT_768	[p26l447t483r562b533],
5	.	.	O	.	_	0	SENT_768	[p26l447t483r562b533],

1	Activity	NN	O	activity	_	0	SENT_769	[p26l576t485r775b547],
2	of	IN	O	of	_	0	SENT_769	[p26l788t482r842b533],
3	|	CD	NUMBER	|	num	5	SENT_769	[p26l855t485r1044b540],
4	P	NN	O	p	nn	5	SENT_769	[p26l855t485r1044b540],
5	|	NN	O	|	prep_of	1	SENT_769	[p26l855t485r1044b540],
6	.	.	O	.	_	0	SENT_769	[p26l855t485r1044b540],

1	—	NN	O	—	_	0	SENT_770	[p26l855t485r1044b540],
2	.	.	O	.	_	0	SENT_770	[p26l855t485r1044b540],

1	504	CD	NUMBER	504	nsubj	16	SENT_771	[p26l855t485r1044b540],
2	,	,	O	,	_	0	SENT_771	[p26l855t485r1044b540],
3	a	DT	O	a	det	8	SENT_771	[p26l1058t498r1083b533],
4	novel	JJ	O	novel	amod	8	SENT_771	[p26l1101t483r1240b533],
5	heat	NN	O	heat	nn	8	SENT_771	[p26l1259t483r1548b533],
6	—	CD	NUMBER	—	num	8	SENT_771	[p26l1259t483r1548b533],
7	shock	NN	O	shock	nn	8	SENT_771	[p26l1259t483r1548b533],
8	protein	NN	O	protein	appos	1	SENT_771	[p26l1562t485r1749b545],
9	90	CD	NUMBER	90	num	10	SENT_771	[p26l1765t486r1827b533],
10	inhibitor	NN	O	inhibitor	dep	8	SENT_771	[p26l1843t483r2076b540],
11	,	,	O	,	_	0	SENT_771	[p26l1843t483r2076b540],
12	in	IN	O	in	_	0	SENT_771	[p26l132t563r174b610],
13	patients	NNS	O	patient	prep_in	1	SENT_771	[p26l193t563r403b623],
14	with	IN	O	with	prep	13	SENT_771	[p26l417t561r530b611],
15	molecularly	RB	O	molecularly	pcomp	14	SENT_771	[p26l549t561r856b625],
16	deﬁned	VBN	O	deﬁned	_	0	SENT_771	[p26l869t560r1068b611],
17	non	JJ	O	non	amod	20	SENT_771	[p26l1086t561r1453b611],
18	—	JJ	O	—	amod	20	SENT_771	[p26l1086t561r1453b611],
19	small	JJ	O	small	amod	20	SENT_771	[p26l1086t561r1453b611],
20	—	NN	O	—	tmod	16	SENT_771	[p26l1086t561r1453b611],
21	cell	NN	O	cell	nn	23	SENT_771	[p26l1086t561r1453b611],
22	lung	NN	O	lung	nn	23	SENT_771	[p26l1473t561r1586b624],
23	cancer	NN	O	cancer	dep	20	SENT_771	[p26l1602t576r1784b611],
24	.	.	O	.	_	0	SENT_771	[p26l1602t576r1784b611],

1	J.	NNP	PERSON	J.	nn	2	SENT_772	[p26l1794t563r1829b611],
2	Clin	NNP	PERSON	Clin	_	0	SENT_772	[p26l1845t561r1949b611],
3	.	.	O	.	_	0	SENT_772	[p26l1845t561r1949b611],

1	Oncol	NN	O	oncol	_	0	SENT_773	[p26l1966t561r2125b611],
2	.	.	O	.	_	0	SENT_773	[p26l1966t561r2125b611],

1	28	CD	NUMBER	28	_	0	SENT_774	[p26l130t641r210b694],
2	,	,	O	,	_	0	SENT_774	[p26l130t641r210b694],
3	4953-4960	CD	DURATION	4953-4960	num	4	SENT_774	[p26l223t641r515b687],
4	(	NN	O	(	appos	1	SENT_774	[p26l531t639r632b695],
5	201	CD	NUMBER	201	num	7	SENT_774	[p26l531t639r632b695],
6	o	NN	O	o	nn	7	SENT_774	[p26l646t639r706b694],
7	)	NN	O	)	dep	4	SENT_774	[p26l646t639r706b694],
8	.	.	O	.	_	0	SENT_774	[p26l646t639r706b694],

1	Socinski	NNP	PERSON	Socinski	_	0	SENT_775	[p26l129t716r355b773],
2	,	,	O	,	_	0	SENT_775	[p26l129t716r355b773],
3	M.A.	NNP	O	M.A.	nn	4	SENT_775	[p26l370t718r482b766],
4	etal	NNP	O	etal	appos	1	SENT_775	[p26l496t716r611b766],
5	.	.	O	.	_	0	SENT_775	[p26l496t716r611b766],

1	A	DT	O	a	det	5	SENT_776	[p26l625t718r661b765],
2	multicenter	JJ	O	multicenter	amod	5	SENT_776	[p26l678t716r982b766],
3	phase	NN	O	phase	nn	5	SENT_776	[p26l996t716r1150b778],
4	II	CD	NUMBER	ii	num	5	SENT_776	[p26l1168t718r1189b765],
5	study	NN	O	study	nsubj	13	SENT_776	[p26l1206t716r1352b780],
6	of	IN	O	of	_	0	SENT_776	[p26l1364t715r1419b766],
7	ganetespib	NN	O	ganetespib	nn	8	SENT_776	[p26l1429t716r1724b779],
8	monotherapy	NN	O	monotherapy	prep_of	5	SENT_776	[p26l1740t716r2101b780],
9	in	IN	O	in	_	0	SENT_776	[p26l132t796r174b843],
10	patients	NNS	O	patient	prep_in	8	SENT_776	[p26l193t796r403b856],
11	with	IN	O	with	prep	10	SENT_776	[p26l417t794r530b844],
12	genotypically	RB	O	genotypically	pcomp	11	SENT_776	[p26l547t794r905b858],
13	deﬁned	VBN	O	deﬁned	_	0	SENT_776	[p26l918t793r1117b844],
14	advanced	JJ	O	advanced	amod	16	SENT_776	[p26l1133t794r1387b844],
15	non	JJ	O	non	amod	16	SENT_776	[p26l1406t794r1663b844],
16	—	NN	O	—	tmod	13	SENT_776	[p26l1406t794r1663b844],
17	small	JJ	O	small	amod	20	SENT_776	[p26l1406t794r1663b844],
18	cell	NN	O	cell	nn	20	SENT_776	[p26l1680t794r1763b844],
19	lung	NN	O	lung	nn	20	SENT_776	[p26l1782t794r1895b857],
20	cancer	NN	O	cancer	dep	16	SENT_776	[p26l1912t809r2094b844],
21	.	.	O	.	_	0	SENT_776	[p26l1912t809r2094b844],

1	C/in	NN	O	c/in	_	0	SENT_777	[p26l131t871r236b920],
2	.	.	O	.	_	0	SENT_777	[p26l131t871r236b920],

1	CancerRes	NNS	O	cancerre	_	0	SENT_778	[p26l251t873r533b920],
2	.	.	O	.	_	0	SENT_778	[p26l251t873r533b920],

1	19	CD	NUMBER	19	_	0	SENT_779	[p26l551t875r628b928],
2	,	,	O	,	_	0	SENT_779	[p26l551t875r628b928],
3	3068-3077	CD	DURATION	3068-3077	number	4	SENT_779	[p26l643t874r932b920],
4	(	CD	NUMBER	(	appos	1	SENT_779	[p26l949t872r1123b928],
5	2013	CD	DATE	2013	num	6	SENT_779	[p26l949t872r1123b928],
6	)	NN	O	)	dep	4	SENT_779	[p26l949t872r1123b928],
7	.	.	O	.	_	0	SENT_779	[p26l949t872r1123b928],

1	Felip	NNP	PERSON	Felip	_	0	SENT_780	[p26l131t949r263b1012],
2	,	,	O	,	_	0	SENT_780	[p26l131t949r263b1012],
3	E.	NNP	O	E.	nn	4	SENT_780	[p26l280t952r318b999],
4	etal	NN	O	etal	appos	1	SENT_780	[p26l332t949r448b999],
5	.	.	O	.	_	0	SENT_780	[p26l332t949r448b999],

1	Phase	NN	O	phase	nn	3	SENT_781	[p26l465t949r615b999],
2	II	CD	NUMBER	ii	num	3	SENT_781	[p26l633t952r654b998],
3	activity	NN	O	activity	nsubj	22	SENT_781	[p26l670t952r862b1013],
4	of	IN	O	of	_	0	SENT_781	[p26l874t949r929b999],
5	the	DT	O	the	det	8	SENT_781	[p26l938t949r1023b999],
6	HSP9O	NN	O	hsp9o	nn	8	SENT_781	[p26l1040t951r1207b999],
7	inhibitor	NN	O	inhibitor	nn	8	SENT_781	[p26l1223t949r1447b999],
8	AUY922	NN	O	auy922	prep_of	3	SENT_781	[p26l1459t952r1667b999],
9	in	IN	O	in	_	0	SENT_781	[p26l1684t952r1727b998],
10	patients	NNS	O	patient	prep_in	8	SENT_781	[p26l1745t952r1956b1012],
11	with	IN	O	with	_	0	SENT_781	[p26l1969t949r2083b999],
12	ALK	NN	O	alk	nn	13	SENT_781	[p26l129t1027r541b1090],
13	—	NN	O	—	prep_with	10	SENT_781	[p26l129t1027r541b1090],
14	rearranged	VBN	O	rearrange	partmod	13	SENT_781	[p26l129t1027r541b1090],
15	(	CD	NUMBER	(	num	16	SENT_781	[p26l559t1028r729b1085],
16	ALK	NN	O	alk	dobj	14	SENT_781	[p26l559t1028r729b1085],
17	+	CC	O	+	_	0	SENT_781	[p26l559t1028r729b1085],
18	)	NN	O	)	dobj	14	SENT_781	[p26l559t1028r729b1085],
19	or	CC	O	or	_	0	SENT_781	[p26l746t1042r799b1077],
20	EGFR	NN	O	egfr	conj_or	18	SENT_781	[p26l814t1027r1193b1077],
21	—	CD	NUMBER	—	num	20	SENT_781	[p26l814t1027r1193b1077],
22	mutated	VBN	O	mutate	_	0	SENT_781	[p26l814t1027r1193b1077],
23	advanced	JJ	O	advanced	amod	25	SENT_781	[p26l1209t1027r1463b1077],
24	non	JJ	O	non	amod	25	SENT_781	[p26l1482t1027r1738b1077],
25	—	NN	O	—	tmod	22	SENT_781	[p26l1482t1027r1738b1077],
26	small	JJ	O	small	amod	29	SENT_781	[p26l1482t1027r1738b1077],
27	cell	NN	O	cell	nn	29	SENT_781	[p26l1755t1027r1839b1077],
28	lung	NN	O	lung	nn	29	SENT_781	[p26l1858t1027r1971b1090],
29	cancer	NN	O	cancer	dep	25	SENT_781	[p26l130t1107r439b1153],
30	.	.	O	.	_	0	SENT_781	[p26l130t1107r439b1153],

1	Ann	NNP	PERSON	Ann	_	0	SENT_782	[p26l130t1107r439b1153],
2	.	.	O	.	_	0	SENT_782	[p26l130t1107r439b1153],

1	Oncol	NN	O	oncol	_	0	SENT_783	[p26l454t1104r614b1153],
2	.	.	O	.	_	0	SENT_783	[p26l454t1104r614b1153],

1	23	CD	NUMBER	23	_	0	SENT_784	[p26l629t1107r708b1161],
2	,	,	O	,	_	0	SENT_784	[p26l629t1107r708b1161],
3	ix1	CD	NUMBER	ix1	num	4	SENT_784	[p26l725t1107r787b1153],
4	52	CD	NUMBER	52	dep	1	SENT_784	[p26l801t1107r875b1161],
5	;	:	O	;	_	0	SENT_784	[p26l801t1107r875b1161],
6	abstr	NN	O	abstr	dep	4	SENT_784	[p26l890t1104r1029b1153],
7	.	.	O	.	_	0	SENT_784	[p26l890t1104r1029b1153],

1	4380	CD	NUMBER	4380	_	0	SENT_785	[p26l1042t1107r1171b1153],
2	(	CD	NUMBER	(	number	3	SENT_785	[p26l1187t1105r1288b1161],
3	201	CD	NUMBER	201	dep	1	SENT_785	[p26l1187t1105r1288b1161],
4	2	CD	NUMBER	2	num	5	SENT_785	[p26l1302t1105r1362b1161],
5	)	NN	O	)	dep	3	SENT_785	[p26l1302t1105r1362b1161],
6	.	.	O	.	_	0	SENT_785	[p26l1302t1105r1362b1161],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_786	[p26l21t1238r140b1259],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	_	0	SENT_786	[p26l149t1238r374b1259],
3	&	CC	O	&	_	0	SENT_786	[p26l381t1238r601b1259],
4	THERAPEUTlCS	NNP	O	THERAPEUTlCS	nn	6	SENT_786	[p26l381t1238r601b1259],
5	|	NNP	O	|	nn	6	SENT_786	[p26l611t1236r613b1266],
6	VOLUME	NNP	O	VOLUME	conj_and	2	SENT_786	[p26l621t1238r729b1259],
7	95	CD	NUMBER	95	num	8	SENT_786	[p26l737t1238r764b1259],
8	NUMBER	NN	O	number	dep	2	SENT_786	[p26l774t1238r882b1259],
9	1	CD	NUMBER	1	number	10	SENT_786	[p26l892t1239r899b1259],
10	]	CD	NUMBER	]	num	11	SENT_786	[p26l912t1236r915b1266],
11	JANUARY	NNP	DATE	JANUARY	dep	8	SENT_786	[p26l924t1238r1042b1259],
12	2014	CD	DATE	2014	num	13	SENT_786	[p26l1049t1238r1108b1259],
13	23	CD	DATE	23	dep	2	SENT_786	[p26l2109t1238r2139b1259],

